treatment_id	A549_LUNG	column_name	broad_id	name	dose	screen_id	moa	target	disease.area	indication	smiles	phase	dose_recode
BRD-A00077618-236-07-6::2.5::HTS	-0.2535409223	BRD-A00077618-236-07-6::2.5::HTS	BRD-A00077618-236-07-6	8-bromo-cGMP	2.5	HTS	PKA activator	PRKG1			Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1	Preclinical	5
BRD-A00100033-001-08-9::2.5::HTS	-0.50675100063	BRD-A00100033-001-08-9::2.5::HTS	BRD-A00100033-001-08-9	nifurtimox	2.5	HTS	DNA inhibitor		infectious disease	Chagas disease, African trypanosomiasis	CC1CS(=O)(=O)CCN1N=Cc1ccc(o1)[N+]([O-])=O	Launched	5
BRD-A00147595-001-01-5::2.5::HTS	-0.47785073255599997	BRD-A00147595-001-01-5::2.5::HTS	BRD-A00147595-001-01-5	balaglitazone	2.5	HTS	insulin sensitizer, PPAR receptor partial agonist	PPARG			Cn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O	Phase 3	5
BRD-A00218260-001-03-4::2.5::HTS	0.309236648918	BRD-A00218260-001-03-4::2.5::HTS	BRD-A00218260-001-03-4	flutrimazole	2.5	HTS	sterol demethylase inhibitor		infectious disease	mycosis	Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1	Launched	5
BRD-A00376169-001-01-6::2.5::HTS	-0.504879782505	BRD-A00376169-001-01-6::2.5::HTS	BRD-A00376169-001-01-6	KBG	2.5	HTS	neprilysin inhibitor	MME			OC1O[C@@H]2COC(O[C@H]2[C@H](O)[C@H]1O)c1ccccc1	Phase 2	5
BRD-A00520476-001-07-4::2.5::HTS	0.227663307885	BRD-A00520476-001-07-4::2.5::HTS	BRD-A00520476-001-07-4	otenzepad	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12, CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12	Phase 3	5
BRD-A00546892-001-02-6::2.5::HTS	-0.255813554213	BRD-A00546892-001-02-6::2.5::HTS	BRD-A00546892-001-02-6	biperiden	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	neurology/psychiatry	Parkinson's Disease	OC(CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1, OC(CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1	Launched	5
BRD-A00578795-001-04-3::2.5::HTS	-1.36740291574	BRD-A00578795-001-04-3::2.5::HTS	BRD-A00578795-001-04-3	zaltoprofen	2.5	HTS	cyclooxygenase inhibitor		endocrinology, neurology/psychiatry	fever, pain relief	CC(C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1	Launched	5
BRD-A00758722-001-04-9::2.5::HTS	-0.0628858391492	BRD-A00758722-001-04-9::2.5::HTS	BRD-A00758722-001-04-9	noretynodrel	2.5	HTS	progestogen hormone	PGR	endocrinology	contraceptive	C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C	Launched	5
BRD-A00827783-001-24-6::2.5::HTS	-0.0699950264895	BRD-A00827783-001-24-6::2.5::HTS	BRD-A00827783-001-24-6	dyphylline	2.5	HTS	adenosine receptor antagonist, phosphodiesterase inhibitor	ADORA1, ADORA2A, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B	pulmonary	asthma, bronchitis, emphysema	Cn1c2ncn(CC(O)CO)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(O)CO)c2c(=O)n(C)c1=O	Launched	5
BRD-A00993607-003-24-6::2.5::HTS	0.112412719351	BRD-A00993607-003-24-6::2.5::HTS	BRD-A00993607-003-24-6	alprenolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A	cardiology	angina pectoris	CC(C)NCC(O)COc1ccccc1CC=C	Launched	5
BRD-A01098288-001-02-9::2.5::HTS	0.153387967795	BRD-A01098288-001-02-9::2.5::HTS	BRD-A01098288-001-02-9	azelnidipine	2.5	HTS	calcium channel blocker	CACNA1C	cardiology	hypertension	CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1, CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1, CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1	Launched	5
BRD-A01412266-001-01-0::2.5::HTS	-0.163196280375	BRD-A01412266-001-01-0::2.5::HTS	BRD-A01412266-001-01-0	hydroxypropyl-beta-cyclodextrin	2.5	HTS					CC(O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COCC(C)O)O[C@H](O[C@@H]4[C@@H](COCC(C)O)O[C@H](O[C@@H]5[C@@H](COCC(C)O)O[C@H](O[C@@H]6[C@@H](COCC(C)O)O[C@H](O[C@@H]7[C@@H](COCC(C)O)O[C@H](O[C@@H]8[C@@H](COCC(C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O	Phase 2	5
BRD-A01493904-003-12-1::2.5::HTS	-0.119357001908	BRD-A01493904-003-12-1::2.5::HTS	BRD-A01493904-003-12-1	WB-4101	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A			COc1cccc(OC)c1OCCNCC1COc2ccccc2O1	Preclinical	5
BRD-A01563671-001-02-7::2.5::HTS	0.571839834485	BRD-A01563671-001-02-7::2.5::HTS	BRD-A01563671-001-02-7	cleviprex	2.5	HTS	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC	Launched	5
BRD-A01593789-001-03-1::2.5::HTS	0.240420617048	BRD-A01593789-001-03-1::2.5::HTS	BRD-A01593789-001-03-1	chlormadinone-acetate	2.5	HTS	5 alpha reductase inhibitor	PGR	endocrinology	hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea	CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O	Launched	5
BRD-A01636364-003-15-1::2.5::HTS	0.223505224006	BRD-A01636364-003-15-1::2.5::HTS	BRD-A01636364-003-15-1	bupivacaine	2.5	HTS	sodium channel blocker	KCNA5, PTGER1, SCN10A, SCN4A	neurology/psychiatry	peripheral nerve block, caudal epidural block, lumbar epidural block	CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C, CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C	Launched	5
BRD-A01643550-001-04-9::2.5::HTS	-0.9341698014700002	BRD-A01643550-001-04-9::2.5::HTS	BRD-A01643550-001-04-9	prednisolone-acetate	2.5	HTS	glucocorticoid receptor agonist	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Launched	5
BRD-A01787639-003-16-9::2.5::HTS	0.40671678282300006	BRD-A01787639-003-16-9::2.5::HTS	BRD-A01787639-003-16-9	naftopidil	2.5	HTS	adrenergic receptor antagonist	ADRA1A	urology	benign prostatic hyperplasia (BPH)	COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1	Launched	5
BRD-A01907367-001-01-7::2.5::HTS	-0.35725027410599997	BRD-A01907367-001-01-7::2.5::HTS	BRD-A01907367-001-01-7	FK-33-824	2.5	HTS	opioid receptor agonist	OPRM1			C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CCS(C)=O	Phase 2	5
BRD-A02006392-001-16-4::2.5::HTS	0.197776520834	BRD-A02006392-001-16-4::2.5::HTS	BRD-A02006392-001-16-4	nitrendipine	2.5	HTS	calcium channel blocker	CACNA1C, CACNA1D, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2, CACNG1, KCNN4	cardiology	hypertension	CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC	Launched	5
BRD-A02180903-001-04-5::2.5::HTS	-0.428680113705	BRD-A02180903-001-04-5::2.5::HTS	BRD-A02180903-001-04-5	betamethasone	2.5	HTS	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO	Launched	5
BRD-A02710418-003-11-8::2.5::HTS	-0.229669313674	BRD-A02710418-003-11-8::2.5::HTS	BRD-A02710418-003-11-8	meptazinol	2.5	HTS	opioid receptor agonist	BCHE	neurology/psychiatry	pain relief	CCC1(CCCCN(C)C1)c1cccc(O)c1, CCC1(CCCCN(C)C1)c1cccc(O)c1, CCC1(CCCCN(C)C1)c1cccc(O)c1	Launched	5
BRD-A02743701-001-03-6::2.5::HTS	0.23750113663800002	BRD-A02743701-001-03-6::2.5::HTS	BRD-A02743701-001-03-6	cilnidipine	2.5	HTS	calcium channel blocker	CACNA1B	cardiology	hypertension	COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1	Launched	5
BRD-A02759312-003-24-5::2.5::HTS	0.316824201676	BRD-A02759312-003-24-5::2.5::HTS	BRD-A02759312-003-24-5	betaxolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC	Launched	5
BRD-A02990301-003-06-6::2.5::HTS	-0.40286818573399996	BRD-A02990301-003-06-6::2.5::HTS	BRD-A02990301-003-06-6	lofexidine	2.5	HTS	adrenergic receptor agonist	ADRA2A	neurology/psychiatry	opioid withdrawal	CC(Oc1c(Cl)cccc1Cl)C1=NCCN1, CC(Oc1c(Cl)cccc1Cl)C1=NCCN1	Launched	5
BRD-A03061970-003-07-3::2.5::HTS	0.16378585880899998	BRD-A03061970-003-07-3::2.5::HTS	BRD-A03061970-003-07-3	alizapride	2.5	HTS	dopamine receptor antagonist	DRD2	gastroenterology	nausea	COc1cc2[nH]nnc2cc1C(=O)NCC1CCCN1CC=C	Launched	5
BRD-A03216249-003-24-3::2.5::HTS	-1.16959217612	BRD-A03216249-003-24-3::2.5::HTS	BRD-A03216249-003-24-3	mepivacaine	2.5	HTS	potassium channel blocker, sodium channel blocker	SCN10A	neurology/psychiatry	local anesthetic	CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C	Launched	5
BRD-A03359064-001-02-3::2.5::HTS	0.097531351184	BRD-A03359064-001-02-3::2.5::HTS	BRD-A03359064-001-02-3	ICI-89406	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2			OC(CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N	Phase 1	5
BRD-A03506276-001-01-5::2.5::HTS	-3.7330348403699993	BRD-A03506276-001-01-5::2.5::HTS	BRD-A03506276-001-01-5	XL888	2.5	HTS	HSP inhibitor				CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O	Phase 1	5
BRD-A03623303-045-09-5::2.5::HTS	-1.01980307925	BRD-A03623303-045-09-5::2.5::HTS	BRD-A03623303-045-09-5	metoprolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1	Launched	5
BRD-A03880619-001-01-0::2.5::HTS	0.27888596205	BRD-A03880619-001-01-0::2.5::HTS	BRD-A03880619-001-01-0	bismuth-subcitrate-potassium	2.5	HTS			gastroenterology	duodenal ulcer disease	OC(=O)CC(O)(CC(=O)O[Bi]1OC(=O)CC(O)(CC(O)=O)C(=O)O1)C(O)=O, OC(=O)CC(O)(CC(=O)O[Bi]1OC(=O)CC(O)(CC(O)=O)C(=O)O1)C(O)=O	Launched	5
BRD-A03932035-004-04-3::2.5::HTS	-0.519069085947	BRD-A03932035-004-04-3::2.5::HTS	BRD-A03932035-004-04-3	methscopolamine	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Launched	5
BRD-A04203391-001-08-3::2.5::HTS	0.152174014676	BRD-A04203391-001-08-3::2.5::HTS	BRD-A04203391-001-08-3	piricapiron	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O	Phase 2	5
BRD-A04252265-003-01-4::2.5::HTS	-0.273456319135	BRD-A04252265-003-01-4::2.5::HTS	BRD-A04252265-003-01-4	eperisone	2.5	HTS	acetylcholine receptor antagonist	CYP2J2	neurology/psychiatry	amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury	CCc1ccc(cc1)C(=O)C(C)CN1CCCCC1	Launched	5
BRD-A04322457-003-17-9::2.5::HTS	0.251397997306	BRD-A04322457-003-17-9::2.5::HTS	BRD-A04322457-003-17-9	isoprenaline	2.5	HTS	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3, MAPK1, PIK3R1, PIK3R2, PIK3R3	cardiology, pulmonary	bradycardia, heart block, asthma	CC(C)NCC(O)c1ccc(O)c(O)c1, CC(C)NCC(O)c1ccc(O)c(O)c1, CC(C)NCC(O)c1ccc(O)c(O)c1, CC(C)NCC(O)c1ccc(O)c(O)c1	Launched	5
BRD-A04327189-001-15-1::2.5::HTS	0.599390380695	BRD-A04327189-001-15-1::2.5::HTS	BRD-A04327189-001-15-1	synephrine	2.5	HTS	adrenergic receptor agonist	ADRA1A			CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1	Launched	5
BRD-A04327189-003-03-3::2.5::HTS	-0.10636973433000001	BRD-A04327189-003-03-3::2.5::HTS	BRD-A04327189-003-03-3	synephrine	2.5	HTS	adrenergic receptor agonist	ADRA1A			CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1	Launched	5
BRD-A04352665-001-05-3::2.5::HTS	-0.25068725685	BRD-A04352665-001-05-3::2.5::HTS	BRD-A04352665-001-05-3	maraviroc	2.5	HTS	CC chemokine receptor antagonist	CCR5	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1, CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1	Launched	5
BRD-A04497688-001-04-2::2.5::HTS	-0.08128210481110001	BRD-A04497688-001-04-2::2.5::HTS	BRD-A04497688-001-04-2	trilostane	2.5	HTS	3beta-hydroxy-delta5-steroid dehydrogenase inhibitor	ESR1, ESR2, HSD3B1, HSD3B2	endocrinology	Cushing's syndrome	C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O	Launched	5
BRD-A04506385-001-01-2::2.5::HTS	-0.73399620861	BRD-A04506385-001-01-2::2.5::HTS	BRD-A04506385-001-01-2	stepronin	2.5	HTS	mucolytic agent				CC(SC(=O)c1cccs1)C(=O)NCC(O)=O	Launched	5
BRD-A04553218-050-16-2::2.5::HTS	-0.09878061468510001	BRD-A04553218-050-16-2::2.5::HTS	BRD-A04553218-050-16-2	chlorphenamine	2.5	HTS	histamine receptor antagonist	HRH1, SLC6A2, SLC6A3, SLC6A4	allergy	allergic rhinitis, urticaria	CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1	Launched	5
BRD-A04661934-001-02-9::2.5::HTS	-0.19781306895599998	BRD-A04661934-001-02-9::2.5::HTS	BRD-A04661934-001-02-9	2-PMDQ	2.5	HTS	adrenergic receptor antagonist	ADRA1A			O=C1Nc2ccccc2C2=NC(CN3CCN(CC3)c3ccccc3)CN12	Preclinical	5
BRD-A05186015-003-19-8::2.5::HTS	-0.15825424100500002	BRD-A05186015-003-19-8::2.5::HTS	BRD-A05186015-003-19-8	bupropion	2.5	HTS	dopamine uptake inhibitor	CHRNA3, SLC6A2, SLC6A3	neurology/psychiatry	depression	CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1, CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1, CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1	Launched	5
BRD-A05334458-001-02-8::2.5::HTS	-0.138976004307	BRD-A05334458-001-02-8::2.5::HTS	BRD-A05334458-001-02-8	lisofylline	2.5	HTS	interleukin receptor antagonist, STAT inhibitor				CC(O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	Phase 2	5
BRD-A05457250-001-08-4::2.5::HTS	-0.699742245625	BRD-A05457250-001-08-4::2.5::HTS	BRD-A05457250-001-08-4	BAY-K-8644-(+/-)	2.5	HTS	L-type calcium channel activator				COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1C(F)(F)F)[N+]([O-])=O	Preclinical	5
BRD-A05515753-001-03-2::2.5::HTS	0.0576312769969	BRD-A05515753-001-03-2::2.5::HTS	BRD-A05515753-001-03-2	erdosteine	2.5	HTS	mucolytic agent		pulmonary, infectious disease	bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections	OC(=O)CSCC(=O)NC1CCSC1=O, OC(=O)CSCC(=O)NC1CCSC1=O, OC(=O)CSCC(=O)NC1CCSC1=O	Launched	5
BRD-A05523972-001-01-5::2.5::HTS	0.264876928043	BRD-A05523972-001-01-5::2.5::HTS	BRD-A05523972-001-01-5	telmesteine	2.5	HTS	mucolytic agent				CCOC(=O)N1CSCC1C(O)=O	Launched	5
BRD-A05674712-001-06-0::2.5::HTS	-0.033354081448499995	BRD-A05674712-001-06-0::2.5::HTS	BRD-A05674712-001-06-0	mevalonic-d,-l-acid-lactone	2.5	HTS					CC1(O)CCOC(=O)C1	Preclinical	5
BRD-A05729358-001-02-0::2.5::HTS	0.130388999752	BRD-A05729358-001-02-0::2.5::HTS	BRD-A05729358-001-02-0	CPCCOEt	2.5	HTS	glutamate receptor antagonist	GRM1			CCOC(=O)C12CC1\C(=N/O)c1ccccc1O2, CCOC(=O)C12CC1\C(=N/O)c1ccccc1O2	Preclinical	5
BRD-A05906449-004-01-1::2.5::HTS	0.0814762614302	BRD-A05906449-004-01-1::2.5::HTS	BRD-A05906449-004-01-1	lappaconite	2.5	HTS	sodium channel blocker				CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O	Phase 2	5
BRD-A06352418-001-25-9::2.5::HTS	-0.292579988182	BRD-A06352418-001-25-9::2.5::HTS	BRD-A06352418-001-25-9	terfenadine	2.5	HTS	histamine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2			CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1	Withdrawn	5
BRD-A06352508-001-03-7::2.5::HTS	0.7238881427789999	BRD-A06352508-001-03-7::2.5::HTS	BRD-A06352508-001-03-7	SB-218078	2.5	HTS	CHK inhibitor	CHEK1			O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13	Preclinical	5
BRD-A06390036-001-04-6::2.5::HTS	0.136358209459	BRD-A06390036-001-04-6::2.5::HTS	BRD-A06390036-001-04-6	hydroquinidine	2.5	HTS	antiarrhythmic		cardiology	cardiac arrythmia	CC[C@H]1CN2CCC1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	Launched	5
BRD-A06426627-001-03-5::2.5::HTS	-0.786827264575	BRD-A06426627-001-03-5::2.5::HTS	BRD-A06426627-001-03-5	diclazuril	2.5	HTS	antiprotozoal agent		infectious disease	equine protozoal myeloencephalitis (EPM)	Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O	Launched	5
BRD-A06627858-236-03-0::2.5::HTS	-2.0805911283099996	BRD-A06627858-236-03-0::2.5::HTS	BRD-A06627858-236-03-0	monensin	2.5	HTS	bacterial permeability inducer				CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C	Launched	5
BRD-A06771424-004-01-7::2.5::HTS	0.0373808983866	BRD-A06771424-004-01-7::2.5::HTS	BRD-A06771424-004-01-7	anisotropine	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	CCCC(CCC)C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C	Launched	5
BRD-A06916187-001-02-9::2.5::HTS	0.17446393320300002	BRD-A06916187-001-02-9::2.5::HTS	BRD-A06916187-001-02-9	CPI-613	2.5	HTS	pyruvate dehydrogenase inhibitor	PDHA1			OC(=O)CCCCC(CCSCc1ccccc1)SCc1ccccc1	Phase 2	5
BRD-A06935312-001-04-3::2.5::HTS	0.005902637607229999	BRD-A06935312-001-04-3::2.5::HTS	BRD-A06935312-001-04-3	fusidic-acid	2.5	HTS	bacterial 30S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)\C2=C(/CCC=C(C)C)C(O)=O	Launched	5
BRD-A07000685-001-04-4::2.5::HTS	0.39387167878799995	BRD-A07000685-001-04-4::2.5::HTS	BRD-A07000685-001-04-4	hydrocortisone-hemisuccinate	2.5	HTS					C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O	Phase 2/Phase 3	5
BRD-A07164067-001-01-2::2.5::HTS	-0.31477271618299996	BRD-A07164067-001-01-2::2.5::HTS	BRD-A07164067-001-01-2	meluadrine	2.5	HTS					CC(C)(C)NCC(O)c1ccc(O)cc1Cl	Preclinical	5
BRD-A07207424-001-13-2::2.5::HTS	-0.21170208289200002	BRD-A07207424-001-13-2::2.5::HTS	BRD-A07207424-001-13-2	Ro-20-1724	2.5	HTS	phosphodiesterase inhibitor	PDE3A, PDE4A, PDE4B, PDE4C, PDE4D			CCCCOc1cc(CC2CNC(=O)N2)ccc1OC, CCCCOc1cc(CC2CNC(=O)N2)ccc1OC	Preclinical	5
BRD-A07232941-001-02-7::2.5::HTS	-0.373184576325	BRD-A07232941-001-02-7::2.5::HTS	BRD-A07232941-001-02-7	8-M-PDOT	2.5	HTS	melatonin receptor agonist	MTNR1A, MTNR1B			CCC(=O)NC1CCc2cccc(OC)c2C1, CCC(=O)NC1CCc2cccc(OC)c2C1	Preclinical	5
BRD-A07395371-003-10-0::2.5::HTS	0.0918790145774	BRD-A07395371-003-10-0::2.5::HTS	BRD-A07395371-003-10-0	esmolol	2.5	HTS	adrenergic receptor antagonist	ADRB1	cardiology	ventricular tachycardia (VT), hypertension	COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1	Launched	5
BRD-A07440155-003-25-4::2.5::HTS	-0.22718087328000003	BRD-A07440155-003-25-4::2.5::HTS	BRD-A07440155-003-25-4	labetalol	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2	cardiology	hypertension	CC(CCc1ccccc1)NCC(O)c1ccc(O)c(c1)C(N)=O	Launched	5
BRD-A07563059-035-01-3::2.5::HTS	-0.0035306213907500003	BRD-A07563059-035-01-3::2.5::HTS	BRD-A07563059-035-01-3	bopindolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3, HTR1A, HTR1B	cardiology	hypertension, coronary artery disease (CAD)	Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1	Launched	5
BRD-A07600638-060-05-2::2.5::HTS	-0.302006928271	BRD-A07600638-060-05-2::2.5::HTS	BRD-A07600638-060-05-2	meclocycline-sulfosalicylate	2.5	HTS	bacterial 50S ribosomal subunit inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	Launched	5
BRD-A07704283-001-01-3::2.5::HTS	-0.514458027604	BRD-A07704283-001-01-3::2.5::HTS	BRD-A07704283-001-01-3	isofloxythepin	2.5	HTS	dopamine receptor antagonist				CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1	Phase 2	5
BRD-A07780951-001-08-9::2.5::HTS	-0.051682203307400004	BRD-A07780951-001-08-9::2.5::HTS	BRD-A07780951-001-08-9	metaproterenol	2.5	HTS	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, asthma, bronchitis, emphysema	CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NCC(O)c1cc(O)cc(O)c1	Launched	5
BRD-A07780951-065-10-0::2.58::HTS	0.09028894082019999	BRD-A07780951-065-10-0::2.58::HTS	BRD-A07780951-065-10-0	metaproterenol	2.58	HTS	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, asthma, bronchitis, emphysema	CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NCC(O)c1cc(O)cc(O)c1	Launched	5
BRD-A07815743-001-01-1::2.5::HTS	-0.203797526272	BRD-A07815743-001-01-1::2.5::HTS	BRD-A07815743-001-01-1	kakonein	2.5	HTS	GABA receptor antagonist, serotonin receptor antagonist				OCC1OC(C(O)C(O)C1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	Phase 2	5
BRD-A07870296-001-07-4::2.5::HTS	0.400256989697	BRD-A07870296-001-07-4::2.5::HTS	BRD-A07870296-001-07-4	bicuculline-(+)	2.5	HTS	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1			CN1CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21, CN1CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21	Preclinical	5
BRD-A07893380-213-01-7::2.5::HTS	0.08614837036560001	BRD-A07893380-213-01-7::2.5::HTS	BRD-A07893380-213-01-7	vigabatrin	2.5	HTS	GABA aminotransferase inhibitor	ABAT, GABBR1, SLC32A1	neurology/psychiatry	seizures, spasms	NC(CCC(O)=O)C=C	Launched	5
BRD-A07932845-050-15-8::2.5::HTS	-0.0269973694136	BRD-A07932845-050-15-8::2.5::HTS	BRD-A07932845-050-15-8	metitepine	2.5	HTS	anti-HCVE2	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1, CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1, CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1	Preclinical	5
BRD-A07947329-001-01-4::2.5::HTS	0.0595620105885	BRD-A07947329-001-01-4::2.5::HTS	BRD-A07947329-001-01-4	buparvaquone	2.5	HTS	antiprotozoal agent				CC(C)(C)C1CCC(CC2C(=O)C(=O)c3ccccc3C2=O)CC1	Launched	5
BRD-A07986123-001-02-8::2.5::HTS	0.142471761739	BRD-A07986123-001-02-8::2.5::HTS	BRD-A07986123-001-02-8	galeterone	2.5	HTS	androgen receptor modulator	AR, CYP17A1			C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12	Phase 3	5
BRD-A08079565-001-01-8::2.5::HTS	0.210027925177	BRD-A08079565-001-01-8::2.5::HTS	BRD-A08079565-001-01-8	CDBA	2.5	HTS					OCC1OC2OC3C(CO)OC(OC4C(CO)OC(OC5C(CO)OC(OC6C(CO)OC(OC7C(CO)OC(OC8C(CO)OC(OC1C(O)C2O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O	Phase 3	5
BRD-A08187463-001-12-9::2.5::HTS	-0.18311113211399999	BRD-A08187463-001-12-9::2.5::HTS	BRD-A08187463-001-12-9	racecadotril	2.5	HTS	enkephalinase inhibitor	MME	gastroenterology	diarrhea	CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1	Launched	5
BRD-A08255417-001-14-7::2.5::HTS	0.260898262677	BRD-A08255417-001-14-7::2.5::HTS	BRD-A08255417-001-14-7	famprofazone	2.5	HTS	cyclooxygenase inhibitor				CC(Cc1ccccc1)N(C)Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C, CC(Cc1ccccc1)N(C)Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C	Preclinical	5
BRD-A08302182-001-01-7::2.5::HTS	0.670598314154	BRD-A08302182-001-01-7::2.5::HTS	BRD-A08302182-001-01-7	etonogestrel	2.5	HTS	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	CCC12CC(=C)C3C(CCC4=CC(=O)CCC34)C1CC[C@@]2(O)C#C	Launched	5
BRD-A08545410-003-07-8::2.38::HTS	-0.693218333326	BRD-A08545410-003-07-8::2.38::HTS	BRD-A08545410-003-07-8	doxycycline	2.38	HTS	metalloproteinase inhibitor	MMP8	dental	periodontitis	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12	Launched	5
BRD-A08545410-003-08-6::2.5::HTS	-0.26776962192299997	BRD-A08545410-003-08-6::2.5::HTS	BRD-A08545410-003-08-6	doxycycline	2.5	HTS	metalloproteinase inhibitor	MMP8	dental	periodontitis	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12	Launched	5
BRD-A08545410-311-01-8::2.5::HTS	0.499604082437	BRD-A08545410-311-01-8::2.5::HTS	BRD-A08545410-311-01-8	doxycycline	2.5	HTS	metalloproteinase inhibitor	MMP8	dental	periodontitis	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12	Launched	5
BRD-A08545410-311-03-4::2.5::HTS	-2.27226365125	BRD-A08545410-311-03-4::2.5::HTS	BRD-A08545410-311-03-4	doxycycline	2.5	HTS	metalloproteinase inhibitor	MMP8	dental	periodontitis	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12	Launched	5
BRD-A08660406-001-05-9::2.5::HTS	-0.318457057558	BRD-A08660406-001-05-9::2.5::HTS	BRD-A08660406-001-05-9	iodixanol	2.5	HTS	radiopaque medium		radiology	contrast agent	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I, CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I	Launched	5
BRD-A08715367-001-01-7::2.87::HTS	-0.467642750004	BRD-A08715367-001-01-7::2.87::HTS	BRD-A08715367-001-01-7	L-Theanine	2.87	HTS	glutamate receptor antagonist				CCNC(=O)CCC(N)C(O)=O	Launched	5
BRD-A08840375-001-01-3::2.5::HTS	0.13450701793	BRD-A08840375-001-01-3::2.5::HTS	BRD-A08840375-001-01-3	CID-5458317	2.5	HTS	MAP kinase phosphatase inhibitor	MAPK3			O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1	Preclinical	5
BRD-A09056319-003-07-7::2.5::HTS	0.574286224254	BRD-A09056319-003-07-7::2.5::HTS	BRD-A09056319-003-07-7	alfuzosin	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, KCNH2	urology	benign prostatic hyperplasia (BPH)	COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1, COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1	Launched	5
BRD-A09062839-003-10-0::2.5::HTS	0.00801142096443	BRD-A09062839-003-10-0::2.5::HTS	BRD-A09062839-003-10-0	amyleine	2.5	HTS	local anesthetic				CCC(C)(CN(C)C)OC(=O)c1ccccc1	Preclinical	5
BRD-A09094913-065-01-0::2.5::HTS	-1.06613875538	BRD-A09094913-065-01-0::2.5::HTS	BRD-A09094913-065-01-0	strychnine	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB			O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c1ccccc61	Preclinical	5
BRD-A09349126-001-10-7::2.5::HTS	-0.155808303559	BRD-A09349126-001-10-7::2.5::HTS	BRD-A09349126-001-10-7	norethindrone-acetate	2.5	HTS	progesterone receptor agonist		endocrinology, orthopedics, obstetrics/gynecology	menopause, osteoporosis, vaginal atrophy	CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C	Launched	5
BRD-A09370961-001-01-0::2.5::HTS	-0.174407856961	BRD-A09370961-001-01-0::2.5::HTS	BRD-A09370961-001-01-0	ioxilan	2.5	HTS	radiopaque medium		radiology	angiography	CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I	Launched	5
BRD-A09467419-003-22-4::2.5::HTS	0.23127120449900002	BRD-A09467419-003-22-4::2.5::HTS	BRD-A09467419-003-22-4	mebeverine	2.5	HTS	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1	Launched	5
BRD-A09472452-015-23-4::2.5::HTS	-0.008161754566359999	BRD-A09472452-015-23-4::2.5::HTS	BRD-A09472452-015-23-4	flecainide	2.5	HTS	sodium channel blocker	KCNA5, KCNA7, SCN4A, SCN5A	cardiology	ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias	FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1	Launched	5
BRD-A09533288-003-31-2::2.5::HTS	-0.301754496134	BRD-A09533288-003-31-2::2.5::HTS	BRD-A09533288-003-31-2	verapamil	2.5	HTS	calcium channel blocker	CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4	cardiology	hypertension	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC	Launched	5
BRD-A09554849-236-07-6::2.5::HTS	0.15599855357	BRD-A09554849-236-07-6::2.5::HTS	BRD-A09554849-236-07-6	8-bromo-cAMP	2.5	HTS	PKA activator				Nc1ncnc2n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c(Br)nc12	Preclinical	5
BRD-A09722536-002-18-0::2.5::HTS	0.6663020065959999	BRD-A09722536-002-18-0::2.5::HTS	BRD-A09722536-002-18-0	cyclophosphamide	2.5	HTS	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7	hematologic malignancy, oncology	Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer	ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1	Launched	5
BRD-A09735281-001-02-5::2.5::HTS	-0.48469003758900003	BRD-A09735281-001-02-5::2.5::HTS	BRD-A09735281-001-02-5	boceprevir	2.5	HTS	HCV inhibitor	CMA1, CTSA, CTSF, CTSK, CTSL, CTSS	infectious disease	hepatitis C	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C	Launched	5
BRD-A09828896-004-11-0::2.5::HTS	-0.108451570142	BRD-A09828896-004-11-0::2.5::HTS	BRD-A09828896-004-11-0	SKF-81297	2.5	HTS	dopamine receptor agonist	DRD1, DRD5			Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1	Preclinical	5
BRD-A09925278-003-05-6::2.5::HTS	0.0995675537597	BRD-A09925278-003-05-6::2.5::HTS	BRD-A09925278-003-05-6	etilefrine	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRB1	neurology/psychiatry, otolaryngology, endocrinology, pulmonary	headache, nasal congestion, fever, cough suppressant, common cold	CCNCC(O)c1cccc(O)c1	Launched	5
BRD-A10039652-001-01-2::2.5::HTS	-0.597726297508	BRD-A10039652-001-01-2::2.5::HTS	BRD-A10039652-001-01-2	tipranavir	2.5	HTS	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1	Launched	5
BRD-A10070317-003-28-3::2.5::HTS	0.17454813145999998	BRD-A10070317-003-28-3::2.5::HTS	BRD-A10070317-003-28-3	propranolol	2.5	HTS	adrenergic receptor antagonist		cardiology, neurology/psychiatry	hypertension, angina pectoris, migraine headache	CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12	Launched	5
BRD-A10111329-001-04-6::2.5::HTS	-0.113781837947	BRD-A10111329-001-04-6::2.5::HTS	BRD-A10111329-001-04-6	adenosine-phosphate	2.5	HTS	adenosine receptor agonist	ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4			Nc1ncnc2n(cnc12)C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O	Launched	5
BRD-A10420615-001-04-4::2.5::HTS	0.301395623446	BRD-A10420615-001-04-4::2.5::HTS	BRD-A10420615-001-04-4	cyclopiazonic-acid	2.5	HTS	ATPase inhibitor	ATP2A1			CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O, CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O	Preclinical	5
BRD-A10523515-001-07-9::2.5::HTS	0.0713554722662	BRD-A10523515-001-07-9::2.5::HTS	BRD-A10523515-001-07-9	GSK429286A	2.5	HTS	rho associated kinase inhibitor	ROCK1			CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F	Preclinical	5
BRD-A10652366-238-04-1::2.5::HTS	-0.24621965288699998	BRD-A10652366-238-04-1::2.5::HTS	BRD-A10652366-238-04-1	fosfomycin	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	C[C@@H]1O[C@@H]1P(O)(O)=O, CC1OC1P(O)(O)=O	Launched	5
BRD-A10662413-043-11-2::2.5::HTS	0.22109125145999997	BRD-A10662413-043-11-2::2.5::HTS	BRD-A10662413-043-11-2	prenylamine	2.5	HTS	calcium channel blocker	CALM1, MYLK2			CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1	Withdrawn	5
BRD-A10739734-003-10-6::2.5::HTS	-0.0941160909241	BRD-A10739734-003-10-6::2.5::HTS	BRD-A10739734-003-10-6	efaroxan	2.5	HTS	adrenergic receptor antagonist	ADORA2A			CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1	Phase 2	5
BRD-A10903566-003-07-7::2.5::HTS	0.543598021128	BRD-A10903566-003-07-7::2.5::HTS	BRD-A10903566-003-07-7	imiloxan	2.5	HTS	adrenergic receptor antagonist	ADRA2A, ADRA2B			CCn1ccnc1CC1COc2ccccc2O1	Phase 1	5
BRD-A10967948-003-06-3::2.5::HTS	-0.257512573248	BRD-A10967948-003-06-3::2.5::HTS	BRD-A10967948-003-06-3	granisetron	2.5	HTS	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	CN1C2CCCC1CC(C2)NC(=O)c1nn(C)c2ccccc12, CN1C2CCCC1CC(C2)NC(=O)c1nn(C)c2ccccc12	Launched	5
BRD-A10977446-001-12-1::2.5::HTS	0.38888384372100004	BRD-A10977446-001-12-1::2.5::HTS	BRD-A10977446-001-12-1	carvedilol	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA	cardiology	myocardial infarction, hypertension	COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12	Launched	5
BRD-A11070335-236-02-1::2.5::HTS	0.175844171386	BRD-A11070335-236-02-1::2.5::HTS	BRD-A11070335-236-02-1	carbazochrome	2.5	HTS			hematology	hemorrhage	CN1C(CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O	Launched	5
BRD-A11132253-001-08-2::2.5::HTS	-0.280590879826	BRD-A11132253-001-08-2::2.5::HTS	BRD-A11132253-001-08-2	nadide	2.5	HTS	electron acceptor	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2			NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O	Launched	5
BRD-A11551002-001-04-6::2.5::HTS	0.833788399632	BRD-A11551002-001-04-6::2.5::HTS	BRD-A11551002-001-04-6	dehydrocholate-acid	2.5	HTS					CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O	Preclinical	5
BRD-A11662333-001-03-3::2.5::HTS	0.432441797896	BRD-A11662333-001-03-3::2.5::HTS	BRD-A11662333-001-03-3	meparfylon	2.5	HTS					CCC(C)(O)C#C	Preclinical	5
BRD-A11731518-001-01-7::2.5::HTS	0.06972642673830001	BRD-A11731518-001-01-7::2.5::HTS	BRD-A11731518-001-01-7	BAY-85-8050	2.5	HTS					NC(CC(F)C(O)=O)C(O)=O	Phase 1	5
BRD-A11776908-065-01-5::2.5::HTS	0.423705348911	BRD-A11776908-065-01-5::2.5::HTS	BRD-A11776908-065-01-5	enilconazole	2.5	HTS	sterol demethylase inhibitor	CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2	infectious disease	skin infections	Clc1ccc(C(Cn2ccnc2)OCC=C)c(Cl)c1	Launched	5
BRD-A11813248-003-02-4::2.5::HTS	-0.528296390721	BRD-A11813248-003-02-4::2.5::HTS	BRD-A11813248-003-02-4	AM-92016	2.5	HTS	potassium channel blocker	GRIN1			CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc1ccc(NS(C)(=O)=O)cc1, CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc1ccc(NS(C)(=O)=O)cc1	Preclinical	5
BRD-A11815689-001-01-1::2.5::HTS	-4.82643421665	BRD-A11815689-001-01-1::2.5::HTS	BRD-A11815689-001-01-1	proscillaridin-a	2.5	HTS			cardiology	congestive heart failure, cardiac arrythmia	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O	Launched	5
BRD-A11990600-001-03-4::2.5::HTS	-1.44218937717	BRD-A11990600-001-03-4::2.5::HTS	BRD-A11990600-001-03-4	lorazepam	2.5	HTS	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	status epilepticus	OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O	Launched	5
BRD-A12077521-003-01-5::2.5::HTS	-0.173389760713	BRD-A12077521-003-01-5::2.5::HTS	BRD-A12077521-003-01-5	cefepime	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, skin infections, intra-abdominal infections	CO\N=C(\C(=O)NC1C2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	5
BRD-A12230535-001-06-7::2.5::HTS	-0.620494062721	BRD-A12230535-001-06-7::2.5::HTS	BRD-A12230535-001-06-7	nutlin-3	2.5	HTS	MDM inhibitor	MDM2, TP53			COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1	Preclinical	5
BRD-A12237696-001-04-2::2.5::HTS	0.36241540952699997	BRD-A12237696-001-04-2::2.5::HTS	BRD-A12237696-001-04-2	L-Citrulline	2.5	HTS	nitric oxide stimulant	ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6	cardiology, urology	hypertension, erectile dysfunction	NC(CCCNC(N)=O)C(O)=O	Launched	5
BRD-A12417644-001-07-6::2.31::HTS	-0.67724528982	BRD-A12417644-001-07-6::2.31::HTS	BRD-A12417644-001-07-6	usniacin-(+)	2.31	HTS	MAP kinase activator	PTPN1			CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O	Preclinical	5
BRD-A12454076-001-01-9::2.5::HTS	0.313296513562	BRD-A12454076-001-01-9::2.5::HTS	BRD-A12454076-001-01-9	L-Hydroxyproline	2.5	HTS					OC1CNC(C1)C(O)=O	Launched	5
BRD-A12896037-001-04-3::2.5::HTS	-0.068708350514	BRD-A12896037-001-04-3::2.5::HTS	BRD-A12896037-001-04-3	cisapride	2.5	HTS	serotonin receptor agonist	HTR2A, HTR3A, HTR4, KCNH2			COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC	Withdrawn	5
BRD-A12994259-001-02-1::2.5::HTS	-0.2154875155	BRD-A12994259-001-02-1::2.5::HTS	BRD-A12994259-001-02-1	pomalidomide	2.5	HTS	angiogenesis inhibitor, tumor necrosis factor production inhibitor	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12	Launched	5
BRD-A13084692-001-17-3::2.5::HTS	-1.05602200979	BRD-A13084692-001-17-3::2.5::HTS	BRD-A13084692-001-17-3	troglitazone	2.5	HTS	insulin sensitizer, PPAR receptor agonist	ACSL4, ESRRA, ESRRG, PPARG, SERPINE1, SLC29A1, TRPM3			Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O, Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	Withdrawn	5
BRD-A13133631-001-04-0::2.5::HTS	-0.018766704721299998	BRD-A13133631-001-04-0::2.5::HTS	BRD-A13133631-001-04-0	fluorometholone	2.5	HTS	glucocorticoid receptor agonist	NR3C1	ophthalmology	eye inflammation	C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12	Launched	5
BRD-A13188892-066-21-5::2.5::HTS	0.10774165345100001	BRD-A13188892-066-21-5::2.5::HTS	BRD-A13188892-066-21-5	doxazosin	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, KCNH2, KCNH6, KCNH7	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1	Launched	5
BRD-A13323580-001-04-8::2.5::HTS	-0.119330776854	BRD-A13323580-001-04-8::2.5::HTS	BRD-A13323580-001-04-8	perillyl-alcohol	2.5	HTS	apoptosis stimulant, farnesyltransferase inhibitor	FNTA			CC(=C)C1CCC(CO)=CC1, CC(=C)C1CCC(CO)=CC1	Phase 2	5
BRD-A13561534-003-02-0::2.5::HTS	0.07117622530760001	BRD-A13561534-003-02-0::2.5::HTS	BRD-A13561534-003-02-0	ornithine	2.5	HTS	NFkB pathway modulator	ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4			NCCCC(N)C(O)=O	Launched	5
BRD-A13598753-001-01-2::2.5::HTS	-0.042237972139800004	BRD-A13598753-001-01-2::2.5::HTS	BRD-A13598753-001-01-2	5'-Chloro-5'-deoxy-ENBA-(+/-)	2.5	HTS	adenosine receptor agonist	ADORA1			O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(NC3CC4CCC3C4)ncnc12, O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(NC3CC4CCC3C4)ncnc12	Preclinical	5
BRD-A13946108-001-17-1::2.5::HTS	0.114635039691	BRD-A13946108-001-17-1::2.5::HTS	BRD-A13946108-001-17-1	sulindac	2.5	HTS	cyclooxygenase inhibitor	AKR1B1, MAPK3, PPARD, PTGDR2, PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis	CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O, CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O, CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O, CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O	Launched	5
BRD-A13964793-001-02-6::2.5::HTS	-0.0304411832848	BRD-A13964793-001-02-6::2.5::HTS	BRD-A13964793-001-02-6	TC1	2.5	HTS	beta-secretase inhibitor	BACE1			OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1	Preclinical	5
BRD-A14208071-004-19-8::2.5::HTS	0.0461972666242	BRD-A14208071-004-19-8::2.5::HTS	BRD-A14208071-004-19-8	oxyphenonium	2.5	HTS	cholinergic receptor antagonist	CHRM1	gastroenterology	peptic ulcer disease (PUD)	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1	Launched	5
BRD-A14240607-003-26-1::2.5::HTS	-0.0927810548656	BRD-A14240607-003-26-1::2.5::HTS	BRD-A14240607-003-26-1	octopamine	2.5	HTS	trace amine associated receptor agonist	F10, TAAR1			NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1	Preclinical	5
BRD-A14262390-065-01-8::2.5::HTS	-0.0610664978145	BRD-A14262390-065-01-8::2.5::HTS	BRD-A14262390-065-01-8	guanadrel	2.5	HTS	adrenergic inhibitor	SLC6A2	cardiology	hypertension	NC(=N)NCC1COC2(CCCCC2)O1	Launched	5
BRD-A14316475-001-02-3::2.5::HTS	-0.19940130337900003	BRD-A14316475-001-02-3::2.5::HTS	BRD-A14316475-001-02-3	SN-6	2.5	HTS	sodium/calcium exchange inhibitor				CCOC(=O)C1CSC(N1)Cc1ccc(OCc2ccc([N+]([O-])=O)cc2)cc1, CCOC(=O)C1CSC(N1)Cc1ccc(OCc2ccc([N+]([O-])=O)cc2)cc1	Preclinical	5
BRD-A14344385-001-03-2::2.5::HTS	-2.82841309764	BRD-A14344385-001-03-2::2.5::HTS	BRD-A14344385-001-03-2	IDRA-21	2.5	HTS	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1	Preclinical	5
BRD-A14395271-074-17-8::2.5::HTS	0.309259244996	BRD-A14395271-074-17-8::2.5::HTS	BRD-A14395271-074-17-8	mesoridazine	2.5	HTS	dopamine receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O	Launched	5
BRD-A14574269-051-02-2::2.5::HTS	0.256320464027	BRD-A14574269-051-02-2::2.5::HTS	BRD-A14574269-051-02-2	UB-165	2.5	HTS	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNB2			Clc1ccc(cn1)C1=CCCC2CCC1N2, Clc1ccc(cn1)C1=CCCC2CCC1N2	Preclinical	5
BRD-A14886633-001-01-6::2.5::HTS	0.158122847995	BRD-A14886633-001-01-6::2.5::HTS	BRD-A14886633-001-01-6	norgestrel	2.5	HTS	progesterone receptor agonist	PGR	endocrinology	contraceptive	CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Launched	5
BRD-A14941520-051-01-0::2.5::HTS	-0.0632873351814	BRD-A14941520-051-01-0::2.5::HTS	BRD-A14941520-051-01-0	dofequidar	2.5	HTS	MRP inhibitor, P glycoprotein inhibitor	ABCB1			OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1	Phase 3	5
BRD-A14966924-003-07-7::2.5::HTS	0.428869480429	BRD-A14966924-003-07-7::2.5::HTS	BRD-A14966924-003-07-7	alaproclate	2.5	HTS	serotonin receptor antagonist	SLC6A4			CC(N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1	Phase 2	5
BRD-A15035311-001-01-8::2.5::HTS	0.0654781822232	BRD-A15035311-001-01-8::2.5::HTS	BRD-A15035311-001-01-8	diadenosine-tetraphosphate	2.5	HTS	adenosine kinase inhibitor	P2RY13, P2RY2			Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C(O)C2O)n2cnc3c(N)ncnc23)C(O)C1O	Phase 1	5
BRD-A15202882-003-02-7::2.5::HTS	-0.217084021367	BRD-A15202882-003-02-7::2.5::HTS	BRD-A15202882-003-02-7	milnacipran	2.5	HTS	serotonin-norepinephrine reuptake inhibitor (SNRI)	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A4	rheumatology	fibromyalgia	CCN(CC)C(=O)C1(CC1CN)c1ccccc1, CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)c1ccccc1	Launched	5
BRD-A15297126-001-04-3::2.5::HTS	-0.265532255041	BRD-A15297126-001-04-3::2.5::HTS	BRD-A15297126-001-04-3	fluocinolone-acetonide	2.5	HTS	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Launched	5
BRD-A15397381-001-02-5::2.5::HTS	-0.480538440315	BRD-A15397381-001-02-5::2.5::HTS	BRD-A15397381-001-02-5	L-Cystine	2.5	HTS		CTNS, SLC3A1, SLC7A11, SLC7A9			NC(CSSCC(N)C(O)=O)C(O)=O, NC(CSSCC(N)C(O)=O)C(O)=O, N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O	Launched	5
BRD-A15415227-003-02-9::2.5::HTS	0.264540214776	BRD-A15415227-003-02-9::2.5::HTS	BRD-A15415227-003-02-9	GW-1929	2.5	HTS	PPAR receptor agonist	PPARG			CN(CCOc1ccc(CC(Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1	Preclinical	5
BRD-A15435692-003-02-3::2.5::HTS	0.301068946482	BRD-A15435692-003-02-3::2.5::HTS	BRD-A15435692-003-02-3	BMY-14802	2.5	HTS	sigma receptor antagonist	HTR1A			OC(CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1	Phase 2	5
BRD-A15530910-001-02-1::2.5::HTS	0.149966645174	BRD-A15530910-001-02-1::2.5::HTS	BRD-A15530910-001-02-1	SDZ-21009	2.5	HTS	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A, HTR1B			CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1	Preclinical	5
BRD-A15909516-001-06-6::2.5::HTS	-0.160682556851	BRD-A15909516-001-06-6::2.5::HTS	BRD-A15909516-001-06-6	rebamipide	2.5	HTS	free radical scavenger	FPR1	gastroenterology	peptic ulcer disease (PUD), gastritis	OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1, OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	Launched	5
BRD-A15931911-001-03-8::2.5::HTS	-0.14361810750700002	BRD-A15931911-001-03-8::2.5::HTS	BRD-A15931911-001-03-8	bucladesine	2.5	HTS	adenosine receptor agonist, cAMP stimulant	PRKACA	dermatology	skin ulcer	CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC	Launched	5
BRD-A16296925-001-01-3::2.5::HTS	0.11463780081700001	BRD-A16296925-001-01-3::2.5::HTS	BRD-A16296925-001-01-3	indobufen	2.5	HTS	cyclooxygenase inhibitor, platelet aggregation inhibitor	PTGS1, PTGS2	hematology	thrombosis	CCC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O	Launched	5
BRD-A16347691-001-13-1::2.5::HTS	-0.32051582858399996	BRD-A16347691-001-13-1::2.5::HTS	BRD-A16347691-001-13-1	thioctic-acid	2.5	HTS	reducing agent	ACHE, LIAS, LIPT1, PTGS2, SLC5A6			OC(=O)CCCCC1CCSS1	Launched	5
BRD-A16350940-001-01-9::2.5::HTS	-0.353970325792	BRD-A16350940-001-01-9::2.5::HTS	BRD-A16350940-001-01-9	doramectin	2.5	HTS			infectious disease	gastrointestinal roundworms	CO[C@H]1C[C@H](OC2[C@H](C)OC(C[C@@H]2OC)O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(C5)O[C@H](C5CCCCC5)[C@@H](C)C=C2)[C@]34O)O[C@@H](C)[C@@H]1O	Launched	5
BRD-A16439188-001-01-1::2.5::HTS	-0.0064391328957499995	BRD-A16439188-001-01-1::2.5::HTS	BRD-A16439188-001-01-1	quinestrol	2.5	HTS	estrogen receptor agonist	ESR1	endocrinology	menopause	C[C@]12CCC3C(CCc4cc(OC5CCCC5)ccc34)C1CC[C@@]2(O)C#C	Launched	5
BRD-A16665823-001-02-0::2.5::HTS	-0.0596835982572	BRD-A16665823-001-02-0::2.5::HTS	BRD-A16665823-001-02-0	butoconazole	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1, Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1	Launched	5
BRD-A16694057-001-06-8::2.5::HTS	-0.126855929334	BRD-A16694057-001-06-8::2.5::HTS	BRD-A16694057-001-06-8	BADGE	2.5	HTS	PPAR receptor antagonist	PPARG			CC(C)(c1ccc(OCC2CO2)cc1)c1ccc(OCC2CO2)cc1	Preclinical	5
BRD-A16700644-003-04-4::2.5::HTS	0.000783164613946	BRD-A16700644-003-04-4::2.5::HTS	BRD-A16700644-003-04-4	isoxsuprine	2.5	HTS	adrenergic receptor agonist	ADRB2	rheumatology, cardiology	Raynaud's disease, arteriosclerosis, Buerger's disease	CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1	Launched	5
BRD-A16997652-001-02-3::2.5::HTS	-0.28355779585700003	BRD-A16997652-001-02-3::2.5::HTS	BRD-A16997652-001-02-3	protirelin	2.5	HTS	thyrotropin releasing hormone receptor agonist	TRHR	radiology	thyroid function diagnostic	NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1	Launched	5
BRD-A17300716-001-01-5::2.5::HTS	-0.0640832042312	BRD-A17300716-001-01-5::2.5::HTS	BRD-A17300716-001-01-5	dehydroacetic-acid	2.5	HTS					CC(=O)C1C(=O)OC(C)=CC1=O	Preclinical	5
BRD-A17407635-001-04-0::2.5::HTS	0.184602070014	BRD-A17407635-001-04-0::2.5::HTS	BRD-A17407635-001-04-0	alclometasone-dipropionate	2.5	HTS	glucocorticoid receptor agonist	CYP3A4, NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	CCC(=O)OCC(=O)C1(OC(=O)CC)[C@H](C)C[C@H]2C3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Launched	5
BRD-A17411484-001-11-9::2.5::HTS	-0.09670399168369999	BRD-A17411484-001-11-9::2.5::HTS	BRD-A17411484-001-11-9	carprofen	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis	CC(C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21, CC(C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21	Launched	5
BRD-A17428743-003-09-0::2.5::HTS	0.40013505610399996	BRD-A17428743-003-09-0::2.5::HTS	BRD-A17428743-003-09-0	BW-723C86	2.5	HTS	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12, CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12	Preclinical	5
BRD-A17453586-003-02-3::2.5::HTS	-0.649709814792	BRD-A17453586-003-02-3::2.5::HTS	BRD-A17453586-003-02-3	MDL-72832	2.5	HTS	serotonin receptor agonist	HTR1A			O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1	Preclinical	5
BRD-A17462676-003-11-6::2.5::HTS	-0.750128069592	BRD-A17462676-003-11-6::2.5::HTS	BRD-A17462676-003-11-6	bambuterol	2.5	HTS	adrenergic receptor agonist	ADRB2, BCHE	pulmonary	asthma	CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C	Launched	5
BRD-A17655518-001-24-4::2.5::HTS	-0.340086263724	BRD-A17655518-001-24-4::2.5::HTS	BRD-A17655518-001-24-4	ibuprofen	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental	headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache	CC(C)Cc1ccc(cc1)C(C)C(O)=O, CC(C)Cc1ccc(cc1)C(C)C(O)=O	Launched	5
BRD-A17846016-001-13-9::2.5::HTS	-1.3840919003799999	BRD-A17846016-001-13-9::2.5::HTS	BRD-A17846016-001-13-9	trolox	2.5	HTS	antioxidant				Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O	Launched	5
BRD-A17883755-001-06-1::2.5::HTS	0.042357377468300005	BRD-A17883755-001-06-1::2.5::HTS	BRD-A17883755-001-06-1	lenalidomide	2.5	HTS	anticancer agent	CDH5, CRBN, PTGS2, TNF, TNFSF11	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O	Launched	5
BRD-A18043272-001-09-9::2.5::HTS	-0.133117867614	BRD-A18043272-001-09-9::2.5::HTS	BRD-A18043272-001-09-9	phensuximide	2.5	HTS	succinimide antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	CN1C(=O)CC(C1=O)c1ccccc1	Launched	5
BRD-A18056626-003-22-3::2.5::HTS	0.00259516983719	BRD-A18056626-003-22-3::2.5::HTS	BRD-A18056626-003-22-3	methacholine	2.5	HTS	acetylcholine receptor agonist	CHRM2, CHRM3, CHRM4	pulmonary	bronchial hyperresponsiveness diagnostic	CC(C[N+](C)(C)C)OC(C)=O	Launched	5
BRD-A18074780-003-02-0::2.5::HTS	0.138001808572	BRD-A18074780-003-02-0::2.5::HTS	BRD-A18074780-003-02-0	AGN-192403	2.5	HTS	imidazoline receptor ligand	NISCH			CC(C)[C@@H]1C2CCC(C2)[C@H]1N, CC(C)[C@@H]1C2CCC(C2)[C@H]1N	Preclinical	5
BRD-A18233884-003-02-7::2.5::HTS	0.244436883004	BRD-A18233884-003-02-7::2.5::HTS	BRD-A18233884-003-02-7	bevantolol	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRB1, ADRB2	cardiology	angina pectoris, hypertension	COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC	Launched	5
BRD-A18396475-001-15-3::2.56::HTS	-0.423532498838	BRD-A18396475-001-15-3::2.56::HTS	BRD-A18396475-001-15-3	malic-acid	2.56	HTS		CS, ME2, PKD2L1			OC(CC(O)=O)C(O)=O, OC(CC(O)=O)C(O)=O	Launched	5
BRD-A18611368-001-01-5::2.5::HTS	-0.19779455842799998	BRD-A18611368-001-01-5::2.5::HTS	BRD-A18611368-001-01-5	tazobactam	2.5	HTS	beta lactamase inhibitor		infectious disease	pneumonia	C[C@]1(Cn2ccnn2)C(N2C(CC2=O)S1(=O)=O)C(O)=O	Launched	5
BRD-A18627414-001-04-9::2.5::HTS	-0.263979383834	BRD-A18627414-001-04-9::2.5::HTS	BRD-A18627414-001-04-9	cyanocobalamin	2.5	HTS	methylmalonyl CoA mutase stimulant, vitamin B	MMAA, MMACHC, MTHFR, MTR, MTRR, MUT	hematology, infectious disease, gastroenterology	anemia, fish tapeworm infestation, celiac disease	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12	Launched	5
BRD-A18696154-003-22-6::2.5::HTS	0.36073561130099996	BRD-A18696154-003-22-6::2.5::HTS	BRD-A18696154-003-22-6	idazoxan	2.5	HTS	adrenergic receptor antagonist	ADRA2A			C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1	Phase 3	5
BRD-A18763547-300-05-5::2.5::HTS	0.49044117416500005	BRD-A18763547-300-05-5::2.5::HTS	BRD-A18763547-300-05-5	BAX-channel-blocker	2.5	HTS	cytochrome C release inhibitor	BAX			OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12, OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12	Preclinical	5
BRD-A18795974-004-07-3::2.5::HTS	-0.246791582324	BRD-A18795974-004-07-3::2.5::HTS	BRD-A18795974-004-07-3	7-hydroxy-DPAT	2.5	HTS	dopamine receptor agonist	DRD2, DRD3			CCCN(CCC)C1CCc2ccc(O)cc2C1, CCCN(CCC)C1CCc2ccc(O)cc2C1, CCCN(CCC)C1CCc2ccc(O)cc2C1	Preclinical	5
BRD-A19102171-066-01-4::2.5::HTS	0.24987705181699998	BRD-A19102171-066-01-4::2.5::HTS	BRD-A19102171-066-01-4	naltriben	2.5	HTS	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O	Preclinical	5
BRD-A19195498-050-14-1::2.5::HTS	-0.304899990293	BRD-A19195498-050-14-1::2.5::HTS	BRD-A19195498-050-14-1	trimipramine	2.5	HTS	norepinephrine reputake inhibitor, tricyclic antidepressant	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR3A, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	CC(CN(C)C)CN1c2ccccc2CCc2ccccc12, CC(CN(C)C)CN1c2ccccc2CCc2ccccc12	Launched	5
BRD-A19585813-003-03-3::2.5::HTS	-0.760747443268	BRD-A19585813-003-03-3::2.5::HTS	BRD-A19585813-003-03-3	methylphenidate	2.5	HTS	dopamine-norepinephrine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD), narcolepsy	COC(=O)C(C1CCCCN1)c1ccccc1	Launched	5
BRD-A19633847-050-32-1::2.5::HTS	-0.041369410121	BRD-A19633847-050-32-1::2.5::HTS	BRD-A19633847-050-32-1	perhexiline	2.5	HTS	carnitine palmitoyltransferase inhibitor	CPT1A, CPT2	cardiology	angina pectoris	C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1	Launched	5
BRD-A19661776-003-27-6::2.5::HTS	-0.0780790636784	BRD-A19661776-003-27-6::2.5::HTS	BRD-A19661776-003-27-6	mianserin	2.5	HTS	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7, OPRK1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21	Launched	5
BRD-A19736161-001-06-7::2.5::HTS	-0.29640537078400003	BRD-A19736161-001-06-7::2.5::HTS	BRD-A19736161-001-06-7	ondansetron	2.5	HTS	serotonin receptor antagonist	HTR1A, HTR1B, HTR3A, HTR3B, HTR4, OPRM1	gastroenterology	nausea, vomiting	Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C, Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C, Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C	Launched	5
BRD-A19795905-001-08-0::2.5::HTS	0.353352201023	BRD-A19795905-001-08-0::2.5::HTS	BRD-A19795905-001-08-0	atovaquone	2.5	HTS	mitochondrial electron transport inhibitor	DHODH	infectious disease	pneumonia	Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)C1C(=O)C(=O)c2ccccc2C1=O, Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)C1C(=O)C(=O)c2ccccc2C1=O	Launched	5
BRD-A19952358-001-11-3::2.5::HTS	-0.053169019967	BRD-A19952358-001-11-3::2.5::HTS	BRD-A19952358-001-11-3	closantel	2.5	HTS	chitinase inhibitor, NFkB pathway inhibitor		infectious disease	liver flukes	Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O, Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O, Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O, Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O	Launched	5
BRD-A19958636-065-04-4::2.5::HTS	0.391690009529	BRD-A19958636-065-04-4::2.5::HTS	BRD-A19958636-065-04-4	tuaminoheptane	2.5	HTS			otolaryngology	nasal congestion	CCCCCC(C)N	Launched	5
BRD-A20119038-003-07-8::2.5::HTS	0.436106835211	BRD-A20119038-003-07-8::2.5::HTS	BRD-A20119038-003-07-8	mecamylamine	2.5	HTS	acetylcholine receptor antagonist	CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7	cardiology	hypertension	CNC1(C)C2CCC(C2)C1(C)C	Launched	5
BRD-A20239487-001-24-9::2.5::HTS	-0.257295178907	BRD-A20239487-001-24-9::2.5::HTS	BRD-A20239487-001-24-9	atenolol-(+/-)	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1	Launched	5
BRD-A20348246-001-15-8::2.5::HTS	0.158929898032	BRD-A20348246-001-15-8::2.5::HTS	BRD-A20348246-001-15-8	chlormezanone	2.5	HTS	GABA receptor modulator	GABRA1, TSPO			CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O, CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O, CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O	Withdrawn	5
BRD-A20550616-001-02-9::2.5::HTS	0.0377572362492	BRD-A20550616-001-02-9::2.5::HTS	BRD-A20550616-001-02-9	halothane	2.5	HTS	glutamate receptor antagonist	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GNG2, GRIN2A, GRIN3A, GRIN3B, KCNJ3, KCNJ6, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9, KCNMA1, KCNN4, MT-ND1, NPSR1, RHO	neurology/psychiatry	general anaesthetic	FC(F)(F)C(Cl)Br, FC(F)(F)C(Cl)Br	Launched	5
BRD-A20644369-001-08-6::2.5::HTS	0.947760110647	BRD-A20644369-001-08-6::2.5::HTS	BRD-A20644369-001-08-6	canrenone	2.5	HTS	mineralocorticoid receptor antagonist	NR3C2			C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1	Withdrawn	5
BRD-A20758144-001-04-5::2.5::HTS	0.24535493915999998	BRD-A20758144-001-04-5::2.5::HTS	BRD-A20758144-001-04-5	prasterone-acetate	2.5	HTS					CC(=O)O[C@H]1CC[C@]2(C)C3CC[C@@]4(C)C(CCC4=O)C3CC=C2C1	Preclinical	5
BRD-A20781140-001-01-7::2.5::HTS	-0.0733584364156	BRD-A20781140-001-01-7::2.5::HTS	BRD-A20781140-001-01-7	plovamer-acetate	2.5	HTS		TAT, TH, YARS, YARS2			NC(Cc1ccc(O)cc1)C(O)=O, NC(Cc1ccc(O)cc1)C(O)=O	Phase 2	5
BRD-A20839672-003-01-5::2.5::HTS	-0.00491948825321	BRD-A20839672-003-01-5::2.5::HTS	BRD-A20839672-003-01-5	cefmenoxime	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	CO\N=C(\C(=O)NC1C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	5
BRD-A21276153-001-01-1::2.5::HTS	-0.161973469876	BRD-A21276153-001-01-1::2.5::HTS	BRD-A21276153-001-01-1	2,6-dimethylpiperidine	2.5	HTS					CC1CCCC(C)N1	Preclinical	5
BRD-A21607826-003-05-1::2.5::HTS	0.567751484088	BRD-A21607826-003-05-1::2.5::HTS	BRD-A21607826-003-05-1	medetomidine	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	CC(c1c[nH]cn1)c1cccc(C)c1C, CC(c1c[nH]cn1)c1cccc(C)c1C, CC(c1c[nH]cn1)c1cccc(C)c1C	Launched	5
BRD-A21858158-001-23-5::2.5::HTS	0.39642778892999997	BRD-A21858158-001-23-5::2.5::HTS	BRD-A21858158-001-23-5	praziquantel	2.5	HTS	anthelmintic agent		infectious disease	gastrointestinal parasites, cystic hydatid disease, schistosomiasis	O=C(C1CCCCC1)N1CC2N(CCc3ccccc23)C(=O)C1, O=C(C1CCCCC1)N1CC2N(CCc3ccccc23)C(=O)C1	Launched	5
BRD-A22032524-074-06-5::2.5::HTS	-0.082310696644	BRD-A22032524-074-06-5::2.5::HTS	BRD-A22032524-074-06-5	amlodipine	2.5	HTS	calcium channel blocker	CA1, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1, CACNA2D3, CACNB1, CACNB2, SMPD1	cardiology	hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)	CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC	Launched	5
BRD-A22081593-001-11-1::2.5::HTS	-0.44698060046599997	BRD-A22081593-001-11-1::2.5::HTS	BRD-A22081593-001-11-1	sulmazole	2.5	HTS	adenosine receptor antagonist				COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O	Phase 1	5
BRD-A22106989-001-05-0::2.5::HTS	0.0261979063165	BRD-A22106989-001-05-0::2.5::HTS	BRD-A22106989-001-05-0	phenothrin	2.5	HTS			infectious disease	lice	CC(C)=CC1C(C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C, CC(C)=CC1C(C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C	Launched	5
BRD-A22143024-231-03-8::2.5::HTS	0.224782416593	BRD-A22143024-231-03-8::2.5::HTS	BRD-A22143024-231-03-8	estropipate	2.5	HTS	estrogen receptor agonist	ESR1, ESR2	orthopedics, endocrinology, obstetrics/gynecology	osteoporosis, menopause, vaginal atrophy, hypoestrogenism	C[C@]12CCC3C(CCc4cc(OS(O)(=O)=O)ccc34)C1CCC2=O	Launched	5
BRD-A22152765-003-10-0::2.5::HTS	0.125891396853	BRD-A22152765-003-10-0::2.5::HTS	BRD-A22152765-003-10-0	tridihexethyl	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology, ophthalmology	peptic ulcer disease (PUD), nystagmus	CC[N+](CC)(CC)CCC(O)(C1CCCCC1)c1ccccc1	Launched	5
BRD-A22256192-003-22-7::2.5::HTS	-0.532838785537	BRD-A22256192-003-22-7::2.5::HTS	BRD-A22256192-003-22-7	terazosin	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, KCNH2, KCNH6, KCNH7	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1	Launched	5
BRD-A22267103-003-13-1::2.5::HTS	0.35803319851599996	BRD-A22267103-003-13-1::2.5::HTS	BRD-A22267103-003-13-1	drofenine	2.5	HTS			neurology/psychiatry	spasms	CCN(CC)CCOC(=O)C(C1CCCCC1)c1ccccc1	Launched	5
BRD-A22305049-003-13-6::2.5::HTS	0.17048541329599998	BRD-A22305049-003-13-6::2.5::HTS	BRD-A22305049-003-13-6	benfluorex	2.5	HTS	gluconeogenesis inhibitor	HMGCR			CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1	Withdrawn	5
BRD-A22380646-236-05-8::2.51::HTS	0.109080360207	BRD-A22380646-236-05-8::2.51::HTS	BRD-A22380646-236-05-8	pantoprazole	2.51	HTS	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome	COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC, COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC, COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC	Launched	5
BRD-A22642447-001-01-9::2.5::HTS	0.545516601214	BRD-A22642447-001-01-9::2.5::HTS	BRD-A22642447-001-01-9	licarbazepine	2.5	HTS	voltage-gated sodium channel blocker	SCN5A			NC(=O)N1c2ccccc2CC(O)c2ccccc12, NC(=O)N1c2ccccc2CC(O)c2ccccc12	Phase 3	5
BRD-A22707317-001-10-8::2.5::HTS	0.36399439495499997	BRD-A22707317-001-10-8::2.5::HTS	BRD-A22707317-001-10-8	SB-205384	2.5	HTS	GABA receptor modulator	GABRA3, GABRA5, GABRA6			CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N	Preclinical	5
BRD-A22769835-300-05-7::2.5::HTS	0.0790205626405	BRD-A22769835-300-05-7::2.5::HTS	BRD-A22769835-300-05-7	homochlorcyclizine	2.5	HTS	antihistamine	HRH1	allergy	allergic rhinitis	CN1CCCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1	Launched	5
BRD-A22844106-001-26-0::2.5::HTS	-0.189642865664	BRD-A22844106-001-26-0::2.5::HTS	BRD-A22844106-001-26-0	tenoxicam	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, orthopedics	rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis	CN1C(C(=O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O	Launched	5
BRD-A23067620-300-01-3::2.5::HTS	0.555480651083	BRD-A23067620-300-01-3::2.5::HTS	BRD-A23067620-300-01-3	itraconazole	2.5	HTS	cytochrome P450 inhibitor	CYP51A1	infectious disease	onychomycosis, histoplasmosis, blastomycosis, aspergillosis	CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O	Launched	5
BRD-A23072235-050-18-5::2.5::HTS	-0.159248193946	BRD-A23072235-050-18-5::2.5::HTS	BRD-A23072235-050-18-5	pheniramine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1	Launched	5
BRD-A23127772-001-02-3::2.5::HTS	-0.028213887157700002	BRD-A23127772-001-02-3::2.5::HTS	BRD-A23127772-001-02-3	sclareol	2.5	HTS					CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C	Preclinical	5
BRD-A23359898-003-10-0::2.5::HTS	0.215570824799	BRD-A23359898-003-10-0::2.5::HTS	BRD-A23359898-003-10-0	sibutramine	2.5	HTS	serotonin-norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A3, SLC6A4			CC(C)CC(N(C)C)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N(C)C)C1(CCC1)c1ccc(Cl)cc1	Withdrawn	5
BRD-A23603052-001-03-2::2.5::HTS	0.0558794332079	BRD-A23603052-001-03-2::2.5::HTS	BRD-A23603052-001-03-2	rifampin	2.5	HTS	RNA polymerase inhibitor	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C	Launched	5
BRD-A24122750-001-03-7::2.5::HTS	0.0768244899338	BRD-A24122750-001-03-7::2.5::HTS	BRD-A24122750-001-03-7	saclofen	2.5	HTS	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			NCC(CS(O)(=O)=O)c1ccc(Cl)cc1	Preclinical	5
BRD-A24191444-046-02-1::2.5::HTS	0.355184507961	BRD-A24191444-046-02-1::2.5::HTS	BRD-A24191444-046-02-1	ifenprodil	2.5	HTS	adrenergic receptor antagonist, glutamate receptor antagonist	GRIN1, GRIN2B			CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1	Launched	5
BRD-A24191444-046-03-9::2.4::HTS	0.194955214799	BRD-A24191444-046-03-9::2.4::HTS	BRD-A24191444-046-03-9	ifenprodil	2.4	HTS	adrenergic receptor antagonist, glutamate receptor antagonist	GRIN1, GRIN2B			CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1	Launched	5
BRD-A24228527-213-01-9::2.5::HTS	0.7926090689920001	BRD-A24228527-213-01-9::2.5::HTS	BRD-A24228527-213-01-9	ofloxacin	2.5	HTS	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, otolaryngology, gastroenterology, endocrinology	respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections	CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	Launched	5
BRD-A24284985-001-09-9::2.5::HTS	-0.378060714809	BRD-A24284985-001-09-9::2.5::HTS	BRD-A24284985-001-09-9	anabasine	2.5	HTS	acetylcholine receptor agonist				C1CCC(NC1)c1cccnc1	Preclinical	5
BRD-A24297246-001-03-9::2.5::HTS	-0.283125482509	BRD-A24297246-001-03-9::2.5::HTS	BRD-A24297246-001-03-9	troleandomycin	2.5	HTS	protein synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, tonsillitis, sinusitis	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](OC3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	Launched	5
BRD-A24397426-001-10-4::2.5::HTS	0.629128715954	BRD-A24397426-001-10-4::2.5::HTS	BRD-A24397426-001-10-4	nadifloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	Launched	5
BRD-A24514565-001-09-7::2.5::HTS	0.717356080178	BRD-A24514565-001-09-7::2.5::HTS	BRD-A24514565-001-09-7	warfarin	2.5	HTS	vitamin K antagonist	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O	Launched	5
BRD-A24543851-001-05-7::2.5::HTS	-0.19612977698399997	BRD-A24543851-001-05-7::2.5::HTS	BRD-A24543851-001-05-7	nornicotine	2.5	HTS	acetylcholine receptor agonist				C1CNC(C1)c1cccnc1	Preclinical	5
BRD-A24560335-300-01-2::2.5::HTS	0.226646503497	BRD-A24560335-300-01-2::2.5::HTS	BRD-A24560335-300-01-2	efatutazone	2.5	HTS	PPAR receptor agonist	PPARG			Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N	Phase 2	5
BRD-A24587114-066-22-5::2.5::HTS	0.347286591905	BRD-A24587114-066-22-5::2.5::HTS	BRD-A24587114-066-22-5	isoetharine	2.5	HTS	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	bronchospasm, asthma	CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1	Launched	5
BRD-A25004090-001-08-4::2.5::HTS	1.13040748642	BRD-A25004090-001-08-4::2.5::HTS	BRD-A25004090-001-08-4	erastin	2.5	HTS	ion channel antagonist	VDAC2			CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1	Preclinical	5
BRD-A25143711-001-02-2::2.5::HTS	0.261608898862	BRD-A25143711-001-02-2::2.5::HTS	BRD-A25143711-001-02-2	hydrocortisone-valerate	2.5	HTS	glucocorticoid receptor agonist		dermatology	corticosteroid-responsive dermatoses	CCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)CO	Launched	5
BRD-A25234499-001-18-3::2.5::HTS	-0.334272269763	BRD-A25234499-001-18-3::2.5::HTS	BRD-A25234499-001-18-3	aminoglutethimide	2.5	HTS	glucocorticoid receptor antagonist	CYP11A1, CYP19A1	endocrinology, oncology	Cushing's syndrome, breast cancer	CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1	Launched	5
BRD-A25569250-001-03-3::2.5::HTS	-0.200512473452	BRD-A25569250-001-03-3::2.5::HTS	BRD-A25569250-001-03-3	KI-16425	2.5	HTS	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl	Preclinical	5
BRD-A25608658-001-01-1::2.5::HTS	-0.582689706328	BRD-A25608658-001-01-1::2.5::HTS	BRD-A25608658-001-01-1	narasin	2.5	HTS	antiprotozoal agent		infectious disease	coccidiosis	CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O	Launched	5
BRD-A25619068-003-03-4::2.5::HTS	0.08538857116250001	BRD-A25619068-003-03-4::2.5::HTS	BRD-A25619068-003-03-4	fadrozole	2.5	HTS	aromatase inhibitor	CYP11B1, CYP19A1	oncology	breast cancer	N#Cc1ccc(cc1)C1CCCc2cncn12	Launched	5
BRD-A25687296-300-04-3::2.5::HTS	-0.37694345288500003	BRD-A25687296-300-04-3::2.5::HTS	BRD-A25687296-300-04-3	emetine	2.5	HTS	protein synthesis inhibitor	RPS2			CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12	Phase 2	5
BRD-A25800195-001-02-2::2.5::HTS	-0.701385298136	BRD-A25800195-001-02-2::2.5::HTS	BRD-A25800195-001-02-2	L-Cysteinesulfinic-acid	2.5	HTS	glutamate receptor agonist	GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2			N[C@@H](CS(O)=O)C(O)=O	Preclinical	5
BRD-A26032986-050-02-1::2.5::HTS	-0.05416123908	BRD-A26032986-050-02-1::2.5::HTS	BRD-A26032986-050-02-1	zaldaride	2.5	HTS	calmodulin antagonist	CALM1			CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12	Phase 3	5
BRD-A26334849-001-06-2::2.5::HTS	0.048417396791199996	BRD-A26334849-001-06-2::2.5::HTS	BRD-A26334849-001-06-2	propafenone	2.5	HTS	antiarrhythmic	ADRB1, ADRB2, KCNA5, KCNH2, SCN5A	cardiology	atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias	CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1, CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1	Launched	5
BRD-A26384407-001-25-1::2.5::HTS	-0.359990098617	BRD-A26384407-001-25-1::2.5::HTS	BRD-A26384407-001-25-1	chlorthalidone	2.5	HTS	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA4, CA7, SLC12A1, SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure	NS(=O)(=O)c1cc(ccc1Cl)C1(O)NC(=O)c2ccccc12	Launched	5
BRD-A26387268-050-04-4::2.5::HTS	0.498010311798	BRD-A26387268-050-04-4::2.5::HTS	BRD-A26387268-050-04-4	ergonovine	2.5	HTS	adrenergic receptor agonist, serotonin receptor agonist	ADRA1A, HTR1E	hematology	postpartum hemorrhage (PPH)	CC(CO)NC(=O)C1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34	Launched	5
BRD-A26503646-001-16-6::2.5::HTS	-0.0870706324457	BRD-A26503646-001-16-6::2.5::HTS	BRD-A26503646-001-16-6	formestane	2.5	HTS	aromatase inhibitor	CYP19A1	oncology	breast cancer	C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O	Launched	5
BRD-A26690767-066-01-9::2.5::HTS	-0.203945641921	BRD-A26690767-066-01-9::2.5::HTS	BRD-A26690767-066-01-9	saquinavir	2.5	HTS	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1CC2CCCCC2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	Launched	5
BRD-A26711594-003-10-6::2.5::HTS	0.036528601833300006	BRD-A26711594-003-10-6::2.5::HTS	BRD-A26711594-003-10-6	nicardipine	2.5	HTS	calcium channel blocker	ADORA3, ADRA1A, ADRA1B, ADRA1D, CACNA1C, CACNA1D, CACNA2D1, CACNB2, CALM1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, PDE1A, PDE1B	cardiology	chronic stable angina, hypertension	COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1	Launched	5
BRD-A26845397-051-01-9::2.5::HTS	-0.271819404677	BRD-A26845397-051-01-9::2.5::HTS	BRD-A26845397-051-01-9	isamoltane	2.5	HTS	adrenergic receptor antagonist	HTR1A, HTR1B			CC(C)NCC(O)COc1ccccc1-n1cccc1	Phase 1	5
BRD-A27143604-001-02-0::2.5::HTS	0.0679328747954	BRD-A27143604-001-02-0::2.5::HTS	BRD-A27143604-001-02-0	diarylpropionitrile	2.5	HTS	estrogen receptor agonist	ESR2			Oc1ccc(CC(C#N)c2ccc(O)cc2)cc1	Preclinical	5
BRD-A27290375-330-01-1::2.5::HTS	-0.0368586040029	BRD-A27290375-330-01-1::2.5::HTS	BRD-A27290375-330-01-1	atropine	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology	cycloplegia, mydriasis, amblyopia	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1	Launched	5
BRD-A27370296-001-03-0::2.5::HTS	0.414610599891	BRD-A27370296-001-03-0::2.5::HTS	BRD-A27370296-001-03-0	cyclandelate	2.5	HTS	calcium channel blocker	CACNA2D1, CES1	cardiology, rheumatology	claudication, arteriosclerosis, Raynaud's disease	CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1, CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1, CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1	Launched	5
BRD-A27376179-001-01-3::2.5::HTS	-1.54213322714	BRD-A27376179-001-01-3::2.5::HTS	BRD-A27376179-001-01-3	lestaurtinib	2.5	HTS	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	FLT3, NTRK1			C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13	Phase 3	5
BRD-A27732521-003-08-3::2.5::HTS	-0.208440679148	BRD-A27732521-003-08-3::2.5::HTS	BRD-A27732521-003-08-3	tolperisone	2.5	HTS	voltage-gated sodium channel blocker	CYP2C19, CYP2D6	neurology/psychiatry, infectious disease, rheumatology, cardiology	muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease	CC(CN1CCCCC1)C(=O)c1ccc(C)cc1, CC(CN1CCCCC1)C(=O)c1ccc(C)cc1	Launched	5
BRD-A27883417-300-01-6::2.5::HTS	-1.8835157653599999	BRD-A27883417-300-01-6::2.5::HTS	BRD-A27883417-300-01-6	alexidine	2.5	HTS	phosphatidylglycerophosphatase inhibitor	PTPMT1			CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC	Preclinical	5
BRD-A27887842-001-04-0::2.5::HTS	0.03468644441469999	BRD-A27887842-001-04-0::2.5::HTS	BRD-A27887842-001-04-0	prednisolone	2.5	HTS	glucocorticoid receptor agonist	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO	Launched	5
BRD-A27924917-001-03-3::2.5::HTS	0.108049641482	BRD-A27924917-001-03-3::2.5::HTS	BRD-A27924917-001-03-3	2-hydroxysaclofen	2.5	HTS	GABA receptor antagonist	GABBR1, GABBR2			NCC(O)(CS(O)(=O)=O)c1ccc(Cl)cc1	Preclinical	5
BRD-A28044053-001-01-7::2.5::HTS	0.0708387994557	BRD-A28044053-001-01-7::2.5::HTS	BRD-A28044053-001-01-7	arotinolol	2.5	HTS	adrenergic receptor antagonist	ADRB3	cardiology, neurology/psychiatry	hypertension, tremors	CC(C)(C)NCC(O)CSc1nc(cs1)-c1ccc(s1)C(N)=O	Launched	5
BRD-A28301258-001-03-0::2.5::HTS	-1.25060219172	BRD-A28301258-001-03-0::2.5::HTS	BRD-A28301258-001-03-0	salinomycin	2.5	HTS			infectious disease	coccidiosis	CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O	Launched	5
BRD-A28301258-001-04-8::2.5::HTS	-0.546556877802	BRD-A28301258-001-04-8::2.5::HTS	BRD-A28301258-001-04-8	salinomycin	2.5	HTS			infectious disease	coccidiosis	CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O	Launched	5
BRD-A28318179-003-08-5::2.5::HTS	-0.400534671654	BRD-A28318179-003-08-5::2.5::HTS	BRD-A28318179-003-08-5	aminomethyltransferase	2.5	HTS	nitric oxide synthase inhibitor	NOS2			CC1CCN=C(N)S1	Preclinical	5
BRD-A28329383-001-02-1::2.5::HTS	-0.329914178707	BRD-A28329383-001-02-1::2.5::HTS	BRD-A28329383-001-02-1	MTPG	2.5	HTS	glutamate receptor antagonist	GRM2, GRM3			CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1	Preclinical	5
BRD-A28467416-002-01-0::2.5::HTS	-4.31111469983	BRD-A28467416-002-01-0::2.5::HTS	BRD-A28467416-002-01-0	PKI-179	2.5	HTS	mTOR inhibitor, PI3K inhibitor	MTOR			O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2	Phase 1	5
BRD-A28545468-003-16-6::2.5::HTS	-0.18006319864999998	BRD-A28545468-003-16-6::2.5::HTS	BRD-A28545468-003-16-6	selegiline	2.5	HTS	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	Parkinson's Disease	CC(Cc1ccccc1)N(C)CC#C	Launched	5
BRD-A28856712-003-26-0::2.5::HTS	0.451842353917	BRD-A28856712-003-26-0::2.5::HTS	BRD-A28856712-003-26-0	tetrahydrozoline	2.5	HTS	adrenergic receptor agonist		ophthalmology	eye irritation	C1CN=C(N1)C1CCCc2ccccc12, C1CN=C(N1)C1CCCc2ccccc12	Launched	5
BRD-A28887267-001-19-3::2.5::HTS	0.670886957539	BRD-A28887267-001-19-3::2.5::HTS	BRD-A28887267-001-19-3	proxyphylline	2.5	HTS			pulmonary	asthma	CC(O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	Launched	5
BRD-A28940325-001-24-0::2.5::HTS	0.00767251721046	BRD-A28940325-001-24-0::2.5::HTS	BRD-A28940325-001-24-0	trichlormethiazide	2.5	HTS	chloride channel blocker	ATP1A1, CA1, CA2, CA4, SLC12A1, SLC12A3	cardiology	hypertension, edema	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl	Launched	5
BRD-A28958257-001-01-2::2.5::HTS	0.312042618911	BRD-A28958257-001-01-2::2.5::HTS	BRD-A28958257-001-01-2	centpropazine	2.5	HTS	inositol monophosphatase inhibitor				CCC(=O)c1ccc(OCC(O)CN2CCN(CC2)c2ccccc2)cc1, CCC(=O)c1ccc(OCC(O)CN2CCN(CC2)c2ccccc2)cc1	Phase 3	5
BRD-A28970875-300-04-9::2.5::HTS	-4.01019821305	BRD-A28970875-300-04-9::2.5::HTS	BRD-A28970875-300-04-9	puromycin	2.5	HTS	protein synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1	Preclinical	5
BRD-A29111201-001-04-8::2.5::HTS	0.380283031755	BRD-A29111201-001-04-8::2.5::HTS	BRD-A29111201-001-04-8	ethisterone	2.5	HTS	progestogen hormone	TYR			CC12CCC3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C	Launched	5
BRD-A29260609-003-26-0::2.5::HTS	0.0540614075399	BRD-A29260609-003-26-0::2.5::HTS	BRD-A29260609-003-26-0	acebutolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, ventricular arrhythmias	CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O	Launched	5
BRD-A29281099-003-03-2::2.5::HTS	0.166517381036	BRD-A29281099-003-03-2::2.5::HTS	BRD-A29281099-003-03-2	clorprenaline	2.5	HTS	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	asthma	CC(C)NCC(O)c1ccccc1Cl	Launched	5
BRD-A29289453-001-04-7::2.5::HTS	0.09302250274150001	BRD-A29289453-001-04-7::2.5::HTS	BRD-A29289453-001-04-7	PCA-4248	2.5	HTS	platelet activating factor receptor antagonist	PTAFR			COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSc1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSc1ccccc1	Phase 1	5
BRD-A29349577-001-23-0::2.5::HTS	-0.0583327407443	BRD-A29349577-001-23-0::2.5::HTS	BRD-A29349577-001-23-0	dropropizine	2.5	HTS	antitussive		pulmonary	cough suppressant	OCC(O)CN1CCN(CC1)c1ccccc1, OCC(O)CN1CCN(CC1)c1ccccc1, OCC(O)CN1CCN(CC1)c1ccccc1	Launched	5
BRD-A29426959-050-13-2::2.5::HTS	0.148120789522	BRD-A29426959-050-13-2::2.5::HTS	BRD-A29426959-050-13-2	carbinoxamine	2.5	HTS	histamine receptor antagonist	HRH1	allergy, ophthalmology, otolaryngology, dermatology	allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism	CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1	Launched	5
BRD-A29485665-001-12-8::2.5::HTS	-0.472036940237	BRD-A29485665-001-12-8::2.5::HTS	BRD-A29485665-001-12-8	bicalutamide	2.5	HTS	androgen receptor antagonist	AR	oncology	prostate cancer	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	Launched	5
BRD-A29520968-001-02-7::2.5::HTS	0.0848454654937	BRD-A29520968-001-02-7::2.5::HTS	BRD-A29520968-001-02-7	acifran	2.5	HTS	cholesterol inhibitor	HCAR2, HCAR3			CC1(OC(=CC1=O)C(O)=O)c1ccccc1, CC1(OC(=CC1=O)C(O)=O)c1ccccc1	Phase 3	5
BRD-A29623586-001-01-3::2.5::HTS	0.0616624646706	BRD-A29623586-001-01-3::2.5::HTS	BRD-A29623586-001-01-3	anisodamine	2.5	HTS	lipid peroxidase inhibitor	ADRA1A			CN1C2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1	Phase 3	5
BRD-A29644307-050-17-0::2.5::HTS	-0.289497080276	BRD-A29644307-050-17-0::2.5::HTS	BRD-A29644307-050-17-0	nomifensine	2.5	HTS	dopamine uptake inhibitor, noradrenaline uptake inhibitor	DRD2, MAOA, MAOB, MPO, SLC6A2, SLC6A3			CN1CC(c2ccccc2)c2cccc(N)c2C1, CN1CC(c2ccccc2)c2cccc(N)c2C1, CN1CC(c2ccccc2)c2cccc(N)c2C1	Withdrawn	5
BRD-A29700858-304-01-8::2.5::HTS	-0.08924525491289999	BRD-A29700858-304-01-8::2.5::HTS	BRD-A29700858-304-01-8	carbenoxolone	2.5	HTS	11-beta hydroxysteroid dehydrogenase inhibitor	GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3	gastroenterology, dental	peptic ulcer disease (PUD), mouth inflammation	CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O, CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O, CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O	Launched	5
BRD-A29700858-304-02-6::2.5::HTS	0.413803240589	BRD-A29700858-304-02-6::2.5::HTS	BRD-A29700858-304-02-6	carbenoxolone	2.5	HTS	11-beta hydroxysteroid dehydrogenase inhibitor	GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3	gastroenterology, dental	peptic ulcer disease (PUD), mouth inflammation	CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O, CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O, CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O	Launched	5
BRD-A29731977-001-04-5::2.5::HTS	0.21034761090100002	BRD-A29731977-001-04-5::2.5::HTS	BRD-A29731977-001-04-5	17-hydroxyprogesterone-caproate	2.5	HTS	progesterone receptor agonist	AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR			CCCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O	Launched	5
BRD-A29734509-011-13-6::2.5::HTS	0.0684104882459	BRD-A29734509-011-13-6::2.5::HTS	BRD-A29734509-011-13-6	disopyramide	2.5	HTS	sodium channel blocker	CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A	cardiology	ventricular tachycardia (VT), ventricular arrhythmias	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C	Launched	5
BRD-A29844814-300-01-5::2.5::HTS	0.126317600856	BRD-A29844814-300-01-5::2.5::HTS	BRD-A29844814-300-01-5	ABT-202	2.5	HTS	acetylcholine receptor agonist				NC1CCN(C1)c1cccnc1	Phase 1	5
BRD-A29854054-236-12-6::2.5::HTS	0.239564365773	BRD-A29854054-236-12-6::2.5::HTS	BRD-A29854054-236-12-6	lorglumide	2.5	HTS	CCK receptor antagonist	CCKAR, CCKBR			CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1	Phase 1	5
BRD-A29944538-003-08-3::2.5::HTS	-0.393642943345	BRD-A29944538-003-08-3::2.5::HTS	BRD-A29944538-003-08-3	proxodolol	2.5	HTS	adrenergic receptor antagonist				Cc1noc(COc2ccccc2OCC(O)CNC(C)(C)C)n1	Launched	5
BRD-A30051119-002-01-8::2.5::HTS	-0.011823041195799999	BRD-A30051119-002-01-8::2.5::HTS	BRD-A30051119-002-01-8	amikacin	2.5	HTS	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1OC1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)C1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1OC1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	Launched	5
BRD-A30205217-001-11-2::2.5::HTS	0.338321028648	BRD-A30205217-001-11-2::2.5::HTS	BRD-A30205217-001-11-2	ethotoin	2.5	HTS	hydantoin antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	CCN1C(=O)NC(C1=O)c1ccccc1, CCN1C(=O)NC(C1=O)c1ccccc1	Launched	5
BRD-A30403214-001-03-3::0.25::HTS	0.325832933012	BRD-A30403214-001-03-3::0.25::HTS	BRD-A30403214-001-03-3	edelfosine	0.25	HTS	phospholipase inhibitor				CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC, CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC	Phase 2	3
BRD-A30582499-003-05-1::2.5::HTS	0.0215011186821	BRD-A30582499-003-05-1::2.5::HTS	BRD-A30582499-003-05-1	tiletamine	2.5	HTS	glutamate receptor antagonist		neurology/psychiatry	anesthetic	CCNC1(CCCCC1=O)c1cccs1	Launched	5
BRD-A30590053-003-02-9::2.5::HTS	0.278196284445	BRD-A30590053-003-02-9::2.5::HTS	BRD-A30590053-003-02-9	MR-16728	2.5	HTS	acetylcholine release enhancer				O=C(NCCCN1CCCCCC1)C(C1CCCCC1)c1ccccc1	Preclinical	5
BRD-A30655177-001-14-0::2.5::HTS	0.133630337514	BRD-A30655177-001-14-0::2.5::HTS	BRD-A30655177-001-14-0	LFM-A13	2.5	HTS	Bruton's tyrosine kinase (BTK) inhibitor	BTK			CC(=O)C(C#N)C(=O)Nc1cc(Br)ccc1Br	Preclinical	5
BRD-A30693873-003-12-8::2.5::HTS	-0.247922647338	BRD-A30693873-003-12-8::2.5::HTS	BRD-A30693873-003-12-8	diperodon	2.5	HTS	local anesthetic				O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1, O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1	Preclinical	5
BRD-A30703952-201-01-2::2.5::HTS	0.070678103633	BRD-A30703952-201-01-2::2.5::HTS	BRD-A30703952-201-01-2	ganglioside-gm1	2.5	HTS					CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(OC4OC(CO)C(O)C(O)C4O)C3NC(C)=O)C(OC3(CC(O)C(NC(C)=O)C(O3)C(O)C(O)CO)C(O)=O)C2O)C(O)C1O)[C@H](O)\C=C\CCCCCCCCCCCCC	Phase 2	5
BRD-A30815329-001-10-5::2.5::HTS	0.120019595573	BRD-A30815329-001-10-5::2.5::HTS	BRD-A30815329-001-10-5	felodipine	2.5	HTS	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2, CALM1, CFTR, NR3C2, PDE1A, PDE1B, TNNC1, TNNC2	cardiology	hypertension	CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC	Launched	5
BRD-A30886737-001-02-9::2.5::HTS	0.0177817916775	BRD-A30886737-001-02-9::2.5::HTS	BRD-A30886737-001-02-9	florfenicol	2.5	HTS	protein synthesis inhibitor		pulmonary	bovine respiratory disease (BRD)	CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl	Launched	5
BRD-A30984645-001-01-5::2.5::HTS	0.45790338733900005	BRD-A30984645-001-01-5::2.5::HTS	BRD-A30984645-001-01-5	GDC-0834	2.5	HTS	Bruton's tyrosine kinase (BTK) inhibitor	BTK			CN1CCN(C)C(=O)C1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1, CN1CCN(C)C(=O)C1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1	Phase 1	5
BRD-A31095847-001-02-3::2.5::HTS	1.0615938549600001	BRD-A31095847-001-02-3::2.5::HTS	BRD-A31095847-001-02-3	mozavaptan	2.5	HTS	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12	Launched	5
BRD-A31159102-003-30-4::2.5::HTS	0.387015549982	BRD-A31159102-003-30-4::2.5::HTS	BRD-A31159102-003-30-4	fluoxetine	2.5	HTS	selective serotonin reuptake inhibitor (SSRI)	ANO1, HTR2B, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	Launched	5
BRD-A31454688-001-01-6::2.5::HTS	0.0295289754477	BRD-A31454688-001-01-6::2.5::HTS	BRD-A31454688-001-01-6	monostearin	2.5	HTS					CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO	Preclinical	5
BRD-A31521121-001-26-4::2.5::HTS	0.0321793563005	BRD-A31521121-001-26-4::2.5::HTS	BRD-A31521121-001-26-4	methocarbamol	2.5	HTS	muscle relaxant	CA1	neurology/psychiatry	muscle relaxant	COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O	Launched	5
BRD-A31564021-001-01-8::2.5::HTS	-0.08415014218070001	BRD-A31564021-001-01-8::2.5::HTS	BRD-A31564021-001-01-8	isoflurane	2.5	HTS	inhaled anaesthetic	ATP2C1, ATP5D, CALM1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	FC(F)OC(Cl)C(F)(F)F, FC(F)OC(Cl)C(F)(F)F	Launched	5
BRD-A31800922-003-25-1::2.5::HTS	-0.10371679838199999	BRD-A31800922-003-25-1::2.5::HTS	BRD-A31800922-003-25-1	procyclidine	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	parkinsonism, Parkinson's Disease, akathisia, dystonia	OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1, OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1	Launched	5
BRD-A31811760-001-06-7::2.5::HTS	0.142338790028	BRD-A31811760-001-06-7::2.5::HTS	BRD-A31811760-001-06-7	miltefosine	2.5	HTS	membrane integrity inhibitor	PLA2G1B	infectious disease	leishmaniasis	CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C	Launched	5
BRD-A31990649-304-02-3::2.5::HTS	0.204424435702	BRD-A31990649-304-02-3::2.5::HTS	BRD-A31990649-304-02-3	adenosine-triphosphate	2.5	HTS	adenosine receptor agonist	ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7			Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	Phase 2	5
BRD-A32172948-001-07-6::2.5::HTS	-0.247390652662	BRD-A32172948-001-07-6::2.5::HTS	BRD-A32172948-001-07-6	methiopril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE			CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O	Phase 2	5
BRD-A32269193-001-01-5::2.5::HTS	-0.621379041095	BRD-A32269193-001-01-5::2.5::HTS	BRD-A32269193-001-01-5	VGX-1027	2.5	HTS	tumor necrosis factor receptor antagonist	TLR4			OC(=O)CC1CC(=NO1)c1ccccc1	Phase 1	5
BRD-A32505112-001-04-4::2.5::HTS	-0.254594649838	BRD-A32505112-001-04-4::2.5::HTS	BRD-A32505112-001-04-4	trandolapril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction	CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O	Launched	5
BRD-A32597168-001-03-6::2.5::HTS	0.576880990218	BRD-A32597168-001-03-6::2.5::HTS	BRD-A32597168-001-03-6	letosteine	2.5	HTS	mucolytic agent		pulmonary, infectious disease	bronchitis, pneumonia	CCOC(=O)CSCCC1NC(CS1)C(O)=O	Launched	5
BRD-A32673558-003-03-9::2.5::HTS	0.0341847942947	BRD-A32673558-003-03-9::2.5::HTS	BRD-A32673558-003-03-9	aceclidine	2.5	HTS	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology	glaucoma	CC(=O)OC1CN2CCC1CC2, CC(=O)OC1CN2CCC1CC2, CC(=O)OC1CN2CCC1CC2	Launched	5
BRD-A32988684-003-08-7::2.5::HTS	0.140679813844	BRD-A32988684-003-08-7::2.5::HTS	BRD-A32988684-003-08-7	heptaminol	2.5	HTS	vasoconstrictor		cardiology	hypotension	CC(N)CCCC(C)(C)O	Launched	5
BRD-A33084557-001-06-6::2.5::HTS	-0.193081000284	BRD-A33084557-001-06-6::2.5::HTS	BRD-A33084557-001-06-6	tioconazole	2.5	HTS	sterol demethylase inhibitor	CYP51A1	infectious disease	yeast infection	Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl, Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl	Launched	5
BRD-A33168282-003-18-0::2.5::HTS	0.404870383403	BRD-A33168282-003-18-0::2.5::HTS	BRD-A33168282-003-18-0	sotalol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2, KCNH2	cardiology	atrial fibrillation (AF), ventricular arrhythmias	CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1	Launched	5
BRD-A33447119-001-10-8::2.5::HTS	0.668587002988	BRD-A33447119-001-10-8::2.5::HTS	BRD-A33447119-001-10-8	oxfendazole	2.5	HTS	anthelmintic agent		infectious disease	lungworms, tapeworm, gastrointestinal roundworms	COC(=O)Nc1nc2ccc(cc2[nH]1)S(=O)c1ccccc1, COC(=O)Nc1nc2ccc(cc2[nH]1)S(=O)c1ccccc1	Launched	5
BRD-A33514596-003-01-2::2.5::HTS	-0.14395521569800002	BRD-A33514596-003-01-2::2.5::HTS	BRD-A33514596-003-01-2	N-benzylnaltrindole	2.5	HTS	opioid receptor antagonist				Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1	Preclinical	5
BRD-A33692381-001-01-9::2.5::HTS	0.187762545331	BRD-A33692381-001-01-9::2.5::HTS	BRD-A33692381-001-01-9	zidovudine	2.5	HTS	nucleoside reverse transcriptase inhibitor	TERT	infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)	Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O	Launched	5
BRD-A33697453-008-02-4::2.5::HTS	0.557934040316	BRD-A33697453-008-02-4::2.5::HTS	BRD-A33697453-008-02-4	fenticonazole	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1	Launched	5
BRD-A33711280-003-03-1::2.5::HTS	-0.25455766351500003	BRD-A33711280-003-03-1::2.5::HTS	BRD-A33711280-003-03-1	metixene	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	neurology/psychiatry	Parkinson's Disease	CN1CCCC(CC2c3ccccc3Sc3ccccc23)C1	Launched	5
BRD-A34006693-001-15-4::2.5::HTS	0.155349893739	BRD-A34006693-001-15-4::2.5::HTS	BRD-A34006693-001-15-4	suprofen	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2			CC(C(O)=O)c1ccc(cc1)C(=O)c1cccs1, CC(C(O)=O)c1ccc(cc1)C(=O)c1cccs1	Withdrawn	5
BRD-A34205397-001-04-5::2.5::HTS	0.0787531828237	BRD-A34205397-001-04-5::2.5::HTS	BRD-A34205397-001-04-5	suloctidil	2.5	HTS	adrenergic receptor antagonist				CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1	Withdrawn	5
BRD-A34255068-001-34-5::2.5::HTS	0.329460530718	BRD-A34255068-001-34-5::2.5::HTS	BRD-A34255068-001-34-5	rolipram	2.5	HTS	phosphodiesterase inhibitor				COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1	Phase 3	5
BRD-A34358106-003-01-6::2.5::HTS	-0.1671416644	BRD-A34358106-003-01-6::2.5::HTS	BRD-A34358106-003-01-6	sarpogrelate	2.5	HTS	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C	endocrinology, cardiology, rheumatology	diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease	COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(O)=O)c1, COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(O)=O)c1	Launched	5
BRD-A34716233-004-03-5::2.5::HTS	0.378978960899	BRD-A34716233-004-03-5::2.5::HTS	BRD-A34716233-004-03-5	AMPA-(RS)	2.5	HTS	glutamate receptor agonist	GRIN1			Cc1onc(O)c1CC(N)C(O)=O, Cc1onc(O)c1CC(N)C(O)=O	Preclinical	5
BRD-A34751532-001-06-9::2.5::HTS	-0.117000934093	BRD-A34751532-001-06-9::2.5::HTS	BRD-A34751532-001-06-9	homosalate	2.5	HTS	HSP inducer				CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O	Preclinical	5
BRD-A35379661-001-04-6::2.5::HTS	0.105908143511	BRD-A35379661-001-04-6::2.5::HTS	BRD-A35379661-001-04-6	sphingosylphosphorylcholine	2.5	HTS	gene expression stimulant	GPR12			CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C	Preclinical	5
BRD-A35588707-001-05-5::2.5::HTS	-1.68576444286	BRD-A35588707-001-05-5::2.5::HTS	BRD-A35588707-001-05-5	teniposide	2.5	HTS	topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12	Launched	5
BRD-A35623999-001-05-7::2.5::HTS	-0.33367966077	BRD-A35623999-001-05-7::2.5::HTS	BRD-A35623999-001-05-7	CGP-37157	2.5	HTS	mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor	SLC8A1			Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1, Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1	Preclinical	5
BRD-A35868371-005-01-6::2.5::HTS	-0.364732340848	BRD-A35868371-005-01-6::2.5::HTS	BRD-A35868371-005-01-6	troventol	2.5	HTS					CCC(CO)(C(=O)OC1CC2CCC(C1)[N+]2(C)C)c1ccccc1	Phase 1	5
BRD-A35912562-001-02-8::2.5::HTS	0.433860633047	BRD-A35912562-001-02-8::2.5::HTS	BRD-A35912562-001-02-8	pregnenolone-succinate	2.5	HTS	GABA receptor negative allosteric modulator				CC(=O)[C@H]1CCC2C3CC=C4C[C@H](CC[C@]4(C)C3CC[C@]12C)OC(=O)CCC(O)=O	Preclinical	5
BRD-A35989968-001-04-2::2.5::HTS	0.0483336430193	BRD-A35989968-001-04-2::2.5::HTS	BRD-A35989968-001-04-2	megestrol-acetate	2.5	HTS	progesterone receptor agonist	NR3C1, PGR	neurology/psychiatry, endocrinology	anorexia, cachexia	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC12C)C(C)=O	Launched	5
BRD-A36010170-001-04-0::2.5::HTS	0.0411408990328	BRD-A36010170-001-04-0::2.5::HTS	BRD-A36010170-001-04-0	amcinonide	2.5	HTS	glucocorticoid receptor agonist	ANXA1, NR3C1	dermatology	corticosteroid-responsive dermatoses	CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1CC1C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C	Launched	5
BRD-A36057565-001-01-0::2.5::HTS	-5.38829543227	BRD-A36057565-001-01-0::2.5::HTS	BRD-A36057565-001-01-0	bruceantin	2.5	HTS	protein synthesis inhibitor				COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O	Phase 2	5
BRD-A36074203-003-07-6::2.5::HTS	-0.261748780003	BRD-A36074203-003-07-6::2.5::HTS	BRD-A36074203-003-07-6	remacemide	2.5	HTS	glutamate receptor antagonist	GRIN1			CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1	Phase 3	5
BRD-A36217750-001-16-3::2.5::HTS	0.159526685882	BRD-A36217750-001-16-3::2.5::HTS	BRD-A36217750-001-16-3	sulfinpyrazone	2.5	HTS	uricosuric blocker	ABCC1, ABCC2, FPR1, SLC22A12	rheumatology	gout	O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1	Launched	5
BRD-A36267905-003-18-4::2.5::HTS	-1.5702342968599998	BRD-A36267905-003-18-4::2.5::HTS	BRD-A36267905-003-18-4	buphenine	2.5	HTS	adrenergic receptor agonist	ADRB2	rheumatology	Raynaud's disease	CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1	Launched	5
BRD-A36318220-001-08-8::2.5::HTS	0.143488234632	BRD-A36318220-001-08-8::2.5::HTS	BRD-A36318220-001-08-8	necrostatin-1	2.5	HTS	RIPK inhibitor	RIPK1			CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O, CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O, CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O, CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O	Preclinical	5
BRD-A36331462-001-02-1::2.5::HTS	-5.288787700169999	BRD-A36331462-001-02-1::2.5::HTS	BRD-A36331462-001-02-1	oprozomib	2.5	HTS	proteasome inhibitor				COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1	Phase 1/Phase 2	5
BRD-A36456202-001-01-3::2.5::HTS	0.141469814265	BRD-A36456202-001-01-3::2.5::HTS	BRD-A36456202-001-01-3	colistin-b-sulfate	2.5	HTS	bacterial permeability inducer		infectious disease	gram-negative bacterial infections	CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O	Launched	5
BRD-A37288617-003-02-2::2.5::HTS	-0.39265171999700005	BRD-A37288617-003-02-2::2.5::HTS	BRD-A37288617-003-02-2	amfepramone	2.5	HTS	adrenergic receptor agonist	SLC6A2, SLC6A3	endocrinology	obesity	CCN(CC)C(C)C(=O)c1ccccc1	Launched	5
BRD-A37347161-003-02-6::2.5::HTS	-0.299646911995	BRD-A37347161-003-02-6::2.5::HTS	BRD-A37347161-003-02-6	BRL-52537	2.5	HTS	opioid receptor agonist	OPRK1			Clc1ccc(CC(=O)N2CCCCC2CN2CCCC2)cc1Cl	Preclinical	5
BRD-A37390343-003-03-5::2.5::HTS	0.04821673798119999	BRD-A37390343-003-03-5::2.5::HTS	BRD-A37390343-003-03-5	amorolfine	2.5	HTS	membrane integrity inhibitor		infectious disease	onychomycosis	CCC(C)(C)c1ccc(CC(C)CN2C[C@H](C)O[C@H](C)C2)cc1, CCC(C)(C)c1ccc(CC(C)CN2C[C@H](C)O[C@H](C)C2)cc1	Launched	5
BRD-A37441042-003-04-8::2.5::HTS	-0.733460797677	BRD-A37441042-003-04-8::2.5::HTS	BRD-A37441042-003-04-8	tulobuterol	2.5	HTS	adrenergic receptor agonist	ADRB2	pulmonary	asthma	CC(C)(C)NCC(O)c1ccccc1Cl	Launched	5
BRD-A37492983-001-10-3::2.5::HTS	0.295039636743	BRD-A37492983-001-10-3::2.5::HTS	BRD-A37492983-001-10-3	iocetamic-acid	2.5	HTS	radiopaque medium		radiology	contrast agent	CC(CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O	Launched	5
BRD-A37704979-001-10-7::2.5::HTS	0.172844821501	BRD-A37704979-001-10-7::2.5::HTS	BRD-A37704979-001-10-7	SB-203580	2.5	HTS	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF			CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1	Preclinical	5
BRD-A38076815-003-10-3::2.5::HTS	-0.565076376057	BRD-A38076815-003-10-3::2.5::HTS	BRD-A38076815-003-10-3	glafenine	2.5	HTS	DeltaF508-CFTR Correctors	CFTR			OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12, OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12	Withdrawn	5
BRD-A38218502-001-01-2::2.5::HTS	-0.6291431311869999	BRD-A38218502-001-01-2::2.5::HTS	BRD-A38218502-001-01-2	metenkephalin	2.5	HTS	immunostimulant	OPRD1			CSCCC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)C(N)Cc1ccc(O)cc1)C(O)=O	Phase 2	5
BRD-A38350138-001-04-9::2.5::HTS	-0.128107654338	BRD-A38350138-001-04-9::2.5::HTS	BRD-A38350138-001-04-9	ketoconazole	2.5	HTS	sterol demethylase inhibitor	AR, CYP19A1, CYP21A2, KCNA10	dermatology	seborrheic dermatitis	CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1	Launched	5
BRD-A38592941-001-02-7::2.5::HTS	-0.15214762647299998	BRD-A38592941-001-02-7::2.5::HTS	BRD-A38592941-001-02-7	timonacic	2.5	HTS	antioxidant	ANXA5			OC(=O)C1CSCN1	Launched	5
BRD-A38747044-001-02-3::2.5::HTS	-0.150626309543	BRD-A38747044-001-02-3::2.5::HTS	BRD-A38747044-001-02-3	KU14R	2.5	HTS	imidazoline receptor antagonist				CCC1(Cc2ccccc2O1)c1ncc[nH]1, CCC1(Cc2ccccc2O1)c1ncc[nH]1	Preclinical	5
BRD-A39052811-048-11-0::2.5::HTS	0.378171125684	BRD-A39052811-048-11-0::2.5::HTS	BRD-A39052811-048-11-0	mosapride	2.5	HTS	serotonin receptor agonist	HTR4	gastroenterology	hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome	CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1, CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1	Launched	5
BRD-A39189014-003-22-7::2.5::HTS	0.265628467592	BRD-A39189014-003-22-7::2.5::HTS	BRD-A39189014-003-22-7	methoxamine	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N	Launched	5
BRD-A39230911-001-10-2::2.5::HTS	-0.137530528275	BRD-A39230911-001-10-2::2.5::HTS	BRD-A39230911-001-10-2	chlorphensin-carbamate	2.5	HTS	muscle relaxant				NC(=O)OCC(O)COc1ccc(Cl)cc1	Preclinical	5
BRD-A39255369-001-03-1::2.5::HTS	-0.018948923672	BRD-A39255369-001-03-1::2.5::HTS	BRD-A39255369-001-03-1	DCPIB	2.5	HTS	chloride channel blocker, gap junction modulator, glutamate inhibitor	SLC1A2			CCCCC1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1	Preclinical	5
BRD-A39390670-236-10-7::2.5::HTS	-1.09902044417	BRD-A39390670-236-10-7::2.5::HTS	BRD-A39390670-236-10-7	rabeprazole	2.5	HTS	ATPase inhibitor, gastrin inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome	COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C	Launched	5
BRD-A39791822-001-05-1::2.5::HTS	0.588028618716	BRD-A39791822-001-05-1::2.5::HTS	BRD-A39791822-001-05-1	hydroxyprogesterone	2.5	HTS	progesterone receptor agonist	PGR	obstetrics/gynecology	spontaneous preterm birth	CC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C	Launched	5
BRD-A39935389-001-05-9::2.5::HTS	-0.10917726404200001	BRD-A39935389-001-05-9::2.5::HTS	BRD-A39935389-001-05-9	teroxirone	2.5	HTS	DNA inhibitor				O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1	Phase 1	5
BRD-A40084411-003-07-7::2.5::HTS	0.558199608288	BRD-A40084411-003-07-7::2.5::HTS	BRD-A40084411-003-07-7	CGP-12177	2.5	HTS	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			CC(C)(C)NCC(O)COc1cccc2[nH]c(O)nc12	Phase 1	5
BRD-A40413915-003-01-2::2.5::HTS	0.220708428558	BRD-A40413915-003-01-2::2.5::HTS	BRD-A40413915-003-01-2	NTNCB	2.5	HTS	neuropeptide receptor antagonist	NPY5R			[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1	Preclinical	5
BRD-A40639672-234-18-0::2.5::HTS	0.5158092058829999	BRD-A40639672-234-18-0::2.5::HTS	BRD-A40639672-234-18-0	ketorolac	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2			OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1, OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1, OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1	Launched	5
BRD-A40777960-001-04-2::2.5::HTS	-0.0438817282902	BRD-A40777960-001-04-2::2.5::HTS	BRD-A40777960-001-04-2	aminohydroxybutyric-acid	2.5	HTS			neurology/psychiatry	epilepsy	NCC(O)CC(O)=O	Launched	5
BRD-A40787240-066-04-6::2.5::HTS	0.004573518477859999	BRD-A40787240-066-04-6::2.5::HTS	BRD-A40787240-066-04-6	gemifloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		pulmonary, infectious disease	bronchitis, pneumonia	CO\N=C1/CN(CC1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	Launched	5
BRD-A40940854-001-01-1::2.5::HTS	0.41367628115000005	BRD-A40940854-001-01-1::2.5::HTS	BRD-A40940854-001-01-1	ibuproxam	2.5	HTS	cyclooxygenase inhibitor, prostaglandin inhibitor	ALOX5	endocrinology, rheumatology, neurology/psychiatry	fever, joint inflammation, pain relief	CC(C)Cc1ccc(cc1)C(C)C(=O)NO	Launched	5
BRD-A41250306-001-11-7::2.5::HTS	-0.55830641948	BRD-A41250306-001-11-7::2.5::HTS	BRD-A41250306-001-11-7	cyclopenthiazide	2.5	HTS	thiazide diuretic		cardiology	hypertension, congestive heart failure	NS(=O)(=O)c1cc2c(NC(CC3CCCC3)NS2(=O)=O)cc1Cl	Launched	5
BRD-A41304429-001-14-8::2.5::HTS	0.38944578911600003	BRD-A41304429-001-14-8::2.5::HTS	BRD-A41304429-001-14-8	practolol	2.5	HTS	adrenergic receptor antagonist	ADRB1			CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1	Withdrawn	5
BRD-A41385909-001-01-3::2.5::HTS	-0.0452501377482	BRD-A41385909-001-01-3::2.5::HTS	BRD-A41385909-001-01-3	bornyl-acetate	2.5	HTS					CC(=O)OC1CC2CCC1(C)C2(C)C, CC(=O)OC1CC2CCC1(C)C2(C)C	Preclinical	5
BRD-A41450521-075-10-8::2.5::HTS	0.184167011092	BRD-A41450521-075-10-8::2.5::HTS	BRD-A41450521-075-10-8	tosufloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	Launched	5
BRD-A41451487-001-11-2::2.5::HTS	0.140583127528	BRD-A41451487-001-11-2::2.5::HTS	BRD-A41451487-001-11-2	PK-11195	2.5	HTS	benzodiazepine receptor antagonist	TSPO			CCC(C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl, CCC(C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl	Phase 1	5
BRD-A41692738-001-07-6::2.5::HTS	-0.31607271242199997	BRD-A41692738-001-07-6::2.5::HTS	BRD-A41692738-001-07-6	TGX-221	2.5	HTS	PI3K inhibitor	PIK3CB, PIK3CD			CC(Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, CC(Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1	Preclinical	5
BRD-A41714661-001-02-0::2.5::HTS	-0.155799890882	BRD-A41714661-001-02-0::2.5::HTS	BRD-A41714661-001-02-0	bilobalide	2.5	HTS	GABA receptor modulator	GLRA1, GLRA2, GLRB, HTR3A, HTR3B			CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)C123	Preclinical	5
BRD-A41774846-001-01-4::2.5::HTS	-0.0833422833695	BRD-A41774846-001-01-4::2.5::HTS	BRD-A41774846-001-01-4	algestone-acetophenide	2.5	HTS			endocrinology	contraceptive	CC(=O)[C@@]12OC(C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1	Launched	5
BRD-A41995253-001-04-5::2.5::HTS	0.0296396553631	BRD-A41995253-001-04-5::2.5::HTS	BRD-A41995253-001-04-5	brucine	2.5	HTS	glycine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC, COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC, COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC	Preclinical	5
BRD-A42167015-003-10-2::2.5::HTS	-0.182176226759	BRD-A42167015-003-10-2::2.5::HTS	BRD-A42167015-003-10-2	carteolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12	Launched	5
BRD-A42270467-001-04-4::2.5::HTS	0.5297324654869999	BRD-A42270467-001-04-4::2.5::HTS	BRD-A42270467-001-04-4	tenatoprazole	2.5	HTS	ATPase inhibitor	IDO1			COc1ccc2[nH]c(nc2n1)S(=O)Cc1ncc(C)c(OC)c1C	Phase 2	5
BRD-A42553870-001-14-3::2.5::HTS	0.6894213932080001	BRD-A42553870-001-14-3::2.5::HTS	BRD-A42553870-001-14-3	L-152804	2.5	HTS	neuropeptide receptor antagonist	NPY5R			CC1(C)CC(=O)C(C2c3ccccc3OC3=C2C(=O)CC(C)(C)C3)C(=O)C1, CC1(C)CC(=O)C(C2c3ccccc3OC3=C2C(=O)CC(C)(C)C3)C(=O)C1	Preclinical	5
BRD-A42571354-300-12-0::2.5::HTS	0.0326942649722	BRD-A42571354-300-12-0::2.5::HTS	BRD-A42571354-300-12-0	cetirizine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1	Launched	5
BRD-A42628519-001-12-4::2.5::HTS	0.123898281831	BRD-A42628519-001-12-4::2.5::HTS	BRD-A42628519-001-12-4	iopanic-acid	2.5	HTS	thyroid hormone inhibitor				CCC(Cc1c(I)cc(I)c(N)c1I)C(O)=O	Preclinical	5
BRD-A42699921-001-02-8::2.5::HTS	-0.0341997400131	BRD-A42699921-001-02-8::2.5::HTS	BRD-A42699921-001-02-8	teriflunomide	2.5	HTS	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F	Launched	5
BRD-A42699921-001-03-6::2.6::HTS	-0.040690901667800004	BRD-A42699921-001-03-6::2.6::HTS	BRD-A42699921-001-03-6	teriflunomide	2.6	HTS	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F	Launched	5
BRD-A42746051-001-02-9::2.5::HTS	-0.12891449390999998	BRD-A42746051-001-02-9::2.5::HTS	BRD-A42746051-001-02-9	melengestrol-acetate	2.5	HTS	progesterone receptor agonist				CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C	Preclinical	5
BRD-A42759514-001-20-5::2.5::HTS	-1.1880031122399999	BRD-A42759514-001-20-5::2.5::HTS	BRD-A42759514-001-20-5	ornidazole	2.5	HTS	antiprotozoal agent		infectious disease	protozoan infection	Cc1ncc(n1CC(O)CCl)[N+]([O-])=O, Cc1ncc(n1CC(O)CCl)[N+]([O-])=O, Cc1ncc(n1CC(O)CCl)[N+]([O-])=O	Launched	5
BRD-A43082461-001-06-3::2.5::HTS	-0.505578308568	BRD-A43082461-001-06-3::2.5::HTS	BRD-A43082461-001-06-3	linalool	2.5	HTS	anticonvulsant				CC(C)=CCCC(C)(O)C=C	Phase 1	5
BRD-A43082555-001-01-1::2.5::HTS	0.548021606469	BRD-A43082555-001-01-1::2.5::HTS	BRD-A43082555-001-01-1	loxoprofen	2.5	HTS	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGS2	neurology/psychiatry	pain relief	CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1, CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1	Launched	5
BRD-A43082555-001-02-9::2.5::HTS	0.0401114935226	BRD-A43082555-001-02-9::2.5::HTS	BRD-A43082555-001-02-9	loxoprofen	2.5	HTS	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGS2	neurology/psychiatry	pain relief	CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1, CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1	Launched	5
BRD-A43435802-001-02-0::2.5::HTS	0.012443759216	BRD-A43435802-001-02-0::2.5::HTS	BRD-A43435802-001-02-0	mercaptosuccinic-acid	2.5	HTS					OC(=O)CC(S)C(O)=O, OC(=O)CC(S)C(O)=O	Launched	5
BRD-A43598550-001-09-4::2.5::HTS	0.253808621784	BRD-A43598550-001-09-4::2.5::HTS	BRD-A43598550-001-09-4	3-alpha-Hydroxy-5-beta-androstan-17-one	2.5	HTS					C[C@]12CCC3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical	5
BRD-A43671941-003-11-9::2.5::HTS	-0.171950512168	BRD-A43671941-003-11-9::2.5::HTS	BRD-A43671941-003-11-9	oxprenolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	angina pectoris, hypertension, cardiac arrythmia	CC(C)NCC(O)COc1ccccc1OCC=C	Launched	5
BRD-A43809092-003-02-1::2.5::HTS	0.170865696432	BRD-A43809092-003-02-1::2.5::HTS	BRD-A43809092-003-02-1	clobutinol	2.5	HTS	antitussive				CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1	Withdrawn	5
BRD-A43882281-001-15-5::2.5::HTS	-0.47348292232100003	BRD-A43882281-001-15-5::2.5::HTS	BRD-A43882281-001-15-5	pinacidil	2.5	HTS	ATP channel activator, potassium channel activator	ABCC8, ABCC9	cardiology	hypertension	CC(N\C(Nc1ccncc1)=N\C#N)C(C)(C)C, CC(N\C(Nc1ccncc1)=N\C#N)C(C)(C)C	Launched	5
BRD-A43885598-001-08-1::2.5::HTS	0.298226766371	BRD-A43885598-001-08-1::2.5::HTS	BRD-A43885598-001-08-1	SID-7969543	2.5	HTS	steroidogenic factor antagonist	NR5A1			CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O	Preclinical	5
BRD-A43930669-003-02-8::2.5::HTS	0.559246258504	BRD-A43930669-003-02-8::2.5::HTS	BRD-A43930669-003-02-8	L-368899	2.5	HTS	oxytocin receptor antagonist	AVPR1A, AVPR2, OXTR			Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C, Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C	Phase 1	5
BRD-A43999749-004-04-1::2.5::HTS	-0.042590607161499996	BRD-A43999749-004-04-1::2.5::HTS	BRD-A43999749-004-04-1	homatropine-methylbromide	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology	uveal tract inflammation	C[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1	Launched	5
BRD-A44008656-036-25-8::2.5::HTS	0.14543685705700002	BRD-A44008656-036-25-8::2.5::HTS	BRD-A44008656-036-25-8	doxylamine	2.5	HTS	histamine receptor antagonist	CHRM1, HRH1	neurology/psychiatry	sedative	CN(C)CCOC(C)(c1ccccc1)c1ccccn1, CN(C)CCOC(C)(c1ccccc1)c1ccccn1	Launched	5
BRD-A44090213-001-25-6::2.5::HTS	0.226807855096	BRD-A44090213-001-25-6::2.5::HTS	BRD-A44090213-001-25-6	indoprofen	2.5	HTS	cyclooxygenase inhibitor, prostanoid receptor antagonist	CXCR1, CXCR2, PTGS1, PTGS2			CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O	Withdrawn	5
BRD-A44133049-003-07-8::2.5::HTS	-0.5506965409719999	BRD-A44133049-003-07-8::2.5::HTS	BRD-A44133049-003-07-8	azasetron	2.5	HTS	serotonin receptor antagonist	HTR3A, HTR3B	infectious disease	genitial herpes	CN1C(=O)COc2c1cc(Cl)cc2C(=O)NC1CN2CCC1CC2	Launched	5
BRD-A44448661-001-04-8::2.5::HTS	-0.0013612636262299999	BRD-A44448661-001-04-8::2.5::HTS	BRD-A44448661-001-04-8	pentobarbital	2.5	HTS	barbiturate antiepileptic, GABA receptor modulator	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B			CCCC(C)C1(CC)C(=O)NC(=O)NC1=O	Withdrawn	5
BRD-A44500574-001-01-8::2.5::HTS	-2.29863033101	BRD-A44500574-001-01-8::2.5::HTS	BRD-A44500574-001-01-8	FLI-06	2.5	HTS	notch signaling inhibitor				CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1	Preclinical	5
BRD-A44696962-001-01-4::2.5::HTS	0.09526616399280001	BRD-A44696962-001-01-4::2.5::HTS	BRD-A44696962-001-01-4	acetyl-11-keto-beta-boswellic-acid	2.5	HTS	lipoxygenase inhibitor	HSD11B1, HSD11B2			C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)C4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)(C5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C	Phase 2	5
BRD-A44863528-001-13-2::2.5::HTS	-0.50142784211	BRD-A44863528-001-13-2::2.5::HTS	BRD-A44863528-001-13-2	proglumide	2.5	HTS	CCK receptor antagonist	CCKAR, CCKBR			CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)c1ccccc1	Withdrawn	5
BRD-A44936478-001-01-1::2.5::HTS	0.212113911474	BRD-A44936478-001-01-1::2.5::HTS	BRD-A44936478-001-01-1	cephalosporin-c-zn	2.5	HTS	bacterial cell wall synthesis inhibitor				CC(=O)OCC1=C2N3C(SC1)[C@H](NC(=O)CCCC(N)C(=O)O[Zn]OC2=O)C3=O	Preclinical	5
BRD-A45044890-236-02-3::2.5::HTS	0.187002272144	BRD-A45044890-236-02-3::2.5::HTS	BRD-A45044890-236-02-3	methylprednisolone-sodium-succinate	2.5	HTS	glucocorticoid receptor agonist		endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry	hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis	C[C@H]1CC2C3CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]3(C)C[C@H](O)C2[C@@]2(C)C=CC(=O)C=C12	Launched	5
BRD-A45107007-001-03-4::2.5::HTS	-0.48916235064999997	BRD-A45107007-001-03-4::2.5::HTS	BRD-A45107007-001-03-4	salubrinal	2.5	HTS	eukaryotic translation initiation factor inhibitor	EIF2S1			ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12, ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12, ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12, ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12	Preclinical	5
BRD-A45153512-001-01-0::2.5::HTS	0.034509688157800006	BRD-A45153512-001-01-0::2.5::HTS	BRD-A45153512-001-01-0	bimatoprost	2.5	HTS	prostanoid receptor agonist	AKR1C3, PTGER1, PTGER3, PTGFR	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(O)CCc1ccccc1	Launched	5
BRD-A45498368-001-07-1::2.5::HTS	-2.5787524593	BRD-A45498368-001-07-1::2.5::HTS	BRD-A45498368-001-07-1	WYE-125132	2.5	HTS	mTOR inhibitor	MTOR			CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1	Preclinical	5
BRD-A45543382-001-10-0::2.5::HTS	-0.400039647821	BRD-A45543382-001-10-0::2.5::HTS	BRD-A45543382-001-10-0	metrizamide	2.5	HTS	radiopaque medium		radiology	contrast agent	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I	Launched	5
BRD-A45869167-001-10-0::2.5::HTS	-0.486590681141	BRD-A45869167-001-10-0::2.5::HTS	BRD-A45869167-001-10-0	sal003	2.5	HTS	eukaryotic translation initiation factor inhibitor	EIF2A			Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1, Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1, Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1	Preclinical	5
BRD-A45889380-300-07-1::2.5::HTS	0.7509326156139999	BRD-A45889380-300-07-1::2.5::HTS	BRD-A45889380-300-07-1	mepacrine	2.5	HTS	cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator	PLA2G1B, PLA2G4A, PLA2G6, PLCL1	infectious disease	giardiasis	CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12, CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12, CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12	Launched	5
BRD-A45906415-001-01-9::2.5::HTS	-0.372303388434	BRD-A45906415-001-01-9::2.5::HTS	BRD-A45906415-001-01-9	K-MAP	2.5	HTS					OCC1OC(Nc2ccc(cc2)C(O)=O)C(O)C(O)C1O	Phase 2	5
BRD-A46066006-004-22-6::2.5::HTS	-0.211283295861	BRD-A46066006-004-22-6::2.5::HTS	BRD-A46066006-004-22-6	clidinium	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis	C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(c1ccccc1)c1ccccc1	Launched	5
BRD-A46179541-311-02-0::2.5::HTS	0.289303956088	BRD-A46179541-311-02-0::2.5::HTS	BRD-A46179541-311-02-0	doxapram	2.5	HTS	potassium channel blocker	KCNK3, KCNK9	pulmonary, neurology/psychiatry	respiratory depression, central nervous system depression, acute hypercapnia (AHC)	CCN1CC(CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1, CCN1CC(CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1	Launched	5
BRD-A46186775-369-02-0::2.5::HTS	0.572160365886	BRD-A46186775-369-02-0::2.5::HTS	BRD-A46186775-369-02-0	hydrocortisone-phosphate	2.5	HTS		ANXA1, NOS2, NR3C1	pulmonary, gastroenterology, hematologic malignancy, ophthalmology	asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis	CC12C[C@H](O)C3C(CCC4=CC(=O)CCC34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O	Launched	5
BRD-A46393198-003-16-6::2.5::HTS	0.271196907579	BRD-A46393198-003-16-6::2.5::HTS	BRD-A46393198-003-16-6	tetramisole	2.5	HTS	immunostimulant		infectious disease	gastrointestinal parasites	C1CN2CC(N=C2S1)c1ccccc1, C1CN2CC(N=C2S1)c1ccccc1	Launched	5
BRD-A46717658-236-02-5::2.5::HTS	0.370182905669	BRD-A46717658-236-02-5::2.5::HTS	BRD-A46717658-236-02-5	azlocillin	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)SC2C(NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2C1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched	5
BRD-A46813902-001-01-6::2.5::HTS	-0.296450749067	BRD-A46813902-001-01-6::2.5::HTS	BRD-A46813902-001-01-6	iododexetimide	2.5	HTS	acetylcholine receptor antagonist				Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1	Phase 2	5
BRD-A46876182-003-02-8::2.5::HTS	-0.463561060841	BRD-A46876182-003-02-8::2.5::HTS	BRD-A46876182-003-02-8	levobunolol-(+/-)	2.5	HTS	adrenergic receptor antagonist				CC(C)(C)NCC(O)COc1cccc2C(=O)CCCc12	Preclinical	5
BRD-A47342814-003-01-8::2.5::HTS	-0.127968791966	BRD-A47342814-003-01-8::2.5::HTS	BRD-A47342814-003-01-8	naltrindole	2.5	HTS	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O	Preclinical	5
BRD-A47364545-003-02-6::2.5::HTS	0.157436572394	BRD-A47364545-003-02-6::2.5::HTS	BRD-A47364545-003-02-6	SK&F-10047-(+)	2.5	HTS	sigma receptor agonist	SIGMAR1			C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C	Phase 1	5
BRD-A47449001-004-13-7::2.5::HTS	0.304065411995	BRD-A47449001-004-13-7::2.5::HTS	BRD-A47449001-004-13-7	ipratropium	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1, CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1, CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1	Launched	5
BRD-A47494775-003-11-3::2.5::HTS	0.4199131255	BRD-A47494775-003-11-3::2.5::HTS	BRD-A47494775-003-11-3	dipivefrine	2.5	HTS	adrenergic receptor agonist	ACHE, ADRA1A, ADRA2A, ADRB2, BCHE	ophthalmology	glaucoma, intraocular pressure	CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1	Launched	5
BRD-A47598013-004-16-0::2.5::HTS	0.339127911018	BRD-A47598013-004-16-0::2.5::HTS	BRD-A47598013-004-16-0	citalopram	2.5	HTS	selective serotonin reuptake inhibitor (SSRI)	SLC6A2, SLC6A4	neurology/psychiatry	depression	CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1	Launched	5
BRD-A47706533-001-02-6::2.5::HTS	0.8329554922969999	BRD-A47706533-001-02-6::2.5::HTS	BRD-A47706533-001-02-6	buthionine-sulfoximine	2.5	HTS	glutathione transferase inhibitor	GCLM			CCCCS(=N)(=O)CC[C@H](N)C(O)=O	Phase 1	5
BRD-A47790386-001-03-6::2.61::HTS	-0.0488269852647	BRD-A47790386-001-03-6::2.61::HTS	BRD-A47790386-001-03-6	balofloxacin	2.61	HTS	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	CNC1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1, CNC1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1	Launched	5
BRD-A47884604-051-01-2::2.5::HTS	-0.061580510595000006	BRD-A47884604-051-01-2::2.5::HTS	BRD-A47884604-051-01-2	cyanopindolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, HTR1A, HTR1D			CC(C)(C)NCC(O)COc1cccc2[nH]c(cc12)C#N	Phase 2	5
BRD-A47953250-001-01-7::2.5::HTS	-1.62290016241	BRD-A47953250-001-01-7::2.5::HTS	BRD-A47953250-001-01-7	ecamsule-triethanolamine	2.5	HTS			dermatology	skin protectant, sunscreen lotion	CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C	Launched	5
BRD-A48015106-004-08-9::2.5::HTS	-0.459865502636	BRD-A48015106-004-08-9::2.5::HTS	BRD-A48015106-004-08-9	8-hydroxy-DPAT	2.5	HTS	serotonin receptor agonist	CDK1, CHEK1, CHEK2, GSK3B, HTR5A, HTR7, LCK, MAPK14, MARK1, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG			CCCN(CCC)C1CCc2cccc(O)c2C1	Preclinical	5
BRD-A48180038-003-24-3::2.5::HTS	0.152950741587	BRD-A48180038-003-24-3::2.5::HTS	BRD-A48180038-003-24-3	trihexyphenidyl	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	neurology/psychiatry	parkinsonism	OC(CCN1CCCCC1)(C1CCCCC1)c1ccccc1	Launched	5
BRD-A48237631-001-04-8::2.5::HTS	-4.27962356111	BRD-A48237631-001-04-8::2.5::HTS	BRD-A48237631-001-04-8	mitomycin-c	2.5	HTS	DNA alkylating agent, DNA synthesis inhibitor		oncology	pancreatic cancer, gastric adenocarcinoma	CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O	Launched	5
BRD-A48261811-001-08-1::2.5::HTS	-0.476495049234	BRD-A48261811-001-08-1::2.5::HTS	BRD-A48261811-001-08-1	argatroban	2.5	HTS	thrombin inhibitor	F2	hematology	heparin-induced thrombocytopenia (HIT)	C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)c1cccc2CC(C)CNc12, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)c1cccc2CC(C)CNc12	Launched	5
BRD-A48300215-001-04-8::2.5::HTS	-0.288631266701	BRD-A48300215-001-04-8::2.5::HTS	BRD-A48300215-001-04-8	ajmaline	2.5	HTS	sodium channel blocker	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O	Launched	5
BRD-A48430263-003-17-2::2.5::HTS	0.335380363274	BRD-A48430263-003-17-2::2.5::HTS	BRD-A48430263-003-17-2	pioglitazone	2.5	HTS	insulin sensitizer, PPAR receptor agonist	PPARG, TRPM3	endocrinology	diabetes mellitus	CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1, CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1, CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1, CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1	Launched	5
BRD-A48720949-001-04-0::2.5::HTS	0.244517400728	BRD-A48720949-001-04-0::2.5::HTS	BRD-A48720949-001-04-0	testosterone-propionate	2.5	HTS	androgen receptor agonist	AR			CCC(=O)O[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C	Launched	5
BRD-A49035384-003-28-9::2.39::HTS	0.09161837244580001	BRD-A49035384-003-28-9::2.39::HTS	BRD-A49035384-003-28-9	methacycline	2.39	HTS	protein synthesis inhibitor		pulmonary	bronchitis	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	Launched	5
BRD-A49035384-003-30-5::2.5::HTS	0.403149290405	BRD-A49035384-003-30-5::2.5::HTS	BRD-A49035384-003-30-5	methacycline	2.5	HTS	protein synthesis inhibitor		pulmonary	bronchitis	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	Launched	5
BRD-A49046702-003-08-3::2.5::HTS	-0.281346989941	BRD-A49046702-003-08-3::2.5::HTS	BRD-A49046702-003-08-3	SKF-89976A	2.5	HTS	GABA uptake inhibitor	SLC6A1			OC(=O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1, OC(=O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1	Preclinical	5
BRD-A49160188-003-12-7::2.5::HTS	-0.06873999689060001	BRD-A49160188-003-12-7::2.5::HTS	BRD-A49160188-003-12-7	donepezil	2.5	HTS	acetylcholinesterase inhibitor	ACHE, HTR2A	neurology/psychiatry	Alzheimer's disease	COc1cc2CC(CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC, COc1cc2CC(CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC	Launched	5
BRD-A49172652-001-27-1::2.5::HTS	0.778799484642	BRD-A49172652-001-27-1::2.5::HTS	BRD-A49172652-001-27-1	lansoprazole	2.5	HTS	ATPase inhibitor	ATP4A, ATP4B	gastroenterology	heartburn	Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1	Launched	5
BRD-A49225603-045-10-0::2.5::HTS	0.054577399082399995	BRD-A49225603-045-10-0::2.5::HTS	BRD-A49225603-045-10-0	alimemazine	2.5	HTS	histamine receptor agonist	HRH1	neurology/psychiatry	sedative	CC(CN(C)C)CN1c2ccccc2Sc2ccccc12	Launched	5
BRD-A49358627-001-14-6::2.5::HTS	0.0841696074099	BRD-A49358627-001-14-6::2.5::HTS	BRD-A49358627-001-14-6	ciprofibrate	2.5	HTS	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O	Launched	5
BRD-A49399758-015-01-8::2.5::HTS	-0.8241519248070001	BRD-A49399758-015-01-8::2.5::HTS	BRD-A49399758-015-01-8	desmopressin-acetate	2.5	HTS	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	endocrinology, urology	central diabetes insipidus, nocturnal enuresis	NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CCSSCC(NC(=O)C(CC(N)=O)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCNC(N)=N)C(=O)NCC(N)=O	Launched	5
BRD-A49447682-001-02-4::2.5::HTS	0.45914328401999993	BRD-A49447682-001-02-4::2.5::HTS	BRD-A49447682-001-02-4	desoximetasone	2.5	HTS	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO	Launched	5
BRD-A49544621-003-02-8::2.5::HTS	0.301894800542	BRD-A49544621-003-02-8::2.5::HTS	BRD-A49544621-003-02-8	AC-7954-(+/-)	2.5	HTS	urotensin receptor agonist	UTS2R			CN(C)CCC1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1, CN(C)CCC1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1	Preclinical	5
BRD-A49622760-001-01-9::2.5::HTS	0.032390490654	BRD-A49622760-001-01-9::2.5::HTS	BRD-A49622760-001-01-9	faropenem	2.5	HTS	lactamase inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis	CC(O)C1C2SC(C3CCCO3)=C(N2C1=O)C(O)=O	Launched	5
BRD-A49765801-001-04-1::2.5::HTS	-0.019227625039500002	BRD-A49765801-001-04-1::2.5::HTS	BRD-A49765801-001-04-1	fludroxycortide	2.5	HTS	glucocorticoid receptor agonist	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Launched	5
BRD-A49838158-001-01-1::2.5::HTS	0.110348072576	BRD-A49838158-001-01-1::2.5::HTS	BRD-A49838158-001-01-1	phenprocoumon	2.5	HTS	vitamin K antagonist	VKORC1	hematology	thrombosis, pulmonary embolism (PE)	CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O	Launched	5
BRD-A49906757-004-09-8::2.5::HTS	0.166517688139	BRD-A49906757-004-09-8::2.5::HTS	BRD-A49906757-004-09-8	scopolamine-n-oxide	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI			C[N+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Preclinical	5
BRD-A50028488-001-01-6::2.5::HTS	0.5249314599830001	BRD-A50028488-001-01-6::2.5::HTS	BRD-A50028488-001-01-6	TCS2002	2.5	HTS	glycogen synthase kinase inhibitor	GSK3B			Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)S(C)=O)c2c1, Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)S(C)=O)c2c1	Preclinical	5
BRD-A50049929-001-01-9::2.5::HTS	0.252692271655	BRD-A50049929-001-01-9::2.5::HTS	BRD-A50049929-001-01-9	oxazepam	2.5	HTS	GABA benzodiazepine site receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3	neurology/psychiatry	anxiety	OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O	Launched	5
BRD-A50064262-001-04-7::2.5::HTS	-0.770426960358	BRD-A50064262-001-04-7::2.5::HTS	BRD-A50064262-001-04-7	flumethasone-pivalate	2.5	HTS	glucocorticoid receptor agonist	NR3C1, SERPINA6			C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C	Launched	5
BRD-A50157456-065-20-6::2.5::HTS	-1.18695628656	BRD-A50157456-065-20-6::2.5::HTS	BRD-A50157456-065-20-6	terbutaline	2.5	HTS	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1	Launched	5
BRD-A50311610-300-10-4::2.5::HTS	-0.119392514243	BRD-A50311610-300-10-4::2.5::HTS	BRD-A50311610-300-10-4	meclizine	2.5	HTS	constitutive androstane receptor (CAR) agonist	HRH1, NR1I3	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness	Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1	Launched	5
BRD-A50675702-001-07-1::2.5::HTS	-0.327482228234	BRD-A50675702-001-07-1::2.5::HTS	BRD-A50675702-001-07-1	fipronil	2.5	HTS	chloride channel blocker, GABA gated chloride channel blocker				Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)S(=O)C(F)(F)F	Launched	5
BRD-A50684349-003-02-9::2.5::HTS	-0.437627293943	BRD-A50684349-003-02-9::2.5::HTS	BRD-A50684349-003-02-9	fenoldopam	2.5	HTS	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD4, DRD5	cardiology	hypertension	Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12, Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12	Launched	5
BRD-A50737080-001-03-0::2.5::HTS	0.038525384743	BRD-A50737080-001-03-0::2.5::HTS	BRD-A50737080-001-03-0	CGK-733	2.5	HTS	ATM kinase inhibitor, ATR kinase inhibitor	ATM, ATR			[O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F, [O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F, [O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F, [O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F	Preclinical	5
BRD-A50764878-003-02-8::2.5::HTS	-0.368398201474	BRD-A50764878-003-02-8::2.5::HTS	BRD-A50764878-003-02-8	MDL-73005EF	2.5	HTS	serotonin receptor antagonist	HTR1A			O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2ccccc2O1	Phase 1	5
BRD-A50922295-001-01-3::2.5::HTS	0.35392389577699995	BRD-A50922295-001-01-3::2.5::HTS	BRD-A50922295-001-01-3	valganciclovir	2.5	HTS	DNA synthesis inhibitor		infectious disease	cytomegalovirus (CMV)	CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c1nc(N)[nH]c2=O, CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c1nc(N)[nH]c2=O	Launched	5
BRD-A50998626-001-02-1::2.5::HTS	0.35854476558799997	BRD-A50998626-001-02-1::2.5::HTS	BRD-A50998626-001-02-1	palomid-529	2.5	HTS	AKT inhibitor, mTOR inhibitor	MTOR			COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1	Phase 1	5
BRD-A51078674-003-01-0::2.5::HTS	-0.052699919967400005	BRD-A51078674-003-01-0::2.5::HTS	BRD-A51078674-003-01-0	diclofensine	2.5	HTS	dopamine reuptake inhibitor	DRD1, MAOA, MAOB			COc1ccc2C(CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1	Phase 3	5
BRD-A51355958-003-01-9::2.5::HTS	-0.451687549595	BRD-A51355958-003-01-9::2.5::HTS	BRD-A51355958-003-01-9	nebracetam	2.5	HTS	acetylcholine receptor agonist	CHRM1			NCC1CN(Cc2ccccc2)C(=O)C1	Phase 3	5
BRD-A51382177-236-03-0::2.5::HTS	0.465863057971	BRD-A51382177-236-03-0::2.5::HTS	BRD-A51382177-236-03-0	fosinopril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C	Launched	5
BRD-A51407134-001-01-9::2.5::HTS	0.265083006494	BRD-A51407134-001-01-9::2.5::HTS	BRD-A51407134-001-01-9	2-octyldodecan-1-ol	2.5	HTS					CCCCCCCCCCC(CO)CCCCCCCC, CCCCCCCCCCC(CO)CCCCCCCC	Preclinical	5
BRD-A51571244-001-01-9::2.5::HTS	1.26803780736	BRD-A51571244-001-01-9::2.5::HTS	BRD-A51571244-001-01-9	hypoestoxide	2.5	HTS	IKK inhibitor	IKBKB, IL1B, TNF			CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C	Phase 1	5
BRD-A51713165-003-02-6::2.5::HTS	-0.144941299389	BRD-A51713165-003-02-6::2.5::HTS	BRD-A51713165-003-02-6	3-CPMT	2.5	HTS	dopamine reuptake inhibitor				CN1C2CCC1CC(C2)OC(c1ccccc1)c1ccc(Cl)cc1	Preclinical	5
BRD-A51714012-003-13-6::2.5::HTS	0.37924912151699997	BRD-A51714012-003-13-6::2.5::HTS	BRD-A51714012-003-13-6	venlafaxine	2.5	HTS	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder	COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1, COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1, COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1	Launched	5
BRD-A51747092-003-03-0::2.5::HTS	0.161129663569	BRD-A51747092-003-03-0::2.5::HTS	BRD-A51747092-003-03-0	moprolol	2.5	HTS	adrenergic receptor antagonist		cardiology, ophthalmology, neurology/psychiatry	hypertension, glaucoma, anxiety	COc1ccccc1OCC(O)CNC(C)C	Launched	5
BRD-A51820102-008-28-9::2.5::HTS	-0.443309413795	BRD-A51820102-008-28-9::2.5::HTS	BRD-A51820102-008-28-9	econazole	2.5	HTS	lanosterol demethylase inhibitor, sterol demethylase inhibitor	CYP51A1, NPY1R, NPY2R, TRPM2, TRPV5	infectious disease	tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1	Launched	5
BRD-A51829654-003-07-7::2.5::HTS	-0.24401309788199999	BRD-A51829654-003-07-7::2.5::HTS	BRD-A51829654-003-07-7	BRL-15572	2.5	HTS	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1, OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1, OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1	Preclinical	5
BRD-A51831848-001-01-7::2.5::HTS	-0.06981757176289999	BRD-A51831848-001-01-7::2.5::HTS	BRD-A51831848-001-01-7	enflurane	2.5	HTS	membrane permeability inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, KCNN4			FC(F)OC(F)(F)C(F)Cl	Launched	5
BRD-A51964809-003-12-6::2.5::HTS	-0.8050742005879999	BRD-A51964809-003-12-6::2.5::HTS	BRD-A51964809-003-12-6	halofantrine	2.5	HTS	antimalarial agent	KCNH2, KCNN4	infectious disease	malaria	CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F	Launched	5
BRD-A52460047-001-01-3::2.5::HTS	0.253085273777	BRD-A52460047-001-01-3::2.5::HTS	BRD-A52460047-001-01-3	methylatropine-nitrate	2.5	HTS	acetylcholine receptor antagonist	CHRM1			C[N+]1(C)C2CCC1CC(C2)OC(=O)C(CO)c1ccccc1	Preclinical	5
BRD-A52588987-004-08-2::2.5::HTS	-0.24200137923099999	BRD-A52588987-004-08-2::2.5::HTS	BRD-A52588987-004-08-2	SKF-83566	2.5	HTS	dopamine receptor antagonist	DRD1, DRD5			CN1CCc2cc(Br)c(O)cc2C(C1)c1ccccc1, CN1CCc2cc(Br)c(O)cc2C(C1)c1ccccc1	Preclinical	5
BRD-A52660433-066-02-1::2.5::HTS	0.733069437348	BRD-A52660433-066-02-1::2.5::HTS	BRD-A52660433-066-02-1	tetrindole	2.5	HTS	monoamine oxidase inhibitor	MAOA			C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1	Phase 3	5
BRD-A52922642-001-03-7::2.5::HTS	0.44372462516500005	BRD-A52922642-001-03-7::2.5::HTS	BRD-A52922642-001-03-7	gallopamil	2.5	HTS	L-type calcium channel blocker	ATP2A2	cardiology	hypertension, cardiac arrythmia	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC	Launched	5
BRD-A53037217-001-02-0::2.5::HTS	0.096839608462	BRD-A53037217-001-02-0::2.5::HTS	BRD-A53037217-001-02-0	BTZ043-racemate	2.5	HTS	DPRE1 inhibitor				CC1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1	Preclinical	5
BRD-A53037300-001-01-0::2.5::HTS	-0.150141543134	BRD-A53037300-001-01-0::2.5::HTS	BRD-A53037300-001-01-0	2-fluoro-2-deoxy-D-galactose	2.5	HTS		LCT			OCC1OC(O)C(F)C(O)C1O	Phase 1	5
BRD-A53134341-001-03-2::2.5::HTS	0.615165796074	BRD-A53134341-001-03-2::2.5::HTS	BRD-A53134341-001-03-2	Ro-106-9920	2.5	HTS	NFkB pathway inhibitor				O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1	Preclinical	5
BRD-A53151380-001-01-2::2.5::HTS	0.653128115657	BRD-A53151380-001-01-2::2.5::HTS	BRD-A53151380-001-01-2	prednisolone-tebutate	2.5	HTS	anti-inflammatory agent				CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C	Launched	5
BRD-A53539450-004-01-7::2.5::HTS	-0.029582713081400005	BRD-A53539450-004-01-7::2.5::HTS	BRD-A53539450-004-01-7	neo-gilurytmal	2.5	HTS					CCC[N+]12[C@H]3C[C@]45C(O)C3[C@@H](CC1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O	Launched	5
BRD-A53561827-004-23-1::2.5::HTS	0.500554408376	BRD-A53561827-004-23-1::2.5::HTS	BRD-A53561827-004-23-1	pipenzolate	2.5	HTS	cholinergic receptor antagonist	CHRM1	neurology/psychiatry	spasms	CC[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1, CC[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1	Launched	5
BRD-A53566267-001-01-9::2.5::HTS	-0.40014580773	BRD-A53566267-001-01-9::2.5::HTS	BRD-A53566267-001-01-9	anecortave-acetate	2.5	HTS	angiogenesis inhibitor		ophthalmology	macular degeneration	CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C	Launched	5
BRD-A53576514-048-14-3::2.5::HTS	-0.09647981831369999	BRD-A53576514-048-14-3::2.5::HTS	BRD-A53576514-048-14-3	orphenadrine	2.5	HTS	acetylcholine receptor antagonist	GRIN1, GRIN2D, GRIN3A, GRIN3B, HRH1, SCN10A, SLC6A2	neurology/psychiatry	muscle pain	CN(C)CCOC(c1ccccc1)c1ccccc1C, CN(C)CCOC(c1ccccc1)c1ccccc1C	Launched	5
BRD-A53813595-001-01-8::2.5::HTS	0.193685082466	BRD-A53813595-001-01-8::2.5::HTS	BRD-A53813595-001-01-8	PGL5001	2.5	HTS	JNK inhibitor	MAPK10, MAPK8, MAPK9			N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1, N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1, N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1	Phase 2	5
BRD-A53951045-004-01-6::2.5::HTS	-0.170902950136	BRD-A53951045-004-01-6::2.5::HTS	BRD-A53951045-004-01-6	butylscopolamine-bromide	2.5	HTS	cholinergic receptor antagonist		gastroenterology	abdominal pain	CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1	Launched	5
BRD-A53952395-003-25-1::2.5::HTS	0.0359071119988	BRD-A53952395-003-25-1::2.5::HTS	BRD-A53952395-003-25-1	prilocaine	2.5	HTS	local anesthetic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	anesthetic	CCCNC(C)C(=O)Nc1ccccc1C, CCCNC(C)C(=O)Nc1ccccc1C	Launched	5
BRD-A54236247-003-04-3::2.5::HTS	-0.13687645116699998	BRD-A54236247-003-04-3::2.5::HTS	BRD-A54236247-003-04-3	ephedrine-(racemic)	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA2A	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	CNC(C)C(O)c1ccccc1	Launched	5
BRD-A54275602-001-01-0::2.5::HTS	0.0681032636655	BRD-A54275602-001-01-0::2.5::HTS	BRD-A54275602-001-01-0	lanoconazole	2.5	HTS	sterol demethylase inhibitor		infectious disease	fungal infection	Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1	Launched	5
BRD-A54490543-066-11-9::2.5::HTS	0.331355262709	BRD-A54490543-066-11-9::2.5::HTS	BRD-A54490543-066-11-9	pirlindole	2.5	HTS	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	Cc1ccc2n3CCNC4CCCc(c34)c2c1	Launched	5
BRD-A54927599-001-16-9::2.5::HTS	-0.23302981892400002	BRD-A54927599-001-16-9::2.5::HTS	BRD-A54927599-001-16-9	KF-38789	2.5	HTS	P selectin inhibitor	SELP			COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1	Preclinical	5
BRD-A55272860-001-14-6::2.5::HTS	0.011121245475000001	BRD-A55272860-001-14-6::2.5::HTS	BRD-A55272860-001-14-6	sulpiride	2.5	HTS	dopamine receptor antagonist		neurology/psychiatry	schizophrenia, schizophrenia	CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	Launched	5
BRD-A55272860-001-15-3::2.5::HTS	0.305296741598	BRD-A55272860-001-15-3::2.5::HTS	BRD-A55272860-001-15-3	sulpiride	2.5	HTS	dopamine receptor antagonist		neurology/psychiatry	schizophrenia, schizophrenia	CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	Launched	5
BRD-A55312468-001-04-7::1.24::HTS	-3.10399363443	BRD-A55312468-001-04-7::1.24::HTS	BRD-A55312468-001-04-7	k-strophanthidin	1.24	HTS	ATPase inhibitor	ATP1A1			C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1	Phase 2	4
BRD-A55393291-001-09-9::2.5::HTS	0.306887290727	BRD-A55393291-001-09-9::2.5::HTS	BRD-A55393291-001-09-9	testosterone	2.5	HTS	androgen receptor agonist	AR	endocrinology	hypogonadism	C[C@]12CCC3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@@H]2O	Launched	5
BRD-A55424491-001-19-9::2.5::HTS	-1.3736467815900002	BRD-A55424491-001-19-9::2.5::HTS	BRD-A55424491-001-19-9	methotrexate	2.5	HTS	dihydrofolate reductase inhibitor	DHFR	oncology, hematologic malignancy, dermatology, rheumatology	gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O	Launched	5
BRD-A55455283-001-01-3::2.5::HTS	-0.464292306131	BRD-A55455283-001-01-3::2.5::HTS	BRD-A55455283-001-01-3	2-ethyl-1,3-hexanediol	2.5	HTS					CCCC(O)C(CC)CO, CCCC(O)C(CC)CO	Preclinical	5
BRD-A55464252-001-01-2::2.5::HTS	0.26401342654800003	BRD-A55464252-001-01-2::2.5::HTS	BRD-A55464252-001-01-2	3-(4-methylbenzylidene)camphor	2.5	HTS	endocrine disruptor		dermatology	sunscreen lotion	Cc1ccc(cc1)\C=C1\C2CCC(C)(C1=O)C2(C)C	Launched	5
BRD-A55469827-001-07-4::2.5::HTS	0.681304893667	BRD-A55469827-001-07-4::2.5::HTS	BRD-A55469827-001-07-4	mephenesin	2.5	HTS	muscle relaxant		neurology/psychiatry	muscle relaxant	Cc1ccccc1OCC(O)CO	Launched	5
BRD-A55484088-050-02-5::2.5::HTS	-1.0012899560500002	BRD-A55484088-050-02-5::2.5::HTS	BRD-A55484088-050-02-5	BNTX	2.5	HTS	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1	Preclinical	5
BRD-A55664972-236-02-6::2.5::HTS	-0.46919485907200004	BRD-A55664972-236-02-6::2.5::HTS	BRD-A55664972-236-02-6	sodium-tetradecyl-sulfate	2.5	HTS		PROC, PROS1	dermatology	varicose veins, varicose veins	CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O, CCCCCCCCCCCCCCOS(O)(=O)=O	Launched	5
BRD-A55913614-316-09-6::2.5::HTS	-0.24478498991	BRD-A55913614-316-09-6::2.5::HTS	BRD-A55913614-316-09-6	primaquine	2.5	HTS	antimalarial agent, DNA inhibitor	KRT7, NQO2	infectious disease	malaria	COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1	Launched	5
BRD-A55962179-001-22-1::2.5::HTS	-0.049646879207	BRD-A55962179-001-22-1::2.5::HTS	BRD-A55962179-001-22-1	omeprazole	2.5	HTS	ATPase inhibitor	ATP4A, CLCN2	gastroenterology	heartburn	COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C	Launched	5
BRD-A56085258-001-01-8::2.5::HTS	-0.212834174167	BRD-A56085258-001-01-8::2.5::HTS	BRD-A56085258-001-01-8	LGX818	2.5	HTS	RAF inhibitor	BRAF			COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C	Phase 3	5
BRD-A56152450-001-02-0::2.5::HTS	-0.100581526306	BRD-A56152450-001-02-0::2.5::HTS	BRD-A56152450-001-02-0	dimercaprol	2.5	HTS	chelating agent		neurology/psychiatry	metal toxicity	OCC(S)CS, OCC(S)CS	Launched	5
BRD-A56359832-001-11-1::2.5::HTS	-0.667168839877	BRD-A56359832-001-11-1::2.5::HTS	BRD-A56359832-001-11-1	zileuton	2.5	HTS	leukotriene synthesis inhibitor, lipoxygenase inhibitor	ALOX5	pulmonary	asthma	CC(N(O)C(N)=O)c1cc2ccccc2s1, CC(N(O)C(N)=O)c1cc2ccccc2s1, CC(N(O)C(N)=O)c1cc2ccccc2s1, CC(N(O)C(N)=O)c1cc2ccccc2s1	Launched	5
BRD-A56371469-001-03-3::2.5::HTS	0.325511602111	BRD-A56371469-001-03-3::2.5::HTS	BRD-A56371469-001-03-3	AGI-5198	2.5	HTS	isocitrate dehydrogenase inhibitor	IDH1			Cc1nccn1CC(=O)N(C(C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1	Preclinical	5
BRD-A56592690-001-04-3::2.5::HTS	0.053003658414599995	BRD-A56592690-001-04-3::2.5::HTS	BRD-A56592690-001-04-3	PX-12	2.5	HTS	thioredoxin inhibitor	TXN, TXNRD1			CCC(C)SSc1ncc[nH]1	Phase 2	5
BRD-A56675431-001-12-3::2.5::HTS	-0.0370720473662	BRD-A56675431-001-12-3::2.5::HTS	BRD-A56675431-001-12-3	althiazide	2.5	HTS	diuretic		cardiology	hypertension	NS(=O)(=O)c1cc2c(NC(CSCC=C)NS2(=O)=O)cc1Cl	Launched	5
BRD-A56858165-001-04-4::2.5::HTS	-0.173674668059	BRD-A56858165-001-04-4::2.5::HTS	BRD-A56858165-001-04-4	cefadroxil	2.5	HTS	bacterial cell wall synthesis inhibitor	SLC15A1, SLC15A2, SLC22A6, SLC22A8	infectious disease, otolaryngology	urinary tract infections, skin infections, tonsillitis, pharyngitis	CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(N)c1ccc(O)cc1)C2=O)C(O)=O	Launched	5
BRD-A56987319-001-12-9::2.5::HTS	-0.0116678851921	BRD-A56987319-001-12-9::2.5::HTS	BRD-A56987319-001-12-9	SQ-22536	2.5	HTS	adenylyl cyclase inhibitor	ADCY1			Nc1ncnc2n(cnc12)C1CCCO1, Nc1ncnc2n(cnc12)C1CCCO1	Preclinical	5
BRD-A57133233-003-11-0::2.5::HTS	0.0128274426731	BRD-A57133233-003-11-0::2.5::HTS	BRD-A57133233-003-11-0	chlorcyclizine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	CN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1	Launched	5
BRD-A57382968-001-29-0::2.5::HTS	-0.7526699395399999	BRD-A57382968-001-29-0::2.5::HTS	BRD-A57382968-001-29-0	piroxicam	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O	Launched	5
BRD-A57592049-001-01-6::2.5::HTS	0.269106983789	BRD-A57592049-001-01-6::2.5::HTS	BRD-A57592049-001-01-6	methsuximide	2.5	HTS	T-type calcium channel binder	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	CN1C(=O)CC(C)(C1=O)c1ccccc1	Launched	5
BRD-A57798112-001-03-7::2.5::HTS	-3.40410716514	BRD-A57798112-001-03-7::2.5::HTS	BRD-A57798112-001-03-7	PD-318088	2.5	HTS	MEK inhibitor	MAP2K1			OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F	Preclinical	5
BRD-A57798559-004-02-3::2.5::HTS	0.21626242092099998	BRD-A57798559-004-02-3::2.5::HTS	BRD-A57798559-004-02-3	bicuculline-methochloride-(-)	2.5	HTS	GABA receptor antagonist				C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21, C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21, C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21	Preclinical	5
BRD-A57833392-001-01-7::2.5::HTS	0.107088441019	BRD-A57833392-001-01-7::2.5::HTS	BRD-A57833392-001-01-7	oxymatrine	2.5	HTS					[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23	Launched	5
BRD-A57886255-001-01-1::2.5::HTS	0.98053798817	BRD-A57886255-001-01-1::2.5::HTS	BRD-A57886255-001-01-1	golgicide-a	2.5	HTS	ARF inhibitor	GBF1			Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1	Preclinical	5
BRD-A57900429-003-05-8::2.5::HTS	0.234065586112	BRD-A57900429-003-05-8::2.5::HTS	BRD-A57900429-003-05-8	hydrastinine	2.5	HTS	haemostatic agent				CN1CCc2cc3OCOc3cc2C1O, CN1CCc2cc3OCOc3cc2C1O	Preclinical	5
BRD-A57957888-001-08-0::2.5::HTS	0.22710002375399999	BRD-A57957888-001-08-0::2.5::HTS	BRD-A57957888-001-08-0	citiolone	2.5	HTS	lipotropic, mucolytic agent				CC(=O)NC1CCSC1=O	Preclinical	5
BRD-A58048407-001-18-8::2.5::HTS	-0.34855357626199995	BRD-A58048407-001-18-8::2.5::HTS	BRD-A58048407-001-18-8	nimodipine	2.5	HTS	calcium channel blocker	AHR, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CFTR, NR3C2	hematology	hemorrhage	COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C	Launched	5
BRD-A58193911-003-18-7::2.5::HTS	-1.9570495264400003	BRD-A58193911-003-18-7::2.5::HTS	BRD-A58193911-003-18-7	oxyphencyclimine	2.5	HTS	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1	Launched	5
BRD-A58564983-001-04-6::2.5::HTS	0.158449717776	BRD-A58564983-001-04-6::2.5::HTS	BRD-A58564983-001-04-6	selamectin	2.5	HTS	nematocide		infectious disease	flea control	CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O	Launched	5
BRD-A58955223-001-03-8::2.5::HTS	0.0611261073865	BRD-A58955223-001-03-8::2.5::HTS	BRD-A58955223-001-03-8	sulforaphane	2.5	HTS	anticancer agent, aryl hydrocarbon receptor antagonist	NFE2L2			CS(=O)CCCCN=C=S	Phase 2	5
BRD-A59001851-001-02-1::2.5::HTS	-0.376529947086	BRD-A59001851-001-02-1::2.5::HTS	BRD-A59001851-001-02-1	ginkgolide-b	2.5	HTS	platelet activating factor receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			C[C@@H]1C(=O)OC2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@]4(C(=O)O5)[C@@]12O	Phase 3	5
BRD-A59174698-003-18-5::2.5::HTS	-0.327451253121	BRD-A59174698-003-18-5::2.5::HTS	BRD-A59174698-003-18-5	ritodrine	2.5	HTS	adrenergic receptor agonist	ADRB2	obstetrics/gynecology	premature labor	C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1	Launched	5
BRD-A59198242-003-02-9::2.5::HTS	0.18028156542399998	BRD-A59198242-003-02-9::2.5::HTS	BRD-A59198242-003-02-9	viloxazine	2.5	HTS	norepinephrine reuptake inhibitor	SLC6A2	neurology/psychiatry	depression	CCOc1ccccc1OCC1CNCCO1	Launched	5
BRD-A59303141-001-10-4::2.5::HTS	-0.0588975162055	BRD-A59303141-001-10-4::2.5::HTS	BRD-A59303141-001-10-4	quinethazone	2.5	HTS	thiazide diuretic	CA1, CA2, SLC12A1, SLC12A2, SLC12A3	cardiology	hypertension	CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O	Launched	5
BRD-A59337442-051-05-3::2.5::HTS	0.0134885920315	BRD-A59337442-051-05-3::2.5::HTS	BRD-A59337442-051-05-3	xamoterol	2.5	HTS	adrenergic receptor agonist	ADRB1			OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1	Phase 3	5
BRD-A59413292-001-08-2::2.5::HTS	-0.14656064716199999	BRD-A59413292-001-08-2::2.5::HTS	BRD-A59413292-001-08-2	dexpanthenol	2.5	HTS			gastroenterology	paralytic ileus	CC(C)(CO)[C@@H](O)C(=O)NCCCO, CC(C)(CO)C(O)C(=O)NCCCO	Launched	5
BRD-A59709458-001-01-8::2.5::HTS	-0.22195950224599997	BRD-A59709458-001-01-8::2.5::HTS	BRD-A59709458-001-01-8	PHCCC	2.5	HTS	glutamate receptor agonist	GRM1, GRM4			O\N=C1/C2CC2(Oc2ccccc12)C(=O)Nc1ccccc1, O\N=C1/C2CC2(Oc2ccccc12)C(=O)Nc1ccccc1	Preclinical	5
BRD-A60197193-001-14-6::2.5::HTS	-1.02689455805	BRD-A60197193-001-14-6::2.5::HTS	BRD-A60197193-001-14-6	amisulpride	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC	Launched	5
BRD-A60217728-001-11-2::2.5::HTS	0.191966305429	BRD-A60217728-001-11-2::2.5::HTS	BRD-A60217728-001-11-2	iohexol	2.5	HTS	radiopaque medium		radiology	contrast agent	CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I	Launched	5
BRD-A60594020-034-01-1::2.5::HTS	-0.11555563904	BRD-A60594020-034-01-1::2.5::HTS	BRD-A60594020-034-01-1	8-hydroxy-PIPAT	2.5	HTS	dopamine receptor ligand	DRD2, DRD3			CCCN(C\C=C\I)C1CCc2cccc(O)c2C1	Preclinical	5
BRD-A60786380-412-01-5::2.5::HTS	-0.459820545185	BRD-A60786380-412-01-5::2.5::HTS	BRD-A60786380-412-01-5	sodium-stibogluconate	2.5	HTS	tyrosine phosphatase inhibitor	PTPN6, TOP1	infectious disease	leishmaniasis	OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O	Launched	5
BRD-A61154809-001-15-9::2.5::HTS	0.104807475123	BRD-A61154809-001-15-9::2.5::HTS	BRD-A61154809-001-15-9	gliclazide	2.5	HTS	ATP channel blocker, insulin secretagogue	ABCC8, VEGFA	endocrinology	diabetes mellitus	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1	Launched	5
BRD-A61194565-003-27-0::2.5::HTS	0.21594607712900002	BRD-A61194565-003-27-0::2.5::HTS	BRD-A61194565-003-27-0	benserazide	2.5	HTS	DOPA decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	NC(CO)C(=O)NNCc1ccc(O)c(O)c1O, NC(CO)C(=O)NNCc1ccc(O)c(O)c1O	Launched	5
BRD-A61221616-001-04-3::2.5::HTS	-0.212961681602	BRD-A61221616-001-04-3::2.5::HTS	BRD-A61221616-001-04-3	medroxyprogesterone-acetate	2.5	HTS	progesterone receptor agonist		endocrinology	contraceptive	C[C@H]1CC2C3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CCC2[C@@]2(C)CCC(=O)C=C12, C[C@H]1CC2C3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CCC2[C@@]2(C)CCC(=O)C=C12	Launched	5
BRD-A61392169-001-02-7::2.5::HTS	0.159769250111	BRD-A61392169-001-02-7::2.5::HTS	BRD-A61392169-001-02-7	eliprodil	2.5	HTS	glutamate receptor antagonist	GRIN1, GRIN2B			OC(CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1	Phase 3	5
BRD-A61676498-001-06-6::2.5::HTS	0.33667021851499995	BRD-A61676498-001-06-6::2.5::HTS	BRD-A61676498-001-06-6	climbazole	2.5	HTS	enzyme inducer		dermatology	dandruff, eczema	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1, CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1	Launched	5
BRD-A61793559-001-15-6::2.5::HTS	0.22667939535999998	BRD-A61793559-001-15-6::2.5::HTS	BRD-A61793559-001-15-6	metolazone	2.5	HTS	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O, CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O, CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O	Launched	5
BRD-A61850409-001-10-7::2.5::HTS	0.391106146483	BRD-A61850409-001-10-7::2.5::HTS	BRD-A61850409-001-10-7	alpha-tochopheryl-acetate	2.5	HTS	antioxidant		endocrinology	vitamin E deficiency	CC(C)CCCC(C)CCCC(C)CCCC1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1	Launched	5
BRD-A62021152-003-03-4::2.5::HTS	-0.0091785199529	BRD-A62021152-003-03-4::2.5::HTS	BRD-A62021152-003-03-4	WAY-161503	2.5	HTS	serotonin receptor agonist	HTR2C			Clc1cc2NC(=O)C3CNCCN3c2cc1Cl, Clc1cc2NC(=O)C3CNCCN3c2cc1Cl	Preclinical	5
BRD-A62057054-001-03-1::2.5::HTS	-0.0516659561155	BRD-A62057054-001-03-1::2.5::HTS	BRD-A62057054-001-03-1	MDL-11939	2.5	HTS	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			OC(C1CCN(CCc2ccccc2)CC1)c1ccccc1, OC(C1CCN(CCc2ccccc2)CC1)c1ccccc1	Phase 2	5
BRD-A62071884-001-04-6::2.5::HTS	-0.320658260755	BRD-A62071884-001-04-6::2.5::HTS	BRD-A62071884-001-04-6	siguazodan	2.5	HTS	phosphodiesterase inhibitor	PDE3A			CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)CC1C, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)CC1C	Phase 1	5
BRD-A62209527-001-04-5::2.5::HTS	0.23923577815299998	BRD-A62209527-001-04-5::2.5::HTS	BRD-A62209527-001-04-5	ZM-226600	2.5	HTS	Kir6 channel (KATP) activator				CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F	Preclinical	5
BRD-A62421304-004-18-9::2.5::HTS	-0.0705035604346	BRD-A62421304-004-18-9::2.5::HTS	BRD-A62421304-004-18-9	mepenzolate	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD)	C[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1, C[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1	Launched	5
BRD-A62428732-300-06-3::2.5::HTS	-0.186119265507	BRD-A62428732-300-06-3::2.5::HTS	BRD-A62428732-300-06-3	hydroxyzine	2.5	HTS	antihistamine	HRH1	neurology/psychiatry, allergy, dermatology	anxiety, urticaria, itching, dermatosis, anxiety, urticaria, itching, dermatosis	OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1, OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1	Launched	5
BRD-A62731508-001-05-8::2.5::HTS	0.184378007177	BRD-A62731508-001-05-8::2.5::HTS	BRD-A62731508-001-05-8	cortisone	2.5	HTS	glucocorticoid receptor agonist	NR3C1	gastroenterology, rheumatology, dermatology	ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema	C[C@]12CC(=O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO	Launched	5
BRD-A63310107-001-04-8::2.5::HTS	-0.25872403567499996	BRD-A63310107-001-04-8::2.5::HTS	BRD-A63310107-001-04-8	miglitol	2.5	HTS	glucosidase inhibitor	GAA, GANAB, GANC, MGAM	endocrinology	diabetes mellitus	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@@H](O)[C@@H](O)C(O)C1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	Launched	5
BRD-A63444178-001-01-5::2.5::HTS	-0.39876008952200004	BRD-A63444178-001-01-5::2.5::HTS	BRD-A63444178-001-01-5	ME0328	2.5	HTS	PARP inhibitor	PARP3			CC(NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1	Preclinical	5
BRD-A63546914-003-02-0::2.5::HTS	0.550665863158	BRD-A63546914-003-02-0::2.5::HTS	BRD-A63546914-003-02-0	Ro-04-5595	2.5	HTS		GRIN2B			COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O	Preclinical	5
BRD-A63675168-001-01-6::2.5::HTS	0.38864024516900003	BRD-A63675168-001-01-6::2.5::HTS	BRD-A63675168-001-01-6	brivudine	2.5	HTS	DNA directed DNA polymerase inhibitor		infectious disease	shingles	OC[C@H]1O[C@H](CC1O)n1cc(\C=C\Br)c(=O)[nH]c1=O	Launched	5
BRD-A63752151-001-01-2::2.5::HTS	-0.219160492139	BRD-A63752151-001-01-2::2.5::HTS	BRD-A63752151-001-01-2	fidarestat	2.5	HTS	aldose reductase inhibitor	AKR1B1			NC(=O)C1CC2(NC(=O)NC2=O)c2cc(F)ccc2O1	Phase 3	5
BRD-A63780829-001-11-4::2.5::HTS	0.40123598923299997	BRD-A63780829-001-11-4::2.5::HTS	BRD-A63780829-001-11-4	hyperin	2.5	HTS	aldose reductase inhibitor	ACE, AKR1B1			OCC1OC(Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)C(O)C(O)C1O	Preclinical	5
BRD-A64011898-001-01-0::2.5::HTS	0.023329247582400004	BRD-A64011898-001-01-0::2.5::HTS	BRD-A64011898-001-01-0	androstenone	2.5	HTS	steroid				CC12CCC3C(CCC4CC(=O)CCC34C)C1CC=C2	Preclinical	5
BRD-A64064900-001-02-3::2.5::HTS	-5.52376545665	BRD-A64064900-001-02-3::2.5::HTS	BRD-A64064900-001-02-3	sangivamycin	2.5	HTS	DNA inhibitor				NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12	Phase 1	5
BRD-A64092382-003-18-3::2.5::HTS	0.27792157835700004	BRD-A64092382-003-18-3::2.5::HTS	BRD-A64092382-003-18-3	mexiletine	2.5	HTS	sodium channel blocker	AHR, SCN4A, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C	Launched	5
BRD-A64125466-236-04-6::2.5::HTS	0.526806670119	BRD-A64125466-236-04-6::2.5::HTS	BRD-A64125466-236-04-6	dehydrocholate	2.5	HTS					C[C@H](CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)CC1CC3=O	Preclinical	5
BRD-A64227845-004-09-3::2.5::HTS	-0.508278462206	BRD-A64227845-004-09-3::2.5::HTS	BRD-A64227845-004-09-3	SKF-77434	2.5	HTS	dopamine receptor agonist	DRD1			Oc1cc2CCN(CC=C)CC(c3ccccc3)c2cc1O	Preclinical	5
BRD-A64242993-001-05-6::2.5::HTS	-2.22532872464	BRD-A64242993-001-05-6::2.5::HTS	BRD-A64242993-001-05-6	lanatoside-c	2.5	HTS	cardiac glycoside				C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	Preclinical	5
BRD-A64406146-001-01-2::2.5::HTS	0.07627230315399999	BRD-A64406146-001-01-2::2.5::HTS	BRD-A64406146-001-01-2	timofibrate	2.5	HTS	cholesterol inhibitor, lipase clearing factor inhibitor	LPL			CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSCC1C(O)=O	Phase 2	5
BRD-A64553394-001-04-4::2.68::HTS	-0.045783207269900004	BRD-A64553394-001-04-4::2.68::HTS	BRD-A64553394-001-04-4	DPI-201106	2.68	HTS	sodium channel activator	ADRB2			OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1	Phase 2	5
BRD-A64610707-001-04-4::2.5::HTS	0.233459094917	BRD-A64610707-001-04-4::2.5::HTS	BRD-A64610707-001-04-4	pranoprofen	2.5	HTS	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1, CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1, CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1	Launched	5
BRD-A64698388-003-01-7::2.5::HTS	0.08397806466	BRD-A64698388-003-01-7::2.5::HTS	BRD-A64698388-003-01-7	levo-phencynonate	2.5	HTS	acetylcholine receptor antagonist	CHRM1			CN1CC2CCCC(C1)C2OC(=O)C(O)(C1CCCC1)c1ccccc1	Launched	5
BRD-A64743628-001-01-5::2.5::HTS	-1.38508808614	BRD-A64743628-001-01-5::2.5::HTS	BRD-A64743628-001-01-5	isometheptene-mucate	2.5	HTS		ADRA1A, SLC18A2	neurology/psychiatry	headache	CNC(C)CCC=C(C)C	Launched	5
BRD-A64808605-003-02-7::2.5::HTS	0.180801095828	BRD-A64808605-003-02-7::2.5::HTS	BRD-A64808605-003-02-7	AH11110	2.5	HTS	adrenergic receptor ligand	ADRA1B			OC(COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1	Preclinical	5
BRD-A64977602-001-15-9::2.5::HTS	0.27698459393	BRD-A64977602-001-15-9::2.5::HTS	BRD-A64977602-001-15-9	mirtazapine	2.5	HTS	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD5, HRH1, HRH3, HTR2A, HTR2B, HTR2C, HTR3A, HTR7, OPRK1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	CN1CCN2C(C1)c1ccccc1Cc1cccnc21, CN1CCN2C(C1)c1ccccc1Cc1cccnc21, CN1CCN2C(C1)c1ccccc1Cc1cccnc21, CN1CCN2C(C1)c1ccccc1Cc1cccnc21	Launched	5
BRD-A65013509-003-24-4::2.5::HTS	0.325495897688	BRD-A65013509-003-24-4::2.5::HTS	BRD-A65013509-003-24-4	oxybutynin	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	urology	urinary incontinence	CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1, CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1, CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1	Launched	5
BRD-A65051990-001-12-9::2.5::HTS	-0.263654482836	BRD-A65051990-001-12-9::2.5::HTS	BRD-A65051990-001-12-9	acenocoumarol	2.5	HTS	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	CC(=O)CC(c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O	Launched	5
BRD-A65145453-001-06-1::2.5::HTS	0.19572562939399998	BRD-A65145453-001-06-1::2.5::HTS	BRD-A65145453-001-06-1	ATPA	2.5	HTS	glutamate receptor agonist	GRIA2, GRIK1			CC(C)(C)c1onc(O)c1CC(N)C(O)=O, CC(C)(C)c1onc(O)c1CC(N)C(O)=O	Preclinical	5
BRD-A65248799-001-01-7::2.5::HTS	-0.5642790613650001	BRD-A65248799-001-01-7::2.5::HTS	BRD-A65248799-001-01-7	EMD-53998	2.5	HTS	phosphodiesterase inhibitor	TNNC1			COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C	Phase 1	5
BRD-A65280694-003-13-7::2.5::HTS	0.07354886212339999	BRD-A65280694-003-13-7::2.5::HTS	BRD-A65280694-003-13-7	molindone	2.5	HTS	dopamine receptor antagonist	CHRM1, DRD2, HRH1, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	CCc1c(C)[nH]c2CCC(CN3CCOCC3)C(=O)c12	Launched	5
BRD-A65440446-001-04-1::2.5::HTS	0.373246612812	BRD-A65440446-001-04-1::2.5::HTS	BRD-A65440446-001-04-1	cimaterol	2.5	HTS	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			CC(C)NCC(O)c1ccc(N)c(c1)C#N	Preclinical	5
BRD-A65449987-001-10-4::2.5::HTS	-0.00573907745177	BRD-A65449987-001-10-4::2.5::HTS	BRD-A65449987-001-10-4	flunisolide	2.5	HTS	cytochrome P450 inhibitor	NR3C1	allergy	allergic rhinitis	CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)[C@@]2(O1)C(=O)CO	Launched	5
BRD-A65597028-003-07-3::2.5::HTS	0.0568355907169	BRD-A65597028-003-07-3::2.5::HTS	BRD-A65597028-003-07-3	RX-821002	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C			COC1(COc2ccccc2O1)C1=NCCN1, COC1(COc2ccccc2O1)C1=NCCN1	Preclinical	5
BRD-A65615053-003-02-2::2.5::HTS	0.267405892742	BRD-A65615053-003-02-2::2.5::HTS	BRD-A65615053-003-02-2	zacopride	2.5	HTS	serotonin receptor antagonist	HTR3A, HTR3B, HTR4, HTR5A			COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2, COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2	Phase 2	5
BRD-A65671304-001-07-5::2.5::HTS	-0.30435672544799997	BRD-A65671304-001-07-5::2.5::HTS	BRD-A65671304-001-07-5	candesartan-cilextil	2.5	HTS	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension, congestive heart failure	CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Launched	5
BRD-A65767837-001-04-4::2.5::HTS	0.341044609131	BRD-A65767837-001-04-4::2.5::HTS	BRD-A65767837-001-04-4	hydrocortisone-acetate	2.5	HTS	glucocorticoid receptor agonist	NR3C1, NR3C2	dermatology	corticosteroid-responsive dermatoses	CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C	Launched	5
BRD-A65797496-048-09-3::2.5::HTS	-0.21159546928599998	BRD-A65797496-048-09-3::2.5::HTS	BRD-A65797496-048-09-3	deptropine	2.5	HTS	histamine receptor antagonist	HRH1			CN1[C@H]2CC[C@@H]1CC(C2)OC1c2ccccc2CCc2ccccc12	Preclinical	5
BRD-A65818372-001-05-3::2.5::HTS	0.221234029813	BRD-A65818372-001-05-3::2.5::HTS	BRD-A65818372-001-05-3	ioversol	2.5	HTS	radiopaque medium		radiology	contrast agent	OCCN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I	Launched	5
BRD-A66116161-001-02-3::2.5::HTS	-0.121476706765	BRD-A66116161-001-02-3::2.5::HTS	BRD-A66116161-001-02-3	AM-1241	2.5	HTS	cannabinoid receptor agonist	CNR1, CNR2			CN1CCCCC1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12	Preclinical	5
BRD-A66419424-001-02-4::2.5::HTS	-5.5487164490100005	BRD-A66419424-001-02-4::2.5::HTS	BRD-A66419424-001-02-4	ixazomib-citrate	2.5	HTS	proteasome inhibitor		hematologic malignancy	multiple myeloma	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O	Launched	5
BRD-A66435872-332-01-8::2.5::HTS	-0.08694903525110001	BRD-A66435872-332-01-8::2.5::HTS	BRD-A66435872-332-01-8	HTMT	2.5	HTS	histamine receptor agonist	HRH4			CC(CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1c[nH]cn1, CC(CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1c[nH]cn1	Preclinical	5
BRD-A66869276-001-02-9::2.5::HTS	0.4761598048899999	BRD-A66869276-001-02-9::2.5::HTS	BRD-A66869276-001-02-9	diflorasone-diacetate	2.5	HTS	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	C[C@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O	Launched	5
BRD-A66920069-001-01-3::2.5::HTS	-0.333331178635	BRD-A66920069-001-01-3::2.5::HTS	BRD-A66920069-001-01-3	fenigam	2.5	HTS	benzodiazepine receptor agonist	GABBR1, GABBR2	neurology/psychiatry	posttraumatic stress disorder, anxiety, depression	NCC(CC(O)=O)c1ccccc1	Launched	5
BRD-A66966115-001-01-0::2.5::HTS	0.034237559511299996	BRD-A66966115-001-01-0::2.5::HTS	BRD-A66966115-001-01-0	NM107	2.5	HTS	RNA polymerase inhibitor				CC1(O)C(O)C(CO)OC1n1ccc(N)nc1=O	Phase 2	5
BRD-A67006024-001-04-8::2.5::HTS	0.252442737075	BRD-A67006024-001-04-8::2.5::HTS	BRD-A67006024-001-04-8	SNAP	2.5	HTS	nitric oxide donor	PTPN1			CC(=O)NC(C(O)=O)C(C)(C)S[N+][O-], CC(=O)NC(C(O)=O)C(C)(C)S[N+][O-]	Phase 2	5
BRD-A67060370-001-02-9::2.5::HTS	0.46089181126699996	BRD-A67060370-001-02-9::2.5::HTS	BRD-A67060370-001-02-9	albendazole-oxide	2.5	HTS	anthelmintic agent		infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	CCCS(=O)c1ccc2nc(NC(=O)OC)[nH]c2c1	Launched	5
BRD-A67097164-001-18-7::2.5::HTS	0.210336222365	BRD-A67097164-001-18-7::2.5::HTS	BRD-A67097164-001-18-7	ifosfamide	2.5	HTS	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl	Launched	5
BRD-A67101513-001-03-7::2.5::HTS	0.303639451478	BRD-A67101513-001-03-7::2.5::HTS	BRD-A67101513-001-03-7	hygromycin-b	2.5	HTS	polypeptide synthesis inhibitor				CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@@H]3OC4(O[C@@H]3[C@@H]2O)O[C@H](C(N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O	Preclinical	5
BRD-A67181951-001-01-2::2.5::HTS	-0.017449635799900002	BRD-A67181951-001-01-2::2.5::HTS	BRD-A67181951-001-01-2	gadobutrol	2.5	HTS	radiopaque medium		radiology	MRI contrast agent	OCC(O)[C@@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2	Launched	5
BRD-A67363467-001-01-3::2.5::HTS	0.35940135450599997	BRD-A67363467-001-01-3::2.5::HTS	BRD-A67363467-001-01-3	dihydrostreptomycin	2.5	HTS	bacterial 30S ribosomal subunit inhibitor				CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO	Withdrawn	5
BRD-A67482312-001-02-6::2.5::HTS	-0.027174682113900003	BRD-A67482312-001-02-6::2.5::HTS	BRD-A67482312-001-02-6	4-P-PDOT	2.5	HTS	melatonin receptor antagonist	MTNR1A, MTNR1B			CCC(=O)NC1CC(c2ccccc2)c2ccccc2C1, CCC(=O)NC1CC(c2ccccc2)c2ccccc2C1	Preclinical	5
BRD-A67514145-003-05-8::2.5::HTS	0.273019862195	BRD-A67514145-003-05-8::2.5::HTS	BRD-A67514145-003-05-8	furaltadone	2.5	HTS	bacterial DNA inhibitor				[O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1	Launched	5
BRD-A67516570-001-02-8::2.5::HTS	-1.27176699574	BRD-A67516570-001-02-8::2.5::HTS	BRD-A67516570-001-02-8	lafutidine	2.5	HTS	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1	Launched	5
BRD-A67521319-001-01-6::2.5::HTS	-0.181347491663	BRD-A67521319-001-01-6::2.5::HTS	BRD-A67521319-001-01-6	pimonidazole	2.5	HTS					OC(CN1CCCCC1)Cn1ccnc1[N+]([O-])=O	Phase 3	5
BRD-A67616246-001-07-9::2.5::HTS	0.161991495303	BRD-A67616246-001-07-9::2.5::HTS	BRD-A67616246-001-07-9	levomequitazine	2.5	HTS	histamine receptor antagonist	HRH1			C(C1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12	Phase 2	5
BRD-A67748489-001-10-0::2.5::HTS	-2.09263417433	BRD-A67748489-001-10-0::2.5::HTS	BRD-A67748489-001-10-0	K-858	2.5	HTS	kinesin-like spindle protein inhibitor	KIF11			CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1	Preclinical	5
BRD-A67862938-034-14-9::2.5::HTS	-0.49843203244999995	BRD-A67862938-034-14-9::2.5::HTS	BRD-A67862938-034-14-9	naftidrofuryl	2.5	HTS	adrenergic receptor antagonist		cardiology	claudication	CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12	Launched	5
BRD-A67975844-001-01-8::2.5::HTS	-0.162604470813	BRD-A67975844-001-01-8::2.5::HTS	BRD-A67975844-001-01-8	NSC-405020	2.5	HTS	matrix metalloprotease inhibitor	MMP1			CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1, CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-A68083442-001-01-6::2.5::HTS	0.150914926471	BRD-A68083442-001-01-6::2.5::HTS	BRD-A68083442-001-01-6	pranidipine	2.5	HTS	calcium channel blocker	CACNA1C			COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1	Phase 2	5
BRD-A68281735-001-18-6::0.25::HTS	0.184754492599	BRD-A68281735-001-18-6::0.25::HTS	BRD-A68281735-001-18-6	REV-5901	0.25	HTS	leukotriene receptor antagonist, lipoxygenase inhibitor	ALOX5			CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1	Phase 2	3
BRD-A68304895-003-02-2::2.5::HTS	-0.879872409943	BRD-A68304895-003-02-2::2.5::HTS	BRD-A68304895-003-02-2	BTS-54505	2.5	HTS	dopamine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1	Withdrawn	5
BRD-A68464583-001-02-5::2.5::HTS	0.440813433728	BRD-A68464583-001-02-5::2.5::HTS	BRD-A68464583-001-02-5	mazindol	2.5	HTS	dopamine reuptake inhibitor, selective serotonin reuptake inhibitor (SSRI)	SLC6A2, SLC6A3, SLC6A4	genetics	duchenne muscular dystrophy (DMD)	OC1(N2CCN=C2c2ccccc12)c1ccc(Cl)cc1	Launched	5
BRD-A68493689-001-01-9::2.5::HTS	-0.36289839256800005	BRD-A68493689-001-01-9::2.5::HTS	BRD-A68493689-001-01-9	simeprevir	2.5	HTS	HCV inhibitor	CYP1A2, CYP3A4	infectious disease	hepatitis C	COc1ccc2c(O[C@@H]3C[C@@H]4C(C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C	Launched	5
BRD-A68509429-003-03-9::2.5::HTS	0.0887796020765	BRD-A68509429-003-03-9::2.5::HTS	BRD-A68509429-003-03-9	ethylnorepinephrine	2.5	HTS	bronchodilator				CCC(N)C(O)c1ccc(O)c(O)c1	Preclinical	5
BRD-A68589262-001-04-3::2.5::HTS	-0.102004561996	BRD-A68589262-001-04-3::2.5::HTS	BRD-A68589262-001-04-3	troxipide	2.5	HTS	glucosamine synthetase stimulant		gastroenterology	gastroesophageal reflux disease (GERD)	COc1cc(cc(OC)c1OC)C(=O)NC1CCCNC1, COc1cc(cc(OC)c1OC)C(=O)NC1CCCNC1	Launched	5
BRD-A68631409-001-05-4::2.5::HTS	-1.3855582571899998	BRD-A68631409-001-05-4::2.5::HTS	BRD-A68631409-001-05-4	evodiamine	2.5	HTS	ATPase inhibitor, TRPV agonist	TRPV1			CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12	Preclinical	5
BRD-A68723818-050-32-5::2.5::HTS	-0.37946399274400006	BRD-A68723818-050-32-5::2.5::HTS	BRD-A68723818-050-32-5	brompheniramine	2.5	HTS	histamine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1	allergy, otolaryngology	allergic rhinitis, common cold	CN(C)CCC(c1ccc(Br)cc1)c1ccccn1, CN(C)CCC(c1ccc(Br)cc1)c1ccccn1	Launched	5
BRD-A68888262-003-15-1::2.5::HTS	0.199114583043	BRD-A68888262-003-15-1::2.5::HTS	BRD-A68888262-003-15-1	azelastine	2.5	HTS	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	CN1CCCC(CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O, CN1CCCC(CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O	Launched	5
BRD-A68942014-003-01-7::2.5::HTS	-0.43149512632299997	BRD-A68942014-003-01-7::2.5::HTS	BRD-A68942014-003-01-7	amitifadine	2.5	HTS	serotonin transporter (SERT) inhibitor	SLC6A2, SLC6A3, SLC6A4			Clc1ccc(cc1Cl)C12CC1CNC2	Phase 3	5
BRD-A68969091-001-12-7::2.57::HTS	-5.5169900606699995	BRD-A68969091-001-12-7::2.57::HTS	BRD-A68969091-001-12-7	echinomycin	2.57	HTS	DNA intercalating agent				CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1	Phase 2	5
BRD-A69275535-001-01-5::2.5::HTS	-0.634913503661	BRD-A69275535-001-01-5::2.5::HTS	BRD-A69275535-001-01-5	pinitol	2.5	HTS	gamma secretase inhibitor				COC1C(O)[C@@H](O)C(O)C(O)[C@H]1O	Phase 2	5
BRD-A69636825-003-04-7::2.5::HTS	-0.163271597027	BRD-A69636825-003-04-7::2.5::HTS	BRD-A69636825-003-04-7	diltiazem	2.5	HTS	calcium channel blocker	CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5	cardiology	hypertension, angina pectoris	COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)C1Sc2ccccc2N(CCN(C)C)C(=O)C1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O	Launched	5
BRD-A69651145-003-07-2::2.5::HTS	0.25353178696	BRD-A69651145-003-07-2::2.5::HTS	BRD-A69651145-003-07-2	minocycline	2.5	HTS	bacterial 30S ribosomal subunit inhibitor	ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA	endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C	Launched	5
BRD-A69777949-001-24-2::2.5::HTS	-0.0641156563158	BRD-A69777949-001-24-2::2.5::HTS	BRD-A69777949-001-24-2	flumequine	2.5	HTS	topoisomerase inhibitor		infectious disease	urinary tract infections	CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O	Launched	5
BRD-A69815203-001-07-6::2.5::HTS	-0.11789525429099999	BRD-A69815203-001-07-6::2.5::HTS	BRD-A69815203-001-07-6	cyclosporin-a	2.5	HTS	calcineurin inhibitor	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	Launched	5
BRD-A69917777-065-02-2::2.5::HTS	0.220788766435	BRD-A69917777-065-02-2::2.5::HTS	BRD-A69917777-065-02-2	aminopentamide	2.5	HTS	acetylcholine receptor antagonist	CHRM1	gastroenterology	acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea	CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C	Launched	5
BRD-A70083328-001-23-5::2.5::HTS	-2.68062094546	BRD-A70083328-001-23-5::2.5::HTS	BRD-A70083328-001-23-5	secnidazole	2.5	HTS	acetylcholinesterase inhibitor, microtubule inhibitor		infectious disease	protozoan infection	CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O	Launched	5
BRD-A70083328-001-24-3::2.5::HTS	0.0637731192244	BRD-A70083328-001-24-3::2.5::HTS	BRD-A70083328-001-24-3	secnidazole	2.5	HTS	acetylcholinesterase inhibitor, microtubule inhibitor		infectious disease	protozoan infection	CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O	Launched	5
BRD-A70268693-050-01-2::2.5::HTS	0.013698082503599999	BRD-A70268693-050-01-2::2.5::HTS	BRD-A70268693-050-01-2	PG-9	2.5	HTS	acetylcholine receptor agonist				CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1	Preclinical	5
BRD-A70407468-001-02-0::2.5::HTS	-0.48529667388000003	BRD-A70407468-001-02-0::2.5::HTS	BRD-A70407468-001-02-0	PSB-36	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CCCCn1c(=O)n(CCCO)c2nc([nH]c2c1=O)C12CC3CC1CC(C2)C3, CCCCn1c(=O)n(CCCO)c2nc([nH]c2c1=O)C12CC3CC1CC(C2)C3	Preclinical	5
BRD-A70514680-003-11-2::2.5::HTS	0.315916693265	BRD-A70514680-003-11-2::2.5::HTS	BRD-A70514680-003-11-2	articaine	2.5	HTS	local anesthetic		neurology/psychiatry	local anesthetic	CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC	Launched	5
BRD-A70649075-008-30-8::2.5::HTS	0.0371464541865	BRD-A70649075-008-30-8::2.5::HTS	BRD-A70649075-008-30-8	sulconazole	2.5	HTS	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1	Launched	5
BRD-A70858459-001-01-7::2.5::HTS	0.307257910761	BRD-A70858459-001-01-7::2.5::HTS	BRD-A70858459-001-01-7	estramustine	2.5	HTS	DNA alkylating agent	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O	Launched	5
BRD-A70998768-004-01-1::2.5::HTS	0.159442450081	BRD-A70998768-004-01-1::2.5::HTS	BRD-A70998768-004-01-1	pinaverium	2.5	HTS	T-type calcium channel blocker	CACNA1C	gastroenterology	irritable bowel syndrome	COc1cc(Br)c(C[N+]2(CCOCCC3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC	Launched	5
BRD-A71033472-003-23-9::2.5::HTS	-0.331460335786	BRD-A71033472-003-23-9::2.5::HTS	BRD-A71033472-003-23-9	fendiline	2.5	HTS	calcium channel blocker	HTR2B			CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1	Preclinical	5
BRD-A71157293-003-10-0::2.5::HTS	0.191793242881	BRD-A71157293-003-10-0::2.5::HTS	BRD-A71157293-003-10-0	fursultiamine	2.5	HTS	vitamin B				C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSCC1CCCO1	Launched	5
BRD-A71262238-001-08-4::2.5::HTS	-0.283733735296	BRD-A71262238-001-08-4::2.5::HTS	BRD-A71262238-001-08-4	nafadotride	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3, HTR1A			CCCCN1CCCC1CNC(=O)c1cc(C#N)c2ccccc2c1OC	Preclinical	5
BRD-A71407503-001-01-8::2.5::HTS	-0.000372947351638	BRD-A71407503-001-01-8::2.5::HTS	BRD-A71407503-001-01-8	inimur	2.5	HTS	other antifungal				CSCC1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1, CSCC1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1	Launched	5
BRD-A71725768-001-01-3::2.5::HTS	-0.179428273396	BRD-A71725768-001-01-3::2.5::HTS	BRD-A71725768-001-01-3	metoxibutropate	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2			COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1	Launched	5
BRD-A71774530-001-05-9::2.5::HTS	-0.11784726760500001	BRD-A71774530-001-05-9::2.5::HTS	BRD-A71774530-001-05-9	lufenuron	2.5	HTS	chitin inhibitor		infectious disease	flea control	FC(C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl	Launched	5
BRD-A72066420-001-04-5::2.5::HTS	0.35243700916000004	BRD-A72066420-001-04-5::2.5::HTS	BRD-A72066420-001-04-5	mifobate	2.5	HTS	PPAR receptor antagonist	PPARG			COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC	Phase 2	5
BRD-A72212290-300-01-4::2.5::HTS	-0.116768119738	BRD-A72212290-300-01-4::2.5::HTS	BRD-A72212290-300-01-4	eprazinone	2.5	HTS	mucolytic agent		pulmonary	bronchospasm	CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1, CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1	Launched	5
BRD-A72309220-001-04-1::2.5::HTS	0.08610996256010002	BRD-A72309220-001-04-1::2.5::HTS	BRD-A72309220-001-04-1	metergoline	2.5	HTS	dopamine receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1CC(CNC(=O)OCc2ccccc2)C[C@@H]2C1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13	Launched	5
BRD-A72390365-001-15-2::2.5::HTS	0.0326765204846	BRD-A72390365-001-15-2::2.5::HTS	BRD-A72390365-001-15-2	choline-alfoscerate	2.5	HTS	acetylcholine precursor	GM2A			C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO	Launched	5
BRD-A72483914-001-03-7::2.5::HTS	0.19868405524500002	BRD-A72483914-001-03-7::2.5::HTS	BRD-A72483914-001-03-7	spiroxatrine	2.5	HTS	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B			O=C1NCN(c2ccccc2)C11CCN(CC2COc3ccccc3O2)CC1	Preclinical	5
BRD-A72703248-003-04-9::2.5::HTS	0.30902255735899997	BRD-A72703248-003-04-9::2.5::HTS	BRD-A72703248-003-04-9	SKF-96365	2.5	HTS	calcium channel blocker	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2			COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1	Preclinical	5
BRD-A72711497-236-03-8::2.5::HTS	0.7234349098299999	BRD-A72711497-236-03-8::2.5::HTS	BRD-A72711497-236-03-8	lasalocid	2.5	HTS	bacterial permeability inducer		infectious disease	coccidiosis	CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O	Launched	5
BRD-A72716251-001-01-5::0.91::HTS	-6.36085308672	BRD-A72716251-001-01-5::0.91::HTS	BRD-A72716251-001-01-5	peruvoside	0.91	HTS	cardiac glycoside				CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O	Phase 1	4
BRD-A72767275-003-01-6::2.5::HTS	-0.121957257579	BRD-A72767275-003-01-6::2.5::HTS	BRD-A72767275-003-01-6	nalmefene	2.5	HTS	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	pulmonary	respiratory depression	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2CC3N(CC4CC4)CCC45C(Oc1c24)C(=C)CCC35O	Launched	5
BRD-A73368467-003-17-6::2.5::HTS	-0.654860385386	BRD-A73368467-003-17-6::2.5::HTS	BRD-A73368467-003-17-6	fexofenadine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1	Launched	5
BRD-A73427433-240-01-3::2.5::HTS	-0.914683481502	BRD-A73427433-240-01-3::2.5::HTS	BRD-A73427433-240-01-3	adaprev	2.5	HTS	TGF beta receptor inhibitor	IGF2R, M6PR			OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O	Phase 3	5
BRD-A73556557-001-06-4::2.5::HTS	-0.553199188383	BRD-A73556557-001-06-4::2.5::HTS	BRD-A73556557-001-06-4	tagatose	2.5	HTS	phosphorylase inhibitor	PYGL			OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO	Phase 3	5
BRD-A73709786-001-01-3::2.5::HTS	0.501597272985	BRD-A73709786-001-01-3::2.5::HTS	BRD-A73709786-001-01-3	LB-100	2.5	HTS	protein phosphatase inhibitor				CN1CCN(CC1)C(=O)C1[C@H]2CC[C@H](O2)C1C(O)=O, CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O, CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O	Phase 1	5
BRD-A73871920-236-03-6::2.5::HTS	-2.70867322814	BRD-A73871920-236-03-6::2.5::HTS	BRD-A73871920-236-03-6	nanchangmycin	2.5	HTS	other antibiotic				CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C	Preclinical	5
BRD-A73908300-001-06-7::2.5::HTS	-0.19715691329399998	BRD-A73908300-001-06-7::2.5::HTS	BRD-A73908300-001-06-7	EX-527	2.5	HTS	SIRT inhibitor	SIRT1			NC(=O)C1CCCc2c1[nH]c1ccc(Cl)cc21, NC(=O)C1CCCc2c1[nH]c1ccc(Cl)cc21	Phase 2	5
BRD-A73930134-001-03-0::2.5::HTS	-0.192443316195	BRD-A73930134-001-03-0::2.5::HTS	BRD-A73930134-001-03-0	5-hydroxytryptophan	2.5	HTS	neurotransmitter	SLC36A1, SLC36A2	neurology/psychiatry	insomnia	NC(Cc1c[nH]c2ccc(O)cc12)C(O)=O, NC(Cc1c[nH]c2ccc(O)cc12)C(O)=O	Launched	5
BRD-A74208568-003-01-5::2.5::HTS	-0.7059474695810001	BRD-A74208568-003-01-5::2.5::HTS	BRD-A74208568-003-01-5	CGP-54626	2.5	HTS	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-A74387232-001-02-5::2.5::HTS	-0.055005430233300005	BRD-A74387232-001-02-5::2.5::HTS	BRD-A74387232-001-02-5	PMPA	2.5	HTS	glutamate receptor antagonist	FOLH1			OC(=O)CCC(CP(O)(O)=O)C(O)=O	Preclinical	5
BRD-A74391928-051-01-3::2.5::HTS	-0.20099554255899998	BRD-A74391928-051-01-3::2.5::HTS	BRD-A74391928-051-01-3	ibutilide	2.5	HTS	potassium channel blocker	CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6	cardiology	atrial fibrillation (AF)	CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1	Launched	5
BRD-A74391928-051-02-1::2.64::HTS	-0.136864300489	BRD-A74391928-051-02-1::2.64::HTS	BRD-A74391928-051-02-1	ibutilide	2.64	HTS	potassium channel blocker	CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6	cardiology	atrial fibrillation (AF)	CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1	Launched	5
BRD-A74667430-001-23-6::2.5::HTS	0.132934811819	BRD-A74667430-001-23-6::2.5::HTS	BRD-A74667430-001-23-6	etodolac	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2, RXRA	rheumatology	osteoarthritis, rheumatoid arthritis	CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12, CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12	Launched	5
BRD-A74765037-001-01-1::2.5::HTS	-0.7295382185889999	BRD-A74765037-001-01-1::2.5::HTS	BRD-A74765037-001-01-1	estradiol-benzoate	2.5	HTS	contraceptive agent	ESR1			C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O	Preclinical	5
BRD-A74914197-001-02-9::2.5::HTS	-3.24442368462	BRD-A74914197-001-02-9::2.5::HTS	BRD-A74914197-001-02-9	pralatrexate	2.5	HTS	dihydrofolate reductase inhibitor	DHFR, TYMS	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	Launched	5
BRD-A74975734-004-10-7::2.5::HTS	-0.10803379916099999	BRD-A74975734-004-10-7::2.5::HTS	BRD-A74975734-004-10-7	homatropine	2.5	HTS	acetylcholine receptor antagonist	CES1, CHRM1	ophthalmology	pupil dilation	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)c1ccccc1	Launched	5
BRD-A74980173-001-11-9::2.5::HTS	0.412252068534	BRD-A74980173-001-11-9::2.5::HTS	BRD-A74980173-001-11-9	gatifloxacin	2.5	HTS	bacterial DNA gyrase inhibitor				COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	Withdrawn	5
BRD-A75140635-003-10-9::2.5::HTS	0.34569191077699996	BRD-A75140635-003-10-9::2.5::HTS	BRD-A75140635-003-10-9	isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,	2.5	HTS					COc1cc2CCNC(C)c2cc1OC	Preclinical	5
BRD-A75305484-001-01-3::2.5::HTS	0.149824688471	BRD-A75305484-001-01-3::2.5::HTS	BRD-A75305484-001-01-3	anidulafungin	2.5	HTS	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, fungal infection, esophageal candidiasis	CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)NC1CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(NC(=O)C(NC(=O)C2CC(O)CN2C(=O)C(NC1=O)C(C)O)C(O)C(O)c1ccc(O)cc1)C(C)O	Launched	5
BRD-A75369945-001-01-2::2.5::HTS	0.0555608721025	BRD-A75369945-001-01-2::2.5::HTS	BRD-A75369945-001-01-2	vitamin-b12	2.5	HTS			hematology	megaloblastic anemia	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2[N+]3=C1C(C)=C1[C@@H](CCC(N)=O)C(C)(C)C4=[N+]1[Co]31(C#N)N3C([C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]23C)=C(C)C2=[N+]1C(=C4)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12	Launched	5
BRD-A75479906-001-02-4::2.5::HTS	0.508582190238	BRD-A75479906-001-02-4::2.5::HTS	BRD-A75479906-001-02-4	rimantadine	2.5	HTS	antiviral, RNA synthesis inhibitor		infectious disease	influenza A virus infection	CC(N)C12CC3CC(CC(C3)C1)C2, CC(N)C12CC3CC(CC(C3)C1)C2	Launched	5
BRD-A75552914-001-15-0::2.5::HTS	-0.33031827201499997	BRD-A75552914-001-15-0::2.5::HTS	BRD-A75552914-001-15-0	isoxicam	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2			CN1C(C(=O)Nc2cc(C)on2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2cc(C)on2)C(=O)c2ccccc2S1(=O)=O	Withdrawn	5
BRD-A75726477-003-21-3::2.5::HTS	-0.821681422857	BRD-A75726477-003-21-3::2.5::HTS	BRD-A75726477-003-21-3	clenbuterol	2.5	HTS	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3, NGF, TNF	pulmonary	chronic obstructive pulmonary disease (COPD), asthma	CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1	Launched	5
BRD-A75769826-003-02-1::2.5::HTS	-0.0422232358624	BRD-A75769826-003-02-1::2.5::HTS	BRD-A75769826-003-02-1	SDM25N	2.5	HTS	opioid receptor antagonist	OPRD1			CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O	Preclinical	5
BRD-A75817871-001-06-7::2.5::HTS	0.207670092075	BRD-A75817871-001-06-7::2.5::HTS	BRD-A75817871-001-06-7	blebbistatin-(+/-)	2.5	HTS	ATPase inhibitor	MYH2			Cc1ccc2N=C3N(CCC3(O)C(=O)c2c1)c1ccccc1	Preclinical	5
BRD-A75850590-213-01-0::2.5::HTS	-0.361355932905	BRD-A75850590-213-01-0::2.5::HTS	BRD-A75850590-213-01-0	lomefloxacin	2.5	HTS	bacterial DNA gyrase inhibitor	TOP2A	infectious disease	respiratory tract infections, urinary tract infections	CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12	Launched	5
BRD-A75919782-399-02-6::2.5::HTS	0.195393301784	BRD-A75919782-399-02-6::2.5::HTS	BRD-A75919782-399-02-6	leucovorin	2.5	HTS	folate receptor ligand	TYMS	oncology	osteosarcoma	Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	Launched	5
BRD-A76672327-003-02-0::2.5::HTS	0.0997500670348	BRD-A76672327-003-02-0::2.5::HTS	BRD-A76672327-003-02-0	clindamycin-palmitate	2.5	HTS	bacterial 50S ribosomal subunit inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections	CCCCCCCCCCCCCCCC(=O)OC1C(O)C(O)C(OC1SC)C(NC(=O)C1CC(CCC)CN1C)C(C)Cl	Launched	5
BRD-A77218119-001-03-5::2.5::HTS	0.26998669851999996	BRD-A77218119-001-03-5::2.5::HTS	BRD-A77218119-001-03-5	SYM-2206	2.5	HTS	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1C, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1C	Preclinical	5
BRD-A77291778-003-22-0::2.5::HTS	-0.724116081015	BRD-A77291778-003-22-0::2.5::HTS	BRD-A77291778-003-22-0	cyclopentolate	2.5	HTS	acetylcholine receptor antagonist	CHRM1	ophthalmology	mydriasis, cycloplegia	CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1	Launched	5
BRD-A77577770-003-08-9::2.5::HTS	-0.0574366856821	BRD-A77577770-003-08-9::2.5::HTS	BRD-A77577770-003-08-9	palmitoylcarnitine	2.5	HTS	protein kinase inhibitor				CCCCCCCCCCCCCCCC(=O)OC(CC(O)=O)C[N+](C)(C)C	Preclinical	5
BRD-A78093359-001-06-3::2.5::HTS	0.116386250132	BRD-A78093359-001-06-3::2.5::HTS	BRD-A78093359-001-06-3	MRS1845	2.5	HTS	calcium channel blocker				CCOC(=O)C1=C(C)N(CC#C)C(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC	Preclinical	5
BRD-A78195072-001-06-2::2.5::HTS	-0.410074345484	BRD-A78195072-001-06-2::2.5::HTS	BRD-A78195072-001-06-2	imexon	2.5	HTS	apoptosis stimulant, ribonucleotide reductase inhibitor	RRM1, RRM2			N=C1NC(=O)N2CC12	Phase 2	5
BRD-A78322124-003-14-0::2.5::HTS	0.24199272676199998	BRD-A78322124-003-14-0::2.5::HTS	BRD-A78322124-003-14-0	dobutamine	2.5	HTS	adrenergic receptor agonist	ADRB1, ADRB2	cardiology	congestive heart failure	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	Launched	5
BRD-A78341343-001-01-6::2.5::HTS	0.163000485955	BRD-A78341343-001-01-6::2.5::HTS	BRD-A78341343-001-01-6	regadenoson	2.5	HTS	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3	radiology	myocardial perfusion imaging (MPI)	CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)C(O)C3O)c2n1	Launched	5
BRD-A78377521-001-05-5::2.5::HTS	-0.35118076153300004	BRD-A78377521-001-05-5::2.5::HTS	BRD-A78377521-001-05-5	monastrol	2.5	HTS	kinesin inhibitor	KIF11			CCOC(=O)C1=C(C)NC(=S)NC1c1cccc(O)c1, CCOC(=O)C1=C(C)NC(=S)NC1c1cccc(O)c1	Preclinical	5
BRD-A78391468-001-02-8::2.5::HTS	-0.0996002695413	BRD-A78391468-001-02-8::2.5::HTS	BRD-A78391468-001-02-8	prednisolone-hemisuccinate	2.5	HTS	glucocorticoid receptor agonist	NR3C1			C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O	Preclinical	5
BRD-A78588743-001-03-4::2.5::HTS	-0.786726227013	BRD-A78588743-001-03-4::2.5::HTS	BRD-A78588743-001-03-4	editol	2.5	HTS					CC(O)CN(CCN(CC(C)O)CC(C)O)CC(C)O	Preclinical	5
BRD-A78723049-001-01-2::2.5::HTS	-0.206884674361	BRD-A78723049-001-01-2::2.5::HTS	BRD-A78723049-001-01-2	cefotetan	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis	CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O	Launched	5
BRD-A78877355-001-03-0::2.5::HTS	-0.48373110073799996	BRD-A78877355-001-03-0::2.5::HTS	BRD-A78877355-001-03-0	nefopam	2.5	HTS	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	CN1CCOC(c2ccccc2)c2ccccc2C1, CN1CCOC(c2ccccc2)c2ccccc2C1	Launched	5
BRD-A78952587-001-01-5::2.5::HTS	0.250001344587	BRD-A78952587-001-01-5::2.5::HTS	BRD-A78952587-001-01-5	A740003	2.5	HTS	purinergic receptor antagonist	P2RX7			COc1ccc(CC(=O)NC(N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC, COc1ccc(CC(=O)NC(N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC	Preclinical	5
BRD-A79431551-001-01-1::2.5::HTS	-0.782870244068	BRD-A79431551-001-01-1::2.5::HTS	BRD-A79431551-001-01-1	3-deazaadenosine	2.5	HTS	adenosylhomocysteinase inhibitor	AHCY			Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)C(O)C1O	Phase 2	5
BRD-A79672927-001-20-7::2.5::HTS	-0.0098669270205	BRD-A79672927-001-20-7::2.5::HTS	BRD-A79672927-001-20-7	tropicamide	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	ophthalmology	mydriasis diagnostic, cycloplegia diagnostic	CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1, CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1, CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1, CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1	Launched	5
BRD-A79768653-001-12-0::2.5::HTS	0.084712372264	BRD-A79768653-001-12-0::2.5::HTS	BRD-A79768653-001-12-0	sirolimus	2.5	HTS	mTOR inhibitor	FGF2, FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O	Launched	5
BRD-A79803969-003-16-1::2.5::HTS	-0.673325112147	BRD-A79803969-003-16-1::2.5::HTS	BRD-A79803969-003-16-1	memantine	2.5	HTS	glutamate receptor antagonist	CHRFAM7A, DRD2, GRIN1, GRIN2A, GRIN2B, GRIN3A, HTR3A	neurology/psychiatry	Alzheimer's disease, senile dementia	CC12CC3CC(C)(C1)CC(N)(C3)C2, CC12CC3CC(C)(C1)CC(N)(C3)C2, CC12CC3CC(C)(C1)CC(N)(C3)C2	Launched	5
BRD-A79981887-003-16-4::2.5::HTS	-0.24267860772799998	BRD-A79981887-003-16-4::2.5::HTS	BRD-A79981887-003-16-4	midodrine	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	COc1ccc(OC)c(c1)C(O)CNC(=O)CN	Launched	5
BRD-A80017228-001-25-7::2.5::HTS	-0.051632216461199996	BRD-A80017228-001-25-7::2.5::HTS	BRD-A80017228-001-25-7	bendroflumethiazide	2.5	HTS	sodium/potassium/chloride transporter inhibitor	CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3	cardiology	hypertension	NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F	Launched	5
BRD-A80213327-305-08-3::2.5::HTS	0.56026440701	BRD-A80213327-305-08-3::2.5::HTS	BRD-A80213327-305-08-3	NSC-23766	2.5	HTS	Ras GTPase inhibitor				CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1	Preclinical	5
BRD-A80871782-004-06-9::2.5::HTS	0.30900023059500004	BRD-A80871782-004-06-9::2.5::HTS	BRD-A80871782-004-06-9	hydroxyamphetamine	2.5	HTS	trace amine associated receptor agonist	TAAR1	ophthalmology	mydriasis	CC(N)Cc1ccc(O)cc1	Launched	5
BRD-A80908310-003-13-8::2.5::HTS	-0.0777260567654	BRD-A80908310-003-13-8::2.5::HTS	BRD-A80908310-003-13-8	cloperastine	2.5	HTS	antitussive		pulmonary	cough suppressant	Clc1ccc(cc1)C(OCCN1CCCCC1)c1ccccc1	Launched	5
BRD-A81129465-001-03-8::2.5::HTS	-0.270193382358	BRD-A81129465-001-03-8::2.5::HTS	BRD-A81129465-001-03-8	fenoprofen	2.5	HTS	prostaglandin inhibitor	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1	Launched	5
BRD-A81233518-004-16-1::2.5::HTS	-0.255259214738	BRD-A81233518-004-16-1::2.5::HTS	BRD-A81233518-004-16-1	glycopyrrolate	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)c1ccccc1	Launched	5
BRD-A81370665-001-03-6::2.5::HTS	-0.416150110157	BRD-A81370665-001-03-6::2.5::HTS	BRD-A81370665-001-03-6	BI-D1870	2.5	HTS	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6			CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12	Preclinical	5
BRD-A81513827-001-03-6::2.5::HTS	-0.625955926723	BRD-A81513827-001-03-6::2.5::HTS	BRD-A81513827-001-03-6	saxagliptin	2.5	HTS	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2	Launched	5
BRD-A81541225-001-06-8::2.5::HTS	-1.3903556584399999	BRD-A81541225-001-06-8::2.5::HTS	BRD-A81541225-001-06-8	oligomycin-a	2.5	HTS	ATP synthase inhibitor, ATPase inhibitor	ATP5A1			CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C	Preclinical	5
BRD-A81615860-003-01-7::2.5::HTS	0.176481538735	BRD-A81615860-003-01-7::2.5::HTS	BRD-A81615860-003-01-7	fenclonine-(+/-)	2.5	HTS	tryptophan hydroxylase inhibitor	PAH, TPH1, TPH2			NC(Cc1ccc(Cl)cc1)C(O)=O	Preclinical	5
BRD-A82035391-001-02-7::2.5::HTS	-0.146445445506	BRD-A82035391-001-02-7::2.5::HTS	BRD-A82035391-001-02-7	tolvaptan	2.5	HTS	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology, cardiology, gastroenterology	hyponatremia, congestive heart failure, hepatic cirrhosis	Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc23)c(C)c1, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc23)c(C)c1	Launched	5
BRD-A82396632-008-29-0::2.5::HTS	-0.201909572149	BRD-A82396632-008-29-0::2.5::HTS	BRD-A82396632-008-29-0	miconazole	2.5	HTS	bacterial cell wall synthesis inhibitor	KCNH2, KCNH6, KCNH7, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, NOS2, NOS3, TRPM2, TRPV5	infectious disease, neurology/psychiatry	yeast infection, itching	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Launched	5
BRD-A82522119-001-01-7::2.5::HTS	-0.411302458091	BRD-A82522119-001-01-7::2.5::HTS	BRD-A82522119-001-01-7	tibolone	2.5	HTS	androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist	ESR1	obstetrics/gynecology	endometriosis	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)C12	Launched	5
BRD-A82772293-001-03-2::2.5::HTS	-0.498707619838	BRD-A82772293-001-03-2::2.5::HTS	BRD-A82772293-001-03-2	mepazine	2.5	HTS	MALT1 inhibitor (JH)	MALT1			CN1CCCC(CN2c3ccccc3Sc3ccccc23)C1	Phase 2	5
BRD-A83029242-001-05-3::2.5::HTS	0.530296563651	BRD-A83029242-001-05-3::2.5::HTS	BRD-A83029242-001-05-3	prasugrel	2.5	HTS	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction, acute coronary syndrome (ACS)	CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F, CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F, CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F, CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F	Launched	5
BRD-A83644949-236-01-6::2.5::HTS	0.535018140367	BRD-A83644949-236-01-6::2.5::HTS	BRD-A83644949-236-01-6	ardeparin	2.5	HTS	thrombin inhibitor	SERPINC1, SERPIND1			CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O	Withdrawn	5
BRD-A83650191-004-02-8::2.5::HTS	-0.318062015462	BRD-A83650191-004-02-8::2.5::HTS	BRD-A83650191-004-02-8	A61603	2.5	HTS	adrenergic receptor agonist	ADRA1A			CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1	Preclinical	5
BRD-A83802939-304-04-2::2.5::HTS	0.5277610085159999	BRD-A83802939-304-04-2::2.5::HTS	BRD-A83802939-304-04-2	dexamethasone-sodium-phosphate	2.5	HTS	glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O, C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O	Launched	5
BRD-A83937277-001-10-5::2.5::HTS	-0.634902771986	BRD-A83937277-001-10-5::2.5::HTS	BRD-A83937277-001-10-5	mephenytoin	2.5	HTS	hydantoin antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	CCC1(NC(=O)N(C)C1=O)c1ccccc1	Launched	5
BRD-A84174393-236-07-1::2.5::HTS	0.0424817582431	BRD-A84174393-236-07-1::2.5::HTS	BRD-A84174393-236-07-1	meloxicam	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O	Launched	5
BRD-A84389633-001-05-7::2.5::HTS	0.345973537717	BRD-A84389633-001-05-7::2.5::HTS	BRD-A84389633-001-05-7	tropanyl-3,5-dimethylbenzoate	2.5	HTS	serotonin receptor antagonist	HTR3A, HTR3B			CN1C2CCC1CC(C2)OC(=O)c1cc(C)cc(C)c1	Preclinical	5
BRD-A84481105-003-31-3::2.5::HTS	-0.166042128092	BRD-A84481105-003-31-3::2.5::HTS	BRD-A84481105-003-31-3	thioridazine	2.5	HTS	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCNH2			CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1	Withdrawn	5
BRD-A84575140-001-02-4::2.5::HTS	0.821621463679	BRD-A84575140-001-02-4::2.5::HTS	BRD-A84575140-001-02-4	pimobendan	2.5	HTS	calcium sensitizer, phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	COc1ccc(cc1)-c1nc2cc(ccc2[nH]1)C1=NNC(=O)CC1C	Launched	5
BRD-A84687895-001-03-2::2.5::HTS	-0.12418317071599999	BRD-A84687895-001-03-2::2.5::HTS	BRD-A84687895-001-03-2	nilvadipine	2.5	HTS	calcium channel blocker	CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNA2D3, CACNB2	cardiology	hypertension, cerebral artery occlusion	COC(=O)C1=C(NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N, COC(=O)C1=C(NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N	Launched	5
BRD-A84907376-300-03-8::2.5::HTS	0.25121949566	BRD-A84907376-300-03-8::2.5::HTS	BRD-A84907376-300-03-8	alcuronium	2.5	HTS	muscle relaxant	CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7	neurology/psychiatry	muscle relaxant	OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2C5[C@]6(CC[N@@+]7(CC=C)C\C(=C/CO)[C@H](C[C@@H]67)\C5=C\N(C31)c1ccccc41)c1ccccc21	Launched	5
BRD-A85025557-001-02-5::2.5::HTS	-0.550509270382	BRD-A85025557-001-02-5::2.5::HTS	BRD-A85025557-001-02-5	NCS-382	2.5	HTS	GABA receptor antagonist	GABBR1, GABBR2, SLC52A2			OC1c2ccccc2CCC\C1=C/C(O)=O	Preclinical	5
BRD-A85216385-003-02-4::2.5::HTS	-0.10088763476299999	BRD-A85216385-003-02-4::2.5::HTS	BRD-A85216385-003-02-4	3-alpha-bis-(4-fluorophenyl)-methoxytropane	2.5	HTS	dopamine uptake inhibitor	CHRM1, SLC6A2, SLC6A3, SLC6A4			CN1C2CCC1CC(C2)OC(c1ccc(F)cc1)c1ccc(F)cc1	Preclinical	5
BRD-A85242401-001-12-3::2.5::HTS	0.745036268235	BRD-A85242401-001-12-3::2.5::HTS	BRD-A85242401-001-12-3	ascorbic-acid	2.5	HTS	antioxidant	ALKBH2, ALKBH3, BBOX1, DBH, EGLN1, EGLN2, EGLN3, KDM5D, LCT, OGFOD1, OGFOD2, P3H1, P3H2, P3H3, P4HA1, P4HTM, PAM, PHYH, PLOD1, PLOD2, PLOD3, SLC23A1, SLC23A2, TMLHE	endocrinology	scurvy	OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O	Launched	5
BRD-A85472596-001-02-2::2.5::HTS	0.227971018646	BRD-A85472596-001-02-2::2.5::HTS	BRD-A85472596-001-02-2	L-670596	2.5	HTS	prostanoid receptor antagonist				CS(=O)(=O)c1ccc(Cn2c3C(CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1	Preclinical	5
BRD-A85548292-001-01-8::2.5::HTS	0.11182993649800001	BRD-A85548292-001-01-8::2.5::HTS	BRD-A85548292-001-01-8	piketoprofen	2.5	HTS	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	CC(C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1	Launched	5
BRD-A85587465-001-03-3::2.5::HTS	-0.0522842349952	BRD-A85587465-001-03-3::2.5::HTS	BRD-A85587465-001-03-3	bemesetron	2.5	HTS	serotonin receptor antagonist	HTR3A, HTR3B			CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1, CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1	Phase 3	5
BRD-A85651701-001-19-7::2.5::HTS	0.253175189579	BRD-A85651701-001-19-7::2.5::HTS	BRD-A85651701-001-19-7	clopamide	2.5	HTS	sodium/chloride cotransporter inhibitor		cardiology	hypertension	CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	Launched	5
BRD-A85667082-001-12-7::2.5::HTS	-0.42967746277900004	BRD-A85667082-001-12-7::2.5::HTS	BRD-A85667082-001-12-7	fulvestrant	2.5	HTS	estrogen receptor antagonist	ESR1, ESR2, GPER1	oncology	breast cancer	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31	Launched	5
BRD-A85876464-001-01-5::2.5::HTS	0.236564253335	BRD-A85876464-001-01-5::2.5::HTS	BRD-A85876464-001-01-5	nibentan	2.5	HTS	potassium channel blocker				CCN(CC)CCCCC(NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1	Phase 2	5
BRD-A86044036-001-26-5::2.5::HTS	-0.24659416290999997	BRD-A86044036-001-26-5::2.5::HTS	BRD-A86044036-001-26-5	flurbiprofen-(+/-)	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1, CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1	Launched	5
BRD-A86216746-046-02-6::2.5::HTS	-0.16649195871	BRD-A86216746-046-02-6::2.5::HTS	BRD-A86216746-046-02-6	varenicline	2.5	HTS	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNA6, CHRNA7	neurology/psychiatry	smoking cessation	C1C2CNCC1c1cc3nccnc3cc21	Launched	5
BRD-A86248581-001-01-4::2.5::HTS	-0.24046107468400002	BRD-A86248581-001-01-4::2.5::HTS	BRD-A86248581-001-01-4	tetrahydrouridine	2.5	HTS	cytidine deaminase inhibitor	CDA			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O	Phase 2	5
BRD-A86354194-002-01-7::2.5::HTS	-0.865566836087	BRD-A86354194-002-01-7::2.5::HTS	BRD-A86354194-002-01-7	L-(+)-Rhamnose-Monohydrate	2.5	HTS					C[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O	Preclinical	5
BRD-A86414188-003-01-5::2.5::HTS	-0.35785897957699997	BRD-A86414188-003-01-5::2.5::HTS	BRD-A86414188-003-01-5	ractopamine	2.5	HTS	adrenergic receptor agonist				CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1, CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1	Launched	5
BRD-A86415025-050-01-0::2.5::HTS	0.0578594437691	BRD-A86415025-050-01-0::2.5::HTS	BRD-A86415025-050-01-0	1-(1,2-Diphenylethyl)piperidine-(+/-)	2.5	HTS	glutamate receptor antagonist				C(C(N1CCCCC1)c1ccccc1)c1ccccc1	Preclinical	5
BRD-A86619021-001-04-8::2.5::HTS	0.7834332007439999	BRD-A86619021-001-04-8::2.5::HTS	BRD-A86619021-001-04-8	andrographolide	2.5	HTS	tumor necrosis factor production inhibitor	NFKB1			C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CCC12	Phase 2	5
BRD-A86871940-001-01-9::2.5::HTS	-0.661728955858	BRD-A86871940-001-01-9::2.5::HTS	BRD-A86871940-001-01-9	nicaraven	2.5	HTS	free radical scavenger				CC(CNC(=O)c1cccnc1)NC(=O)c1cccnc1	Phase 3	5
BRD-A87130939-001-07-9::2.5::HTS	-0.033533583544799996	BRD-A87130939-001-07-9::2.5::HTS	BRD-A87130939-001-07-9	masoprocol	2.5	HTS	lipoxygenase inhibitor	ALOX5	dermatology	actinic keratosis (AK)	CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1	Launched	5
BRD-A87435144-001-01-6::2.5::HTS	0.08702483303139999	BRD-A87435144-001-01-6::2.5::HTS	BRD-A87435144-001-01-6	AZD7545	2.5	HTS	pyruvate dehydrogenase kinase inhibitor	PDK1			CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1	Phase 1	5
BRD-A87479750-001-02-7::2.5::HTS	-0.131843016822	BRD-A87479750-001-02-7::2.5::HTS	BRD-A87479750-001-02-7	tenidap	2.5	HTS	cyclooxygenase inhibitor	KCNJ4, PTGS1			NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12, NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12	Phase 3	5
BRD-A87673115-001-04-1::2.5::HTS	-0.16836660842700002	BRD-A87673115-001-04-1::2.5::HTS	BRD-A87673115-001-04-1	moguisteine	2.5	HTS	ATP-sensitive potassium channel inhibitor				CCOC(=O)CC(=O)N1CCSC1COc1ccccc1OC	Phase 2	5
BRD-A87715314-003-14-4::2.5::HTS	0.29701412882399997	BRD-A87715314-003-14-4::2.5::HTS	BRD-A87715314-003-14-4	pronethalol	2.5	HTS	adrenergic receptor antagonist				CC(C)NCC(O)c1ccc2ccccc2c1, CC(C)NCC(O)c1ccc2ccccc2c1	Withdrawn	5
BRD-A87983072-001-01-1::2.5::HTS	0.520603924	BRD-A87983072-001-01-1::2.5::HTS	BRD-A87983072-001-01-1	benzotript	2.5	HTS	CCK receptor antagonist	CCKAR, CCKBR			OC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	Phase 1	5
BRD-A88080608-001-04-2::2.5::HTS	-0.28511110992	BRD-A88080608-001-04-2::2.5::HTS	BRD-A88080608-001-04-2	equilin	2.5	HTS	estrogen receptor agonist	HSD17B1			CC12CCC3C(=CCc4cc(O)ccc34)C1CCC2=O	Preclinical	5
BRD-A88138582-001-04-8::2.5::HTS	-0.319359290259	BRD-A88138582-001-04-8::2.5::HTS	BRD-A88138582-001-04-8	halcinonide	2.5	HTS	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl	Launched	5
BRD-A88369366-001-01-7::2.5::HTS	-0.0412224879332	BRD-A88369366-001-01-7::2.5::HTS	BRD-A88369366-001-01-7	trelagliptin	2.5	HTS	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O	Launched	5
BRD-A88548664-004-02-7::2.5::HTS	-0.10071021851199999	BRD-A88548664-004-02-7::2.5::HTS	BRD-A88548664-004-02-7	SKF-38393	2.5	HTS	dopamine receptor agonist	CALY, DRD1, DRD5			Oc1cc2CCNCC(c3ccccc3)c2cc1O	Preclinical	5
BRD-A88684804-001-04-3::2.5::HTS	0.23995590144	BRD-A88684804-001-04-3::2.5::HTS	BRD-A88684804-001-04-3	bucetin	2.5	HTS	analgesic agent				CCOc1ccc(NC(=O)CC(C)O)cc1	Withdrawn	5
BRD-A89164055-001-03-3::2.5::HTS	0.23182193498000003	BRD-A89164055-001-03-3::2.5::HTS	BRD-A89164055-001-03-3	sorbinil	2.5	HTS	aldose reductase inhibitor	AKR1B1			Fc1ccc2OCCC3(NC(=O)NC3=O)c2c1	Phase 3	5
BRD-A89175223-051-14-8::2.5::HTS	0.736043676756	BRD-A89175223-051-14-8::2.5::HTS	BRD-A89175223-051-14-8	bisoprolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension	CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1, CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1, CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1, CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1	Launched	5
BRD-A89196962-300-01-7::2.5::HTS	-0.25597771887299997	BRD-A89196962-300-01-7::2.5::HTS	BRD-A89196962-300-01-7	dalargin	2.5	HTS	opioid receptor agonist	OPRM1			CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)C(N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O	Phase 2	5
BRD-A89337244-001-02-9::2.5::HTS	-0.26724763521899997	BRD-A89337244-001-02-9::2.5::HTS	BRD-A89337244-001-02-9	PD-102807	2.5	HTS	acetylcholine receptor antagonist	CHRM4			CCOC(=O)c1c(C)[nH]c2ccc3OC4N(CCc5cc(OC)ccc45)Cc3c12, CCOC(=O)c1c(C)[nH]c2ccc3OC4N(CCc5cc(OC)ccc45)Cc3c12	Preclinical	5
BRD-A89585551-003-16-6::2.5::HTS	0.04594188559930001	BRD-A89585551-003-16-6::2.5::HTS	BRD-A89585551-003-16-6	mefloquine	2.5	HTS	adenosine receptor antagonist, hemoglobin antagonist	ADORA2A, HBA1	infectious disease	malaria	OC(C1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F	Launched	5
BRD-A89594340-003-11-5::2.5::HTS	0.015297762778	BRD-A89594340-003-11-5::2.5::HTS	BRD-A89594340-003-11-5	carnitine-(D/L)	2.5	HTS					C[N+](C)(C)CC(O)CC(O)=O, C[N+](C)(C)CC(O)CC(O)=O	Phase 3	5
BRD-A89672324-001-03-0::2.5::HTS	-0.0483966816768	BRD-A89672324-001-03-0::2.5::HTS	BRD-A89672324-001-03-0	CGP-55845	2.5	HTS	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-A90272038-001-01-7::2.5::HTS	-0.164505494339	BRD-A90272038-001-01-7::2.5::HTS	BRD-A90272038-001-01-7	CGP-37849	2.5	HTS	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O	Phase 1	5
BRD-A90515964-001-16-5::2.5::HTS	0.540115870514	BRD-A90515964-001-16-5::2.5::HTS	BRD-A90515964-001-16-5	guaifenesin	2.5	HTS	expectorant		pulmonary	cough suppressant	COc1ccccc1OCC(O)CO, COc1ccccc1OCC(O)CO	Launched	5
BRD-A90547603-001-02-5::2.5::HTS	-0.30692667045099997	BRD-A90547603-001-02-5::2.5::HTS	BRD-A90547603-001-02-5	eptifibatide	2.5	HTS	platelet aggregation inhibitor	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O	Launched	5
BRD-A90551241-001-10-8::2.5::HTS	0.060233296938199996	BRD-A90551241-001-10-8::2.5::HTS	BRD-A90551241-001-10-8	lornoxicam	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, neurology/psychiatry	osteoarthritis, sciata	CN1C(C(=O)Nc2ccccn2)C(=O)c2sc(Cl)cc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2sc(Cl)cc2S1(=O)=O	Launched	5
BRD-A90625545-001-02-0::2.5::HTS	0.0783436469293	BRD-A90625545-001-02-0::2.5::HTS	BRD-A90625545-001-02-0	clinofibrate	2.5	HTS	lipase clearing factor inhibitor	LPL	endocrinology	hypertriglyceridemia	CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(OC(C)(CC)C(O)=O)cc1)C(O)=O	Launched	5
BRD-A90695733-001-07-4::2.5::HTS	-0.09643197474880001	BRD-A90695733-001-07-4::2.5::HTS	BRD-A90695733-001-07-4	manidipine	2.5	HTS	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	5
BRD-A90799790-001-19-9::2.5::HTS	0.198583026013	BRD-A90799790-001-19-9::2.5::HTS	BRD-A90799790-001-19-9	isradipine	2.5	HTS	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2	cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C	Launched	5
BRD-A90926615-001-01-9::2.5::HTS	-0.0534905832374	BRD-A90926615-001-01-9::2.5::HTS	BRD-A90926615-001-01-9	adrafinil	2.5	HTS	adrenergic receptor agonist		neurology/psychiatry	fatigue	ONC(=O)CS(=O)C(c1ccccc1)c1ccccc1, ONC(=O)CS(=O)C(c1ccccc1)c1ccccc1	Launched	5
BRD-A91008255-003-24-8::2.5::HTS	-0.093894052707	BRD-A91008255-003-24-8::2.5::HTS	BRD-A91008255-003-24-8	bepridil	2.5	HTS	calcium channel blocker	ATP1A1, CACNA1A, CACNA1H, CACNA2D2, CALM1, KCNQ1, KCNQ4, PDE1A, PDE1B, TNNC1	cardiology	angina pectoris	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	Launched	5
BRD-A91366704-001-01-9::2.5::HTS	-0.126456696758	BRD-A91366704-001-01-9::2.5::HTS	BRD-A91366704-001-01-9	eprinomectin	2.5	HTS	benzodiazepine receptor agonist		infectious disease	gastrointestinal roundworms, lungworms	CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C	Launched	5
BRD-A91452556-001-04-0::2.5::HTS	-0.255010919497	BRD-A91452556-001-04-0::2.5::HTS	BRD-A91452556-001-04-0	estradiol-cypionate	2.5	HTS	estrogen receptor agonist	ESR1	endocrinology	hypoestrogenism, menopause	C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1	Launched	5
BRD-A91699651-316-10-9::2.5::HTS	-0.7938540808210001	BRD-A91699651-316-10-9::2.5::HTS	BRD-A91699651-316-10-9	chloroquine	2.5	HTS	antimalarial agent	GSTA2, MRGPRX1, TLR9, TNF	infectious disease	malaria, amebiasis	CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12	Launched	5
BRD-A91733352-300-04-5::2.5::HTS	-0.11779173698300001	BRD-A91733352-300-04-5::2.5::HTS	BRD-A91733352-300-04-5	camylofine-chlorhydrate	2.5	HTS			gastroenterology	abdominal pain	CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1	Launched	5
BRD-A91822151-001-05-0::2.5::HTS	0.0498183173994	BRD-A91822151-001-05-0::2.5::HTS	BRD-A91822151-001-05-0	picrotin	2.5	HTS	GABA receptor antagonist	GABRA1, GABRR1, GLRA1, GLRA2, GLRA3, GLRB			CC(C)(O)C1C2OC(=O)C1C1(O)CC3OC33C(=O)OC2C13C	Phase 2	5
BRD-A91831168-003-02-5::2.5::HTS	-0.194695240858	BRD-A91831168-003-02-5::2.5::HTS	BRD-A91831168-003-02-5	tetrahydropapaverine	2.5	HTS					COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC	Preclinical	5
BRD-A92096630-001-02-8::2.5::HTS	0.0565698369409	BRD-A92096630-001-02-8::2.5::HTS	BRD-A92096630-001-02-8	shikimic-acid	2.5	HTS					O[C@@H]1CC(=CC(O)C1O)C(O)=O	Preclinical	5
BRD-A92439610-001-05-7::2.5::HTS	-0.149439085991	BRD-A92439610-001-05-7::2.5::HTS	BRD-A92439610-001-05-7	triamcinolone-acetonide	2.5	HTS	glucocorticoid receptor agonist, immunosuppressant	NR3C1	dermatology	corticosteroid-responsive dermatoses	CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Launched	5
BRD-A92537424-001-04-7::2.5::HTS	-0.238006307445	BRD-A92537424-001-04-7::2.5::HTS	BRD-A92537424-001-04-7	danazol	2.5	HTS	estrogen receptor antagonist, progesterone receptor agonist	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C	Launched	5
BRD-A92630576-050-24-1::2.5::HTS	-0.07263343777489999	BRD-A92630576-050-24-1::2.5::HTS	BRD-A92630576-050-24-1	trimebutine	2.5	HTS	opioid receptor agonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1	Launched	5
BRD-A92670106-003-05-4::2.5::HTS	0.08992168392510001	BRD-A92670106-003-05-4::2.5::HTS	BRD-A92670106-003-05-4	tocainide	2.5	HTS	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	CC(N)C(=O)Nc1c(C)cccc1C	Launched	5
BRD-A92800748-001-05-5::2.5::HTS	0.35452081643100003	BRD-A92800748-001-05-5::2.5::HTS	BRD-A92800748-001-05-5	tie2-kinase-inhibitor	2.5	HTS	TIE tyrosine kinase inhibitor	KDR, MAPK14			COc1ccc2cc(ccc2c1)-c1nc([nH]c1-c1ccncc1)-c1ccc(cc1)S(C)=O	Preclinical	5
BRD-A92826379-001-01-5::2.5::HTS	-0.553845076507	BRD-A92826379-001-01-5::2.5::HTS	BRD-A92826379-001-01-5	lupanine	2.5	HTS	sodium channel blocker	INS			O=C1CCCC2C3CC(CN12)[C@@H]1CCCCN1C3	Phase 1	5
BRD-A92872453-001-01-8::2.5::HTS	0.014579100041799999	BRD-A92872453-001-01-8::2.5::HTS	BRD-A92872453-001-01-8	N-acetylmannosamine	2.5	HTS		CHIT1			CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O	Phase 1	5
BRD-A92933783-050-01-6::2.5::HTS	0.264745009153	BRD-A92933783-050-01-6::2.5::HTS	BRD-A92933783-050-01-6	SM-21	2.5	HTS	sigma receptor antagonist	PGRMC1			CCC(Oc1ccc(Cl)cc1)C(=O)OC1CC2CCC(C1)N2C	Preclinical	5
BRD-A93000692-001-08-1::2.5::HTS	-0.672434812226	BRD-A93000692-001-08-1::2.5::HTS	BRD-A93000692-001-08-1	ciglitazone	2.5	HTS	PPAR receptor agonist	PPARG			CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1	Phase 2	5
BRD-A93093700-001-02-9::2.5::HTS	-0.8479525266079999	BRD-A93093700-001-02-9::2.5::HTS	BRD-A93093700-001-02-9	temazepam	2.5	HTS	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO			CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1	Withdrawn	5
BRD-A93236127-001-04-5::2.5::HTS	-4.61969799932	BRD-A93236127-001-04-5::2.5::HTS	BRD-A93236127-001-04-5	digitoxin	2.5	HTS	ATPase inhibitor	ATP1A1			C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C	Launched	5
BRD-A93255169-001-28-3::2.5::HTS	-0.35388811795999997	BRD-A93255169-001-28-3::2.5::HTS	BRD-A93255169-001-28-3	thalidomide	2.5	HTS	tumor necrosis factor production inhibitor	CRBN, FGFR2, NFKB1, ORM1, ORM2, PTGS2, TNF			O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12, O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12	Launched	5
BRD-A93353767-008-02-2::2.5::HTS	0.383655173057	BRD-A93353767-008-02-2::2.5::HTS	BRD-A93353767-008-02-2	isoconazole	2.5	HTS	fungal lanosterol demethylase inhibitor	CYP17A1	infectious disease	gram-positive bacterial infections	Clc1ccc(C(Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1	Launched	5
BRD-A93407926-001-01-1::2.5::HTS	-0.518469816941	BRD-A93407926-001-01-1::2.5::HTS	BRD-A93407926-001-01-1	allopurinol-riboside	2.5	HTS	anti-leishmanial agent				OC[C@H]1O[C@H](C(O)[C@H]1O)n1[nH]cc2c1ncnc2=O	Phase 2	5
BRD-A93477898-001-04-2::2.5::HTS	-0.5338462261300001	BRD-A93477898-001-04-2::2.5::HTS	BRD-A93477898-001-04-2	PETCM	2.5	HTS	caspase activator	CASP3			OC(Cc1ccncc1)C(Cl)(Cl)Cl	Preclinical	5
BRD-A93695607-322-02-5::2.47::HTS	0.444149617058	BRD-A93695607-322-02-5::2.47::HTS	BRD-A93695607-322-02-5	nicotine	2.47	HTS	acetylcholine receptor agonist	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1	Launched	5
BRD-A93699261-236-03-4::2.5::HTS	-0.433616217047	BRD-A93699261-236-03-4::2.5::HTS	BRD-A93699261-236-03-4	sodium-danshensu	2.5	HTS					OC(Cc1ccc(O)c(O)c1)C(O)=O, OC(Cc1ccc(O)c(O)c1)C(O)=O	Preclinical	5
BRD-A93964801-003-03-3::2.5::HTS	0.371282974481	BRD-A93964801-003-03-3::2.5::HTS	BRD-A93964801-003-03-3	clinafloxacin	2.5	HTS	bacterial DNA gyrase inhibitor				NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1	Phase 3	5
BRD-A94008949-001-01-9::2.5::HTS	-0.012789017730299997	BRD-A94008949-001-01-9::2.5::HTS	BRD-A94008949-001-01-9	telithromycin	2.5	HTS	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor	CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7	infectious disease	pneumonia	CCC1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](OC2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@@H](C)[C@@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC, CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC	Launched	5
BRD-A94033181-001-01-4::2.5::HTS	0.08174575262619999	BRD-A94033181-001-01-4::2.5::HTS	BRD-A94033181-001-01-4	AZD6765	2.5	HTS	glutamate receptor antagonist	GRIN1			NC(Cc1ccccn1)c1ccccc1	Phase 2	5
BRD-A94276798-001-01-4::2.5::HTS	0.173637929999	BRD-A94276798-001-01-4::2.5::HTS	BRD-A94276798-001-01-4	talinolol	2.5	HTS	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	CC(C)(C)NCC(O)COc1ccc(NC(=O)NC2CCCCC2)cc1	Launched	5
BRD-A94323479-001-02-8::2.5::HTS	-0.640727652853	BRD-A94323479-001-02-8::2.5::HTS	BRD-A94323479-001-02-8	ki16198	2.5	HTS	lipoprotein antagonist	LPA			COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)OC(C)c1ccccc1Cl	Preclinical	5
BRD-A94523291-304-02-7::2.5::HTS	0.29743926659200004	BRD-A94523291-304-02-7::2.5::HTS	BRD-A94523291-304-02-7	prednisolone-sodium-phosphate	2.5	HTS	glucocorticoid receptor agonist	NR3C1	allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology	allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, asthma, meningitis, psoriatic arthritis, rheumatoid arthritis	C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O	Launched	5
BRD-A94543220-001-24-7::2.5::HTS	0.273018340908	BRD-A94543220-001-24-7::2.5::HTS	BRD-A94543220-001-24-7	bifonazole	2.5	HTS	sterol demethylase inhibitor	CYP2B6	infectious disease	tinea pedis, tinea cruris	c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1, c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1	Launched	5
BRD-A94624445-236-17-0::2.5::HTS	-0.437556265949	BRD-A94624445-236-17-0::2.5::HTS	BRD-A94624445-236-17-0	bucladesine	2.5	HTS	adenosine receptor agonist, cAMP stimulant	PRKACA	dermatology	skin ulcer	CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC	Launched	5
BRD-A94709349-001-08-3::2.5::HTS	0.370152802667	BRD-A94709349-001-08-3::2.5::HTS	BRD-A94709349-001-08-3	metaxalone	2.5	HTS	muscle relaxant		neurology/psychiatry	muscle pain	Cc1cc(C)cc(OCC2CNC(=O)O2)c1	Launched	5
BRD-A94756469-001-04-7::2.5::HTS	-5.298329947869999	BRD-A94756469-001-04-7::2.5::HTS	BRD-A94756469-001-04-7	digoxin	2.5	HTS	ATPase inhibitor	ATP1A1	cardiology	congestive heart failure, atrial fibrillation (AF)	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C	Launched	5
BRD-A94993966-001-04-4::2.5::HTS	-1.06942452737	BRD-A94993966-001-04-4::2.5::HTS	BRD-A94993966-001-04-4	vildagliptin	2.5	HTS	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N, OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N	Launched	5
BRD-A94993966-001-05-1::2.63::HTS	-0.222861330842	BRD-A94993966-001-05-1::2.63::HTS	BRD-A94993966-001-05-1	vildagliptin	2.63	HTS	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N, OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N	Launched	5
BRD-A95121829-001-08-9::2.5::HTS	0.41266903333300003	BRD-A95121829-001-08-9::2.5::HTS	BRD-A95121829-001-08-9	ginkgolide-a	2.5	HTS	GABA receptor antagonist	GLRA1, GLRB			C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Preclinical	5
BRD-A95340155-001-09-7::2.5::HTS	0.0534609799316	BRD-A95340155-001-09-7::2.5::HTS	BRD-A95340155-001-09-7	methyclothiazide	2.5	HTS	chloride reabsorption inhibitor	CA1, CA2, CA4, SLC12A1, SLC12A3	cardiology	hypertension, edema	CN1C(CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O	Launched	5
BRD-A95602221-003-02-1::2.5::HTS	-0.388529590339	BRD-A95602221-003-02-1::2.5::HTS	BRD-A95602221-003-02-1	celiprolol	2.5	HTS	adrenergic receptor antagonist	ADRA2A, ADRB1, ADRB2	genetics	Ehlers-Danlos syndrome (EDS)	CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(C)=O	Launched	5
BRD-A95696066-003-13-8::2.5::HTS	-0.25175632444	BRD-A95696066-003-13-8::2.5::HTS	BRD-A95696066-003-13-8	nisoxetine	2.5	HTS	norepinephrine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			CNCCC(Oc1ccccc1OC)c1ccccc1	Phase 1	5
BRD-A95755460-001-01-3::2.5::HTS	-0.697087839073	BRD-A95755460-001-01-3::2.5::HTS	BRD-A95755460-001-01-3	talarozole	2.5	HTS	cytochrome P450 inhibitor	CYP26A1			CCC(CC)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1	Phase 2	5
BRD-A95869247-001-26-9::2.5::HTS	-0.304175005595	BRD-A95869247-001-26-9::2.5::HTS	BRD-A95869247-001-26-9	indapamide	2.5	HTS	thiazide diuretic	KCNE1, KCNQ1, SLC12A3	cardiology	hypertension, congestive heart failure	CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O, CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	Launched	5
BRD-A95886749-001-03-5::2.5::HTS	0.292850282482	BRD-A95886749-001-03-5::2.5::HTS	BRD-A95886749-001-03-5	colfosceril-palmitate	2.5	HTS	pulmonary surfactant		pulmonary	respiratory distress syndrome (RDS)	CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC	Launched	5
BRD-A95939040-001-01-2::2.5::HTS	-0.0038077324000700004	BRD-A95939040-001-01-2::2.5::HTS	BRD-A95939040-001-01-2	sertaconazole	2.5	HTS	sterol demethylase inhibitor		infectious disease	tinea pedis	Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1	Launched	5
BRD-A96292436-003-16-1::2.5::HTS	-0.33466191125399997	BRD-A96292436-003-16-1::2.5::HTS	BRD-A96292436-003-16-1	eflornithine	2.5	HTS	ornithine decarboxylase inhibitor	ARG2, ODC1	dermatology	facial hair reduction	NCCCC(N)(C(F)F)C(O)=O	Launched	5
BRD-A96407378-001-15-1::2.5::HTS	0.218716555314	BRD-A96407378-001-15-1::2.5::HTS	BRD-A96407378-001-15-1	allantoin	2.5	HTS	cosmetic		dermatology	skin protectant	NC(=O)NC1NC(=O)NC1=O	Launched	5
BRD-A96456596-001-02-2::2.5::HTS	-0.109108391794	BRD-A96456596-001-02-2::2.5::HTS	BRD-A96456596-001-02-2	FPL-55712	2.5	HTS	leukotriene receptor antagonist				CCCc1c(OCC(O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O	Phase 1	5
BRD-A96485169-001-14-3::2.5::HTS	0.23656498981	BRD-A96485169-001-14-3::2.5::HTS	BRD-A96485169-001-14-3	EBPC	2.5	HTS	aldose reductase inhibitor	AKR1B1			CCOC(=O)C1CN(Cc2ccccc2)C(=O)C1=O	Preclinical	5
BRD-A96529864-001-01-3::2.5::HTS	0.45264765514	BRD-A96529864-001-01-3::2.5::HTS	BRD-A96529864-001-01-3	isosteviol	2.5	HTS					C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)C3CC2	Phase 2	5
BRD-A96977263-001-03-7::2.5::HTS	-0.538078740952	BRD-A96977263-001-03-7::2.5::HTS	BRD-A96977263-001-03-7	M-14157	2.5	HTS	ATP-sensitive potassium channel antagonist	KCNQ1			CCCCCC(O)CCCC(O)=O	Phase 2	5
BRD-A97104540-004-15-0::2.5::HTS	-0.455298007826	BRD-A97104540-004-15-0::2.5::HTS	BRD-A97104540-004-15-0	fenoterol	2.5	HTS	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1	Withdrawn	5
BRD-A97437073-050-14-5::2.5::HTS	0.09698346419960001	BRD-A97437073-050-14-5::2.5::HTS	BRD-A97437073-050-14-5	rosiglitazone	2.5	HTS	insulin sensitizer, PPAR receptor agonist	ACSL4, FFAR1, PPARG, TRPC5, TRPM3			CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1	Withdrawn	5
BRD-A97479839-003-13-3::2.5::HTS	0.309673364755	BRD-A97479839-003-13-3::2.5::HTS	BRD-A97479839-003-13-3	piperidolate	2.5	HTS	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	spasms	CCN1CCCC(C1)OC(=O)C(c1ccccc1)c1ccccc1	Launched	5
BRD-A97674275-001-11-8::2.5::HTS	0.224301175317	BRD-A97674275-001-11-8::2.5::HTS	BRD-A97674275-001-11-8	ranolazine	2.5	HTS	sodium channel blocker	SCN10A, SCN4A, SCN5A, SCN9A	cardiology	chronic stable angina	COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1, COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1, COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1, COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1	Launched	5
BRD-A97701745-001-16-0::2.5::HTS	-0.052181142895200004	BRD-A97701745-001-16-0::2.5::HTS	BRD-A97701745-001-16-0	pindolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B	cardiology	hypertension	CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12	Launched	5
BRD-A97730597-003-11-5::2.5::HTS	-0.282466991602	BRD-A97730597-003-11-5::2.5::HTS	BRD-A97730597-003-11-5	hexylcaine	2.5	HTS	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	local anesthetic	CC(CNC1CCCCC1)OC(=O)c1ccccc1	Launched	5
BRD-A97739905-001-26-5::2.5::HTS	-0.354864889605	BRD-A97739905-001-26-5::2.5::HTS	BRD-A97739905-001-26-5	ketoprofen	2.5	HTS	cyclooxygenase inhibitor	CXCR1, PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1	Launched	5
BRD-A98174560-001-02-1::2.5::HTS	0.320424560807	BRD-A98174560-001-02-1::2.5::HTS	BRD-A98174560-001-02-1	chloralose	2.5	HTS					OCC(O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl	Preclinical	5
BRD-A98299281-050-09-6::2.5::HTS	-0.5758467803589999	BRD-A98299281-050-09-6::2.5::HTS	BRD-A98299281-050-09-6	hydroxytacrine-maleate-(r,s)	2.5	HTS	cholinesterase inhibitor	ACHE			Nc1c2C(O)CCCc2nc2ccccc12	Preclinical	5
BRD-A98378129-001-02-2::2.5::HTS	-0.372939563347	BRD-A98378129-001-02-2::2.5::HTS	BRD-A98378129-001-02-2	talniflumate	2.5	HTS	cyclooxygenase inhibitor	CLCA1	neurology/psychiatry	pain relief	FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1, FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1	Launched	5
BRD-A98845662-036-03-7::2.5::HTS	0.17526997052299997	BRD-A98845662-036-03-7::2.5::HTS	BRD-A98845662-036-03-7	desvenlafaxine	2.5	HTS	serotonin-norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1	Launched	5
BRD-A98990573-003-01-3::2.5::HTS	0.205375233599	BRD-A98990573-003-01-3::2.5::HTS	BRD-A98990573-003-01-3	epinastine	2.5	HTS	histamine receptor antagonist	ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7	ophthalmology	conjunctivitis	NC1=NCC2N1c1ccccc1Cc1ccccc21	Launched	5
BRD-A99117172-065-04-0::2.5::HTS	0.343731019635	BRD-A99117172-065-04-0::2.5::HTS	BRD-A99117172-065-04-0	hydroxychloroquine	2.5	HTS	antimalarial agent	TLR7, TLR9	infectious disease	malaria	CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12	Launched	5
BRD-A99388803-001-01-5::2.5::HTS	0.323931086805	BRD-A99388803-001-01-5::2.5::HTS	BRD-A99388803-001-01-5	metipranolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2			CC(C)NCC(O)COc1cc(C)c(OC(C)=O)c(C)c1C	Withdrawn	5
BRD-A99633051-001-07-0::2.5::HTS	-0.157231627888	BRD-A99633051-001-07-0::2.5::HTS	BRD-A99633051-001-07-0	ethosuximide	2.5	HTS	succinimide antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	epilepsy	CCC1(C)CC(=O)NC1=O, CCC1(C)CC(=O)NC1=O	Launched	5
BRD-A99833829-003-27-1::2.5::HTS	0.264178937661	BRD-A99833829-003-27-1::2.5::HTS	BRD-A99833829-003-27-1	bethanechol	2.5	HTS	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	urology	urinary retention	CC(C[N+](C)(C)C)OC(N)=O, CC(C[N+](C)(C)C)OC(N)=O, CC(C[N+](C)(C)C)OC(N)=O	Launched	5
BRD-A99888680-001-03-8::2.38::HTS	0.154267199815	BRD-A99888680-001-03-8::2.38::HTS	BRD-A99888680-001-03-8	paliperidone	2.38	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	Launched	5
BRD-A99888680-001-04-6::2.5::HTS	-0.307424903787	BRD-A99888680-001-04-6::2.5::HTS	BRD-A99888680-001-04-6	paliperidone	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	Launched	5
BRD-A99939097-001-24-2::2.5::HTS	0.0483471366478	BRD-A99939097-001-24-2::2.5::HTS	BRD-A99939097-001-24-2	carisoprodol	2.5	HTS	acetylcholine receptor antagonist	CYP2C19	neurology/psychiatry	muscle relaxant	CCCC(C)(COC(N)=O)COC(=O)NC(C)C	Launched	5
BRD-K00077635-304-01-2::2.5::HTS	0.19974801510200002	BRD-K00077635-304-01-2::2.5::HTS	BRD-K00077635-304-01-2	estramustine-phosphate	2.5	HTS	DNA synthesis inhibitor, microtubule inhibitor	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	Launched	5
BRD-K00091711-001-01-2::2.5::HTS	-0.221547418735	BRD-K00091711-001-01-2::2.5::HTS	BRD-K00091711-001-01-2	RWJ-21757	2.5	HTS	toll-like receptor agonist	TLR7			Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)n(CC=C)c2c(=O)[nH]1, Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)n(CC=C)c2c(=O)[nH]1, Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)n(CC=C)c2c(=O)[nH]1	Phase 1	5
BRD-K00152668-001-01-5::2.5::HTS	-6.6356736639600005	BRD-K00152668-001-01-5::2.5::HTS	BRD-K00152668-001-01-5	adarotene	2.5	HTS	retinoid receptor agonist	RARB, RARG			OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	Phase 1	5
BRD-K00259736-001-16-4::2.5::HTS	-0.7772458268800001	BRD-K00259736-001-16-4::2.5::HTS	BRD-K00259736-001-16-4	colchicine	2.5	HTS	microtubule inhibitor	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC	Launched	5
BRD-K00312224-001-09-5::2.5::HTS	-0.405816265964	BRD-K00312224-001-09-5::2.5::HTS	BRD-K00312224-001-09-5	PPT	2.5	HTS	estrogen receptor agonist	ESR1			CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1	Preclinical	5
BRD-K00317371-001-06-1::2.4::HTS	-3.5230625682	BRD-K00317371-001-06-1::2.4::HTS	BRD-K00317371-001-06-1	RITA	2.4	HTS	MDM inhibitor	MDM2			OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1	Preclinical	5
BRD-K00337317-001-06-6::2.5::HTS	0.21459596070099998	BRD-K00337317-001-06-6::2.5::HTS	BRD-K00337317-001-06-6	NU-7441	2.5	HTS	DNA dependent protein kinase inhibitor	PRKDC			O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1	Preclinical	5
BRD-K00405906-001-01-9::2.5::HTS	0.13109852498299998	BRD-K00405906-001-01-9::2.5::HTS	BRD-K00405906-001-01-9	phloroglucin	2.5	HTS					Oc1cc(O)cc(O)c1	Launched	5
BRD-K00486786-001-02-2::2.5::HTS	0.0172358215228	BRD-K00486786-001-02-2::2.5::HTS	BRD-K00486786-001-02-2	Ro-08-2750	2.5	HTS		NGF			Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O	Preclinical	5
BRD-K00494077-066-01-9::2.5::HTS	-0.191834072876	BRD-K00494077-066-01-9::2.5::HTS	BRD-K00494077-066-01-9	trovafloxacin	2.5	HTS	bacterial DNA gyrase inhibitor	TOP2A			N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	Withdrawn	5
BRD-K00519864-341-03-3::2.39::HTS	0.232180513937	BRD-K00519864-341-03-3::2.39::HTS	BRD-K00519864-341-03-3	peramivir	2.39	HTS	neuraminidase inhibitor		infectious disease	influenza A virus infection	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	Launched	5
BRD-K00521308-019-01-9::2.5::HTS	-0.0280920009967	BRD-K00521308-019-01-9::2.5::HTS	BRD-K00521308-019-01-9	ATN-161	2.5	HTS	integrin antagonist	ITGA5, ITGAV, ITGB1, ITGB3			CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	Phase 2	5
BRD-K00535541-001-05-5::2.5::HTS	-0.49136754415399997	BRD-K00535541-001-05-5::2.5::HTS	BRD-K00535541-001-05-5	9-aminoacridine	2.5	HTS					Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12	Preclinical	5
BRD-K00535541-001-06-3::2.5::HTS	-1.57877497585	BRD-K00535541-001-06-3::2.5::HTS	BRD-K00535541-001-06-3	9-aminoacridine	2.5	HTS					Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12	Preclinical	5
BRD-K00573984-003-01-5::2.5::HTS	0.106228183294	BRD-K00573984-003-01-5::2.5::HTS	BRD-K00573984-003-01-5	delapril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1	Launched	5
BRD-K00603606-003-24-0::2.5::HTS	0.030125458635400004	BRD-K00603606-003-24-0::2.5::HTS	BRD-K00603606-003-24-0	ticlopidine	2.5	HTS	purinergic receptor antagonist	P2RY12	hematology, neurology/psychiatry	thrombosis, stroke	Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1	Launched	5
BRD-K00610438-003-02-5::2.5::HTS	-0.137035820737	BRD-K00610438-003-02-5::2.5::HTS	BRD-K00610438-003-02-5	altanserin	2.5	HTS	serotonin receptor antagonist	HTR2A			Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1	Phase 2	5
BRD-K00615600-001-12-9::2.5::HTS	0.190112331495	BRD-K00615600-001-12-9::2.5::HTS	BRD-K00615600-001-12-9	AG-14361	2.5	HTS	PARP inhibitor	PARP1			CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23	Preclinical	5
BRD-K00627859-003-03-7::2.5::HTS	0.23741062881799999	BRD-K00627859-003-03-7::2.5::HTS	BRD-K00627859-003-03-7	tubastatin-a	2.5	HTS	HDAC inhibitor	HDAC6			CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO	Preclinical	5
BRD-K00662280-001-09-4::2.5::HTS	-0.08660703744100001	BRD-K00662280-001-09-4::2.5::HTS	BRD-K00662280-001-09-4	CL-218872	2.5	HTS	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F	Phase 1	5
BRD-K00673382-001-18-9::2.5::HTS	-0.129696156367	BRD-K00673382-001-18-9::2.5::HTS	BRD-K00673382-001-18-9	famotidine	2.5	HTS	histamine receptor antagonist	HRH2	gastroenterology	heartburn	NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1	Launched	5
BRD-K00674894-001-01-4::2.5::HTS	-0.07878378438080001	BRD-K00674894-001-01-4::2.5::HTS	BRD-K00674894-001-01-4	orteronel	2.5	HTS	androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor	CYP17A1			CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12	Phase 3	5
BRD-K00911143-001-01-9::2.5::HTS	-0.11096245765000001	BRD-K00911143-001-01-9::2.5::HTS	BRD-K00911143-001-01-9	brexpiprazole	2.5	HTS	dopamine receptor partial agonist	DRD2	neurology/psychiatry	depression, schizophrenia	O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1	Launched	5
BRD-K00911807-003-01-2::2.5::HTS	0.0251414171618	BRD-K00911807-003-01-2::2.5::HTS	BRD-K00911807-003-01-2	D-Phenylalanine	2.5	HTS	enkephalinase inhibitor	CCBL1, CRH, HCAR3			N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O	Preclinical	5
BRD-K00926464-001-01-8::2.5::HTS	0.015438009256799999	BRD-K00926464-001-01-8::2.5::HTS	BRD-K00926464-001-01-8	IMREG-1	2.5	HTS					N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O	Phase 3	5
BRD-K00938507-001-17-8::2.5::HTS	0.0679350787341	BRD-K00938507-001-17-8::2.5::HTS	BRD-K00938507-001-17-8	sulfamethoxypyridazine	2.5	HTS	bacterial antifolate				COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1	Withdrawn	5
BRD-K01029106-001-01-4::2.52::HTS	-1.3309694226100002	BRD-K01029106-001-01-4::2.52::HTS	BRD-K01029106-001-01-4	picolinic-acid	2.52	HTS	chelating agent				O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1	Phase 2	5
BRD-K01039503-001-01-2::2.5::HTS	0.39110945307800005	BRD-K01039503-001-01-2::2.5::HTS	BRD-K01039503-001-01-2	sofalcone	2.5	HTS	mucus protecting agent	CBR1	gastroenterology	peptic ulcer disease (PUD)	CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1	Launched	5
BRD-K01095011-001-15-9::2.5::HTS	-0.23029051632199998	BRD-K01095011-001-15-9::2.5::HTS	BRD-K01095011-001-15-9	finasteride	2.5	HTS	5 alpha reductase inhibitor	AKR1D1, SRD5A1, SRD5A2	endocrinology	androgenetic alopecia	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K01109406-001-03-7::2.5::HTS	-0.0545407437382	BRD-K01109406-001-03-7::2.5::HTS	BRD-K01109406-001-03-7	nitisinone	2.5	HTS	hydroxyphenylpyruvate dioxygenase inhibitor	HPD	metabolism	tyrosinemia	[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F	Launched	5
BRD-K01174345-001-01-9::2.5::HTS	0.569510836219	BRD-K01174345-001-01-9::2.5::HTS	BRD-K01174345-001-01-9	anamorelin	2.5	HTS	growth hormone secretagogue receptor agonist	GHSR			CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N	Phase 3	5
BRD-K01244426-236-12-1::2.5::HTS	0.172061910781	BRD-K01244426-236-12-1::2.5::HTS	BRD-K01244426-236-12-1	cloxacillin	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	Launched	5
BRD-K01292756-001-25-0::2.5::HTS	0.0329972053734	BRD-K01292756-001-25-0::2.5::HTS	BRD-K01292756-001-25-0	pimozide	2.5	HTS	dopamine receptor antagonist	CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2	neurology/psychiatry	Tourette's disorder	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	Launched	5
BRD-K01294196-001-01-5::2.5::HTS	0.477891551071	BRD-K01294196-001-01-5::2.5::HTS	BRD-K01294196-001-01-5	sucrose-octaacetate	2.5	HTS					CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O	Preclinical	5
BRD-K01295354-001-02-8::2.5::HTS	-1.14287113124	BRD-K01295354-001-02-8::2.5::HTS	BRD-K01295354-001-02-8	uric-acid	2.5	HTS		PYGL			O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1	Phase 3	5
BRD-K01377300-001-01-1::2.5::HTS	0.408300760625	BRD-K01377300-001-01-1::2.5::HTS	BRD-K01377300-001-01-1	CZC24832	2.5	HTS	PI3K inhibitor	PIK3CG			CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1, CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1	Preclinical	5
BRD-K01493881-001-29-4::2.5::HTS	0.067003891771	BRD-K01493881-001-29-4::2.5::HTS	BRD-K01493881-001-29-4	apigenin	2.5	HTS	casein kinase inhibitor, cell proliferation inhibitor	AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1			Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1	Preclinical	5
BRD-K01507359-001-22-9::2.5::HTS	-0.350432534691	BRD-K01507359-001-22-9::2.5::HTS	BRD-K01507359-001-22-9	rifampin	2.5	HTS	RNA polymerase inhibitor	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C	Launched	5
BRD-K01567962-001-23-0::2.5::HTS	0.35529479781999995	BRD-K01567962-001-23-0::2.5::HTS	BRD-K01567962-001-23-0	pyrazolanthrone	2.5	HTS	JNK inhibitor	MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK			O=C1c2ccccc2-c2n[nH]c3cccc1c23, O=C1c2ccccc2-c2n[nH]c3cccc1c23	Preclinical	5
BRD-K01577834-001-15-1::2.5::HTS	-0.506445626034	BRD-K01577834-001-15-1::2.5::HTS	BRD-K01577834-001-15-1	adenosine	2.5	HTS	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4	cardiology	Wolff-Parkinson-White Syndrome (WPW)	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Launched	5
BRD-K01614093-001-02-6::2.5::HTS	-0.6002946224229999	BRD-K01614093-001-02-6::2.5::HTS	BRD-K01614093-001-02-6	dihydromyricetin	2.5	HTS					O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1	Preclinical	5
BRD-K01624185-001-05-7::2.5::HTS	0.444810274475	BRD-K01624185-001-05-7::2.5::HTS	BRD-K01624185-001-05-7	maltobionic-acid	2.5	HTS	matrix metalloprotease inhibitor		dermatology	cosmetic	OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O	Launched	5
BRD-K01649396-003-07-1::2.5::HTS	0.333842207841	BRD-K01649396-003-07-1::2.5::HTS	BRD-K01649396-003-07-1	indatraline	2.5	HTS	norepinephrine transporter inhibitor	MAOA, MAOB			CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-K01653460-001-01-1::2.5::HTS	-0.441815879143	BRD-K01653460-001-01-1::2.5::HTS	BRD-K01653460-001-01-1	chlorindanol	2.5	HTS					Oc1ccc(Cl)c2CCCc12	Preclinical	5
BRD-K01663662-003-20-2::2.5::HTS	0.394072107311	BRD-K01663662-003-20-2::2.5::HTS	BRD-K01663662-003-20-2	diphenidol	2.5	HTS	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	vertigo	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	Launched	5
BRD-K01669786-001-02-2::2.5::HTS	-1.16519844167	BRD-K01669786-001-02-2::2.5::HTS	BRD-K01669786-001-02-2	triapine	2.5	HTS	ribonucleotide reductase inhibitor	RRM1, RRM2			NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N	Phase 2	5
BRD-K01674964-300-06-3::2.5::HTS	0.14105965792199998	BRD-K01674964-300-06-3::2.5::HTS	BRD-K01674964-300-06-3	histamine	2.5	HTS	histamine receptor agonist	HRH1, HRH2, HRH3, HRH4	allergy	allergic rhinitis	NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1	Launched	5
BRD-K01683783-001-02-6::2.5::HTS	-1.50740610366	BRD-K01683783-001-02-6::2.5::HTS	BRD-K01683783-001-02-6	TAK-901	2.5	HTS	Aurora kinase inhibitor	AURKB			CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12	Phase 1	5
BRD-K01767299-050-02-1::2.5::HTS	0.145460738143	BRD-K01767299-050-02-1::2.5::HTS	BRD-K01767299-050-02-1	ciproxifan	2.5	HTS	histamine receptor antagonist	ADRA2A, ADRA2C, HRH3, HRH4, HTR3A			O=C(C1CC1)c1ccc(OCCCc2c[nH]cn2)cc1	Preclinical	5
BRD-K01773560-001-02-4::2.59::HTS	-0.304267375043	BRD-K01773560-001-02-4::2.59::HTS	BRD-K01773560-001-02-4	UNC2250	2.59	HTS	MER tyrosine kinase inhibitor	MERTK			CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1	Preclinical	5
BRD-K01815685-001-15-5::2.5::HTS	0.27066658436	BRD-K01815685-001-15-5::2.5::HTS	BRD-K01815685-001-15-5	indole-3-carbinol	2.5	HTS	aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor	AHR			OCc1c[nH]c2ccccc12	Phase 2/Phase 3	5
BRD-K01824921-001-18-5::2.5::HTS	-0.41315341145400003	BRD-K01824921-001-18-5::2.5::HTS	BRD-K01824921-001-18-5	DPCPX	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)C1CCCC1	Phase 1	5
BRD-K01868942-003-02-7::2.5::HTS	-0.251389083769	BRD-K01868942-003-02-7::2.5::HTS	BRD-K01868942-003-02-7	RS-23597-190	2.5	HTS	serotonin receptor antagonist	HTR4			COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1	Preclinical	5
BRD-K01902415-001-11-7::2.5::HTS	0.32234503730999997	BRD-K01902415-001-11-7::2.5::HTS	BRD-K01902415-001-11-7	pirinixic-acid	2.5	HTS	PPAR receptor agonist	PPARA			Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C	Preclinical	5
BRD-K01942991-005-08-2::2.5::HTS	-0.144254539036	BRD-K01942991-005-08-2::2.5::HTS	BRD-K01942991-005-08-2	oxotremorine-m	2.5	HTS	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O	Preclinical	5
BRD-K01950558-001-14-7::2.5::HTS	-0.057944269696899996	BRD-K01950558-001-14-7::2.5::HTS	BRD-K01950558-001-14-7	succinylsulfathiazole	2.5	HTS	dihydrofolate reductase inhibitor	DHFR			OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Phase 2	5
BRD-K01980392-003-11-6::2.5::HTS	0.254618591269	BRD-K01980392-003-11-6::2.5::HTS	BRD-K01980392-003-11-6	guvacine	2.5	HTS	GABA uptake inhibitor	SLC6A1, SLC6A11, SLC6A12, SLC6A13			OC(=O)C1=CCCNC1	Preclinical	5
BRD-K01995783-001-01-6::2.5::HTS	0.0346006344227	BRD-K01995783-001-01-6::2.5::HTS	BRD-K01995783-001-01-6	AMG-9810	2.5	HTS	TRPV antagonist	TRPV1			CC(C)(C)c1ccc(cc1)\C=C\C(=O)Nc1ccc2OCCOc2c1, CC(C)(C)c1ccc(cc1)\C=C\C(=O)Nc1ccc2OCCOc2c1	Preclinical	5
BRD-K02017404-300-06-2::2.5::HTS	0.20302526598499998	BRD-K02017404-300-06-2::2.5::HTS	BRD-K02017404-300-06-2	NVP-BSK805	2.5	HTS	JAK inhibitor	JAK2			Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1	Preclinical	5
BRD-K02079473-001-01-3::2.5::HTS	-0.0665192017796	BRD-K02079473-001-01-3::2.5::HTS	BRD-K02079473-001-01-3	oxatomide	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	5
BRD-K02113016-001-15-4::2.5::HTS	0.0122300127765	BRD-K02113016-001-15-4::2.5::HTS	BRD-K02113016-001-15-4	olaparib	2.5	HTS	PARP inhibitor	PARP1, PARP2	oncology	ovarian cancer	Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1	Launched	5
BRD-K02123250-001-06-7::2.5::HTS	0.25631430222600005	BRD-K02123250-001-06-7::2.5::HTS	BRD-K02123250-001-06-7	JNJ-38877605	2.5	HTS	tyrosine kinase inhibitor	MET			Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1	Phase 1	5
BRD-K02130563-001-11-4::2.5::HTS	-5.89598226278	BRD-K02130563-001-11-4::2.5::HTS	BRD-K02130563-001-11-4	panobinostat	2.5	HTS	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	Launched	5
BRD-K02241333-001-02-7::2.5::HTS	-0.792449083117	BRD-K02241333-001-02-7::2.5::HTS	BRD-K02241333-001-02-7	CHIR-124	2.5	HTS	CHK inhibitor	CHEK1			Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1	Preclinical	5
BRD-K02265150-001-26-5::2.5::HTS	-0.26055763132	BRD-K02265150-001-26-5::2.5::HTS	BRD-K02265150-001-26-5	amoxapine	2.5	HTS	norepinephrine reputake inhibitor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1	Launched	5
BRD-K02292852-001-02-1::2.5::HTS	0.411212943771	BRD-K02292852-001-02-1::2.5::HTS	BRD-K02292852-001-02-1	cefoperazone	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O	Launched	5
BRD-K02314383-001-01-3::2.5::HTS	-0.25363984393800004	BRD-K02314383-001-01-3::2.5::HTS	BRD-K02314383-001-01-3	epitiostanol	2.5	HTS	androgen receptor agonist	AR			C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O	Launched	5
BRD-K02389548-001-02-5::2.5::HTS	-0.193859395376	BRD-K02389548-001-02-5::2.5::HTS	BRD-K02389548-001-02-5	RG2833	2.5	HTS	HDAC inhibitor	HDAC1, HDAC3			Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N	Phase 1	5
BRD-K02404261-001-16-7::2.5::HTS	-0.00219804505769	BRD-K02404261-001-16-7::2.5::HTS	BRD-K02404261-001-16-7	caffeine	2.5	HTS	adenosine receptor antagonist, phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3	neurology/psychiatry	fatigue, drowsiness, fatigue, drowsiness	Cn1cnc2n(C)c(=O)n(C)c(=O)c12	Launched	5
BRD-K02407574-001-09-7::2.5::HTS	-1.6378223704700001	BRD-K02407574-001-09-7::2.5::HTS	BRD-K02407574-001-09-7	parbendazole	2.5	HTS	tubulin polymerization inhibitor	TUBB			CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1	Preclinical	5
BRD-K02464583-001-02-2::2.5::HTS	0.11292418937200001	BRD-K02464583-001-02-2::2.5::HTS	BRD-K02464583-001-02-2	ethyl-paraben	2.5	HTS					CCOC(=O)c1ccc(O)cc1	Preclinical	5
BRD-K02475039-001-01-0::2.5::HTS	0.15258674595000002	BRD-K02475039-001-01-0::2.5::HTS	BRD-K02475039-001-01-0	ethopabate	2.5	HTS	antiprotozoal agent		infectious disease	coccidiosis	CCOc1cc(NC(C)=O)ccc1C(=O)OC	Launched	5
BRD-K02501528-001-01-1::2.5::HTS	-0.278452116001	BRD-K02501528-001-01-1::2.5::HTS	BRD-K02501528-001-01-1	S18986	2.5	HTS	glutamate receptor modulator	GRIA1, GRIA2, GRIA3, GRIA4			O=S1(=O)N[C@H]2CCCN2c2ccccc12	Phase 2	5
BRD-K02594908-001-16-4::2.5::HTS	-0.9569907467309999	BRD-K02594908-001-16-4::2.5::HTS	BRD-K02594908-001-16-4	sulfanilamide	2.5	HTS	carbonic anhydrase inhibitor	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O	Launched	5
BRD-K02637541-001-18-0::2.5::HTS	0.256803778878	BRD-K02637541-001-18-0::2.5::HTS	BRD-K02637541-001-18-0	celecoxib	2.5	HTS	cyclooxygenase inhibitor	CA12, PDPK1, PTGS2	rheumatology, endocrinology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)	Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F	Launched	5
BRD-K02703275-001-07-5::2.5::HTS	0.00396137645596	BRD-K02703275-001-07-5::2.5::HTS	BRD-K02703275-001-07-5	gedunin	2.5	HTS	HSP inhibitor	HSP90AA1			CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1	Preclinical	5
BRD-K02715688-001-02-1::2.5::HTS	0.398570047887	BRD-K02715688-001-02-1::2.5::HTS	BRD-K02715688-001-02-1	hydrastine-(1r,-9s)	2.5	HTS	tyrosine hydroxylase inhibitor				COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12	Preclinical	5
BRD-K02733959-236-07-7::2.5::HTS	0.271495615544	BRD-K02733959-236-07-7::2.5::HTS	BRD-K02733959-236-07-7	cefuroxime	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1	Launched	5
BRD-K02764365-001-13-6::2.5::HTS	-0.0892647403963	BRD-K02764365-001-13-6::2.5::HTS	BRD-K02764365-001-13-6	methiazole	2.5	HTS	anthelmintic agent				COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1	Preclinical	5
BRD-K02816415-001-01-9::2.5::HTS	-0.171258844571	BRD-K02816415-001-01-9::2.5::HTS	BRD-K02816415-001-01-9	CRT0044876	2.5	HTS					OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1	Preclinical	5
BRD-K02867583-300-08-9::2.5::HTS	0.47270380504799997	BRD-K02867583-300-08-9::2.5::HTS	BRD-K02867583-300-08-9	minaprine	2.5	HTS	serotonin reuptake inhibitor	ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4			Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1	Withdrawn	5
BRD-K02898090-001-02-7::2.5::HTS	0.0682463818975	BRD-K02898090-001-02-7::2.5::HTS	BRD-K02898090-001-02-7	kifunensine	2.5	HTS	mannosidase inhibitor	MAN1B1, MAN2A1			OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12	Phase 1	5
BRD-K02900412-001-11-3::2.5::HTS	0.0852511724285	BRD-K02900412-001-11-3::2.5::HTS	BRD-K02900412-001-11-3	clofoctol	2.5	HTS	protein synthesis inhibitor		infectious disease	gram-positive bacterial infections	CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1	Launched	5
BRD-K02908048-003-06-4::2.5::HTS	-0.05100177266969999	BRD-K02908048-003-06-4::2.5::HTS	BRD-K02908048-003-06-4	preclamol	2.5	HTS	dopamine receptor agonist	DRD2			CCCN1CCC[C@@H](C1)c1cccc(O)c1	Phase 2	5
BRD-K02943813-001-01-9::2.5::HTS	0.042565527262399996	BRD-K02943813-001-01-9::2.5::HTS	BRD-K02943813-001-01-9	dasabuvir	2.5	HTS	HCV inhibitor		infectious disease	hepatitis C	COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1	Launched	5
BRD-K02950022-001-02-9::2.5::HTS	0.405944631837	BRD-K02950022-001-02-9::2.5::HTS	BRD-K02950022-001-02-9	BMS-299897	2.5	HTS	gamma secretase inhibitor				C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O	Phase 1	5
BRD-K02953697-001-09-2::2.5::HTS	-0.0809574492672	BRD-K02953697-001-09-2::2.5::HTS	BRD-K02953697-001-09-2	naringin	2.5	HTS	cytochrome P450 inhibitor	SLCO1A2			C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O	Preclinical	5
BRD-K02965346-001-07-5::2.5::HTS	0.167484496321	BRD-K02965346-001-07-5::2.5::HTS	BRD-K02965346-001-07-5	SU-11274	2.5	HTS	hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor	MET			CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1	Preclinical	5
BRD-K02965577-001-03-4::0.25::HTS	0.033880280986599995	BRD-K02965577-001-03-4::0.25::HTS	BRD-K02965577-001-03-4	secalciferol	0.25	HTS	vitamin D receptor agonist	VDR	critical care	bone fracture	C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C	Launched	3
BRD-K02992638-001-11-8::2.5::HTS	-0.508030260105	BRD-K02992638-001-11-8::2.5::HTS	BRD-K02992638-001-11-8	lamivudine	2.5	HTS	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B	Nc1ccn(C2CSC(CO)O2)c(=O)n1, Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1	Launched	5
BRD-K03063480-001-05-8::2.5::HTS	0.636736824068	BRD-K03063480-001-05-8::2.5::HTS	BRD-K03063480-001-05-8	PF-477736	2.5	HTS	CHK inhibitor	CHEK1, CHEK2			Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	Phase 1	5
BRD-K03063480-001-06-6::2.42::HTS	-0.6228599653019999	BRD-K03063480-001-06-6::2.42::HTS	BRD-K03063480-001-06-6	PF-477736	2.42	HTS	CHK inhibitor	CHEK1, CHEK2			Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	Phase 1	5
BRD-K03095347-001-06-1::2.5::HTS	-0.274217260553	BRD-K03095347-001-06-1::2.5::HTS	BRD-K03095347-001-06-1	levosimendan	2.5	HTS	calcium sensitizer	KCNJ11, KCNJ8, PDE3A, TNNC1	cardiology	congestive heart failure	C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1	Launched	5
BRD-K03109492-001-02-2::2.5::HTS	0.0162017041702	BRD-K03109492-001-02-2::2.5::HTS	BRD-K03109492-001-02-2	NSC-663284	2.5	HTS	CDC inhibitor	CDC25A, CDC25B, CDC25C			ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O	Preclinical	5
BRD-K03155172-001-02-2::2.5::HTS	-0.133237112915	BRD-K03155172-001-02-2::2.5::HTS	BRD-K03155172-001-02-2	GSK3787	2.5	HTS	PPAR receptor antagonist	PPARD			FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1	Preclinical	5
BRD-K03164761-001-02-1::2.5::HTS	0.313928329197	BRD-K03164761-001-02-1::2.5::HTS	BRD-K03164761-001-02-1	thiazovivin	2.5	HTS	rho associated kinase inhibitor				O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1	Preclinical	5
BRD-K03194791-001-04-8::2.5::HTS	-0.25073401173099996	BRD-K03194791-001-04-8::2.5::HTS	BRD-K03194791-001-04-8	roflumilast	2.5	HTS	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis	FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl	Launched	5
BRD-K03243820-001-23-8::2.37::HTS	-1.47204716695	BRD-K03243820-001-23-8::2.37::HTS	BRD-K03243820-001-23-8	trifluridine	2.37	HTS	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	Launched	5
BRD-K03243820-001-25-3::2.5::HTS	-0.0835384348188	BRD-K03243820-001-25-3::2.5::HTS	BRD-K03243820-001-25-3	trifluridine	2.5	HTS	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	Launched	5
BRD-K03273112-001-01-8::2.5::HTS	0.448862945654	BRD-K03273112-001-01-8::2.5::HTS	BRD-K03273112-001-01-8	1-azakenpaullone	2.5	HTS	glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1	Preclinical	5
BRD-K03289018-001-02-7::2.5::HTS	-0.784131845744	BRD-K03289018-001-02-7::2.5::HTS	BRD-K03289018-001-02-7	CCT137690	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB, AURKC			CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1	Preclinical	5
BRD-K03289534-001-01-4::2.5::HTS	0.290438891619	BRD-K03289534-001-01-4::2.5::HTS	BRD-K03289534-001-01-4	lersivirine	2.5	HTS	non-nucleoside reverse transcriptase inhibitor				CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N	Phase 2	5
BRD-K03294269-001-08-0::2.5::HTS	-1.5710566707499998	BRD-K03294269-001-08-0::2.5::HTS	BRD-K03294269-001-08-0	NU6027	2.5	HTS	CDK inhibitor	CCNA2, CDK2			Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1	Preclinical	5
BRD-K03301001-003-02-5::2.5::HTS	-0.0868443233707	BRD-K03301001-003-02-5::2.5::HTS	BRD-K03301001-003-02-5	A-7	2.5	HTS	calmodulin antagonist				NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	Preclinical	5
BRD-K03353589-236-01-4::2.5::HTS	0.226013669368	BRD-K03353589-236-01-4::2.5::HTS	BRD-K03353589-236-01-4	ecabet	2.5	HTS	gastrin inhibitor, urease inhibitor	NOXO1	ophthalmology	dry eye syndrome	CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O	Launched	5
BRD-K03384561-001-02-7::2.5::HTS	-2.58425081882	BRD-K03384561-001-02-7::2.5::HTS	BRD-K03384561-001-02-7	roquinimex	2.5	HTS	angiogenesis inhibitor, tumor necrosis factor production inhibitor				CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1	Phase 3	5
BRD-K03390685-001-01-7::2.5::HTS	-5.3176726827	BRD-K03390685-001-01-7::2.5::HTS	BRD-K03390685-001-01-7	cobimetinib	2.5	HTS	MEK inhibitor		oncology	melanoma	OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1	Launched	5
BRD-K03406345-001-27-8::2.5::HTS	-0.10501430681500001	BRD-K03406345-001-27-8::2.5::HTS	BRD-K03406345-001-27-8	azacitidine	2.5	HTS	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	Launched	5
BRD-K03449891-001-08-6::2.5::HTS	-1.43769800342	BRD-K03449891-001-08-6::2.5::HTS	BRD-K03449891-001-08-6	foretinib	2.5	HTS	VEGFR inhibitor	FLT1, FLT4, KDR, MET			COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1	Phase 2	5
BRD-K03504028-001-07-6::2.5::HTS	0.035250701777199994	BRD-K03504028-001-07-6::2.5::HTS	BRD-K03504028-001-07-6	amygdalin	2.5	HTS	caspase activator	CASP3			OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	5
BRD-K03549949-001-01-0::2.5::HTS	-0.799589849566	BRD-K03549949-001-01-0::2.5::HTS	BRD-K03549949-001-01-0	XL388	2.5	HTS	mTOR inhibitor	MTOR			Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O	Preclinical	5
BRD-K03564313-001-03-3::2.5::HTS	0.141026096536	BRD-K03564313-001-03-3::2.5::HTS	BRD-K03564313-001-03-3	DMNB	2.5	HTS	DNA dependent protein kinase inhibitor				COc1cc(C=O)c(cc1OC)[N+]([O-])=O	Preclinical	5
BRD-K03601870-001-01-2::2.5::HTS	-3.5654000188099997	BRD-K03601870-001-01-2::2.5::HTS	BRD-K03601870-001-01-2	ixabepilone	2.5	HTS	microtubule stabilizing agent	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Launched	5
BRD-K03739921-001-06-8::2.5::HTS	-0.0977139293633	BRD-K03739921-001-06-8::2.5::HTS	BRD-K03739921-001-06-8	hypoxanthine	2.5	HTS	PARP inhibitor	PNP			O=c1[nH]cnc2nc[nH]c12	Preclinical	5
BRD-K04111260-001-10-0::2.5::HTS	0.02286764236	BRD-K04111260-001-10-0::2.5::HTS	BRD-K04111260-001-10-0	raclopride	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3, HTR1A			CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC	Launched	5
BRD-K04112579-001-07-0::2.5::HTS	-0.103227591715	BRD-K04112579-001-07-0::2.5::HTS	BRD-K04112579-001-07-0	nepafenac	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	ophthalmology	eye inflammation	NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N	Launched	5
BRD-K04176066-001-08-3::2.5::HTS	-0.184639008758	BRD-K04176066-001-08-3::2.5::HTS	BRD-K04176066-001-08-3	bergenin	2.5	HTS	interleukin inhibitor	IL1B, TNF			COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O	Preclinical	5
BRD-K04185004-003-11-9::2.5::HTS	0.5802663736020001	BRD-K04185004-003-11-9::2.5::HTS	BRD-K04185004-003-11-9	oxybuprocaine	2.5	HTS	local anesthetic	SCN10A	neurology/psychiatry	local anesthetic	CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC	Launched	5
BRD-K04196797-001-24-4::2.5::HTS	0.366054195824	BRD-K04196797-001-24-4::2.5::HTS	BRD-K04196797-001-24-4	oxcarbazepine	2.5	HTS	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12	Launched	5
BRD-K04264130-001-01-4::2.5::HTS	-0.487175219313	BRD-K04264130-001-01-4::2.5::HTS	BRD-K04264130-001-01-4	favipiravir	2.5	HTS	RNA polymerase inhibitor				NC(=O)c1nc(F)cnc1O	Phase 3	5
BRD-K04394237-001-03-7::2.49::HTS	-0.6155242550159999	BRD-K04394237-001-03-7::2.49::HTS	BRD-K04394237-001-03-7	drospirenone	2.49	HTS	mineralocorticoid receptor antagonist	AR, NR3C2, PGR	endocrinology	contraceptive	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1	Launched	5
BRD-K04394237-001-06-0::2.5::HTS	0.203195857014	BRD-K04394237-001-06-0::2.5::HTS	BRD-K04394237-001-06-0	drospirenone	2.5	HTS	mineralocorticoid receptor antagonist	AR, NR3C2, PGR	endocrinology	contraceptive	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1	Launched	5
BRD-K04414442-001-08-3::2.5::HTS	0.152549574222	BRD-K04414442-001-08-3::2.5::HTS	BRD-K04414442-001-08-3	SB-222200	2.5	HTS	tachykinin antagonist	TACR3			CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1	Preclinical	5
BRD-K04430056-001-17-7::2.5::HTS	0.329054398259	BRD-K04430056-001-17-7::2.5::HTS	BRD-K04430056-001-17-7	7-nitroindazole	2.5	HTS	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12	Preclinical	5
BRD-K04430056-236-02-1::2.5::HTS	-2.41506077051	BRD-K04430056-236-02-1::2.5::HTS	BRD-K04430056-236-02-1	7-nitroindazole	2.5	HTS	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12	Preclinical	5
BRD-K04497194-001-02-1::2.5::HTS	-0.725509129179	BRD-K04497194-001-02-1::2.5::HTS	BRD-K04497194-001-02-1	lithocholic-acid	2.5	HTS	FXR antagonist, vitamin D receptor agonist	GPBAR1, NR1H4, NR1I2, VDR			C[C@H](CCC(O)=O)[C@@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Preclinical	5
BRD-K04548931-003-16-5::2.5::HTS	-4.00218596852	BRD-K04548931-003-16-5::2.5::HTS	BRD-K04548931-003-16-5	epirubicin	2.5	HTS	topoisomerase inhibitor	CHD1, TOP2A	oncology	breast cancer	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	Launched	5
BRD-K04552268-001-02-4::5::HTS	-0.19151491971	BRD-K04552268-001-02-4::5::HTS	BRD-K04552268-001-02-4	4-pyrimidinecarbonitrile	5.0	HTS					N#Cc1ccncn1	Preclinical	5
BRD-K04568635-300-01-4::2.5::HTS	-3.1821436954	BRD-K04568635-300-01-4::2.5::HTS	BRD-K04568635-300-01-4	octenidine	2.5	HTS	membrane integrity inhibitor				CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1	Launched	5
BRD-K04622161-001-02-3::2.5::HTS	0.261706470662	BRD-K04622161-001-02-3::2.5::HTS	BRD-K04622161-001-02-3	YO-01027	2.5	HTS	gamma secretase inhibitor				C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	Preclinical	5
BRD-K04623885-001-07-5::2.5::HTS	-0.167668280501	BRD-K04623885-001-07-5::2.5::HTS	BRD-K04623885-001-07-5	BIBR-1532	2.5	HTS	telomerase inhibitor	TERT			C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1	Preclinical	5
BRD-K04657451-001-01-0::2.5::HTS	-0.39366471471500003	BRD-K04657451-001-01-0::2.5::HTS	BRD-K04657451-001-01-0	D-delta-Tocopherol	2.5	HTS					CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1	Launched	5
BRD-K04691817-001-01-8::2.5::HTS	0.344116659	BRD-K04691817-001-01-8::2.5::HTS	BRD-K04691817-001-01-8	AGI-6780	2.5	HTS	isocitrate dehydrogenase inhibitor	IDH2			FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1	Preclinical	5
BRD-K04704168-003-14-3::2.5::HTS	-0.0578221006662	BRD-K04704168-003-14-3::2.5::HTS	BRD-K04704168-003-14-3	clemizole	2.5	HTS	HCV inhibitor		allergy	allergic rhinitis	Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1	Launched	5
BRD-K04804440-001-09-5::2.5::HTS	-0.0319643549268	BRD-K04804440-001-09-5::2.5::HTS	BRD-K04804440-001-09-5	ciprofloxacin	2.5	HTS	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology	otitis	OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	Launched	5
BRD-K04833372-001-06-2::2.5::HTS	0.00789901802824	BRD-K04833372-001-06-2::2.5::HTS	BRD-K04833372-001-06-2	GSK1904529A	2.5	HTS	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	IGF1R, INSR			CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O	Preclinical	5
BRD-K04851519-001-06-8::2.5::HTS	-0.392204861492	BRD-K04851519-001-06-8::2.5::HTS	BRD-K04851519-001-06-8	aloe-emodin	2.5	HTS	anticancer agent	CASP8			OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Preclinical	5
BRD-K04923131-001-15-4::2.5::HTS	1.34845229053	BRD-K04923131-001-15-4::2.5::HTS	BRD-K04923131-001-15-4	GSK-3-inhibitor-IX	2.5	HTS	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	GSK3A, GSK3B			O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12	Preclinical	5
BRD-K04956647-003-02-5::2.5::HTS	0.24262153458799998	BRD-K04956647-003-02-5::2.5::HTS	BRD-K04956647-003-02-5	nebivolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension	O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1, OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1	Launched	5
BRD-K04993719-001-01-7::2.5::HTS	0.5177637103130001	BRD-K04993719-001-01-7::2.5::HTS	BRD-K04993719-001-01-7	LY2334737	2.5	HTS	antitumor agent, ribonucleotide reductase inhibitor				CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	Phase 1	5
BRD-K05048137-001-03-9::1.57::HTS	0.0720944416273	BRD-K05048137-001-03-9::1.57::HTS	BRD-K05048137-001-03-9	phytosphingosine	1.57	HTS					CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO	Phase 1	4
BRD-K05104363-001-10-0::2.5::HTS	-1.8724649120599997	BRD-K05104363-001-10-0::2.5::HTS	BRD-K05104363-001-10-0	PD-184352	2.5	HTS	MEK inhibitor	MAP2K1, MAP3K1, MAP3K2			Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F	Phase 2	5
BRD-K05151076-001-02-6::2.5::HTS	-0.0267140462507	BRD-K05151076-001-02-6::2.5::HTS	BRD-K05151076-001-02-6	ZK-164015	2.5	HTS	estrogen receptor antagonist	ESR1, ESR2			CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1	Preclinical	5
BRD-K05181084-003-03-7::2.5::HTS	0.252351058515	BRD-K05181084-003-03-7::2.5::HTS	BRD-K05181084-003-03-7	NGB-2904	2.5	HTS	dopamine receptor antagonist	DRD3			Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl	Preclinical	5
BRD-K05236810-001-19-0::2.5::HTS	0.487732022738	BRD-K05236810-001-19-0::2.5::HTS	BRD-K05236810-001-19-0	luteolin	2.5	HTS	glucosidase inhibitor	TOP1			Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1	Phase 2	5
BRD-K05361803-001-03-9::2.5::HTS	0.7015640558130001	BRD-K05361803-001-03-9::2.5::HTS	BRD-K05361803-001-03-9	SC-10	2.5	HTS	protein kinase activator	PRKCA			CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	Preclinical	5
BRD-K05395900-322-05-4::2.5::HTS	-0.321905260822	BRD-K05395900-322-05-4::2.5::HTS	BRD-K05395900-322-05-4	nicotine	2.5	HTS	acetylcholine receptor agonist	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1	Launched	5
BRD-K05434375-001-06-5::2.5::HTS	0.61918213575	BRD-K05434375-001-06-5::2.5::HTS	BRD-K05434375-001-06-5	HA-1004	2.5	HTS	calcium channel blocker				NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12	Phase 2	5
BRD-K05444225-001-01-7::2.5::HTS	-0.08478106497160001	BRD-K05444225-001-01-7::2.5::HTS	BRD-K05444225-001-01-7	E7449	2.5	HTS	PARP inhibitor	PARP1, PARP2, TNKS, TNKS2			O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23	Phase 1/Phase 2	5
BRD-K05445342-001-05-3::2.57::HTS	-3.8738009332699996	BRD-K05445342-001-05-3::2.57::HTS	BRD-K05445342-001-05-3	WP1066	2.57	HTS	STAT inhibitor	STAT3			C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	Phase 1	5
BRD-K05446112-001-01-8::2.5::HTS	-0.148568139824	BRD-K05446112-001-01-8::2.5::HTS	BRD-K05446112-001-01-8	ledipasvir	2.5	HTS	HCV inhibitor		infectious disease	hepatitis C	COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1ncc([nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched	5
BRD-K05464208-001-05-7::2.5::HTS	0.545846962355	BRD-K05464208-001-05-7::2.5::HTS	BRD-K05464208-001-05-7	JX-401	2.5	HTS	p38 MAPK inhibitor	MAPK14			COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1	Preclinical	5
BRD-K05524748-003-04-4::2.5::HTS	0.377485255267	BRD-K05524748-003-04-4::2.5::HTS	BRD-K05524748-003-04-4	dronedarone	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12	Launched	5
BRD-K05528470-305-02-2::2.5::HTS	-0.0006019990158130001	BRD-K05528470-305-02-2::2.5::HTS	BRD-K05528470-305-02-2	L-745870	2.5	HTS	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7			Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1	Preclinical	5
BRD-K05619559-001-12-7::2.5::HTS	-0.538769891975	BRD-K05619559-001-12-7::2.5::HTS	BRD-K05619559-001-12-7	tobramycin	2.5	HTS	bacterial 30S ribosomal subunit inhibitor		infectious disease	bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	Launched	5
BRD-K05638300-001-01-2::2.5::HTS	-0.14095386962099998	BRD-K05638300-001-01-2::2.5::HTS	BRD-K05638300-001-01-2	sevoflurane	2.5	HTS	membrane integrity inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F	Launched	5
BRD-K05658747-001-02-9::2.5::HTS	0.35660291619900003	BRD-K05658747-001-02-9::2.5::HTS	BRD-K05658747-001-02-9	raltegravir	2.5	HTS	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C	Launched	5
BRD-K05673000-236-12-1::2.5::HTS	0.0057180757266399995	BRD-K05673000-236-12-1::2.5::HTS	BRD-K05673000-236-12-1	dicloxacillin	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl	Launched	5
BRD-K05674516-001-01-7::2.5::HTS	0.101872254303	BRD-K05674516-001-01-7::2.5::HTS	BRD-K05674516-001-01-7	PSI-7976	2.5	HTS	HCV inhibitor				CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	Preclinical	5
BRD-K05674516-001-02-5::2.5::HTS	0.172126919084	BRD-K05674516-001-02-5::2.5::HTS	BRD-K05674516-001-02-5	sofosbuvir	2.5	HTS	RNA polymerase inhibitor		infectious disease	hepatitis C	CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	Launched	5
BRD-K05677083-001-05-4::2.5::HTS	-0.677960686421	BRD-K05677083-001-05-4::2.5::HTS	BRD-K05677083-001-05-4	PACOCF3	2.5	HTS	phospholipase inhibitor	PLA2G4A			CCCCCCCCCCCCCCCC(=O)C(F)(F)F	Preclinical	5
BRD-K05804044-001-06-0::2.5::HTS	-0.5418651329199999	BRD-K05804044-001-06-0::2.5::HTS	BRD-K05804044-001-06-0	AZ-628	2.5	HTS	RAF inhibitor	BRAF, RAF1			Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1	Preclinical	5
BRD-K05850076-001-01-5::2.5::HTS	-0.29357234003000005	BRD-K05850076-001-01-5::2.5::HTS	BRD-K05850076-001-01-5	sotagliflozin	2.5	HTS	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2			CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1	Phase 3	5
BRD-K05878375-236-05-7::2.5::HTS	0.216100270478	BRD-K05878375-236-05-7::2.5::HTS	BRD-K05878375-236-05-7	sodium-butyrate	2.5	HTS	HDAC inhibitor	BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8			CCCC(O)=O, CCCC(O)=O	Phase 2	5
BRD-K05900209-001-03-4::2.47::HTS	-0.7542816190430001	BRD-K05900209-001-03-4::2.47::HTS	BRD-K05900209-001-03-4	dexlansoprazole	2.47	HTS	ATPase inhibitor	ATP4A, ATP4B	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE)	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1	Launched	5
BRD-K05906022-001-05-1::2.5::HTS	-0.349794712462	BRD-K05906022-001-05-1::2.5::HTS	BRD-K05906022-001-05-1	limonin	2.5	HTS	HIV protease inhibitor				CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1	Preclinical	5
BRD-K05907307-001-07-1::2.5::HTS	0.234000892071	BRD-K05907307-001-07-1::2.5::HTS	BRD-K05907307-001-07-1	nonivamide	2.5	HTS	TRPV agonist	TRPV1	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1	Launched	5
BRD-K05919151-001-01-6::2.5::HTS	-0.134101314542	BRD-K05919151-001-01-6::2.5::HTS	BRD-K05919151-001-01-6	dixanthogen	2.5	HTS					CCOC(=S)SSC(=S)OCC	Preclinical	5
BRD-K05977355-001-19-0::2.5::HTS	-0.292767134527	BRD-K05977355-001-19-0::2.5::HTS	BRD-K05977355-001-19-0	fluconazole	2.5	HTS	sterol demethylase inhibitor	CYP51A1	infectious disease	esophageal candidiasis, meningitis	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Launched	5
BRD-K06147391-300-06-8::2.5::HTS	0.297891823757	BRD-K06147391-300-06-8::2.5::HTS	BRD-K06147391-300-06-8	telenzepine	2.5	HTS	acetylcholine receptor antagonist	CHRM1			CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1, CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1	Phase 3	5
BRD-K06152156-001-01-8::2.5::HTS	0.177190586238	BRD-K06152156-001-01-8::2.5::HTS	BRD-K06152156-001-01-8	methoxyflurane	2.5	HTS	membrane permeability inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl	Launched	5
BRD-K06181161-048-15-1::2.5::HTS	-0.27722633185199996	BRD-K06181161-048-15-1::2.5::HTS	BRD-K06181161-048-15-1	carbetapentane	2.5	HTS	acetylcholine receptor antagonist	CHRM2	otolaryngology, pulmonary	common cold, nasal congestion, bronchitis	CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1	Launched	5
BRD-K06208435-003-08-2::2.5::HTS	0.13983840454000002	BRD-K06208435-003-08-2::2.5::HTS	BRD-K06208435-003-08-2	YS-035	2.5	HTS	calcium channel blocker				COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC	Preclinical	5
BRD-K06221026-001-06-8::2.5::HTS	0.0504891276879	BRD-K06221026-001-06-8::2.5::HTS	BRD-K06221026-001-06-8	DUP-697	2.5	HTS	cyclooxygenase inhibitor	PTGS2			CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1	Phase 1	5
BRD-K06222852-001-03-2::2.5::HTS	-0.0885830829552	BRD-K06222852-001-03-2::2.5::HTS	BRD-K06222852-001-03-2	posaconazole	2.5	HTS	sterol demethylase inhibitor	CYP3A4	infectious disease	oropharyngeal candidiasis	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O	Launched	5
BRD-K06234293-001-04-2::2.5::HTS	-0.332848814453	BRD-K06234293-001-04-2::2.5::HTS	BRD-K06234293-001-04-2	LY364947	2.5	HTS	TGF beta receptor inhibitor, p38 MAPK inhibitor	TGFBR1			c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1	Preclinical	5
BRD-K06240250-001-01-6::2.5::HTS	0.606014290185	BRD-K06240250-001-01-6::2.5::HTS	BRD-K06240250-001-01-6	rilpivirine	2.5	HTS	non-nucleoside reverse transcriptase inhibitor	NR1I2, SCN10A	infectious disease	human immunodeficiency virus (HIV-1)	Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1	Launched	5
BRD-K06294530-001-01-5::2.5::HTS	0.6082489100840001	BRD-K06294530-001-01-5::2.5::HTS	BRD-K06294530-001-01-5	UK-383367	2.5	HTS	Procollagen C-Endopeptidase Inhibitors	BMP1			NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	Phase 1	5
BRD-K06335600-003-20-7::2.5::HTS	0.047569369476199996	BRD-K06335600-003-20-7::2.5::HTS	BRD-K06335600-003-20-7	tizanidine	2.5	HTS	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, NISCH	neurology/psychiatry	spasms	Clc1ccc2nsnc2c1NC1=NCCN1, Clc1ccc2nsnc2c1NC1=NCCN1, Clc1ccc2nsnc2c1NC1=NCCN1	Launched	5
BRD-K06388322-312-02-6::2.5::HTS	0.00670119425029	BRD-K06388322-312-02-6::2.5::HTS	BRD-K06388322-312-02-6	pramipexole	2.5	HTS	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1	Launched	5
BRD-K06408664-001-03-5::2.5::HTS	0.286394260461	BRD-K06408664-001-03-5::2.5::HTS	BRD-K06408664-001-03-5	fludrocortisone-acetate	2.5	HTS		AR, NR3C1, NR3C2	endocrinology	Addison's disease, adrenogenital syndrome	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Launched	5
BRD-K06426971-001-02-7::2.5::HTS	-0.853330989914	BRD-K06426971-001-02-7::2.5::HTS	BRD-K06426971-001-02-7	ryuvidine	2.5	HTS	histone lysine methyltransferase inhibitor	CDK2, CDK4			Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O	Preclinical	5
BRD-K06542892-001-01-9::2.5::HTS	-0.461846734771	BRD-K06542892-001-01-9::2.5::HTS	BRD-K06542892-001-01-9	ASP3026	2.5	HTS	ALK tyrosine kinase receptor inhibitor	ALK			COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	Phase 1	5
BRD-K06543683-066-02-1::2.5::HTS	0.164317144754	BRD-K06543683-066-02-1::2.5::HTS	BRD-K06543683-066-02-1	bisindolylmaleimide-ix	2.5	HTS	PKC inhibitor	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1			Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12	Preclinical	5
BRD-K06557128-001-07-0::2.5::HTS	0.191494110927	BRD-K06557128-001-07-0::2.5::HTS	BRD-K06557128-001-07-0	voriconazole	2.5	HTS	cytochrome P450 inhibitor	CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1	infectious disease	esophageal candidiasis, aspergillosis, skin infections	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Launched	5
BRD-K06593056-001-04-8::2.5::HTS	-0.376582238066	BRD-K06593056-001-04-8::2.5::HTS	BRD-K06593056-001-04-8	LE-135	2.5	HTS	retinoid receptor agonist	RARB			CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C	Preclinical	5
BRD-K06644925-001-03-0::2.5::HTS	0.0478629360275	BRD-K06644925-001-03-0::2.5::HTS	BRD-K06644925-001-03-0	oleamide	2.5	HTS	cannabinoid receptor agonist	HTR7, PLA2G2A			CCCCCCCC\C=C/CCCCCCCC(N)=O	Preclinical	5
BRD-K06674495-334-03-2::2.5::HTS	0.105686448089	BRD-K06674495-334-03-2::2.5::HTS	BRD-K06674495-334-03-2	nafamostat	2.5	HTS	serine protease inhibitor	ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7			NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N	Launched	5
BRD-K06749501-001-02-1::2.5::HTS	-0.0149500504337	BRD-K06749501-001-02-1::2.5::HTS	BRD-K06749501-001-02-1	GSK1838705A	2.5	HTS	insulin growth factor receptor inhibitor	ALK, IGF1R, INSR, RPS6KA1			CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	Preclinical	5
BRD-K06753942-001-14-5::2.5::HTS	-1.00029571175	BRD-K06753942-001-14-5::2.5::HTS	BRD-K06753942-001-14-5	nobiletin	2.5	HTS	MEK inhibitor	MAP2K1			COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	Preclinical	5
BRD-K06762493-001-08-1::2.5::HTS	0.21747312224399998	BRD-K06762493-001-08-1::2.5::HTS	BRD-K06762493-001-08-1	isbufylline	2.5	HTS	phosphodiesterase inhibitor				CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	Phase 2	5
BRD-K06814349-304-01-9::2.5::HTS	-5.03621753516	BRD-K06814349-304-01-9::2.5::HTS	BRD-K06814349-304-01-9	fosbretabulin	2.5	HTS	tubulin polymerization inhibitor, VE-cadherin antagonist	CDH5			COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O	Phase 3	5
BRD-K06854232-001-19-9::2.5::HTS	-0.878210333358	BRD-K06854232-001-19-9::2.5::HTS	BRD-K06854232-001-19-9	AM-580	2.5	HTS	retinoid receptor agonist	RARA			CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O	Preclinical	5
BRD-K06858286-001-01-3::2.5::HTS	-0.941199974833	BRD-K06858286-001-01-3::2.5::HTS	BRD-K06858286-001-01-3	cabazitaxel	2.5	HTS	microtubule inhibitor	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C	Launched	5
BRD-K06878038-001-18-6::2.5::HTS	0.21509266884599998	BRD-K06878038-001-18-6::2.5::HTS	BRD-K06878038-001-18-6	deferiprone	2.5	HTS	chelating agent	UGT1A6	hematology	transfusional hemosiderosis, thalassemia, iron overload	Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C	Launched	5
BRD-K06900071-001-01-2::2.5::HTS	0.09310157352810002	BRD-K06900071-001-01-2::2.5::HTS	BRD-K06900071-001-01-2	tebipenem	2.5	HTS	bacterial cell wall synthesis inhibitor	CNR1	infectious disease, otolaryngology	pneumonia, otitis	C[C@@H](O)[C@@H]1[C@@H]2[C@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C	Launched	5
BRD-K06902185-003-01-7::2.5::HTS	-0.151897697208	BRD-K06902185-003-01-7::2.5::HTS	BRD-K06902185-003-01-7	minoxidil	2.5	HTS	KATP activator, Kir6 channel (KATP) activator, vasodilator	ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1	endocrinology	androgenetic alopecia	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	Launched	5
BRD-K06980535-003-25-9::2.5::HTS	-0.583636896638	BRD-K06980535-003-25-9::2.5::HTS	BRD-K06980535-003-25-9	promazine	2.5	HTS	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	CN(C)CCCN1c2ccccc2Sc2ccccc12, CN(C)CCCN1c2ccccc2Sc2ccccc12	Launched	5
BRD-K07106112-003-03-8::2.5::HTS	-0.07876981678460002	BRD-K07106112-003-03-8::2.5::HTS	BRD-K07106112-003-03-8	BMS-599626	2.5	HTS	EGFR inhibitor, protein tyrosine kinase inhibitor	EGFR, ERBB2, ERBB4			Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12	Phase 1	5
BRD-K07160047-001-01-3::2.5::HTS	0.0584363558605	BRD-K07160047-001-01-3::2.5::HTS	BRD-K07160047-001-01-3	fiacitabine	2.5	HTS	DNA synthesis inhibitor				Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	Phase 2	5
BRD-K07166362-330-02-8::2.5::HTS	-0.28545575529399997	BRD-K07166362-330-02-8::2.5::HTS	BRD-K07166362-330-02-8	streptomycin	2.5	HTS	bacterial 30S ribosomal subunit inhibitor		infectious disease	tuberculosis	CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O, CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O	Launched	5
BRD-K07202345-001-19-4::2.5::HTS	0.33320812844000003	BRD-K07202345-001-19-4::2.5::HTS	BRD-K07202345-001-19-4	frentizole	2.5	HTS	immunosuppressant				COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1	Phase 1	5
BRD-K07208025-001-29-7::2.5::HTS	-0.331639285286	BRD-K07208025-001-29-7::2.5::HTS	BRD-K07208025-001-29-7	trimethoprim	2.5	HTS	dihydrofolate reductase inhibitor	DHFR, TYMS	infectious disease, gastroenterology	urinary tract infections, ear infections, diarrhea	COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC	Launched	5
BRD-K07220430-001-18-4::2.5::HTS	-0.607992083255	BRD-K07220430-001-18-4::2.5::HTS	BRD-K07220430-001-18-4	cinnarazine	2.5	HTS	calcium channel blocker		neurology/psychiatry, gastroenterology, ophthalmology	Meniere's disease, nausea, vomiting, Cogan's syndrome	C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	5
BRD-K07220430-001-19-2::2.5::HTS	0.145293892202	BRD-K07220430-001-19-2::2.5::HTS	BRD-K07220430-001-19-2	cinnarazine	2.5	HTS	calcium channel blocker		neurology/psychiatry, gastroenterology, ophthalmology	Meniere's disease, nausea, vomiting, Cogan's syndrome	C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	5
BRD-K07237224-001-19-6::2.5::HTS	0.39028284741499997	BRD-K07237224-001-19-6::2.5::HTS	BRD-K07237224-001-19-6	moclobemide	2.5	HTS	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression, anxiety	Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1	Launched	5
BRD-K07265709-003-05-6::2.61::HTS	0.0227694492905	BRD-K07265709-003-05-6::2.61::HTS	BRD-K07265709-003-05-6	dexrazoxane	2.61	HTS	chelating agent, topoisomerase inhibitor	TOP2A, TOP2B	cardiology	cardiomyopathy	C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1	Launched	5
BRD-K07283971-001-01-3::2.5::HTS	0.141373134203	BRD-K07283971-001-01-3::2.5::HTS	BRD-K07283971-001-01-3	oxyclozanide	2.5	HTS			infectious disease	fascioliasis	Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl	Launched	5
BRD-K07310275-001-02-5::2.5::HTS	-5.46026503957	BRD-K07310275-001-02-5::2.5::HTS	BRD-K07310275-001-02-5	PF-04691502	2.5	HTS	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O	Phase 2	5
BRD-K07359318-001-03-9::2.45::HTS	-0.39433776081999994	BRD-K07359318-001-03-9::2.45::HTS	BRD-K07359318-001-03-9	benfotiamine	2.45	HTS	antioxidant	AGER	rheumatology	lumbago	C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1	Launched	5
BRD-K07441213-001-18-9::2.5::HTS	-0.050246529805300005	BRD-K07441213-001-18-9::2.5::HTS	BRD-K07441213-001-18-9	paroxypropione	2.5	HTS	gonadotropin inhibitor				CCC(=O)c1ccc(O)cc1	Launched	5
BRD-K07442505-001-03-6::2.5::HTS	0.10584736100299999	BRD-K07442505-001-03-6::2.5::HTS	BRD-K07442505-001-03-6	BAM7	2.5	HTS	BAX activator	BAX			CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1	Preclinical	5
BRD-K07487750-001-03-3::2.5::HTS	0.101094108629	BRD-K07487750-001-03-3::2.5::HTS	BRD-K07487750-001-03-3	WHI-P154	2.5	HTS	JAK inhibitor	EGFR, JAK1, JAK2, JAK3			COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	Preclinical	5
BRD-K07507905-236-02-6::2.5::HTS	-0.0819209200282	BRD-K07507905-236-02-6::2.5::HTS	BRD-K07507905-236-02-6	BRL-37344	2.5	HTS	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1	Phase 2	5
BRD-K07572174-001-39-4::2.48::HTS	0.918006271031	BRD-K07572174-001-39-4::2.48::HTS	BRD-K07572174-001-39-4	curcumin	2.48	HTS	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH			COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1	Launched	5
BRD-K07609981-001-01-7::2.5::HTS	-0.08352205291380001	BRD-K07609981-001-01-7::2.5::HTS	BRD-K07609981-001-01-7	dexloxiglumide	2.5	HTS	CCK receptor antagonist	CCKAR			CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1	Phase 3	5
BRD-K07612980-001-05-3::2.59::HTS	-4.31061744387	BRD-K07612980-001-05-3::2.59::HTS	BRD-K07612980-001-05-3	sparfloxacin	2.59	HTS	bacterial DNA gyrase inhibitor	TOP2A			C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	Withdrawn	5
BRD-K07612980-001-07-9::2.5::HTS	-0.669283799124	BRD-K07612980-001-07-9::2.5::HTS	BRD-K07612980-001-07-9	sparfloxacin	2.5	HTS	bacterial DNA gyrase inhibitor	TOP2A			C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	Withdrawn	5
BRD-K07691486-001-15-5::2.5::HTS	-0.183806944186	BRD-K07691486-001-15-5::2.5::HTS	BRD-K07691486-001-15-5	roscovitine	2.5	HTS	CDK inhibitor	CDK2, CDK9			CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	Phase 2	5
BRD-K07736136-001-04-6::2.51::HTS	-0.017740382207900002	BRD-K07736136-001-04-6::2.51::HTS	BRD-K07736136-001-04-6	VX-702	2.51	HTS	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK14			NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F	Phase 2	5
BRD-K07753030-003-17-6::2.5::HTS	-0.13068059304000001	BRD-K07753030-003-17-6::2.5::HTS	BRD-K07753030-003-17-6	acecainide	2.5	HTS	polarization inhibitor	SCN5A			CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1	Phase 3	5
BRD-K07762753-001-04-4::2.5::HTS	-0.039496945181800004	BRD-K07762753-001-04-4::2.5::HTS	BRD-K07762753-001-04-4	aminopurvalanol-a	2.5	HTS	CDK inhibitor, tyrosine kinase inhibitor	CDK1, CDK2, CDK5, CDK6			CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical	5
BRD-K07798980-001-01-9::2.5::HTS	0.19311801452999997	BRD-K07798980-001-01-9::2.5::HTS	BRD-K07798980-001-01-9	PSI-6130	2.5	HTS	RNA polymerase inhibitor				C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	Phase 1	5
BRD-K07857022-002-01-1::2.5::HTS	0.0935935463938	BRD-K07857022-002-01-1::2.5::HTS	BRD-K07857022-002-01-1	alvimopan	2.5	HTS	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	postoperative ileus	C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1	Launched	5
BRD-K07881437-001-03-8::2.5::HTS	-2.44780147836	BRD-K07881437-001-03-8::2.5::HTS	BRD-K07881437-001-03-8	danusertib	2.5	HTS	Aurora kinase inhibitor, growth factor receptor inhibitor	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK			CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1	Phase 2	5
BRD-K07881437-001-04-6::2.41::HTS	-1.69135285669	BRD-K07881437-001-04-6::2.41::HTS	BRD-K07881437-001-04-6	danusertib	2.41	HTS	Aurora kinase inhibitor, growth factor receptor inhibitor	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK			CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1	Phase 2	5
BRD-K07940445-310-02-9::2.5::HTS	0.155886071624	BRD-K07940445-310-02-9::2.5::HTS	BRD-K07940445-310-02-9	quinine	2.5	HTS	hemozoin biocrystallization inhibitor	GP9, KCNB2, KCNN4, SLC29A4	infectious disease	malaria	COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	Launched	5
BRD-K07954936-001-01-3::2.5::HTS	-0.18831331576299998	BRD-K07954936-001-01-3::2.5::HTS	BRD-K07954936-001-01-3	2-iminobiotin	2.5	HTS	nitric oxide synthase inhibitor	NOS1, NOS2			OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12	Phase 2	5
BRD-K07955840-001-02-3::2.5::HTS	-2.64556750032	BRD-K07955840-001-02-3::2.5::HTS	BRD-K07955840-001-02-3	PF-05212384	2.5	HTS	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1	Phase 2	5
BRD-K07972848-001-02-0::2.5::HTS	-5.90677614393	BRD-K07972848-001-02-0::2.5::HTS	BRD-K07972848-001-02-0	GSK2126458	2.5	HTS	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1	Phase 1	5
BRD-K08033334-003-04-3::2.5::HTS	0.25887544206	BRD-K08033334-003-04-3::2.5::HTS	BRD-K08033334-003-04-3	lincomycin	2.5	HTS	bacterial 30S ribosomal subunit inhibitor		gastroenterology	enteritis	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H]([C@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O	Launched	5
BRD-K08037784-001-12-6::2.5::HTS	-0.537995094088	BRD-K08037784-001-12-6::2.5::HTS	BRD-K08037784-001-12-6	arbutin	2.5	HTS	melanin inhibitor	TYR			OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2/Phase 3	5
BRD-K08078237-001-19-8::2.5::HTS	-2.09386037664	BRD-K08078237-001-19-8::2.5::HTS	BRD-K08078237-001-19-8	tetrandrine	2.5	HTS	calcium channel blocker	SLC6A3			COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34	Preclinical	5
BRD-K08109215-001-06-4::2.5::HTS	0.261781891632	BRD-K08109215-001-06-4::2.5::HTS	BRD-K08109215-001-06-4	I-BET-762	2.5	HTS	bromodomain inhibitor	BRD2, BRD3, BRD4			CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12	Phase 2	5
BRD-K08109516-001-07-8::2.5::HTS	-0.100657618968	BRD-K08109516-001-07-8::2.5::HTS	BRD-K08109516-001-07-8	L-701324	2.5	HTS	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12	Preclinical	5
BRD-K08111240-001-02-8::2.5::HTS	0.0248367313595	BRD-K08111240-001-02-8::2.5::HTS	BRD-K08111240-001-02-8	danoprevir	2.5	HTS	HCV inhibitor				CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1	Phase 2	5
BRD-K08111712-001-16-7::2.5::HTS	0.47340343408299995	BRD-K08111712-001-16-7::2.5::HTS	BRD-K08111712-001-16-7	chloramphenicol	2.5	HTS	bacterial 50S ribosomal subunit inhibitor	CD55	infectious disease, endocrinology	meningitis, fever, cholera	OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	Launched	5
BRD-K08188887-001-02-4::2.5::HTS	-0.24830498755199998	BRD-K08188887-001-02-4::2.5::HTS	BRD-K08188887-001-02-4	astragaloside-a	2.5	HTS	antiinflammatory agent				CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C	Preclinical	5
BRD-K08206212-002-01-0::2.5::HTS	-0.104288364784	BRD-K08206212-002-01-0::2.5::HTS	BRD-K08206212-002-01-0	entecavir	2.5	HTS	DNA replication inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1	Launched	5
BRD-K08223200-001-01-1::2.5::HTS	-0.228781563222	BRD-K08223200-001-01-1::2.5::HTS	BRD-K08223200-001-01-1	WAY-200070	2.5	HTS	estrogen receptor agonist	ERBB2, ERBB3, ERBB4, ESR2			Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1	Preclinical	5
BRD-K08231299-001-08-1::2.5::HTS	-0.14428282826400002	BRD-K08231299-001-08-1::2.5::HTS	BRD-K08231299-001-08-1	propoxur	2.5	HTS					CNC(=O)Oc1ccccc1OC(C)C	Launched	5
BRD-K08248804-001-01-8::2.5::HTS	0.183925635545	BRD-K08248804-001-01-8::2.5::HTS	BRD-K08248804-001-01-8	LCL-161	2.5	HTS	XIAP inhibitor	BIRC2, XIAP			CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1	Phase 2	5
BRD-K08251020-001-01-0::2.5::HTS	-0.242301717361	BRD-K08251020-001-01-0::2.5::HTS	BRD-K08251020-001-01-0	falecalcitriol	2.5	HTS	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	5
BRD-K08252256-236-33-8::2.5::HTS	-0.11797356945800001	BRD-K08252256-236-33-8::2.5::HTS	BRD-K08252256-236-33-8	diclofenac	2.5	HTS	cyclooxygenase inhibitor	AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A	rheumatology, neurology/psychiatry	rheumatoid arthritis, osteoarthritis, migraine headache	OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	Launched	5
BRD-K08273968-001-19-0::2.5::HTS	-0.253905956089	BRD-K08273968-001-19-0::2.5::HTS	BRD-K08273968-001-19-0	griseofulvin	2.5	HTS	tubulin polymerization inhibitor	KRT12	infectious disease	ringworm, tinea pedis	COc1cc(OC)c(Cl)c2O[C@]3([C@H](C)CC(=O)C=C3OC)C(=O)c12, COc1cc(OC)c(Cl)c2O[C@]3([C@H](C)CC(=O)C=C3OC)C(=O)c12	Launched	5
BRD-K08287586-001-14-3::2.5::HTS	-0.3051623343	BRD-K08287586-001-14-3::2.5::HTS	BRD-K08287586-001-14-3	butyl-paraben	2.5	HTS	DNA synthesis inhibitor				CCCCOC(=O)c1ccc(O)cc1	Preclinical	5
BRD-K08288352-001-03-6::2.5::HTS	-0.23481432859200002	BRD-K08288352-001-03-6::2.5::HTS	BRD-K08288352-001-03-6	1-ethyl-2-pyrrolidone	2.5	HTS	transdermal absorption-enhancing compound				CCN1CCCC1=O	Preclinical	5
BRD-K08303368-001-10-0::2.5::HTS	0.179844579393	BRD-K08303368-001-10-0::2.5::HTS	BRD-K08303368-001-10-0	chlorpyrifos	2.5	HTS	acetylcholinesterase inhibitor	ACHE			CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl	Launched	5
BRD-K08310154-001-03-8::2.5::HTS	-0.135620543378	BRD-K08310154-001-03-8::2.5::HTS	BRD-K08310154-001-03-8	AG-1024	2.5	HTS	insulin growth factor receptor inhibitor	IGF1R			CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O	Preclinical	5
BRD-K08356259-003-24-7::2.5::HTS	-0.165078932516	BRD-K08356259-003-24-7::2.5::HTS	BRD-K08356259-003-24-7	xylometazoline	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	otolaryngology, allergy	nasal congestion, allergic rhinitis	Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C	Launched	5
BRD-K08493205-001-04-9::2.5::HTS	0.567721947878	BRD-K08493205-001-04-9::2.5::HTS	BRD-K08493205-001-04-9	salicyl-alcohol	2.5	HTS					OCc1ccccc1O	Preclinical	5
BRD-K08525451-003-05-2::2.5::HTS	-1.22147383673	BRD-K08525451-003-05-2::2.5::HTS	BRD-K08525451-003-05-2	sarafloxacin	2.5	HTS	bacterial DNA gyrase inhibitor				OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O	Launched	5
BRD-K08542803-001-03-1::0.8::HTS	-1.98204102783	BRD-K08542803-001-03-1::0.8::HTS	BRD-K08542803-001-03-1	gambogic-acid	0.8	HTS	caspase activator	BCL2			CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C	Phase 2	4
BRD-K08547377-394-03-5::2.5::HTS	-0.801321019958	BRD-K08547377-394-03-5::2.5::HTS	BRD-K08547377-394-03-5	irinotecan	2.5	HTS	topoisomerase inhibitor	TOP1, TOP1MT	oncology	colorectal cancer	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	Launched	5
BRD-K08586861-001-01-1::2.5::HTS	-0.750084933662	BRD-K08586861-001-01-1::2.5::HTS	BRD-K08586861-001-01-1	ramatroban	2.5	HTS	prostanoid receptor antagonist	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1	Launched	5
BRD-K08619574-334-05-4::2.5::HTS	-0.00767311693983	BRD-K08619574-334-05-4::2.5::HTS	BRD-K08619574-334-05-4	thioproperazine	2.5	HTS	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	Launched	5
BRD-K08619838-300-05-7::2.5::HTS	0.103620372577	BRD-K08619838-300-05-7::2.5::HTS	BRD-K08619838-300-05-7	tremorine	2.5	HTS	acetylcholine receptor agonist				C(C#CCN1CCCC1)N1CCCC1	Preclinical	5
BRD-K08640512-003-02-3::2.5::HTS	-0.36577220049099995	BRD-K08640512-003-02-3::2.5::HTS	BRD-K08640512-003-02-3	RS-100329	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1D			Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O	Preclinical	5
BRD-K08681769-323-03-7::2.5::HTS	-0.05883607795490001	BRD-K08681769-323-03-7::2.5::HTS	BRD-K08681769-323-03-7	ibandronate	2.5	HTS	bone resorption inhibitor	FDPS	orthopedics	osteoporosis	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	5
BRD-K08703257-001-12-1::2.5::HTS	-0.380818851303	BRD-K08703257-001-12-1::2.5::HTS	BRD-K08703257-001-12-1	3-amino-benzamide	2.5	HTS	PARP inhibitor	PARP1			NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1	Phase 2	5
BRD-K08791496-001-01-0::2.5::HTS	0.264464767463	BRD-K08791496-001-01-0::2.5::HTS	BRD-K08791496-001-01-0	fenaclon	2.5	HTS					ClCCC(=O)NCCc1ccccc1	Preclinical	5
BRD-K08799216-001-05-3::2.5::HTS	0.436453683794	BRD-K08799216-001-05-3::2.5::HTS	BRD-K08799216-001-05-3	pelitinib	2.5	HTS	EGFR inhibitor	EGFR			CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 2	5
BRD-K08832567-001-11-5::2.5::HTS	-0.587929230542	BRD-K08832567-001-11-5::2.5::HTS	BRD-K08832567-001-11-5	naringenin	2.5	HTS	aromatase inhibitor, TRPV antagonist	CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1			Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	Phase 1	5
BRD-K08837089-236-01-6::2.5::HTS	0.0139225464525	BRD-K08837089-236-01-6::2.5::HTS	BRD-K08837089-236-01-6	actinoquinol	2.5	HTS					CCOc1ccc(c2cccnc12)S(O)(=O)=O	Preclinical	5
BRD-K08859203-001-01-9::2.5::HTS	-0.21443760142299997	BRD-K08859203-001-01-9::2.5::HTS	BRD-K08859203-001-01-9	DU-728	2.5	HTS	structural glycoprotein antagonist	ITGA2B, ITGB3			N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O	Phase 1	5
BRD-K08864679-001-02-2::2.5::HTS	-0.566921263403	BRD-K08864679-001-02-2::2.5::HTS	BRD-K08864679-001-02-2	fexaramine	2.5	HTS	FXR agonist	NR1H4			COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1	Preclinical	5
BRD-K08893438-001-04-9::2.52::HTS	0.207892518198	BRD-K08893438-001-04-9::2.52::HTS	BRD-K08893438-001-04-9	CCG-50014	2.52	HTS	G protein signaling inhibitor	RGS4, RGS8			Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O	Preclinical	5
BRD-K08924299-003-06-1::2.5::HTS	0.0245750646718	BRD-K08924299-003-06-1::2.5::HTS	BRD-K08924299-003-06-1	palonosetron	2.5	HTS	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2	Launched	5
BRD-K08953028-001-09-6::2.5::HTS	0.7071846621150001	BRD-K08953028-001-09-6::2.5::HTS	BRD-K08953028-001-09-6	U-0521	2.5	HTS	catechol O methyltransferase inhibitor	COMT			CC(C)C(=O)c1ccc(O)c(O)c1	Preclinical	5
BRD-K08976401-001-18-5::2.5::HTS	-0.209969307218	BRD-K08976401-001-18-5::2.5::HTS	BRD-K08976401-001-18-5	azelaic-acid	2.5	HTS	tyrosinase inhibitor	AKR1D1, SRD5A2, TYR	dermatology	rosacea	OC(=O)CCCCCCCC(O)=O	Launched	5
BRD-K08996725-332-01-7::2.5::HTS	-0.21710026345699998	BRD-K08996725-332-01-7::2.5::HTS	BRD-K08996725-332-01-7	zolantidine	2.5	HTS	histamine receptor antagonist				C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1	Preclinical	5
BRD-K08998509-001-02-4::2.5::HTS	0.361743752791	BRD-K08998509-001-02-4::2.5::HTS	BRD-K08998509-001-02-4	fananserin	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1	Phase 2	5
BRD-K08999871-213-01-5::2.5::HTS	-0.0531652700169	BRD-K08999871-213-01-5::2.5::HTS	BRD-K08999871-213-01-5	pipemidic-acid	2.5	HTS	topoisomerase inhibitor		infectious disease	gram-negative bacterial infections	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1	Launched	5
BRD-K09090523-001-02-1::2.5::HTS	0.262382643756	BRD-K09090523-001-02-1::2.5::HTS	BRD-K09090523-001-02-1	firocoxib	2.5	HTS	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O	Launched	5
BRD-K09090949-001-01-9::2.5::HTS	-0.175517526199	BRD-K09090949-001-01-9::2.5::HTS	BRD-K09090949-001-01-9	CP-945,598	2.5	HTS	cannabinoid receptor antagonist	CNR1			CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O	Phase 3	5
BRD-K09126848-003-01-9::2.5::HTS	-0.022195151464999997	BRD-K09126848-003-01-9::2.5::HTS	BRD-K09126848-003-01-9	nepicastat	2.5	HTS	dopamine beta hydroxylase inhibitor	DBH			NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1	Phase 2	5
BRD-K09132007-001-07-5::2.5::HTS	-0.44137365227200004	BRD-K09132007-001-07-5::2.5::HTS	BRD-K09132007-001-07-5	D-4476	2.5	HTS	TGF beta receptor inhibitor	CSNK1A1, CSNK1D, TGFB1			NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1	Preclinical	5
BRD-K09255212-001-16-6::2.5::HTS	-0.32235440875599997	BRD-K09255212-001-16-6::2.5::HTS	BRD-K09255212-001-16-6	clioquinol	2.5	HTS	chelating agent	OPRK1			Oc1c(I)cc(Cl)c2cccnc12	Withdrawn	5
BRD-K09295674-001-09-8::2.5::HTS	0.9071305255709999	BRD-K09295674-001-09-8::2.5::HTS	BRD-K09295674-001-09-8	carzenide	2.5	HTS		CA1, CA12, CA14, CA2, CA6, CA9			NS(=O)(=O)c1ccc(cc1)C(O)=O	Preclinical	5
BRD-K09338665-001-07-1::2.5::HTS	0.071035860211	BRD-K09338665-001-07-1::2.5::HTS	BRD-K09338665-001-07-1	1-octanol	2.5	HTS		GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1			CCCCCCCCO, CCCCCCCCO	Phase 2	5
BRD-K09353376-001-03-9::2.5::HTS	0.12102978611300001	BRD-K09353376-001-03-9::2.5::HTS	BRD-K09353376-001-03-9	tariquidar	2.5	HTS	P glycoprotein inhibitor	ABCB1			COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC	Phase 3	5
BRD-K09372874-001-01-0::2.5::HTS	-0.778449677296	BRD-K09372874-001-01-0::2.5::HTS	BRD-K09372874-001-01-0	merimepodib	2.5	HTS	inosine monophosphate dehydrogenase inhibitor	IMPDH1			COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1	Phase 2	5
BRD-K09397065-003-06-1::2.5::HTS	-0.299416624305	BRD-K09397065-003-06-1::2.5::HTS	BRD-K09397065-003-06-1	SR-57227A	2.5	HTS	serotonin receptor agonist	HTR3A			NC1CCN(CC1)c1cccc(Cl)n1	Phase 2	5
BRD-K09416995-001-39-9::2.5::HTS	0.7960767732790001	BRD-K09416995-001-39-9::2.5::HTS	BRD-K09416995-001-39-9	lovastatin	2.5	HTS	HMGCR inhibitor	HDAC2, HMGCR, ITGAL, NR1I2	cardiology, endocrinology	coronary heart disease, myocardial infarction, hypercholesterolemia	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	Launched	5
BRD-K09426783-300-01-0::2.5::HTS	-4.31460161507	BRD-K09426783-300-01-0::2.5::HTS	BRD-K09426783-300-01-0	TAS-103	2.5	HTS	topoisomerase inhibitor	TOP1			CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12	Phase 1	5
BRD-K09443272-001-03-3::2.5::HTS	-1.19255143214	BRD-K09443272-001-03-3::2.5::HTS	BRD-K09443272-001-03-3	PHA-680632	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB, AURKC			CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1	Preclinical	5
BRD-K09471561-001-18-2::2.5::HTS	-0.326459082652	BRD-K09471561-001-18-2::2.5::HTS	BRD-K09471561-001-18-2	levofloxacin	2.5	HTS	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, otolaryngology, pulmonary, urology	pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	Launched	5
BRD-K09537769-001-04-0::2.5::HTS	-0.108806097222	BRD-K09537769-001-04-0::2.5::HTS	BRD-K09537769-001-04-0	NU-7026	2.5	HTS	DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	PRKDC			O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1	Preclinical	5
BRD-K09549677-300-03-4::2.5::HTS	-0.0904455041597	BRD-K09549677-300-03-4::2.5::HTS	BRD-K09549677-300-03-4	mibefradil	2.5	HTS	T-type calcium channel blocker	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4			COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	Withdrawn	5
BRD-K09602097-001-13-6::2.5::HTS	-0.367471252904	BRD-K09602097-001-13-6::2.5::HTS	BRD-K09602097-001-13-6	forskolin	2.5	HTS	adenylyl cyclase activator	ADCY2, ADCY5, GNAS			CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	Launched	5
BRD-K09619322-001-03-8::2.5::HTS	-0.254909886784	BRD-K09619322-001-03-8::2.5::HTS	BRD-K09619322-001-03-8	CD-1530	2.5	HTS	retinoid receptor agonist	RARG			OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2	Preclinical	5
BRD-K09619578-001-01-3::2.5::HTS	0.116288227994	BRD-K09619578-001-01-3::2.5::HTS	BRD-K09619578-001-01-3	DS2-(806622)	2.5	HTS					Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1	Preclinical	5
BRD-K09635314-001-03-4::2.5::HTS	0.19573891445099997	BRD-K09635314-001-03-4::2.5::HTS	BRD-K09635314-001-03-4	m-3M3FBS	2.5	HTS		PLCB2, PLCB3, PLCD1, PLCG1, PLCG2			Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F	Preclinical	5
BRD-K09659835-003-01-4::2.5::HTS	-0.24251655329100003	BRD-K09659835-003-01-4::2.5::HTS	BRD-K09659835-003-01-4	loreclezole	2.5	HTS	benzodiazepine receptor agonist	GABRB2, GABRB3			Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl	Phase 2	5
BRD-K09711437-001-04-3::2.5::HTS	-0.0226428078808	BRD-K09711437-001-04-3::2.5::HTS	BRD-K09711437-001-04-3	varespladib	2.5	HTS	secretory phospholipase inhibitor	PLA2G2A			CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1	Phase 3	5
BRD-K09757388-065-04-0::2.5::HTS	0.484746105471	BRD-K09757388-065-04-0::2.5::HTS	BRD-K09757388-065-04-0	atazanavir	2.5	HTS	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	Launched	5
BRD-K09778810-001-10-6::2.5::HTS	-0.535552114424	BRD-K09778810-001-10-6::2.5::HTS	BRD-K09778810-001-10-6	FGIN-1-27	2.5	HTS	inositol monophosphatase inhibitor	TSPO			CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1	Preclinical	5
BRD-K09785578-001-01-2::2.5::HTS	0.784253874938	BRD-K09785578-001-01-2::2.5::HTS	BRD-K09785578-001-01-2	bakuchiol	2.5	HTS	DNA polymerase inhibitor	HIF1A			CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1	Phase 2	5
BRD-K09877029-001-01-2::2.5::HTS	-1.10073924789	BRD-K09877029-001-01-2::2.5::HTS	BRD-K09877029-001-01-2	VS-4718	2.5	HTS	focal adhesion kinase inhibitor				CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F	Phase 1	5
BRD-K09900591-001-26-7::2.5::HTS	-0.8418727779109999	BRD-K09900591-001-26-7::2.5::HTS	BRD-K09900591-001-26-7	caffeic-acid	2.5	HTS	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	ALOX5, MIF			OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1	Preclinical	5
BRD-K09951645-001-06-8::2.5::HTS	-0.222961069516	BRD-K09951645-001-06-8::2.5::HTS	BRD-K09951645-001-06-8	dabrafenib	2.5	HTS	RAF inhibitor	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F	Launched	5
BRD-K10029415-005-06-9::2.5::HTS	-0.353242655477	BRD-K10029415-005-06-9::2.5::HTS	BRD-K10029415-005-06-9	enisamium-iodide	2.5	HTS					C[n+]1ccc(cc1)C(=O)NCc1ccccc1	Launched	5
BRD-K10065684-001-07-4::2.5::HTS	-0.24843325763399998	BRD-K10065684-001-07-4::2.5::HTS	BRD-K10065684-001-07-4	dantron	2.5	HTS	laxative				Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12	Withdrawn	5
BRD-K10071630-001-01-0::2.5::HTS	0.325457966356	BRD-K10071630-001-01-0::2.5::HTS	BRD-K10071630-001-01-0	ertugliflozin	2.5	HTS	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	CCOc1ccc(Cc2cc(ccc2Cl)[C@@]23OC[C@@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1	Launched	5
BRD-K10176267-001-03-3::2.5::HTS	0.231763924314	BRD-K10176267-001-03-3::2.5::HTS	BRD-K10176267-001-03-3	L-701252	2.5	HTS	glutamate receptor antagonist	GRIN1			Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12	Preclinical	5
BRD-K10177585-003-02-4::2.5::HTS	0.08808423164160001	BRD-K10177585-003-02-4::2.5::HTS	BRD-K10177585-003-02-4	PSB-11	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA3			CC[C@@H]1CN2C(=N1)c1[nH]c(nc1N(C)C2=O)-c1ccccc1, CC[C@@H]1CN2C(=N1)c1[nH]c(nc1N(C)C2=O)-c1ccccc1	Preclinical	5
BRD-K10196357-003-02-0::2.5::HTS	0.351341874574	BRD-K10196357-003-02-0::2.5::HTS	BRD-K10196357-003-02-0	besifloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		ophthalmology	conjunctivitis	N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1	Launched	5
BRD-K10314788-003-12-7::2.5::HTS	0.594130900648	BRD-K10314788-003-12-7::2.5::HTS	BRD-K10314788-003-12-7	meclofenoxate	2.5	HTS	nootropic agent		neurology/psychiatry	senile dementia, Alzheimer's disease	CN(C)CCOC(=O)COc1ccc(Cl)cc1	Launched	5
BRD-K10362825-001-03-4::2.5::HTS	-3.7509716203800005	BRD-K10362825-001-03-4::2.5::HTS	BRD-K10362825-001-03-4	teniposide	2.5	HTS	topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12	Launched	5
BRD-K10575656-034-01-0::2.5::HTS	0.381545344833	BRD-K10575656-034-01-0::2.5::HTS	BRD-K10575656-034-01-0	MRS3777	2.5	HTS	adenosine receptor antagonist	ADORA2A			C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2[nH]cnc12	Preclinical	5
BRD-K10598093-303-06-1::2.5::HTS	-0.030200032513799997	BRD-K10598093-303-06-1::2.5::HTS	BRD-K10598093-303-06-1	hexamethonium	2.5	HTS	cholinergic receptor antagonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6			C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C	Preclinical	5
BRD-K10670311-001-15-5::2.5::HTS	-0.22083720633099999	BRD-K10670311-001-15-5::2.5::HTS	BRD-K10670311-001-15-5	sulfasalazine	2.5	HTS	cyclooxygenase inhibitor	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1	Launched	5
BRD-K10671814-001-14-8::2.5::HTS	-0.202850161411	BRD-K10671814-001-14-8::2.5::HTS	BRD-K10671814-001-14-8	sulfaphenazole	2.5	HTS	dihydropteroate synthetase inhibitor	DHPS	infectious disease	urinary tract infections	Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1	Launched	5
BRD-K10673031-004-02-0::2.5::HTS	-0.700555830538	BRD-K10673031-004-02-0::2.5::HTS	BRD-K10673031-004-02-0	S-Isopropylisothiourea	2.5	HTS	nitric oxide synthase inhibitor	NOS3			CC(C)SC(N)=N	Preclinical	5
BRD-K10705233-001-02-2::2.5::HTS	-0.126616959483	BRD-K10705233-001-02-2::2.5::HTS	BRD-K10705233-001-02-2	GW-405833	2.5	HTS	cannabinoid receptor agonist	CNR2			COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1	Preclinical	5
BRD-K10706131-046-03-6::2.5::HTS	0.268638229738	BRD-K10706131-046-03-6::2.5::HTS	BRD-K10706131-046-03-6	rivastigmine	2.5	HTS	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease, Parkinson's Disease, senile dementia	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	Launched	5
BRD-K10759144-001-04-3::2.5::HTS	0.005683322020520001	BRD-K10759144-001-04-3::2.5::HTS	BRD-K10759144-001-04-3	xylose	2.5	HTS					OC[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@H](O)[C@@H](O)C=O	Launched	5
BRD-K10784860-003-02-3::2.5::HTS	-0.20906949445599998	BRD-K10784860-003-02-3::2.5::HTS	BRD-K10784860-003-02-3	temocapril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1	Launched	5
BRD-K10799896-001-26-2::2.5::HTS	0.109605040555	BRD-K10799896-001-26-2::2.5::HTS	BRD-K10799896-001-26-2	clobetasol-propionate	2.5	HTS	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl	Launched	5
BRD-K10836013-001-01-3::2.5::HTS	0.11903614493300001	BRD-K10836013-001-01-3::2.5::HTS	BRD-K10836013-001-01-3	sitafloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		infectious disease	buruli ulcer	N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F	Launched	5
BRD-K10843433-001-22-7::2.5::HTS	-0.638506512113	BRD-K10843433-001-22-7::2.5::HTS	BRD-K10843433-001-22-7	phenylbutazone	2.5	HTS	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGIS, PTGS1, PTGS2			CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	Withdrawn	5
BRD-K10843433-001-23-5::2.58::HTS	0.042495474985999995	BRD-K10843433-001-23-5::2.58::HTS	BRD-K10843433-001-23-5	phenylbutazone	2.58	HTS	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGIS, PTGS1, PTGS2			CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	Withdrawn	5
BRD-K10845183-304-01-6::2.5::HTS	-0.286303411236	BRD-K10845183-304-01-6::2.5::HTS	BRD-K10845183-304-01-6	tiludronate	2.5	HTS	bone resorption inhibitor, osteoclast inhibitor	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O	Launched	5
BRD-K10852020-001-04-5::2.5::HTS	-0.0386263203193	BRD-K10852020-001-04-5::2.5::HTS	BRD-K10852020-001-04-5	tolcapone	2.5	HTS	catechol O methyltransferase inhibitor	COMT			Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O	Withdrawn	5
BRD-K10852020-001-05-2::2.57::HTS	0.244450520955	BRD-K10852020-001-05-2::2.57::HTS	BRD-K10852020-001-05-2	tolcapone	2.57	HTS	catechol O methyltransferase inhibitor	COMT			Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O	Withdrawn	5
BRD-K10859802-001-01-0::2.5::HTS	0.0329150416583	BRD-K10859802-001-01-0::2.5::HTS	BRD-K10859802-001-01-0	APD668	2.5	HTS	glucose dependent insulinotropic receptor agonist	GPR119			CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O	Phase 1	5
BRD-K10878147-001-02-2::2.5::HTS	0.332141198556	BRD-K10878147-001-02-2::2.5::HTS	BRD-K10878147-001-02-2	OAC1	2.5	HTS	Oct activator				O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1	Preclinical	5
BRD-K10906636-001-02-9::2.67::HTS	-0.10021689497099999	BRD-K10906636-001-02-9::2.67::HTS	BRD-K10906636-001-02-9	silodosin	2.67	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F	Launched	5
BRD-K10961822-001-05-1::2.5::HTS	-2.32034903575	BRD-K10961822-001-05-1::2.5::HTS	BRD-K10961822-001-05-1	latanoprost	2.5	HTS	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1	Launched	5
BRD-K10974103-001-21-1::2.5::HTS	0.381126966361	BRD-K10974103-001-21-1::2.5::HTS	BRD-K10974103-001-21-1	diloxanide	2.5	HTS	protein synthesis inhibitor		infectious disease	amebiasis	CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1	Launched	5
BRD-K10990317-001-04-5::2.5::HTS	0.0843988747985	BRD-K10990317-001-04-5::2.5::HTS	BRD-K10990317-001-04-5	clotiapine	2.5	HTS			neurology/psychiatry	psychosis	CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12	Launched	5
BRD-K11046126-001-02-0::2.5::HTS	0.388984301186	BRD-K11046126-001-02-0::2.5::HTS	BRD-K11046126-001-02-0	VUF10166	2.5	HTS	serotonin receptor antagonist	HTR3A, HTR3B			CN1CCN(CC1)c1nc2ccccc2nc1Cl	Preclinical	5
BRD-K11071038-001-01-7::2.5::HTS	0.07019264804860001	BRD-K11071038-001-01-7::2.5::HTS	BRD-K11071038-001-01-7	ICI-162846	2.5	HTS	histamine receptor antagonist	HRH2			NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F	Phase 1	5
BRD-K11073688-001-01-6::2.5::HTS	0.25483402565900004	BRD-K11073688-001-01-6::2.5::HTS	BRD-K11073688-001-01-6	CPI-1189	2.5	HTS	tumor necrosis factor release inhibitor	TNF			CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C	Phase 2	5
BRD-K11094367-001-10-1::2.5::HTS	0.0318127090421	BRD-K11094367-001-10-1::2.5::HTS	BRD-K11094367-001-10-1	acetanilide	2.5	HTS	hydrogen peroxide decomposition inhibitor				CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1	Preclinical	5
BRD-K11099631-001-07-6::2.5::HTS	-0.129606229576	BRD-K11099631-001-07-6::2.5::HTS	BRD-K11099631-001-07-6	gadoterate-meglumine	2.5	HTS	radiopaque medium		radiology	MRI contrast agent	OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1, OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1	Launched	5
BRD-K11124378-001-04-6::2.5::HTS	0.46575994566699996	BRD-K11124378-001-04-6::2.5::HTS	BRD-K11124378-001-04-6	ceftibuten	2.5	HTS	bacterial cell wall synthesis inhibitor		pulmonary, otolaryngology	bronchitis, otitis, pharyngitis, tonsillitis	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O	Launched	5
BRD-K11129031-001-27-5::2.5::HTS	0.650884192427	BRD-K11129031-001-27-5::2.5::HTS	BRD-K11129031-001-27-5	gemfibrozil	2.5	HTS	lipoprotein lipase activator	LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1	endocrinology, cardiology	hyperlipidemia, coronary heart disease	Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1	Launched	5
BRD-K11153516-001-05-5::2.5::HTS	-0.0546173882652	BRD-K11153516-001-05-5::2.5::HTS	BRD-K11153516-001-05-5	iniparib	2.5	HTS	PARP inhibitor	PARP1			NC(=O)c1ccc(I)c(c1)[N+]([O-])=O	Phase 3	5
BRD-K11196887-001-21-2::2.5::HTS	-0.23402753094	BRD-K11196887-001-21-2::2.5::HTS	BRD-K11196887-001-21-2	norfloxacin	2.5	HTS	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	Launched	5
BRD-K11196887-001-22-0::2.49::HTS	0.0242548355393	BRD-K11196887-001-22-0::2.49::HTS	BRD-K11196887-001-22-0	norfloxacin	2.49	HTS	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	Launched	5
BRD-K11215326-001-03-7::2.31::HTS	0.00710604690876	BRD-K11215326-001-03-7::2.31::HTS	BRD-K11215326-001-03-7	tazemetostat	2.31	HTS	histone lysine methyltransferase inhibitor	EZH2			CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1	Phase 2	5
BRD-K11244467-001-08-5::2.5::HTS	-0.838366286858	BRD-K11244467-001-08-5::2.5::HTS	BRD-K11244467-001-08-5	ambazone	2.5	HTS	DNA damage inducer				NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1	Phase 1	5
BRD-K11267252-001-04-4::2.5::HTS	-0.0640309310649	BRD-K11267252-001-04-4::2.5::HTS	BRD-K11267252-001-04-4	alectinib	2.5	HTS	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1	Launched	5
BRD-K11292736-300-02-8::2.5::HTS	0.193102040405	BRD-K11292736-300-02-8::2.5::HTS	BRD-K11292736-300-02-8	ambenonium	2.5	HTS	cholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl	Launched	5
BRD-K11373525-003-02-1::2.5::HTS	-0.38097023957099996	BRD-K11373525-003-02-1::2.5::HTS	BRD-K11373525-003-02-1	ZD-7155	2.5	HTS	angiotensin receptor antagonist	AGTR1			CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nnn[nH]3)C(=O)CCc2c(CC)n1	Preclinical	5
BRD-K11399644-003-11-3::2.5::HTS	-0.41525679573200003	BRD-K11399644-003-11-3::2.5::HTS	BRD-K11399644-003-11-3	phenformin	2.5	HTS	AMPK activator	KCNJ8, PRKAA1			NC(=N)NC(=N)NCCc1ccccc1, NC(=N)NC(=N)NCCc1ccccc1, NC(=N)NC(=N)NCCc1ccccc1	Withdrawn	5
BRD-K11411329-001-01-3::2.5::HTS	-0.7300024485009999	BRD-K11411329-001-01-3::2.5::HTS	BRD-K11411329-001-01-3	NOV-002	2.5	HTS		GSR, GSTM2			N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	Phase 3	5
BRD-K11433652-001-17-0::2.5::HTS	-0.441301953329	BRD-K11433652-001-17-0::2.5::HTS	BRD-K11433652-001-17-0	aspirin	2.5	HTS	cyclooxygenase inhibitor	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O	Launched	5
BRD-K11510141-001-01-8::2.5::HTS	0.256076606417	BRD-K11510141-001-01-8::2.5::HTS	BRD-K11510141-001-01-8	teprenone	2.5	HTS	mucus protecting agent		dermatology	cosmetic	CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C	Launched	5
BRD-K11558771-001-13-9::2.5::HTS	-0.12004505000099999	BRD-K11558771-001-13-9::2.5::HTS	BRD-K11558771-001-13-9	droxinostat	2.5	HTS	HDAC inhibitor	HDAC6, HDAC8			Cc1cc(Cl)ccc1OCCCC(=O)NO	Preclinical	5
BRD-K11590034-002-03-4::2.49::HTS	-1.06921349939	BRD-K11590034-002-03-4::2.49::HTS	BRD-K11590034-002-03-4	morin	2.49	HTS	cytochrome P450 inhibitor	ADORA2A, ESR2, FASN, MCL1, SLC22A12			Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O	Preclinical	5
BRD-K11595419-001-01-4::2.5::HTS	0.005267157322319999	BRD-K11595419-001-01-4::2.5::HTS	BRD-K11595419-001-01-4	dipeptamin	2.5	HTS					C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O, C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	Launched	5
BRD-K11630072-001-13-2::2.5::HTS	-2.08825566263	BRD-K11630072-001-13-2::2.5::HTS	BRD-K11630072-001-13-2	carmofur	2.5	HTS	thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O	Launched	5
BRD-K11631773-001-10-8::2.58::HTS	0.277298721085	BRD-K11631773-001-10-8::2.58::HTS	BRD-K11631773-001-10-8	sesamin	2.58	HTS	NFkB pathway inhibitor				C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1	Preclinical	5
BRD-K11636097-001-03-1::2.5::HTS	-0.705531766165	BRD-K11636097-001-03-1::2.5::HTS	BRD-K11636097-001-03-1	JNJ-7706621	2.5	HTS	CDK inhibitor	AURKA, AURKB, CDK1, CDK2			Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F	Preclinical	5
BRD-K11640013-001-15-8::2.5::HTS	0.0408390667634	BRD-K11640013-001-15-8::2.5::HTS	BRD-K11640013-001-15-8	sulfamethazine	2.5	HTS	PABA antagonist		gastroenterology	enteritis, enteritis	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	Launched	5
BRD-K11640013-236-10-1::2.5::HTS	-0.706671889475	BRD-K11640013-236-10-1::2.5::HTS	BRD-K11640013-236-10-1	sulfamethazine	2.5	HTS	PABA antagonist		gastroenterology	enteritis, enteritis	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	Launched	5
BRD-K11663430-001-02-3::2.5::HTS	0.473898013705	BRD-K11663430-001-02-3::2.5::HTS	BRD-K11663430-001-02-3	pyroxamide	2.5	HTS	HDAC inhibitor	HDAC1			ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1	Phase 1	5
BRD-K11672787-001-01-5::2.5::HTS	-0.265780384758	BRD-K11672787-001-01-5::2.5::HTS	BRD-K11672787-001-01-5	rostafuroxine	2.5	HTS	ATPase inhibitor	ATP1A1			C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1	Phase 2	5
BRD-K11696279-003-02-3::2.5::HTS	0.143895471421	BRD-K11696279-003-02-3::2.5::HTS	BRD-K11696279-003-02-3	BU-239	2.5	HTS	imidazoline receptor ligand, imidazoline receptor agonist				C1CN=C(N1)c1cnc2ccccc2n1	Preclinical	5
BRD-K11717138-001-30-3::2.5::HTS	-0.287197009799	BRD-K11717138-001-30-3::2.5::HTS	BRD-K11717138-001-30-3	benzbromarone	2.5	HTS	chloride channel blocker	ABCC1	rheumatology	gout	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	Launched	5
BRD-K11742128-003-23-4::2.5::HTS	-0.237218323418	BRD-K11742128-003-23-4::2.5::HTS	BRD-K11742128-003-23-4	triprolidine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1	Launched	5
BRD-K11756522-001-09-9::2.5::HTS	0.166158673944	BRD-K11756522-001-09-9::2.5::HTS	BRD-K11756522-001-09-9	furazolidone	2.5	HTS	bacterial DNA inhibitor		gastroenterology, infectious disease	diarrhea, enteritis, cholera	[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1	Launched	5
BRD-K11796549-001-04-5::2.5::HTS	0.0547739552284	BRD-K11796549-001-04-5::2.5::HTS	BRD-K11796549-001-04-5	NBQX	2.5	HTS	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B			NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	Preclinical	5
BRD-K11853856-001-01-7::2.5::HTS	0.021462490206200002	BRD-K11853856-001-01-7::2.5::HTS	BRD-K11853856-001-01-7	PJ-34	2.5	HTS	PARP inhibitor	EEF2, PARP1, PARP15, PARP3			CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1	Preclinical	5
BRD-K11900042-001-14-4::2.5::HTS	0.147742165329	BRD-K11900042-001-14-4::2.5::HTS	BRD-K11900042-001-14-4	methylthiouracil	2.5	HTS			endocrinology	hyperthyroidism	Cc1cc(=O)[nH]c(=S)[nH]1, Cc1cc(=O)[nH]c(=S)[nH]1	Launched	5
BRD-K11911061-003-11-9::2.5::HTS	0.04009970443	BRD-K11911061-003-11-9::2.5::HTS	BRD-K11911061-003-11-9	GR-127935	2.5	HTS	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1	Preclinical	5
BRD-K11927976-050-02-9::2.5::HTS	-2.62386224323	BRD-K11927976-050-02-9::2.5::HTS	BRD-K11927976-050-02-9	ER-27319	2.5	HTS	mediator release inhibitor, SYK inhibitor	SYK			Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O	Preclinical	5
BRD-K11973162-003-01-8::2.5::HTS	-0.8575586900929999	BRD-K11973162-003-01-8::2.5::HTS	BRD-K11973162-003-01-8	tipiracil	2.5	HTS	thymidine phosphorylase inhibitor	TYMP	oncology	colorectal cancer	Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O	Launched	5
BRD-K12014493-001-02-2::2.5::HTS	-0.0307421996342	BRD-K12014493-001-02-2::2.5::HTS	BRD-K12014493-001-02-2	betaine	2.5	HTS	nitric oxide donor		metabolism	homocystinuria	C[N+](C)(C)CC(O)=O	Launched	5
BRD-K12040459-001-06-0::2.5::HTS	0.215335155509	BRD-K12040459-001-06-0::2.5::HTS	BRD-K12040459-001-06-0	AT7867	2.5	HTS	AKT inhibitor	AKT2, GSK3B, PKIA, PRKACA			Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1	Preclinical	5
BRD-K12047401-001-01-5::2.5::HTS	0.752685629551	BRD-K12047401-001-01-5::2.5::HTS	BRD-K12047401-001-01-5	palifosfamide	2.5	HTS	DNA alkylating agent				OP(=O)(NCCCl)NCCCl, OP(=O)(NCCCl)NCCCl	Phase 3	5
BRD-K12068470-001-02-5::2.36::HTS	-2.85034801263	BRD-K12068470-001-02-5::2.36::HTS	BRD-K12068470-001-02-5	LY2608204	2.36	HTS	glucokinase activator	GCK			O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	Phase 2	5
BRD-K12068470-001-04-1::2.5::HTS	0.34268281115000004	BRD-K12068470-001-04-1::2.5::HTS	BRD-K12068470-001-04-1	LY2608204	2.5	HTS	glucokinase activator	GCK			O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	Phase 2	5
BRD-K12079898-001-02-6::2.5::HTS	0.04812743574469999	BRD-K12079898-001-02-6::2.5::HTS	BRD-K12079898-001-02-6	PD-160170	2.5	HTS	neuropeptide receptor antagonist	NPY1R			CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O	Preclinical	5
BRD-K12102668-001-25-5::2.5::HTS	0.426158605373	BRD-K12102668-001-25-5::2.5::HTS	BRD-K12102668-001-25-5	nialamide	2.5	HTS	monoamine oxidase inhibitor	COMT, MAOA, MAOB			O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1	Withdrawn	5
BRD-K12120659-305-02-2::2.5::HTS	0.329600464837	BRD-K12120659-305-02-2::2.5::HTS	BRD-K12120659-305-02-2	GR-144053	2.5	HTS	integrin antagonist	ITGA2B, ITGB3			NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1	Preclinical	5
BRD-K12184916-001-15-4::2.5::HTS	-3.0755123949299996	BRD-K12184916-001-15-4::2.5::HTS	BRD-K12184916-001-15-4	NVP-BEZ235	2.5	HTS	mTOR inhibitor, PI3K inhibitor	ATR, MTOR, PIK3CA, PIK3CD, PIK3CG			Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1	Phase 2	5
BRD-K12219985-001-26-1::2.5::HTS	0.10873020942600001	BRD-K12219985-001-26-1::2.5::HTS	BRD-K12219985-001-26-1	glipizide	2.5	HTS	sulfonylurea	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus, hyperglycemia	Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched	5
BRD-K12244279-001-05-8::2.5::HTS	0.474982791894	BRD-K12244279-001-05-8::2.5::HTS	BRD-K12244279-001-05-8	MEK1-2-inhibitor	2.5	HTS	MEK inhibitor	MAP2K2			N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F	Preclinical	5
BRD-K12251893-065-04-7::2.5::HTS	-1.44322043504	BRD-K12251893-065-04-7::2.5::HTS	BRD-K12251893-065-04-7	vincristine	2.5	HTS	tubulin polymerization inhibitor	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC	Launched	5
BRD-K12329651-001-18-8::2.5::HTS	-0.20862089890799998	BRD-K12329651-001-18-8::2.5::HTS	BRD-K12329651-001-18-8	androsterone	2.5	HTS	androgen receptor agonist				C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical	5
BRD-K12343256-001-08-9::2.5::HTS	-2.49696883375	BRD-K12343256-001-08-9::2.5::HTS	BRD-K12343256-001-08-9	trametinib	2.5	HTS	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	Launched	5
BRD-K12502280-001-08-0::2.5::HTS	1.06746405685	BRD-K12502280-001-08-0::2.5::HTS	BRD-K12502280-001-08-0	TG-101348	2.5	HTS	FLT3 inhibitor, JAK inhibitor	BRD4, JAK1, JAK2, JAK3, TYK2			Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C	Phase 3	5
BRD-K12513978-001-24-1::2.5::HTS	-0.276520467726	BRD-K12513978-001-24-1::2.5::HTS	BRD-K12513978-001-24-1	fenbufen	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2			OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1	Launched	5
BRD-K12539416-001-01-4::2.5::HTS	-0.113151055747	BRD-K12539416-001-01-4::2.5::HTS	BRD-K12539416-001-01-4	sulbutiamine	2.5	HTS	acetylcholine receptor antagonist		neurology/psychiatry	asthenia	CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O	Launched	5
BRD-K12539581-001-23-7::2.5::HTS	-2.26043404348	BRD-K12539581-001-23-7::2.5::HTS	BRD-K12539581-001-23-7	nocodazole	2.5	HTS	tubulin polymerization inhibitor	HPGDS			COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1	Preclinical	5
BRD-K12568846-001-14-6::2.5::HTS	-0.327249100314	BRD-K12568846-001-14-6::2.5::HTS	BRD-K12568846-001-14-6	amidopyrine	2.5	HTS	analgesic agent		dermatology	dermatitis herpetiformis (DH)	CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O	Launched	5
BRD-K12609457-001-03-1::2.5::HTS	-0.460654436478	BRD-K12609457-001-03-1::2.5::HTS	BRD-K12609457-001-03-1	exalamide	2.5	HTS	membrane permeability inhibitor				CCCCCCOc1ccccc1C(N)=O	Launched	5
BRD-K12614344-003-01-8::2.5::HTS	0.10496814318900001	BRD-K12614344-003-01-8::2.5::HTS	BRD-K12614344-003-01-8	CGS-21680	2.5	HTS	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CCNC(=O)[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12	Preclinical	5
BRD-K12630395-001-14-9::2.5::HTS	0.000139666932625	BRD-K12630395-001-14-9::2.5::HTS	BRD-K12630395-001-14-9	harmane	2.5	HTS	monoamine oxidase inhibitor	MAOA, MAOB			Cc1nccc2c3ccccc3[nH]c12	Preclinical	5
BRD-K12735121-001-01-4::2.5::HTS	0.187857719646	BRD-K12735121-001-01-4::2.5::HTS	BRD-K12735121-001-01-4	TG-100801	2.5	HTS	src inhibitor, VEGFR inhibitor	FGFR1, FLT1, KDR, SRC			Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl	Phase 2	5
BRD-K12737986-001-01-4::2.5::HTS	0.0200376898832	BRD-K12737986-001-01-4::2.5::HTS	BRD-K12737986-001-01-4	veliparib	2.5	HTS	PARP inhibitor	PARP1, PARP2			C[C@]1(CCCN1)c1nc2c(cccc2[nH]1)C(N)=O	Phase 3	5
BRD-K12762134-001-06-2::2.5::HTS	-0.348103488305	BRD-K12762134-001-06-2::2.5::HTS	BRD-K12762134-001-06-2	XAV-939	2.5	HTS	tankyrase inhibitor	TNKS, TNKS2			Oc1nc(nc2CCSCc12)-c1ccc(cc1)C(F)(F)F, Oc1nc(nc2CCSCc12)-c1ccc(cc1)C(F)(F)F, Oc1nc(nc2CCSCc12)-c1ccc(cc1)C(F)(F)F	Preclinical	5
BRD-K12769093-003-01-3::2.5::HTS	-0.182644839597	BRD-K12769093-003-01-3::2.5::HTS	BRD-K12769093-003-01-3	PNU-37883	2.5	HTS	ATP-sensitive potassium channel antagonist				C1CCC(CC1)N\C(N1CCOCC1)=N\C12CC3CC(CC(C3)C1)C2, C1CCC(CC1)N\C(N1CCOCC1)=N\C12CC3CC(CC(C3)C1)C2	Preclinical	5
BRD-K12787259-001-04-3::2.5::HTS	-0.814828788327	BRD-K12787259-001-04-3::2.5::HTS	BRD-K12787259-001-04-3	CX-5461	2.5	HTS	RNA polymerase inhibitor				CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O	Phase 1	5
BRD-K12807006-001-18-5::2.5::HTS	-0.043479060970999996	BRD-K12807006-001-18-5::2.5::HTS	BRD-K12807006-001-18-5	kaempferol	2.5	HTS	bone resorption inhibitor, estrogen-related receptor inverse agonist	AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1			Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O	Preclinical	5
BRD-K12829205-003-02-8::2.5::HTS	-1.21478186088	BRD-K12829205-003-02-8::2.5::HTS	BRD-K12829205-003-02-8	mechlorethamine	2.5	HTS	DNA inhibitor		hematologic malignancy, hematology, infectious disease, oncology	Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma	CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl	Launched	5
BRD-K12867552-001-04-7::2.5::HTS	-2.08907011719	BRD-K12867552-001-04-7::2.5::HTS	BRD-K12867552-001-04-7	PCI-24781	2.5	HTS	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6			CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO	Phase 1/Phase 2	5
BRD-K12885236-001-02-7::2.5::HTS	-1.32629872156	BRD-K12885236-001-02-7::2.5::HTS	BRD-K12885236-001-02-7	dapivirine	2.5	HTS	non-nucleoside reverse transcriptase inhibitor	CYP3A4, CYP3A5			Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1	Phase 3	5
BRD-K12932420-001-02-3::2.5::HTS	-0.135240657888	BRD-K12932420-001-02-3::2.5::HTS	BRD-K12932420-001-02-3	YM-976	2.5	HTS	phosphodiesterase inhibitor	PDE4A			CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1	Phase 1	5
BRD-K12968785-001-13-3::2.5::HTS	0.622897433839	BRD-K12968785-001-13-3::2.5::HTS	BRD-K12968785-001-13-3	bergapten	2.5	HTS					COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12	Preclinical	5
BRD-K12994359-001-18-4::2.5::HTS	-0.776912279882	BRD-K12994359-001-18-4::2.5::HTS	BRD-K12994359-001-18-4	valdecoxib	2.5	HTS	cyclooxygenase inhibitor	CA12, PTGS2			Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1	Withdrawn	5
BRD-K13044802-213-20-7::2.5::HTS	-1.3604080494	BRD-K13044802-213-20-7::2.5::HTS	BRD-K13044802-213-20-7	ciclopirox	2.5	HTS	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1	Launched	5
BRD-K13049116-001-05-7::2.5::HTS	-1.10632393449	BRD-K13049116-001-05-7::2.5::HTS	BRD-K13049116-001-05-7	BMS-754807	2.5	HTS	IGF-1 inhibitor	AKT1, IGF1R			C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1	Phase 2	5
BRD-K13050303-001-17-3::2.5::HTS	-0.11073696033	BRD-K13050303-001-17-3::2.5::HTS	BRD-K13050303-001-17-3	uridine	2.5	HTS	dopamine receptor agonist	LSM6, TYMP			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O	Phase 2	5
BRD-K13050303-001-18-1::2.5::HTS	-0.140568998958	BRD-K13050303-001-18-1::2.5::HTS	BRD-K13050303-001-18-1	uridine	2.5	HTS	dopamine receptor agonist	LSM6, TYMP			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O	Phase 2	5
BRD-K13050541-001-01-9::2.8::HTS	-3.96270678639	BRD-K13050541-001-01-9::2.8::HTS	BRD-K13050541-001-01-9	acivicin	2.8	HTS	gamma glutamyltransferase Inhibitors	CTPS1			N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O	Phase 2	5
BRD-K13078532-001-28-4::2.5::HTS	-0.633585604389	BRD-K13078532-001-28-4::2.5::HTS	BRD-K13078532-001-28-4	hydrochlorothiazide	2.5	HTS	thiazide diuretic	CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3	cardiology	hypertension, congestive heart failure	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl	Launched	5
BRD-K13087974-001-02-5::2.5::HTS	0.029129826183	BRD-K13087974-001-02-5::2.5::HTS	BRD-K13087974-001-02-5	CGP-52411	2.5	HTS	EGFR inhibitor	EGFR			O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12	Preclinical	5
BRD-K13094524-001-07-5::2.63::HTS	0.162993013228	BRD-K13094524-001-07-5::2.63::HTS	BRD-K13094524-001-07-5	PFI-1	2.63	HTS	bromodomain inhibitor	BRD4			COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1	Preclinical	5
BRD-K13112821-001-17-4::2.5::HTS	-0.669172102253	BRD-K13112821-001-17-4::2.5::HTS	BRD-K13112821-001-17-4	artemisinin	2.5	HTS	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched	5
BRD-K13167095-001-02-9::2.5::HTS	-5.27235267378	BRD-K13167095-001-02-9::2.5::HTS	BRD-K13167095-001-02-9	AR-42	2.5	HTS	HDAC inhibitor	HDAC1			CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1	Phase 1	5
BRD-K13169950-001-14-4::2.5::HTS	-2.68145959407	BRD-K13169950-001-14-4::2.5::HTS	BRD-K13169950-001-14-4	NSC-3852	2.5	HTS	HDAC inhibitor	HDAC1			Oc1ccc([N+][O-])c2cccnc12	Preclinical	5
BRD-K13183738-317-10-2::2.5::HTS	-1.9312491977400001	BRD-K13183738-317-10-2::2.5::HTS	BRD-K13183738-317-10-2	pentamidine	2.5	HTS	anti-pneumocystis agent	TRDMT1	infectious disease	pneumonia	NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1	Launched	5
BRD-K13211965-003-02-8::2.5::HTS	0.217686494753	BRD-K13211965-003-02-8::2.5::HTS	BRD-K13211965-003-02-8	L-741742	2.5	HTS	dopamine receptor antagonist	DRD3, DRD4, SCN1A, SCN3A			Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1	Preclinical	5
BRD-K13238168-001-02-0::2.5::HTS	0.202606850319	BRD-K13238168-001-02-0::2.5::HTS	BRD-K13238168-001-02-0	haloprogin	2.5	HTS	other antifungal		infectious disease	tinea pedis	Clc1cc(Cl)c(OCC#CI)cc1Cl	Launched	5
BRD-K13238618-001-05-9::2.5::HTS	-0.16624173185399999	BRD-K13238618-001-05-9::2.5::HTS	BRD-K13238618-001-05-9	carsalam	2.5	HTS	analgesic agent				O=c1[nH]c(=O)c2ccccc2o1	Preclinical	5
BRD-K13249881-001-02-3::2.5::HTS	-0.714836203711	BRD-K13249881-001-02-3::2.5::HTS	BRD-K13249881-001-02-3	piperazine	2.5	HTS	benzodiazepine receptor agonist	GABRB3	infectious disease	gastrointestinal roundworms	C1CNCCN1	Launched	5
BRD-K13261168-300-01-0::2.5::HTS	-0.09143339285730001	BRD-K13261168-300-01-0::2.5::HTS	BRD-K13261168-300-01-0	quinelorane	2.5	HTS	dopamine receptor agonist	DRD2, DRD3			CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12	Phase 3	5
BRD-K13296708-001-05-8::2.5::HTS	0.347583079991	BRD-K13296708-001-05-8::2.5::HTS	BRD-K13296708-001-05-8	rimonabant	2.5	HTS	cannabinoid receptor antagonist	CNR1, GPR55			Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Withdrawn	5
BRD-K13302470-001-02-7::2.5::HTS	-0.418322400671	BRD-K13302470-001-02-7::2.5::HTS	BRD-K13302470-001-02-7	KY02111	2.5	HTS	Wnt pathway inhibitor	DKK1			COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC	Preclinical	5
BRD-K13314656-001-01-0::2.5::HTS	0.495995905758	BRD-K13314656-001-01-0::2.5::HTS	BRD-K13314656-001-01-0	ebastine	2.5	HTS	histamine receptor antagonist	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Launched	5
BRD-K13356952-001-25-1::2.5::HTS	0.43028883890299996	BRD-K13356952-001-25-1::2.5::HTS	BRD-K13356952-001-25-1	methazolamide	2.5	HTS	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	glaucoma, intraocular pressure	CC(=O)N=c1sc(nn1C)S(N)(=O)=O, CC(=O)N=c1sc(nn1C)S(N)(=O)=O, CC(=O)N=c1sc(nn1C)S(N)(=O)=O	Launched	5
BRD-K13387373-004-14-5::2.5::HTS	0.007504605510140001	BRD-K13387373-004-14-5::2.5::HTS	BRD-K13387373-004-14-5	thonzonium	2.5	HTS	ATPase inhibitor				CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1	Launched	5
BRD-K13390322-001-06-3::2.5::HTS	-3.12902543722	BRD-K13390322-001-06-3::2.5::HTS	BRD-K13390322-001-06-3	AT-7519	2.5	HTS	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9			Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1	Phase 2	5
BRD-K13409143-001-01-9::2.5::HTS	-0.6230905158910001	BRD-K13409143-001-01-9::2.5::HTS	BRD-K13409143-001-01-9	isopropyl-myristate	2.5	HTS			dermatology	cosmetic	CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C	Launched	5
BRD-K13421763-001-06-2::2.5::HTS	0.258063868231	BRD-K13421763-001-06-2::2.5::HTS	BRD-K13421763-001-06-2	aminothiazole	2.5	HTS	cyclin D inhibitor	NOS2			Nc1nccs1, Nc1nccs1, Nc1nccs1	Preclinical	5
BRD-K13474508-001-01-2::2.5::HTS	0.662150478263	BRD-K13474508-001-01-2::2.5::HTS	BRD-K13474508-001-01-2	L-655,708	2.5	HTS	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRG2			CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21	Preclinical	5
BRD-K13486660-001-01-0::2.5::HTS	-0.174932159126	BRD-K13486660-001-01-0::2.5::HTS	BRD-K13486660-001-01-0	sulfacarbamide	2.5	HTS					NC(=O)NS(=O)(=O)c1ccc(N)cc1	Withdrawn	5
BRD-K13495773-001-11-4::2.5::HTS	0.151938564502	BRD-K13495773-001-11-4::2.5::HTS	BRD-K13495773-001-11-4	creatinine	2.5	HTS					CN1CC(=O)NC1=N, CN1CC(=O)NC1=N	Preclinical	5
BRD-K13511380-001-01-4::2.5::HTS	-0.195484681156	BRD-K13511380-001-01-4::2.5::HTS	BRD-K13511380-001-01-4	naringin-dihydrochalcone	2.5	HTS	cytochrome P450 inhibitor				C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Preclinical	5
BRD-K13514097-001-05-3::2.5::HTS	-0.274500577439	BRD-K13514097-001-05-3::2.5::HTS	BRD-K13514097-001-05-3	everolimus	2.5	HTS	mTOR inhibitor	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO	Launched	5
BRD-K13566078-001-02-3::2.5::HTS	0.028703764246	BRD-K13566078-001-02-3::2.5::HTS	BRD-K13566078-001-02-3	BMS-345541	2.5	HTS	IKK inhibitor	CHUK, IKBKB			Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12	Preclinical	5
BRD-K13571841-001-14-4::2.5::HTS	0.432155343872	BRD-K13571841-001-14-4::2.5::HTS	BRD-K13571841-001-14-4	pepstatin	2.5	HTS	aspartic protease inhibitor	CTSB, CTSD, CTSL, REN			CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O	Preclinical	5
BRD-K13606314-001-01-3::2.5::HTS	0.37063396805699994	BRD-K13606314-001-01-3::2.5::HTS	BRD-K13606314-001-01-3	P5091	2.5	HTS	ubiquitin specific protease inhibitor	USP7			CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O	Preclinical	5
BRD-K13619941-213-01-8::2.5::HTS	0.181773552359	BRD-K13619941-213-01-8::2.5::HTS	BRD-K13619941-213-01-8	aceglutamide	2.5	HTS			gastroenterology	peptic ulcer disease (PUD)	CC(=O)N[C@@H](CCC(N)=O)C(O)=O	Launched	5
BRD-K13646352-001-03-8::2.5::HTS	-2.0762393411	BRD-K13646352-001-03-8::2.5::HTS	BRD-K13646352-001-03-8	midostaurin	2.5	HTS	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1	Launched	5
BRD-K13662825-001-07-5::2.5::HTS	-5.71896642019	BRD-K13662825-001-07-5::2.5::HTS	BRD-K13662825-001-07-5	dinaciclib	2.5	HTS	CDK inhibitor	CDK1, CDK2, CDK5, CDK9			CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO	Phase 3	5
BRD-K13756951-001-01-4::2.5::HTS	0.440178186124	BRD-K13756951-001-01-4::2.5::HTS	BRD-K13756951-001-01-4	bitopertin	2.5	HTS	glycine transporter inhibitor, GlyT-1 inhibitor	SLC6A5, SLC6A9			C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F	Phase 3	5
BRD-K13800121-001-01-5::2.5::HTS	-1.07459228827	BRD-K13800121-001-01-5::2.5::HTS	BRD-K13800121-001-01-5	parecoxib	2.5	HTS	cyclooxygenase inhibitor	LTF	neurology/psychiatry	pain relief	CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1	Launched	5
BRD-K13810148-311-03-2::2.5::HTS	-4.4427538212	BRD-K13810148-311-03-2::2.5::HTS	BRD-K13810148-311-03-2	givinostat	2.5	HTS	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1	Phase 2	5
BRD-K13819402-003-10-2::2.4::HTS	-0.0810482913545	BRD-K13819402-003-10-2::2.4::HTS	BRD-K13819402-003-10-2	desoxypeganine	2.4	HTS	acetylcholinesterase inhibitor, monoamine oxidase inhibitor	ACHE			C1CN2Cc3ccccc3N=C2C1	Phase 1	5
BRD-K13829090-303-02-9::2.5::HTS	0.193857535035	BRD-K13829090-303-02-9::2.5::HTS	BRD-K13829090-303-02-9	IEM1460	2.5	HTS	glutamate receptor antagonist	GRIA2			C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2	Preclinical	5
BRD-K13888115-003-02-2::2.5::HTS	-0.00307242322936	BRD-K13888115-003-02-2::2.5::HTS	BRD-K13888115-003-02-2	LY2365109	2.5	HTS	Glycine transporter 1 inhibitor	SLC6A9			CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O, CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O	Preclinical	5
BRD-K13926615-003-03-3::2.5::HTS	0.262920811693	BRD-K13926615-003-03-3::2.5::HTS	BRD-K13926615-003-03-3	vardenafil	2.5	HTS	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H	urology	erectile dysfunction	CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1	Launched	5
BRD-K13949769-001-01-7::2.5::HTS	0.038768160307400004	BRD-K13949769-001-01-7::2.5::HTS	BRD-K13949769-001-01-7	tenovin-6	2.5	HTS	SIRT inhibitor	SIRT1, SIRT2, SIRT3			CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	Preclinical	5
BRD-K13994703-003-15-8::2.5::HTS	0.193574451384	BRD-K13994703-003-15-8::2.5::HTS	BRD-K13994703-003-15-8	propranolol-(S)	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3, HTR1A, HTR1B, HTR5A, SLC10A1			CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12	Preclinical	5
BRD-K14003026-003-09-0::2.46::HTS	0.230110866838	BRD-K14003026-003-09-0::2.46::HTS	BRD-K14003026-003-09-0	ritodrine	2.46	HTS	adrenergic receptor agonist	ADRB2	obstetrics/gynecology	premature labor	C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1	Launched	5
BRD-K14109347-001-03-4::2.5::HTS	-0.234963261199	BRD-K14109347-001-03-4::2.5::HTS	BRD-K14109347-001-03-4	LY2603618	2.5	HTS	CHK inhibitor	CHEK1			Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1	Phase 2	5
BRD-K14116214-001-09-6::2.5::HTS	0.34484806421400005	BRD-K14116214-001-09-6::2.5::HTS	BRD-K14116214-001-09-6	sulfamonomethoxine	2.5	HTS	bacterial antifolate		infectious disease	urinary tract infections	COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1	Launched	5
BRD-K14127446-005-22-7::2.5::HTS	-0.41628063929700004	BRD-K14127446-005-22-7::2.5::HTS	BRD-K14127446-005-22-7	isopropamide-iodide	2.5	HTS	acetylcholine receptor antagonist	CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD), gastrointestinal acidosis	CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C	Launched	5
BRD-K14175878-001-01-6::2.5::HTS	-0.0925529577529	BRD-K14175878-001-01-6::2.5::HTS	BRD-K14175878-001-01-6	MK-0812	2.5	HTS	CC chemokine receptor antagonist	CCR2			CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F	Phase 2	5
BRD-K14235254-001-01-2::2.5::HTS	0.0923780684475	BRD-K14235254-001-01-2::2.5::HTS	BRD-K14235254-001-01-2	GTS21	2.5	HTS	cholinergic receptor agonist	CHRNA7			COc1ccc(\C=C2CCCN=C/2c2cccnc2)c(OC)c1	Phase 1/Phase 2	5
BRD-K14329163-001-03-9::2.5::HTS	0.744333348645	BRD-K14329163-001-03-9::2.5::HTS	BRD-K14329163-001-03-9	BAY-K-8644-(s)-(-)	2.5	HTS	L-type calcium channel activator	CACNA1C			COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O	Preclinical	5
BRD-K14349461-003-13-1::2.5::HTS	-0.116923442568	BRD-K14349461-003-13-1::2.5::HTS	BRD-K14349461-003-13-1	pyridoxine	2.5	HTS	vitamin B	DDC, PDXK	metabolism	vitamin B6 deficiency	Cc1ncc(CO)c(CO)c1O, Cc1ncc(CO)c(CO)c1O	Launched	5
BRD-K14385366-001-04-4::2.59::HTS	-0.0082474120682	BRD-K14385366-001-04-4::2.59::HTS	BRD-K14385366-001-04-4	FG-4592	2.59	HTS	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN2			Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12	Phase 3	5
BRD-K14395568-001-16-3::2.5::HTS	0.24514230686500002	BRD-K14395568-001-16-3::2.5::HTS	BRD-K14395568-001-16-3	NECA	2.5	HTS	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, HSP90B1			CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	Launched	5
BRD-K14401183-001-10-7::2.5::HTS	0.412095722118	BRD-K14401183-001-10-7::2.5::HTS	BRD-K14401183-001-10-7	avobenzone	2.5	HTS	UV blocker	TYR	dermatology	cosmetic, sunscreen lotion	COc1ccc(cc1)C(=O)CC(=O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)CC(=O)c1ccc(cc1)C(C)(C)C	Launched	5
BRD-K14496212-066-04-8::2.5::HTS	0.07798951716199999	BRD-K14496212-066-04-8::2.5::HTS	BRD-K14496212-066-04-8	bromocriptine	2.5	HTS	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	endocrinology, neurology/psychiatry	hyperprolactinemia, Parkinson's Disease, acromegaly	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C	Launched	5
BRD-K14529030-001-01-9::2.5::HTS	0.55049646061	BRD-K14529030-001-01-9::2.5::HTS	BRD-K14529030-001-01-9	meisoindigo	2.5	HTS	STAT inhibitor	STAT3			CN1C(=O)\C(c2ccccc12)=C1\C(=O)Nc2ccccc12	Phase 3	5
BRD-K14560436-001-01-4::2.5::HTS	-2.65868190114	BRD-K14560436-001-01-4::2.5::HTS	BRD-K14560436-001-01-4	TG-02	2.5	HTS	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2			CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2	Phase 1	5
BRD-K14618467-001-04-6::2.5::HTS	-1.12107800077	BRD-K14618467-001-04-6::2.5::HTS	BRD-K14618467-001-04-6	IKK-16	2.5	HTS	IKK inhibitor	IKBKB			O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1	Preclinical	5
BRD-K14619660-001-01-5::2.5::HTS	0.09738412062200001	BRD-K14619660-001-01-5::2.5::HTS	BRD-K14619660-001-01-5	altrenogest	2.5	HTS	progestogen hormone	PGR	endocrinology	estrus	C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(O)CC=C, C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(O)CC=C	Launched	5
BRD-K14653796-001-01-1::2.5::HTS	0.289231351869	BRD-K14653796-001-01-1::2.5::HTS	BRD-K14653796-001-01-1	tasquinimod	2.5	HTS	angiogenesis inhibitor, S100A9 inhibitor	HDAC4			COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12	Phase 3	5
BRD-K14704277-001-22-6::2.5::HTS	0.27260393406100003	BRD-K14704277-001-22-6::2.5::HTS	BRD-K14704277-001-22-6	cinoxacin	2.5	HTS	topoisomerase inhibitor		infectious disease	urinary tract infections	CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12	Launched	5
BRD-K14705039-001-16-4::2.5::HTS	0.282708762111	BRD-K14705039-001-16-4::2.5::HTS	BRD-K14705039-001-16-4	sulfathiazole	2.5	HTS	dihydropteroate synthase inhibitor				Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Launched	5
BRD-K14711741-001-02-1::2.5::HTS	0.137374729368	BRD-K14711741-001-02-1::2.5::HTS	BRD-K14711741-001-02-1	PF-4708671	2.5	HTS	ribosomal protein inhibitor	RPS6KB1			CCc1cncnc1N1CCN(CC1)Cc1nc2cc(ccc2[nH]1)C(F)(F)F, CCc1cncnc1N1CCN(CC1)Cc1nc2cc(ccc2[nH]1)C(F)(F)F	Preclinical	5
BRD-K14762862-001-01-9::2.5::HTS	0.566942333441	BRD-K14762862-001-01-9::2.5::HTS	BRD-K14762862-001-01-9	I-BZA	2.5	HTS					CCN(CC)CCNC(=O)c1ccc(I)cc1	Phase 2	5
BRD-K14763542-001-02-3::2.5::HTS	-0.80570368187	BRD-K14763542-001-02-3::2.5::HTS	BRD-K14763542-001-02-3	flurothyl	2.5	HTS					FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F	Preclinical	5
BRD-K14765469-003-12-2::2.5::HTS	-0.0983157131288	BRD-K14765469-003-12-2::2.5::HTS	BRD-K14765469-003-12-2	vesamicol	2.5	HTS	acetylcholinesterase inhibitor	SLC18A3			O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1	Preclinical	5
BRD-K14767410-001-02-3::2.5::HTS	0.252762613339	BRD-K14767410-001-02-3::2.5::HTS	BRD-K14767410-001-02-3	SC-560	2.5	HTS	cyclooxygenase inhibitor	PTGS1			COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	Preclinical	5
BRD-K14796088-003-26-8::2.5::HTS	-0.383983613536	BRD-K14796088-003-26-8::2.5::HTS	BRD-K14796088-003-26-8	berberine	2.5	HTS	LDL receptor activator	LDLR			COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC	Phase 2/Phase 3	5
BRD-K14807180-001-02-5::2.5::HTS	0.188727437439	BRD-K14807180-001-02-5::2.5::HTS	BRD-K14807180-001-02-5	SB-221284	2.5	HTS	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F	Preclinical	5
BRD-K14870255-001-02-3::2.5::HTS	0.101439193414	BRD-K14870255-001-02-3::2.5::HTS	BRD-K14870255-001-02-3	R-428	2.5	HTS	AXL kinase inhibitor	AXL			Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1	Phase 1	5
BRD-K14880289-001-02-2::2.5::HTS	0.103410422931	BRD-K14880289-001-02-2::2.5::HTS	BRD-K14880289-001-02-2	GW-501516	2.5	HTS	PPAR receptor agonist	PPARA, PPARD			Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F	Phase 2	5
BRD-K14920963-304-02-7::2.5::HTS	0.224189414056	BRD-K14920963-304-02-7::2.5::HTS	BRD-K14920963-304-02-7	erythrosine	2.5	HTS	coloring agent				OC(=O)c1ccccc1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	Preclinical	5
BRD-K14965640-001-12-4::2.5::HTS	-0.38170861974	BRD-K14965640-001-12-4::2.5::HTS	BRD-K14965640-001-12-4	ibuprofen-(s)	2.5	HTS	cyclooxygenase inhibitor	ASIC1, BCL2, CFTR, FABP2, PLAT, PPARG, PTGS1, PTGS2, SLC5A8, THBD			CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O	Preclinical	5
BRD-K14991967-001-02-6::2.5::HTS	0.732323189492	BRD-K14991967-001-02-6::2.5::HTS	BRD-K14991967-001-02-6	GSK650394	2.5	HTS	serum/glucocorticoid regulated kinase inhibitor	SGK1, SGK2			OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1	Preclinical	5
BRD-K14993104-001-05-9::2.5::HTS	0.0418387150701	BRD-K14993104-001-05-9::2.5::HTS	BRD-K14993104-001-05-9	bemegride	2.5	HTS	chemoreceptor agonist	GABRA1	critical care	poison antidote	CCC1(C)CC(=O)NC(=O)C1	Launched	5
BRD-K15010214-364-02-7::2.5::HTS	-0.524016386587	BRD-K15010214-364-02-7::2.5::HTS	BRD-K15010214-364-02-7	emedastine	2.5	HTS	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1, CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1	Launched	5
BRD-K15025317-001-15-1::2.5::HTS	-0.8993217070139999	BRD-K15025317-001-15-1::2.5::HTS	BRD-K15025317-001-15-1	BAY-11-7082	2.5	HTS	NFkB pathway inhibitor	RELA			Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N	Preclinical	5
BRD-K15045219-001-01-8::2.5::HTS	-0.05721536706830001	BRD-K15045219-001-01-8::2.5::HTS	BRD-K15045219-001-01-8	salazodine	2.5	HTS					COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1	Phase 2	5
BRD-K15071410-001-01-1::2.5::HTS	-0.260132485595	BRD-K15071410-001-01-1::2.5::HTS	BRD-K15071410-001-01-1	tiotidine	2.5	HTS	histamine receptor antagonist	HRH2			CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N	Phase 2	5
BRD-K15086322-050-01-3::2.5::HTS	-0.163355540736	BRD-K15086322-050-01-3::2.5::HTS	BRD-K15086322-050-01-3	JNJ-10191584	2.5	HTS	histamine receptor antagonist	HRH4			CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1	Preclinical	5
BRD-K15108141-001-06-6::2.5::HTS	-1.28862792105	BRD-K15108141-001-06-6::2.5::HTS	BRD-K15108141-001-06-6	gemcitabine	2.5	HTS	ribonucleotide reductase inhibitor	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	Launched	5
BRD-K15164005-001-05-6::2.5::HTS	0.20942870408599998	BRD-K15164005-001-05-6::2.5::HTS	BRD-K15164005-001-05-6	apoptosis-activator-II	2.5	HTS	carboxylesterase inhibitor	BCHE, CES1			Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	Preclinical	5
BRD-K15170068-001-03-2::2.89::HTS	0.0505185307187	BRD-K15170068-001-03-2::2.89::HTS	BRD-K15170068-001-03-2	swainsonine	2.89	HTS	alpha mannosidase inhibitor	MAN2A1			O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O	Phase 2	5
BRD-K15179513-001-03-4::2.5::HTS	-0.161380074064	BRD-K15179513-001-03-4::2.5::HTS	BRD-K15179513-001-03-4	NVP-ADW742	2.5	HTS	insulin growth factor receptor inhibitor	IGF1R			Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1	Preclinical	5
BRD-K15179879-001-03-2::2.5::HTS	-2.6891611385000003	BRD-K15179879-001-03-2::2.5::HTS	BRD-K15179879-001-03-2	carfilzomib	2.5	HTS	proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	Launched	5
BRD-K15196155-001-02-3::2.5::HTS	0.303429675279	BRD-K15196155-001-02-3::2.5::HTS	BRD-K15196155-001-02-3	IBC-293	2.5	HTS	hydroxycarboxylic acid receptor agonist	HCAR3			CC(C)n1nnc2cc(ccc12)C(O)=O	Preclinical	5
BRD-K15231341-001-01-5::2.5::HTS	0.24428171474	BRD-K15231341-001-01-5::2.5::HTS	BRD-K15231341-001-01-5	hemomex-s	2.5	HTS		PPARG			CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C	Launched	5
BRD-K15318383-201-01-5::2.5::HTS	0.062530238616	BRD-K15318383-201-01-5::2.5::HTS	BRD-K15318383-201-01-5	ammonium-glycyrrhizinate	2.5	HTS	thrombin inhibitor	HSD11B1, HSD11B2, SLCO1B1, SLCO1B3	dermatology	cosmetic	C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@]4(C)CC[C@H](O[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)C(O)=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O, C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@]4(C)CC[C@H](O[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)C(O)=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O	Launched	5
BRD-K15318909-001-10-5::2.5::HTS	0.279438594969	BRD-K15318909-001-10-5::2.5::HTS	BRD-K15318909-001-10-5	PRIMA1	2.5	HTS	TP53 inhibitor	ACHE			OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O	Preclinical	5
BRD-K15337272-001-01-3::2.5::HTS	-0.233432638676	BRD-K15337272-001-01-3::2.5::HTS	BRD-K15337272-001-01-3	C-751	2.5	HTS					CCOC(=O)c1c[nH]cn1	Preclinical	5
BRD-K15409150-001-05-8::2.5::HTS	-0.48102584121200004	BRD-K15409150-001-05-8::2.5::HTS	BRD-K15409150-001-05-8	penfluridol	2.5	HTS	T-type calcium channel blocker	CACNA1G	neurology/psychiatry	schizophrenia	OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F	Launched	5
BRD-K15424032-001-03-6::2.5::HTS	0.601580327567	BRD-K15424032-001-03-6::2.5::HTS	BRD-K15424032-001-03-6	SB-228357	2.5	HTS	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F	Preclinical	5
BRD-K15426076-001-01-2::2.5::HTS	0.349258721017	BRD-K15426076-001-01-2::2.5::HTS	BRD-K15426076-001-01-2	iguratimod	2.5	HTS	cyclooxygenase inhibitor, NFkB pathway inhibitor	PTGS2	rheumatology	rheumatoid arthritis	CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1	Launched	5
BRD-K15502390-001-20-9::2.5::HTS	-0.357245890344	BRD-K15502390-001-20-9::2.5::HTS	BRD-K15502390-001-20-9	nevirapine	2.5	HTS	non-nucleoside reverse transcriptase inhibitor	CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5	infectious disease	human immunodeficiency virus (HIV-1)	Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1, Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1	Launched	5
BRD-K15507868-001-03-7::2.5::HTS	-0.049301877203800006	BRD-K15507868-001-03-7::2.5::HTS	BRD-K15507868-001-03-7	tesaglitazar	2.5	HTS	insulin sensitizer, PPAR receptor agonist	PPARA, PPARG			CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O	Phase 3	5
BRD-K15519488-050-01-3::2.5::HTS	0.459812852866	BRD-K15519488-050-01-3::2.5::HTS	BRD-K15519488-050-01-3	CS-110266	2.5	HTS	dopamine receptor agonist	SLC6A3			C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1	Preclinical	5
BRD-K15563106-001-18-0::2.5::HTS	0.00731553649778	BRD-K15563106-001-18-0::2.5::HTS	BRD-K15563106-001-18-0	phloretin	2.5	HTS	sodium/glucose cotransporter inhibitor	AQP9, CLCN3, SLC23A1			Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1	Launched	5
BRD-K15567136-003-27-2::2.5::HTS	-0.448573757444	BRD-K15567136-003-27-2::2.5::HTS	BRD-K15567136-003-27-2	papaverine	2.5	HTS	phosphodiesterase inhibitor	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC	Launched	5
BRD-K15588452-003-02-7::2.5::HTS	-0.759791713216	BRD-K15588452-003-02-7::2.5::HTS	BRD-K15588452-003-02-7	R-96544	2.5	HTS	serotonin receptor antagonist	HTR2A			COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1	Preclinical	5
BRD-K15600710-066-04-1::2.5::HTS	-4.839031219690001	BRD-K15600710-066-04-1::2.5::HTS	BRD-K15600710-066-04-1	obatoclax	2.5	HTS	BCL inhibitor	BCL2			COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1	Phase 3	5
BRD-K15601958-001-03-9::2.5::HTS	0.130375668267	BRD-K15601958-001-03-9::2.5::HTS	BRD-K15601958-001-03-9	SEW-2871	2.5	HTS	lysophospholipid receptor agonist	S1PR1			FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F	Preclinical	5
BRD-K15697815-001-16-2::2.5::HTS	0.144626560259	BRD-K15697815-001-16-2::2.5::HTS	BRD-K15697815-001-16-2	ursodiol	2.5	HTS	nuclear factor erythroid derived, like (NRF2) activator	NR1H4	gastroenterology	gallstones	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K15766189-001-09-8::2.5::HTS	0.294899430498	BRD-K15766189-001-09-8::2.5::HTS	BRD-K15766189-001-09-8	cefdinir	2.5	HTS	bacterial cell wall synthesis inhibitor	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O	Launched	5
BRD-K15791587-003-02-5::2.5::HTS	-0.053006660651500004	BRD-K15791587-003-02-5::2.5::HTS	BRD-K15791587-003-02-5	L-733060	2.5	HTS	tachykinin antagonist	TACR1			FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F	Preclinical	5
BRD-K15834839-001-02-3::2.5::HTS	0.0850896014301	BRD-K15834839-001-02-3::2.5::HTS	BRD-K15834839-001-02-3	lobendazole	2.5	HTS	anthelmintic agent				CCOC(=O)Nc1nc2ccccc2[nH]1	Preclinical	5
BRD-K15868788-003-07-7::2.5::HTS	0.114392645983	BRD-K15868788-003-07-7::2.5::HTS	BRD-K15868788-003-07-7	SDZ-205-557	2.5	HTS	serotonin receptor antagonist	HTR3A, HTR3B			CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC	Preclinical	5
BRD-K15891719-001-05-1::2.45::HTS	0.13340453141	BRD-K15891719-001-05-1::2.45::HTS	BRD-K15891719-001-05-1	tenofovir	2.45	HTS	HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O	Launched	5
BRD-K15898725-001-01-7::2.5::HTS	-1.29629197692	BRD-K15898725-001-01-7::2.5::HTS	BRD-K15898725-001-01-7	maytansinol-isobutyrate	2.5	HTS					CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2	Preclinical	5
BRD-K15916496-001-27-9::2.5::HTS	-0.122064764538	BRD-K15916496-001-27-9::2.5::HTS	BRD-K15916496-001-27-9	clotrimazole	2.5	HTS	cytochrome P450 inhibitor, imidazoline receptor ligand	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Launched	5
BRD-K15933101-003-06-1::2.5::HTS	-0.050598013107199996	BRD-K15933101-003-06-1::2.5::HTS	BRD-K15933101-003-06-1	ropinirole	2.5	HTS	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12	Launched	5
BRD-K15976406-001-03-3::2.5::HTS	-0.41796094881800006	BRD-K15976406-001-03-3::2.5::HTS	BRD-K15976406-001-03-3	telbivudine	2.5	HTS	DNA polymerase inhibitor	TK2	infectious disease	hepatitis B	Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O	Launched	5
BRD-K16037980-001-01-1::2.5::HTS	-0.040530377341	BRD-K16037980-001-01-1::2.5::HTS	BRD-K16037980-001-01-1	Z160	2.5	HTS	N-type calcium channel blocker	CACNA2D1			O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	Phase 2	5
BRD-K16077845-001-06-1::2.5::HTS	-0.387692322144	BRD-K16077845-001-06-1::2.5::HTS	BRD-K16077845-001-06-1	fentiazac	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1	Launched	5
BRD-K16136380-001-01-7::2.5::HTS	-2.45733299801	BRD-K16136380-001-01-7::2.5::HTS	BRD-K16136380-001-01-7	pyrithione-zinc	2.5	HTS	ATP synthase inhibitor	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	Launched	5
BRD-K16189898-003-03-3::2.5::HTS	1.10201409644	BRD-K16189898-003-03-3::2.5::HTS	BRD-K16189898-003-03-3	CHIR-99021	2.5	HTS	glycogen synthase kinase inhibitor	CDK1, GSK3A, GSK3B, MAPK1			Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl	Preclinical	5
BRD-K16195444-003-26-0::2.5::HTS	-0.6618727248899999	BRD-K16195444-003-26-0::2.5::HTS	BRD-K16195444-003-26-0	oxymetazoline	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C	Launched	5
BRD-K16277217-001-10-9::2.5::HTS	0.0417940934249	BRD-K16277217-001-10-9::2.5::HTS	BRD-K16277217-001-10-9	piperacetazine	2.5	HTS	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	Launched	5
BRD-K16295392-003-01-3::2.5::HTS	-1.0585484299799999	BRD-K16295392-003-01-3::2.5::HTS	BRD-K16295392-003-01-3	atrasentan	2.5	HTS	endothelin receptor antagonist	EDNRA			CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1	Phase 3	5
BRD-K16338837-001-02-6::2.5::HTS	-0.763696784916	BRD-K16338837-001-02-6::2.5::HTS	BRD-K16338837-001-02-6	CCMI	2.5	HTS	acetylcholine receptor allosteric modulator	CHRNA7			Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1	Preclinical	5
BRD-K16444452-001-09-1::2.5::HTS	-0.789402386621	BRD-K16444452-001-09-1::2.5::HTS	BRD-K16444452-001-09-1	ibudilast	2.5	HTS	leukotriene receptor antagonist, phosphodiesterase inhibitor	IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary, neurology/psychiatry	asthma, stroke	CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C	Launched	5
BRD-K16474819-001-09-6::2.5::HTS	0.623619195062	BRD-K16474819-001-09-6::2.5::HTS	BRD-K16474819-001-09-6	metacetamol	2.5	HTS	analgesic agent				CC(=O)Nc1cccc(O)c1	Preclinical	5
BRD-K16478699-001-09-2::2.5::HTS	-0.337705274102	BRD-K16478699-001-09-2::2.5::HTS	BRD-K16478699-001-09-2	PLX-4720	2.5	HTS	RAF inhibitor	BRAF, KDR			CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F	Preclinical	5
BRD-K16484091-001-01-1::2.5::HTS	0.146073925217	BRD-K16484091-001-01-1::2.5::HTS	BRD-K16484091-001-01-1	metocurine	2.5	HTS	acetylcholine receptor antagonist	CHRM2, CHRNA2	neurology/psychiatry	muscle relaxant	COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3	Launched	5
BRD-K16485616-001-08-9::2.5::HTS	-4.6291077316800004	BRD-K16485616-001-08-9::2.5::HTS	BRD-K16485616-001-08-9	mocetinostat	2.5	HTS	HDAC inhibitor	HDAC1, HDAC11, HDAC2, HDAC3			Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1	Phase 2	5
BRD-K16508793-001-05-9::2.5::HTS	-0.160290763912	BRD-K16508793-001-05-9::2.5::HTS	BRD-K16508793-001-05-9	diazepam	2.5	HTS	benzodiazepine receptor agonist	ADRA1A, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO	neurology/psychiatry	generalized anxiety disorder (GAD), abstinence from alcohol, hallucinosis, tremors	CN1c2ccc(Cl)cc2C(=NCC1=O)c1ccccc1	Launched	5
BRD-K16542329-001-13-5::2.5::HTS	-0.20426738739300002	BRD-K16542329-001-13-5::2.5::HTS	BRD-K16542329-001-13-5	zaprinast	2.5	HTS	phosphodiesterase inhibitor	GPR35, PDE1A, PDE4D, PDE5A, PDE9A			CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1, CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1, CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1	Phase 2	5
BRD-K16551357-001-03-2::2.5::HTS	-0.0231600019967	BRD-K16551357-001-03-2::2.5::HTS	BRD-K16551357-001-03-2	evacetrapib	2.5	HTS	cholesteryl ester transfer protein inhibitor	CETP			Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1	Phase 3	5
BRD-K16551401-003-03-4::2.5::HTS	-0.34777275145900005	BRD-K16551401-003-03-4::2.5::HTS	BRD-K16551401-003-03-4	PNU-22394	2.5	HTS	serotonin receptor agonist	HTR2A, HTR2B, HTR2C, MAOA, MAOB			Cn1c2CCNCCc2c2ccccc12	Phase 2	5
BRD-K16664969-001-03-3::2.5::HTS	-0.0191593091251	BRD-K16664969-001-03-3::2.5::HTS	BRD-K16664969-001-03-3	GTP-14564	2.5	HTS	FLT3 inhibitor, tyrosine kinase inhibitor	CSF1R, FLT3, KIT, PDGFRB			c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21	Preclinical	5
BRD-K16730910-001-07-3::2.5::HTS	-0.0373438125134	BRD-K16730910-001-07-3::2.5::HTS	BRD-K16730910-001-07-3	regorafenib	2.5	HTS	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1	Launched	5
BRD-K16732600-001-01-7::2.5::HTS	0.223735266425	BRD-K16732600-001-01-7::2.5::HTS	BRD-K16732600-001-01-7	MK-0893	2.5	HTS	glucagon receptor antagonist	GCGR			COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1	Phase 2	5
BRD-K16757695-050-02-5::2.5::HTS	0.434628228786	BRD-K16757695-050-02-5::2.5::HTS	BRD-K16757695-050-02-5	PRX-08066	2.5	HTS	serotonin receptor antagonist	HTR2B			Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N	Phase 2	5
BRD-K16758059-001-01-8::2.5::HTS	-0.20773226410300002	BRD-K16758059-001-01-8::2.5::HTS	BRD-K16758059-001-01-8	perfluamine	2.5	HTS					FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F	Launched	5
BRD-K16761703-001-03-8::2.5::HTS	-0.69915146867	BRD-K16761703-001-03-8::2.5::HTS	BRD-K16761703-001-03-8	sotrastaurin	2.5	HTS	PKC inhibitor	PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ			CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1	Phase 2	5
BRD-K16803204-001-01-6::2.5::HTS	-0.634893497686	BRD-K16803204-001-01-6::2.5::HTS	BRD-K16803204-001-01-6	filgotinib	2.5	HTS	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	Phase 2	5
BRD-K16810791-001-01-0::2.5::HTS	-0.47593545748599997	BRD-K16810791-001-01-0::2.5::HTS	BRD-K16810791-001-01-0	LGK-974	2.5	HTS	porcupine inhibitor	PORCN			Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C	Phase 2	5
BRD-K16898998-001-01-6::2.5::HTS	-0.767196966697	BRD-K16898998-001-01-6::2.5::HTS	BRD-K16898998-001-01-6	bevirimat-dimeglumine	2.5	HTS	HIV capsid assembly inhibitor				CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	Phase 2	5
BRD-K17008822-303-02-1::2.5::HTS	0.349017757606	BRD-K17008822-303-02-1::2.5::HTS	BRD-K17008822-303-02-1	BD-1008	2.5	HTS	sigma receptor antagonist				CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-K17016787-001-16-7::2.5::HTS	-0.396952655519	BRD-K17016787-001-16-7::2.5::HTS	BRD-K17016787-001-16-7	estriol	2.5	HTS	estrogen receptor agonist	ESR1, ESR2	endocrinology, obstetrics/gynecology, infectious disease	menopause, vaginal atrophy, urinary tract infections	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, CC12CCC3C(CCc4cc(O)ccc34)C1C[C@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O	Launched	5
BRD-K17026858-001-01-2::2.5::HTS	-0.51889777724	BRD-K17026858-001-01-2::2.5::HTS	BRD-K17026858-001-01-2	pibenzimol	2.5	HTS	DNA inhibitor				c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1	Phase 2	5
BRD-K17061841-001-03-5::2.5::HTS	-1.22273492548	BRD-K17061841-001-03-5::2.5::HTS	BRD-K17061841-001-03-5	stattic	2.5	HTS					[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1	Preclinical	5
BRD-K17068645-003-04-2::2.5::HTS	0.35792384766999996	BRD-K17068645-003-04-2::2.5::HTS	BRD-K17068645-003-04-2	bendamustine	2.5	HTS	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)	Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl	Launched	5
BRD-K17075857-001-17-6::2.5::HTS	0.42804435868100005	BRD-K17075857-001-17-6::2.5::HTS	BRD-K17075857-001-17-6	chloroxine	2.5	HTS	opioid receptor antagonist	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12	Launched	5
BRD-K17075857-001-18-4::2.5::HTS	0.4645265307	BRD-K17075857-001-18-4::2.5::HTS	BRD-K17075857-001-18-4	chloroxine	2.5	HTS	opioid receptor antagonist	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12	Launched	5
BRD-K17203476-001-01-9::2.5::HTS	-2.0665124348	BRD-K17203476-001-01-9::2.5::HTS	BRD-K17203476-001-01-9	LY2874455	2.5	HTS	FGFR antagonist	FGFR1, FGFR2, FGFR3, FGFR4, KDR			C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl	Phase 1	5
BRD-K17205817-001-06-1::2.5::HTS	0.25648048656100003	BRD-K17205817-001-06-1::2.5::HTS	BRD-K17205817-001-06-1	sulfametopyrazine	2.5	HTS	PABA antagonist		infectious disease	malaria, urinary tract infections, respiratory tract infections	COc1nccnc1NS(=O)(=O)c1ccc(N)cc1	Launched	5
BRD-K17223896-001-10-0::2.5::HTS	0.555009124293	BRD-K17223896-001-10-0::2.5::HTS	BRD-K17223896-001-10-0	chloroxylenol	2.5	HTS	ATP synthase inhibitor		infectious disease	skin infections	Cc1cc(O)cc(C)c1Cl	Launched	5
BRD-K17294426-050-12-3::2.5::HTS	-0.32676811663800004	BRD-K17294426-050-12-3::2.5::HTS	BRD-K17294426-050-12-3	clebopride	2.5	HTS	dopamine receptor antagonist	ACHE, DRD2	gastroenterology	nausea	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1	Launched	5
BRD-K17368287-001-18-3::2.5::HTS	-0.765286566493	BRD-K17368287-001-18-3::2.5::HTS	BRD-K17368287-001-18-3	adrenosterone	2.5	HTS	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1, HSD11B2			C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical	5
BRD-K17378184-300-05-9::2.5::HTS	0.528818328402	BRD-K17378184-300-05-9::2.5::HTS	BRD-K17378184-300-05-9	BP-897	2.5	HTS	dopamine receptor agonist	ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B			COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1	Phase 2	5
BRD-K17415526-001-03-5::2.5::HTS	0.199281563197	BRD-K17415526-001-03-5::2.5::HTS	BRD-K17415526-001-03-5	tyrphostin-AG-835	2.5	HTS	protein tyrosine kinase inhibitor	EGFR			C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1	Preclinical	5
BRD-K17443395-065-02-2::2.5::HTS	0.121625367036	BRD-K17443395-065-02-2::2.5::HTS	BRD-K17443395-065-02-2	abacavir	2.5	HTS	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1	Launched	5
BRD-K17497770-001-03-6::2.5::HTS	0.530540182544	BRD-K17497770-001-03-6::2.5::HTS	BRD-K17497770-001-03-6	butein	2.5	HTS	EGFR inhibitor, src inhibitor	ACE			Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1	Preclinical	5
BRD-K17498618-344-02-6::2.5::HTS	-0.8503194861869999	BRD-K17498618-344-02-6::2.5::HTS	BRD-K17498618-344-02-6	betaxolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC	Launched	5
BRD-K17500877-001-02-1::2.5::HTS	-0.349940298385	BRD-K17500877-001-02-1::2.5::HTS	BRD-K17500877-001-02-1	bropirimine	2.5	HTS	interferon inducer				Nc1nc(-c2ccccc2)c(Br)c(=O)[nH]1	Phase 3	5
BRD-K17513304-001-01-9::2.5::HTS	0.186020548359	BRD-K17513304-001-01-9::2.5::HTS	BRD-K17513304-001-01-9	firategrast	2.5	HTS	integrin antagonist	ITGA4			CCOCc1cc(OC)c(-c2ccc(C[C@H](NC(=O)c3c(F)cccc3F)C(O)=O)cc2)c(OC)c1	Phase 2	5
BRD-K17518951-001-03-0::2.5::HTS	-0.05124993471480001	BRD-K17518951-001-03-0::2.5::HTS	BRD-K17518951-001-03-0	penicillamine-(D)	2.5	HTS	chelating agent		metabolism, rheumatology, nephrology	Wilson's disease, rheumatoid arthritis, cystinuria	CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O	Launched	5
BRD-K17555800-003-01-5::2.5::HTS	-0.015771893670299998	BRD-K17555800-003-01-5::2.5::HTS	BRD-K17555800-003-01-5	talmapimod	2.5	HTS	p38 MAPK inhibitor	MAPK11, MAPK14			C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C	Phase 2	5
BRD-K17561142-003-32-5::2.5::HTS	0.494427092476	BRD-K17561142-003-32-5::2.5::HTS	BRD-K17561142-003-32-5	amiodarone	2.5	HTS	potassium channel blocker	ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2	cardiology	ventricular arrhythmias	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1	Launched	5
BRD-K17565903-066-23-1::2.5::HTS	-0.0540715173786	BRD-K17565903-066-23-1::2.5::HTS	BRD-K17565903-066-23-1	pridinol	2.5	HTS	muscle relaxant		neurology/psychiatry	muscle relaxant	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	Launched	5
BRD-K17702546-001-03-2::2.5::HTS	0.344643709168	BRD-K17702546-001-03-2::2.5::HTS	BRD-K17702546-001-03-2	PD-168393	2.5	HTS	EGFR inhibitor	EGFR, ERBB2, SRC			Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1	Preclinical	5
BRD-K17705806-003-04-4::2.5::HTS	0.884553555987	BRD-K17705806-003-04-4::2.5::HTS	BRD-K17705806-003-04-4	JTC-801	2.5	HTS	opioid receptor antagonist	OPRL1			CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1	Phase 2	5
BRD-K17743125-001-08-4::2.5::HTS	-3.6379943667300005	BRD-K17743125-001-08-4::2.5::HTS	BRD-K17743125-001-08-4	belinostat	2.5	HTS	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1	Launched	5
BRD-K17743697-066-03-6::2.5::HTS	-0.125450754541	BRD-K17743697-066-03-6::2.5::HTS	BRD-K17743697-066-03-6	KB-R7943	2.5	HTS	sodium/calcium exchange inhibitor	SLC8A1, TRPC3, TRPC5, TRPC6			NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1	Preclinical	5
BRD-K17774839-001-02-9::2.5::HTS	-0.08808081613919999	BRD-K17774839-001-02-9::2.5::HTS	BRD-K17774839-001-02-9	JNJ-7777120	2.5	HTS	histamine receptor antagonist	HRH4			CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical	5
BRD-K17849083-001-31-1::2.5::HTS	0.0735095096576	BRD-K17849083-001-31-1::2.5::HTS	BRD-K17849083-001-31-1	tranilast	2.5	HTS	angiogenesis inhibitor	HPGDS, HRH1	pulmonary	asthma	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	Launched	5
BRD-K17849083-001-32-9::2.43::HTS	0.100796648311	BRD-K17849083-001-32-9::2.43::HTS	BRD-K17849083-001-32-9	tranilast	2.43	HTS	angiogenesis inhibitor	HPGDS, HRH1	pulmonary	asthma	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	Launched	5
BRD-K17850764-236-11-9::2.5::HTS	-0.620712493853	BRD-K17850764-236-11-9::2.5::HTS	BRD-K17850764-236-11-9	cloprostenol-(+/-)	2.5	HTS	prostaglandin receptor agonist	PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R			O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	Launched	5
BRD-K17868609-001-05-0::2.5::HTS	0.298899625011	BRD-K17868609-001-05-0::2.5::HTS	BRD-K17868609-001-05-0	BRL-54443	2.5	HTS	serotonin receptor agonist	HTR1E, HTR1F			CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12	Preclinical	5
BRD-K17874705-300-03-2::2.5::HTS	-0.747298807711	BRD-K17874705-300-03-2::2.5::HTS	BRD-K17874705-300-03-2	2-pyridylethylamine	2.5	HTS	histamine receptor agonist	HRH1			NCCc1ccccn1, NCCc1ccccn1	Preclinical	5
BRD-K17894950-001-14-3::2.5::HTS	0.305681839954	BRD-K17894950-001-14-3::2.5::HTS	BRD-K17894950-001-14-3	indirubin	2.5	HTS	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3A			O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O	Phase 2/Phase 3	5
BRD-K17953908-001-01-7::2.5::HTS	-0.117232716032	BRD-K17953908-001-01-7::2.5::HTS	BRD-K17953908-001-01-7	LY2886721	2.5	HTS	beta-secretase inhibitor	BACE1			NC1=N[C@]2(COC[C@@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F	Phase 1/Phase 2	5
BRD-K17977438-048-02-4::2.5::HTS	0.301327292936	BRD-K17977438-048-02-4::2.5::HTS	BRD-K17977438-048-02-4	oxelaidin	2.5	HTS	antitussive		pulmonary	cough suppressant	CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1	Launched	5
BRD-K17979676-001-01-2::2.5::HTS	0.22189573183699998	BRD-K17979676-001-01-2::2.5::HTS	BRD-K17979676-001-01-2	eprobemide	2.5	HTS	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	Clc1ccc(cc1)C(=O)NCCCN1CCOCC1	Launched	5
BRD-K18036262-001-02-8::2.5::HTS	0.06524007658509999	BRD-K18036262-001-02-8::2.5::HTS	BRD-K18036262-001-02-8	L-168049	2.5	HTS	glucagon receptor antagonist	GCGR			CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1	Preclinical	5
BRD-K18059238-001-10-4::0.25::HTS	0.07602143944	BRD-K18059238-001-10-4::0.25::HTS	BRD-K18059238-001-10-4	gamma-linolenic-acid	0.25	HTS	cyclooxygenase inhibitor, prostanoid receptor agonist	PTGS1, PTGS2			CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O	Phase 2	3
BRD-K18131774-001-17-6::2.5::HTS	0.305301946011	BRD-K18131774-001-17-6::2.5::HTS	BRD-K18131774-001-17-6	ethoxzolamide	2.5	HTS	carbonic anhydrase inhibitor	CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9	ophthalmology, gastroenterology	glaucoma, duodenal ulcer disease	CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O	Launched	5
BRD-K18135438-001-16-7::2.5::HTS	0.256617585511	BRD-K18135438-001-16-7::2.5::HTS	BRD-K18135438-001-16-7	chenodeoxycholic-acid	2.5	HTS	11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist	HSD11B1, NR1H4	cardiology, gastroenterology	cerebral cholesterosis, gallstones	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K18157228-001-01-7::2.5::HTS	-3.2145013045099997	BRD-K18157228-001-01-7::2.5::HTS	BRD-K18157228-001-01-7	fdcyd	2.5	HTS	DNA methyltransferase inhibitor				Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1	Phase 2	5
BRD-K18163608-001-05-6::2.48::HTS	0.610256522771	BRD-K18163608-001-05-6::2.48::HTS	BRD-K18163608-001-05-6	HA14-1	2.48	HTS	BCL inhibitor	BCL2			CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC	Preclinical	5
BRD-K18172896-001-02-5::2.5::HTS	-0.236139409093	BRD-K18172896-001-02-5::2.5::HTS	BRD-K18172896-001-02-5	eltanolone	2.5	HTS	membrane integrity inhibitor	GABRA1, GABRB2, GABRG2			CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 3	5
BRD-K18194590-065-08-0::2.5::HTS	0.116777099821	BRD-K18194590-065-08-0::2.5::HTS	BRD-K18194590-065-08-0	mephentermine	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3	cardiology	hypotension	CNC(C)(C)Cc1ccccc1	Launched	5
BRD-K18250272-003-11-0::2.5::HTS	-0.126945831898	BRD-K18250272-003-11-0::2.5::HTS	BRD-K18250272-003-11-0	propoxycaine	2.5	HTS	local anesthetic		neurology/psychiatry	anesthetic	CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC	Launched	5
BRD-K18316707-001-02-7::2.5::HTS	-0.17345508426399997	BRD-K18316707-001-02-7::2.5::HTS	BRD-K18316707-001-02-7	O-1918	2.5	HTS	cannabinoid receptor antagonist				COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C	Preclinical	5
BRD-K18323388-001-01-1::2.5::HTS	-0.0651492814685	BRD-K18323388-001-01-1::2.5::HTS	BRD-K18323388-001-01-1	uridine-triacetate	2.5	HTS			nephrology	orotic aciduria	CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O	Launched	5
BRD-K18324993-001-01-6::2.5::HTS	0.267356438277	BRD-K18324993-001-01-6::2.5::HTS	BRD-K18324993-001-01-6	budipine	2.5	HTS	glutamate receptor antagonist	GRIN1	neurology/psychiatry	Parkinson's Disease	CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1	Launched	5
BRD-K18375018-376-02-3::2.5::HTS	0.28960256633000003	BRD-K18375018-376-02-3::2.5::HTS	BRD-K18375018-376-02-3	spermine	2.5	HTS		CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5			NCCCNCCCCNCCCN	Preclinical	5
BRD-K18424115-003-01-3::2.5::HTS	0.6027640490380001	BRD-K18424115-003-01-3::2.5::HTS	BRD-K18424115-003-01-3	TG-100572	2.5	HTS	src inhibitor, VEGFR inhibitor	KDR, SRC			Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl	Preclinical	5
BRD-K18518344-001-15-9::2.5::HTS	-5.44814259281	BRD-K18518344-001-15-9::2.5::HTS	BRD-K18518344-001-15-9	digitoxigenin	2.5	HTS	ATPase inhibitor	ATP1A1			C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1	Preclinical	5
BRD-K18574842-236-17-7::2.5::HTS	-1.03188899603	BRD-K18574842-236-17-7::2.5::HTS	BRD-K18574842-236-17-7	nafcillin	2.5	HTS	bacterial cell wall synthesis inhibitor	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	Launched	5
BRD-K18574842-323-10-8::2.51::HTS	0.16899236206300003	BRD-K18574842-323-10-8::2.51::HTS	BRD-K18574842-323-10-8	nafcillin	2.51	HTS	bacterial cell wall synthesis inhibitor	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	Launched	5
BRD-K18613660-001-05-5::2.5::HTS	0.0914374005615	BRD-K18613660-001-05-5::2.5::HTS	BRD-K18613660-001-05-5	mexeneone	2.5	HTS					COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1	Preclinical	5
BRD-K18619710-001-14-4::2.5::HTS	-5.04288823627	BRD-K18619710-001-14-4::2.5::HTS	BRD-K18619710-001-14-4	digoxigenin	2.5	HTS	steroid				C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1	Preclinical	5
BRD-K18673820-001-15-5::2.5::HTS	0.202640709104	BRD-K18673820-001-15-5::2.5::HTS	BRD-K18673820-001-15-5	folic-acid	2.5	HTS	folate receptor ligand	FOLR2, FOLR3, SLC19A1, SLC46A1	hematology	megaloblastic anemia	Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1	Launched	5
BRD-K18678457-003-02-8::2.5::HTS	0.08069048898419999	BRD-K18678457-003-02-8::2.5::HTS	BRD-K18678457-003-02-8	ZD-7288	2.5	HTS	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			CCN(c1ccccc1)c1cc(NC)[n+](C)c(C)n1, CCN(c1ccccc1)c1cc(NC)[n+](C)c(C)n1	Phase 2	5
BRD-K18772613-303-02-4::2.5::HTS	0.23819759613400002	BRD-K18772613-303-02-4::2.5::HTS	BRD-K18772613-303-02-4	benzoquinonium-dibromide	2.5	HTS	cholinergic receptor antagonist	CHRNA1			CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1	Preclinical	5
BRD-K18779551-003-07-8::2.5::HTS	0.711863894121	BRD-K18779551-003-07-8::2.5::HTS	BRD-K18779551-003-07-8	bifemelane	2.5	HTS	acetylcholine release enhancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1	Launched	5
BRD-K18787491-001-08-6::2.5::HTS	-0.571412043105	BRD-K18787491-001-08-6::2.5::HTS	BRD-K18787491-001-08-6	U-0126	2.5	HTS	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N	Preclinical	5
BRD-K18834913-001-01-1::2.5::HTS	-0.573914883746	BRD-K18834913-001-01-1::2.5::HTS	BRD-K18834913-001-01-1	LB42708	2.5	HTS	farnesyltransferase inhibitor				Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1	Preclinical	5
BRD-K18849474-001-04-4::2.61::HTS	0.264281516735	BRD-K18849474-001-04-4::2.61::HTS	BRD-K18849474-001-04-4	dalcetrapib	2.61	HTS	cholesteryl ester transfer protein inhibitor	CETP			CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C	Phase 3	5
BRD-K18850819-001-04-6::2.5::HTS	-0.140335135177	BRD-K18850819-001-04-6::2.5::HTS	BRD-K18850819-001-04-6	MK-0752	2.5	HTS	gamma secretase inhibitor				OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1	Phase 1/Phase 2	5
BRD-K18895904-001-16-1::2.5::HTS	0.0923557824212	BRD-K18895904-001-16-1::2.5::HTS	BRD-K18895904-001-16-1	olanzapine	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder	CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12	Launched	5
BRD-K18905250-003-02-4::2.5::HTS	0.270606486028	BRD-K18905250-003-02-4::2.5::HTS	BRD-K18905250-003-02-4	ST-91	2.5	HTS	adrenergic receptor agonist				CCc1cccc(CC)c1N=C1NCCN1, CCc1cccc(CC)c1N=C1NCCN1	Preclinical	5
BRD-K18910433-001-36-6::2.58::HTS	-0.0294567836706	BRD-K18910433-001-36-6::2.58::HTS	BRD-K18910433-001-36-6	estradiol	2.58	HTS	estrogen receptor agonist	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	Launched	5
BRD-K18910433-001-43-2::2.5::HTS	0.862082479575	BRD-K18910433-001-43-2::2.5::HTS	BRD-K18910433-001-43-2	estradiol	2.5	HTS	estrogen receptor agonist	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	Launched	5
BRD-K18922609-004-23-1::2.5::HTS	0.425840786374	BRD-K18922609-004-23-1::2.5::HTS	BRD-K18922609-004-23-1	neostigmine	2.5	HTS	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	Launched	5
BRD-K18948558-001-01-9::2.5::HTS	-0.48534329681599997	BRD-K18948558-001-01-9::2.5::HTS	BRD-K18948558-001-01-9	clevudine	2.5	HTS	DNA polymerase inhibitor		infectious disease	hepatitis B	Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2F)c(=O)[nH]c1=O	Launched	5
BRD-K18961567-001-01-1::2.5::HTS	-1.9579533495700001	BRD-K18961567-001-01-1::2.5::HTS	BRD-K18961567-001-01-1	LY2801653	2.5	HTS	MET inhibitor	MET			Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1	Phase 2	5
BRD-K19034817-001-01-4::2.5::HTS	0.163326180511	BRD-K19034817-001-01-4::2.5::HTS	BRD-K19034817-001-01-4	pacritinib	2.5	HTS	FLT3 inhibitor, JAK inhibitor	FLT3, JAK1, JAK2, JAK3			C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3	Phase 3	5
BRD-K19061412-001-02-4::2.5::HTS	-0.11485683668600001	BRD-K19061412-001-02-4::2.5::HTS	BRD-K19061412-001-02-4	mubritinib	2.5	HTS	protein tyrosine kinase inhibitor	EGFR, ERBB2			FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	Phase 1	5
BRD-K19085898-001-01-8::2.5::HTS	-0.576467522038	BRD-K19085898-001-01-8::2.5::HTS	BRD-K19085898-001-01-8	darapladib	2.5	HTS	phospholipase inhibitor	PLA2G7			CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1	Phase 3	5
BRD-K19111024-001-20-9::2.5::HTS	-0.253136754801	BRD-K19111024-001-20-9::2.5::HTS	BRD-K19111024-001-20-9	clofibric-acid	2.5	HTS	PPAR receptor agonist	PPARA			CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O	Launched	5
BRD-K19136521-001-08-9::2.5::HTS	1.03005668866	BRD-K19136521-001-08-9::2.5::HTS	BRD-K19136521-001-08-9	indirubin-3-monoxime	2.5	HTS	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK2, CDK5, CDK5R1, GSK3B			O\N=C1c2ccccc2NC/1=C1\C(=O)Nc2ccccc12	Preclinical	5
BRD-K19171642-001-02-3::2.5::HTS	0.0124483639245	BRD-K19171642-001-02-3::2.5::HTS	BRD-K19171642-001-02-3	CP-91149	2.5	HTS	glycogen phosphorylase inhibitor	PYGL			CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical	5
BRD-K19180152-001-02-6::2.5::HTS	-0.522565431254	BRD-K19180152-001-02-6::2.5::HTS	BRD-K19180152-001-02-6	meprobamate	2.5	HTS		GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	anxiety	CCCC(C)(COC(N)=O)COC(N)=O	Launched	5
BRD-K19203487-001-01-4::2.5::HTS	-1.01250345082	BRD-K19203487-001-01-4::2.5::HTS	BRD-K19203487-001-01-4	SPP301	2.5	HTS	endothelin receptor antagonist	EDNRA			COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1	Phase 3	5
BRD-K19227686-001-18-6::2.5::HTS	-0.264350901772	BRD-K19227686-001-18-6::2.5::HTS	BRD-K19227686-001-18-6	phenolphthalein	2.5	HTS	indicator dye	UGT1A9			Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1	Withdrawn	5
BRD-K19284129-001-02-6::2.5::HTS	-0.35332630648	BRD-K19284129-001-02-6::2.5::HTS	BRD-K19284129-001-02-6	salvinorin-a	2.5	HTS	opioid receptor agonist	OPRD1, OPRK1, OPRM1			COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1	Phase 1	5
BRD-K19295594-015-14-3::2.29::HTS	-2.45303257686	BRD-K19295594-015-14-3::2.29::HTS	BRD-K19295594-015-14-3	gossypol	2.29	HTS	BCL inhibitor, MCL1 inhibitor	BCL2			CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	Phase 2	5
BRD-K19309090-300-05-5::2.5::HTS	-0.38206434345299994	BRD-K19309090-300-05-5::2.5::HTS	BRD-K19309090-300-05-5	SR-95639A	2.5	HTS	acetylcholine receptor agonist	CHRM1			C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1	Preclinical	5
BRD-K19318328-001-01-3::2.5::HTS		BRD-K19318328-001-01-3::2.5::HTS	BRD-K19318328-001-01-3	FR-139317	2.5	HTS	endothelin receptor antagonist	EDNRA			CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O	Phase 1	5
BRD-K19333160-001-01-3::2.5::HTS	0.423629598467	BRD-K19333160-001-01-3::2.5::HTS	BRD-K19333160-001-01-3	RKI-1447	2.5	HTS	rho associated kinase inhibitor	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2			Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1	Preclinical	5
BRD-K19352500-070-12-4::2.5::HTS	0.143826577359	BRD-K19352500-070-12-4::2.5::HTS	BRD-K19352500-070-12-4	prochlorperazine	2.5	HTS	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4	gastroenterology	nausea, vomiting	CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched	5
BRD-K19388745-003-01-7::2.5::HTS	-0.122352937508	BRD-K19388745-003-01-7::2.5::HTS	BRD-K19388745-003-01-7	colforsin-daproate	2.5	HTS	adenylyl cyclase activator				CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C	Launched	5
BRD-K19412355-001-01-0::2.5::HTS	0.176014539434	BRD-K19412355-001-01-0::2.5::HTS	BRD-K19412355-001-01-0	SB-242235	2.5	HTS	p38 MAPK inhibitor	HSPB1, MAPK14			COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1	Phase 1	5
BRD-K19416115-001-05-3::2.5::HTS	-0.101610651756	BRD-K19416115-001-05-3::2.5::HTS	BRD-K19416115-001-05-3	sitagliptin	2.5	HTS	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F	Launched	5
BRD-K19438463-001-05-5::2.5::HTS	-0.359372040814	BRD-K19438463-001-05-5::2.5::HTS	BRD-K19438463-001-05-5	CNQX	2.5	HTS	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N	Phase 1	5
BRD-K19456237-001-27-6::2.5::HTS	0.24820741771899998	BRD-K19456237-001-27-6::2.5::HTS	BRD-K19456237-001-27-6	piracetam	2.5	HTS	acetylcholine receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4	neurology/psychiatry	senile dementia	NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O	Launched	5
BRD-K19462402-003-24-6::2.5::HTS	0.1532486914	BRD-K19462402-003-24-6::2.5::HTS	BRD-K19462402-003-24-6	buflomedil	2.5	HTS	adrenergic receptor antagonist, calcium channel blocker	ADRA1A	cardiology	peripheral artery disease (PAD)	COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1	Launched	5
BRD-K19477839-001-07-6::2.5::HTS	-0.0233612136484	BRD-K19477839-001-07-6::2.5::HTS	BRD-K19477839-001-07-6	SGX523	2.5	HTS	hepatocyte growth factor receptor inhibitor	MET			Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1	Phase 1	5
BRD-K19507340-001-22-1::2.38::HTS	0.286150341367	BRD-K19507340-001-22-1::2.38::HTS	BRD-K19507340-001-22-1	megestrol-acetate	2.38	HTS	progesterone receptor agonist	NR3C1, PGR	neurology/psychiatry, endocrinology	anorexia, cachexia	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC12C)C(C)=O	Launched	5
BRD-K19540840-001-09-4::2.5::HTS	0.560228750536	BRD-K19540840-001-09-4::2.5::HTS	BRD-K19540840-001-09-4	saracatinib	2.5	HTS	src inhibitor	ABL1, LCK, SRC, YES1			CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1	Phase 2/Phase 3	5
BRD-K19601669-001-03-5::2.5::HTS	-0.477357312732	BRD-K19601669-001-03-5::2.5::HTS	BRD-K19601669-001-03-5	ruxolitinib-(S)	2.5	HTS	JAK inhibitor	JAK1, JAK2			N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	Preclinical	5
BRD-K19605405-001-02-7::2.5::HTS	0.5320240937430001	BRD-K19605405-001-02-7::2.5::HTS	BRD-K19605405-001-02-7	ZM-241385	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1	Preclinical	5
BRD-K19615002-001-02-3::2.5::HTS	-0.158405005996	BRD-K19615002-001-02-3::2.5::HTS	BRD-K19615002-001-02-3	creatine	2.5	HTS		CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8			CN(CC(O)=O)C(N)=N	Launched	5
BRD-K19655798-001-01-9::2.5::HTS	-0.0787052412958	BRD-K19655798-001-01-9::2.5::HTS	BRD-K19655798-001-01-9	compound-401	2.5	HTS	DNA dependent protein kinase inhibitor	MTOR, PRKDC			O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1	Preclinical	5
BRD-K19669037-001-01-1::2.5::HTS	-0.229355114904	BRD-K19669037-001-01-1::2.5::HTS	BRD-K19669037-001-01-1	GGTI-298	2.5	HTS	GGTase inhibitor	CDKN1A			COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12	Preclinical	5
BRD-K19672466-001-02-3::2.5::HTS	0.173098614139	BRD-K19672466-001-02-3::2.5::HTS	BRD-K19672466-001-02-3	ethimizol	2.5	HTS					CCn1cnc(C(=O)NC)c1C(=O)NC	Phase 1	5
BRD-K19687926-379-07-4::2.5::HTS	0.579110811445	BRD-K19687926-379-07-4::2.5::HTS	BRD-K19687926-379-07-4	lapatinib	2.5	HTS	EGFR inhibitor	EGFR, ERBB2	oncology	breast cancer	CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	Launched	5
BRD-K19741547-003-01-7::2.5::HTS	-0.07272192417880001	BRD-K19741547-003-01-7::2.5::HTS	BRD-K19741547-003-01-7	vernakalant	2.5	HTS	potassium channel blocker	KCNA5	cardiology	atrial fibrillation (AF)	COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC	Launched	5
BRD-K19761926-001-02-8::2.5::HTS	0.27912676101399997	BRD-K19761926-001-02-8::2.5::HTS	BRD-K19761926-001-02-8	eplerenone	2.5	HTS	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure, hypertension	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13	Launched	5
BRD-K19761926-001-03-6::2.45::HTS	0.0275032873953	BRD-K19761926-001-03-6::2.45::HTS	BRD-K19761926-001-03-6	eplerenone	2.45	HTS	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure, hypertension	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13	Launched	5
BRD-K19796430-001-05-6::2.5::HTS	-0.25810497611600003	BRD-K19796430-001-05-6::2.5::HTS	BRD-K19796430-001-05-6	sonidegib	2.5	HTS	smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1	Launched	5
BRD-K19939891-001-05-4::2.5::HTS	0.0853069857473	BRD-K19939891-001-05-4::2.5::HTS	BRD-K19939891-001-05-4	TIC10	2.5	HTS	AKT inhibitor, TRAIL modulator	AKT1, MAPK1			Cc1ccccc1CN1CC2=C(CCN(Cc3ccccc3)C2=O)N2CCN=C12, Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2	Phase 2	5
BRD-K19972289-001-01-4::2.5::HTS	0.18259375248	BRD-K19972289-001-01-4::2.5::HTS	BRD-K19972289-001-01-4	octinoxate	2.5	HTS			dermatology	sunscreen lotion	CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1	Launched	5
BRD-K20001883-001-02-7::2.5::HTS	0.7575603800249999	BRD-K20001883-001-02-7::2.5::HTS	BRD-K20001883-001-02-7	apabetalone	2.5	HTS	apolipoprotein expression enhancer	BRD3			COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1	Phase 3	5
BRD-K20008181-001-01-3::2.5::HTS	-0.580063906872	BRD-K20008181-001-01-3::2.5::HTS	BRD-K20008181-001-01-3	LCQ908	2.5	HTS	diacylglycerol O acyltransferase inhibitor	DGAT1			OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1	Phase 3	5
BRD-K20013301-001-02-6::2.5::HTS	0.649467174388	BRD-K20013301-001-02-6::2.5::HTS	BRD-K20013301-001-02-6	LY411575	2.5	HTS	gamma secretase inhibitor				C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	Preclinical	5
BRD-K20075662-300-04-0::2.5::HTS	-0.0839149476664	BRD-K20075662-300-04-0::2.5::HTS	BRD-K20075662-300-04-0	betazole	2.5	HTS	histamine receptor agonist	HRH2	gastroenterology	gastric hypersecretion diagnostic	NCCc1cc[nH]n1	Launched	5
BRD-K20079257-001-09-6::2.5::HTS	-0.233408786818	BRD-K20079257-001-09-6::2.5::HTS	BRD-K20079257-001-09-6	rufinamide	2.5	HTS	voltage-gated sodium channel blocker	GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	NC(=O)c1cn(Cc2c(F)cccc2F)nn1	Launched	5
BRD-K20141153-003-13-7::2.5::HTS	0.283646569119	BRD-K20141153-003-13-7::2.5::HTS	BRD-K20141153-003-13-7	atomoxetine	2.5	HTS	norepinephrine transporter inhibitor	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1	Launched	5
BRD-K20152659-001-04-6::2.5::HTS	-0.025173463391400003	BRD-K20152659-001-04-6::2.5::HTS	BRD-K20152659-001-04-6	dihomo-gamma-linolenic-acid	2.5	HTS	prostanoid receptor agonist	PTGS1, PTGS2			CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O	Phase 2	5
BRD-K20168442-004-06-3::2.5::HTS	-0.013705114776000001	BRD-K20168442-004-06-3::2.5::HTS	BRD-K20168442-004-06-3	vecuronium	2.5	HTS	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry	muscle relaxant	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	Launched	5
BRD-K20285085-001-07-1::2.5::HTS	-0.304289669097	BRD-K20285085-001-07-1::2.5::HTS	BRD-K20285085-001-07-1	R406	2.5	HTS	SYK inhibitor	RET, SYK			COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC	Phase 1	5
BRD-K20285085-074-04-5::2.5::HTS	0.289799318127	BRD-K20285085-074-04-5::2.5::HTS	BRD-K20285085-074-04-5	R406	2.5	HTS	SYK inhibitor	RET, SYK			COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC	Phase 1	5
BRD-K20290250-001-01-3::2.5::HTS	-0.7770935968420001	BRD-K20290250-001-01-3::2.5::HTS	BRD-K20290250-001-01-3	BIX-02188	2.5	HTS	MEK inhibitor	MAP2K5			CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1	Preclinical	5
BRD-K20290250-001-02-1::2.38::HTS	-0.12406780356899999	BRD-K20290250-001-02-1::2.38::HTS	BRD-K20290250-001-02-1	BIX-02188	2.38	HTS	MEK inhibitor	MAP2K5			CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1	Preclinical	5
BRD-K20313525-001-04-6::2.5::HTS	-0.245964186773	BRD-K20313525-001-04-6::2.5::HTS	BRD-K20313525-001-04-6	rosmarinic-acid	2.5	HTS	GABA transaminase inhibitor	MCL1, TYR			OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1	Launched	5
BRD-K20338176-001-17-7::2.5::HTS	0.040437814032900005	BRD-K20338176-001-17-7::2.5::HTS	BRD-K20338176-001-17-7	cefaclor	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis	N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1	Launched	5
BRD-K20372197-001-03-1::2.5::HTS	0.33050002346900004	BRD-K20372197-001-03-1::2.5::HTS	BRD-K20372197-001-03-1	droxidopa	2.5	HTS	norepinephrine precursor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH	cardiology, neurology/psychiatry	hypertension, Parkinson's Disease	N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O	Launched	5
BRD-K20417253-001-01-9::2.5::HTS	0.712212706909	BRD-K20417253-001-01-9::2.5::HTS	BRD-K20417253-001-01-9	oxiniacic-acid	2.5	HTS					OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1	Preclinical	5
BRD-K20431737-001-08-1::2.5::HTS	0.22198092951499998	BRD-K20431737-001-08-1::2.5::HTS	BRD-K20431737-001-08-1	benzoylpas	2.5	HTS					OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O	Preclinical	5
BRD-K20482099-001-09-4::2.5::HTS	0.12317297022700001	BRD-K20482099-001-09-4::2.5::HTS	BRD-K20482099-001-09-4	rutin	2.5	HTS	antioxidant, capillary stabilizing agent, nitric oxide scavenger	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	Launched	5
BRD-K20482099-001-11-0::2.5::HTS	-0.282605811701	BRD-K20482099-001-11-0::2.5::HTS	BRD-K20482099-001-11-0	rutin	2.5	HTS	antioxidant, capillary stabilizing agent, nitric oxide scavenger	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	Launched	5
BRD-K20545304-001-01-6::2.5::HTS	0.10968991263399999	BRD-K20545304-001-01-6::2.5::HTS	BRD-K20545304-001-01-6	bardoxolone	2.5	HTS	nuclear factor erythroid derived, like (NRF2) activator	NOS2, PPARG			CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O	Phase 1	5
BRD-K20548681-001-01-3::2.5::HTS	0.0989171126474	BRD-K20548681-001-01-3::2.5::HTS	BRD-K20548681-001-01-3	SCP-1	2.5	HTS	analgesic agent				Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1	Phase 1	5
BRD-K20605374-001-05-4::2.5::HTS	-5.834284985630001	BRD-K20605374-001-05-4::2.5::HTS	BRD-K20605374-001-05-4	NSC-697923	2.5	HTS	ubiquitin-conjugating enzyme inhibitor	UBE2N			Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O	Preclinical	5
BRD-K20655524-003-12-0::2.5::HTS	-0.222111891786	BRD-K20655524-003-12-0::2.5::HTS	BRD-K20655524-003-12-0	mefexamide	2.5	HTS	psychoactive drug				CCN(CC)CCNC(=O)COc1ccc(OC)cc1	Preclinical	5
BRD-K20714604-003-02-9::2.5::HTS	0.035339120265199996	BRD-K20714604-003-02-9::2.5::HTS	BRD-K20714604-003-02-9	RS-56812	2.5	HTS	serotonin receptor partial agonist	HTR3A			Cn1cc(C(=O)C(=O)N[C@H]2CN3CCC2CC3)c2ccccc12	Preclinical	5
BRD-K20722021-001-02-1::2.5::HTS	-0.5101561068980001	BRD-K20722021-001-02-1::2.5::HTS	BRD-K20722021-001-02-1	CEP-32496	2.5	HTS	RAF inhibitor	BRAF, RAF1			COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC	Phase 1/Phase 2	5
BRD-K20738689-001-01-2::2.5::HTS	0.321022073577	BRD-K20738689-001-01-2::2.5::HTS	BRD-K20738689-001-01-2	dazmegrel	2.5	HTS	thromboxane synthase inhibitor	TBXAS1			Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O	Phase 2	5
BRD-K20742498-003-02-9::2.5::HTS	-0.316427923944	BRD-K20742498-003-02-9::2.5::HTS	BRD-K20742498-003-02-9	RS-39604	2.5	HTS	serotonin receptor antagonist	HTR4			COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1	Preclinical	5
BRD-K20745393-003-01-0::2.5::HTS	-0.15930705725400002	BRD-K20745393-003-01-0::2.5::HTS	BRD-K20745393-003-01-0	olprinone	2.5	HTS	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N	Launched	5
BRD-K20755323-001-05-9::2.5::HTS	0.350388126588	BRD-K20755323-001-05-9::2.5::HTS	BRD-K20755323-001-05-9	SKI-II	2.5	HTS	sphingosine kinase inhibitor	SPHK1			Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1	Preclinical	5
BRD-K20897876-001-10-0::2.5::HTS	0.590325121262	BRD-K20897876-001-10-0::2.5::HTS	BRD-K20897876-001-10-0	castanospermine	2.5	HTS	glucosidase inhibitor	GAA, GBA			O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12	Phase 2	5
BRD-K20920669-304-09-1::2.5::HTS	-0.44808358851999996	BRD-K20920669-304-09-1::2.5::HTS	BRD-K20920669-304-09-1	cromoglicic-acid	2.5	HTS	immunosuppressant	KCNMA1, S100P	pulmonary, ophthalmology, allergy, gastroenterology	asthma, conjunctivitis, urticaria, ulcerative colitis	OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O	Launched	5
BRD-K20958582-001-01-4::2.5::HTS	-0.662149129376	BRD-K20958582-001-01-4::2.5::HTS	BRD-K20958582-001-01-4	TH-302	2.5	HTS	DNA alkylating agent				Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O	Phase 3	5
BRD-K20995441-001-02-5::2.5::HTS	-0.08818359466499999	BRD-K20995441-001-02-5::2.5::HTS	BRD-K20995441-001-02-5	U-54494A	2.5	HTS	opioid receptor agonist	OPRK1			CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-K21025364-001-04-9::2.5::HTS	-3.28733031945	BRD-K21025364-001-04-9::2.5::HTS	BRD-K21025364-001-04-9	NVP-TAE226	2.5	HTS	protein tyrosine kinase inhibitor	PTK2			CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl	Preclinical	5
BRD-K21025364-001-05-6::2.44::HTS	-3.29297894887	BRD-K21025364-001-05-6::2.44::HTS	BRD-K21025364-001-05-6	NVP-TAE226	2.44	HTS	protein tyrosine kinase inhibitor	PTK2			CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl	Preclinical	5
BRD-K21071223-001-02-8::2.5::HTS	-0.13191700235	BRD-K21071223-001-02-8::2.5::HTS	BRD-K21071223-001-02-8	VP-20629	2.5	HTS	beta amyloid antagonist	PLA2G2E, SLC36A1			OC(=O)CCc1c[nH]c2ccccc12	Phase 1	5
BRD-K21123171-001-02-9::2.5::HTS	-0.172549164692	BRD-K21123171-001-02-9::2.5::HTS	BRD-K21123171-001-02-9	pramiracetam	2.5	HTS	acetylcholine receptor agonist				CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	Launched	5
BRD-K21160401-065-01-0::2.5::HTS	0.627603525665	BRD-K21160401-065-01-0::2.5::HTS	BRD-K21160401-065-01-0	dextroamphetamine	2.5	HTS	monoamine oxidase inhibitor	ADRA1A, ADRA1B, SLC18A2, SLC6A2, SLC6A3, TAAR1	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD), narcolepsy	C[C@H](N)Cc1ccccc1	Launched	5
BRD-K21164796-001-02-8::2.5::HTS	0.286029615044	BRD-K21164796-001-02-8::2.5::HTS	BRD-K21164796-001-02-8	beta-naphthol	2.5	HTS					Oc1ccc2ccccc2c1	Preclinical	5
BRD-K21283037-001-21-5::2.5::HTS	-0.0887979875422	BRD-K21283037-001-21-5::2.5::HTS	BRD-K21283037-001-21-5	riluzole	2.5	HTS	glutamate inhibitor	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1	Launched	5
BRD-K21295289-001-01-6::2.5::HTS	-0.20836826014	BRD-K21295289-001-01-6::2.5::HTS	BRD-K21295289-001-01-6	senicapoc	2.5	HTS	intermediate conductance potassium channel blocker	KCNN4			NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1	Phase 3	5
BRD-K21361524-001-01-1::2.5::HTS	-3.4778065680699997	BRD-K21361524-001-01-1::2.5::HTS	BRD-K21361524-001-01-1	selinexor	2.5	HTS	exportin antagonist	XPO1			FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1	Phase 2/Phase 3	5
BRD-K21372554-003-01-7::2.5::HTS	0.40305724092399997	BRD-K21372554-003-01-7::2.5::HTS	BRD-K21372554-003-01-7	cefetamet-pivoxil	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1	Launched	5
BRD-K21396683-001-04-8::2.5::HTS	-0.0457648386181	BRD-K21396683-001-04-8::2.5::HTS	BRD-K21396683-001-04-8	marimastat	2.5	HTS	matrix metalloprotease inhibitor	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9			CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C	Phase 3	5
BRD-K21450440-001-14-6::2.5::HTS	-1.0552716018500001	BRD-K21450440-001-14-6::2.5::HTS	BRD-K21450440-001-14-6	benzthiazide	2.5	HTS	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA4, CA9, SLC12A3	cardiology	hypertension, edema	NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O, NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O	Launched	5
BRD-K21452876-003-01-8::2.5::HTS	-0.210944312315	BRD-K21452876-003-01-8::2.5::HTS	BRD-K21452876-003-01-8	chlorazanil	2.5	HTS					Nc1ncnc(Nc2ccc(Cl)cc2)n1	Preclinical	5
BRD-K21520694-236-02-6::2.5::HTS	-0.22820863284600001	BRD-K21520694-236-02-6::2.5::HTS	BRD-K21520694-236-02-6	sulfacetamide	2.5	HTS	PABA antagonist		ophthalmology	conjunctivitis	CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1	Launched	5
BRD-K21528677-001-02-8::2.44::HTS	-0.124710527818	BRD-K21528677-001-02-8::2.44::HTS	BRD-K21528677-001-02-8	desonide	2.44	HTS	glucocorticoid receptor agonist	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Launched	5
BRD-K21528677-001-03-6::2.5::HTS	-0.371686745699	BRD-K21528677-001-03-6::2.5::HTS	BRD-K21528677-001-03-6	desonide	2.5	HTS	glucocorticoid receptor agonist	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Launched	5
BRD-K21547160-001-01-4::2.5::HTS	0.15774633621099998	BRD-K21547160-001-01-4::2.5::HTS	BRD-K21547160-001-01-4	sufentanil	2.5	HTS	opioid receptor modulator	OPRD1, OPRK1, OPRM1	neurology/psychiatry	anesthetic	CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1	Launched	5
BRD-K21548250-003-19-1::2.5::HTS	-0.0237379447325	BRD-K21548250-003-19-1::2.5::HTS	BRD-K21548250-003-19-1	moracizine	2.5	HTS	sodium channel blocker	SCN5A	cardiology	ventricular arrhythmias	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1	Launched	5
BRD-K21565985-001-22-5::2.5::HTS	0.0400282058858	BRD-K21565985-001-22-5::2.5::HTS	BRD-K21565985-001-22-5	xylazine	2.5	HTS	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1	Launched	5
BRD-K21615095-001-08-4::2.5::HTS	0.25815449926600004	BRD-K21615095-001-08-4::2.5::HTS	BRD-K21615095-001-08-4	acetohydroxamic-acid	2.5	HTS	urease inhibitor	MMP12	infectious disease	urinary tract infections	CC(=O)NO	Launched	5
BRD-K21670884-001-01-9::2.5::HTS	0.49300175214599995	BRD-K21670884-001-01-9::2.5::HTS	BRD-K21670884-001-01-9	cariporide	2.5	HTS	sodium/hydrogen exchanger inhibitor	SLC9A1			CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N	Phase 3	5
BRD-K21672174-001-03-0::2.5::HTS	-0.485773828751	BRD-K21672174-001-03-0::2.5::HTS	BRD-K21672174-001-03-0	Ro-28-1675	2.5	HTS	glucokinase activator	GCK			CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1	Preclinical	5
BRD-K21673112-003-01-3::2.5::HTS	0.191296182349	BRD-K21673112-003-01-3::2.5::HTS	BRD-K21673112-003-01-3	BF2.649	2.5	HTS	histamine receptor antagonist	HRH3			Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1	Phase 3	5
BRD-K21680192-300-14-4::2.5::HTS	-2.26579606174	BRD-K21680192-300-14-4::2.5::HTS	BRD-K21680192-300-14-4	mitoxantrone	2.5	HTS	topoisomerase inhibitor	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12	Launched	5
BRD-K21718444-001-06-8::2.5::HTS	-1.0323394074299999	BRD-K21718444-001-06-8::2.5::HTS	BRD-K21718444-001-06-8	KW-2449	2.5	HTS	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	ABL1, AURKA, AURKB, FLT3			O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12	Phase 1	5
BRD-K21728777-001-02-3::2.5::HTS	-1.1062421527200001	BRD-K21728777-001-02-3::2.5::HTS	BRD-K21728777-001-02-3	AMG900	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12	Phase 1	5
BRD-K21733600-001-14-1::2.5::HTS	-0.06937928344210001	BRD-K21733600-001-14-1::2.5::HTS	BRD-K21733600-001-14-1	rofecoxib	2.5	HTS	cyclooxygenase inhibitor	ELN, PTGS2			CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1	Withdrawn	5
BRD-K21771665-304-04-2::2.5::HTS	-0.562357170711	BRD-K21771665-304-04-2::2.5::HTS	BRD-K21771665-304-04-2	merbromin	2.5	HTS	antiseptic		infectious disease	first-aid antiseptic	O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12	Launched	5
BRD-K21782625-001-02-4::2.5::HTS	-0.48417120285099996	BRD-K21782625-001-02-4::2.5::HTS	BRD-K21782625-001-02-4	AMG458	2.5	HTS	MET inhibitor	MET			COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1	Preclinical	5
BRD-K21782625-001-03-2::2.45::HTS	-0.43985123075300003	BRD-K21782625-001-03-2::2.45::HTS	BRD-K21782625-001-03-2	AMG458	2.45	HTS	MET inhibitor	MET			COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1	Preclinical	5
BRD-K21867462-001-02-9::2.5::HTS	0.152959257382	BRD-K21867462-001-02-9::2.5::HTS	BRD-K21867462-001-02-9	GSK2816126	2.5	HTS	histone lysine methyltransferase inhibitor	EZH2			CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	Phase 1	5
BRD-K21884483-001-03-7::2.5::HTS	0.326057252475	BRD-K21884483-001-03-7::2.5::HTS	BRD-K21884483-001-03-7	mizolastine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	urticaria, allergic rhinitis	CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nccc(=O)[nH]1	Launched	5
BRD-K21906513-001-04-0::2.36::HTS	0.32098654476300004	BRD-K21906513-001-04-0::2.36::HTS	BRD-K21906513-001-04-0	UNC669	2.36	HTS	L3MBTL antagonist	L3MBTL1			Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1	Preclinical	5
BRD-K21908111-001-01-8::2.5::HTS	-0.47525771088	BRD-K21908111-001-01-8::2.5::HTS	BRD-K21908111-001-01-8	AZD1208	2.5	HTS	Pim kinase inhibitor	PIM1, PIM2, PIM3			N[C@@H]1CCCN(C1)c1c(cccc1-c1ccccc1)\C=C1/SC(=O)NC1=O	Phase 1	5
BRD-K21910317-001-12-3::2.5::HTS	0.052644993746600005	BRD-K21910317-001-12-3::2.5::HTS	BRD-K21910317-001-12-3	2,4-dinitrophenol	2.5	HTS	ATP synthase inhibitor	APP			Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O	Preclinical	5
BRD-K21913543-001-02-4::2.5::HTS	-0.175312249396	BRD-K21913543-001-02-4::2.5::HTS	BRD-K21913543-001-02-4	fluorescein	2.5	HTS		SLC22A6	ophthalmology	ophthalmology diagnostic	Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1	Launched	5
BRD-K21937671-001-09-2::2.53::HTS	-0.519324477456	BRD-K21937671-001-09-2::2.53::HTS	BRD-K21937671-001-09-2	loxistatin-acid	2.53	HTS	cysteine peptidase inhibitor	CTSB			CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O	Preclinical	5
BRD-K21937671-001-10-0::2.5::HTS	-0.147200460309	BRD-K21937671-001-10-0::2.5::HTS	BRD-K21937671-001-10-0	loxistatin-acid	2.5	HTS	cysteine peptidase inhibitor	CTSB			CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O	Preclinical	5
BRD-K22009844-001-12-5::2.5::HTS	0.09349474735789999	BRD-K22009844-001-12-5::2.5::HTS	BRD-K22009844-001-12-5	phenprobamate	2.5	HTS	muscle relaxant		neurology/psychiatry	anxiety, muscle relaxant	NC(=O)OCCCc1ccccc1	Launched	5
BRD-K22024824-001-03-7::2.5::HTS	0.408887734212	BRD-K22024824-001-03-7::2.5::HTS	BRD-K22024824-001-03-7	RG4733	2.5	HTS	gamma secretase inhibitor	PSEN1			CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O	Phase 2	5
BRD-K22025381-003-01-9::2.5::HTS	0.25477461478	BRD-K22025381-003-01-9::2.5::HTS	BRD-K22025381-003-01-9	U-18666A	2.5	HTS	oxidosqualene cyclase inhibitor				CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1	Preclinical	5
BRD-K22031190-001-23-6::2.5::HTS	-0.158662615086	BRD-K22031190-001-23-6::2.5::HTS	BRD-K22031190-001-23-6	diflunisal	2.5	HTS	prostanoid receptor antagonist	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F	Launched	5
BRD-K22097830-001-01-9::2.5::HTS	0.194607233228	BRD-K22097830-001-01-9::2.5::HTS	BRD-K22097830-001-01-9	OCO-1112	2.5	HTS	cholesterol inhibitor				CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O	Phase 2	5
BRD-K22127577-001-03-7::2.58::HTS	-6.389524567860001	BRD-K22127577-001-03-7::2.58::HTS	BRD-K22127577-001-03-7	crenolanib	2.58	HTS	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1	Phase 2	5
BRD-K22134346-001-22-3::2.5::HTS	0.648554380628	BRD-K22134346-001-22-3::2.5::HTS	BRD-K22134346-001-22-3	simvastatin	2.5	HTS	HMGCR inhibitor	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	Launched	5
BRD-K22134346-001-24-9::2.42::HTS	0.8884630750839999	BRD-K22134346-001-24-9::2.42::HTS	BRD-K22134346-001-24-9	simvastatin	2.42	HTS	HMGCR inhibitor	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	Launched	5
BRD-K22193694-001-13-6::2.5::HTS	-0.102795108048	BRD-K22193694-001-13-6::2.5::HTS	BRD-K22193694-001-13-6	dioxybenzone	2.5	HTS	topical sunscreen agent				COc1ccc(C(=O)c2ccccc2O)c(O)c1	Preclinical	5
BRD-K22261391-001-01-2::2.5::HTS	0.722600748011	BRD-K22261391-001-01-2::2.5::HTS	BRD-K22261391-001-01-2	pirodavir	2.5	HTS					CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1	Phase 2	5
BRD-K22314899-001-02-4::2.5::HTS	0.335155788488	BRD-K22314899-001-02-4::2.5::HTS	BRD-K22314899-001-02-4	CH223191	2.5	HTS	aryl hydrocarbon receptor antagonist	AHR			Cc1cc(ccc1NC(=O)c1ccnn1C)\N=N\c1ccccc1C	Preclinical	5
BRD-K22356203-001-01-8::2.5::HTS	0.00509939749804	BRD-K22356203-001-01-8::2.5::HTS	BRD-K22356203-001-01-8	IDO5L	2.5	HTS	indoleamine 2,3-dioxygenase inhibitor	IDO1			Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1	Preclinical	5
BRD-K22385716-001-02-5::2.5::HTS	0.04466719738580001	BRD-K22385716-001-02-5::2.5::HTS	BRD-K22385716-001-02-5	LY303511	2.5	HTS	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	BRD2, BRD3, BRD4			O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1	Preclinical	5
BRD-K22482860-001-21-4::2.5::HTS	0.426139121435	BRD-K22482860-001-21-4::2.5::HTS	BRD-K22482860-001-21-4	dalfampridine	2.5	HTS	potassium channel blocker	KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2	neurology/psychiatry	multiple sclerosis	Nc1ccncc1, Nc1ccncc1	Launched	5
BRD-K22503835-001-11-0::2.5::HTS	-0.692742931083	BRD-K22503835-001-11-0::2.5::HTS	BRD-K22503835-001-11-0	scriptaid	2.5	HTS	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23	Preclinical	5
BRD-K22520627-001-01-7::2.5::HTS	-0.215896675082	BRD-K22520627-001-01-7::2.5::HTS	BRD-K22520627-001-01-7	DVD-111	2.5	HTS					CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1	Phase 2	5
BRD-K22662435-001-18-3::2.5::HTS	-0.0449354329621	BRD-K22662435-001-18-3::2.5::HTS	BRD-K22662435-001-18-3	ganciclovir	2.5	HTS	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1, Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1, Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1	Launched	5
BRD-K22662435-001-19-1::2.5::HTS	-0.306561382667	BRD-K22662435-001-19-1::2.5::HTS	BRD-K22662435-001-19-1	ganciclovir	2.5	HTS	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1, Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1, Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1	Launched	5
BRD-K22662557-300-01-7::2.5::HTS	0.44429442041	BRD-K22662557-300-01-7::2.5::HTS	BRD-K22662557-300-01-7	WIN-64338	2.5	HTS	bradykinin receptor antagonist	BDKRB2			CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1	Preclinical	5
BRD-K22685337-001-13-4::2.5::HTS	0.176667511574	BRD-K22685337-001-13-4::2.5::HTS	BRD-K22685337-001-13-4	roxarsone	2.5	HTS	antiprotozoal agent		endocrinology	weight-gain aid	Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O	Launched	5
BRD-K22745370-003-02-3::2.5::HTS	0.0712401827948	BRD-K22745370-003-02-3::2.5::HTS	BRD-K22745370-003-02-3	2-BFI	2.5	HTS	imidazoline receptor ligand	ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB			C1CN=C(N1)c1cc2ccccc2o1	Preclinical	5
BRD-K22749967-046-02-3::2.5::HTS	0.304821527954	BRD-K22749967-046-02-3::2.5::HTS	BRD-K22749967-046-02-3	ABT-239	2.5	HTS	histamine receptor antagonist	HRH1, HRH2, HRH3			C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N	Phase 1	5
BRD-K22822991-001-02-3::2.5::HTS	-0.482599253381	BRD-K22822991-001-02-3::2.5::HTS	BRD-K22822991-001-02-3	odanacatib	2.5	HTS	cathepsin inhibitor	CTSK			CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N	Phase 3	5
BRD-K22829793-001-01-0::2.5::HTS	-0.23282580145399998	BRD-K22829793-001-01-0::2.5::HTS	BRD-K22829793-001-01-0	ZCL-278	2.5	HTS	CDC inhibitor	CDC42			Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	Preclinical	5
BRD-K22861715-001-17-4::2.5::HTS	-0.716595635571	BRD-K22861715-001-17-4::2.5::HTS	BRD-K22861715-001-17-4	chrysin	2.5	HTS	breast cancer resistance protein inhibitor	AKR1B1, CDK6, CYP19A1, CYP1B1			Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1	Phase 1	5
BRD-K22936972-003-23-6::2.5::HTS	0.149448430317	BRD-K22936972-003-23-6::2.5::HTS	BRD-K22936972-003-23-6	diphenylpyraline	2.5	HTS	dopamine uptake inhibitor	HRH1, SLC6A3	allergy	allergic rhinitis	CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Launched	5
BRD-K23067689-001-02-1::2.4::HTS	0.238263469934	BRD-K23067689-001-02-1::2.4::HTS	BRD-K23067689-001-02-1	zanamivir	2.4	HTS	neuraminidase inhibitor	NEU2	infectious disease	influenza A virus infection	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	Launched	5
BRD-K23082237-003-01-5::2.5::HTS	-0.163619820988	BRD-K23082237-003-01-5::2.5::HTS	BRD-K23082237-003-01-5	butaclamol	2.5	HTS	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A			CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc([C@H]2C1)c34	Phase 2	5
BRD-K23163214-050-15-1::2.5::HTS	-0.0403125196546	BRD-K23163214-050-15-1::2.5::HTS	BRD-K23163214-050-15-1	dizocilpine-(-)	2.5	HTS	glutamate receptor antagonist				C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21	Phase 1	5
BRD-K23190681-001-01-1::2.5::HTS	1.20070709335	BRD-K23190681-001-01-1::2.5::HTS	BRD-K23190681-001-01-1	AV-412	2.5	HTS	protein tyrosine kinase inhibitor	EGFR, ERBB2			CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C	Phase 1	5
BRD-K23204545-001-16-4::2.5::HTS	0.0258698870873	BRD-K23204545-001-16-4::2.5::HTS	BRD-K23204545-001-16-4	busulfan	2.5	HTS	DNA inhibitor		hematologic malignancy	chronic myeloid leukemia (CML)	CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O	Launched	5
BRD-K23228615-001-02-8::2.5::HTS	-1.53394346227	BRD-K23228615-001-02-8::2.5::HTS	BRD-K23228615-001-02-8	GDC-0980	2.5	HTS	mTOR inhibitor, PI3K inhibitor	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK			C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1	Phase 2	5
BRD-K23248433-001-01-8::2.5::HTS	-0.145385585073	BRD-K23248433-001-01-8::2.5::HTS	BRD-K23248433-001-01-8	camicinal	2.5	HTS	motilin receptor agonist	MLNR			C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1	Phase 2	5
BRD-K23301018-001-11-7::2.63::HTS	0.13990307052	BRD-K23301018-001-11-7::2.63::HTS	BRD-K23301018-001-11-7	broxyquinoline	2.63	HTS	antiprotozoal agent				Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12	Phase 1	5
BRD-K23335153-300-02-5::2.5::HTS	0.380335625444	BRD-K23335153-300-02-5::2.5::HTS	BRD-K23335153-300-02-5	AMN-082	2.5	HTS	glutamate receptor modulator	GRM7			C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	Preclinical	5
BRD-K23363278-001-02-1::2.5::HTS	-4.23439022166	BRD-K23363278-001-02-1::2.5::HTS	BRD-K23363278-001-02-1	CYT-997	2.5	HTS	tubulin polymerization inhibitor	TUBB			CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1	Phase 2	5
BRD-K23383398-001-09-9::2.5::HTS	-1.01594859725	BRD-K23383398-001-09-9::2.5::HTS	BRD-K23383398-001-09-9	T-0901317	2.5	HTS	LXR agonist	NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB			OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	Preclinical	5
BRD-K23403298-003-01-9::2.5::HTS	-0.111674732382	BRD-K23403298-003-01-9::2.5::HTS	BRD-K23403298-003-01-9	benzyldimethylhexadecylammonium	2.5	HTS	cationic surfactant				CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	Preclinical	5
BRD-K23541596-300-07-2::2.5::HTS	0.239155771076	BRD-K23541596-300-07-2::2.5::HTS	BRD-K23541596-300-07-2	dimaprit	2.5	HTS	histamine receptor agonist	HRH2, HRH3, HRH4			CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N	Preclinical	5
BRD-K23566484-001-15-1::2.5::HTS	-0.141314114795	BRD-K23566484-001-15-1::2.5::HTS	BRD-K23566484-001-15-1	nilutamide	2.5	HTS	androgen receptor antagonist	AR	oncology	prostate cancer	CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Launched	5
BRD-K23586533-001-03-6::2.5::HTS	-0.5537516147	BRD-K23586533-001-03-6::2.5::HTS	BRD-K23586533-001-03-6	clindamycin	2.5	HTS	protein synthesis inhibitor		infectious disease	respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	Launched	5
BRD-K23647661-001-02-2::2.5::HTS	0.109282621725	BRD-K23647661-001-02-2::2.5::HTS	BRD-K23647661-001-02-2	volinanserin	2.5	HTS	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, KCNH2			COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC, COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC	Phase 3	5
BRD-K23672206-001-01-4::2.5::HTS	-0.516146095764	BRD-K23672206-001-01-4::2.5::HTS	BRD-K23672206-001-01-4	BCI-540	2.5	HTS	glutamate receptor agonist				Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C	Phase 2	5
BRD-K23677682-003-01-2::2.5::HTS	-2.00987878113	BRD-K23677682-003-01-2::2.5::HTS	BRD-K23677682-003-01-2	voreloxin	2.5	HTS	topoisomerase inhibitor	TOP2A			CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1	Phase 3	5
BRD-K23728141-001-01-2::2.5::HTS	0.22533779447900001	BRD-K23728141-001-01-2::2.5::HTS	BRD-K23728141-001-01-2	tafamidis-meglumine	2.5	HTS	transthyretin amyloid inhibitor	TTR	neurology/psychiatry	familial amyloid polyneuropathy (FAP)	OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1	Launched	5
BRD-K23779958-001-05-8::2.5::HTS	-1.19051664264	BRD-K23779958-001-05-8::2.5::HTS	BRD-K23779958-001-05-8	dichlorvos	2.5	HTS	acetylcholinesterase inhibitor				COP(=O)(OC)OC=C(Cl)Cl	Launched	5
BRD-K23913458-001-20-7::2.5::HTS	-0.648384068173	BRD-K23913458-001-20-7::2.5::HTS	BRD-K23913458-001-20-7	coumarin	2.5	HTS	vitamin K antagonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6	gastroenterology, pulmonary	ulcerative colitis, asthma, celiac disease	O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1	Launched	5
BRD-K23922020-075-02-9::2.5::HTS	0.247806917663	BRD-K23922020-075-02-9::2.5::HTS	BRD-K23922020-075-02-9	arecaidine-propargyl-ester	2.5	HTS	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			CN1CCC=C(C1)C(=O)OCC#C, CN1CCC=C(C1)C(=O)OCC#C	Preclinical	5
BRD-K23925186-001-01-0::2.5::HTS	0.596501313623	BRD-K23925186-001-01-0::2.5::HTS	BRD-K23925186-001-01-0	oridonin	2.5	HTS	BCL inhibitor	BCL2			O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C	Preclinical	5
BRD-K23925186-001-02-8::2.51::HTS	1.7739009791299998	BRD-K23925186-001-02-8::2.51::HTS	BRD-K23925186-001-02-8	oridonin	2.51	HTS	BCL inhibitor	BCL2			O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C	Preclinical	5
BRD-K23952234-236-01-8::2.5::HTS	0.251027388108	BRD-K23952234-236-01-8::2.5::HTS	BRD-K23952234-236-01-8	BMS-986020	2.5	HTS	lysophosphatidic acid receptor antagonist	LPAR1			C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1	Phase 2	5
BRD-K23976833-001-01-0::2.5::HTS	0.48344707121799996	BRD-K23976833-001-01-0::2.5::HTS	BRD-K23976833-001-01-0	travoprost	2.5	HTS	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F	Launched	5
BRD-K23984367-075-15-2::2.5::HTS	-0.824451493114	BRD-K23984367-075-15-2::2.5::HTS	BRD-K23984367-075-15-2	sorafenib	2.5	HTS	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1	Launched	5
BRD-K24048528-001-01-7::2.59::HTS	0.174792657658	BRD-K24048528-001-01-7::2.59::HTS	BRD-K24048528-001-01-7	abiraterone-acetate	2.59	HTS	androgen biosynthesis inhibitor	CYP17A1	oncology	prostate cancer	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1	Launched	5
BRD-K24048528-001-02-5::2.5::HTS	0.0730434934674	BRD-K24048528-001-02-5::2.5::HTS	BRD-K24048528-001-02-5	abiraterone-acetate	2.5	HTS	androgen biosynthesis inhibitor	CYP17A1	oncology	prostate cancer	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1	Launched	5
BRD-K24084088-001-11-3::2.5::HTS	0.108812938742	BRD-K24084088-001-11-3::2.5::HTS	BRD-K24084088-001-11-3	paraxanthine	2.5	HTS	adenosine receptor antagonist				Cn1cnc2[nH]c(=O)n(C)c(=O)c12	Phase 1	5
BRD-K24179883-001-16-7::2.5::HTS	0.282002944096	BRD-K24179883-001-16-7::2.5::HTS	BRD-K24179883-001-16-7	arsanilic-acid	2.5	HTS		LYZ			Nc1ccc(cc1)[As](O)(O)=O	Phase 1	5
BRD-K24187789-001-01-7::2.5::HTS	-0.10360863009099999	BRD-K24187789-001-01-7::2.5::HTS	BRD-K24187789-001-01-7	VU0238429	2.5	HTS	acetylcholine receptor allosteric modulator	CHRM5			COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1	Preclinical	5
BRD-K24201553-003-11-5::2.5::HTS	-0.0161291679187	BRD-K24201553-003-11-5::2.5::HTS	BRD-K24201553-003-11-5	SB-269970	2.5	HTS	serotonin receptor antagonist	HTR7			CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	Preclinical	5
BRD-K24219278-001-01-6::2.5::HTS	0.19289935035300002	BRD-K24219278-001-01-6::2.5::HTS	BRD-K24219278-001-01-6	amineptine	2.5	HTS	dopamine receptor agonist	SLC6A2, SLC6A4			OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12	Withdrawn	5
BRD-K24227647-364-01-5::2.5::HTS	0.0872587506106	BRD-K24227647-364-01-5::2.5::HTS	BRD-K24227647-364-01-5	TC2559	2.5	HTS	acetylcholine receptor agonist	CHRNA4			CCOc1cncc(\C=C\CCNC)c1, CCOc1cncc(\C=C\CCNC)c1	Preclinical	5
BRD-K24242599-001-02-8::2.5::HTS	0.270494259026	BRD-K24242599-001-02-8::2.5::HTS	BRD-K24242599-001-02-8	GW-2580	2.5	HTS	cFMS kinase inhibitor	CSF1R			COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1	Preclinical	5
BRD-K24255045-001-05-3::2.5::HTS	0.182622629249	BRD-K24255045-001-05-3::2.5::HTS	BRD-K24255045-001-05-3	fluoxymesterone	2.5	HTS	androgen receptor modulator	AR, ESR1, NR3C1, PRLR	endocrinology	hypogonadism	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Launched	5
BRD-K24258499-001-05-8::2.5::HTS	0.423502001601	BRD-K24258499-001-05-8::2.5::HTS	BRD-K24258499-001-05-8	vanillin	2.5	HTS		ABAT, ALDH5A1			COc1cc(C=O)ccc1O	Preclinical	5
BRD-K24297741-001-05-2::2.5::HTS	-0.18889991837	BRD-K24297741-001-05-2::2.5::HTS	BRD-K24297741-001-05-2	urethane	2.5	HTS	local anesthetic				CCOC(N)=O	Preclinical	5
BRD-K24312986-001-01-2::2.5::HTS	-0.599670393198	BRD-K24312986-001-01-2::2.5::HTS	BRD-K24312986-001-01-2	tecovirimat	2.5	HTS	orthopoxvirus egress inhibitor				FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O	Phase 3	5
BRD-K24443618-001-10-2::2.5::HTS	-0.32113126070500003	BRD-K24443618-001-10-2::2.5::HTS	BRD-K24443618-001-10-2	etebenecid	2.5	HTS	uricosuric blocker				CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O	Preclinical	5
BRD-K24507548-001-01-8::2.5::HTS	0.5118197951110001	BRD-K24507548-001-01-8::2.5::HTS	BRD-K24507548-001-01-8	cintriamide	2.5	HTS					COc1cc(cc(OC)c1OC)\C=C\C(N)=O	Preclinical	5
BRD-K24548560-342-02-1::2.5::HTS	-0.021888972854499998	BRD-K24548560-342-02-1::2.5::HTS	BRD-K24548560-342-02-1	evans-blue	2.5	HTS	glutamate receptor negative allosteric modulator	GRIA1, PTPN1			Cc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(c(C)c1)\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O	Launched	5
BRD-K24556098-001-16-7::2.45::HTS	0.241209289747	BRD-K24556098-001-16-7::2.45::HTS	BRD-K24556098-001-16-7	deoxycorticosterone-acetate	2.45	HTS	progestogen hormone	NR3C2			CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Preclinical	5
BRD-K24556098-001-19-1::2.5::HTS	0.688863691072	BRD-K24556098-001-19-1::2.5::HTS	BRD-K24556098-001-19-1	deoxycorticosterone-acetate	2.5	HTS	progestogen hormone	NR3C2			CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Preclinical	5
BRD-K24556407-001-02-3::2.5::HTS	0.273193351999	BRD-K24556407-001-02-3::2.5::HTS	BRD-K24556407-001-02-3	ETP-46464	2.5	HTS	ATR kinase inhibitor				CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1	Preclinical	5
BRD-K24566386-001-01-9::2.5::HTS	0.444428659368	BRD-K24566386-001-01-9::2.5::HTS	BRD-K24566386-001-01-9	SD-208	2.5	HTS	TGF beta receptor inhibitor	TGFBR1			Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1	Preclinical	5
BRD-K24576554-001-04-8::2.5::HTS	-1.43310676081	BRD-K24576554-001-04-8::2.5::HTS	BRD-K24576554-001-04-8	AT-9283	2.5	HTS	Aurora kinase inhibitor, JAK inhibitor	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A			O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1	Phase 2	5
BRD-K24593301-001-02-3::2.54::HTS	-2.49351255366	BRD-K24593301-001-02-3::2.54::HTS	BRD-K24593301-001-02-3	AZD3463	2.54	HTS	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor	ALK, IGF1R			COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1	Preclinical	5
BRD-K24601397-001-01-1::2.5::HTS	-0.581283368819	BRD-K24601397-001-01-1::2.5::HTS	BRD-K24601397-001-01-1	phlorizin	2.5	HTS	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A11, SLC5A2, SLC5A3			OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O	Preclinical	5
BRD-K24603946-001-02-1::2.5::HTS	-0.488127928566	BRD-K24603946-001-02-1::2.5::HTS	BRD-K24603946-001-02-1	5-hydroxymethyl-tolterodine	2.5	HTS	acetylcholine receptor antagonist	CHRM3			CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C	Phase 1	5
BRD-K24616672-003-20-1::2.5::HTS	-0.00996343358215	BRD-K24616672-003-20-1::2.5::HTS	BRD-K24616672-003-20-1	procaine	2.5	HTS	HMGCR inhibitor	CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3	neurology/psychiatry	anesthetic	CCN(CC)CCOC(=O)c1ccc(N)cc1, CCN(CC)CCOC(=O)c1ccc(N)cc1	Launched	5
BRD-K24689407-001-06-3::2.5::HTS	-0.156798278165	BRD-K24689407-001-06-3::2.5::HTS	BRD-K24689407-001-06-3	3-bromo-7-nitroindazole	2.5	HTS	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			[O-][N+](=O)c1cccc2c(Br)n[nH]c12, [O-][N+](=O)c1cccc2c(Br)n[nH]c12	Preclinical	5
BRD-K24696047-001-02-3::2.5::HTS	0.0800060341837	BRD-K24696047-001-02-3::2.5::HTS	BRD-K24696047-001-02-3	NVP-AEW541	2.5	HTS	IGF-1 inhibitor	IGF1R, INSR			Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1	Preclinical	5
BRD-K24697665-001-01-4::2.5::HTS	0.208787916351	BRD-K24697665-001-01-4::2.5::HTS	BRD-K24697665-001-01-4	bucillamine	2.5	HTS	immunosuppressant		rheumatology	rheumatoid arthritis	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O, CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	Launched	5
BRD-K24715592-406-02-1::2.53::HTS	-1.0275797060299998	BRD-K24715592-406-02-1::2.53::HTS	BRD-K24715592-406-02-1	ethacridine-lactate-monohydrate	2.53	HTS	DNA intercalating agent				CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	Preclinical	5
BRD-K24723746-036-02-5::2.5::HTS	-0.0575636706259	BRD-K24723746-036-02-5::2.5::HTS	BRD-K24723746-036-02-5	solifenacin-succinate	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1, O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1	Launched	5
BRD-K24771047-001-01-6::2.5::HTS	0.261464824414	BRD-K24771047-001-01-6::2.5::HTS	BRD-K24771047-001-01-6	ampalex	2.5	HTS	glutamate receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4			O=C(N1CCCCC1)c1ccc2nccnc2c1	Phase 2	5
BRD-K24790130-001-07-1::2.5::HTS	0.12119760131799999	BRD-K24790130-001-07-1::2.5::HTS	BRD-K24790130-001-07-1	tricaprylin	2.5	HTS			dermatology	cosmetic	CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC	Launched	5
BRD-K24820488-001-01-7::2.5::HTS	0.037959080380599995	BRD-K24820488-001-01-7::2.5::HTS	BRD-K24820488-001-01-7	CH-170	2.5	HTS					Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1	Phase 1	5
BRD-K24821794-001-01-4::2.5::HTS	0.711880842702	BRD-K24821794-001-01-4::2.5::HTS	BRD-K24821794-001-01-4	SGC-CBP30	2.5	HTS	bromodomain inhibitor	CREBBP, EP300			COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl	Preclinical	5
BRD-K24844714-001-24-5::2.5::HTS	-1.9069268220500002	BRD-K24844714-001-24-5::2.5::HTS	BRD-K24844714-001-24-5	5-fluorouracil	2.5	HTS	thymidylate synthase inhibitor	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O	Launched	5
BRD-K24869513-001-02-1::2.5::HTS	0.0792161954606	BRD-K24869513-001-02-1::2.5::HTS	BRD-K24869513-001-02-1	CNX-2006	2.5	HTS	EGFR inhibitor	EGFR			COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F	Preclinical	5
BRD-K24943235-001-01-3::2.5::HTS	0.0851900008637	BRD-K24943235-001-01-3::2.5::HTS	BRD-K24943235-001-01-3	grazoprevir	2.5	HTS	HCV inhibitor				COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C	Launched	5
BRD-K24968862-001-01-0::2.5::HTS	-0.137965280055	BRD-K24968862-001-01-0::2.5::HTS	BRD-K24968862-001-01-0	SB-683698	2.5	HTS	integrin antagonist	ITGA4, ITGAV, ITGB1, ITGB7			COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1	Phase 1	5
BRD-K25015158-001-01-2::2.5::HTS	0.114221589717	BRD-K25015158-001-01-2::2.5::HTS	BRD-K25015158-001-01-2	limaprost-alfadex	2.5	HTS	prostanoid receptor agonist	PTGER1	cardiology	claudication	CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O	Launched	5
BRD-K25114078-003-08-1::2.5::HTS	-0.33452956313099996	BRD-K25114078-003-08-1::2.5::HTS	BRD-K25114078-003-08-1	aminoguanidine	2.5	HTS	nitric oxide synthase inhibitor	NOS2			NNC(N)=N, NNC(N)=N	Phase 3	5
BRD-K25140590-001-03-0::2.5::HTS	-0.51858103516	BRD-K25140590-001-03-0::2.5::HTS	BRD-K25140590-001-03-0	CX-516	2.5	HTS	glutamate receptor modulator				O=C(N1CCCCC1)c1ccc2OCOc2c1	Phase 2/Phase 3	5
BRD-K25186396-001-09-6::2.5::HTS	0.43466001741099997	BRD-K25186396-001-09-6::2.5::HTS	BRD-K25186396-001-09-6	tangeritin	2.5	HTS	cell cycle inhibitor				COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	Preclinical	5
BRD-K25204779-001-01-1::2.5::HTS	0.26953881339	BRD-K25204779-001-01-1::2.5::HTS	BRD-K25204779-001-01-1	pritelivir	2.5	HTS	helicase primase inhibitor				CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O	Phase 2	5
BRD-K25224017-001-25-0::2.5::HTS	0.256549461189	BRD-K25224017-001-25-0::2.5::HTS	BRD-K25224017-001-25-0	pirenperone	2.5	HTS	serotonin receptor antagonist	HTR2A, HTR7			Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1	Preclinical	5
BRD-K25244359-066-03-4::2.68::HTS	-0.679242704243	BRD-K25244359-066-03-4::2.68::HTS	BRD-K25244359-066-03-4	apatinib	2.68	HTS	RET tyrosine kinase inhibitor	CSK, KDR, KIT, RET			O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1	Phase 3	5
BRD-K25279140-001-01-5::2.5::HTS	-0.381546697192	BRD-K25279140-001-01-5::2.5::HTS	BRD-K25279140-001-01-5	MK-8745	2.5	HTS	Aurora kinase inhibitor	AURKA			Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1	Preclinical	5
BRD-K25311561-001-10-7::2.5::HTS	0.264832327722	BRD-K25311561-001-10-7::2.5::HTS	BRD-K25311561-001-10-7	KU-55933	2.5	HTS	ATM kinase inhibitor	ATM, PRKDC			O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1, O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1	Preclinical	5
BRD-K25312248-001-01-5::2.5::HTS	-0.29763993491	BRD-K25312248-001-01-5::2.5::HTS	BRD-K25312248-001-01-5	matrine	2.5	HTS	opioid receptor agonist	OPRK1			O=C1CCC[C@@H]2[C@@H]3CCCN4CCC[C@H](CN12)[C@@H]34	Phase 2	5
BRD-K25317177-065-01-4::2.5::HTS	-0.277630121911	BRD-K25317177-065-01-4::2.5::HTS	BRD-K25317177-065-01-4	modaline	2.5	HTS					Cc1nccnc1N1CCCCC1	Preclinical	5
BRD-K25340465-001-11-1::2.58::HTS	-1.04085749489	BRD-K25340465-001-11-1::2.58::HTS	BRD-K25340465-001-11-1	OSI-930	2.58	HTS	KIT inhibitor, VEGFR inhibitor	KDR, KIT			FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1	Phase 1	5
BRD-K25359048-001-02-6::2.5::HTS	-0.0896716239785	BRD-K25359048-001-02-6::2.5::HTS	BRD-K25359048-001-02-6	WZ811	2.5	HTS	CC chemokine receptor antagonist	CXCR4			C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1	Preclinical	5
BRD-K25394294-001-14-9::2.5::HTS	-0.19312588365299999	BRD-K25394294-001-14-9::2.5::HTS	BRD-K25394294-001-14-9	oxaprozin	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1	Launched	5
BRD-K25412176-001-01-9::2.5::HTS	0.16826707400899998	BRD-K25412176-001-01-9::2.5::HTS	BRD-K25412176-001-01-9	GSK2110183	2.5	HTS	AKT inhibitor	AKT1, AKT2, AKT3			Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1	Phase 2	5
BRD-K25433859-003-25-4::2.5::HTS	-0.37325752978	BRD-K25433859-003-25-4::2.5::HTS	BRD-K25433859-003-25-4	maprotiline	2.5	HTS	norepinephrine reputake inhibitor, tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2	neurology/psychiatry	depression, dysthymic disorder	CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21	Launched	5
BRD-K25486274-300-01-0::2.5::HTS	0.0450739507553	BRD-K25486274-300-01-0::2.5::HTS	BRD-K25486274-300-01-0	DRF053-(R)	2.5	HTS	CDK inhibitor	CSNK1A1			CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1	Preclinical	5
BRD-K25596805-001-01-8::2.5::HTS	-0.196551011865	BRD-K25596805-001-01-8::2.5::HTS	BRD-K25596805-001-01-8	JNJ-16259685	2.5	HTS	glutamate receptor antagonist	GRM1			CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1	Preclinical	5
BRD-K25630527-001-03-8::2.5::HTS	-0.845790243373	BRD-K25630527-001-03-8::2.5::HTS	BRD-K25630527-001-03-8	LY2784544	2.5	HTS	JAK inhibitor	JAK2, JAK3			Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1	Phase 2	5
BRD-K25649279-001-02-0::2.5::HTS	0.23628453415800002	BRD-K25649279-001-02-0::2.5::HTS	BRD-K25649279-001-02-0	2-iodomelatonin	2.5	HTS	melatonin receptor agonist	MTNR1A, MTNR1B, NQO2			COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1	Preclinical	5
BRD-K25650355-065-02-0::2.5::HTS	0.10022962849	BRD-K25650355-065-02-0::2.5::HTS	BRD-K25650355-065-02-0	physostigmine	2.5	HTS	cholinesterase inhibitor	ACHE, BCHE	cardiology, neurology/psychiatry, ophthalmology, gastroenterology	hypotension, Alzheimer's disease, glaucoma, gastroparesis	CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	Launched	5
BRD-K25690923-001-02-4::2.5::HTS	-0.014180326399499999	BRD-K25690923-001-02-4::2.5::HTS	BRD-K25690923-001-02-4	4-iodo-6-phenylpyrimidine	2.5	HTS	macrophage migration inhibiting factor inhibitor	MIF			Ic1cc(ncn1)-c1ccccc1	Preclinical	5
BRD-K25691735-001-09-5::2.5::HTS	-0.281984264454	BRD-K25691735-001-09-5::2.5::HTS	BRD-K25691735-001-09-5	chuanxiongzine	2.5	HTS					Cc1nc(C)c(C)nc1C	Phase 2	5
BRD-K25699529-003-01-1::2.5::HTS	-0.0401734368015	BRD-K25699529-003-01-1::2.5::HTS	BRD-K25699529-003-01-1	tapentadol	2.5	HTS	opioid receptor agonist	HTR3A, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A4	neurology/psychiatry	acute pain, muscle pain	CC[C@@H]([C@@H](C)CN(C)C)c1cccc(O)c1, CC[C@H]([C@@H](C)CN(C)C)c1cccc(O)c1, CC[C@H]([C@@H](C)CN(C)C)c1cccc(O)c1	Launched	5
BRD-K25723200-001-02-7::2.5::HTS	-0.319876857718	BRD-K25723200-001-02-7::2.5::HTS	BRD-K25723200-001-02-7	azilsartan-medoxomil	2.5	HTS	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	Launched	5
BRD-K25835157-001-01-4::2.5::HTS	0.08303890999369999	BRD-K25835157-001-01-4::2.5::HTS	BRD-K25835157-001-01-4	PRT062070	2.5	HTS	JAK inhibitor, syk inhibitor	SYK			CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1	Phase 1	5
BRD-K25837718-001-03-8::2.5::HTS	-0.42390000978500003	BRD-K25837718-001-03-8::2.5::HTS	BRD-K25837718-001-03-8	josamycin	2.5	HTS	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O	Launched	5
BRD-K25875056-001-02-0::2.5::HTS	-0.656820202041	BRD-K25875056-001-02-0::2.5::HTS	BRD-K25875056-001-02-0	SC-9	2.5	HTS	protein tyrosine kinase activator	PRKCA			Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1	Preclinical	5
BRD-K25906698-303-02-7::2.5::HTS	0.218427006051	BRD-K25906698-303-02-7::2.5::HTS	BRD-K25906698-303-02-7	immepip	2.5	HTS	histamine receptor agonist	HRH3, HRH4			C(C1CCNCC1)c1c[nH]cn1	Preclinical	5
BRD-K25943794-001-02-3::2.5::HTS	0.314419113644	BRD-K25943794-001-02-3::2.5::HTS	BRD-K25943794-001-02-3	blonanserin	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1	Launched	5
BRD-K25991633-001-01-9::2.5::HTS	-0.378214817914	BRD-K25991633-001-01-9::2.5::HTS	BRD-K25991633-001-01-9	BMS-649	2.5	HTS	retinoid receptor agonist	RXRA			CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O	Preclinical	5
BRD-K26005076-001-12-8::2.5::HTS	0.326650688497	BRD-K26005076-001-12-8::2.5::HTS	BRD-K26005076-001-12-8	gramine	2.5	HTS	norepinephrine reputake inhibitor				CN(C)Cc1c[nH]c2ccccc12	Preclinical	5
BRD-K26011976-001-01-0::2.5::HTS	-0.084806913557	BRD-K26011976-001-01-0::2.5::HTS	BRD-K26011976-001-01-0	licochalcone-a	2.5	HTS	topoisomerase inhibitor	PTPN1			COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C	Phase 3	5
BRD-K26060080-065-05-6::2.5::HTS	-0.576273217763	BRD-K26060080-065-05-6::2.5::HTS	BRD-K26060080-065-05-6	adenine	2.5	HTS	protein synthesis stimulant	ACACB, ACP1, APRT, MTAP, PECR, SRPK2			Nc1ncnc2[nH]cnc12, Nc1ncnc2[nH]cnc12, Nc1ncnc2[nH]cnc12, Nc1ncnc2[nH]cnc12	Preclinical	5
BRD-K26160755-003-02-6::2.5::HTS	-0.0141328869441	BRD-K26160755-003-02-6::2.5::HTS	BRD-K26160755-003-02-6	RS-45041-190	2.5	HTS	imidazoline receptor agonist				Clc1cccc2CN(Cc12)C1=NCCN1	Preclinical	5
BRD-K26168087-001-09-7::2.5::HTS	-1.1877607949299998	BRD-K26168087-001-09-7::2.5::HTS	BRD-K26168087-001-09-7	magnolol	2.5	HTS	PPAR receptor agonist	GABRA1, PPARG			Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O	Preclinical	5
BRD-K26222048-001-01-7::2.5::HTS	0.0747442255935	BRD-K26222048-001-01-7::2.5::HTS	BRD-K26222048-001-01-7	trans-10,cis-12-Conjugated-linoleic-acid	2.5	HTS					CCCCC\C=C/C=C/CCCCCCCCC(O)=O	Launched	5
BRD-K26253904-001-01-5::2.5::HTS	-1.00579367612	BRD-K26253904-001-01-5::2.5::HTS	BRD-K26253904-001-01-5	NMS-873	2.5	HTS	ATPase inhibitor	VCP			Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O	Preclinical	5
BRD-K26262077-238-01-5::2.5::HTS	-0.0231091974116	BRD-K26262077-238-01-5::2.5::HTS	BRD-K26262077-238-01-5	acamprosate	2.5	HTS	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5	neurology/psychiatry	abstinence from alcohol	CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O	Launched	5
BRD-K26305185-001-02-1::2.5::HTS	0.362576506632	BRD-K26305185-001-02-1::2.5::HTS	BRD-K26305185-001-02-1	K-Ras(G12C)-inhibitor-6	2.5	HTS	K-ras inhibitor				SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl	Preclinical	5
BRD-K26325692-003-01-3::2.5::HTS	0.106857515087	BRD-K26325692-003-01-3::2.5::HTS	BRD-K26325692-003-01-3	API-001	2.5	HTS	sigma receptor antagonist	SIGMAR1			Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	Phase 2	5
BRD-K26341917-001-01-3::2.5::HTS	0.138320290989	BRD-K26341917-001-01-3::2.5::HTS	BRD-K26341917-001-01-3	L-ergothioneine	2.5	HTS	free radical scavenger				C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O	Phase 2	5
BRD-K26349472-001-01-3::2.5::HTS	0.363088199093	BRD-K26349472-001-01-3::2.5::HTS	BRD-K26349472-001-01-3	OG-L002	2.5	HTS	histone lysine demethylase inhibitor	KDM1A			N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1	Preclinical	5
BRD-K26373640-001-05-1::2.5::HTS	-0.110820988688	BRD-K26373640-001-05-1::2.5::HTS	BRD-K26373640-001-05-1	IKK-2-inhibitor	2.5	HTS	IKK inhibitor, SYK inhibitor	IKBKB			NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1	Preclinical	5
BRD-K26502378-001-07-9::2.5::HTS	0.5633692366049999	BRD-K26502378-001-07-9::2.5::HTS	BRD-K26502378-001-07-9	vanitiolide	2.5	HTS					COc1cc(ccc1O)C(=S)N1CCOCC1	Preclinical	5
BRD-K26531771-001-01-4::2.5::HTS	0.435653663054	BRD-K26531771-001-01-4::2.5::HTS	BRD-K26531771-001-01-4	EPZ-5676	2.5	HTS	histone lysine methyltransferase inhibitor	DOT1L			CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1	Phase 1	5
BRD-K26531771-001-02-2::2.35::HTS	0.6866349322930001	BRD-K26531771-001-02-2::2.35::HTS	BRD-K26531771-001-02-2	EPZ-5676	2.35	HTS	histone lysine methyltransferase inhibitor	DOT1L			CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1	Phase 1	5
BRD-K26548821-003-10-5::2.5::HTS	0.178005208548	BRD-K26548821-003-10-5::2.5::HTS	BRD-K26548821-003-10-5	quinpirol-(-)	2.5	HTS	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C			CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@@H]12	Phase 2	5
BRD-K26573499-300-02-1::2.5::HTS	-0.130277182241	BRD-K26573499-300-02-1::2.5::HTS	BRD-K26573499-300-02-1	DMAB-anabaseine	2.5	HTS	adrenergic receptor agonist	CHRNA7			CN(C)c1ccc(cc1)\C=C1CCCN=C/1c1cccnc1, CN(C)c1ccc(cc1)\C=C1CCCN=C/1c1cccnc1	Preclinical	5
BRD-K26581543-001-01-6::2.5::HTS	-0.30500029117	BRD-K26581543-001-01-6::2.5::HTS	BRD-K26581543-001-01-6	bifendate	2.5	HTS					COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC	Launched	5
BRD-K26603252-003-04-9::2.5::HTS	0.659193860618	BRD-K26603252-003-04-9::2.5::HTS	BRD-K26603252-003-04-9	PD-153035	2.5	HTS	EGFR inhibitor	EGFR, KDR			COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC	Phase 1	5
BRD-K26619122-001-02-1::2.5::HTS	0.151853470951	BRD-K26619122-001-02-1::2.5::HTS	BRD-K26619122-001-02-1	thiocolchicoside	2.5	HTS	GABA receptor antagonist	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC	Launched	5
BRD-K26634012-001-04-9::2.5::HTS	-0.215760748727	BRD-K26634012-001-04-9::2.5::HTS	BRD-K26634012-001-04-9	tilmicosin	2.5	HTS	bacterial 50S ribosomal subunit inhibitor		pulmonary	bovine respiratory disease (BRD)	CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC	Launched	5
BRD-K26657438-001-15-2::2.5::HTS	0.0137649661724	BRD-K26657438-001-15-2::2.5::HTS	BRD-K26657438-001-15-2	imiquimod	2.5	HTS	interferon inducer, toll-like receptor agonist	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12	Launched	5
BRD-K26667523-001-02-5::2.5::HTS	-4.50865729287	BRD-K26667523-001-02-5::2.5::HTS	BRD-K26667523-001-02-5	TAK-733	2.5	HTS	MEK inhibitor	MAP2K1			Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O	Phase 1	5
BRD-K26701552-001-01-8::2.5::HTS	-0.055007386518900005	BRD-K26701552-001-01-8::2.5::HTS	BRD-K26701552-001-01-8	tegobuvir	2.5	HTS	HCV inhibitor, protease inhibitor				Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1	Phase 3	5
BRD-K26712974-001-01-5::2.5::HTS	-0.367378275229	BRD-K26712974-001-01-5::2.5::HTS	BRD-K26712974-001-01-5	VX-765	2.5	HTS	caspase inhibitor	CASP1			CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C	Phase 2	5
BRD-K26739552-003-15-4::2.5::HTS	0.0644572379569	BRD-K26739552-003-15-4::2.5::HTS	BRD-K26739552-003-15-4	fenspiride	2.5	HTS	bronchodilator		pulmonary, otolaryngology	asthma, otitis, sinusitis, rhinopharyngitis, laryngitis	O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1	Launched	5
BRD-K26756394-001-02-2::2.5::HTS	0.544187105423	BRD-K26756394-001-02-2::2.5::HTS	BRD-K26756394-001-02-2	VE-821	2.5	HTS	ATR kinase inhibitor	ATR			CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1	Preclinical	5
BRD-K26801045-001-02-9::2.5::HTS	0.187667300875	BRD-K26801045-001-02-9::2.5::HTS	BRD-K26801045-001-02-9	pipamperone	2.5	HTS	dopamine receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A	neurology/psychiatry	schizophrenia	NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1	Launched	5
BRD-K26807903-001-04-3::2.5::HTS	0.344255451854	BRD-K26807903-001-04-3::2.5::HTS	BRD-K26807903-001-04-3	aklomide	2.5	HTS			infectious disease	coccidiosis	NC(=O)c1ccc(cc1Cl)[N+]([O-])=O	Launched	5
BRD-K26818574-305-04-3::2.5::HTS	0.445923634454	BRD-K26818574-305-04-3::2.5::HTS	BRD-K26818574-305-04-3	BIX-01294	2.5	HTS	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	Preclinical	5
BRD-K26823213-001-02-9::2.5::HTS	-1.0578362956999998	BRD-K26823213-001-02-9::2.5::HTS	BRD-K26823213-001-02-9	GW-842166	2.5	HTS	cannabinoid receptor agonist	CNR2			FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	Phase 2	5
BRD-K26824830-001-02-0::2.5::HTS	0.452804565514	BRD-K26824830-001-02-0::2.5::HTS	BRD-K26824830-001-02-0	azomycin-(2-nitroimidazole)	2.5	HTS	protein synthesis inhibitor				[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1	Preclinical	5
BRD-K26833429-001-02-8::2.5::HTS	1.12958306174	BRD-K26833429-001-02-8::2.5::HTS	BRD-K26833429-001-02-8	costunolide	2.5	HTS	telomerase inhibitor				C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1	Preclinical	5
BRD-K26838195-075-04-9::2.5::HTS	0.257331231524	BRD-K26838195-075-04-9::2.5::HTS	BRD-K26838195-075-04-9	AST-1306	2.5	HTS	EGFR inhibitor	EGFR, ERBB2			Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1	Phase 1	5
BRD-K26862302-001-05-2::2.5::HTS	0.056476050560099994	BRD-K26862302-001-05-2::2.5::HTS	BRD-K26862302-001-05-2	diosmetin	2.5	HTS	aryl hydrocarbon receptor agonist	CYP1B1	dermatology	cosmetic	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1	Launched	5
BRD-K26901728-001-06-2::2.5::HTS	0.219372476768	BRD-K26901728-001-06-2::2.5::HTS	BRD-K26901728-001-06-2	lumiracoxib	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2			Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1	Withdrawn	5
BRD-K26989966-001-03-5::2.5::HTS	0.346978140634	BRD-K26989966-001-03-5::2.5::HTS	BRD-K26989966-001-03-5	UNC1999	2.5	HTS	histone lysine methyltransferase inhibitor	EZH2			CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C	Preclinical	5
BRD-K26997899-001-02-2::2.5::HTS	-0.752563929938	BRD-K26997899-001-02-2::2.5::HTS	BRD-K26997899-001-02-2	D-64131	2.5	HTS	microtubule inhibitor	TUBB			COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1	Preclinical	5
BRD-K27062708-001-23-1::2.5::HTS	-0.0230344404929	BRD-K27062708-001-23-1::2.5::HTS	BRD-K27062708-001-23-1	chlorotrianisene	2.5	HTS	estrogenic hormone	ESR1, ESR2	endocrinology, oncology	menopause, prostate cancer	COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1	Launched	5
BRD-K27135764-001-08-7::2.5::HTS	-0.308380550214	BRD-K27135764-001-08-7::2.5::HTS	BRD-K27135764-001-08-7	xanthone	2.5	HTS	antimalarial agent				O=c1c2ccccc2oc2ccccc12	Preclinical	5
BRD-K27141178-003-07-3::2.5::HTS	-0.299908583869	BRD-K27141178-003-07-3::2.5::HTS	BRD-K27141178-003-07-3	SB-203186	2.5	HTS	serotonin receptor antagonist	HTR4			O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12	Preclinical	5
BRD-K27168049-001-02-8::2.5::HTS	0.453150449098	BRD-K27168049-001-02-8::2.5::HTS	BRD-K27168049-001-02-8	SDZ-220-581	2.5	HTS	glutamate receptor antagonist	GRIN1			N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O	Preclinical	5
BRD-K27182532-001-02-3::2.5::HTS	-0.0229433226142	BRD-K27182532-001-02-3::2.5::HTS	BRD-K27182532-001-02-3	metatinib	2.5	HTS	Bcr-Abl kinase inhibitor	ABL1, BCR			Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	Phase 1	5
BRD-K27184429-300-01-3::2.5::HTS	-0.186135682382	BRD-K27184429-300-01-3::2.5::HTS	BRD-K27184429-300-01-3	levocetirizine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1	Launched	5
BRD-K27204852-001-01-9::2.5::HTS	-0.150968385303	BRD-K27204852-001-01-9::2.5::HTS	BRD-K27204852-001-01-9	balicatib	2.5	HTS	cathepsin inhibitor	CTSK			CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N	Phase 2	5
BRD-K27217864-001-22-3::2.5::HTS	-0.0143020696209	BRD-K27217864-001-22-3::2.5::HTS	BRD-K27217864-001-22-3	butamben	2.5	HTS	sodium channel blocker				CCCCOC(=O)c1ccc(N)cc1	Withdrawn	5
BRD-K27305650-001-16-6::2.5::HTS	0.6070736563069999	BRD-K27305650-001-16-6::2.5::HTS	BRD-K27305650-001-16-6	LY294002	2.5	HTS	mTOR inhibitor, PI3K inhibitor, DNA dependent protein kinase inhibitor, phosphodiesterase inhibitor, PLK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1			O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1	Preclinical	5
BRD-K27316855-001-13-3::2.44::HTS	0.365459727409	BRD-K27316855-001-13-3::2.44::HTS	BRD-K27316855-001-13-3	calcitriol	2.44	HTS	vitamin D receptor agonist	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	5
BRD-K27316855-001-19-0::2.5::HTS	-0.09689729820810002	BRD-K27316855-001-19-0::2.5::HTS	BRD-K27316855-001-19-0	calcitriol	2.5	HTS	vitamin D receptor agonist	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	5
BRD-K27335680-001-10-0::2.5::HTS	0.286208736666	BRD-K27335680-001-10-0::2.5::HTS	BRD-K27335680-001-10-0	rhein	2.5	HTS		HSP90AA1			OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Phase 1	5
BRD-K27351809-001-09-5::2.5::HTS	-0.0912112298718	BRD-K27351809-001-09-5::2.5::HTS	BRD-K27351809-001-09-5	nomegestrol-acetate	2.5	HTS	progesterone receptor agonist	PGR	endocrinology	contraceptive	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O	Launched	5
BRD-K27382019-418-01-9::2.5::HTS	0.242863900755	BRD-K27382019-418-01-9::2.5::HTS	BRD-K27382019-418-01-9	piperaquine-phosphate	2.5	HTS	antimalarial agent		infectious disease	malaria	Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1	Launched	5
BRD-K27393415-001-01-0::2.5::HTS	-0.66197032158	BRD-K27393415-001-01-0::2.5::HTS	BRD-K27393415-001-01-0	xipamide	2.5	HTS	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O	Launched	5
BRD-K27406233-001-07-7::2.5::HTS	0.00450443810013	BRD-K27406233-001-07-7::2.5::HTS	BRD-K27406233-001-07-7	acetyl-l-leucine	2.5	HTS			neurology/psychiatry	vertigo	CC(C)C[C@H](NC(C)=O)C(O)=O	Launched	5
BRD-K27721098-065-08-6::2.5::HTS	0.301929246437	BRD-K27721098-065-08-6::2.5::HTS	BRD-K27721098-065-08-6	clopidogrel	2.5	HTS	purinergic receptor antagonist	P2RY12	cardiology, neurology/psychiatry	myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)	COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl	Launched	5
BRD-K27737647-300-03-0::2.5::HTS	0.20607686371599998	BRD-K27737647-300-03-0::2.5::HTS	BRD-K27737647-300-03-0	H-89	2.5	HTS	PKA inhibitor	GSG2, PKIA, PRKACA			Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1	Preclinical	5
BRD-K27771035-001-02-5::2.5::HTS	0.19040587748399998	BRD-K27771035-001-02-5::2.5::HTS	BRD-K27771035-001-02-5	clindamycin-phosphate	2.5	HTS	protein synthesis inhibitor		obstetrics/gynecology	bacterial vaginosis	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O	Launched	5
BRD-K27799744-001-02-8::2.52::HTS	-0.09224024636700001	BRD-K27799744-001-02-8::2.52::HTS	BRD-K27799744-001-02-8	cyclovirobuxin-d	2.52	HTS	calcium channel modulator				CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C	Preclinical	5
BRD-K27853494-003-04-7::2.5::HTS	0.08601645941870001	BRD-K27853494-003-04-7::2.5::HTS	BRD-K27853494-003-04-7	1s,2r-phenylpropanolamine	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRB1, ADRB2, DRD1			C[C@@H](N)[C@@H](O)c1ccccc1	Withdrawn	5
BRD-K27871792-001-01-8::2.5::HTS	-0.655100044874	BRD-K27871792-001-01-8::2.5::HTS	BRD-K27871792-001-01-8	flucloxacillin	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, dermatology, gastroenterology	gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl	Launched	5
BRD-K27911943-001-02-8::2.5::HTS	-0.58727629879	BRD-K27911943-001-02-8::2.5::HTS	BRD-K27911943-001-02-8	chromanol-293B-(-)-[3R,4S]	2.5	HTS	potassium channel blocker				CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N	Preclinical	5
BRD-K27938825-001-02-4::2.5::HTS	0.16623700944	BRD-K27938825-001-02-4::2.5::HTS	BRD-K27938825-001-02-4	ASA-404	2.5	HTS	angiogenesis inhibitor				Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C	Phase 3	5
BRD-K27955832-001-02-9::2.5::HTS	0.5031089866699999	BRD-K27955832-001-02-9::2.5::HTS	BRD-K27955832-001-02-9	lomeguatrib	2.5	HTS	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1	Phase 2	5
BRD-K28007504-051-01-2::2.5::HTS	0.652956538063	BRD-K28007504-051-01-2::2.5::HTS	BRD-K28007504-051-01-2	Ro-60-0175	2.5	HTS		HTR2A, HTR2B, HTR2C			C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12	Preclinical	5
BRD-K28029915-001-02-2::2.5::HTS	0.340089342095	BRD-K28029915-001-02-2::2.5::HTS	BRD-K28029915-001-02-2	dolasetron	2.5	HTS	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12	Launched	5
BRD-K28042756-001-01-9::5::HTS	-0.111778614461	BRD-K28042756-001-01-9::5::HTS	BRD-K28042756-001-01-9		5.0	HTS							5
BRD-K28059174-334-01-2::2.5::HTS	0.188722913602	BRD-K28059174-334-01-2::2.5::HTS	BRD-K28059174-334-01-2	INCB-003284	2.5	HTS	CC chemokine receptor antagonist				COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	Phase 2	5
BRD-K28115081-001-02-7::2.5::HTS	0.08856845807710001	BRD-K28115081-001-02-7::2.5::HTS	BRD-K28115081-001-02-7	apafant	2.5	HTS	platelet activating factor receptor antagonist	PTAFR			Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl	Phase 3	5
BRD-K28120222-001-08-4::2.5::HTS	0.729443781814	BRD-K28120222-001-08-4::2.5::HTS	BRD-K28120222-001-08-4	parthenolide-(alternate-stereo)	2.5	HTS	NFkB pathway inhibitor	IKBKB, RELA			C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	Preclinical	5
BRD-K28121004-001-01-1::2.5::HTS	0.0919293442939	BRD-K28121004-001-01-1::2.5::HTS	BRD-K28121004-001-01-1	N-acetylglycyl-D-glutamic-acid	2.5	HTS	glutamate receptor agonist				CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O, CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O	Preclinical	5
BRD-K28143534-001-02-2::2.5::HTS	-0.416557152266	BRD-K28143534-001-02-2::2.5::HTS	BRD-K28143534-001-02-2	cyproheptadine	2.5	HTS	histamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12	Launched	5
BRD-K28143534-003-25-9::2.5::HTS	0.0488967306444	BRD-K28143534-003-25-9::2.5::HTS	BRD-K28143534-003-25-9	cyproheptadine	2.5	HTS	histamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12	Launched	5
BRD-K28183345-003-11-4::2.5::HTS	0.350599593525	BRD-K28183345-003-11-4::2.5::HTS	BRD-K28183345-003-11-4	proguanil	2.5	HTS	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1	Launched	5
BRD-K28192623-066-08-1::2.5::HTS	0.376479125413	BRD-K28192623-066-08-1::2.5::HTS	BRD-K28192623-066-08-1	spiradoline	2.5	HTS	opioid receptor agonist	OPRK1			CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	Phase 2	5
BRD-K28210218-236-08-1::2.5::HTS	-0.170934687282	BRD-K28210218-236-08-1::2.5::HTS	BRD-K28210218-236-08-1	cephalothin	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, surgical prophylaxis	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O	Launched	5
BRD-K28217197-001-01-4::2.5::HTS	-1.4306074998500002	BRD-K28217197-001-01-4::2.5::HTS	BRD-K28217197-001-01-4	ganaxolone	2.5	HTS	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 3	5
BRD-K28307902-001-21-7::2.5::HTS	0.0671690163576	BRD-K28307902-001-21-7::2.5::HTS	BRD-K28307902-001-21-7	flutamide	2.5	HTS	androgen receptor antagonist	AHR, AR	oncology	prostate cancer	CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Launched	5
BRD-K28308851-303-01-8::2.5::HTS	-0.391959576876	BRD-K28308851-303-01-8::2.5::HTS	BRD-K28308851-303-01-8	alpha-methylhistamine-dihydrobromide-(S)-(+)	2.5	HTS	histamine receptor agonist	HRH3			C[C@H](N)Cc1c[nH]cn1	Preclinical	5
BRD-K28343777-001-01-6::2.5::HTS	0.0760745562063	BRD-K28343777-001-01-6::2.5::HTS	BRD-K28343777-001-01-6	20-hydroxyecdysone	2.5	HTS	ecdysone receptor modulator				CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C	Preclinical	5
BRD-K28352084-001-02-3::2.5::HTS	0.321478998893	BRD-K28352084-001-02-3::2.5::HTS	BRD-K28352084-001-02-3	CH5132799	2.5	HTS	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1	Phase 1	5
BRD-K28360340-001-08-3::2.31::HTS	-1.41793204442	BRD-K28360340-001-08-3::2.31::HTS	BRD-K28360340-001-08-3	TW-37	2.31	HTS	BCL inhibitor	BCL2, BCL2L1, MCL1			CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O	Preclinical	5
BRD-K28383148-001-01-4::2.5::HTS	0.42234029020499997	BRD-K28383148-001-01-4::2.5::HTS	BRD-K28383148-001-01-4	AP1903	2.5	HTS					CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1	Phase 1/Phase 2	5
BRD-K28392481-001-05-1::2.5::HTS	0.170732970307	BRD-K28392481-001-05-1::2.5::HTS	BRD-K28392481-001-05-1	AZD4547	2.5	HTS	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR			COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1	Phase 2/Phase 3	5
BRD-K28405228-001-06-7::2.5::HTS	0.027209029224299998	BRD-K28405228-001-06-7::2.5::HTS	BRD-K28405228-001-06-7	mecarbinate	2.5	HTS					CCOC(=O)c1c(C)n(C)c2ccc(O)cc12	Preclinical	5
BRD-K28428262-001-04-1::2.5::HTS	0.760376963434	BRD-K28428262-001-04-1::2.5::HTS	BRD-K28428262-001-04-1	brivanib	2.5	HTS	FGFR inhibitor, VEGFR inhibitor	CYP3A4, FGFR1, FLT1, KCNH2, KDR			C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C	Phase 3	5
BRD-K28442028-001-01-3::2.5::HTS	-0.0389993537074	BRD-K28442028-001-01-3::2.5::HTS	BRD-K28442028-001-01-3	R-1479	2.5	HTS	HCV inhibitor				Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1	Phase 1	5
BRD-K28453807-003-11-2::2.5::HTS	-0.22778993186500002	BRD-K28453807-003-11-2::2.5::HTS	BRD-K28453807-003-11-2	nitrocaramiphen	2.5	HTS	cholinergic receptor antagonist	CHRM1			CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O	Preclinical	5
BRD-K28456624-001-01-1::2.5::HTS	0.496344660404	BRD-K28456624-001-01-1::2.5::HTS	BRD-K28456624-001-01-1	seocalcitol	2.5	HTS	vitamin D receptor agonist	VDR			CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Phase 3	5
BRD-K28492574-001-01-6::2.5::HTS	0.43025361381099997	BRD-K28492574-001-01-6::2.5::HTS	BRD-K28492574-001-01-6	piconol	2.5	HTS					OCc1ccccn1	Preclinical	5
BRD-K28494619-001-28-2::2.5::HTS	-0.8775906376579999	BRD-K28494619-001-28-2::2.5::HTS	BRD-K28494619-001-28-2	sulfamethoxazole	2.5	HTS	PABA antagonist		infectious disease, gastroenterology	pneumonia, enteritis, urinary tract infections	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1	Launched	5
BRD-K28542495-003-13-5::2.5::HTS	-0.286162591099	BRD-K28542495-003-13-5::2.5::HTS	BRD-K28542495-003-13-5	benzydamine	2.5	HTS	prostanoid receptor antagonist		dental, otolaryngology	mouth inflammation, throat inflammation	CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12	Launched	5
BRD-K28570407-001-02-0::2.5::HTS	0.311879886967	BRD-K28570407-001-02-0::2.5::HTS	BRD-K28570407-001-02-0	A-803467	2.5	HTS	sodium channel blocker	SCN10A			COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1	Preclinical	5
BRD-K28578425-001-07-0::2.5::HTS	-0.0836121102958	BRD-K28578425-001-07-0::2.5::HTS	BRD-K28578425-001-07-0	cilostamide	2.5	HTS	phosphodiesterase inhibitor	PDE3A, PDE3B			CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1	Preclinical	5
BRD-K28595280-001-04-5::2.5::HTS	0.0542481735485	BRD-K28595280-001-04-5::2.5::HTS	BRD-K28595280-001-04-5	meglumine	2.5	HTS	excipient				CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	Launched	5
BRD-K28667793-001-28-1::2.5::HTS	-0.25842332599199996	BRD-K28667793-001-28-1::2.5::HTS	BRD-K28667793-001-28-1	pyrazinamide	2.5	HTS	fatty acid synthase inhibitor	FASN	infectious disease	tuberculosis	NC(=O)c1cnccn1, NC(=O)c1cnccn1	Launched	5
BRD-K28690501-001-02-1::2.5::HTS	0.295628946009	BRD-K28690501-001-02-1::2.5::HTS	BRD-K28690501-001-02-1	diosgenin	2.5	HTS	steroid				C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1	Preclinical	5
BRD-K28761384-300-01-0::2.5::HTS	0.133962866469	BRD-K28761384-300-01-0::2.5::HTS	BRD-K28761384-300-01-0	zuclopenthixol	2.5	HTS	dopamine receptor antagonist	ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched	5
BRD-K28761891-001-10-1::2.5::HTS	0.029742860696	BRD-K28761891-001-10-1::2.5::HTS	BRD-K28761891-001-10-1	ramelteon	2.5	HTS	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	insomnia	CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12, CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12	Launched	5
BRD-K28822270-001-01-1::2.5::HTS	-1.6344918340799999	BRD-K28822270-001-01-1::2.5::HTS	BRD-K28822270-001-01-1	resminostat	2.5	HTS	HDAC inhibitor	HDAC1, HDAC3, HDAC6, HDAC8			CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO	Phase 2	5
BRD-K28824103-001-02-8::2.5::HTS	-0.498184789385	BRD-K28824103-001-02-8::2.5::HTS	BRD-K28824103-001-02-8	genipin	2.5	HTS	choleretic agent				COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO	Preclinical	5
BRD-K28824103-001-04-4::2.5::HTS	0.45129542344499995	BRD-K28824103-001-04-4::2.5::HTS	BRD-K28824103-001-04-4	genipin	2.5	HTS	choleretic agent				COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO	Preclinical	5
BRD-K28849549-001-13-4::2.5::HTS	0.17952940236499998	BRD-K28849549-001-13-4::2.5::HTS	BRD-K28849549-001-13-4	mesalazine	2.5	HTS	cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis, inflammatory bowel disease	Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O	Launched	5
BRD-K28861668-001-01-9::2.5::HTS	0.589837099956	BRD-K28861668-001-01-9::2.5::HTS	BRD-K28861668-001-01-9	A922500	2.5	HTS	diacylglycerol O acyltransferase inhibitor	DGAT1			OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	Preclinical	5
BRD-K28863208-001-02-0::2.5::HTS	0.164699825635	BRD-K28863208-001-02-0::2.5::HTS	BRD-K28863208-001-02-0	PNU-282987	2.5	HTS	cholinergic receptor agonist	CHRNA7			Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2	Preclinical	5
BRD-K28907958-001-04-3::2.5::HTS	-1.14825594237	BRD-K28907958-001-04-3::2.5::HTS	BRD-K28907958-001-04-3	CD-437	2.5	HTS	retinoid receptor agonist	RARG			OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	Preclinical	5
BRD-K28912512-001-23-2::2.5::HTS	-0.0032612237752800005	BRD-K28912512-001-23-2::2.5::HTS	BRD-K28912512-001-23-2	nicotinamide	2.5	HTS	protein synthesis stimulant	BST1, LDHA, PARP1, SIRT5	dermatology	acne vulgaris (AV)	NC(=O)c1cccnc1, NC(=O)c1cccnc1, NC(=O)c1cccnc1	Launched	5
BRD-K28936863-051-33-0::2.5::HTS	-0.0487018003408	BRD-K28936863-051-33-0::2.5::HTS	BRD-K28936863-051-33-0	ketotifen	2.5	HTS	histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor	HRH1, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B, PGD	neurology/psychiatry	itching	CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12, CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12, CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12	Launched	5
BRD-K28965160-001-01-1::2.5::HTS	-2.5063254345500003	BRD-K28965160-001-01-1::2.5::HTS	BRD-K28965160-001-01-1	BVD-523	2.5	HTS	MAP kinase inhibitor				CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1	Phase 1/Phase 2	5
BRD-K28971625-003-01-4::2.5::HTS	0.00947332280563	BRD-K28971625-003-01-4::2.5::HTS	BRD-K28971625-003-01-4	ZD-7114	2.5	HTS	adrenergic receptor agonist	ADRB3			COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1	Phase 1	5
BRD-K28982731-001-01-6::2.5::HTS	0.004017890780969999	BRD-K28982731-001-01-6::2.5::HTS	BRD-K28982731-001-01-6	emoxipin	2.5	HTS					CCc1nc(C)ccc1O	Phase 2	5
BRD-K29133151-001-03-2::2.5::HTS	0.329217819982	BRD-K29133151-001-03-2::2.5::HTS	BRD-K29133151-001-03-2	ICI-185,282	2.5	HTS	thromboxane receptor antagonist				OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F	Phase 1	5
BRD-K29173907-001-09-2::2.5::HTS	-0.421490263064	BRD-K29173907-001-09-2::2.5::HTS	BRD-K29173907-001-09-2	isoflupredone-acetate	2.5	HTS		NR3C1			CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Preclinical	5
BRD-K29220403-001-10-8::2.5::HTS	0.119159471367	BRD-K29220403-001-10-8::2.5::HTS	BRD-K29220403-001-10-8	eszopiclone	2.5	HTS	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	insomnia	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)c2nccnc12)c1ccc(Cl)cn1	Launched	5
BRD-K29254801-001-14-7::2.5::HTS	-1.3573047478	BRD-K29254801-001-14-7::2.5::HTS	BRD-K29254801-001-14-7	thiram	2.5	HTS		JAK2	ophthalmology	contact dermatitis	CN(C)C(=S)SSC(=S)N(C)C	Launched	5
BRD-K29322660-001-01-9::2.5::HTS	-0.9576710724240001	BRD-K29322660-001-01-9::2.5::HTS	BRD-K29322660-001-01-9	edoxaban	2.5	HTS	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)	CN(C)C(=O)[C@@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@H](C1)NC(=O)c1nc2CCN(C)Cc2s1	Launched	5
BRD-K29359156-001-30-1::2.5::HTS	0.123301406949	BRD-K29359156-001-30-1::2.5::HTS	BRD-K29359156-001-30-1	ebselen	2.5	HTS	cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor	ALB			O=c1n([se]c2ccccc12)-c1ccccc1	Phase 2/Phase 3	5
BRD-K29392254-001-02-2::2.5::HTS	0.321124522167	BRD-K29392254-001-02-2::2.5::HTS	BRD-K29392254-001-02-2	pantothenic-acid	2.5	HTS	coenzyme A precursor				CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	Launched	5
BRD-K29395450-001-06-8::2.5::HTS	0.31649873541400003	BRD-K29395450-001-06-8::2.5::HTS	BRD-K29395450-001-06-8	PIK-93	2.5	HTS	PI3K inhibitor	PI4KB, PIK3C3, PIK3CG			CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO	Preclinical	5
BRD-K29415052-050-04-8::2.5::HTS	-6.09116499292	BRD-K29415052-050-04-8::2.5::HTS	BRD-K29415052-050-04-8	BGT226	2.5	HTS	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CG			COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1	Phase 1/Phase 2	5
BRD-K29458283-001-29-9::2.5::HTS	-0.44482809254699995	BRD-K29458283-001-29-9::2.5::HTS	BRD-K29458283-001-29-9	chlorambucil	2.5	HTS	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma	OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl	Launched	5
BRD-K29462201-001-01-9::2.5::HTS	0.06804509073869999	BRD-K29462201-001-01-9::2.5::HTS	BRD-K29462201-001-01-9	deserpidine	2.5	HTS	angiotensin converting enzyme inhibitor	ACE, SLC18A2	cardiology	hypertension	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	Launched	5
BRD-K29530284-001-06-2::2.5::HTS	0.179573663925	BRD-K29530284-001-06-2::2.5::HTS	BRD-K29530284-001-06-2	amlexanox	2.5	HTS	histamine receptor modulator	FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13	dental, pulmonary, ophthalmology, allergy	aphthous ulcers, asthma, conjunctivitis, allergic rhinitis	CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O	Launched	5
BRD-K29542628-001-03-9::2.5::HTS	-1.3827922687399998	BRD-K29542628-001-03-9::2.5::HTS	BRD-K29542628-001-03-9	1-naphthyl-PP1	2.5	HTS	src inhibitor	SRC			CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12	Preclinical	5
BRD-K29546239-001-02-3::2.5::HTS	0.173564475067	BRD-K29546239-001-02-3::2.5::HTS	BRD-K29546239-001-02-3	SNC-80	2.5	HTS		OPRD1			CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1	Preclinical	5
BRD-K29582115-066-01-2::2.5::HTS	0.00019649448594599998	BRD-K29582115-066-01-2::2.5::HTS	BRD-K29582115-066-01-2	ziprasidone	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12	Launched	5
BRD-K29582677-300-10-6::2.5::HTS	-0.188442064549	BRD-K29582677-300-10-6::2.5::HTS	BRD-K29582677-300-10-6	flunarizine	2.5	HTS	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1	neurology/psychiatry, cardiology	migraine headache, vertigo, peripheral artery disease (PAD)	Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	Launched	5
BRD-K29653726-001-13-4::2.5::HTS	0.260338874205	BRD-K29653726-001-13-4::2.5::HTS	BRD-K29653726-001-13-4	topiramate	2.5	HTS	carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist	CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, migraine headache	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	Launched	5
BRD-K29656036-001-02-5::2.5::HTS	0.590609711598	BRD-K29656036-001-02-5::2.5::HTS	BRD-K29656036-001-02-5	MK-8245	2.5	HTS	stearoyl-CoA desaturase inhibitor	SCD			OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br	Phase 2	5
BRD-K29668683-300-02-2::2.5::HTS	0.18126513905699998	BRD-K29668683-300-02-2::2.5::HTS	BRD-K29668683-300-02-2	BD-1063	2.5	HTS	sigma receptor antagonist	SIGMAR1			CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1	Preclinical	5
BRD-K29673530-001-05-4::2.5::HTS	0.438426527443	BRD-K29673530-001-05-4::2.5::HTS	BRD-K29673530-001-05-4	hypericin	2.5	HTS	tyrosine kinase inhibitor				Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O	Phase 2	5
BRD-K29713308-001-01-7::2.5::HTS	0.261267462333	BRD-K29713308-001-01-7::2.5::HTS	BRD-K29713308-001-01-7	mebhydrolin	2.5	HTS	antihistamine		allergy	allergic rhinitis, urticaria	CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	Launched	5
BRD-K29713308-077-04-1::2.5::HTS	-1.08386480565	BRD-K29713308-077-04-1::2.5::HTS	BRD-K29713308-077-04-1	mebhydroline-1,5-naphtalenedisulfonate	2.5	HTS					CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	Preclinical	5
BRD-K29735307-001-02-9::2.5::HTS	-0.269709878218	BRD-K29735307-001-02-9::2.5::HTS	BRD-K29735307-001-02-9	ostarine	2.5	HTS	androgen receptor modulator	AR			C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	Phase 3	5
BRD-K29834313-001-01-4::2.5::HTS	0.020893063942	BRD-K29834313-001-01-4::2.5::HTS	BRD-K29834313-001-01-4	myricitrin	2.5	HTS	PKC inhibitor	NOS1, PRKCA			C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](O)[C@H]1O	Preclinical	5
BRD-K29895144-001-01-0::2.5::HTS	0.0594006666824	BRD-K29895144-001-01-0::2.5::HTS	BRD-K29895144-001-01-0	SKLB1002	2.5	HTS	VEGFR inhibitor	KDR			COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC	Preclinical	5
BRD-K29905972-001-06-3::2.5::HTS	-1.49286497739	BRD-K29905972-001-06-3::2.5::HTS	BRD-K29905972-001-06-3	axitinib	2.5	HTS	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1	Launched	5
BRD-K29918010-003-04-1::2.5::HTS	-0.0393315825042	BRD-K29918010-003-04-1::2.5::HTS	BRD-K29918010-003-04-1	glucosamine	2.5	HTS	glycosylated protein precursor	IFNG, IL1B, MMP9, NFKB2, TNF	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis, joint pain, backache	N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	5
BRD-K29950728-048-17-4::2.5::HTS	0.230297900509	BRD-K29950728-048-17-4::2.5::HTS	BRD-K29950728-048-17-4	clomifene	2.5	HTS	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1	Launched	5
BRD-K29968218-001-03-2::2.5::HTS	-1.4753150889700002	BRD-K29968218-001-03-2::2.5::HTS	BRD-K29968218-001-03-2	KX2-391	2.5	HTS	src inhibitor, tubulin polymerization inhibitor	SRC			O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1	Phase 2	5
BRD-K30019776-003-01-5::2.5::HTS	0.00595709938143	BRD-K30019776-003-01-5::2.5::HTS	BRD-K30019776-003-01-5	dexfosfoserine	2.5	HTS	membrane integrity inhibitor	CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2			N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O	Preclinical	5
BRD-K30020243-051-02-5::2.5::HTS	-0.0596825787593	BRD-K30020243-051-02-5::2.5::HTS	BRD-K30020243-051-02-5	aliskiren-hemifumarate	2.5	HTS	renin inhibitor	REN	cardiology	hypertension	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	Launched	5
BRD-K30114692-001-15-9::2.5::HTS	-0.0731936659362	BRD-K30114692-001-15-9::2.5::HTS	BRD-K30114692-001-15-9	methenamine	2.5	HTS	bacterial DNA inhibitor		infectious disease	urinary tract infections	C1N2CN3CN1CN(C2)C3, C1N2CN3CN1CN(C2)C3	Launched	5
BRD-K30126819-304-02-7::2.5::HTS	0.396341478904	BRD-K30126819-304-02-7::2.5::HTS	BRD-K30126819-304-02-7	dimesna	2.5	HTS	tubulin polymerization inhibitor				OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O	Phase 3	5
BRD-K30213273-001-01-6::2.5::HTS	0.23658718322099997	BRD-K30213273-001-01-6::2.5::HTS	BRD-K30213273-001-01-6	fenofibric-acid	2.5	HTS	cytochrome P450 inhibitor	CLCN1, PPARA	cardiology	dyslipidemia	CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O	Launched	5
BRD-K30237152-300-02-5::2.5::HTS	0.18699311242	BRD-K30237152-300-02-5::2.5::HTS	BRD-K30237152-300-02-5	1400W	2.5	HTS	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			CC(=N)NCc1cccc(CN)c1	Preclinical	5
BRD-K30240666-051-15-9::2.5::HTS	0.0657355048679	BRD-K30240666-051-15-9::2.5::HTS	BRD-K30240666-051-15-9	clemastine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	Launched	5
BRD-K30331124-001-01-7::2.5::HTS	-0.110805183692	BRD-K30331124-001-01-7::2.5::HTS	BRD-K30331124-001-01-7	ASC-J9	2.5	HTS	androgen receptor enhancer	AR			COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1	Phase 2	5
BRD-K30373883-001-02-8::2.5::HTS	0.150960002905	BRD-K30373883-001-02-8::2.5::HTS	BRD-K30373883-001-02-8	dutasteride	2.5	HTS	5 alpha reductase inhibitor	SRD5A1, SRD5A2	urology	benign prostatic hyperplasia (BPH)	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F	Launched	5
BRD-K30374899-001-09-3::2.5::HTS	0.0144790719411	BRD-K30374899-001-09-3::2.5::HTS	BRD-K30374899-001-09-3	mannitol-D	2.5	HTS	diuretic		neurology/psychiatry, ophthalmology, gastroenterology	intracranial pressure, intraocular pressure, constipation	OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	Launched	5
BRD-K30421593-050-04-9::2.5::HTS	0.09999381585610001	BRD-K30421593-050-04-9::2.5::HTS	BRD-K30421593-050-04-9	timolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	ocular hypertension, glaucoma	CC(C)(C)NC[C@@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1	Launched	5
BRD-K30431096-004-01-3::2.5::HTS	0.20036007664299998	BRD-K30431096-004-01-3::2.5::HTS	BRD-K30431096-004-01-3	domiphen	2.5	HTS					CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1	Preclinical	5
BRD-K30466858-001-09-6::2.5::HTS	-0.0462245653435	BRD-K30466858-001-09-6::2.5::HTS	BRD-K30466858-001-09-6	ellagic-acid	2.5	HTS	glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor	CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK			Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O	Phase 2	5
BRD-K30480208-001-18-5::2.5::HTS	-0.490239679978	BRD-K30480208-001-18-5::2.5::HTS	BRD-K30480208-001-18-5	torasemide	2.5	HTS	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	SLC12A1	cardiology	edema, congestive heart failure, hypertension	CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1	Launched	5
BRD-K30519779-001-03-1::2.5::HTS	-0.038132942318000004	BRD-K30519779-001-03-1::2.5::HTS	BRD-K30519779-001-03-1	homoquinolinic-acid	2.5	HTS	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			OC(=O)Cc1cccnc1C(O)=O	Preclinical	5
BRD-K30550578-001-01-3::2.5::HTS	-0.192827335047	BRD-K30550578-001-01-3::2.5::HTS	BRD-K30550578-001-01-3	PF-04620110	2.5	HTS	diacylglycerol O acyltransferase inhibitor	DGAT1			Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12	Phase 1	5
BRD-K30553453-001-13-2::2.5::HTS	-0.367045415562	BRD-K30553453-001-13-2::2.5::HTS	BRD-K30553453-001-13-2	hesperetin	2.5	HTS	ACAT inhibitor	DGAT1, MTTP, SOAT1, SOAT2			COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	Launched	5
BRD-K30563334-001-02-9::2.5::HTS	-0.066274109637	BRD-K30563334-001-02-9::2.5::HTS	BRD-K30563334-001-02-9	rifabutin	2.5	HTS	protein synthesis inhibitor	HSP90AA1, HSP90B1	infectious disease	human immunodeficiency virus (HIV-1)	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(c(O)c3C)c(O)c(NC(=O)\C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c1=NC3(CCN(CC(C)C)CC3)N=c21	Launched	5
BRD-K30572193-001-02-0::2.5::HTS	-0.357444063684	BRD-K30572193-001-02-0::2.5::HTS	BRD-K30572193-001-02-0	CTEP	2.5	HTS	glutamate receptor antagonist	GRM5			Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1	Preclinical	5
BRD-K30577245-001-04-3::2.5::HTS	-0.632620273483	BRD-K30577245-001-04-3::2.5::HTS	BRD-K30577245-001-04-3	docetaxel	2.5	HTS	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C	Launched	5
BRD-K30577245-341-01-9::2.5::HTS	-1.2239001914799998	BRD-K30577245-341-01-9::2.5::HTS	BRD-K30577245-341-01-9	docetaxel	2.5	HTS	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C	Launched	5
BRD-K30634073-046-01-0::2.5::HTS	-0.025432498738799998	BRD-K30634073-046-01-0::2.5::HTS	BRD-K30634073-046-01-0	levallorphan	2.5	HTS	opioid antagonist	CHRNA2, OPRM1	pulmonary	respiratory depression	Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1	Launched	5
BRD-K30649484-003-13-7::2.5::HTS	0.322260701903	BRD-K30649484-003-13-7::2.5::HTS	BRD-K30649484-003-13-7	mafenide	2.5	HTS	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA4, CA6, CA9	infectious disease	first-aid antibiotic, skin infections	NCc1ccc(cc1)S(N)(=O)=O	Launched	5
BRD-K30652337-004-02-1::2.5::HTS	0.0886895002454	BRD-K30652337-004-02-1::2.5::HTS	BRD-K30652337-004-02-1	eletriptan	2.5	HTS	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	Launched	5
BRD-K30685142-001-15-4::2.5::HTS	0.465613898265	BRD-K30685142-001-15-4::2.5::HTS	BRD-K30685142-001-15-4	levothyroxine	2.5	HTS	thyroid hormone stimulant	THRA, THRB	endocrinology	myxedema coma	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	Launched	5
BRD-K30707190-001-04-1::2.5::HTS	0.160568212303	BRD-K30707190-001-04-1::2.5::HTS	BRD-K30707190-001-04-1	PNU-74654	2.5	HTS	beta-catenin inhibitor	CTNNB1, TCF4			Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1	Preclinical	5
BRD-K30758549-001-01-8::2.5::HTS	-0.0128853369911	BRD-K30758549-001-01-8::2.5::HTS	BRD-K30758549-001-01-8	isopropyl-palmitate	2.5	HTS	cosmetic moisturizer		dermatology	cosmetic	CCCCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCCCC(=O)OC(C)C	Launched	5
BRD-K30867024-003-03-3::2.5::HTS	0.03979341865	BRD-K30867024-003-03-3::2.5::HTS	BRD-K30867024-003-03-3	SB-216641	2.5	HTS	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C	Preclinical	5
BRD-K30933884-001-01-0::2.5::HTS	0.509741845839	BRD-K30933884-001-01-0::2.5::HTS	BRD-K30933884-001-01-0	UNBS-5162	2.5	HTS	CC chemokine receptor antagonist				CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23	Phase 1	5
BRD-K30977212-001-02-8::2.5::HTS	-0.23701445493099998	BRD-K30977212-001-02-8::2.5::HTS	BRD-K30977212-001-02-8	PIK-293	2.5	HTS	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O	Preclinical	5
BRD-K30990140-003-02-4::2.5::HTS	0.157058797051	BRD-K30990140-003-02-4::2.5::HTS	BRD-K30990140-003-02-4	FR-122047	2.5	HTS	cyclooxygenase inhibitor				COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1	Preclinical	5
BRD-K31054881-300-04-7::2.5::HTS	0.11587629486300001	BRD-K31054881-300-04-7::2.5::HTS	BRD-K31054881-300-04-7	BMY-7378	2.5	HTS	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A			COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1	Preclinical	5
BRD-K31086665-005-04-6::2.5::HTS	-1.7857289173599997	BRD-K31086665-005-04-6::2.5::HTS	BRD-K31086665-005-04-6	NH125	2.5	HTS	eukaryotic translation elongation factor 2 inhibitor				CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C	Preclinical	5
BRD-K31092604-003-03-5::2.5::HTS	0.017033122464100003	BRD-K31092604-003-03-5::2.5::HTS	BRD-K31092604-003-03-5	donitriptan	2.5	HTS	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6			NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12	Phase 2	5
BRD-K31111078-001-04-2::2.5::HTS	-0.037580886638	BRD-K31111078-001-04-2::2.5::HTS	BRD-K31111078-001-04-2	dimethyl-fumarate	2.5	HTS	nuclear factor erythroid derived, like (NRF2) activator	KEAP1	neurology/psychiatry	multiple sclerosis	COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC	Launched	5
BRD-K31135544-001-07-0::2.5::HTS	0.148929013354	BRD-K31135544-001-07-0::2.5::HTS	BRD-K31135544-001-07-0	IB-MECA	2.5	HTS	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12	Phase 3	5
BRD-K31283835-048-04-4::2.5::HTS	0.125787296863	BRD-K31283835-048-04-4::2.5::HTS	BRD-K31283835-048-04-4	tofacitinib	2.5	HTS	JAK inhibitor	JAK1, JAK2, JAK3, TYK2	rheumatology	rheumatoid arthritis	C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N	Launched	5
BRD-K31309378-001-01-5::2.5::HTS	0.0935433732811	BRD-K31309378-001-01-5::2.5::HTS	BRD-K31309378-001-01-5	lucitanib	2.5	HTS	FGFR inhibitor, VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12	Phase 2	5
BRD-K31313613-003-04-2::2.5::HTS	-0.145377367598	BRD-K31313613-003-04-2::2.5::HTS	BRD-K31313613-003-04-2	BS-181	2.5	HTS	CDK inhibitor	CDK7			CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12	Preclinical	5
BRD-K31339321-001-03-6::2.5::HTS	0.21469148097100002	BRD-K31339321-001-03-6::2.5::HTS	BRD-K31339321-001-03-6	lirimilast	2.5	HTS	phosphodiesterase inhibitor				CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl	Phase 2	5
BRD-K31385749-003-01-3::2.5::HTS	0.00239400727442	BRD-K31385749-003-01-3::2.5::HTS	BRD-K31385749-003-01-3	ivabradine	2.5	HTS	HCN channel antagonist, potassium channel blocker, sodium channel blocker	HCN1, HCN3, HCN4	cardiology	angina pectoris	COc1cc2C[C@@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC	Launched	5
BRD-K31468676-237-01-8::2.5::HTS	0.014478088735799999	BRD-K31468676-237-01-8::2.5::HTS	BRD-K31468676-237-01-8	oxonic-acid	2.5	HTS	uricase inhibitor				OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1	Preclinical	5
BRD-K31476763-001-01-5::2.5::HTS	-0.318310551113	BRD-K31476763-001-01-5::2.5::HTS	BRD-K31476763-001-01-5	AZD9668	2.5	HTS	elastase inhibitor	ELANE			Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C	Phase 2	5
BRD-K31491153-003-05-9::2.5::HTS	0.168080513864	BRD-K31491153-003-05-9::2.5::HTS	BRD-K31491153-003-05-9	1-phenylbiguanide	2.5	HTS	serotonin receptor agonist	HTR3A, HTR3B			NC(=N)NC(=N)Nc1ccccc1	Preclinical	5
BRD-K31495718-001-01-1::2.5::HTS	0.378503067774	BRD-K31495718-001-01-1::2.5::HTS	BRD-K31495718-001-01-1	AZD7687	2.5	HTS	diacylglycerol O acyltransferase inhibitor	DGAT1			Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1	Phase 1	5
BRD-K31519811-001-02-2::2.5::HTS	0.156690379357	BRD-K31519811-001-02-2::2.5::HTS	BRD-K31519811-001-02-2	PF-02545920	2.5	HTS	phosphodiesterase inhibitor	PDE10A			Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1	Phase 2	5
BRD-K31553034-001-03-0::2.5::HTS	0.605875645745	BRD-K31553034-001-03-0::2.5::HTS	BRD-K31553034-001-03-0	zibotentan	2.5	HTS	endothelin receptor antagonist	EDNRA			COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1	Phase 3	5
BRD-K31560319-001-01-5::2.5::HTS	-0.60021482319	BRD-K31560319-001-01-5::2.5::HTS	BRD-K31560319-001-01-5	olvanil	2.5	HTS	TRPV agonist	CNR1, GPR119, TRPV1			CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1	Preclinical	5
BRD-K31627533-001-09-5::2.5::HTS	0.42206012127400006	BRD-K31627533-001-09-5::2.5::HTS	BRD-K31627533-001-09-5	rimexolone	2.5	HTS	glucocorticoid receptor agonist	NR3C1, SERPINA6	ophthalmology	anterior uveitis	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Launched	5
BRD-K31633810-003-02-8::2.5::HTS	0.429148580259	BRD-K31633810-003-02-8::2.5::HTS	BRD-K31633810-003-02-8	DAU-5884	2.5	HTS	acetylcholine receptor antagonist	CHRM3			CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O	Preclinical	5
BRD-K31682896-001-24-0::2.5::HTS	0.054450436508300004	BRD-K31682896-001-24-0::2.5::HTS	BRD-K31682896-001-24-0	sulfamethizole	2.5	HTS	bacterial antifolate		infectious disease	urinary tract infections	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	Launched	5
BRD-K31698212-001-02-9::2.5::HTS	0.206802624377	BRD-K31698212-001-02-9::2.5::HTS	BRD-K31698212-001-02-9	icotinib	2.5	HTS	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1	Launched	5
BRD-K31731454-237-02-5::2.5::HTS	-0.303491673575	BRD-K31731454-237-02-5::2.5::HTS	BRD-K31731454-237-02-5	pemirolast	2.5	HTS	mediator release inhibitor	HRH1	pulmonary	asthma	Cc1cccn2c1ncc(-c1nnn[nH]1)c2=O, Cc1cccn2c1ncc(-c1nnn[nH]1)c2=O	Launched	5
BRD-K31812033-003-11-0::2.5::HTS	-1.29207136403	BRD-K31812033-003-11-0::2.5::HTS	BRD-K31812033-003-11-0	levobunolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12	Launched	5
BRD-K31841515-001-07-8::2.5::HTS	0.296495932274	BRD-K31841515-001-07-8::2.5::HTS	BRD-K31841515-001-07-8	oxypurinol	2.5	HTS	xanthine oxidase inhibitor	XDH			O=c1[nH]c2n[nH]cc2c(=O)[nH]1	Phase 2/Phase 3	5
BRD-K31843556-001-04-1::2.5::HTS	0.37256904206600006	BRD-K31843556-001-04-1::2.5::HTS	BRD-K31843556-001-04-1	T-0070907	2.5	HTS	PPAR receptor antagonist	PPARG			[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	Preclinical	5
BRD-K31866293-001-01-6::2.5::HTS	-0.33272751912799997	BRD-K31866293-001-01-6::2.5::HTS	BRD-K31866293-001-01-6	TAK-632	2.5	HTS	RAF inhibitor	BRAF			Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F	Preclinical	5
BRD-K31920458-001-23-6::2.5::HTS	0.325916585828	BRD-K31920458-001-23-6::2.5::HTS	BRD-K31920458-001-23-6	mestranol	2.5	HTS	estrogen receptor agonist	ESR1	endocrinology	contraceptive	COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1	Launched	5
BRD-K31928526-001-02-1::2.5::HTS	-1.3367358418700002	BRD-K31928526-001-02-1::2.5::HTS	BRD-K31928526-001-02-1	barasertib	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB			CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O	Phase 2/Phase 3	5
BRD-K32007074-001-02-9::3.16::HTS	-0.36915560831200006	BRD-K32007074-001-02-9::3.16::HTS	BRD-K32007074-001-02-9	enocitabine	3.16	HTS	DNA synthesis inhibitor	CMPK1, RRM1, TYMS			CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	Launched	5
BRD-K32021043-001-14-3::2.5::HTS	0.561947138485	BRD-K32021043-001-14-3::2.5::HTS	BRD-K32021043-001-14-3	sulfachlorpyridazine	2.5	HTS	bacterial antifolate		infectious disease	urinary tract infections	Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1	Launched	5
BRD-K32101625-001-01-6::2.5::HTS	-0.530374168238	BRD-K32101625-001-01-6::2.5::HTS	BRD-K32101625-001-01-6	LX1031	2.5	HTS	tryptophan hydroxylase inhibitor	TPH1			COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	Phase 2	5
BRD-K32107296-001-16-9::2.5::HTS	0.36198389483599996	BRD-K32107296-001-16-9::2.5::HTS	BRD-K32107296-001-16-9	temozolomide	2.5	HTS	DNA alkylating agent	MGMT	oncology	glioblastoma, astrocytoma	Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O	Launched	5
BRD-K32164935-001-30-8::2.5::HTS	-0.19970898072	BRD-K32164935-001-30-8::2.5::HTS	BRD-K32164935-001-30-8	tolazamide	2.5	HTS	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1	Launched	5
BRD-K32218650-001-01-6::2.5::HTS	-0.5464249546100001	BRD-K32218650-001-01-6::2.5::HTS	BRD-K32218650-001-01-6	MBX-2982	2.5	HTS	glucose dependent insulinotropic receptor agonist	GPR119			CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1	Phase 2	5
BRD-K32247306-001-29-4::2.5::HTS	-0.218830159157	BRD-K32247306-001-29-4::2.5::HTS	BRD-K32247306-001-29-4	primidone	2.5	HTS	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1	Launched	5
BRD-K32273377-001-17-9::2.5::HTS	-0.570338941934	BRD-K32273377-001-17-9::2.5::HTS	BRD-K32273377-001-17-9	sulfadiazine	2.5	HTS	bacterial antifolate		infectious disease, ophthalmology	malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid	Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1	Launched	5
BRD-K32285926-001-02-1::2.5::HTS	-0.22695092244000004	BRD-K32285926-001-02-1::2.5::HTS	BRD-K32285926-001-02-1	AMG-208	2.5	HTS	tyrosine kinase inhibitor	MET			COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1	Phase 1	5
BRD-K32289541-001-01-0::2.5::HTS	0.302842988752	BRD-K32289541-001-01-0::2.5::HTS	BRD-K32289541-001-01-0	EHop-016	2.5	HTS	Ras GTPase inhibitor	RAC1, RAC3			CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12	Preclinical	5
BRD-K32292990-001-03-6::2.5::HTS	0.0816087191588	BRD-K32292990-001-03-6::2.5::HTS	BRD-K32292990-001-03-6	CGP-53353	2.5	HTS	EGFR inhibitor, PKC inhibitor	EGFR, PRKCB			Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1, Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1	Preclinical	5
BRD-K32311154-001-01-0::2.5::HTS	0.015663052942899998	BRD-K32311154-001-01-0::2.5::HTS	BRD-K32311154-001-01-0	nifekalant	2.5	HTS	potassium channel blocker		cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O	Launched	5
BRD-K32318651-001-23-7::2.5::HTS	-0.18696000034000002	BRD-K32318651-001-23-7::2.5::HTS	BRD-K32318651-001-23-7	acyclovir	2.5	HTS	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes, shingles, chicken pox	Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1	Launched	5
BRD-K32318651-001-24-5::2.5::HTS	-0.0546879662813	BRD-K32318651-001-24-5::2.5::HTS	BRD-K32318651-001-24-5	acyclovir	2.5	HTS	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes, shingles, chicken pox	Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1	Launched	5
BRD-K32372024-001-01-0::2.5::HTS	-0.522756854623	BRD-K32372024-001-01-0::2.5::HTS	BRD-K32372024-001-01-0	D-7193	2.5	HTS					CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O	Phase 2	5
BRD-K32405725-001-02-8::2.5::HTS	-1.40733199484	BRD-K32405725-001-02-8::2.5::HTS	BRD-K32405725-001-02-8	etomoxir	2.5	HTS	carnitine palmitoyltransferase inhibitor	CPT1A			CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1	Phase 2	5
BRD-K32501161-300-06-2::2.5::HTS	-1.1118565409399999	BRD-K32501161-300-06-2::2.5::HTS	BRD-K32501161-300-06-2	vanoxerine	2.5	HTS	dopamine uptake inhibitor	SLC6A3			Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1	Phase 3	5
BRD-K32572029-001-04-4::2.5::HTS	0.287823965302	BRD-K32572029-001-04-4::2.5::HTS	BRD-K32572029-001-04-4	orotic-acid	2.5	HTS		DHODH			OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1	Phase 2	5
BRD-K32681104-001-11-6::2.5::HTS	-0.5704688965910001	BRD-K32681104-001-11-6::2.5::HTS	BRD-K32681104-001-11-6	2-aminobenzenesulfonamide	2.5	HTS	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA6, CA9			Nc1ccccc1S(N)(=O)=O	Preclinical	5
BRD-K32730239-001-01-0::2.5::HTS	0.203812476093	BRD-K32730239-001-01-0::2.5::HTS	BRD-K32730239-001-01-0	SU3327	2.5	HTS	JNK inhibitor	MAPK8			Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1	Preclinical	5
BRD-K32744045-001-31-2::2.5::HTS	0.340737257094	BRD-K32744045-001-31-2::2.5::HTS	BRD-K32744045-001-31-2	disulfiram	2.5	HTS	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC	Launched	5
BRD-K32768103-051-02-6::2.5::HTS	0.08111039637619999	BRD-K32768103-051-02-6::2.5::HTS	BRD-K32768103-051-02-6	vonoprazan	2.5	HTS	potassium-competitive acid antagonist	ATP4A	gastroenterology	peptic ulcer disease (PUD)	CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1	Launched	5
BRD-K32821942-001-21-3::2.5::HTS	-0.33253213447200003	BRD-K32821942-001-21-3::2.5::HTS	BRD-K32821942-001-21-3	azathioprine	2.5	HTS	dehydrogenase inhibitor	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O	Launched	5
BRD-K32830106-001-02-6::2.5::HTS	0.180289739441	BRD-K32830106-001-02-6::2.5::HTS	BRD-K32830106-001-02-6	guanfacine	2.5	HTS	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	Launched	5
BRD-K32830106-003-20-4::2.5::HTS	0.232855066841	BRD-K32830106-003-20-4::2.5::HTS	BRD-K32830106-003-20-4	guanfacine	2.5	HTS	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	Launched	5
BRD-K32847234-065-04-6::2.5::HTS	-0.0846179524097	BRD-K32847234-065-04-6::2.5::HTS	BRD-K32847234-065-04-6	sparteine-sulfate	2.5	HTS					C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	Launched	5
BRD-K32977963-001-05-0::2.5::HTS	-0.0668826834675	BRD-K32977963-001-05-0::2.5::HTS	BRD-K32977963-001-05-0	eugenol	2.5	HTS	androgen receptor antagonist	AR	dental	toothache	COc1cc(CC=C)ccc1O	Launched	5
BRD-K33082088-001-03-3::2.5::HTS	0.437142309769	BRD-K33082088-001-03-3::2.5::HTS	BRD-K33082088-001-03-3	retapamulin	2.5	HTS	protein synthesis inhibitor		infectious disease	impetigo	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C	Launched	5
BRD-K33127281-001-05-6::2.5::HTS	-0.106823327503	BRD-K33127281-001-05-6::2.5::HTS	BRD-K33127281-001-05-6	adapalene	2.5	HTS	retinoid receptor agonist	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O	Launched	5
BRD-K33141550-003-05-7::2.5::HTS	0.044600519633400004	BRD-K33141550-003-05-7::2.5::HTS	BRD-K33141550-003-05-7	L-NAME	2.5	HTS	nitric oxide synthase inhibitor	NOS3			COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O	Phase 2/Phase 3	5
BRD-K33151569-003-09-7::2.5::HTS	0.335567979221	BRD-K33151569-003-09-7::2.5::HTS	BRD-K33151569-003-09-7	deoxyepinephrine	2.5	HTS	adrenergic receptor agonist, dopamine receptor agonist	ADRA1A, DRD1, DRD2			CNCCc1ccc(O)c(O)c1	Preclinical	5
BRD-K33183200-303-02-4::2.5::HTS	-0.08340864263989999	BRD-K33183200-303-02-4::2.5::HTS	BRD-K33183200-303-02-4	imetit	2.5	HTS	histamine receptor agonist	HRH3, HRH4			NC(=N)SCCc1c[nH]cn1	Preclinical	5
BRD-K33211335-004-01-7::2.5::HTS	-0.229721108998	BRD-K33211335-004-01-7::2.5::HTS	BRD-K33211335-004-01-7	dextromethorphan	2.5	HTS	glutamate receptor antagonist, sigma receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4	pulmonary	cough suppressant	COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1	Launched	5
BRD-K33219225-001-01-9::2.5::HTS	-0.219035974203	BRD-K33219225-001-01-9::2.5::HTS	BRD-K33219225-001-01-9	allylisothiocyanate	2.5	HTS	TRPV agonist	TRPA1			C=CCN=C=S	Preclinical	5
BRD-K33226500-001-01-0::2.5::HTS	-0.0434116997809	BRD-K33226500-001-01-0::2.5::HTS	BRD-K33226500-001-01-0	indinavir	2.5	HTS	HIV protease inhibitor	CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12	Launched	5
BRD-K33251802-001-01-3::2.5::HTS	0.5645064992000001	BRD-K33251802-001-01-3::2.5::HTS	BRD-K33251802-001-01-3	miglustat	2.5	HTS	Glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	Launched	5
BRD-K33277808-331-01-3::2.5::HTS	-5.09085191078	BRD-K33277808-331-01-3::2.5::HTS	BRD-K33277808-331-01-3	ouabain	2.5	HTS	ATPase inhibitor	ATP1A1	cardiology	hypertension, cardiac arrythmia	C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O	Launched	5
BRD-K33379087-001-07-5::2.5::HTS	-1.23978443345	BRD-K33379087-001-07-5::2.5::HTS	BRD-K33379087-001-07-5	tivantinib	2.5	HTS	tyrosine kinase inhibitor	MET			O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23	Phase 3	5
BRD-K33396764-001-08-7::0.25::HTS	-0.045982572839199994	BRD-K33396764-001-08-7::0.25::HTS	BRD-K33396764-001-08-7	alpha-linolenic-acid	0.25	HTS	omega 3 fatty acid stimulant	ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1			CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O	Phase 3	3
BRD-K33425534-001-12-5::2.5::HTS	-0.281749662314	BRD-K33425534-001-12-5::2.5::HTS	BRD-K33425534-001-12-5	exemestane	2.5	HTS	aromatase inhibitor	CYP19A1	oncology	breast cancer	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O	Launched	5
BRD-K33453211-003-11-5::2.5::HTS	-0.516662770907	BRD-K33453211-003-11-5::2.5::HTS	BRD-K33453211-003-11-5	levocabastine	2.5	HTS	histamine receptor antagonist	HRH1, NTSR2	ophthalmology	conjunctivitis	C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1	Launched	5
BRD-K33459542-001-07-4::2.5::HTS	0.442368606584	BRD-K33459542-001-07-4::2.5::HTS	BRD-K33459542-001-07-4	ditolylguanidine	2.5	HTS	sigma receptor agonist	GRIN1, GRIN2A, GRIN2B, SIGMAR1			Cc1ccccc1NC(=N)Nc1ccccc1C	Preclinical	5
BRD-K33483813-001-10-0::2.5::HTS	-0.132212006294	BRD-K33483813-001-10-0::2.5::HTS	BRD-K33483813-001-10-0	actarit	2.5	HTS	interleukin receptor agonist		rheumatology	rheumatoid arthritis	CC(=O)Nc1ccc(CC(O)=O)cc1	Launched	5
BRD-K33510429-001-03-1::2.5::HTS	-0.0336117514484	BRD-K33510429-001-03-1::2.5::HTS	BRD-K33510429-001-03-1	vanillylacetone	2.5	HTS					COc1cc(CCC(C)=O)ccc1O, COc1cc(CCC(C)=O)ccc1O	Preclinical	5
BRD-K33583600-001-16-1::2.5::HTS	-0.138528357588	BRD-K33583600-001-16-1::2.5::HTS	BRD-K33583600-001-16-1	isoliquiritigenin	2.5	HTS	guanylate cyclase activator	GABBR1			Oc1ccc(cc1)\C=C\C(=O)c1ccc(O)cc1O	Preclinical	5
BRD-K33588785-001-01-9::2.5::HTS	-0.7628508349099999	BRD-K33588785-001-01-9::2.5::HTS	BRD-K33588785-001-01-9	obidoxime	2.5	HTS	cholinesterase reactivator	ACHE	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning	O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1	Launched	5
BRD-K33610132-001-02-9::2.5::HTS	-1.18097780972	BRD-K33610132-001-02-9::2.5::HTS	BRD-K33610132-001-02-9	rociletinib	2.5	HTS	EGFR inhibitor	EGFR			COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O	Phase 3	5
BRD-K33622447-066-01-9::2.5::HTS	0.315961504658	BRD-K33622447-066-01-9::2.5::HTS	BRD-K33622447-066-01-9	abemaciclib	2.5	HTS	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1	Launched	5
BRD-K33681278-036-01-2::2.5::HTS	0.602373703855	BRD-K33681278-036-01-2::2.5::HTS	BRD-K33681278-036-01-2	prucalopride	2.5	HTS	serotonin receptor agonist	HTR4	gastroenterology	constipation	COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12	Launched	5
BRD-K33690734-001-01-5::2.5::HTS	0.46577251954099996	BRD-K33690734-001-01-5::2.5::HTS	BRD-K33690734-001-01-5	5-BDBD	2.5	HTS	purinergic receptor antagonist	P2RX4			Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21	Preclinical	5
BRD-K33720171-001-01-0::2.5::HTS	-0.0459415334074	BRD-K33720171-001-01-0::2.5::HTS	BRD-K33720171-001-01-0	difluprednate	2.5	HTS	glucocorticoid receptor agonist	NR3C1	ophthalmology	endogenous uveitis	CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O	Launched	5
BRD-K33732501-004-01-0::2.5::HTS	0.376012416161	BRD-K33732501-004-01-0::2.5::HTS	BRD-K33732501-004-01-0	methylnaltrexone	2.5	HTS	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	constipation	C[N@@+]1(CC2CC2)CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@@]3(O)CCC4=O)ccc5O	Launched	5
BRD-K33743361-003-02-6::2.5::HTS	-0.0312695150336	BRD-K33743361-003-02-6::2.5::HTS	BRD-K33743361-003-02-6	ML133	2.5	HTS	potassium channel blocker				COc1ccc(CNCc2cccc3ccccc23)cc1	Preclinical	5
BRD-K33809398-001-01-8::2.5::HTS	0.30077465210099996	BRD-K33809398-001-01-8::2.5::HTS	BRD-K33809398-001-01-8	SCMC-Lys	2.5	HTS	mucolytic agent	GSTP1			N[C@@H](CSCC(O)=O)C(O)=O, N[C@@H](CSCC(O)=O)C(O)=O	Launched	5
BRD-K33813875-003-01-8::2.5::HTS	-0.615302934561	BRD-K33813875-003-01-8::2.5::HTS	BRD-K33813875-003-01-8	valnemulin	2.5	HTS	bacterial 50S ribosomal subunit inhibitor		infectious disease, gastroenterology	dysentry, colitis, pneumonia	CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3	Launched	5
BRD-K33814251-001-01-4::2.6::HTS	0.19896157685	BRD-K33814251-001-01-4::2.6::HTS	BRD-K33814251-001-01-4	lubiprostone	2.6	HTS	chloride channel activator	CLCN2	gastroenterology	constipation, irritable bowel syndrome	CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	Launched	5
BRD-K33814251-001-02-2::2.5::HTS	0.409421113226	BRD-K33814251-001-02-2::2.5::HTS	BRD-K33814251-001-02-2	lubiprostone	2.5	HTS	chloride channel activator	CLCN2	gastroenterology	constipation, irritable bowel syndrome	CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	Launched	5
BRD-K33818169-003-04-6::2.5::HTS	-0.201964437649	BRD-K33818169-003-04-6::2.5::HTS	BRD-K33818169-003-04-6	GW-3965	2.5	HTS	LXR agonist	NR1H2, NR1H3			OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	Preclinical	5
BRD-K33852358-001-09-9::2.5::HTS	-0.39530033050700003	BRD-K33852358-001-09-9::2.5::HTS	BRD-K33852358-001-09-9	arofylline	2.5	HTS	phosphodiesterase inhibitor	PDE4A			CCCn1c(=O)n(-c2ccc(Cl)cc2)c2[nH]cnc2c1=O	Phase 3	5
BRD-K33864865-001-02-5::2.5::HTS	-0.041109237864	BRD-K33864865-001-02-5::2.5::HTS	BRD-K33864865-001-02-5	LY225910	2.5	HTS	CCK receptor antagonist	CCKBR			CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O	Preclinical	5
BRD-K33882852-003-02-8::2.5::HTS	-1.15770798823	BRD-K33882852-003-02-8::2.5::HTS	BRD-K33882852-003-02-8	ZK-93423	2.5	HTS	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC	Phase 3	5
BRD-K33892651-001-02-4::2.5::HTS	0.090632942865	BRD-K33892651-001-02-4::2.5::HTS	BRD-K33892651-001-02-4	ML347	2.5	HTS	ALK tyrosine kinase receptor inhibitor	ACVR1, ACVRL1, BMPR1A			COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	Preclinical	5
BRD-K34022604-001-06-6::2.5::HTS	-4.54586382352	BRD-K34022604-001-06-6::2.5::HTS	BRD-K34022604-001-06-6	clofarabine	2.5	HTS	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	Launched	5
BRD-K34032314-001-04-1::2.5::HTS	-0.11434770172	BRD-K34032314-001-04-1::2.5::HTS	BRD-K34032314-001-04-1	betamethasone-valerate	2.5	HTS	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO	Launched	5
BRD-K34058848-304-03-1::2.5::HTS	0.362207047525	BRD-K34058848-304-03-1::2.5::HTS	BRD-K34058848-304-03-1	cefonicid	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1	Launched	5
BRD-K34073885-001-09-3::2.54::HTS	-0.06878430830519999	BRD-K34073885-001-09-3::2.54::HTS	BRD-K34073885-001-09-3	tanshinone-i	2.54	HTS	AP inhibitor	IFNG			Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12	Phase 2	5
BRD-K34122555-057-11-5::2.5::HTS	-0.0249941226224	BRD-K34122555-057-11-5::2.5::HTS	BRD-K34122555-057-11-5	denatonium-benzoate	2.5	HTS					CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1	Preclinical	5
BRD-K34154330-003-06-4::2.5::HTS	-0.16752496696	BRD-K34154330-003-06-4::2.5::HTS	BRD-K34154330-003-06-4	tracazolate	2.5	HTS	GABA receptor modulator	GABRA1			CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12	Phase 2	5
BRD-K34157611-001-16-0::2.5::HTS	-0.832806758318	BRD-K34157611-001-16-0::2.5::HTS	BRD-K34157611-001-16-0	cimetidine	2.5	HTS	histamine receptor antagonist	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N	Launched	5
BRD-K34185671-001-02-8::2.5::HTS	0.106317735837	BRD-K34185671-001-02-8::2.5::HTS	BRD-K34185671-001-02-8	AMG-517	2.5	HTS	TRPV antagonist	TRPV1			CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1	Phase 1	5
BRD-K34313798-001-01-6::2.5::HTS	0.144326744186	BRD-K34313798-001-01-6::2.5::HTS	BRD-K34313798-001-01-6	LY215490	2.5	HTS	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1			OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1	Phase 1	5
BRD-K34321528-003-01-2::2.5::HTS	0.11380618133300001	BRD-K34321528-003-01-2::2.5::HTS	BRD-K34321528-003-01-2	CGP-71683	2.5	HTS	neuropeptide receptor antagonist	NPY5R			Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12	Preclinical	5
BRD-K34328244-001-01-4::2.5::HTS	-0.043272316211299997	BRD-K34328244-001-01-4::2.5::HTS	BRD-K34328244-001-01-4	MF-101	2.5	HTS	estrogen receptor agonist	CYP19A1, XDH			Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1	Phase 3	5
BRD-K34332569-001-01-3::2.5::HTS	0.051538439648400006	BRD-K34332569-001-01-3::2.5::HTS	BRD-K34332569-001-01-3	imidapril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O	Launched	5
BRD-K34341643-001-01-4::2.5::HTS	0.15563538280300002	BRD-K34341643-001-01-4::2.5::HTS	BRD-K34341643-001-01-4	glasdegib	2.5	HTS	hedgehog pathway inhibitor	SMO			CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N	Phase 2	5
BRD-K34388247-236-08-2::2.5::HTS	0.274419560993	BRD-K34388247-236-08-2::2.5::HTS	BRD-K34388247-236-08-2	methicillin	2.5	HTS	bacterial cell wall synthesis inhibitor				COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	Launched	5
BRD-K34411947-001-12-5::2.5::HTS	0.215800311892	BRD-K34411947-001-12-5::2.5::HTS	BRD-K34411947-001-12-5	streptozotocin	2.5	HTS	DNA alkylating agent	SLC2A2	oncology	pancreatic cancer	CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	5
BRD-K34415467-003-13-0::2.5::HTS	0.38854681679999997	BRD-K34415467-003-13-0::2.5::HTS	BRD-K34415467-003-13-0	trimethobenzamide	2.5	HTS	histamine receptor antagonist	DRD2	gastroenterology	vomiting, nausea, gastroenteritis	COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	Launched	5
BRD-K34441861-003-07-0::2.47::HTS	0.00515684342216	BRD-K34441861-003-07-0::2.47::HTS	BRD-K34441861-003-07-0	moexipril	2.47	HTS	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology	hypertension	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	Launched	5
BRD-K34469523-003-03-0::2.5::HTS	-0.199922427487	BRD-K34469523-003-03-0::2.5::HTS	BRD-K34469523-003-03-0	levalbuterol	2.5	HTS	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm	CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1	Launched	5
BRD-K34533029-001-08-5::2.5::HTS	-0.0134428379143	BRD-K34533029-001-08-5::2.5::HTS	BRD-K34533029-001-08-5	tyrphostin-AG-494	2.5	HTS	EGFR inhibitor	EGFR			Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1	Preclinical	5
BRD-K34568562-001-04-3::2.5::HTS	0.723030778885	BRD-K34568562-001-04-3::2.5::HTS	BRD-K34568562-001-04-3	tilorone	2.5	HTS	interferon inducer		infectious disease, gastroenterology, neurology/psychiatry	influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C	CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1	Launched	5
BRD-K34591242-001-04-3::2.5::HTS	0.219951723538	BRD-K34591242-001-04-3::2.5::HTS	BRD-K34591242-001-04-3	methoprene-(s)	2.5	HTS					COC(C)(C)CCC[C@H](C)C\C=C\C(C)=C\C(=O)OC(C)C	Preclinical	5
BRD-K34608650-001-02-4::2.5::HTS	0.25954535486200003	BRD-K34608650-001-02-4::2.5::HTS	BRD-K34608650-001-02-4	GP2a	2.5	HTS	cannabinoid receptor agonist	CNR2			Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1	Preclinical	5
BRD-K34663752-001-09-1::2.5::HTS	-0.232465728132	BRD-K34663752-001-09-1::2.5::HTS	BRD-K34663752-001-09-1	6-chloromelatonin	2.5	HTS	melatonin receptor agonist	MTNR1A, MTNR1B			COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl	Preclinical	5
BRD-K34672903-001-01-7::2.5::HTS	0.0630110928836	BRD-K34672903-001-01-7::2.5::HTS	BRD-K34672903-001-01-7	HEMADO	2.5	HTS		ADORA1, ADORA2A, ADORA2B, ADORA3			CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	Preclinical	5
BRD-K34685430-050-12-5::2.5::HTS	0.43599595230300003	BRD-K34685430-050-12-5::2.5::HTS	BRD-K34685430-050-12-5	methylergometrine	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C	hematology, neurology/psychiatry	postpartum hemorrhage (PPH), migraine headache	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34	Launched	5
BRD-K34713073-001-01-3::2.5::HTS	-0.313774979564	BRD-K34713073-001-01-3::2.5::HTS	BRD-K34713073-001-01-3	PD-123319	2.5	HTS	angiotensin antagonist	AGTR2			CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C	Phase 1	5
BRD-K34730807-001-17-6::2.5::HTS	0.039493018763599994	BRD-K34730807-001-17-6::2.5::HTS	BRD-K34730807-001-17-6	levodopa	2.5	HTS	dopamine precursor	DRD1, DRD2, DRD3, DRD4, DRD5, GPR143	neurology/psychiatry	Parkinson's Disease	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O	Launched	5
BRD-K34776109-001-16-6::2.5::HTS	-0.449268483018	BRD-K34776109-001-16-6::2.5::HTS	BRD-K34776109-001-16-6	glimepiride	2.5	HTS	insulin secretagogue	ABCC8, KCNJ1, KCNJ11	endocrinology	diabetes mellitus	CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O	Launched	5
BRD-K34801930-001-01-9::2.5::HTS	-0.110349197778	BRD-K34801930-001-01-9::2.5::HTS	BRD-K34801930-001-01-9	AZD5069	2.5	HTS	CC chemokine receptor antagonist	CXCR2			C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	Phase 2	5
BRD-K34851558-001-02-3::2.5::HTS	0.668406208005	BRD-K34851558-001-02-3::2.5::HTS	BRD-K34851558-001-02-3	parthenolide-(-)	2.5	HTS	NFkB pathway inhibitor	HDAC1			C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	Preclinical	5
BRD-K34870043-001-01-8::2.5::HTS	-0.035302592815400005	BRD-K34870043-001-01-8::2.5::HTS	BRD-K34870043-001-01-8	adoprazine	2.5	HTS	dopamine receptor antagonist, serotonin receptor agonist	DRD2, HTR1A			Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1	Phase 2	5
BRD-K34888156-213-01-4::2.5::HTS	0.169457209223	BRD-K34888156-213-01-4::2.5::HTS	BRD-K34888156-213-01-4	theobromine	2.5	HTS	phosphodiesterase inhibitor	ADORA1, ADORA2A, PDE4B			Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12	Launched	5
BRD-K35007173-001-07-5::2.5::HTS	-0.442285391571	BRD-K35007173-001-07-5::2.5::HTS	BRD-K35007173-001-07-5	enprofylline	2.5	HTS	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B			CCCn1c2nc[nH]c2c(=O)[nH]c1=O	Phase 3	5
BRD-K35034482-001-01-8::2.5::HTS	-0.200259788798	BRD-K35034482-001-01-8::2.5::HTS	BRD-K35034482-001-01-8	bunazosin	2.5	HTS	adrenergic receptor antagonist	ADRA1A	ophthalmology	glaucoma, intraocular pressure	CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1	Launched	5
BRD-K35079116-001-02-5::2.71::HTS	0.11871502253499999	BRD-K35079116-001-02-5::2.71::HTS	BRD-K35079116-001-02-5	asiatic-acid	2.71	HTS	apoptosis stimulant	PYGM			C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	Preclinical	5
BRD-K35079116-001-03-3::2.5::HTS	0.0591963631563	BRD-K35079116-001-03-3::2.5::HTS	BRD-K35079116-001-03-3	asiatic-acid	2.5	HTS	apoptosis stimulant	PYGM			C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	Preclinical	5
BRD-K35169477-001-01-9::2.5::HTS	0.212665132989	BRD-K35169477-001-01-9::2.5::HTS	BRD-K35169477-001-01-9	taranabant	2.5	HTS	cannabinoid receptor inverse agonist	CNR1			C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N	Phase 3	5
BRD-K35170555-001-09-5::2.5::HTS	-0.516145941876	BRD-K35170555-001-09-5::2.5::HTS	BRD-K35170555-001-09-5	caprylic-acid	2.5	HTS					CCCCCCCC(O)=O, CCCCCCCC(O)=O	Launched	5
BRD-K35189033-001-26-1::2.5::HTS	0.047173293924	BRD-K35189033-001-26-1::2.5::HTS	BRD-K35189033-001-26-1	levonorgestrel	2.5	HTS	estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist	AR, ESR1, PGR, SRD5A1	endocrinology	contraceptive	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Launched	5
BRD-K35240538-001-26-2::2.5::HTS	-0.15714123403799998	BRD-K35240538-001-26-2::2.5::HTS	BRD-K35240538-001-26-2	methylprednisolone	2.5	HTS	glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12	Launched	5
BRD-K35245662-001-01-2::2.5::HTS	-0.0818713287428	BRD-K35245662-001-01-2::2.5::HTS	BRD-K35245662-001-01-2	ciclesonide	2.5	HTS	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1	Launched	5
BRD-K35329391-334-01-7::2.5::HTS	0.573963896569	BRD-K35329391-334-01-7::2.5::HTS	BRD-K35329391-334-01-7	GZD824	2.5	HTS	Bcr-Abl kinase inhibitor	ABL1, BCR			CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1	Preclinical	5
BRD-K35430135-003-02-3::2.5::HTS	-0.116172947458	BRD-K35430135-003-02-3::2.5::HTS	BRD-K35430135-003-02-3	SR-59230A	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12	Preclinical	5
BRD-K35498378-001-06-1::2.5::HTS	0.14702271758500002	BRD-K35498378-001-06-1::2.5::HTS	BRD-K35498378-001-06-1	alrestatin	2.5	HTS	aldose reductase inhibitor	AKR1B1			OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23	Preclinical	5
BRD-K35520305-001-17-7::2.5::HTS	-0.205918341334	BRD-K35520305-001-17-7::2.5::HTS	BRD-K35520305-001-17-7	dacarbazine	2.5	HTS	DNA alkylating agent	PGD, POLA2	oncology, hematologic malignancy	melanoma, Hodgkin's lymphoma	CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O	Launched	5
BRD-K35559145-050-08-5::2.5::HTS	-0.13000092808900002	BRD-K35559145-050-08-5::2.5::HTS	BRD-K35559145-050-08-5	levomepromazine	2.5	HTS	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C	neurology/psychiatry, gastroenterology	psychosis, schizophrenia, bipolar disorder, nausea, insomnia	COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1	Launched	5
BRD-K35586044-003-15-4::2.5::HTS	0.0853846725788	BRD-K35586044-003-15-4::2.5::HTS	BRD-K35586044-003-15-4	yohimbine	2.5	HTS	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8	cardiology	cardiac arrythmia, bradycardia	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	Launched	5
BRD-K35589454-003-01-1::2.5::HTS	-0.221120401651	BRD-K35589454-003-01-1::2.5::HTS	BRD-K35589454-003-01-1	danegaptide	2.5	HTS	gap junction modulator				NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1	Phase 2	5
BRD-K35601925-001-01-9::2.5::HTS	-0.139515171098	BRD-K35601925-001-01-9::2.5::HTS	BRD-K35601925-001-01-9	CS-917	2.5	HTS	fructose biphosphate inhibitor	FBP1			CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O	Phase 2	5
BRD-K35629949-001-02-0::2.5::HTS	-1.28533242678	BRD-K35629949-001-02-0::2.5::HTS	BRD-K35629949-001-02-0	SR-27897	2.5	HTS	CCK receptor antagonist	CCKAR			OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl	Phase 2	5
BRD-K35687421-001-02-5::2.5::HTS	-0.299634629295	BRD-K35687421-001-02-5::2.5::HTS	BRD-K35687421-001-02-5	gimeracil	2.5	HTS	dihydropyrimidine dehydrogenase inhibitor	DPYD	oncology	gastric adenocarcinoma	Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl	Launched	5
BRD-K35698076-001-01-2::2.5::HTS	0.054566825155499994	BRD-K35698076-001-01-2::2.5::HTS	BRD-K35698076-001-01-2	laurocapram	2.5	HTS					CCCCCCCCCCCCN1CCCCCC1=O	Phase 3	5
BRD-K35719256-001-02-6::2.5::HTS	-0.5139856641830001	BRD-K35719256-001-02-6::2.5::HTS	BRD-K35719256-001-02-6	rotundine	2.5	HTS	serotonin receptor agonist	DRD1, DRD2, DRD3, HTR1A			COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC	Launched	5
BRD-K35775715-001-03-1::2.5::HTS	0.102378491076	BRD-K35775715-001-03-1::2.5::HTS	BRD-K35775715-001-03-1	liranaftate	2.5	HTS	fungal squalene epoxidase inhibitor		infectious disease	fungal infection	COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1	Launched	5
BRD-K35781423-001-01-6::2.5::HTS	0.24581711102899997	BRD-K35781423-001-01-6::2.5::HTS	BRD-K35781423-001-01-6	SANT-2	2.5	HTS	smoothened receptor antagonist	SHH, SMO			CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1	Preclinical	5
BRD-K35952844-236-01-6::2.5::HTS	-0.349703560346	BRD-K35952844-236-01-6::2.5::HTS	BRD-K35952844-236-01-6	sodium-glucoheptonate	2.5	HTS					OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	Launched	5
BRD-K35952844-238-01-2::2.5::HTS	0.24094743208900002	BRD-K35952844-238-01-2::2.5::HTS	BRD-K35952844-238-01-2	calcium-gluceptate	2.5	HTS					OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	Launched	5
BRD-K35960502-001-20-0::2.5::HTS	0.213199770053	BRD-K35960502-001-20-0::2.5::HTS	BRD-K35960502-001-20-0	niclosamide	2.5	HTS	DNA replication inhibitor, STAT inhibitor	STAT3	infectious disease	tapeworm	Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O	Launched	5
BRD-K36016295-001-04-5::2.5::HTS	0.7062704727779999	BRD-K36016295-001-04-5::2.5::HTS	BRD-K36016295-001-04-5	KU-60019	2.5	HTS	ATM kinase inhibitor	ATM			C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1	Preclinical	5
BRD-K36021395-300-02-4::2.5::HTS	0.353881839444	BRD-K36021395-300-02-4::2.5::HTS	BRD-K36021395-300-02-4	ABT-702	2.5	HTS	adenosine kinase inhibitor	ADK			Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1	Preclinical	5
BRD-K36040345-001-01-1::2.5::HTS	0.206414666296	BRD-K36040345-001-01-1::2.5::HTS	BRD-K36040345-001-01-1	TXA127	2.5	HTS	angiotensin receptor agonist				CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(O)=O	Phase 2	5
BRD-K36055864-001-19-2::2.5::HTS	-1.69644382583	BRD-K36055864-001-19-2::2.5::HTS	BRD-K36055864-001-19-2	cycloheximide	2.5	HTS	protein synthesis inhibitor	RPL3			C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1	Preclinical	5
BRD-K36116267-001-15-3::2.5::HTS	0.807968566176	BRD-K36116267-001-15-3::2.5::HTS	BRD-K36116267-001-15-3	pyrithyldione	2.5	HTS	psychoactive drug				CCC1(CC)C(=O)NC=CC1=O	Withdrawn	5
BRD-K36198571-001-02-0::2.5::HTS	-0.333733271684	BRD-K36198571-001-02-0::2.5::HTS	BRD-K36198571-001-02-0	WAY-170523	2.5	HTS	metalloproteinase inhibitor	MMP13			Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO	Preclinical	5
BRD-K36207157-001-07-0::2.52::HTS	-0.552526514476	BRD-K36207157-001-07-0::2.52::HTS	BRD-K36207157-001-07-0	chlorprothixene	2.52	HTS	dopamine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C	neurology/psychiatry	schizophrenia, bipolar disorder	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	Launched	5
BRD-K36207157-001-09-6::2.5::HTS	-0.57566606694	BRD-K36207157-001-09-6::2.5::HTS	BRD-K36207157-001-09-6	chlorprothixene	2.5	HTS	dopamine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C	neurology/psychiatry	schizophrenia, bipolar disorder	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	Launched	5
BRD-K36222532-001-01-8::2.5::HTS	-2.0788278245800003	BRD-K36222532-001-01-8::2.5::HTS	BRD-K36222532-001-01-8	broxaldine	2.5	HTS					Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1	Preclinical	5
BRD-K36234266-001-09-8::2.5::HTS	0.34985772393700004	BRD-K36234266-001-09-8::2.5::HTS	BRD-K36234266-001-09-8	carmustine	2.5	HTS	DNA alkylating agent, DNA inhibitor	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	[O-][N+]N(CCCl)C(=O)NCCCl	Launched	5
BRD-K36258877-001-03-1::2.5::HTS	-0.271006019952	BRD-K36258877-001-03-1::2.5::HTS	BRD-K36258877-001-03-1	AZ-10417808	2.5	HTS	caspase inhibitor	CASP3			[O-][N+](=O)c1cc(C(=O)NCC=C)c2nc(Nc3ccc(Cl)c(Cl)c3)[nH]c(=O)c2c1, [O-][N+](=O)c1cc(C(=O)NCC=C)c2nc(Nc3ccc(Cl)c(Cl)c3)[nH]c(=O)c2c1	Preclinical	5
BRD-K36262466-001-06-3::2.5::HTS	-0.241583801581	BRD-K36262466-001-06-3::2.5::HTS	BRD-K36262466-001-06-3	aceneuramic-acid	2.5	HTS		AZGP1, CES1, MBL2, REG1A, SELE, SELP, SIGLEC1			CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	Phase 3	5
BRD-K36269323-300-02-6::2.5::HTS	-0.6424341329300001	BRD-K36269323-300-02-6::2.5::HTS	BRD-K36269323-300-02-6	asymmetrical-dimethylarginine	2.5	HTS	nitric oxide synthase inhibitor	NOS2, NOS3			CN(C)C(=N)NCCC[C@H](N)C(O)=O	Phase 1	5
BRD-K36270037-001-01-7::2.5::HTS	0.554188311186	BRD-K36270037-001-01-7::2.5::HTS	BRD-K36270037-001-01-7	esculin	2.5	HTS	antioxidant				OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@@H](O)[C@@H](O)[C@@H]1O	Phase 1	5
BRD-K36363294-001-04-2::2.5::HTS	0.486581295917	BRD-K36363294-001-04-2::2.5::HTS	BRD-K36363294-001-04-2	I-BET151	2.5	HTS	bromodomain inhibitor	BRD2, BRD3, BRD4			COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C	Preclinical	5
BRD-K36381762-300-02-7::2.5::HTS	0.0264374412383	BRD-K36381762-300-02-7::2.5::HTS	BRD-K36381762-300-02-7	nor-Binaltorphimine-dihydrochloride	2.5	HTS	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O	Preclinical	5
BRD-K36386086-001-01-1::2.5::HTS	-0.573628672956	BRD-K36386086-001-01-1::2.5::HTS	BRD-K36386086-001-01-1	dolutegravir	2.5	HTS	HIV integrase inhibitor	CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1	infectious disease	human immunodeficiency virus (HIV-1)	C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	Launched	5
BRD-K36395411-003-02-2::2.5::HTS	0.349575209015	BRD-K36395411-003-02-2::2.5::HTS	BRD-K36395411-003-02-2	SB-206553	2.5	HTS	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1	Preclinical	5
BRD-K36449075-001-01-0::2.5::HTS	0.000520305952206	BRD-K36449075-001-01-0::2.5::HTS	BRD-K36449075-001-01-0	copper-histidine	2.5	HTS		HAL, HARS, HDC, SLC15A3, SLC15A4, SLC38A3, SLC38A5			N[C@H](Cc1c[nH]cn1)C(O)=O	Phase 3	5
BRD-K36461289-001-05-8::2.5::HTS	0.20032154137699998	BRD-K36461289-001-05-8::2.5::HTS	BRD-K36461289-001-05-8	picrotoxinin	2.5	HTS	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C	Preclinical	5
BRD-K36467523-001-02-8::2.5::HTS	0.253193270781	BRD-K36467523-001-02-8::2.5::HTS	BRD-K36467523-001-02-8	bindarit	2.5	HTS	NFkB pathway inhibitor	CCL2, CCL7, CCL8			CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O	Phase 2	5
BRD-K36529613-001-02-6::2.5::HTS	-2.73091355922	BRD-K36529613-001-02-6::2.5::HTS	BRD-K36529613-001-02-6	PU-H71	2.5	HTS	HSP inhibitor	HSP90AA1			CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12	Phase 1	5
BRD-K36627727-001-05-4::2.5::HTS	-0.218744138816	BRD-K36627727-001-05-4::2.5::HTS	BRD-K36627727-001-05-4	tamibarotene	2.5	HTS	retinoid receptor agonist	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12	Launched	5
BRD-K36660044-001-24-2::2.5::HTS	-0.0676568327165	BRD-K36660044-001-24-2::2.5::HTS	BRD-K36660044-001-24-2	bufexamac	2.5	HTS	cyclooxygenase inhibitor	HDAC10, HDAC6			CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1	Withdrawn	5
BRD-K36680103-001-01-6::2.5::HTS	-0.0565171431804	BRD-K36680103-001-01-6::2.5::HTS	BRD-K36680103-001-01-6	omecamtiv-mecarbil	2.5	HTS	cardiac myosin activator	MYBPC3			COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1	Phase 2	5
BRD-K36711084-001-02-0::2.5::HTS	-0.323754197084	BRD-K36711084-001-02-0::2.5::HTS	BRD-K36711084-001-02-0	cyromazine	2.5	HTS					Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1	Launched	5
BRD-K36732695-001-01-9::2.5::HTS	-0.151978495022	BRD-K36732695-001-01-9::2.5::HTS	BRD-K36732695-001-01-9	setiptiline	2.5	HTS	adrenergic receptor antagonist	HRH1, HTR2A, HTR2C	neurology/psychiatry	depression	CN1CCC2=C(C1)c1ccccc1Cc1ccccc21	Launched	5
BRD-K36739687-001-03-0::2.5::HTS	-0.17894147785300002	BRD-K36739687-001-03-0::2.5::HTS	BRD-K36739687-001-03-0	stemregenin-1	2.5	HTS	aryl hydrocarbon receptor antagonist	AHR			CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12	Preclinical	5
BRD-K36740062-001-06-6::2.5::HTS	-0.31914331589699996	BRD-K36740062-001-06-6::2.5::HTS	BRD-K36740062-001-06-6	GSK1070916	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB, AURKC, CYP2D6, CYP3A4			CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1	Phase 1	5
BRD-K36756879-003-08-7::2.5::HTS	0.479775406251	BRD-K36756879-003-08-7::2.5::HTS	BRD-K36756879-003-08-7	ethaverine	2.5	HTS	calcium channel blocker		neurology/psychiatry	muscle relaxant, spasms	CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC	Launched	5
BRD-K36775483-001-01-4::2.5::HTS	0.10801913638800001	BRD-K36775483-001-01-4::2.5::HTS	BRD-K36775483-001-01-4	DMeOB	2.5	HTS		GRM5			COc1cccc(c1)\C=N\N=C\c1cccc(OC)c1	Preclinical	5
BRD-K36788280-001-01-2::2.5::HTS	-2.50979390727	BRD-K36788280-001-01-2::2.5::HTS	BRD-K36788280-001-01-2	ribociclib	2.5	HTS	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1	Launched	5
BRD-K36859431-300-02-3::2.5::HTS	-0.563246848606	BRD-K36859431-300-02-3::2.5::HTS	BRD-K36859431-300-02-3	sapropterin	2.5	HTS	phenylalanine 4-hydroxylase stimulant	NOS3, PAH, TH, TPH1	metabolism	hyperphenylalaninemia (HPA)	C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(O)c2N1	Launched	5
BRD-K36862742-001-25-6::2.5::HTS	0.344761321861	BRD-K36862742-001-25-6::2.5::HTS	BRD-K36862742-001-25-6	hydroflumethiazide	2.5	HTS	sodium/potassium/chloride transporter inhibitor	ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F	Launched	5
BRD-K36864847-303-02-5::2.5::HTS	-0.0127943786105	BRD-K36864847-303-02-5::2.5::HTS	BRD-K36864847-303-02-5	BD-1047	2.5	HTS	adrenergic receptor antagonist	SIGMAR1			CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-K36889451-001-01-1::2.5::HTS	-2.8710006611799996	BRD-K36889451-001-01-1::2.5::HTS	BRD-K36889451-001-01-1	tetramethylthiuram-monosulfide	2.5	HTS					CN(C)C(=S)SC(=S)N(C)C	Preclinical	5
BRD-K36927236-001-32-6::2.5::HTS	0.32847539599500003	BRD-K36927236-001-32-6::2.5::HTS	BRD-K36927236-001-32-6	glyburide	2.5	HTS	ATP channel blocker, insulin secretagogue, sulfonylurea	ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1	endocrinology	diabetes mellitus, hyperglycemia	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched	5
BRD-K36965586-003-08-8::2.5::HTS	0.276061366652	BRD-K36965586-003-08-8::2.5::HTS	BRD-K36965586-003-08-8	m-Chlorophenylbiguanide	2.5	HTS		HTR3A, HTR3B			NC(=N)NC(=N)Nc1cccc(Cl)c1	Preclinical	5
BRD-K36970462-001-01-6::2.5::HTS	0.263902935747	BRD-K36970462-001-01-6::2.5::HTS	BRD-K36970462-001-01-6	tonabersat	2.5	HTS	gap junction modulator, nitric oxide production inhibitor				CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1	Phase 2	5
BRD-K36984403-001-02-7::2.5::HTS	-0.117177005516	BRD-K36984403-001-02-7::2.5::HTS	BRD-K36984403-001-02-7	go-6983	2.5	HTS	protein kinase inhibitor	PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ			COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1	Preclinical	5
BRD-K37069697-001-01-3::2.5::HTS	-0.201243529351	BRD-K37069697-001-01-3::2.5::HTS	BRD-K37069697-001-01-3	fexinidazole	2.5	HTS					CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1	Phase 2/Phase 3	5
BRD-K37083340-001-02-3::2.5::HTS	0.3924371004300001	BRD-K37083340-001-02-3::2.5::HTS	BRD-K37083340-001-02-3	lycopene	2.5	HTS	free radical scavenger				CC(C)=CCC\C(C)=C\C=C\C(C)=C\C=C\C(C)=C\C=C\C=C(C)\C=C\C=C(C)\C=C\C=C(/C)CCC=C(C)C	Phase 3	5
BRD-K37111771-300-02-6::2.5::HTS	-0.125950785189	BRD-K37111771-300-02-6::2.5::HTS	BRD-K37111771-300-02-6	trientine	2.5	HTS	chelating agent	CA14	metabolism	Wilson's disease	NCCNCCNCCN	Launched	5
BRD-K37130656-001-04-6::2.5::HTS	-0.614457389075	BRD-K37130656-001-04-6::2.5::HTS	BRD-K37130656-001-04-6	rivaroxaban	2.5	HTS	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)	Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O	Launched	5
BRD-K37203094-001-02-5::2.5::HTS	0.028414382878900003	BRD-K37203094-001-02-5::2.5::HTS	BRD-K37203094-001-02-5	1-hexadecanol	2.5	HTS			dermatology	cosmetic	CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO	Launched	5
BRD-K37237504-001-02-7::2.5::HTS	0.333686686134	BRD-K37237504-001-02-7::2.5::HTS	BRD-K37237504-001-02-7	CEP-33779	2.5	HTS	JAK inhibitor	JAK2			CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1	Preclinical	5
BRD-K37249724-001-25-7::2.5::HTS	0.11761786216299999	BRD-K37249724-001-25-7::2.5::HTS	BRD-K37249724-001-25-7	astemizole	2.5	HTS	histamine receptor antagonist	HRH1, KCNH1, KCNH2			COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1	Withdrawn	5
BRD-K37270826-001-27-6::2.66::HTS	-0.943103597845	BRD-K37270826-001-27-6::2.66::HTS	BRD-K37270826-001-27-6	mifepristone	2.66	HTS	glucocorticoid receptor antagonist, progesterone receptor antagonist	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C	Launched	5
BRD-K37270826-001-31-8::2.5::HTS	-0.652043732005	BRD-K37270826-001-31-8::2.5::HTS	BRD-K37270826-001-31-8	mifepristone	2.5	HTS	glucocorticoid receptor antagonist, progesterone receptor antagonist	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C	Launched	5
BRD-K37289225-001-36-4::2.5::HTS	-0.0259894289511	BRD-K37289225-001-36-4::2.5::HTS	BRD-K37289225-001-36-4	clozapine	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12	Launched	5
BRD-K37312348-001-15-0::2.5::HTS	0.8723690507870001	BRD-K37312348-001-15-0::2.5::HTS	BRD-K37312348-001-15-0	kenpaullone	2.5	HTS	CDK inhibitor, glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1	Preclinical	5
BRD-K37355418-236-01-6::2.5::HTS	-0.696529337265	BRD-K37355418-236-01-6::2.5::HTS	BRD-K37355418-236-01-6	efaproxiral	2.5	HTS	haemoglobin oxygen release stimulant	HBA1, HBB			Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1	Phase 3	5
BRD-K37379014-001-01-2::2.5::HTS	-4.479099957240001	BRD-K37379014-001-01-2::2.5::HTS	BRD-K37379014-001-01-2	filanesib	2.5	HTS	kinesin inhibitor, kinesin-like spindle protein inhibitor	KIF11			CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F	Phase 3	5
BRD-K37385792-003-02-1::2.5::HTS	-0.17404756807900001	BRD-K37385792-003-02-1::2.5::HTS	BRD-K37385792-003-02-1	conivaptan	2.5	HTS	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology	hyponatremia	Cc1nc2CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc3-c2[nH]1	Launched	5
BRD-K37516142-001-10-5::2.5::HTS	0.0381475382651	BRD-K37516142-001-10-5::2.5::HTS	BRD-K37516142-001-10-5	idebenone	2.5	HTS	calcium channel modulator		neurology/psychiatry, ophthalmology	Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O	Launched	5
BRD-K37561857-001-15-5::2.5::HTS	0.452104601148	BRD-K37561857-001-15-5::2.5::HTS	BRD-K37561857-001-15-5	zardaverine	2.5	HTS	phosphodiesterase inhibitor	PDE4D			COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1	Phase 2	5
BRD-K37590257-001-02-8::2.5::HTS	-0.32516768439	BRD-K37590257-001-02-8::2.5::HTS	BRD-K37590257-001-02-8	GSK256066	2.5	HTS	phosphodiesterase inhibitor	PDE4A			COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1	Phase 2	5
BRD-K37618799-001-03-0::2.5::HTS	-0.283567061723	BRD-K37618799-001-03-0::2.5::HTS	BRD-K37618799-001-03-0	MRS-1220	2.5	HTS	adenosine receptor antagonist	ADORA2B, ADORA3			Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1	Preclinical	5
BRD-K37682401-001-09-3::2.44::HTS	0.13186788890599999	BRD-K37682401-001-09-3::2.44::HTS	BRD-K37682401-001-09-3	piromidic-acid	2.44	HTS	bacterial DNA gyrase inhibitor				CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	Phase 2	5
BRD-K37682401-213-01-1::2.5::HTS	-0.524333328684	BRD-K37682401-213-01-1::2.5::HTS	BRD-K37682401-213-01-1	piromidic-acid	2.5	HTS	bacterial DNA gyrase inhibitor				CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	Phase 2	5
BRD-K37687095-001-06-9::2.5::HTS	-4.46185537476	BRD-K37687095-001-06-9::2.5::HTS	BRD-K37687095-001-06-9	AZD8330	2.5	HTS	MEK inhibitor				Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O	Phase 1	5
BRD-K37687387-237-01-7::2.5::HTS	0.533201643837	BRD-K37687387-237-01-7::2.5::HTS	BRD-K37687387-237-01-7	RU-28318	2.5	HTS	cytochrome P450 inhibitor	NR3C2			CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12	Phase 2	5
BRD-K37688416-003-13-1::2.5::HTS	0.321054292779	BRD-K37688416-003-13-1::2.5::HTS	BRD-K37688416-003-13-1	fipexide	2.5	HTS	psychoactive drug				Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1	Withdrawn	5
BRD-K37694030-003-12-7::2.5::HTS	0.169864940341	BRD-K37694030-003-12-7::2.5::HTS	BRD-K37694030-003-12-7	doxepin	2.5	HTS	histamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HRH2, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, KCNH2, SLC6A2, SLC6A4	neurology/psychiatry	depression, anxiety	CN(C)CC\C=C1\c2ccccc2COc2ccccc12, CN(C)CC\C=C1\c2ccccc2COc2ccccc12	Launched	5
BRD-K37714784-305-02-1::2.5::HTS	-0.0899533414328	BRD-K37714784-305-02-1::2.5::HTS	BRD-K37714784-305-02-1	ABT-724	2.5	HTS	dopamine receptor agonist	DRD4			C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1	Phase 2	5
BRD-K37720887-001-07-8::2.5::HTS	-0.325590944562	BRD-K37720887-001-07-8::2.5::HTS	BRD-K37720887-001-07-8	SB-525334	2.5	HTS	TGF beta receptor inhibitor	TGFBR1			Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C	Preclinical	5
BRD-K37723606-001-01-5::2.5::HTS	0.25951256198100003	BRD-K37723606-001-01-5::2.5::HTS	BRD-K37723606-001-01-5	dioscin	2.5	HTS	apoptosis stimulant	CXCR3			C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1	Preclinical	5
BRD-K37753391-046-03-2::2.5::HTS	0.398235527056	BRD-K37753391-046-03-2::2.5::HTS	BRD-K37753391-046-03-2	tylosin	2.5	HTS	protein synthesis inhibitor		infectious disease, gastroenterology	gram-positive bacterial infections, colitis	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC	Launched	5
BRD-K37764012-001-04-1::2.5::HTS	-3.62844006015	BRD-K37764012-001-04-1::2.5::HTS	BRD-K37764012-001-04-1	PF-03758309	2.5	HTS	p21 activated kinase inhibitor	PAK4			CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1	Phase 1	5
BRD-K37793595-003-01-7::2.5::HTS	-0.0778783252315	BRD-K37793595-003-01-7::2.5::HTS	BRD-K37793595-003-01-7	afobazole	2.5	HTS	anxiolytic		neurology/psychiatry	anxiety	CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1	Launched	5
BRD-K37798499-001-27-2::2.5::HTS	-1.01133400811	BRD-K37798499-001-27-2::2.5::HTS	BRD-K37798499-001-27-2	etoposide	2.5	HTS	topoisomerase inhibitor	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	Launched	5
BRD-K37814297-050-09-6::2.5::HTS	0.23043609394900003	BRD-K37814297-050-09-6::2.5::HTS	BRD-K37814297-050-09-6	acepromazine	2.5	HTS	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	sedative	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O	Launched	5
BRD-K37846922-001-09-4::0.25::HTS	0.26938670110999996	BRD-K37846922-001-09-4::0.25::HTS	BRD-K37846922-001-09-4	3,3'-diindolylmethane	0.25	HTS	CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor	AR, HIF1A, IFNG, PI3			C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	Phase 3	3
BRD-K37865504-001-04-1::2.5::HTS	-0.8680924912639999	BRD-K37865504-001-04-1::2.5::HTS	BRD-K37865504-001-04-1	LY2183240	2.5	HTS	FAAH inhibitor, FAAH reuptake inhibitor	FAAH			CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1	Preclinical	5
BRD-K37872686-003-01-9::2.5::HTS	-0.682457243436	BRD-K37872686-003-01-9::2.5::HTS	BRD-K37872686-003-01-9	tirofiban	2.5	HTS	platelet aggregation inhibitor, structural glycoprotein antagonist	ITGA2B, ITGB3	cardiology	myocardial infarction, refactory angina	CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O	Launched	5
BRD-K37890730-001-15-1::2.5::HTS	-4.33951996573	BRD-K37890730-001-15-1::2.5::HTS	BRD-K37890730-001-15-1	camptothecin	2.5	HTS	topoisomerase inhibitor	TOP1			CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O	Phase 3	5
BRD-K37949327-001-06-3::2.5::HTS	0.102362238028	BRD-K37949327-001-06-3::2.5::HTS	BRD-K37949327-001-06-3	etidronic-acid	2.5	HTS	bone resorption inhibitor	ATP6V1A, PTPRS	endocrinology, orthopedics	Paget's disease, heterotopic ossification	CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O	Launched	5
BRD-K37952347-001-01-4::2.5::HTS	0.000465808034358	BRD-K37952347-001-01-4::2.5::HTS	BRD-K37952347-001-01-4	L-732,138	2.5	HTS	tachykinin antagonist	TACR1, TACR2			CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F	Preclinical	5
BRD-K37991163-003-13-4::2.5::HTS	0.0831105332153	BRD-K37991163-003-13-4::2.5::HTS	BRD-K37991163-003-13-4	paroxetine	2.5	HTS	selective serotonin reuptake inhibitor (SSRI)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder	Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1	Launched	5
BRD-K38003476-001-09-1::2.5::HTS	-0.161256432916	BRD-K38003476-001-09-1::2.5::HTS	BRD-K38003476-001-09-1	clocortolone-pivalate	2.5	HTS	steroid	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C	Launched	5
BRD-K38055836-001-21-1::2.5::HTS	0.384933811234	BRD-K38055836-001-21-1::2.5::HTS	BRD-K38055836-001-21-1	ethamivan	2.5	HTS	respiratory stimulant				CCN(CC)C(=O)c1ccc(O)c(OC)c1, CCN(CC)C(=O)c1ccc(O)c(OC)c1	Preclinical	5
BRD-K38140108-002-01-2::2.5::HTS	-0.426482297639	BRD-K38140108-002-01-2::2.5::HTS	BRD-K38140108-002-01-2	gadodiamide	2.5	HTS	radiopaque medium		radiology	MRI contrast agent	CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	Launched	5
BRD-K38158531-001-02-1::2.5::HTS	-0.557578459734	BRD-K38158531-001-02-1::2.5::HTS	BRD-K38158531-001-02-1	traxoprodil	2.5	HTS	glutamate receptor antagonist	GRIN2B			C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1	Phase 2	5
BRD-K38183498-001-02-0::2.5::HTS	0.0682064608092	BRD-K38183498-001-02-0::2.5::HTS	BRD-K38183498-001-02-0	clonazepam	2.5	HTS	GABA benzodiazepine site receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1	Launched	5
BRD-K38197229-001-29-9::2.5::HTS	-0.18053948714	BRD-K38197229-001-29-9::2.5::HTS	BRD-K38197229-001-29-9	bumetanide	2.5	HTS	solute carrier family member inhibitor	CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5	cardiology	edema, congestive heart failure	CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O	Launched	5
BRD-K38287497-001-01-2::2.5::HTS	0.373920719577	BRD-K38287497-001-01-2::2.5::HTS	BRD-K38287497-001-01-2	narlaprevir	2.5	HTS	HCV inhibitor				CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	Phase 2/Phase 3	5
BRD-K38305202-001-17-4::2.5::HTS	-0.130843077014	BRD-K38305202-001-17-4::2.5::HTS	BRD-K38305202-001-17-4	domperidone	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3	infectious disease	fescue toxicosis	Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1	Launched	5
BRD-K38323065-001-19-9::2.5::HTS	-0.771267497254	BRD-K38323065-001-19-9::2.5::HTS	BRD-K38323065-001-19-9	phenacetin	2.5	HTS	cyclooxygenase inhibitor	PTGS1			CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1	Withdrawn	5
BRD-K38332599-001-01-3::2.5::HTS	-1.8450151819599998	BRD-K38332599-001-01-3::2.5::HTS	BRD-K38332599-001-01-3	uprosertib	2.5	HTS	AKT inhibitor	AKT1, AKT2, AKT3			Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1	Phase 2	5
BRD-K38350380-001-01-8::2.5::HTS	-0.639506208908	BRD-K38350380-001-01-8::2.5::HTS	BRD-K38350380-001-01-8	FK-3311	2.5	HTS	cyclooxygenase inhibitor	PTGS2			CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1	Phase 2	5
BRD-K38370968-050-01-3::2.5::HTS	-0.0801882754385	BRD-K38370968-050-01-3::2.5::HTS	BRD-K38370968-050-01-3	3-AQC	2.5	HTS	serotonin receptor agonist	HTR3A			C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N	Preclinical	5
BRD-K38380126-001-01-4::2.5::HTS	-0.167410097705	BRD-K38380126-001-01-4::2.5::HTS	BRD-K38380126-001-01-4	thiamet-g	2.5	HTS	GLCNAC phosphotransferase inhibitor	MGEA5			CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1	Preclinical	5
BRD-K38436528-003-26-1::2.5::HTS	-0.050033285586199995	BRD-K38436528-003-26-1::2.5::HTS	BRD-K38436528-003-26-1	imipramine	2.5	HTS	norepinephrine reputake inhibitor, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry, urology	depression, nocturnal enuresis	CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12	Launched	5
BRD-K38458514-001-01-8::2.5::HTS	-0.39009736791199995	BRD-K38458514-001-01-8::2.5::HTS	BRD-K38458514-001-01-8	diazooxonorleucine	2.5	HTS	glutamate receptor antagonist				N[C@@H](CCC(=O)C=[N+]=N)C(O)=O	Phase 2	5
BRD-K38473998-001-02-0::2.5::HTS	0.106758357019	BRD-K38473998-001-02-0::2.5::HTS	BRD-K38473998-001-02-0	cilomilast	2.5	HTS	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4D			COc1ccc(cc1OC1CCCC1)C1(CCC(CC1)C(O)=O)C#N	Phase 3	5
BRD-K38548312-001-01-0::2.5::HTS	-0.9007772779100001	BRD-K38548312-001-01-0::2.5::HTS	BRD-K38548312-001-01-0	VER-49009	2.5	HTS	HSP inhibitor	HSP90AA1			CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O	Preclinical	5
BRD-K38580127-003-15-4::2.5::HTS	-0.0121906244407	BRD-K38580127-003-15-4::2.5::HTS	BRD-K38580127-003-15-4	serotonin	2.5	HTS	growth factor receptor activator	DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1	neurology/psychiatry	anxiety, depression, sleeplessness	NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12	Launched	5
BRD-K38602774-001-03-2::2.5::HTS	0.137678505845	BRD-K38602774-001-03-2::2.5::HTS	BRD-K38602774-001-03-2	sulisobenzone	2.5	HTS			dermatology	sunscreen lotion	COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1	Launched	5
BRD-K38684403-001-05-4::2.5::HTS	-0.5870422520440001	BRD-K38684403-001-05-4::2.5::HTS	BRD-K38684403-001-05-4	roxithromycin	2.5	HTS	bacterial 50S ribosomal subunit inhibitor	ABCB1, MLNR	infectious disease	respiratory tract infections, urinary tract infections, skin infections	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	5
BRD-K38687824-001-02-5::2.5::HTS	-0.0647570250861	BRD-K38687824-001-02-5::2.5::HTS	BRD-K38687824-001-02-5	beta-amyloid-synthesis-inhibitor	2.5	HTS	beta amyloid synthesis inhibitor	APP			Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1	Preclinical	5
BRD-K38797369-003-01-1::2.46::HTS	-0.0106750724177	BRD-K38797369-003-01-1::2.46::HTS	BRD-K38797369-003-01-1	PD-128907	2.46	HTS	dopamine receptor agonist	DRD2, DRD3			CCCN1CCO[C@H]2[C@@H]1COc1ccc(O)cc21, CCCN1CCO[C@@H]2[C@@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21	Preclinical	5
BRD-K38852836-001-02-1::2.5::HTS	-4.80853772621	BRD-K38852836-001-02-1::2.5::HTS	BRD-K38852836-001-02-1	ganetespib	2.5	HTS	HSP inhibitor	HSP90AA1			CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O	Phase 3	5
BRD-K38860038-001-01-2::2.5::HTS	-1.05939487058	BRD-K38860038-001-01-2::2.5::HTS	BRD-K38860038-001-01-2	JK-184	2.5	HTS	hedgehog pathway inhibitor				CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1	Preclinical	5
BRD-K38868394-001-01-3::2.5::HTS	0.191571020225	BRD-K38868394-001-01-3::2.5::HTS	BRD-K38868394-001-01-3	MK-0773	2.5	HTS	androgen receptor modulator	AR			CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O	Phase 2	5
BRD-K38903228-001-13-5::2.5::HTS	0.045379326353900004	BRD-K38903228-001-13-5::2.5::HTS	BRD-K38903228-001-13-5	hesperidin	2.5	HTS	flavanone glycoside	CACNA1B			COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1	Launched	5
BRD-K38904395-001-02-3::2.5::HTS	-0.0086813842781	BRD-K38904395-001-02-3::2.5::HTS	BRD-K38904395-001-02-3	SAR131675	2.5	HTS	VEGFR inhibitor	FLT4			CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC	Preclinical	5
BRD-K38911213-003-01-6::2.5::HTS	-0.537894812843	BRD-K38911213-003-01-6::2.5::HTS	BRD-K38911213-003-01-6	apraclonidine	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C	ophthalmology	glaucoma, intraocular pressure	Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1	Launched	5
BRD-K38913877-300-01-9::2.5::HTS	-0.277891175428	BRD-K38913877-300-01-9::2.5::HTS	BRD-K38913877-300-01-9	azimilide	2.5	HTS	potassium channel blocker	KCNA5, KCNE1, KCNH2, KCNQ1			CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1	Phase 3	5
BRD-K38938675-001-01-4::2.5::HTS	0.0147681062137	BRD-K38938675-001-01-4::2.5::HTS	BRD-K38938675-001-01-4	morniflumate	2.5	HTS	anti-inflammatory agent		neurology/psychiatry	pain relief	FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1	Launched	5
BRD-K39023557-001-01-7::2.5::HTS	0.1556319283	BRD-K39023557-001-01-7::2.5::HTS	BRD-K39023557-001-01-7	octocrylene	2.5	HTS			dermatology	sunscreen lotion	CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1	Launched	5
BRD-K39061174-001-01-0::2.62::HTS	0.195423377611	BRD-K39061174-001-01-0::2.62::HTS	BRD-K39061174-001-01-0	beta-glycerophosphoric-acid	2.62	HTS					OCC(CO)OP(O)(O)=O	Preclinical	5
BRD-K39079086-001-07-6::2.5::HTS	0.143114320188	BRD-K39079086-001-07-6::2.5::HTS	BRD-K39079086-001-07-6	cinchonidine	2.5	HTS	P glycoprotein inhibitor				O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	Phase 1	5
BRD-K39120595-304-04-7::2.5::HTS	-0.17171255066500002	BRD-K39120595-304-04-7::2.5::HTS	BRD-K39120595-304-04-7	bithionol	2.5	HTS	autotaxin inhibitor	ESR1, ESR2, MCL1			Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O	Withdrawn	5
BRD-K39160765-003-02-9::2.5::HTS	-0.26307953581	BRD-K39160765-003-02-9::2.5::HTS	BRD-K39160765-003-02-9	4-chlorophenylguanidine	2.5	HTS	urokinase inhibitor	PLAUR			NC(=N)Nc1ccc(Cl)cc1	Preclinical	5
BRD-K39166528-001-01-0::2.5::HTS	0.17246282239500002	BRD-K39166528-001-01-0::2.5::HTS	BRD-K39166528-001-01-0	ID-8	2.5	HTS					COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12	Preclinical	5
BRD-K39171998-001-01-1::2.5::HTS	-2.75311260027	BRD-K39171998-001-01-1::2.5::HTS	BRD-K39171998-001-01-1	STF-118804	2.5	HTS	NAMPT inhibitor	NAMPT			Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1	Preclinical	5
BRD-K39252998-003-01-5::2.5::HTS	0.858121298523	BRD-K39252998-003-01-5::2.5::HTS	BRD-K39252998-003-01-5	atipamezole	2.5	HTS	adrenergic receptor antagonist		neurology/psychiatry	reverse sedative	CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1	Launched	5
BRD-K39339537-001-21-0::2.5::HTS	-0.00885391379671	BRD-K39339537-001-21-0::2.5::HTS	BRD-K39339537-001-21-0	epirizole	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	COc1cc(C)nn1-c1nc(C)cc(OC)n1	Launched	5
BRD-K39371216-001-01-3::2.5::HTS	0.565491161266	BRD-K39371216-001-01-3::2.5::HTS	BRD-K39371216-001-01-3	cyacetacide	2.5	HTS					NNC(=O)CC#N	Preclinical	5
BRD-K39381259-001-01-0::2.5::HTS	0.19056856125399999	BRD-K39381259-001-01-0::2.5::HTS	BRD-K39381259-001-01-0	DMH1	2.5	HTS	ALK tyrosine kinase receptor inhibitor	ACVR1			CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	Preclinical	5
BRD-K39462424-050-09-8::2.5::HTS	0.351337309181	BRD-K39462424-050-09-8::2.5::HTS	BRD-K39462424-050-09-8	dexchlorpheniramine	2.5	HTS	histamine receptor antagonist		allergy, cardiology	allergic conjunctivitis, allergic rhinitis, urticaria, angioedema	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1	Launched	5
BRD-K39467894-001-05-9::2.5::HTS	0.18175108913199997	BRD-K39467894-001-05-9::2.5::HTS	BRD-K39467894-001-05-9	nithiamide	2.5	HTS	bacterial DNA inhibitor				CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O	Preclinical	5
BRD-K39467894-001-06-7::2.5::HTS	0.226021461349	BRD-K39467894-001-06-7::2.5::HTS	BRD-K39467894-001-06-7	nithiamide	2.5	HTS	bacterial DNA inhibitor				CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O	Preclinical	5
BRD-K39484304-001-16-5::2.5::HTS	-5.35951812285	BRD-K39484304-001-16-5::2.5::HTS	BRD-K39484304-001-16-5	triptolide	2.5	HTS	RNA polymerase inhibitor	RELA			CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O	Phase 3	5
BRD-K39495750-001-01-2::2.5::HTS	-0.287006847247	BRD-K39495750-001-01-2::2.5::HTS	BRD-K39495750-001-01-2	chlorobutanol	2.5	HTS			neurology/psychiatry	anesthetic, sedative	CC(C)(O)C(Cl)(Cl)Cl, CC(C)(O)C(Cl)(Cl)Cl	Launched	5
BRD-K39503511-001-03-9::2.5::HTS	-0.07804527072010001	BRD-K39503511-001-03-9::2.5::HTS	BRD-K39503511-001-03-9	quiflapon	2.5	HTS	leukotriene synthesis inhibitor	ALOX5, ALOX5AP			CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	Phase 2	5
BRD-K39558284-001-01-2::2.5::HTS	0.301539266017	BRD-K39558284-001-01-2::2.5::HTS	BRD-K39558284-001-01-2	SDZ-WAG-994	2.5	HTS	adenosine receptor agonist	ADORA1			CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12	Phase 2	5
BRD-K39624409-003-02-6::2.5::HTS	-0.173014289283	BRD-K39624409-003-02-6::2.5::HTS	BRD-K39624409-003-02-6	ADL5859	2.5	HTS	opioid receptor agonist	OPRD1			CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12	Phase 2	5
BRD-K39670393-303-02-1::2.5::HTS	-0.512151342154	BRD-K39670393-303-02-1::2.5::HTS	BRD-K39670393-303-02-1	amthamine	2.5	HTS	histamine receptor agonist	HRH2			Cc1nc(N)sc1CCN	Preclinical	5
BRD-K39693230-001-01-2::2.5::HTS	0.0733785932411	BRD-K39693230-001-01-2::2.5::HTS	BRD-K39693230-001-01-2	N-salicoylaminophenol	2.5	HTS	ribonucleotide reductase inhibitor				Oc1ccc(NC(=O)c2ccccc2O)cc1	Preclinical	5
BRD-K39733634-001-02-6::2.5::HTS	0.0155338373267	BRD-K39733634-001-02-6::2.5::HTS	BRD-K39733634-001-02-6	L-161982	2.5	HTS	prostanoid receptor antagonist	PTGER4			CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C	Preclinical	5
BRD-K39805756-001-01-6::2.5::HTS	0.0454491900928	BRD-K39805756-001-01-6::2.5::HTS	BRD-K39805756-001-01-6	TPPS4	2.5	HTS					OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2	Phase 1	5
BRD-K39841531-001-02-1::2.5::HTS	-0.617679060603	BRD-K39841531-001-02-1::2.5::HTS	BRD-K39841531-001-02-1	TG-101209	2.5	HTS	JAK inhibitor	JAK2, JAK3			CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1	Preclinical	5
BRD-K39915878-036-24-4::2.5::HTS	-0.37346601260799994	BRD-K39915878-036-24-4::2.5::HTS	BRD-K39915878-036-24-4	loxapine	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	schizophrenia	CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12	Launched	5
BRD-K39974922-001-04-3::2.5::HTS	0.255806268794	BRD-K39974922-001-04-3::2.5::HTS	BRD-K39974922-001-04-3	lenvatinib	2.5	HTS	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT4, KDR	oncology	thyroid cancer	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O	Launched	5
BRD-K39983086-001-06-1::2.45::HTS	0.07213533587899999	BRD-K39983086-001-06-1::2.45::HTS	BRD-K39983086-001-06-1	loteprednol	2.45	HTS	glucocorticoid receptor agonist, phospholipase inhibitor	NR3C1	ophthalmology	conjunctivitis	CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl	Launched	5
BRD-K39987650-001-24-1::2.5::HTS	0.107103911579	BRD-K39987650-001-24-1::2.5::HTS	BRD-K39987650-001-24-1	bisacodyl	2.5	HTS	laxative		gastroenterology	constipation	CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1	Launched	5
BRD-K40109029-001-02-9::2.5::HTS	-1.1174468132	BRD-K40109029-001-02-9::2.5::HTS	BRD-K40109029-001-02-9	SB-505124	2.5	HTS	ALK tyrosine kinase receptor inhibitor	TGFBR1			Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C	Preclinical	5
BRD-K40175214-001-11-6::2.5::HTS	-2.59973471961	BRD-K40175214-001-11-6::2.5::HTS	BRD-K40175214-001-11-6	torin-1	2.5	HTS	mTOR inhibitor	MTOR			CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1	Preclinical	5
BRD-K40227168-001-12-9::1.7::HTS	-0.421480234453	BRD-K40227168-001-12-9::1.7::HTS	BRD-K40227168-001-12-9	vinburnine	1.7	HTS	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	stroke	CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41	Launched	4
BRD-K40255344-001-17-6::2.5::HTS	0.10613362679999999	BRD-K40255344-001-17-6::2.5::HTS	BRD-K40255344-001-17-6	tyrphostin-A9	2.5	HTS	protein tyrosine kinase inhibitor, tyrosine kinase inhibitor				CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C	Preclinical	5
BRD-K40269473-001-02-2::2.5::HTS	0.292081330911	BRD-K40269473-001-02-2::2.5::HTS	BRD-K40269473-001-02-2	cathepsin-inhibitor-1	2.5	HTS	cathepsin inhibitor	CTSB, CTSL, CTSV			Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C	Preclinical	5
BRD-K40302533-001-02-9::2.5::HTS	-0.0153284772966	BRD-K40302533-001-02-9::2.5::HTS	BRD-K40302533-001-02-9	PF-5274857	2.5	HTS	smoothened receptor antagonist	SMO			Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O	Preclinical	5
BRD-K40308497-001-01-2::2.54::HTS	0.437588493279	BRD-K40308497-001-01-2::2.54::HTS	BRD-K40308497-001-01-2	crizotinib-(S)	2.54	HTS	MTH1 inhibitor	NUDT1			C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	Preclinical	5
BRD-K40308497-001-02-0::2.5::HTS	0.330161226456	BRD-K40308497-001-02-0::2.5::HTS	BRD-K40308497-001-02-0	crizotinib-(S)	2.5	HTS	MTH1 inhibitor	NUDT1			C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	Preclinical	5
BRD-K40331046-305-01-5::2.5::HTS	-2.48783803607	BRD-K40331046-305-01-5::2.5::HTS	BRD-K40331046-305-01-5	CR8-(R)	2.5	HTS	CDK inhibitor	CCNA2			CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1	Preclinical	5
BRD-K40366680-001-03-3::2.5::HTS	-0.488603083306	BRD-K40366680-001-03-3::2.5::HTS	BRD-K40366680-001-03-3	CAY10505	2.5	HTS	PI3K inhibitor	PIK3CG			Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1	Preclinical	5
BRD-K40438880-305-06-6::2.5::HTS	0.13550834170999998	BRD-K40438880-305-06-6::2.5::HTS	BRD-K40438880-305-06-6	spermidine	2.5	HTS	glutamate receptor modulator	KCNJ4, TXNRD1			NCCCCNCCCN	Preclinical	5
BRD-K40496271-396-01-1::2.34::HTS	-0.0398601128254	BRD-K40496271-396-01-1::2.34::HTS	BRD-K40496271-396-01-1	eltrombopag	2.34	HTS	thrombopoietin receptor agonist	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1	Launched	5
BRD-K40530731-001-11-6::2.5::HTS	0.272921879609	BRD-K40530731-001-11-6::2.5::HTS	BRD-K40530731-001-11-6	hyoscyamine	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1	Launched	5
BRD-K40578143-001-02-6::2.5::HTS	0.07739844930539999	BRD-K40578143-001-02-6::2.5::HTS	BRD-K40578143-001-02-6	GR-79236	2.5	HTS	adenosine receptor agonist	ADORA1, ADORA2A			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12	Phase 1	5
BRD-K40621224-001-06-7::2.5::HTS	-0.235444249482	BRD-K40621224-001-06-7::2.5::HTS	BRD-K40621224-001-06-7	pentetic-acid	2.5	HTS	chelating agent	PGD			OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	Phase 2	5
BRD-K40654626-236-01-5::2.5::HTS	-0.168763149578	BRD-K40654626-236-01-5::2.5::HTS	BRD-K40654626-236-01-5	ditiocarb-sodium-trihydrate	2.5	HTS	immunostimulant	CA1, CA2, CA4			CCN(CC)C(S)=S, CCN(CC)C(S)=S	Phase 3	5
BRD-K40715924-001-01-1::2.5::HTS	0.148919553132	BRD-K40715924-001-01-1::2.5::HTS	BRD-K40715924-001-01-1	medorinone	2.5	HTS					Cc1nccc2[nH]c(=O)ccc12	Phase 1	5
BRD-K40718343-001-02-6::2.5::HTS	0.554846586507	BRD-K40718343-001-02-6::2.5::HTS	BRD-K40718343-001-02-6	AEE788	2.5	HTS	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR			CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	Phase 1/Phase 2	5
BRD-K40738845-001-05-0::2.5::HTS	-0.119928504462	BRD-K40738845-001-05-0::2.5::HTS	BRD-K40738845-001-05-0	BMS-777607	2.5	HTS	AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor	AXL, MERTK, MET, MST1R, TYRO3			CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1	Phase 1/Phase 2	5
BRD-K40758068-001-08-2::2.5::HTS	-0.740986228875	BRD-K40758068-001-08-2::2.5::HTS	BRD-K40758068-001-08-2	efavirenz	2.5	HTS	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1	Launched	5
BRD-K40782193-003-02-9::2.5::HTS	0.127340397446	BRD-K40782193-003-02-9::2.5::HTS	BRD-K40782193-003-02-9	QX-222	2.5	HTS	sodium channel blocker				Cc1cccc(C)c1NC(=O)C[N+](C)(C)C	Preclinical	5
BRD-K40787673-001-02-1::2.5::HTS	-0.291974407443	BRD-K40787673-001-02-1::2.5::HTS	BRD-K40787673-001-02-1	lacitol	2.5	HTS	osmosis stimulant		gastroenterology	constipation	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	Launched	5
BRD-K40797222-001-01-8::2.5::HTS	0.33249220685499997	BRD-K40797222-001-01-8::2.5::HTS	BRD-K40797222-001-01-8	SC-12267	2.5	HTS	dihydroorotate dehydrogenase inhibitor	IL17A			COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1	Phase 2	5
BRD-K40870905-001-01-7::2.5::HTS	-0.7365134418979999	BRD-K40870905-001-01-7::2.5::HTS	BRD-K40870905-001-01-7	CT-7758	2.5	HTS	integrin antagonist	ITGA4			OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1	Phase 2	5
BRD-K40887525-001-21-9::2.5::HTS	0.721859030139	BRD-K40887525-001-21-9::2.5::HTS	BRD-K40887525-001-21-9	ritanserin	2.5	HTS	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1	Phase 3	5
BRD-K40901640-003-01-6::2.5::HTS	0.0419904093229	BRD-K40901640-003-01-6::2.5::HTS	BRD-K40901640-003-01-6	cinanserin	2.5	HTS	serotonin receptor antagonist	HTR2A			CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1	Preclinical	5
BRD-K40905133-001-04-9::2.5::HTS	-0.050132411994500005	BRD-K40905133-001-04-9::2.5::HTS	BRD-K40905133-001-04-9	phenacemide	2.5	HTS	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures	NC(=O)NC(=O)Cc1ccccc1	Launched	5
BRD-K40992116-001-09-7::2.5::HTS	-0.074207458157	BRD-K40992116-001-09-7::2.5::HTS	BRD-K40992116-001-09-7	parachlorophenol	2.5	HTS	antiinfective drug				Oc1ccc(Cl)cc1	Launched	5
BRD-K41024817-325-01-0::2.5::HTS	0.195807136455	BRD-K41024817-325-01-0::2.5::HTS	BRD-K41024817-325-01-0	4-phenolsulfonic-acid	2.5	HTS					Oc1ccc(cc1)S(O)(=O)=O	Preclinical	5
BRD-K41104902-001-01-3::2.5::HTS	0.135793360594	BRD-K41104902-001-01-3::2.5::HTS	BRD-K41104902-001-01-3	GSK2656157	2.5	HTS	PERK inhibitor				Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	Preclinical	5
BRD-K41141507-001-16-2::2.5::HTS	-0.811560559865	BRD-K41141507-001-16-2::2.5::HTS	BRD-K41141507-001-16-2	cyproterone-acetate	2.5	HTS	androgen receptor antagonist	ADORA1, AR	oncology	prostate cancer	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	Launched	5
BRD-K41143549-003-02-4::2.5::HTS	0.0534641225378	BRD-K41143549-003-02-4::2.5::HTS	BRD-K41143549-003-02-4	N20C	2.5	HTS	glutamate receptor antagonist				NC(=O)CNCCC(c1ccccc1)c1ccccc1	Preclinical	5
BRD-K41160163-001-06-8::2.5::HTS	0.162960638377	BRD-K41160163-001-06-8::2.5::HTS	BRD-K41160163-001-06-8	fenobam	2.5	HTS	glutamate receptor antagonist	GRM5			CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1	Phase 2	5
BRD-K41170226-001-13-8::2.5::HTS	0.133197038666	BRD-K41170226-001-13-8::2.5::HTS	BRD-K41170226-001-13-8	deoxycholic-acid	2.5	HTS	biliverdin reductase A activator, G protein-coupled receptor agonist	EFTUD1, FPR1, GPBAR1	endocrinology	submental fat	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Launched	5
BRD-K41185545-001-02-3::2.5::HTS	0.215260025471	BRD-K41185545-001-02-3::2.5::HTS	BRD-K41185545-001-02-3	ambrisentan	2.5	HTS	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1	Launched	5
BRD-K41213548-001-02-0::2.5::HTS	-0.9026763683329999	BRD-K41213548-001-02-0::2.5::HTS	BRD-K41213548-001-02-0	KW-2478	2.5	HTS	HSP inhibitor				CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC	Phase 1/Phase 2	5
BRD-K41234004-001-03-1::0.03::HTS	0.066290224831	BRD-K41234004-001-03-1::0.03::HTS	BRD-K41234004-001-03-1	icomucret	0.03	HTS	mucin production enhancer	LTB4R2			CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O	Phase 3	1
BRD-K41256143-001-12-7::2.5::HTS	0.259716535872	BRD-K41256143-001-12-7::2.5::HTS	BRD-K41256143-001-12-7	dehydroepiandrosterone	2.5	HTS	protein synthesis stimulant	ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1			C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	Launched	5
BRD-K41260949-236-16-8::2.5::HTS	0.369395514909	BRD-K41260949-236-16-8::2.5::HTS	BRD-K41260949-236-16-8	valproic-acid	2.5	HTS	HDAC inhibitor	ABAT, ACADSB, ALDH5A1, HDAC1, HDAC2, HDAC9, OGDH, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O	Launched	5
BRD-K41278234-001-03-0::2.5::HTS	-2.97301830326	BRD-K41278234-001-03-0::2.5::HTS	BRD-K41278234-001-03-0	CUDC-101	2.5	HTS	EGFR inhibitor	EGFR, ERBB2			COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO	Phase 1	5
BRD-K41298358-395-03-4::2.46::HTS	-0.0243300170623	BRD-K41298358-395-03-4::2.46::HTS	BRD-K41298358-395-03-4	tetraethylenepentamine	2.46	HTS	superoxide dismutase inhibitor	SOD1, SOD2			NCCNCCNCCNCCN, NCCNCCNCCNCCN	Phase 2/Phase 3	5
BRD-K41304947-001-03-2::2.5::HTS	-0.234412031772	BRD-K41304947-001-03-2::2.5::HTS	BRD-K41304947-001-03-2	HA-966-(S)-(-)	2.5	HTS	glutamate receptor antagonist	GRIA1			N[C@H]1CCN(O)C1=O	Preclinical	5
BRD-K41312087-001-02-7::2.5::HTS	-1.5147251474899999	BRD-K41312087-001-02-7::2.5::HTS	BRD-K41312087-001-02-7	GW-441756	2.5	HTS	growth factor receptor inhibitor	NTRK1			Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12	Preclinical	5
BRD-K41337261-001-03-0::2.5::HTS	-2.52699590583	BRD-K41337261-001-03-0::2.5::HTS	BRD-K41337261-001-03-0	ZM-306416	2.5	HTS	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR			COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC	Preclinical	5
BRD-K41406082-001-16-2::2.5::HTS	0.0106611602238	BRD-K41406082-001-16-2::2.5::HTS	BRD-K41406082-001-16-2	sulfapyridine	2.5	HTS	PABA antagonist				Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1	Launched	5
BRD-K41410256-304-02-2::2.5::HTS	0.536431089262	BRD-K41410256-304-02-2::2.5::HTS	BRD-K41410256-304-02-2	balsalazide	2.5	HTS	cyclooxygenase inhibitor	ALOX5, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis	OC(=O)CCNC(=O)c1ccc(cc1)N=Nc1ccc(O)c(c1)C(O)=O	Launched	5
BRD-K41434598-003-01-9::2.5::HTS	0.369000351507	BRD-K41434598-003-01-9::2.5::HTS	BRD-K41434598-003-01-9	org-9768	2.5	HTS	adrenergic receptor antagonist	ADRA2A			CC1(CN)Cc2ccccc2C1	Phase 1	5
BRD-K41438959-001-01-7::2.5::HTS	-0.748335177026	BRD-K41438959-001-01-7::2.5::HTS	BRD-K41438959-001-01-7	perampanel	2.5	HTS	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4	neurology/psychiatry	seizures	O=c1c(cc(cn1-c1ccccc1)-c1ccccn1)-c1ccccc1C#N	Launched	5
BRD-K41445866-001-18-8::2.5::HTS	-0.07105461869860001	BRD-K41445866-001-18-8::2.5::HTS	BRD-K41445866-001-18-8	alfaxalone	2.5	HTS	chloride channel agonist, benzodiazepine receptor agonist	GABBR1	neurology/psychiatry	general anaesthetic	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	Launched	5
BRD-K41524689-001-23-5::2.5::HTS	-0.057446671952400004	BRD-K41524689-001-23-5::2.5::HTS	BRD-K41524689-001-23-5	paracetamol	2.5	HTS	cyclooxygenase inhibitor	FAAH, PTGS1, PTGS2, TRPV1	neurology/psychiatry, endocrinology	pain relief, fever	CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1	Launched	5
BRD-K41564320-001-02-0::2.5::HTS	0.178169265699	BRD-K41564320-001-02-0::2.5::HTS	BRD-K41564320-001-02-0	purvalanol-b	2.5	HTS	tyrosine kinase inhibitor	CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2			CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical	5
BRD-K41567364-001-04-6::2.5::HTS	-0.0920193246108	BRD-K41567364-001-04-6::2.5::HTS	BRD-K41567364-001-04-6	SB-334867	2.5	HTS	orexin receptor antagonist	HCRTR1, HCRTR2			Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1	Preclinical	5
BRD-K41567533-001-08-3::2.5::HTS	0.19405661307500002	BRD-K41567533-001-08-3::2.5::HTS	BRD-K41567533-001-08-3	coumophos	2.5	HTS	cholinesterase inhibitor				CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1	Preclinical	5
BRD-K41599323-001-02-3::2.5::HTS	0.09096493549200001	BRD-K41599323-001-02-3::2.5::HTS	BRD-K41599323-001-02-3	lonafarnib	2.5	HTS	farnesyltransferase inhibitor	FNTA, HRAS, KRAS, NRAS			NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1	Phase 3	5
BRD-K41707108-001-05-6::2.5::HTS	0.285209959639	BRD-K41707108-001-05-6::2.5::HTS	BRD-K41707108-001-05-6	ceramide	2.5	HTS	phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator		dermatology	cosmetic	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O	Launched	5
BRD-K41713976-300-02-6::2.5::HTS	-0.9738282080859999	BRD-K41713976-300-02-6::2.5::HTS	BRD-K41713976-300-02-6	E-4031	2.5	HTS	potassium channel blocker	KCNH1, KCNH2			Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1	Phase 1	5
BRD-K41731458-001-15-1::2.5::HTS	-0.35609886632	BRD-K41731458-001-15-1::2.5::HTS	BRD-K41731458-001-15-1	triclosan	2.5	HTS	antibacterial agent	DNMT1			Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl	Launched	5
BRD-K41772907-001-01-2::2.5::HTS	-0.720023619088	BRD-K41772907-001-01-2::2.5::HTS	BRD-K41772907-001-01-2	tolimidone	2.5	HTS	src activator	LYN, SRC			Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1	Phase 2	5
BRD-K41779183-001-01-2::2.5::HTS	-0.037332963332500003	BRD-K41779183-001-01-2::2.5::HTS	BRD-K41779183-001-01-2	CB-03-01	2.5	HTS	androgen receptor antagonist	AR			CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO	Phase 3	5
BRD-K41783120-001-02-8::2.5::HTS	0.012449498675	BRD-K41783120-001-02-8::2.5::HTS	BRD-K41783120-001-02-8	STA-5326	2.5	HTS	interleukin synthesis inhibitor	IL12A			Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1	Phase 2	5
BRD-K41853443-001-02-9::2.5::HTS	0.340270545994	BRD-K41853443-001-02-9::2.5::HTS	BRD-K41853443-001-02-9	1,3-dipropyl-8-phenylxanthine	2.5	HTS	adenosine receptor antagonist				CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)-c1ccccc1	Preclinical	5
BRD-K41859756-001-06-8::2.5::HTS	-2.32194553787	BRD-K41859756-001-06-8::2.5::HTS	BRD-K41859756-001-06-8	NVP-AUY922	2.5	HTS	HSP inhibitor	HSP90AA1, HSP90AB1			CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O	Phase 2	5
BRD-K41866823-001-01-3::2.5::HTS	0.5718338102	BRD-K41866823-001-01-3::2.5::HTS	BRD-K41866823-001-01-3	2-hydroxyethyl-salicylate	2.5	HTS					OCCOC(=O)c1ccccc1O	Launched	5
BRD-K41869275-001-02-8::2.5::HTS	0.32309995233399996	BRD-K41869275-001-02-8::2.5::HTS	BRD-K41869275-001-02-8	2-phenylmelatonin	2.5	HTS	melatonin receptor agonist	MTNR1A, MTNR1B			COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1	Preclinical	5
BRD-K41876534-001-13-7::2.5::HTS	0.48674023013800005	BRD-K41876534-001-13-7::2.5::HTS	BRD-K41876534-001-13-7	tioxolone	2.5	HTS	carbonic anhydrase inhibitor	CA2			Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1	Preclinical	5
BRD-K41918892-001-05-9::2.5::HTS	0.13841743740999998	BRD-K41918892-001-05-9::2.5::HTS	BRD-K41918892-001-05-9	A-769662	2.5	HTS	AMPK activator				Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12	Preclinical	5
BRD-K42090719-001-06-5::2.43::HTS	-0.0814410776646	BRD-K42090719-001-06-5::2.43::HTS	BRD-K42090719-001-06-5	trichloroacetic-acid	2.43	HTS			dermatology	warts	OC(=O)C(Cl)(Cl)Cl, OC(=O)C(Cl)(Cl)Cl	Launched	5
BRD-K42095107-001-17-1::2.5::HTS	0.021735258483	BRD-K42095107-001-17-1::2.5::HTS	BRD-K42095107-001-17-1	daidzein	2.5	HTS	estrogen receptor agonist	ESRRA, ESRRB, ESRRG, TRPC5			Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	Phase 2	5
BRD-K42098891-003-20-5::2.5::HTS	0.12560593097699999	BRD-K42098891-003-20-5::2.5::HTS	BRD-K42098891-003-20-5	protriptyline	2.5	HTS	tricyclic antidepressant	SLC6A2, SLC6A4	neurology/psychiatry	depression	CNCCCC1c2ccccc2C=Cc2ccccc12	Launched	5
BRD-K42191735-001-05-3::2.5::HTS	-2.6852462838499997	BRD-K42191735-001-05-3::2.5::HTS	BRD-K42191735-001-05-3	buparlisib	2.5	HTS	PI3K inhibitor	PIK3CA, PIK3CG			Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	Phase 3	5
BRD-K42205652-001-02-7::2.5::HTS	0.9731052193200002	BRD-K42205652-001-02-7::2.5::HTS	BRD-K42205652-001-02-7	MNS-(3,4-Methylenedioxy-nitrostyrene)	2.5	HTS	src inhibitor, syk inhibitor	SRC, SYK			[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1	Preclinical	5
BRD-K42221274-003-07-7::2.5::HTS	0.148868796668	BRD-K42221274-003-07-7::2.5::HTS	BRD-K42221274-003-07-7	NNC-711	2.5	HTS	GABA uptake inhibitor	SIGMAR1, SLC6A1			OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1	Preclinical	5
BRD-K42260897-001-07-6::2.48::HTS	-0.186328333772	BRD-K42260897-001-07-6::2.48::HTS	BRD-K42260897-001-07-6	ezetimibe	2.48	HTS	cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist	ANPEP, NPC1L1, SOAT1	endocrinology, metabolism	hyperlipidemia, hypercholesterolemia, sitosterolemia	OC(CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1	Launched	5
BRD-K42260897-001-09-2::2.5::HTS	0.07703628918769999	BRD-K42260897-001-09-2::2.5::HTS	BRD-K42260897-001-09-2	ezetimibe	2.5	HTS	cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist	ANPEP, NPC1L1, SOAT1	endocrinology, metabolism	hyperlipidemia, hypercholesterolemia, sitosterolemia	OC(CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1	Launched	5
BRD-K42348709-003-13-1::2.5::HTS	-0.0286479483525	BRD-K42348709-003-13-1::2.5::HTS	BRD-K42348709-003-13-1	cyclobenzaprine	2.5	HTS	adrenergic receptor agonist, serotonin receptor agonist	HTR2A	neurology/psychiatry	spasms	CN(C)CCC=C1c2ccccc2C=Cc2ccccc12	Launched	5
BRD-K42352790-001-05-3::2.5::HTS	0.51613354043	BRD-K42352790-001-05-3::2.5::HTS	BRD-K42352790-001-05-3	anandamide	2.5	HTS	cannabinoid receptor agonist	CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1			CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO	Phase 2	5
BRD-K42417338-045-01-9::2.5::HTS	0.028968899111099997	BRD-K42417338-045-01-9::2.5::HTS	BRD-K42417338-045-01-9	butorphanol-(+)-tartrate	2.5	HTS	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	neurology/psychiatry, gastroenterology	muscle pain, headache, abdominal pain	Oc1ccc2C[C@H]3N(CC4CCC4)CC[C@@]4(CCCC[C@@]34O)c2c1	Launched	5
BRD-K42436189-001-01-2::2.5::HTS	-0.940708759147	BRD-K42436189-001-01-2::2.5::HTS	BRD-K42436189-001-01-2	AZ20	2.5	HTS	ATR kinase inhibitor	ATR, MTOR			C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O	Preclinical	5
BRD-K42452249-001-02-5::2.5::HTS	-0.050108773042900005	BRD-K42452249-001-02-5::2.5::HTS	BRD-K42452249-001-02-5	EO-1428	2.5	HTS	p38 MAPK inhibitor	MAPK11, MAPK14			Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl	Preclinical	5
BRD-K42495768-001-01-7::2.5::HTS	0.608605574302	BRD-K42495768-001-01-7::2.5::HTS	BRD-K42495768-001-01-7	tasisulam	2.5	HTS	apoptosis stimulant				Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1	Phase 3	5
BRD-K42497885-001-01-1::2.5::HTS	-0.385677428895	BRD-K42497885-001-01-1::2.5::HTS	BRD-K42497885-001-01-1	satraplatin	2.5	HTS	DNA alkylating agent				NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O	Phase 3	5
BRD-K42500029-001-03-5::2.5::HTS	0.411415121143	BRD-K42500029-001-03-5::2.5::HTS	BRD-K42500029-001-03-5	CGP-57380	2.5	HTS	MAP kinase inhibitor	AURKB, LCK, MKNK1, MKNK2, SGK1			Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12, Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12, Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12	Preclinical	5
BRD-K42563464-001-01-9::2.5::HTS	-0.422207399748	BRD-K42563464-001-01-9::2.5::HTS	BRD-K42563464-001-01-9	YM-58483	2.5	HTS	calcium channel blocker	TRPC3, TRPC5, TRPM4			Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F	Preclinical	5
BRD-K42679050-001-02-1::2.5::HTS	-0.560536251206	BRD-K42679050-001-02-1::2.5::HTS	BRD-K42679050-001-02-1	Y-27152	2.5	HTS	potassium channel activator	KCNJ8			CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Phase 1	5
BRD-K42748308-300-02-0::2.5::HTS	0.297975096792	BRD-K42748308-300-02-0::2.5::HTS	BRD-K42748308-300-02-0	XE-991	2.5	HTS	potassium channel blocker	KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5			O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12	Preclinical	5
BRD-K42756753-001-01-9::2.5::HTS	-0.300081074679	BRD-K42756753-001-01-9::2.5::HTS	BRD-K42756753-001-01-9	epiandrosterone	2.5	HTS	steroid	G6PD			C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical	5
BRD-K42805893-001-04-9::2.5::HTS	0.417263330422	BRD-K42805893-001-04-9::2.5::HTS	BRD-K42805893-001-04-9	osimertinib	2.5	HTS	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12	Launched	5
BRD-K42828737-044-09-0::2.5::HTS	0.340514538094	BRD-K42828737-044-09-0::2.5::HTS	BRD-K42828737-044-09-0	sunitinib	2.5	HTS	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C	Launched	5
BRD-K42859542-001-03-3::2.5::HTS	0.6792649385539999	BRD-K42859542-001-03-3::2.5::HTS	BRD-K42859542-001-03-3	CFM-2	2.5	HTS	glutamate receptor antagonist				COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC	Preclinical	5
BRD-K42898655-001-01-8::2.5::HTS	-0.436887780764	BRD-K42898655-001-01-8::2.5::HTS	BRD-K42898655-001-01-8	temsirolimus	2.5	HTS	mTOR inhibitor	MTOR	oncology	renal cell carcinoma (RCC)	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO	Launched	5
BRD-K42938903-332-01-1::2.5::HTS	-0.79115450464	BRD-K42938903-332-01-1::2.5::HTS	BRD-K42938903-332-01-1	acetophenazine	2.5	HTS	dopamine receptor antagonist	DRD1, DRD2	neurology/psychiatry	psychosis	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1	Launched	5
BRD-K42948882-305-01-1::2.5::HTS	0.234713653838	BRD-K42948882-305-01-1::2.5::HTS	BRD-K42948882-305-01-1	AMD11070	2.5	HTS	CC chemokine receptor antagonist	CXCR4			NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12	Phase 1/Phase 2	5
BRD-K42959922-001-01-5::2.5::HTS	0.456370971093	BRD-K42959922-001-01-5::2.5::HTS	BRD-K42959922-001-01-5	trans-2-Undecenoic-acid	2.5	HTS					CCCCCCCC\C=C\C(O)=O	Preclinical	5
BRD-K42973005-001-04-0::2.5::HTS	0.5943996893419999	BRD-K42973005-001-04-0::2.5::HTS	BRD-K42973005-001-04-0	CHIR-98014	2.5	HTS	glycogen synthase kinase inhibitor	GSK3A, GSK3B			Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O	Preclinical	5
BRD-K42981054-001-01-9::2.5::HTS	-0.284036893589	BRD-K42981054-001-01-9::2.5::HTS	BRD-K42981054-001-01-9	mibampator	2.5	HTS	glutamate receptor modulator	GRIA1			CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1	Phase 2	5
BRD-K42991124-001-03-0::2.5::HTS	-0.12531252199100001	BRD-K42991124-001-03-0::2.5::HTS	BRD-K42991124-001-03-0	creatinol-phosphate	2.5	HTS					CN(CCOP(O)(O)=O)C(N)=N, CN(CCOP(O)(O)=O)C(N)=N	Launched	5
BRD-K43002771-034-01-6::2.5::HTS	0.367854156109	BRD-K43002771-034-01-6::2.5::HTS	BRD-K43002771-034-01-6	SR-33805	2.5	HTS	calcium channel blocker				COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC	Phase 1	5
BRD-K43055376-001-01-2::2.5::HTS	0.176345378007	BRD-K43055376-001-01-2::2.5::HTS	BRD-K43055376-001-01-2	ADD-233089	2.5	HTS	benzodiazepine receptor agonist				Clc1ccc(cc1)N1CC(=NC1=O)N1CCOCC1	Phase 1	5
BRD-K43106192-320-11-8::2.5::HTS	-0.159220545829	BRD-K43106192-320-11-8::2.5::HTS	BRD-K43106192-320-11-8	gallamine-triethiodide	2.5	HTS	acetylcholine receptor antagonist	ACHE, CHRM2, CHRNA1, CHRNA2	neurology/psychiatry	muscle relaxant	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	Launched	5
BRD-K43149758-001-22-7::2.5::HTS	0.22489328281100002	BRD-K43149758-001-22-7::2.5::HTS	BRD-K43149758-001-22-7	myricetin	2.5	HTS	androgen receptor agonist, cytochrome P450 inhibitor	PIK3CG			Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O	Preclinical	5
BRD-K43164539-001-11-5::2.5::HTS	0.417225363187	BRD-K43164539-001-11-5::2.5::HTS	BRD-K43164539-001-11-5	cholic-acid	2.5	HTS	bile acid	ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B	gastroenterology, neurology/psychiatry, genetics	bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Launched	5
BRD-K43187018-001-03-3::2.52::HTS	-2.50482169483	BRD-K43187018-001-03-3::2.52::HTS	BRD-K43187018-001-03-3	GDC-0349	2.52	HTS	Pim kinase inhibitor	PIK3CA			CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1	Phase 1	5
BRD-K43187796-001-02-3::2.5::HTS	-0.0381246845012	BRD-K43187796-001-02-3::2.5::HTS	BRD-K43187796-001-02-3	3-indolebutyric-acid	2.5	HTS		B2M, HLA-A, TRAC, TRBC1			OC(=O)CCCc1c[nH]c2ccccc12	Preclinical	5
BRD-K43192255-048-03-6::2.5::HTS	0.22636863455400003	BRD-K43192255-048-03-6::2.5::HTS	BRD-K43192255-048-03-6	methyllycaconitine	2.5	HTS	acetylcholine receptor antagonist	CHRNA7			CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14	Preclinical	5
BRD-K43236057-001-07-1::2.6::HTS	-0.79501458148	BRD-K43236057-001-07-1::2.6::HTS	BRD-K43236057-001-07-1	polydatin	2.6	HTS	ICAM1 expression inhibitor	ICAM1			OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	5
BRD-K43305603-004-02-8::2.5::HTS	0.173104039983	BRD-K43305603-004-02-8::2.5::HTS	BRD-K43305603-004-02-8	rocuronium	2.5	HTS	acetylcholine receptor antagonist	CHRM2, CHRNA2, HTR3A	neurology/psychiatry	anesthetic	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	Launched	5
BRD-K43363084-001-01-3::2.5::HTS	0.027397564172	BRD-K43363084-001-01-3::2.5::HTS	BRD-K43363084-001-01-3	atglistatin	2.5	HTS	adipose triglyceride lipase inhibitor				CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C	Preclinical	5
BRD-K43383936-001-05-2::2.5::HTS	-0.31191359556	BRD-K43383936-001-05-2::2.5::HTS	BRD-K43383936-001-05-2	flopropione	2.5	HTS	serotonin receptor antagonist	HTR1A	neurology/psychiatry	spasms	CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O	Launched	5
BRD-K43389675-003-16-7::2.35::HTS	-2.29553399826	BRD-K43389675-003-16-7::2.35::HTS	BRD-K43389675-003-16-7	daunorubicin	2.35	HTS	RNA synthesis inhibitor, topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	Launched	5
BRD-K43389675-003-20-9::2.5::HTS	-2.2593013104599997	BRD-K43389675-003-20-9::2.5::HTS	BRD-K43389675-003-20-9	daunorubicin	2.5	HTS	RNA synthesis inhibitor, topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	Launched	5
BRD-K43389698-001-09-9::2.4::HTS	-2.22930041242	BRD-K43389698-001-09-9::2.4::HTS	BRD-K43389698-001-09-9	BMS-387032	2.4	HTS	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	CDK2, CDK7, CDK9			CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1	Phase 1	5
BRD-K43410529-001-02-3::2.5::HTS	0.16208245328	BRD-K43410529-001-02-3::2.5::HTS	BRD-K43410529-001-02-3	MLN2480	2.5	HTS	RAF inhibitor				C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F	Phase 1	5
BRD-K43449605-001-01-0::2.5::HTS	0.028135892851	BRD-K43449605-001-01-0::2.5::HTS	BRD-K43449605-001-01-0	oncrasin-1	2.5	HTS	apoptosis stimulant				Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1	Preclinical	5
BRD-K43457670-001-27-8::2.5::HTS	0.592578987798	BRD-K43457670-001-27-8::2.5::HTS	BRD-K43457670-001-27-8	acetazolamide	2.5	HTS	carbonic anhydrase inhibitor	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	CC(=O)Nc1nnc(s1)S(N)(=O)=O	Launched	5
BRD-K43471985-001-03-0::2.69::HTS	0.640012566619	BRD-K43471985-001-03-0::2.69::HTS	BRD-K43471985-001-03-0	OTX015	2.69	HTS	bromodomain inhibitor	BRD2, BRD3, BRD4			Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1	Phase 1/Phase 2	5
BRD-K43471985-001-05-5::2.5::HTS	0.9353520333509999	BRD-K43471985-001-05-5::2.5::HTS	BRD-K43471985-001-05-5	OTX015	2.5	HTS	bromodomain inhibitor	BRD2, BRD3, BRD4			Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1	Phase 1/Phase 2	5
BRD-K43578482-001-01-4::2.5::HTS	-0.148077655745	BRD-K43578482-001-01-4::2.5::HTS	BRD-K43578482-001-01-4	defactinib	2.5	HTS	focal adhesion kinase inhibitor	PTK2			CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1	Phase 2	5
BRD-K43586850-001-02-9::2.5::HTS	-0.370059660764	BRD-K43586850-001-02-9::2.5::HTS	BRD-K43586850-001-02-9	lacidipine	2.5	HTS	calcium channel blocker	CACNA1C	cardiology	hypertension	CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC	Launched	5
BRD-K43621685-001-02-5::2.5::HTS	-0.542163586888	BRD-K43621685-001-02-5::2.5::HTS	BRD-K43621685-001-02-5	CP-673451	2.5	HTS	PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA, PDGFRB			COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1	Preclinical	5
BRD-K43644456-001-04-0::2.38::HTS	-6.71774861089	BRD-K43644456-001-04-0::2.38::HTS	BRD-K43644456-001-04-0	WP1130	2.38	HTS	deubiquitinase inhibitor	JAK2, UCHL5, USP14, USP9X			CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	Preclinical	5
BRD-K43786866-300-02-3::2.5::HTS	0.34851275054799996	BRD-K43786866-300-02-3::2.5::HTS	BRD-K43786866-300-02-3	opipramol	2.5	HTS	sigma receptor agonist		neurology/psychiatry	generalized anxiety disorder (GAD)	OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1	Launched	5
BRD-K43797669-001-30-4::2.5::HTS	0.500591680525	BRD-K43797669-001-30-4::2.5::HTS	BRD-K43797669-001-30-4	genistein	2.5	HTS	tyrosine kinase inhibitor	CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5			Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	Phase 2/Phase 3	5
BRD-K43802723-340-01-9::2.5::HTS	-0.028116671519499998	BRD-K43802723-340-01-9::2.5::HTS	BRD-K43802723-340-01-9	AMG-837	2.5	HTS	free fatty acid receptor agonist	FFAR1			CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1	Phase 1	5
BRD-K43806473-066-02-1::2.5::HTS	-0.553675091943	BRD-K43806473-066-02-1::2.5::HTS	BRD-K43806473-066-02-1	camostat-mesilate	2.5	HTS	protease inhibitor	PRSS1	gastroenterology	pancreatitis	CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1	Launched	5
BRD-K43860855-065-11-9::2.5::HTS	-0.029138006331500002	BRD-K43860855-065-11-9::2.5::HTS	BRD-K43860855-065-11-9	iobenguane	2.5	HTS	antineoplastic agent		oncology, cardiology, endocrinology	neuroblastoma, congestive heart failure, pheochromocytoma	NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1	Launched	5
BRD-K43873574-001-01-8::2.5::HTS	0.179305727018	BRD-K43873574-001-01-8::2.5::HTS	BRD-K43873574-001-01-8	ilepcimide	2.5	HTS	anticonvulsant				O=C(C=Cc1ccc2OCOc2c1)N1CCCCC1	Phase 3	5
BRD-K43880410-001-14-4::2.5::HTS	0.6839545688600001	BRD-K43880410-001-14-4::2.5::HTS	BRD-K43880410-001-14-4	pregnenolone	2.5	HTS	glutamate receptor modulator	CYP17A1, SULT2B1			CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K43887077-003-26-3::2.5::HTS	0.163225906952	BRD-K43887077-003-26-3::2.5::HTS	BRD-K43887077-003-26-3	dopamine	2.5	HTS	dopamine receptor agonist	DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4	cardiology, neurology/psychiatry	ventricular arrhythmias, depression, headache, tremors	NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1	Launched	5
BRD-K43905307-001-01-2::2.5::HTS	0.668550958354	BRD-K43905307-001-01-2::2.5::HTS	BRD-K43905307-001-01-2	L-798,106	2.5	HTS	prostanoid receptor antagonist	PTGER3			COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1	Preclinical	5
BRD-K43927145-001-01-2::2.5::HTS	-0.555685669538	BRD-K43927145-001-01-2::2.5::HTS	BRD-K43927145-001-01-2	BIBN4096	2.5	HTS	calcitonin antagonist	CALCA, CALCRL, RAMP1			NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1	Phase 2	5
BRD-K43966364-237-04-8::2.5::HTS	-0.167830083221	BRD-K43966364-237-04-8::2.5::HTS	BRD-K43966364-237-04-8	penicillin-v-potassium	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever	CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched	5
BRD-K44004064-001-07-3::2.5::HTS	0.462107565058	BRD-K44004064-001-07-3::2.5::HTS	BRD-K44004064-001-07-3	acefylline	2.5	HTS	adenosine receptor agonist	ADORA1	pulmonary	asthma	Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O	Launched	5
BRD-K44009692-001-02-3::2.5::HTS	0.278922935934	BRD-K44009692-001-02-3::2.5::HTS	BRD-K44009692-001-02-3	hyodeoxycholic-acid	2.5	HTS	atherosclerosis formation inhibitor				C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 1	5
BRD-K44067360-001-30-3::2.5::HTS	0.535645685657	BRD-K44067360-001-30-3::2.5::HTS	BRD-K44067360-001-30-3	flufenamic-acid	2.5	HTS	chloride channel blocker	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5			OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Preclinical	5
BRD-K44084986-300-08-4::2.5::HTS	-1.08918600502	BRD-K44084986-300-08-4::2.5::HTS	BRD-K44084986-300-08-4	Y-27632	2.5	HTS	rho associated kinase inhibitor	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2			C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1	Preclinical	5
BRD-K44133266-001-10-0::2.5::HTS	-0.49074668663500004	BRD-K44133266-001-10-0::2.5::HTS	BRD-K44133266-001-10-0	sulbactam	2.5	HTS	beta lactamase inhibitor		infectious disease	skin infections, intra-abdominal infections, gynecologic infections	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)C(N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	Launched	5
BRD-K44227013-001-06-4::2.5::HTS	-3.1630329766100003	BRD-K44227013-001-06-4::2.5::HTS	BRD-K44227013-001-06-4	ponatinib	2.5	HTS	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1	Launched	5
BRD-K44273375-001-25-0::2.5::HTS	0.517027732822	BRD-K44273375-001-25-0::2.5::HTS	BRD-K44273375-001-25-0	tolnaftate	2.5	HTS	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea corporis	CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1	Launched	5
BRD-K44276885-001-07-4::2.5::HTS	-0.360278559155	BRD-K44276885-001-07-4::2.5::HTS	BRD-K44276885-001-07-4	acarbose	2.5	HTS	glucosidase inhibitor	AMY2A, GAA, MGAM, SI	endocrinology	diabetes mellitus	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O	Launched	5
BRD-K44309363-003-02-1::2.5::HTS	0.132356114385	BRD-K44309363-003-02-1::2.5::HTS	BRD-K44309363-003-02-1	dexniguldipine	2.5	HTS	calmodulin antagonist	ADORA3			COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1	Phase 2	5
BRD-K44353683-001-08-3::2.5::HTS	-0.628948141555	BRD-K44353683-001-08-3::2.5::HTS	BRD-K44353683-001-08-3	nateglinide	2.5	HTS	insulin secretagogue	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O	Launched	5
BRD-K44366189-001-01-9::2.5::HTS	-0.391265064219	BRD-K44366189-001-01-9::2.5::HTS	BRD-K44366189-001-01-9	anacetrapib	2.5	HTS	cholesteryl ester transfer protein inhibitor	CETP			COc1cc(F)c(cc1-c1ccc(cc1CN1[C@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C	Phase 3	5
BRD-K44408410-001-17-6::2.5::HTS	0.23750028696699998	BRD-K44408410-001-17-6::2.5::HTS	BRD-K44408410-001-17-6	2-methoxyestradiol	2.5	HTS	hypoxia inducible factor inhibitor	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB			COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O	Phase 2	5
BRD-K44442813-001-12-9::2.5::HTS	-0.21336604157800002	BRD-K44442813-001-12-9::2.5::HTS	BRD-K44442813-001-12-9	pidotimod	2.5	HTS	interferon receptor agonist, interleukin receptor agonist		infectious disease	immune adjuvant	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1	Launched	5
BRD-K44590731-001-01-7::2.5::HTS	-0.224252564437	BRD-K44590731-001-01-7::2.5::HTS	BRD-K44590731-001-01-7	TU-2100	2.5	HTS					CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC	Phase 2	5
BRD-K44665581-001-01-8::2.5::HTS	1.38140949417	BRD-K44665581-001-01-8::2.5::HTS	BRD-K44665581-001-01-8	bromosporine	2.5	HTS	bromodomain inhibitor				CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1	Preclinical	5
BRD-K44771174-066-01-0::2.5::HTS	0.0643039932665	BRD-K44771174-066-01-0::2.5::HTS	BRD-K44771174-066-01-0	ibutamoren	2.5	HTS	growth hormone secretagogue receptor agonist	GHR, GHSR			CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1	Phase 2	5
BRD-K44777625-001-03-5::2.5::HTS	0.140960831492	BRD-K44777625-001-03-5::2.5::HTS	BRD-K44777625-001-03-5	FH1	2.5	HTS	hepatocyte function enhancer				CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1, CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1	Preclinical	5
BRD-K44824027-001-02-1::2.5::HTS	0.643512392226	BRD-K44824027-001-02-1::2.5::HTS	BRD-K44824027-001-02-1	beclamide	2.5	HTS	anticonvulsant		neurology/psychiatry	sedative, seizures	ClCCC(=O)NCc1ccccc1	Launched	5
BRD-K44825564-065-01-4::2.5::HTS	-0.509321401296	BRD-K44825564-065-01-4::2.5::HTS	BRD-K44825564-065-01-4	ZAPA	2.5	HTS					NC(=N)S\C=C/C(O)=O	Preclinical	5
BRD-K44827188-001-06-0::2.5::HTS	-0.058539335661500005	BRD-K44827188-001-06-0::2.5::HTS	BRD-K44827188-001-06-0	vismodegib	2.5	HTS	hedgehog pathway inhibitor, smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O	Launched	5
BRD-K44844162-001-01-6::2.5::HTS	0.35176199931900004	BRD-K44844162-001-01-6::2.5::HTS	BRD-K44844162-001-01-6	taselisib	2.5	HTS	PI3K inhibitor	PIK3CA			CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O	Phase 3	5
BRD-K44849676-001-10-5::2.5::HTS	0.41164856448799997	BRD-K44849676-001-10-5::2.5::HTS	BRD-K44849676-001-10-5	capsazepine	2.5	HTS	TRPV agonist	TRPV1, TRPV4			Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1	Preclinical	5
BRD-K44876623-001-03-7::2.5::HTS	0.036364069062900004	BRD-K44876623-001-03-7::2.5::HTS	BRD-K44876623-001-03-7	zolpidem	2.5	HTS	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3	neurology/psychiatry	insomnia	CN(C)C(=O)Cc1c(nc2ccc(C)cn12)-c1ccc(C)cc1	Launched	5
BRD-K44942188-001-09-1::2.5::HTS	-0.23725685771899999	BRD-K44942188-001-09-1::2.5::HTS	BRD-K44942188-001-09-1	fomocaine	2.5	HTS	voltage-gated sodium channel modulator		neurology/psychiatry	local anesthetic	C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1	Launched	5
BRD-K44942604-346-05-4::2.5::HTS	-0.0426290142111	BRD-K44942604-346-05-4::2.5::HTS	BRD-K44942604-346-05-4	pentolinium	2.5	HTS	cholinergic receptor antagonist	CHRNA10, CHRNA3, CHRNA4, CHRNB4	cardiology	hypertension	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	Launched	5
BRD-K44963273-001-06-9::2.5::HTS	0.036621139709300005	BRD-K44963273-001-06-9::2.5::HTS	BRD-K44963273-001-06-9	HQK-1001	2.5	HTS					CCC(C)(C)C(O)=O, CCC(C)(C)C(O)=O	Phase 2	5
BRD-K44974079-001-01-3::2.5::HTS	0.031374347252	BRD-K44974079-001-01-3::2.5::HTS	BRD-K44974079-001-01-3	ticagrelor	2.5	HTS	purinergic receptor antagonist	P2RY12	cardiology	acute coronary syndrome (ACS), myocardial infarction	CCCSc1nc(N[C@@H]2C[C@@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@H](O)[C@H]3O)c2n1	Launched	5
BRD-K44993696-001-12-3::2.5::HTS	0.07555440800260001	BRD-K44993696-001-12-3::2.5::HTS	BRD-K44993696-001-12-3	atenolol-(-)	2.5	HTS	adrenergic receptor antagonist				CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1	Phase 2	5
BRD-K45014108-003-01-8::2.5::HTS	0.279076759166	BRD-K45014108-003-01-8::2.5::HTS	BRD-K45014108-003-01-8	ephedrine	2.5	HTS	adrenergic receptor agonist	ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	CN[C@@H](C)[C@H](O)c1ccccc1	Launched	5
BRD-K45033733-001-12-2::2.5::HTS	-1.3780235616499998	BRD-K45033733-001-12-2::2.5::HTS	BRD-K45033733-001-12-2	famciclovir	2.5	HTS	DNA polymerase inhibitor		dental, infectious disease	cold sore, genitial herpes, shingles	CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O	Launched	5
BRD-K45071273-003-25-6::2.5::HTS	0.10817279347799999	BRD-K45071273-003-25-6::2.5::HTS	BRD-K45071273-003-25-6	tetracaine	2.5	HTS	membrane integrity inhibitor	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	anesthetic	CCCCNc1ccc(cc1)C(=O)OCCN(C)C, CCCCNc1ccc(cc1)C(=O)OCCN(C)C	Launched	5
BRD-K45086103-001-15-5::2.5::HTS	-0.0598052174919	BRD-K45086103-001-15-5::2.5::HTS	BRD-K45086103-001-15-5	sulfaguanidine	2.5	HTS	bacterial antifolate		infectious disease	urinary tract infections	NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1	Launched	5
BRD-K45086103-001-16-3::2.5::HTS	-1.24808030004	BRD-K45086103-001-16-3::2.5::HTS	BRD-K45086103-001-16-3	sulfaguanidine	2.5	HTS	bacterial antifolate		infectious disease	urinary tract infections	NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1	Launched	5
BRD-K45114938-236-01-8::2.35::HTS	0.0771259948587	BRD-K45114938-236-01-8::2.35::HTS	BRD-K45114938-236-01-8	mezlocillin	2.35	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O	Launched	5
BRD-K45117373-001-02-9::2.5::HTS	0.0811137899168	BRD-K45117373-001-02-9::2.5::HTS	BRD-K45117373-001-02-9	Y-26763	2.5	HTS	potassium channel activator	KCNJ8			CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Phase 1	5
BRD-K45152786-001-08-4::2.5::HTS	0.20352135286400003	BRD-K45152786-001-08-4::2.5::HTS	BRD-K45152786-001-08-4	merbarone	2.5	HTS	topoisomerase inhibitor	TOP2A			O=C(Nc1ccccc1)C1C(=O)NC(=S)NC1=O	Phase 2	5
BRD-K45158365-001-11-4::2.5::HTS	0.131681619314	BRD-K45158365-001-11-4::2.5::HTS	BRD-K45158365-001-11-4	valsartan	2.5	HTS	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	Launched	5
BRD-K45163704-001-01-5::2.5::HTS	-0.638097492117	BRD-K45163704-001-01-5::2.5::HTS	BRD-K45163704-001-01-5	midafotel	2.5	HTS	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1, OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1	Phase 3	5
BRD-K45168550-001-01-9::2.5::HTS	0.299835531342	BRD-K45168550-001-01-9::2.5::HTS	BRD-K45168550-001-01-9	SB-756050	2.5	HTS	G protein-coupled receptor agonist	GPBAR1			COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1	Phase 1	5
BRD-K45216060-001-10-0::2.5::HTS	0.9194828477779999	BRD-K45216060-001-10-0::2.5::HTS	BRD-K45216060-001-10-0	mequinol	2.5	HTS		TYR	dermatology	skin depigmentation	COc1ccc(O)cc1, COc1ccc(O)cc1, COc1ccc(O)cc1	Launched	5
BRD-K45216060-001-11-8::2.5::HTS	0.38058593572599997	BRD-K45216060-001-11-8::2.5::HTS	BRD-K45216060-001-11-8	mequinol	2.5	HTS		TYR	dermatology	skin depigmentation	COc1ccc(O)cc1, COc1ccc(O)cc1, COc1ccc(O)cc1	Launched	5
BRD-K45238818-001-02-6::2.5::HTS	0.07465768920789999	BRD-K45238818-001-02-6::2.5::HTS	BRD-K45238818-001-02-6	succinic-acid	2.5	HTS		ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE			OC(=O)CCC(O)=O	Launched	5
BRD-K45245728-335-01-4::2.5::HTS	0.590001871868	BRD-K45245728-335-01-4::2.5::HTS	BRD-K45245728-335-01-4	ursodeoxycholyltaurine	2.5	HTS	cholesterol inhibitor				C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 2	5
BRD-K45252063-001-13-6::2.5::HTS	-0.288560641897	BRD-K45252063-001-13-6::2.5::HTS	BRD-K45252063-001-13-6	clofibrate	2.5	HTS	PPAR receptor agonist	LPL, PPARA	endocrinology, cardiology	hyperlipidemia, cholesterol	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1	Launched	5
BRD-K45275534-001-01-3::2.5::HTS	-0.19906911355700002	BRD-K45275534-001-01-3::2.5::HTS	BRD-K45275534-001-01-3	betrixaban	2.5	HTS	coagulation factor inhibitor	KCNH2	hematology	deep vein thrombosis (DVT)	COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1	Launched	5
BRD-K45293975-001-02-0::2.5::HTS	-0.863689812947	BRD-K45293975-001-02-0::2.5::HTS	BRD-K45293975-001-02-0	7-hydroxystaurosporine	2.5	HTS	CDK inhibitor, CHK inhibitor, PKC inhibitor	CHEK1, MARK3, PDPK1			CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13	Phase 2	5
BRD-K45330754-001-21-7::2.5::HTS	0.112093390726	BRD-K45330754-001-21-7::2.5::HTS	BRD-K45330754-001-21-7	diethylstilbestrol	2.5	HTS	estrogen receptor agonist	ESR1, ESR2, ESRRB, ESRRG			CC\C(c1ccc(O)cc1)=C(\CC)c1ccc(O)cc1, CC\C(c1ccc(O)cc1)=C(\CC)c1ccc(O)cc1	Withdrawn	5
BRD-K45385835-001-02-4::2.5::HTS	-0.535500938639	BRD-K45385835-001-02-4::2.5::HTS	BRD-K45385835-001-02-4	SX-011	2.5	HTS	MAP kinase inhibitor	MAPK14			CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1	Preclinical	5
BRD-K45401373-001-20-9::2.5::HTS	-0.9494908831100001	BRD-K45401373-001-20-9::2.5::HTS	BRD-K45401373-001-20-9	betulinic-acid	2.5	HTS	apoptosis stimulant, NFkB pathway inhibitor	GPBAR1			CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	Phase 1/Phase 2	5
BRD-K45401373-001-22-5::2.5::HTS	-0.776101999496	BRD-K45401373-001-22-5::2.5::HTS	BRD-K45401373-001-22-5	betulinic-acid	2.5	HTS	apoptosis stimulant, NFkB pathway inhibitor	GPBAR1			CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	Phase 1/Phase 2	5
BRD-K45435259-003-11-1::2.5::HTS	0.253512135854	BRD-K45435259-003-11-1::2.5::HTS	BRD-K45435259-003-11-1	SCH-23390	2.5	HTS	dopamine receptor antagonist	DRD1, DRD5, HTR2C, KCNJ4, KCNJ6			CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1	Preclinical	5
BRD-K45437867-005-03-3::2.5::HTS	-0.0386455416398	BRD-K45437867-005-03-3::2.5::HTS	BRD-K45437867-005-03-3	5-methylfurmethiodide	2.5	HTS	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Cc1ccc(C[N+](C)(C)C)o1, Cc1ccc(C[N+](C)(C)C)o1	Preclinical	5
BRD-K45446451-001-05-0::2.5::HTS	-0.45187670559199994	BRD-K45446451-001-05-0::2.5::HTS	BRD-K45446451-001-05-0	JZL-184	2.5	HTS	monoacylglucerol lipase inhibitor	MGLL			OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	Preclinical	5
BRD-K45462423-001-03-7::2.5::HTS	-0.0326325569442	BRD-K45462423-001-03-7::2.5::HTS	BRD-K45462423-001-03-7	VU0361737	2.5	HTS	glutamate receptor positive allosteric modulator	GRM4			COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl	Preclinical	5
BRD-K45479396-050-01-5::2.5::HTS	-0.07811352642739999	BRD-K45479396-050-01-5::2.5::HTS	BRD-K45479396-050-01-5	BP-554	2.5	HTS	serotonin receptor agonist	HTR1A			C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1	Preclinical	5
BRD-K45503887-001-01-1::2.5::HTS	0.19061591852899998	BRD-K45503887-001-01-1::2.5::HTS	BRD-K45503887-001-01-1	delivert	2.5	HTS	angiotensin receptor agonist	AGTR1, AGTR2			CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O	Launched	5
BRD-K45519571-001-01-8::2.5::HTS	-0.0910964176745	BRD-K45519571-001-01-8::2.5::HTS	BRD-K45519571-001-01-8	RN-1747	2.5	HTS	TRPV agonist	TRPV4			[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1	Preclinical	5
BRD-K45528773-001-06-4::2.5::HTS	-2.02868230193	BRD-K45528773-001-06-4::2.5::HTS	BRD-K45528773-001-06-4	M-344	2.5	HTS	HDAC inhibitor				CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO	Preclinical	5
BRD-K45528773-001-07-2::2.59::HTS	-4.01737200574	BRD-K45528773-001-07-2::2.59::HTS	BRD-K45528773-001-07-2	M-344	2.59	HTS	HDAC inhibitor				CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO	Preclinical	5
BRD-K45542189-048-22-1::2.5::HTS	-0.128156269758	BRD-K45542189-048-22-1::2.5::HTS	BRD-K45542189-048-22-1	diethylcarbamazine	2.5	HTS	lipoxygenase inhibitor	ALOX5, PTGS1	infectious disease	filariasis	CCN(CC)C(=O)N1CCN(C)CC1	Launched	5
BRD-K45551181-001-02-1::2.49::HTS	-1.53879705278	BRD-K45551181-001-02-1::2.49::HTS	BRD-K45551181-001-02-1	MPI-0479605	2.49	HTS	mitotic kinase inhibitor	TTK			Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	Preclinical	5
BRD-K45662124-050-01-5::2.5::HTS	-0.6261668305100001	BRD-K45662124-050-01-5::2.5::HTS	BRD-K45662124-050-01-5	3'-fluorobenzylspiperone	2.5	HTS	dopamine receptor ligand	DRD2			Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1	Preclinical	5
BRD-K45664306-001-19-6::2.52::HTS	-0.8960888836480001	BRD-K45664306-001-19-6::2.52::HTS	BRD-K45664306-001-19-6	prednisolone-acetate	2.52	HTS	glucocorticoid receptor agonist	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	Launched	5
BRD-K45724504-001-01-6::1.36::HTS	-4.846513703409999	BRD-K45724504-001-01-6::1.36::HTS	BRD-K45724504-001-01-6	anguidine	1.36	HTS	protein synthesis inhibitor	SLC5A1			CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1	Phase 2	4
BRD-K45746021-003-01-9::2.5::HTS	0.23186854848299998	BRD-K45746021-003-01-9::2.5::HTS	BRD-K45746021-003-01-9	CC-401	2.5	HTS	JNK inhibitor	MAPK8			C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1ncn[nH]1	Phase 1	5
BRD-K45841694-001-11-7::2.65::HTS	0.279262100914	BRD-K45841694-001-11-7::2.65::HTS	BRD-K45841694-001-11-7	IU1	2.65	HTS	ubiquitin C-terminal hydrolase inhibitor	USP14			Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1	Preclinical	5
BRD-K45861246-001-13-4::2.5::HTS	-0.024888725373999998	BRD-K45861246-001-13-4::2.5::HTS	BRD-K45861246-001-13-4	azaperone	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	sedative	Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1	Launched	5
BRD-K45875383-001-01-2::2.5::HTS	0.080195798383	BRD-K45875383-001-01-2::2.5::HTS	BRD-K45875383-001-01-2	XBD173	2.5	HTS	benzodiazepine receptor ligand	TSPO			CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1	Phase 2	5
BRD-K45909031-001-01-5::2.5::HTS	0.460217835467	BRD-K45909031-001-01-5::2.5::HTS	BRD-K45909031-001-01-5	WZ4003	2.5	HTS	AMPK inhibitor	NUAK1, NUAK2			CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1	Preclinical	5
BRD-K45916615-066-02-5::2.5::HTS	0.15852668554000002	BRD-K45916615-066-02-5::2.5::HTS	BRD-K45916615-066-02-5	danofloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		pulmonary	bovine respiratory disease (BRD)	CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	Launched	5
BRD-K45924332-001-16-8::2.5::HTS	0.215167297486	BRD-K45924332-001-16-8::2.5::HTS	BRD-K45924332-001-16-8	amrinone	2.5	HTS	phosphodiesterase inhibitor	PDE3A, PDE3B, PDE4B, TNF	cardiology	congestive heart failure	Nc1cc(c[nH]c1=O)-c1ccncc1	Launched	5
BRD-K46018455-001-27-6::2.5::HTS	0.159843331404	BRD-K46018455-001-27-6::2.5::HTS	BRD-K46018455-001-27-6	bezafibrate	2.5	HTS	PPAR receptor agonist	PPARA, PPARD, PPARG	cardiology	cholesterol	CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O	Launched	5
BRD-K46061689-001-01-9::2.5::HTS	-0.0689145083042	BRD-K46061689-001-01-9::2.5::HTS	BRD-K46061689-001-01-9	desogestrel	2.5	HTS	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Launched	5
BRD-K46133855-304-03-8::2.5::HTS	-0.0684401404997	BRD-K46133855-304-03-8::2.5::HTS	BRD-K46133855-304-03-8	NXY-059	2.5	HTS	free radical scavenger				CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O	Phase 3	5
BRD-K46142322-003-02-4::2.5::HTS	0.19626479690600002	BRD-K46142322-003-02-4::2.5::HTS	BRD-K46142322-003-02-4	RS-67333	2.5	HTS	serotonin receptor partial agonist	HTR4			CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1	Preclinical	5
BRD-K46211610-003-26-7::2.5::HTS	0.274932536287	BRD-K46211610-003-26-7::2.5::HTS	BRD-K46211610-003-26-7	tolazoline	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2	neurology/psychiatry	reverse sedative	C(C1=NCCN1)c1ccccc1, C(C1=NCCN1)c1ccccc1	Launched	5
BRD-K46254452-001-01-5::0.25::HTS	-0.102605817156	BRD-K46254452-001-01-5::0.25::HTS	BRD-K46254452-001-01-5	GABA-linoleamide	0.25	HTS	benzodiazepine receptor agonist				CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O	Phase 2	3
BRD-K46290096-001-01-1::2.5::HTS	0.141731656817	BRD-K46290096-001-01-1::2.5::HTS	BRD-K46290096-001-01-1	preladenant	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1	Phase 3	5
BRD-K46317332-003-17-8::2.5::HTS	0.47064796866499997	BRD-K46317332-003-17-8::2.5::HTS	BRD-K46317332-003-17-8	proadifen	2.5	HTS	nitric oxide synthase inhibitor	NOS1			CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1	Preclinical	5
BRD-K46331928-001-05-8::2.5::HTS	-0.242504222612	BRD-K46331928-001-05-8::2.5::HTS	BRD-K46331928-001-05-8	ethynodiol-diacetate	2.5	HTS		ESR1, PGR	endocrinology	contraceptive	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1	Launched	5
BRD-K46331928-001-06-6::2.38::HTS	-0.616395736615	BRD-K46331928-001-06-6::2.38::HTS	BRD-K46331928-001-06-6	ethynodiol-diacetate	2.38	HTS		ESR1, PGR	endocrinology	contraceptive	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1	Launched	5
BRD-K46384212-001-02-9::2.5::HTS	-0.18851781044399998	BRD-K46384212-001-02-9::2.5::HTS	BRD-K46384212-001-02-9	o-3M3FBS	2.5	HTS	phospholipase activator				Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F	Preclinical	5
BRD-K46386702-001-02-1::2.5::HTS	0.502744719051	BRD-K46386702-001-02-1::2.5::HTS	BRD-K46386702-001-02-1	ARRY-334543	2.5	HTS	EGFR inhibitor	ERBB2			C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1	Phase 2	5
BRD-K46392623-001-02-5::2.5::HTS	0.674070645652	BRD-K46392623-001-02-5::2.5::HTS	BRD-K46392623-001-02-5	TG-100713	2.5	HTS	PI3K inhibitor				Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1	Preclinical	5
BRD-K46424862-001-14-1::2.5::HTS	0.333137860979	BRD-K46424862-001-14-1::2.5::HTS	BRD-K46424862-001-14-1	hymecromone	2.5	HTS	monoamine oxidase inhibitor	MAOA, MAOB			Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12	Phase 2	5
BRD-K46428823-001-02-5::2.5::HTS	-0.0754648546175	BRD-K46428823-001-02-5::2.5::HTS	BRD-K46428823-001-02-5	liothyronine-(isomer)	2.5	HTS					N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	Preclinical	5
BRD-K46435528-001-04-4::2.5::HTS	-0.026073353400300002	BRD-K46435528-001-04-4::2.5::HTS	BRD-K46435528-001-04-4	trichloroethylene	2.5	HTS					ClC=C(Cl)Cl, ClC=C(Cl)Cl	Preclinical	5
BRD-K46435977-003-11-1::2.5::HTS	-0.11968948441800001	BRD-K46435977-003-11-1::2.5::HTS	BRD-K46435977-003-11-1	valaciclovir	2.5	HTS	DNA polymerase inhibitor		infectious disease	shingles, virus herpes simplex (HSV)	CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O	Launched	5
BRD-K46493214-001-06-7::2.5::HTS	0.00487035883234	BRD-K46493214-001-06-7::2.5::HTS	BRD-K46493214-001-06-7	saccharin	2.5	HTS	DNA polymerase inhibitor	CA1, CA12, CA2, CA9			O=C1NS(=O)(=O)c2ccccc12	Launched	5
BRD-K46523383-003-22-9::2.5::HTS	0.287063199122	BRD-K46523383-003-22-9::2.5::HTS	BRD-K46523383-003-22-9	pramoxine	2.5	HTS	topical anesthetic		dermatology	corticosteroid-responsive dermatoses	CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1	Launched	5
BRD-K46556543-001-01-4::2.5::HTS	-0.293816164304	BRD-K46556543-001-01-4::2.5::HTS	BRD-K46556543-001-01-4	potassium-canrenoate	2.5	HTS	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O	Launched	5
BRD-K46556543-237-10-5::2.55::HTS	0.223236488586	BRD-K46556543-237-10-5::2.55::HTS	BRD-K46556543-237-10-5	potassium-canrenoate	2.55	HTS	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O	Launched	5
BRD-K46585355-001-14-3::2.5::HTS	-0.20010594284699998	BRD-K46585355-001-14-3::2.5::HTS	BRD-K46585355-001-14-3	acetylsalicylsalicylic-acid	2.5	HTS	cyclooxygenase inhibitor				CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O	Preclinical	5
BRD-K46654563-238-01-0::2.5::HTS	0.453055629862	BRD-K46654563-238-01-0::2.5::HTS	BRD-K46654563-238-01-0	zofenopril-calcium	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1	Launched	5
BRD-K46690591-001-01-2::2.5::HTS	0.291604654089	BRD-K46690591-001-01-2::2.5::HTS	BRD-K46690591-001-01-2	KP-1212	2.5	HTS					NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1	Phase 2	5
BRD-K46692793-004-01-8::2.5::HTS	0.345370764587	BRD-K46692793-004-01-8::2.5::HTS	BRD-K46692793-004-01-8	umeclidinium	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2	Launched	5
BRD-K46731503-050-01-8::2.5::HTS	0.351090942556	BRD-K46731503-050-01-8::2.5::HTS	BRD-K46731503-050-01-8	fesoterodine	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C	Launched	5
BRD-K46741531-001-02-4::1.58::HTS	-0.361537350243	BRD-K46741531-001-02-4::1.58::HTS	BRD-K46741531-001-02-4	cafestol	1.58	HTS	pregnane X receptor agonist				C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3	Launched	4
BRD-K46742498-003-11-0::2.5::HTS	0.195758709794	BRD-K46742498-003-11-0::2.5::HTS	BRD-K46742498-003-11-0	alosetron	2.5	HTS	serotonin receptor antagonist	HTR3A			Cc1[nH]cnc1CN1CCc2c(C1=O)c1ccccc1n2C	Withdrawn	5
BRD-K46766488-003-02-0::2.5::HTS	0.66310944615	BRD-K46766488-003-02-0::2.5::HTS	BRD-K46766488-003-02-0	S-14506	2.5	HTS	serotonin receptor agonist	HTR1A			COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1	Preclinical	5
BRD-K46791647-001-01-2::2.5::HTS	-0.381348201695	BRD-K46791647-001-01-2::2.5::HTS	BRD-K46791647-001-01-2	stanozolol	2.5	HTS	androgen receptor agonist	AR	hematology	anemia	C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4Cc5[nH]ncc5C[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K46839850-050-04-2::2.5::HTS	0.815835458615	BRD-K46839850-050-04-2::2.5::HTS	BRD-K46839850-050-04-2	cinepazide	2.5	HTS	calcium channel activator				COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCN(CC(=O)N2CCCC2)CC1, COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCN(CC(=O)N2CCCC2)CC1	Withdrawn	5
BRD-K46863940-001-06-2::2.5::HTS	0.008484794993850001	BRD-K46863940-001-06-2::2.5::HTS	BRD-K46863940-001-06-2	dibenzothiophene	2.5	HTS					c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21	Preclinical	5
BRD-K46914825-300-01-0::2.5::HTS	0.481829274839	BRD-K46914825-300-01-0::2.5::HTS	BRD-K46914825-300-01-0	zimelidine	2.5	HTS	selective serotonin reuptake inhibitor (SSRI)	MAOA, MAOB, SLC6A4			CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1	Withdrawn	5
BRD-K46937689-001-15-0::2.5::HTS	0.12377896780200001	BRD-K46937689-001-15-0::2.5::HTS	BRD-K46937689-001-15-0	phenazone	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C	Launched	5
BRD-K46970505-003-01-9::2.5::HTS	0.0534615067208	BRD-K46970505-003-01-9::2.5::HTS	BRD-K46970505-003-01-9	cefozopran	2.5	HTS	bacterial cell wall synthesis inhibitor				CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1	Launched	5
BRD-K46982791-001-09-4::2.5::HTS	0.587825690646	BRD-K46982791-001-09-4::2.5::HTS	BRD-K46982791-001-09-4	cloxyquin	2.5	HTS	potassium channel activator	KCNK18			Oc1ccc(Cl)c2cccnc12	Preclinical	5
BRD-K47000838-001-01-6::1.04::HTS	-0.38556199295599997	BRD-K47000838-001-01-6::1.04::HTS	BRD-K47000838-001-01-6	cytochalasin-b	1.04	HTS	microtubule inhibitor	ACTB			C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C	Phase 2	4
BRD-K47029922-003-10-9::2.5::HTS	0.0383160343544	BRD-K47029922-003-10-9::2.5::HTS	BRD-K47029922-003-10-9	tranylcypromine	2.5	HTS	monoamine oxidase inhibitor	KDM1A, MAOA, MAOB	neurology/psychiatry	depression	N[C@H]1C[C@@H]1c1ccccc1, N[C@@H]1C[C@H]1c1ccccc1, NC1C[C@H]1c1ccccc1, N[C@@H]1C[C@H]1c1ccccc1, N[C@@H]1C[C@H]1c1ccccc1	Launched	5
BRD-K47031502-001-01-6::2.5::HTS	0.157899941448	BRD-K47031502-001-01-6::2.5::HTS	BRD-K47031502-001-01-6	eupatilin	2.5	HTS	mucus protecting agent				COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1	Launched	5
BRD-K47049295-300-01-5::2.5::HTS	-0.414480716336	BRD-K47049295-300-01-5::2.5::HTS	BRD-K47049295-300-01-5	BAN-ORL-24	2.5	HTS	nociceptin/orphanin FQ receptor antagonist	OPRL1			O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1	Preclinical	5
BRD-K47079459-004-04-6::2.5::HTS	-0.0397632219193	BRD-K47079459-004-04-6::2.5::HTS	BRD-K47079459-004-04-6	cetrimonium	2.5	HTS			dermatology	cosmetic	CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C	Launched	5
BRD-K47095176-001-01-6::2.5::HTS	0.14101404930400002	BRD-K47095176-001-01-6::2.5::HTS	BRD-K47095176-001-01-6	talnetant	2.5	HTS	tachykinin antagonist	TACR2, TACR3			CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	Phase 2	5
BRD-K47105409-001-14-5::2.5::HTS	-0.18187079938700002	BRD-K47105409-001-14-5::2.5::HTS	BRD-K47105409-001-14-5	AG-490	2.5	HTS	EGFR inhibitor, JAK inhibitor	EGFR, JAK2, JAK3			Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1, Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1, Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1	Preclinical	5
BRD-K47114202-001-14-6::2.58::HTS	-0.31338784342799997	BRD-K47114202-001-14-6::2.58::HTS	BRD-K47114202-001-14-6	chlorogenic-acid	2.58	HTS	antioxidant	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O	Launched	5
BRD-K47150025-001-05-3::2.5::HTS	-0.0534343913523	BRD-K47150025-001-05-3::2.5::HTS	BRD-K47150025-001-05-3	KI-8751	2.5	HTS	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC	Preclinical	5
BRD-K47177710-001-03-1::2.5::HTS	0.208564160518	BRD-K47177710-001-03-1::2.5::HTS	BRD-K47177710-001-03-1	DAPT	2.5	HTS	gamma secretase inhibitor				C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1	Preclinical	5
BRD-K47192521-001-05-4::0.25::HTS	0.0544523082146	BRD-K47192521-001-05-4::0.25::HTS	BRD-K47192521-001-05-4	icosapent	0.25	HTS	platelet aggregation inhibitor	ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1	endocrinology	hypertriglyceridemia	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	Launched	3
BRD-K47195926-001-06-6::2.5::HTS	0.257668876452	BRD-K47195926-001-06-6::2.5::HTS	BRD-K47195926-001-06-6	acedoben	2.5	HTS					CC(=O)Nc1ccc(cc1)C(O)=O	Phase 2	5
BRD-K47264279-001-08-9::2.5::HTS	-0.061161132888699996	BRD-K47264279-001-08-9::2.5::HTS	BRD-K47264279-001-08-9	psoralen	2.5	HTS		MAOA, MAOB	dermatology	psoriasis, eczema, vitiligo	O=c1ccc2cc3ccoc3cc2o1	Launched	5
BRD-K47278471-003-26-3::2.5::HTS	-0.128611159278	BRD-K47278471-003-26-3::2.5::HTS	BRD-K47278471-003-26-3	diphenhydramine	2.5	HTS	histamine receptor antagonist	HRH1	neurology/psychiatry	headache	CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1	Launched	5
BRD-K47323024-003-24-4::2.5::HTS	0.117817528366	BRD-K47323024-003-24-4::2.5::HTS	BRD-K47323024-003-24-4	methapyrilene	2.5	HTS	histamine receptor antagonist	HRH1			CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1	Withdrawn	5
BRD-K47337578-034-02-5::2.5::HTS	-0.5499952404899999	BRD-K47337578-034-02-5::2.5::HTS	BRD-K47337578-034-02-5	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	2.5	HTS	serotonin receptor antagonist	HTR2A			Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1	Preclinical	5
BRD-K47371940-001-01-6::2.5::HTS	-0.581657581106	BRD-K47371940-001-01-6::2.5::HTS	BRD-K47371940-001-01-6	ecabapide	2.5	HTS					CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1	Phase 3	5
BRD-K47376733-001-08-1::2.5::HTS	-0.46244757079099996	BRD-K47376733-001-08-1::2.5::HTS	BRD-K47376733-001-08-1	JNJ-1661010	2.5	HTS	FAAH inhibitor	FAAH			O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1	Preclinical	5
BRD-K47407372-001-17-1::2.5::HTS	0.400707352239	BRD-K47407372-001-17-1::2.5::HTS	BRD-K47407372-001-17-1	nifenazone	2.5	HTS	analgesic agent		neurology/psychiatry	pain relief	Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C	Launched	5
BRD-K47539947-001-03-7::2.5::HTS	0.177030042282	BRD-K47539947-001-03-7::2.5::HTS	BRD-K47539947-001-03-7	tetradecylthioacetic-acid	2.5	HTS	lipid peroxidase inhibitor				CCCCCCCCCCCCCCSCC(O)=O	Phase 2	5
BRD-K47554101-001-01-2::2.5::HTS	0.339742742221	BRD-K47554101-001-01-2::2.5::HTS	BRD-K47554101-001-01-2	eperezolid	2.5	HTS	bacterial 30S ribosomal subunit inhibitor				CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1	Phase 1	5
BRD-K47557313-001-02-7::2.5::HTS	0.0674392100553	BRD-K47557313-001-02-7::2.5::HTS	BRD-K47557313-001-02-7	LY2109761	2.5	HTS	TGF beta receptor inhibitor	TGFBR1, TGFBR2			C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1	Preclinical	5
BRD-K47598052-001-15-8::2.5::HTS	0.682620253306	BRD-K47598052-001-15-8::2.5::HTS	BRD-K47598052-001-15-8	PP-1	2.5	HTS	src inhibitor	HCK, RET			Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C	Preclinical	5
BRD-K47631482-003-06-2::2.5::HTS	-0.311000591627	BRD-K47631482-003-06-2::2.5::HTS	BRD-K47631482-003-06-2	bromhexine	2.5	HTS	mucolytic agent		pulmonary	chest congestion	CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1	Launched	5
BRD-K47635719-001-21-1::2.5::HTS	-1.10171959604	BRD-K47635719-001-21-1::2.5::HTS	BRD-K47635719-001-21-1	dexamethasone-acetate	2.5	HTS	glucocorticoid receptor agonist		endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O	Launched	5
BRD-K47639036-003-06-6::2.5::HTS	-0.292393663536	BRD-K47639036-003-06-6::2.5::HTS	BRD-K47639036-003-06-6	flavoxate	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2	urology	urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis	Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1	Launched	5
BRD-K47642186-001-01-3::2.5::HTS	0.261046311542	BRD-K47642186-001-01-3::2.5::HTS	BRD-K47642186-001-01-3	piclamilast	2.5	HTS	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl	Phase 2	5
BRD-K47659338-003-02-8::2.5::HTS	-0.0244963186913	BRD-K47659338-003-02-8::2.5::HTS	BRD-K47659338-003-02-8	EMD-386088	2.5	HTS	serotonin receptor agonist	HTR6			Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1	Preclinical	5
BRD-K47679368-236-01-7::2.5::HTS	-0.22289649235800002	BRD-K47679368-236-01-7::2.5::HTS	BRD-K47679368-236-01-7	bromfenac	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2			Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1	Withdrawn	5
BRD-K47780086-001-07-9::2.5::HTS	0.08447395128589999	BRD-K47780086-001-07-9::2.5::HTS	BRD-K47780086-001-07-9	penciclovir	2.5	HTS	DNA directed DNA polymerase inhibitor		dental	cold sore	Nc1nc(O)c2ncn(CCC(CO)CO)c2n1, Nc1nc(O)c2ncn(CCC(CO)CO)c2n1, Nc1nc(O)c2ncn(CCC(CO)CO)c2n1	Launched	5
BRD-K47827687-001-02-2::2.5::HTS	-0.23047770153299998	BRD-K47827687-001-02-2::2.5::HTS	BRD-K47827687-001-02-2	amprenavir	2.5	HTS	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	Launched	5
BRD-K47832606-001-30-1::2.5::HTS	-1.8224403941999998	BRD-K47832606-001-30-1::2.5::HTS	BRD-K47832606-001-30-1	floxuridine	2.5	HTS	DNA synthesis inhibitor	TYMS	oncology	colorectal cancer	OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	Launched	5
BRD-K47869605-001-32-0::2.5::HTS	-0.9379774887860001	BRD-K47869605-001-32-0::2.5::HTS	BRD-K47869605-001-32-0	podophyllotoxin	2.5	HTS	microtubule inhibitor, tubulin polymerization inhibitor	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12	Launched	5
BRD-K47878171-086-06-0::2.5::HTS	0.42172353618299996	BRD-K47878171-086-06-0::2.5::HTS	BRD-K47878171-086-06-0	bephenium-hydroxynaphthoate	2.5	HTS	anthelmintic agent		infectious disease	ascariasis	C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1	Launched	5
BRD-K47886988-001-21-4::2.5::HTS	0.328748154928	BRD-K47886988-001-21-4::2.5::HTS	BRD-K47886988-001-21-4	nalidixic-acid	2.5	HTS	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12	Launched	5
BRD-K47936004-003-11-4::2.5::HTS	0.00668817313905	BRD-K47936004-003-11-4::2.5::HTS	BRD-K47936004-003-11-4	piribedil	2.5	HTS	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B	neurology/psychiatry	Parkinson's Disease, dizziness	C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1	Launched	5
BRD-K47949423-001-03-1::2.56::HTS	0.0649597214308	BRD-K47949423-001-03-1::2.56::HTS	BRD-K47949423-001-03-1	mirabegron	2.56	HTS	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	urology	urinary incontinence	Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1	Launched	5
BRD-K47976015-001-01-2::2.5::HTS	-0.09055302415889999	BRD-K47976015-001-01-2::2.5::HTS	BRD-K47976015-001-01-2	balapiravir	2.5	HTS	RNA polymerase inhibitor				CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]	Phase 2	5
BRD-K47978074-001-02-4::2.5::HTS	0.434653838715	BRD-K47978074-001-02-4::2.5::HTS	BRD-K47978074-001-02-4	trometamol	2.5	HTS		AMD1, CANT1, DCN, NEIL1, VEGFA			NC(CO)(CO)CO, NC(CO)(CO)CO	Launched	5
BRD-K48061146-066-01-7::2.5::HTS	0.07966114723510001	BRD-K48061146-066-01-7::2.5::HTS	BRD-K48061146-066-01-7	benztropine-mesylate	2.5	HTS	acetylcholine receptor antagonist	CHRM1, HRH1, SLC6A3	neurology/psychiatry	extrapyramidal symptoms (EPS), Parkinson's Disease	CN1[C@@H]2CC[C@@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1	Launched	5
BRD-K48068743-001-01-6::2.5::HTS	-0.259378069694	BRD-K48068743-001-01-6::2.5::HTS	BRD-K48068743-001-01-6	teneligliptin	2.5	HTS	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1	Launched	5
BRD-K48141473-001-01-7::2.5::HTS	0.523290936426	BRD-K48141473-001-01-7::2.5::HTS	BRD-K48141473-001-01-7	cebranopadol	2.5	HTS	opioid receptor agonist	OPRL1, OPRM1			CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1	Phase 3	5
BRD-K48168960-001-19-2::2.5::HTS	0.243863822058	BRD-K48168960-001-19-2::2.5::HTS	BRD-K48168960-001-19-2	propylthiouracil	2.5	HTS	thyroid peroxidase inhibitor	DIO1, TPO	endocrinology	hyperthyroidism, Grave's disease, goiter	CCCc1cc(=O)[nH]c(=S)[nH]1, CCCc1cc(=O)[nH]c(=S)[nH]1	Launched	5
BRD-K48173020-001-01-8::2.5::HTS	0.165278039322	BRD-K48173020-001-01-8::2.5::HTS	BRD-K48173020-001-01-8	ameltolide	2.5	HTS	anticonvulsant				Cc1cccc(C)c1NC(=O)c1ccc(N)cc1	Preclinical	5
BRD-K48195008-001-19-9::2.5::HTS	-0.17170954509599998	BRD-K48195008-001-19-9::2.5::HTS	BRD-K48195008-001-19-9	ethinyl-estradiol	2.5	HTS	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2, NR1I2	endocrinology	contraceptive	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C	Launched	5
BRD-K48195801-001-01-6::2.5::HTS	-1.62542103153	BRD-K48195801-001-01-6::2.5::HTS	BRD-K48195801-001-01-6	tecastemizole	2.5	HTS	histamine receptor antagonist	KCNH2			Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1	Phase 3	5
BRD-K48213016-001-01-8::2.5::HTS	0.36748589669799997	BRD-K48213016-001-01-8::2.5::HTS	BRD-K48213016-001-01-8	CC-930	2.5	HTS	JNK inhibitor				O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1	Phase 2	5
BRD-K48247567-001-01-9::2.5::HTS	-0.41346909115900005	BRD-K48247567-001-01-9::2.5::HTS	BRD-K48247567-001-01-9	diatrizoic-acid	2.5	HTS			radiology	contrast agent	CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Launched	5
BRD-K48300629-001-14-5::2.5::HTS	0.307942507268	BRD-K48300629-001-14-5::2.5::HTS	BRD-K48300629-001-14-5	zonisamide	2.5	HTS	sodium channel blocker, T-type calcium channel blocker	CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures, epilepsy	NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12	Launched	5
BRD-K48329353-001-01-3::2.5::HTS	0.5079755729819999	BRD-K48329353-001-01-3::2.5::HTS	BRD-K48329353-001-01-3	6,_7-dehydro-17-acetoxy-progesterone	2.5	HTS	steroidal progestin				CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	Preclinical	5
BRD-K48367671-001-05-9::2.5::HTS	-0.0693602273749	BRD-K48367671-001-05-9::2.5::HTS	BRD-K48367671-001-05-9	febuxostat	2.5	HTS	xanthine oxidase inhibitor	XDH	nephrology	hyperuricemia	CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O	Launched	5
BRD-K48443249-001-01-0::2.5::HTS	-0.385348292843	BRD-K48443249-001-01-0::2.5::HTS	BRD-K48443249-001-01-0	CNX-774	2.5	HTS	Bruton's tyrosine kinase (BTK) inhibitor	BTK			CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1	Preclinical	5
BRD-K48488978-001-05-3::2.5::HTS	0.711498866742	BRD-K48488978-001-05-3::2.5::HTS	BRD-K48488978-001-05-3	YM-201636	2.5	HTS	PI3K inhibitor				Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	Preclinical	5
BRD-K48535733-003-01-2::2.5::HTS	0.100037237667	BRD-K48535733-003-01-2::2.5::HTS	BRD-K48535733-003-01-2	VU0155069	2.5	HTS	phospholipase inhibitor	PLD1			C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1	Preclinical	5
BRD-K48578705-001-16-8::2.5::HTS	-0.0296057369038	BRD-K48578705-001-16-8::2.5::HTS	BRD-K48578705-001-16-8	methyldopa	2.5	HTS	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	Launched	5
BRD-K48578705-001-17-6::2.5::HTS	0.0650991496177	BRD-K48578705-001-17-6::2.5::HTS	BRD-K48578705-001-17-6	methyldopa	2.5	HTS	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	Launched	5
BRD-K48619321-004-16-8::2.54::HTS	0.22359777821899998	BRD-K48619321-004-16-8::2.54::HTS	BRD-K48619321-004-16-8	methscopolamine	2.54	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Launched	5
BRD-K48684885-001-04-2::2.5::HTS	-1.28353251563	BRD-K48684885-001-04-2::2.5::HTS	BRD-K48684885-001-04-2	BAY-11-7085	2.5	HTS	NFkB pathway inhibitor	NFKBIA			CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N	Preclinical	5
BRD-K48692744-001-02-0::2.5::HTS	-0.14963740251399998	BRD-K48692744-001-02-0::2.5::HTS	BRD-K48692744-001-02-0	NU-1025	2.5	HTS	PARP inhibitor	PARP1			Cc1nc2c(O)cccc2c(=O)[nH]1, Cc1nc2c(O)cccc2c(=O)[nH]1	Preclinical	5
BRD-K48722258-300-10-2::2.5::HTS	0.43721273328500004	BRD-K48722258-300-10-2::2.5::HTS	BRD-K48722258-300-10-2	dilazep	2.5	HTS	adenosine reuptake inhibitor	SLC29A1			COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1, COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1	Launched	5
BRD-K48722833-001-07-6::2.5::HTS	0.103528669328	BRD-K48722833-001-07-6::2.5::HTS	BRD-K48722833-001-07-6	iloperidone	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O	Launched	5
BRD-K48812570-001-02-3::2.5::HTS	0.231827263216	BRD-K48812570-001-02-3::2.5::HTS	BRD-K48812570-001-02-3	macitentan	2.5	HTS	endothelin receptor antagonist	EDNRA, EDNRB	endocrinology	contraceptive	CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	Launched	5
BRD-K48826825-001-01-8::2.5::HTS	0.0665797117779	BRD-K48826825-001-01-8::2.5::HTS	BRD-K48826825-001-01-8	S26948	2.5	HTS	PPAR receptor agonist	PPARG			COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC	Preclinical	5
BRD-K48830578-001-01-9::2.5::HTS	0.6598234878620001	BRD-K48830578-001-01-9::2.5::HTS	BRD-K48830578-001-01-9	OMDM-2	2.5	HTS	FAAH inhibitor	GPR119			CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1	Preclinical	5
BRD-K48888725-001-01-9::2.5::HTS	-0.0229057665826	BRD-K48888725-001-01-9::2.5::HTS	BRD-K48888725-001-01-9	CG-400549	2.5	HTS	FABI inhibitor				Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O, Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O	Phase 2	5
BRD-K48892307-001-04-1::2.5::HTS	-0.401626885835	BRD-K48892307-001-04-1::2.5::HTS	BRD-K48892307-001-04-1	sasapyrine	2.5	HTS	NFkB pathway inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O	Launched	5
BRD-K48894757-001-01-8::2.5::HTS	-0.159769965181	BRD-K48894757-001-01-8::2.5::HTS	BRD-K48894757-001-01-8	laropiprant	2.5	HTS	prostanoid receptor antagonist	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R	cardiology	cholesterol	CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12	Launched	5
BRD-K48988407-001-01-2::2.5::HTS	-0.148167798723	BRD-K48988407-001-01-2::2.5::HTS	BRD-K48988407-001-01-2	cytochlor	2.5	HTS					Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1	Phase 1	5
BRD-K48996094-001-01-3::2.5::HTS	0.19945706090799997	BRD-K48996094-001-01-3::2.5::HTS	BRD-K48996094-001-01-3	pentacosanoic-acid	2.5	HTS					CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O	Preclinical	5
BRD-K49027941-001-01-1::2.5::HTS	0.08873947485369998	BRD-K49027941-001-01-1::2.5::HTS	BRD-K49027941-001-01-1	PSB-1115	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O	Preclinical	5
BRD-K49049886-001-08-7::2.5::HTS	1.1607684617799998	BRD-K49049886-001-08-7::2.5::HTS	BRD-K49049886-001-08-7	CGS-15943	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1	Preclinical	5
BRD-K49055432-001-04-2::2.5::HTS	0.21537999416099998	BRD-K49055432-001-04-2::2.5::HTS	BRD-K49055432-001-04-2	A66	2.5	HTS	PI3K inhibitor	PIK3CA			Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C	Preclinical	5
BRD-K49071277-001-04-7::2.5::HTS	0.5875944716870001	BRD-K49071277-001-04-7::2.5::HTS	BRD-K49071277-001-04-7	securinine	2.5	HTS	GABA receptor antagonist, TP53 activator	GABRA1			O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31	Preclinical	5
BRD-K49075727-001-08-5::2.5::HTS	-0.0400763778104	BRD-K49075727-001-08-5::2.5::HTS	BRD-K49075727-001-08-5	nintedanib	2.5	HTS	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1	Launched	5
BRD-K49111258-003-29-7::2.5::HTS	-0.7528894057529999	BRD-K49111258-003-29-7::2.5::HTS	BRD-K49111258-003-29-7	prazosin	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	Launched	5
BRD-K49119234-003-02-6::2.5::HTS	-0.08723798949480001	BRD-K49119234-003-02-6::2.5::HTS	BRD-K49119234-003-02-6	TMPH	2.5	HTS					CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1	Preclinical	5
BRD-K49197823-001-09-8::2.5::HTS	0.0611163873937	BRD-K49197823-001-09-8::2.5::HTS	BRD-K49197823-001-09-8	CV-1808	2.5	HTS	adenosine receptor agonist	ADORA2A			Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical	5
BRD-K49215523-001-04-2::2.5::HTS	0.218512994598	BRD-K49215523-001-04-2::2.5::HTS	BRD-K49215523-001-04-2	GSK2636771	2.5	HTS	PI3K inhibitor	PIK3CB			Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O	Phase 2	5
BRD-K49236613-001-02-3::2.5::HTS	-0.0633296762752	BRD-K49236613-001-02-3::2.5::HTS	BRD-K49236613-001-02-3	6-iodo-nordihydrocapsaicin	2.5	HTS	TRPV antagonist	TRPV1			CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I	Preclinical	5
BRD-K49294207-300-03-8::2.5::HTS	0.45792447275799997	BRD-K49294207-300-03-8::2.5::HTS	BRD-K49294207-300-03-8	BIBU-1361	2.5	HTS	EGFR inhibitor	EGFR			CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	Preclinical	5
BRD-K49313711-001-05-4::2.5::HTS	-0.440491199459	BRD-K49313711-001-05-4::2.5::HTS	BRD-K49313711-001-05-4	ribitol	2.5	HTS					OC[C@H](O)[C@H](O)[C@H](O)CO	Preclinical	5
BRD-K49328571-001-15-0::2.5::HTS	-1.27004142715	BRD-K49328571-001-15-0::2.5::HTS	BRD-K49328571-001-15-0	dasatinib	2.5	HTS	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1	Launched	5
BRD-K49338325-001-03-4::2.5::HTS	-0.0374796938663	BRD-K49338325-001-03-4::2.5::HTS	BRD-K49338325-001-03-4	etofibrate	2.5	HTS	PPAR receptor agonist	PPARA	endocrinology	hypertriglyceridemia	CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1	Launched	5
BRD-K49350383-001-13-7::2.5::HTS	-0.786353256461	BRD-K49350383-001-13-7::2.5::HTS	BRD-K49350383-001-13-7	thioguanine	2.5	HTS	purine antagonist	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1	Launched	5
BRD-K49371609-003-03-8::2.5::HTS	-2.30804295134	BRD-K49371609-003-03-8::2.5::HTS	BRD-K49371609-003-03-8	PIK-75	2.5	HTS	DNA protein kinase inhibitor, PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	Preclinical	5
BRD-K49404994-001-10-9::2.5::HTS	0.230892760031	BRD-K49404994-001-10-9::2.5::HTS	BRD-K49404994-001-10-9	levetiracetam	2.5	HTS	calcium channel blocker	CACNA1B, SCN1A, SV2A	neurology/psychiatry	seizures	CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O	Launched	5
BRD-K49456274-001-01-9::2.5::HTS	-0.764400801488	BRD-K49456274-001-01-9::2.5::HTS	BRD-K49456274-001-01-9	pilaralisib	2.5	HTS	PI3K inhibitor				COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1	Phase 2	5
BRD-K49460120-001-02-5::2.5::HTS	-0.319769965674	BRD-K49460120-001-02-5::2.5::HTS	BRD-K49460120-001-02-5	10058-F4	2.5	HTS	c-Myc inhibitor				CCc1ccc(cc1)\C=C1\SC(=S)NC1=O, CCc1ccc(cc1)\C=C1\SC(=S)NC1=O, CCc1ccc(cc1)\C=C1\SC(=S)NC1=O	Preclinical	5
BRD-K49481516-004-18-3::2.5::HTS	0.028960611502799997	BRD-K49481516-004-18-3::2.5::HTS	BRD-K49481516-004-18-3	galantamine	2.5	HTS	acetylcholinesterase inhibitor	ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG	neurology/psychiatry	senile dementia	COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24	Launched	5
BRD-K49504902-001-01-6::2.5::HTS	0.244943619344	BRD-K49504902-001-01-6::2.5::HTS	BRD-K49504902-001-01-6	SEP-227900	2.5	HTS	D-Amino Acid Oxidase Inhibitor	DAO			OC(=O)c1cc2occc2[nH]1	Phase 1	5
BRD-K49519144-001-04-6::2.5::HTS	-0.0574169832441	BRD-K49519144-001-04-6::2.5::HTS	BRD-K49519144-001-04-6	LY2140023	2.5	HTS	glutamate receptor agonist	GRM3			N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 3	5
BRD-K49522529-001-02-9::2.53::HTS	-0.168638398843	BRD-K49522529-001-02-9::2.53::HTS	BRD-K49522529-001-02-9	alfacalcidol	2.53	HTS	vitamin D receptor agonist	CYP27B1, VDR	endocrinology	vitamin D deficiency	CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	5
BRD-K49522529-001-03-7::2.5::HTS	-0.295932490976	BRD-K49522529-001-03-7::2.5::HTS	BRD-K49522529-001-03-7	alfacalcidol	2.5	HTS	vitamin D receptor agonist	CYP27B1, VDR	endocrinology	vitamin D deficiency	CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	5
BRD-K49545903-003-01-4::2.5::HTS	-0.16515985533	BRD-K49545903-003-01-4::2.5::HTS	BRD-K49545903-003-01-4	4,4-pentamethylenepiperidine	2.5	HTS	M2 channel blocker				C1CCC2(CC1)CCNCC2	Preclinical	5
BRD-K49554218-001-01-0::2.5::HTS	0.38355996326200004	BRD-K49554218-001-01-0::2.5::HTS	BRD-K49554218-001-01-0	carebastine	2.5	HTS	histamine receptor antagonist	HRH1			CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Phase 1	5
BRD-K49555808-001-03-9::2.5::HTS	-0.8469363444050001	BRD-K49555808-001-03-9::2.5::HTS	BRD-K49555808-001-03-9	BMS-707035	2.5	HTS	HIV integrase inhibitor				Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O	Phase 2	5
BRD-K49657628-001-14-8::2.5::HTS	-0.24911216855700002	BRD-K49657628-001-14-8::2.5::HTS	BRD-K49657628-001-14-8	tyrphostin-AG-18	2.5	HTS	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O	Preclinical	5
BRD-K49668410-001-18-8::2.5::HTS	-0.278252167153	BRD-K49668410-001-18-8::2.5::HTS	BRD-K49668410-001-18-8	clarithromycin	2.5	HTS	bacterial 50S ribosomal subunit inhibitor	CYP3A4	otolaryngology, pulmonary, infectious disease	pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	Launched	5
BRD-K49669041-001-08-4::2.5::HTS	-0.279939506608	BRD-K49669041-001-08-4::2.5::HTS	BRD-K49669041-001-08-4	BX-912	2.5	HTS	pyruvate dehydrogenase kinase inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1	Preclinical	5
BRD-K49671696-045-08-5::2.5::HTS	0.310798431599	BRD-K49671696-045-08-5::2.5::HTS	BRD-K49671696-045-08-5	ketanserin	2.5	HTS	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2	cardiology	hypertension	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1	Launched	5
BRD-K49685476-001-15-9::2.5::HTS	0.247996216589	BRD-K49685476-001-15-9::2.5::HTS	BRD-K49685476-001-15-9	TTNPB	2.5	HTS	retinoid receptor agonist	RARA, RARB, RARG			C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C	Phase 1	5
BRD-K49702221-003-01-6::2.5::HTS	0.491440413979	BRD-K49702221-003-01-6::2.5::HTS	BRD-K49702221-003-01-6	SNAP-94847	2.5	HTS		ADRA1A, DRD2			CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1	Preclinical	5
BRD-K49738308-065-04-9::2.5::HTS	-0.0708185138704	BRD-K49738308-065-04-9::2.5::HTS	BRD-K49738308-065-04-9	agmatine	2.5	HTS	nitric oxide synthase inhibitor	ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH			NCCCCNC(N)=N	Phase 3	5
BRD-K49759007-001-11-9::2.5::HTS	-0.349206501399	BRD-K49759007-001-11-9::2.5::HTS	BRD-K49759007-001-11-9	4-hydroxy-phenazone	2.5	HTS					Cc1c(O)c(=O)n(-c2ccccc2)n1C	Preclinical	5
BRD-K49783248-303-08-4::2.5::HTS	0.250717550871	BRD-K49783248-303-08-4::2.5::HTS	BRD-K49783248-303-08-4	decamethonium	2.5	HTS	acetylcholine receptor agonist	ACHE, CHRNA2	neurology/psychiatry	muscle relaxant	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	Launched	5
BRD-K49807096-003-15-5::2.5::HTS	-0.897333682615	BRD-K49807096-003-15-5::2.5::HTS	BRD-K49807096-003-15-5	benazepril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	Launched	5
BRD-K49811169-004-06-6::2.5::HTS	-0.160890593824	BRD-K49811169-004-06-6::2.5::HTS	BRD-K49811169-004-06-6	NSC-9965	2.5	HTS	acetylcholine receptor antagonist	CHRNA4, CHRNB2			CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1	Preclinical	5
BRD-K49840922-001-05-1::2.5::HTS	0.0851194776159	BRD-K49840922-001-05-1::2.5::HTS	BRD-K49840922-001-05-1	etofylline-clofibrate	2.5	HTS	platelet aggregation inhibitor	PPARA			Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O	Launched	5
BRD-K49865102-001-08-4::2.5::HTS	-3.5583786790900005	BRD-K49865102-001-08-4::2.5::HTS	BRD-K49865102-001-08-4	PD-0325901	2.5	HTS	MEK inhibitor	MAP2K1			OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F	Phase 2	5
BRD-K49880111-236-09-2::2.5::HTS	0.19855954055599997	BRD-K49880111-236-09-2::2.5::HTS	BRD-K49880111-236-09-2	cephapirin	2.5	HTS	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O	Launched	5
BRD-K49945136-001-10-0::2.5::HTS	0.237668737051	BRD-K49945136-001-10-0::2.5::HTS	BRD-K49945136-001-10-0	GR-113808	2.5	HTS	serotonin receptor antagonist	HTR4			Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12	Preclinical	5
BRD-K49954789-001-02-9::2.5::HTS	-0.146696339563	BRD-K49954789-001-02-9::2.5::HTS	BRD-K49954789-001-02-9	mesna	2.5	HTS	antioxidant		urology	hemorrhagic cystitis	OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS	Launched	5
BRD-K49962337-001-01-1::2.5::HTS	-0.147164913728	BRD-K49962337-001-01-1::2.5::HTS	BRD-K49962337-001-01-1	baicalin	2.5	HTS	beta glucuronidase inhibitor	PREP			O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	Launched	5
BRD-K49962337-001-02-9::2.56::HTS	0.173324861909	BRD-K49962337-001-02-9::2.56::HTS	BRD-K49962337-001-02-9	baicalin	2.56	HTS	beta glucuronidase inhibitor	PREP			O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	Launched	5
BRD-K50000283-001-04-4::2.5::HTS	0.33742157047300003	BRD-K50000283-001-04-4::2.5::HTS	BRD-K50000283-001-04-4	PHA-767491	2.5	HTS	CDC inhibitor	CDK1, RPS6KB1			O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1	Preclinical	5
BRD-K50018155-003-02-1::2.5::HTS	0.31466699685800004	BRD-K50018155-003-02-1::2.5::HTS	BRD-K50018155-003-02-1	RS-67506	2.5	HTS	serotonin receptor partial agonist	HTR4			COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1	Preclinical	5
BRD-K50031829-001-01-6::2.5::HTS	0.230306305254	BRD-K50031829-001-01-6::2.5::HTS	BRD-K50031829-001-01-6	PF-04447943	2.5	HTS	phosphodiesterase inhibitor	PDE9A			C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2n(ncc2c(=O)[nH]1)C1CCOCC1	Phase 2	5
BRD-K50050533-001-02-1::2.5::HTS	0.016915915761700002	BRD-K50050533-001-02-1::2.5::HTS	BRD-K50050533-001-02-1	docosanol	2.5	HTS	lipase clearing factor inhibitor	TLR7	dental	cold sore	CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO	Launched	5
BRD-K50071428-001-03-3::2.5::HTS	-0.13515182947	BRD-K50071428-001-03-3::2.5::HTS	BRD-K50071428-001-03-3	abiraterone	2.5	HTS	androgen biosynthesis inhibitor	CYP11B1, CYP17A1	oncology	prostate cancer	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1	Launched	5
BRD-K50133271-001-18-7::2.5::HTS	0.321137101719	BRD-K50133271-001-18-7::2.5::HTS	BRD-K50133271-001-18-7	tolfenamic-acid	2.5	HTS	cyclooxygenase inhibitor, prostanoid receptor antagonist		neurology/psychiatry	migraine headache	Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O	Launched	5
BRD-K50135270-300-02-3::2.5::HTS	0.20334917507599998	BRD-K50135270-300-02-3::2.5::HTS	BRD-K50135270-300-02-3	GBR-12935	2.5	HTS	dopamine uptake inhibitor	AGTR1, SLC6A3			C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1	Preclinical	5
BRD-K50140147-001-10-1::2.5::HTS	-2.00069911213	BRD-K50140147-001-10-1::2.5::HTS	BRD-K50140147-001-10-1	NVP-TAE684	2.5	HTS	ALK tyrosine kinase receptor inhibitor	ALK, INSR			COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	Preclinical	5
BRD-K50163129-001-01-4::2.5::HTS	-0.292751000533	BRD-K50163129-001-01-4::2.5::HTS	BRD-K50163129-001-01-4	acrivastine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1	Launched	5
BRD-K50168500-001-07-9::2.5::HTS	-0.352676643166	BRD-K50168500-001-07-9::2.5::HTS	BRD-K50168500-001-07-9	canertinib	2.5	HTS	EGFR inhibitor	AKT1, EGFR, ERBB2, ERBB4			Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl	Phase 3	5
BRD-K50293352-300-02-1::2.5::HTS	0.0499760963497	BRD-K50293352-300-02-1::2.5::HTS	BRD-K50293352-300-02-1	MM77	2.5	HTS	serotonin receptor antagonist	HTR1A			COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1	Preclinical	5
BRD-K50325075-001-02-1::2.5::HTS	0.0816215050256	BRD-K50325075-001-02-1::2.5::HTS	BRD-K50325075-001-02-1	UCL-2077	2.5	HTS	slow afterhyperpolarization channel blocker				C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1	Preclinical	5
BRD-K50388907-001-30-4::2.5::HTS	-0.255103128524	BRD-K50388907-001-30-4::2.5::HTS	BRD-K50388907-001-30-4	fenofibrate	2.5	HTS	PPAR receptor agonist	MMP25, PPARA	endocrinology	hypercholesterolemia, hypertriglyceridemia	CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1	Launched	5
BRD-K50398167-236-22-7::2.5::HTS	0.219309521644	BRD-K50398167-236-22-7::2.5::HTS	BRD-K50398167-236-22-7	meclofenamic-acid	2.5	HTS	cyclooxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2	rheumatology, neurology/psychiatry, endocrinology	joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)	Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl	Launched	5
BRD-K50406511-001-26-0::2.5::HTS	0.689574941991	BRD-K50406511-001-26-0::2.5::HTS	BRD-K50406511-001-26-0	hycanthone	2.5	HTS	RNA synthesis inhibitor		infectious disease	schistosomiasis	CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12	Launched	5
BRD-K50417881-003-17-4::2.5::HTS	0.5302179217040001	BRD-K50417881-003-17-4::2.5::HTS	BRD-K50417881-003-17-4	eticlopride	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3, DRD4			CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC	Preclinical	5
BRD-K50422030-001-05-3::2.5::HTS	0.50239948317	BRD-K50422030-001-05-3::2.5::HTS	BRD-K50422030-001-05-3	clomethiazole	2.5	HTS	GABA receptor antagonist, GABA receptor modulator	GABRA1	neurology/psychiatry	Parkinson's Disease, sedative, muscle relaxant	Cc1ncsc1CCCl, Cc1ncsc1CCCl	Launched	5
BRD-K50495309-001-02-0::2.5::HTS	-0.36908546882200005	BRD-K50495309-001-02-0::2.5::HTS	BRD-K50495309-001-02-0	SRC-kinase-inhibitor-I	2.5	HTS	src inhibitor	CSK, LCK, RIPK2			COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC	Preclinical	5
BRD-K50498985-001-03-3::2.5::HTS	-0.0968427974339	BRD-K50498985-001-03-3::2.5::HTS	BRD-K50498985-001-03-3	taladegib	2.5	HTS	smoothened receptor antagonist	DHH, IHH, SMO			CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F	Phase 2	5
BRD-K50564936-001-01-6::2.5::HTS	0.10044666930099999	BRD-K50564936-001-01-6::2.5::HTS	BRD-K50564936-001-01-6	E-2012	2.5	HTS	gamma secretase modulator	APH1A, APH1B, PSENEN			COc1cc(ccc1-n1cnc(C)c1)\C=C1/CCCN([C@@H](C)c2ccc(F)cc2)C1=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC	Phase 1	5
BRD-K50590187-001-19-9::2.5::HTS	-0.0864813450515	BRD-K50590187-001-19-9::2.5::HTS	BRD-K50590187-001-19-9	capsaicin	2.5	HTS	TRPV agonist	CFTR, TRPV1	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis	COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O	Launched	5
BRD-K50631926-001-02-3::2.5::HTS	-0.0391447854511	BRD-K50631926-001-02-3::2.5::HTS	BRD-K50631926-001-02-3	PIK-294	2.5	HTS	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O	Preclinical	5
BRD-K50677762-001-01-5::2.5::HTS	-1.35360858176	BRD-K50677762-001-01-5::2.5::HTS	BRD-K50677762-001-01-5	oxiracetam	2.5	HTS	acetylcholine receptor agonist				NC(=O)CN1C[C@H](O)CC1=O	Launched	5
BRD-K50785021-001-02-1::2.5::HTS	0.409686381634	BRD-K50785021-001-02-1::2.5::HTS	BRD-K50785021-001-02-1	cyclamic-acid	2.5	HTS					OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1	Preclinical	5
BRD-K50817623-303-05-7::2.5::HTS	0.41026028450999996	BRD-K50817623-303-05-7::2.5::HTS	BRD-K50817623-303-05-7	pancuronium	2.5	HTS	acetylcholine receptor antagonist	CHRM2, CHRM3, CHRNA1, CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	Launched	5
BRD-K50836978-001-02-5::2.5::HTS	-0.073220196442	BRD-K50836978-001-02-5::2.5::HTS	BRD-K50836978-001-02-5	purvalanol-a	2.5	HTS	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC			CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical	5
BRD-K50850824-237-04-8::2.5::HTS	-0.321932190251	BRD-K50850824-237-04-8::2.5::HTS	BRD-K50850824-237-04-8	acesulfame-potassium	2.5	HTS					CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1	Phase 3	5
BRD-K50853363-001-02-3::2.5::HTS	-2.54879165367	BRD-K50853363-001-02-3::2.5::HTS	BRD-K50853363-001-02-3	dienogest	2.5	HTS	progesterone receptor agonist	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N	Launched	5
BRD-K50859149-001-19-5::2.5::HTS	-0.458477013565	BRD-K50859149-001-19-5::2.5::HTS	BRD-K50859149-001-19-5	sulfafurazole	2.5	HTS	bacterial antifolate		infectious disease	urinary tract infections	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	Launched	5
BRD-K50866992-003-09-5::2.5::HTS	-0.169962149751	BRD-K50866992-003-09-5::2.5::HTS	BRD-K50866992-003-09-5	tropisetron	2.5	HTS	serotonin receptor antagonist	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12	Launched	5
BRD-K50866992-003-10-3::2.5::HTS	0.26128710057599996	BRD-K50866992-003-10-3::2.5::HTS	BRD-K50866992-003-10-3	tropisetron	2.5	HTS	serotonin receptor antagonist	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12	Launched	5
BRD-K50891186-001-04-4::2.5::HTS	0.15262421344799998	BRD-K50891186-001-04-4::2.5::HTS	BRD-K50891186-001-04-4	GR-103691	2.5	HTS	dopamine receptor antagonist	DRD3			COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1	Preclinical	5
BRD-K50938287-036-13-8::2.5::HTS	-0.108222705734	BRD-K50938287-036-13-8::2.5::HTS	BRD-K50938287-036-13-8	sumatriptan	2.5	HTS	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7	neurology/psychiatry	migraine headache	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1	Launched	5
BRD-K50938786-003-11-8::2.5::HTS	-0.22460263287300003	BRD-K50938786-003-11-8::2.5::HTS	BRD-K50938786-003-11-8	ropivacaine	2.5	HTS	sodium channel blocker	SCN10A	neurology/psychiatry	anesthetic	CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	Launched	5
BRD-K51033547-003-02-6::2.5::HTS	-0.198272648941	BRD-K51033547-003-02-6::2.5::HTS	BRD-K51033547-003-02-6	tramadol	2.5	HTS	norepinephrine reputake inhibitor, opioid receptor agonist, serotonin reuptake inhibitor	CHRFAM7A, CHRM3, GRIN3A, HTR2C, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A4	neurology/psychiatry	acute pain, chronic pain	COc1cccc(c1)[C@]1(O)CCCC[C@H]1CN(C)C	Launched	5
BRD-K51040301-001-02-1::2.5::HTS	-0.108182527764	BRD-K51040301-001-02-1::2.5::HTS	BRD-K51040301-001-02-1	cobicistat	2.5	HTS	cytochrome P450 inhibitor	CYP3A4, CYP3A43, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Launched	5
BRD-K51087630-001-01-6::2.5::HTS	-0.010509885567299999	BRD-K51087630-001-01-6::2.5::HTS	BRD-K51087630-001-01-6	tirasemtiv	2.5	HTS	troponin activator				CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C	Phase 2	5
BRD-K51143828-003-03-1::2.5::HTS	-0.9791352086280001	BRD-K51143828-003-03-1::2.5::HTS	BRD-K51143828-003-03-1	lurasidone	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12	Launched	5
BRD-K51199656-003-01-4::2.5::HTS	0.503518285255	BRD-K51199656-003-01-4::2.5::HTS	BRD-K51199656-003-01-4	fluoromethylcholine	2.5	HTS					C[N+](C)(CF)CCO	Launched	5
BRD-K51207550-001-23-0::2.5::HTS	-0.528363616356	BRD-K51207550-001-23-0::2.5::HTS	BRD-K51207550-001-23-0	ethionamide	2.5	HTS	mycolic synthesis inhibitor		infectious disease	tuberculosis	CCc1cc(ccn1)C(S)=N, CCc1cc(ccn1)C(S)=N	Launched	5
BRD-K51247865-001-01-2::2.5::HTS	-0.319079831288	BRD-K51247865-001-01-2::2.5::HTS	BRD-K51247865-001-01-2	ipragliflozin-l-proline	2.5	HTS	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1	Launched	5
BRD-K51263939-001-08-6::2.5::HTS	-0.369675939325	BRD-K51263939-001-08-6::2.5::HTS	BRD-K51263939-001-08-6	sarcosine	2.5	HTS	Glycine transporter 1 inhibitor	SLC6A9			CNCC(O)=O	Phase 2	5
BRD-K51313569-003-03-3::2.5::HTS	-0.12093878239900001	BRD-K51313569-003-03-3::2.5::HTS	BRD-K51313569-003-03-3	palbociclib	2.5	HTS	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O	Launched	5
BRD-K51318897-001-15-3::2.5::HTS	-0.9364642890270001	BRD-K51318897-001-15-3::2.5::HTS	BRD-K51318897-001-15-3	fenbendazole	2.5	HTS	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1	Launched	5
BRD-K51324732-001-01-0::2.5::HTS	-0.210669587005	BRD-K51324732-001-01-0::2.5::HTS	BRD-K51324732-001-01-0	meglitinide	2.5	HTS	potassium channel blocker	CCR2			COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O	Phase 2	5
BRD-K51333959-003-01-3::2.5::HTS	0.304124732669	BRD-K51333959-003-01-3::2.5::HTS	BRD-K51333959-003-01-3	siramesine	2.5	HTS	sigma receptor antagonist	ADRA1A, ADRA1B, ADRA1D			Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12	Phase 2	5
BRD-K51350053-048-16-5::2.5::HTS	-0.0992643348875	BRD-K51350053-048-16-5::2.5::HTS	BRD-K51350053-048-16-5	toremifene	2.5	HTS	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1	Launched	5
BRD-K51431759-001-02-9::2.5::HTS	0.0826575798797	BRD-K51431759-001-02-9::2.5::HTS	BRD-K51431759-001-02-9	dextrose	2.5	HTS			endocrinology	hypoglycemia	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O	Launched	5
BRD-K51471001-303-04-7::2.5::HTS	-0.572034991374	BRD-K51471001-303-04-7::2.5::HTS	BRD-K51471001-303-04-7	demecarium	2.5	HTS	acetylcholinesterase inhibitor	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C	Launched	5
BRD-K51474575-001-10-4::2.5::HTS	0.317733645824	BRD-K51474575-001-10-4::2.5::HTS	BRD-K51474575-001-10-4	taurine	2.5	HTS	antioxidant		neurology/psychiatry	anxiety, irritability, sleeplessness	NCCS(O)(=O)=O, NCCS(O)(=O)=O	Launched	5
BRD-K51485625-001-08-4::2.5::HTS	-0.866283144624	BRD-K51485625-001-08-4::2.5::HTS	BRD-K51485625-001-08-4	ritonavir	2.5	HTS	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Launched	5
BRD-K51486818-003-02-8::2.5::HTS	-0.0527398616603	BRD-K51486818-003-02-8::2.5::HTS	BRD-K51486818-003-02-8	lazabemide	2.5	HTS	monoamine oxidase inhibitor	MAOB			NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1	Phase 3	5
BRD-K51541829-050-01-0::2.5::HTS	-0.0329361027779	BRD-K51541829-050-01-0::2.5::HTS	BRD-K51541829-050-01-0	Ro-25-6981	2.5	HTS		GRIN2B			C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1	Preclinical	5
BRD-K51544265-001-04-2::2.5::HTS	0.0870139816298	BRD-K51544265-001-04-2::2.5::HTS	BRD-K51544265-001-04-2	cabozantinib	2.5	HTS	RET tyrosine kinase inhibitor, VEGFR inhibitor	KDR, MET	oncology	medullary thyroid cancer (MTC)	COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC	Launched	5
BRD-K51575138-001-13-2::2.5::HTS	0.449992451023	BRD-K51575138-001-13-2::2.5::HTS	BRD-K51575138-001-13-2	TPCA-1	2.5	HTS	IKK inhibitor	IKBKB			NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1	Preclinical	5
BRD-K51579475-003-02-4::2.5::HTS	-0.216947476133	BRD-K51579475-003-02-4::2.5::HTS	BRD-K51579475-003-02-4	dapoxetine	2.5	HTS	selective serotonin reuptake inhibitor (SSRI)	HTR1A, HTR1B, HTR2C, SLC6A4	urology	premature ejaculation (PE)	CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1	Launched	5
BRD-K51662849-001-05-4::2.5::HTS	-0.14759443824000001	BRD-K51662849-001-05-4::2.5::HTS	BRD-K51662849-001-05-4	ilomastat	2.5	HTS	matrix metalloprotease inhibitor	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9			CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO	Phase 3	5
BRD-K51662849-001-08-8::2.61::HTS	0.322166044571	BRD-K51662849-001-08-8::2.61::HTS	BRD-K51662849-001-08-8	ilomastat	2.61	HTS	matrix metalloprotease inhibitor	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9			CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO	Phase 3	5
BRD-K51671335-001-10-6::2.5::HTS	0.0785517360284	BRD-K51671335-001-10-6::2.5::HTS	BRD-K51671335-001-10-6	levosulpiride	2.5	HTS	dopamine receptor antagonist	CA1, CA12, CA7, DRD2, DRD3	neurology/psychiatry, gastroenterology, urology	schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	Launched	5
BRD-K51677086-001-12-0::2.5::HTS	-0.251861404742	BRD-K51677086-001-12-0::2.5::HTS	BRD-K51677086-001-12-0	erythromycin-ethylsuccinate	2.5	HTS	cytochrome P450 inhibitor, protein synthesis inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	Launched	5
BRD-K51747290-001-12-3::2.5::HTS	-0.310760259195	BRD-K51747290-001-12-3::2.5::HTS	BRD-K51747290-001-12-3	hydroxyurea	2.5	HTS	ribonucleotide reductase inhibitor	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	NC(=O)NO, NC(=O)NO, NC(=O)NO	Launched	5
BRD-K51747290-001-13-1::2.5::HTS	-0.150107897703	BRD-K51747290-001-13-1::2.5::HTS	BRD-K51747290-001-13-1	hydroxyurea	2.5	HTS	ribonucleotide reductase inhibitor	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	NC(=O)NO, NC(=O)NO, NC(=O)NO	Launched	5
BRD-K51751936-001-09-1::2.5::HTS	-0.168178274063	BRD-K51751936-001-09-1::2.5::HTS	BRD-K51751936-001-09-1	alfadolone-acetate	2.5	HTS	benzodiazepine receptor agonist				CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	Phase 2	5
BRD-K51770398-001-01-9::2.5::HTS	-0.482992601038	BRD-K51770398-001-01-9::2.5::HTS	BRD-K51770398-001-01-9	JNJ-17203212	2.5	HTS	TRPV antagonist	TRPV1			FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1	Preclinical	5
BRD-K51791723-003-01-7::2.5::HTS	-2.76174813804	BRD-K51791723-003-01-7::2.5::HTS	BRD-K51791723-003-01-7	P276-00	2.5	HTS	CDK inhibitor	CDK1, CDK4, CDK9			CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	Phase 2	5
BRD-K51885093-001-11-2::2.5::HTS	0.651613865019	BRD-K51885093-001-11-2::2.5::HTS	BRD-K51885093-001-11-2	quinolinic-acid	2.5	HTS	glutamate receptor agonist				OC(=O)c1cccnc1C(O)=O	Preclinical	5
BRD-K51911221-001-01-2::2.5::HTS	-5.59672060354	BRD-K51911221-001-01-2::2.5::HTS	BRD-K51911221-001-01-2	nemorubicin	2.5	HTS	topoisomerase inhibitor	TOP1, TOP2A			CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O	Phase 2	5
BRD-K51918615-303-02-9::2.5::HTS	-0.0031970280219999997	BRD-K51918615-303-02-9::2.5::HTS	BRD-K51918615-303-02-9	iodophenpropit	2.5	HTS	histamine receptor antagonist	HRH3, HRH4			Ic1ccc(CCNC(=N)SCCCc2c[nH]cn2)cc1	Preclinical	5
BRD-K51937257-001-01-4::2.5::HTS	-0.490687893794	BRD-K51937257-001-01-4::2.5::HTS	BRD-K51937257-001-01-4	bilastine	2.5	HTS	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1	Launched	5
BRD-K51967704-001-03-6::2.5::HTS	-5.04305927676	BRD-K51967704-001-03-6::2.5::HTS	BRD-K51967704-001-03-6	BIIB021	2.5	HTS	HSP inhibitor	HSP90AA1			COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C	Phase 2	5
BRD-K52020312-001-26-8::2.5::HTS	-0.502767853613	BRD-K52020312-001-26-8::2.5::HTS	BRD-K52020312-001-26-8	metronidazole	2.5	HTS	DNA inhibitor	CYP2C9, CYP3A4	dermatology	rosacea	Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O	Launched	5
BRD-K52075040-001-09-7::5.6::HTS	0.930752191509	BRD-K52075040-001-09-7::5.6::HTS	BRD-K52075040-001-09-7	cerulenin	5.6	HTS	fatty acid synthase inhibitor	FASN	infectious disease	fungal infection	C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O	Launched	5
BRD-K52075715-001-06-7::2.5::HTS	-0.43068630258100005	BRD-K52075715-001-06-7::2.5::HTS	BRD-K52075715-001-06-7	oxibendazole	2.5	HTS	tubulin polymerization inhibitor	TUBB, TUBB4B	infectious disease	strongyles	CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1	Launched	5
BRD-K52080565-001-09-2::2.5::HTS	-0.0688336882103	BRD-K52080565-001-09-2::2.5::HTS	BRD-K52080565-001-09-2	nandrolone	2.5	HTS	imidazoline receptor agonist	AR, CYP19A1, MAOA, MAOB	hematology	anemia	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O	Launched	5
BRD-K52113681-003-02-1::2.5::HTS	0.406736656867	BRD-K52113681-003-02-1::2.5::HTS	BRD-K52113681-003-02-1	CP-339818	2.5	HTS	potassium channel blocker	KCNA3			CCCCCN=c1ccn(Cc2ccccc2)c2ccccc12	Preclinical	5
BRD-K52172416-001-11-4::2.5::HTS	0.461578756804	BRD-K52172416-001-11-4::2.5::HTS	BRD-K52172416-001-11-4	anastrozole	2.5	HTS	aromatase inhibitor	CYP19A1	oncology	breast cancer	CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N	Launched	5
BRD-K52219182-001-02-4::2.5::HTS	0.238720271506	BRD-K52219182-001-02-4::2.5::HTS	BRD-K52219182-001-02-4	ICI-63197	2.5	HTS	phosphodiesterase inhibitor				CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O	Preclinical	5
BRD-K52233191-001-02-4::2.5::HTS	-1.84552984221	BRD-K52233191-001-02-4::2.5::HTS	BRD-K52233191-001-02-4	R547	2.5	HTS	CDK inhibitor	CDK1, CDK2, CDK4, CDK7			COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N	Phase 1	5
BRD-K52256627-300-06-6::2.5::HTS	-0.774839311989	BRD-K52256627-300-06-6::2.5::HTS	BRD-K52256627-300-06-6	chlorhexidine	2.5	HTS	membrane integrity inhibitor		dermatology, infectious disease, dental	cosmetic, skin infections, gingivitis	Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1	Launched	5
BRD-K52284881-236-02-4::2.5::HTS	0.530703880352	BRD-K52284881-236-02-4::2.5::HTS	BRD-K52284881-236-02-4	chiniofon	2.5	HTS	antiprotozoal agent		infectious disease	amebiasis	Oc1c(I)cc(c2cccnc12)S(O)(=O)=O	Launched	5
BRD-K52313696-001-12-3::2.5::HTS	-0.68129444082	BRD-K52313696-001-12-3::2.5::HTS	BRD-K52313696-001-12-3	tacedinaline	2.5	HTS	HDAC inhibitor	HDAC1			CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N	Phase 3	5
BRD-K52394958-001-02-7::2.5::HTS	0.20788983967099997	BRD-K52394958-001-02-7::2.5::HTS	BRD-K52394958-001-02-7	GR-159897	2.5	HTS	tachykinin antagonist	TAC1, TACR2			COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1	Preclinical	5
BRD-K52396582-001-06-7::2.5::HTS	0.531109768074	BRD-K52396582-001-06-7::2.5::HTS	BRD-K52396582-001-06-7	CF102	2.5	HTS	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12	Phase 2	5
BRD-K52397688-003-06-4::2.5::HTS	-0.147394857406	BRD-K52397688-003-06-4::2.5::HTS	BRD-K52397688-003-06-4	amperozide	2.5	HTS	dopamine receptor antagonist	FAAH, HTR2A	neurology/psychiatry	psychosis	CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	Launched	5
BRD-K52408781-001-02-8::2.5::HTS	0.440730077594	BRD-K52408781-001-02-8::2.5::HTS	BRD-K52408781-001-02-8	clobazam	2.5	HTS	GABA benzodiazepine site receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	seizures	CN1c2ccc(Cl)cc2N(c2ccccc2)C(=O)CC1=O	Launched	5
BRD-K52459018-001-09-1::2.5::HTS	0.237014717614	BRD-K52459018-001-09-1::2.5::HTS	BRD-K52459018-001-09-1	kainic-acid	2.5	HTS	kainate receptor agonist	GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5			CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O	Preclinical	5
BRD-K52459643-001-17-7::2.5::HTS	0.48539325291	BRD-K52459643-001-17-7::2.5::HTS	BRD-K52459643-001-17-7	alprostadil	2.5	HTS	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR	cardiology	congenital heart defects	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	Launched	5
BRD-K52487250-003-01-2::2.5::HTS	0.026190241585800002	BRD-K52487250-003-01-2::2.5::HTS	BRD-K52487250-003-01-2	ICI-215,001	2.5	HTS	adrenergic receptor agonist	ADRB3			O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1	Preclinical	5
BRD-K52512893-001-08-9::2.5::HTS	-0.09695543144819999	BRD-K52512893-001-08-9::2.5::HTS	BRD-K52512893-001-08-9	SC-19220	2.5	HTS	prostanoid receptor antagonist	PTGER1			CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12	Preclinical	5
BRD-K52523550-001-01-5::2.5::HTS	0.0192351684881	BRD-K52523550-001-01-5::2.5::HTS	BRD-K52523550-001-01-5	N-acetylcarnosine	2.5	HTS					CC(=O)NCCC(=O)N[C@@H](Cc1c[nH]cn1)C(O)=O	Phase 2	5
BRD-K52559566-001-02-9::2.5::HTS	0.084039703358	BRD-K52559566-001-02-9::2.5::HTS	BRD-K52559566-001-02-9	monosodium-alpha-luminol	2.5	HTS					Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O	Launched	5
BRD-K52618540-001-09-9::2.5::HTS	0.31300506863899996	BRD-K52618540-001-09-9::2.5::HTS	BRD-K52618540-001-09-9	inositol	2.5	HTS	insulin sensitizer	CDIPT, GBA			O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O	Launched	5
BRD-K52662033-003-21-2::2.5::HTS	-0.12489317801	BRD-K52662033-003-21-2::2.5::HTS	BRD-K52662033-003-21-2	lidocaine	2.5	HTS	histamine receptor agonist	EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C	Launched	5
BRD-K52670952-003-01-4::2.5::HTS	-0.601263990761	BRD-K52670952-003-01-4::2.5::HTS	BRD-K52670952-003-01-4	cis-urocanic-acid	2.5	HTS	serotonin receptor agonist	HTR2A			OC(=O)\C=C\c1c[nH]cn1, OC(=O)\C=C\c1c[nH]cn1	Phase 2	5
BRD-K52751261-001-06-1::2.5::HTS	0.554165068881	BRD-K52751261-001-06-1::2.5::HTS	BRD-K52751261-001-06-1	TAK-715	2.5	HTS	p38 MAPK inhibitor	MAPK14			CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1	Phase 2	5
BRD-K52756523-001-24-7::2.5::HTS	0.150515295259	BRD-K52756523-001-24-7::2.5::HTS	BRD-K52756523-001-24-7	dirithromycin	2.5	HTS	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	Launched	5
BRD-K52762805-001-01-2::2.5::HTS	-0.854203825094	BRD-K52762805-001-01-2::2.5::HTS	BRD-K52762805-001-01-2	epothilone-d	2.5	HTS	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B			C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Phase 2	5
BRD-K52818472-001-02-2::2.5::HTS	-0.263529743439	BRD-K52818472-001-02-2::2.5::HTS	BRD-K52818472-001-02-2	ivacaftor	2.5	HTS	CFTR channel potentiator	CFTR	pulmonary	cystic fibrosis	CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C	Launched	5
BRD-K52911425-001-09-8::2.5::HTS	0.12287561519000001	BRD-K52911425-001-09-8::2.5::HTS	BRD-K52911425-001-09-8	GDC-0941	2.5	HTS	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1	Phase 2	5
BRD-K52959329-238-01-9::2.5::HTS	0.257098910912	BRD-K52959329-238-01-9::2.5::HTS	BRD-K52959329-238-01-9	mitiglinide	2.5	HTS	insulin secretagogue	ABCC8, KCNJ10, PPARG	endocrinology	diabetes mellitus	OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1	Launched	5
BRD-K52989797-003-26-4::2.5::HTS	-0.228169997155	BRD-K52989797-003-26-4::2.5::HTS	BRD-K52989797-003-26-4	clomipramine	2.5	HTS	serotonin transporter (SERT) inhibitor	GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	Launched	5
BRD-K53061490-003-13-9::2.5::HTS	0.0030828053997699997	BRD-K53061490-003-13-9::2.5::HTS	BRD-K53061490-003-13-9	ozagrel	2.5	HTS	thromboxane synthase inhibitor	TBXAS1	neurology/psychiatry	stroke	OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1	Launched	5
BRD-K53083666-001-01-0::2.5::HTS	0.42656639550700004	BRD-K53083666-001-01-0::2.5::HTS	BRD-K53083666-001-01-0	1,5-dicaffeoylquinic-acid	2.5	HTS					O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O	Phase 1	5
BRD-K53097745-001-01-5::2.5::HTS	0.0565514108991	BRD-K53097745-001-01-5::2.5::HTS	BRD-K53097745-001-01-5	pterostilbene	2.5	HTS	cyclooxygenase inhibitor, PPAR receptor agonist	PTGS2			COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1	Phase 2/Phase 3	5
BRD-K53123955-001-10-5::2.5::HTS	-0.0627567847858	BRD-K53123955-001-10-5::2.5::HTS	BRD-K53123955-001-10-5	niridazole	2.5	HTS	phosphofructokinase inhibitor		infectious disease	schistosomiasis	[O-][N+](=O)c1cnc(s1)N1CCNC1=O	Launched	5
BRD-K53124401-001-03-8::0.03::HTS	0.022969728262700002	BRD-K53124401-001-03-8::0.03::HTS	BRD-K53124401-001-03-8	LTB4	0.03	HTS	leukocyte activator	LTB4R, LTB4R2			CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O	Phase 2	1
BRD-K53153417-001-10-4::2.5::HTS	0.187930784174	BRD-K53153417-001-10-4::2.5::HTS	BRD-K53153417-001-10-4	butylated-hydroxytoluene	2.5	HTS	carbonic anhydrase inhibitor	CA2			Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Phase 1	5
BRD-K53205568-001-02-6::2.5::HTS	0.718581554353	BRD-K53205568-001-02-6::2.5::HTS	BRD-K53205568-001-02-6	afalanine	2.5	HTS	dopamine receptor agonist	DRD2			CC(=O)N[C@@H](Cc1ccccc1)C(O)=O	Phase 3	5
BRD-K53220666-001-02-6::2.5::HTS	-0.152192391453	BRD-K53220666-001-02-6::2.5::HTS	BRD-K53220666-001-02-6	trimetozine	2.5	HTS	sedative		neurology/psychiatry	sedative	COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1	Launched	5
BRD-K53234107-001-01-6::2.5::HTS	-0.358295546391	BRD-K53234107-001-01-6::2.5::HTS	BRD-K53234107-001-01-6	IWP-L6	2.5	HTS	porcupine inhibitor	PORCN			O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1	Preclinical	5
BRD-K53263234-001-05-2::2.5::HTS	-0.46721886014499997	BRD-K53263234-001-05-2::2.5::HTS	BRD-K53263234-001-05-2	CITCO	2.5	HTS	constitutive androstane receptor (CAR) agonist	NR1I3			Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-K53318339-001-24-9::2.5::HTS	0.041345155799800005	BRD-K53318339-001-24-9::2.5::HTS	BRD-K53318339-001-24-9	vinpocetine	2.5	HTS	phosphodiesterase inhibitor, sodium channel blocker	PDE1A, PDE1C			CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41	Launched	5
BRD-K53397409-001-12-3::2.5::HTS	0.07060767015569999	BRD-K53397409-001-12-3::2.5::HTS	BRD-K53397409-001-12-3	benzoic-acid	2.5	HTS	food preservative	DAO, HRSP12, PRDX5, RAB9A	infectious disease	tinea pedis	OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1	Launched	5
BRD-K53414658-001-08-2::2.5::HTS	-0.5530281125500001	BRD-K53414658-001-08-2::2.5::HTS	BRD-K53414658-001-08-2	tivozanib	2.5	HTS	VEGFR inhibitor	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB			COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC	Phase 3	5
BRD-K53417444-003-03-1::2.5::HTS	-2.6793569937	BRD-K53417444-003-03-1::2.5::HTS	BRD-K53417444-003-03-1	OTS167	2.5	HTS	maternal embryonic leucine zipper kinase inhibitor	MELK			CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O	Phase 1	5
BRD-K53448858-001-07-0::2.5::HTS	-0.5706679706050001	BRD-K53448858-001-07-0::2.5::HTS	BRD-K53448858-001-07-0	acadesine	2.5	HTS	AMPK activator				NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N	Phase 3	5
BRD-K53508936-001-01-0::2.5::HTS	-0.300574763207	BRD-K53508936-001-01-0::2.5::HTS	BRD-K53508936-001-01-0	CTS-1027	2.5	HTS	metalloproteinase inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1	Phase 2	5
BRD-K53517854-051-01-4::2.5::HTS	-0.410268742329	BRD-K53517854-051-01-4::2.5::HTS	BRD-K53517854-051-01-4	fluvoxamine	2.5	HTS	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN, COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN, COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN	Launched	5
BRD-K53523901-001-04-4::2.5::HTS	-0.156335390863	BRD-K53523901-001-04-4::2.5::HTS	BRD-K53523901-001-04-4	arctigenin	2.5	HTS	MEK inhibitor	CHUK, MAP2K1			COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O	Preclinical	5
BRD-K53532120-003-09-5::2.5::HTS	0.00011569803912700001	BRD-K53532120-003-09-5::2.5::HTS	BRD-K53532120-003-09-5	U-50488-(-)	2.5	HTS	opioid receptor agonist	OPRK1			CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-K53532120-003-11-1::2.5::HTS	0.07384362529560001	BRD-K53532120-003-11-1::2.5::HTS	BRD-K53532120-003-11-1	U-50488-(-)	2.5	HTS	opioid receptor agonist	OPRK1			CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-K53561341-001-07-5::2.5::HTS	-1.0784060464799998	BRD-K53561341-001-07-5::2.5::HTS	BRD-K53561341-001-07-5	aurora-a-inhibitor-i	2.5	HTS	Aurora kinase inhibitor	AURKA			CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1	Preclinical	5
BRD-K53581288-001-02-9::2.5::HTS	-0.864077277189	BRD-K53581288-001-02-9::2.5::HTS	BRD-K53581288-001-02-9	baricitinib	2.5	HTS	JAK inhibitor	JAK1, JAK2			CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	Phase 3	5
BRD-K53665955-001-03-0::2.5::HTS	-0.6009109661850001	BRD-K53665955-001-03-0::2.5::HTS	BRD-K53665955-001-03-0	MK-5108	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB, AURKC			OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F	Phase 1	5
BRD-K53720352-001-03-2::2.5::HTS	-0.03518190183330001	BRD-K53720352-001-03-2::2.5::HTS	BRD-K53720352-001-03-2	cinalukast	2.5	HTS	leukotriene receptor antagonist	CYSLTR1			CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O	Phase 2	5
BRD-K53734668-003-02-0::2.66::HTS	0.848906085711	BRD-K53734668-003-02-0::2.66::HTS	BRD-K53734668-003-02-0	PRT062607	2.66	HTS	syk inhibitor	FGR, MAP3K9, SYK			N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	Phase 2	5
BRD-K53734668-003-04-6::2.5::HTS	0.507746331611	BRD-K53734668-003-04-6::2.5::HTS	BRD-K53734668-003-04-6	PRT062607	2.5	HTS	syk inhibitor	FGR, MAP3K9, SYK			N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	Phase 2	5
BRD-K53737926-003-27-8::2.5::HTS	0.496032541716	BRD-K53737926-003-27-8::2.5::HTS	BRD-K53737926-003-27-8	amitriptyline	2.5	HTS	norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin-norepinephrine reuptake inhibitor (SNRI)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	CN(C)CCC=C1c2ccccc2CCc2ccccc12, CN(C)CCC=C1c2ccccc2CCc2ccccc12	Launched	5
BRD-K53765467-001-02-1::2.5::HTS	-0.288183804993	BRD-K53765467-001-02-1::2.5::HTS	BRD-K53765467-001-02-1	empagliflozin	2.5	HTS	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1	Launched	5
BRD-K53814070-310-01-3::2.5::HTS	0.15500263768	BRD-K53814070-310-01-3::2.5::HTS	BRD-K53814070-310-01-3	ripasudil	2.5	HTS	rho associated kinase inhibitor	ROCK1, ROCK2	ophthalmology	glaucoma, ocular hypertension	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12	Launched	5
BRD-K53852914-001-01-8::2.5::HTS	0.42698310346	BRD-K53852914-001-01-8::2.5::HTS	BRD-K53852914-001-01-8	menbutone	2.5	HTS			gastroenterology	bile stimulation	COc1ccc(C(=O)CCC(O)=O)c2ccccc12	Launched	5
BRD-K53857191-001-22-7::2.5::HTS	-0.18563418645100002	BRD-K53857191-001-22-7::2.5::HTS	BRD-K53857191-001-22-7	risperidone	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder, irritability	Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	Launched	5
BRD-K53913732-001-05-9::2.5::HTS	-0.0979593060867	BRD-K53913732-001-05-9::2.5::HTS	BRD-K53913732-001-05-9	SB-408124	2.5	HTS	orexin receptor antagonist	HCRTR1, HCRTR2			CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	Preclinical	5
BRD-K53963539-004-02-0::2.5::HTS	0.0320238824252	BRD-K53963539-004-02-0::2.5::HTS	BRD-K53963539-004-02-0	vortioxetine	2.5	HTS	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4	neurology/psychiatry	depression	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	Launched	5
BRD-K53972329-001-07-0::2.5::HTS	-0.0448962170605	BRD-K53972329-001-07-0::2.5::HTS	BRD-K53972329-001-07-0	ruxolitinib	2.5	HTS	JAK inhibitor	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	Launched	5
BRD-K53979406-003-02-8::2.5::HTS	-0.140364747362	BRD-K53979406-003-02-8::2.5::HTS	BRD-K53979406-003-02-8	ALX-5407	2.5	HTS	Glycine transporter 1 inhibitor	SLC6A9			CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O	Phase 1	5
BRD-K54006094-051-01-7::2.5::HTS	0.355254408179	BRD-K54006094-051-01-7::2.5::HTS	BRD-K54006094-051-01-7	formoterol	2.5	HTS	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	Launched	5
BRD-K54028654-001-02-6::2.5::HTS	0.036195896472400006	BRD-K54028654-001-02-6::2.5::HTS	BRD-K54028654-001-02-6	cabaletta	2.5	HTS	pharmacological chaperone				OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	5
BRD-K54057105-001-01-2::2.5::HTS	-0.392645599209	BRD-K54057105-001-01-2::2.5::HTS	BRD-K54057105-001-01-2	isobutyramide	2.5	HTS	gene expression stimulant	HBE1, HBG1			CC(C)C(N)=O	Phase 2	5
BRD-K54094468-003-11-1::2.5::HTS	-0.168166006624	BRD-K54094468-003-11-1::2.5::HTS	BRD-K54094468-003-11-1	remoxipride	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR2A, SIGMAR1			CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC	Withdrawn	5
BRD-K54095730-001-03-1::2.5::HTS	-1.44519521211	BRD-K54095730-001-03-1::2.5::HTS	BRD-K54095730-001-03-1	CMPD-1	2.5	HTS	p38 MAPK inhibitor	GNRHR, MAPK14			Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1	Preclinical	5
BRD-K54142781-003-11-8::2.5::HTS	0.22160131943599998	BRD-K54142781-003-11-8::2.5::HTS	BRD-K54142781-003-11-8	cirazoline	2.5	HTS	adrenergic receptor agonist	ADRA1A			C(Oc1ccccc1C1CC1)C1=NCCN1, C(Oc1ccccc1C1CC1)C1=NCCN1	Preclinical	5
BRD-K54187111-001-08-4::2.51::HTS	0.365281981726	BRD-K54187111-001-08-4::2.51::HTS	BRD-K54187111-001-08-4	dichlorisone-acetate	2.51	HTS					CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C	Phase 2	5
BRD-K54187111-001-09-2::2.5::HTS	-0.20251910720600003	BRD-K54187111-001-09-2::2.5::HTS	BRD-K54187111-001-09-2	dichlorisone-acetate	2.5	HTS					CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C	Phase 2	5
BRD-K54247840-004-01-3::2.5::HTS	-5.74021055852	BRD-K54247840-004-01-3::2.5::HTS	BRD-K54247840-004-01-3	halofuginone	2.5	HTS	collagenase inhibitor	COL1A1, MMP2	rheumatology	scleroderma	O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O	Launched	5
BRD-K54256913-001-08-7::2.5::HTS	-1.98460031085	BRD-K54256913-001-08-7::2.5::HTS	BRD-K54256913-001-08-7	MK-1775	2.5	HTS	WEE1 kinase inhibitor	WEE1			CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1	Phase 2	5
BRD-K54262262-001-09-0::2.5::HTS	0.185636212912	BRD-K54262262-001-09-0::2.5::HTS	BRD-K54262262-001-09-0	monobenzone	2.5	HTS	melanin inhibitor	TYR	dermatology	skin depigmentation	Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1	Launched	5
BRD-K54314721-001-10-2::2.5::HTS	0.5209637768	BRD-K54314721-001-10-2::2.5::HTS	BRD-K54314721-001-10-2	zolmitriptan	2.5	HTS	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12	Launched	5
BRD-K54316499-046-04-5::2.5::HTS	0.15496826305	BRD-K54316499-046-04-5::2.5::HTS	BRD-K54316499-046-04-5	tolterodine	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	Launched	5
BRD-K54330070-001-15-4::2.5::HTS	0.190222653796	BRD-K54330070-001-15-4::2.5::HTS	BRD-K54330070-001-15-4	SB-202190	2.5	HTS	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1	Preclinical	5
BRD-K54395039-001-01-7::2.5::HTS	0.116556741788	BRD-K54395039-001-01-7::2.5::HTS	BRD-K54395039-001-01-7	PR-619	2.5	HTS	DUB inhibitor				Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N	Preclinical	5
BRD-K54416256-001-19-9::2.5::HTS	0.057224176201999995	BRD-K54416256-001-19-9::2.5::HTS	BRD-K54416256-001-19-9	methimazole	2.5	HTS	antithyroid agent	TPO	endocrinology	hyperthyroidism	Cn1cc[nH]c1=S, Cn1cc[nH]c1=S	Launched	5
BRD-K54472332-001-03-4::2.5::HTS	-0.10592069949100001	BRD-K54472332-001-03-4::2.5::HTS	BRD-K54472332-001-03-4	elvitegravir	2.5	HTS	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C	Launched	5
BRD-K54496168-003-01-2::2.5::HTS	0.592932802801	BRD-K54496168-003-01-2::2.5::HTS	BRD-K54496168-003-01-2	propacetamol	2.5	HTS	cyclooxygenase inhibitor	PTGS2	endocrinology, neurology/psychiatry	fever, pain relief	CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1	Launched	5
BRD-K54520417-001-01-2::2.5::HTS	-0.199098252907	BRD-K54520417-001-01-2::2.5::HTS	BRD-K54520417-001-01-2	LXR-623	2.5	HTS	LXR agonist	AR, NR1H2, NR1H3, NR1I2, NR3C1			Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F	Phase 1	5
BRD-K54521836-001-02-1::2.5::HTS	-0.005404727003609999	BRD-K54521836-001-02-1::2.5::HTS	BRD-K54521836-001-02-1	thiodiglycol	2.5	HTS					OCCSCCO	Preclinical	5
BRD-K54529596-001-26-3::2.5::HTS	-0.18369864360100002	BRD-K54529596-001-26-3::2.5::HTS	BRD-K54529596-001-26-3	captopril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE, LTA4H, MMP2, MMP9	cardiology, endocrinology, nephrology	hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	Launched	5
BRD-K54606188-001-13-1::2.5::HTS	0.513763667239	BRD-K54606188-001-13-1::2.5::HTS	BRD-K54606188-001-13-1	JQ1-(+)	2.5	HTS	bromodomain inhibitor	BRD4, BRDT			Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1	Preclinical	5
BRD-K54634444-001-05-9::2.5::HTS	-0.0685720536937	BRD-K54634444-001-05-9::2.5::HTS	BRD-K54634444-001-05-9	artesunate	2.5	HTS	DNA synthesis inhibitor		infectious disease	malaria	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched	5
BRD-K54640016-001-04-7::2.5::HTS	-0.102351522822	BRD-K54640016-001-04-7::2.5::HTS	BRD-K54640016-001-04-7	WAY-362450	2.5	HTS	FXR agonist	NR1H4			CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1	Phase 1	5
BRD-K54665485-001-07-9::2.5::HTS	0.279816641702	BRD-K54665485-001-07-9::2.5::HTS	BRD-K54665485-001-07-9	R-59022	2.5	HTS	diacylglycerol kinase inhibitor, protein kinase inhibitor	DGKA			Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1	Preclinical	5
BRD-K54708045-001-02-1::2.5::HTS	0.231224797942	BRD-K54708045-001-02-1::2.5::HTS	BRD-K54708045-001-02-1	nTZDpa	2.5	HTS	PPAR receptor agonist	PPARG			OC(=O)c1n(Cc2ccc(Cl)cc2)c2ccc(Cl)cc2c1Sc1ccccc1, OC(=O)c1n(Cc2ccc(Cl)cc2)c2ccc(Cl)cc2c1Sc1ccccc1	Preclinical	5
BRD-K54759182-003-08-0::2.5::HTS	0.259405037138	BRD-K54759182-003-08-0::2.5::HTS	BRD-K54759182-003-08-0	dosulepin	2.5	HTS	norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression	CN(C)CC\C=C1/c2ccccc2CSc2ccccc12	Launched	5
BRD-K54770957-001-04-3::2.5::HTS	0.38422853146799996	BRD-K54770957-001-04-3::2.5::HTS	BRD-K54770957-001-04-3	etoricoxib	2.5	HTS	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis	Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O	Launched	5
BRD-K54790157-001-15-5::2.5::HTS	0.303559714853	BRD-K54790157-001-15-5::2.5::HTS	BRD-K54790157-001-15-5	trioxsalen	2.5	HTS	DNA synthesis inhibitor		dermatology	vitiligo, eczema	Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1	Launched	5
BRD-K54824716-001-04-0::2.5::HTS	0.599261859093	BRD-K54824716-001-04-0::2.5::HTS	BRD-K54824716-001-04-0	procodazole	2.5	HTS	immunostimulant				OC(=O)CCc1nc2ccccc2[nH]1, OC(=O)CCc1nc2ccccc2[nH]1	Preclinical	5
BRD-K54838207-001-02-0::2.5::HTS	-0.0433081004795	BRD-K54838207-001-02-0::2.5::HTS	BRD-K54838207-001-02-0	fudosteine	2.5	HTS	mucolytic agent		pulmonary	chest congestion	N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O	Launched	5
BRD-K54838207-001-03-8::2.5::HTS	-0.405528151444	BRD-K54838207-001-03-8::2.5::HTS	BRD-K54838207-001-03-8	fudosteine	2.5	HTS	mucolytic agent		pulmonary	chest congestion	N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O	Launched	5
BRD-K54847683-001-03-2::2.5::HTS	0.12976934535700002	BRD-K54847683-001-03-2::2.5::HTS	BRD-K54847683-001-03-2	equol	2.5	HTS	estrogen receptor agonist	ESR1, ESR2			Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1	Launched	5
BRD-K54847683-001-04-0::2.5::HTS	0.10439918017000001	BRD-K54847683-001-04-0::2.5::HTS	BRD-K54847683-001-04-0	equol	2.5	HTS	estrogen receptor agonist	ESR1, ESR2			Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1	Launched	5
BRD-K54936858-001-01-6::2.5::HTS	-0.252718023768	BRD-K54936858-001-01-6::2.5::HTS	BRD-K54936858-001-01-6	DMP-777	2.5	HTS	elastase inhibitor	MPO			CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1	Phase 2	5
BRD-K54997624-001-06-0::2.5::HTS	-0.36888562153000004	BRD-K54997624-001-06-0::2.5::HTS	BRD-K54997624-001-06-0	alpelisib	2.5	HTS	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F	Phase 3	5
BRD-K55013654-003-02-3::2.5::HTS	-0.32878259313999997	BRD-K55013654-003-02-3::2.5::HTS	BRD-K55013654-003-02-3	lorcaserin	2.5	HTS	serotonin receptor agonist	HTR2A, HTR2B, HTR2C	endocrinology	obesity	C[C@H]1CNCCc2ccc(Cl)cc12	Launched	5
BRD-K55034111-066-17-1::2.5::HTS	0.32034860327500003	BRD-K55034111-066-17-1::2.5::HTS	BRD-K55034111-066-17-1	pefloxacin	2.5	HTS	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	gastrointestinal infections, urethritis, gonorrhea, urinary tract infections	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1	Launched	5
BRD-K55044200-001-14-6::2.5::HTS	-0.373300757467	BRD-K55044200-001-14-6::2.5::HTS	BRD-K55044200-001-14-6	amoxicillin	2.5	HTS	penicillin binding protein inhibitor	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	Launched	5
BRD-K55044200-001-15-3::2.5::HTS	-0.7459031681739999	BRD-K55044200-001-15-3::2.5::HTS	BRD-K55044200-001-15-3	amoxicillin	2.5	HTS	penicillin binding protein inhibitor	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	Launched	5
BRD-K55055802-001-10-2::2.5::HTS	-0.046726145261399996	BRD-K55055802-001-10-2::2.5::HTS	BRD-K55055802-001-10-2	etomidate	2.5	HTS	GABA receptor modulator	ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	general anaesthetic	CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1	Launched	5
BRD-K55127134-300-11-2::2.5::HTS	-0.21322881964200002	BRD-K55127134-300-11-2::2.5::HTS	BRD-K55127134-300-11-2	fluphenazine	2.5	HTS	dopamine receptor antagonist	CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	5
BRD-K55160477-001-04-7::2.5::HTS	0.683254140997	BRD-K55160477-001-04-7::2.5::HTS	BRD-K55160477-001-04-7	benzo[d]thiazole-2(3h)-thione	2.5	HTS					Sc1nc2ccccc2s1	Phase 1	5
BRD-K55166090-001-09-0::2.5::HTS	0.259223305644	BRD-K55166090-001-09-0::2.5::HTS	BRD-K55166090-001-09-0	efloxate	2.5	HTS	vasodilator				CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1	Preclinical	5
BRD-K55187425-236-05-2::2.5::HTS	-1.40711581102	BRD-K55187425-236-05-2::2.5::HTS	BRD-K55187425-236-05-2	rigosertib	2.5	HTS	cell cycle inhibitor, PLK inhibitor	PLK1			COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1	Phase 3	5
BRD-K55191674-237-18-3::2.5::HTS	-0.402109601003	BRD-K55191674-237-18-3::2.5::HTS	BRD-K55191674-237-18-3	benzylpenicillin	2.5	HTS	penicillin binding protein inhibitor		infectious disease	celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia	CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched	5
BRD-K55250441-001-13-0::2.5::HTS	-0.7610640793510001	BRD-K55250441-001-13-0::2.5::HTS	BRD-K55250441-001-13-0	sulfadoxine	2.5	HTS	dihydropteroate synthase inhibitor		infectious disease	malaria	COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC	Launched	5
BRD-K55305701-001-01-2::2.5::HTS	-1.78223161662	BRD-K55305701-001-01-2::2.5::HTS	BRD-K55305701-001-01-2	SC-144	2.5	HTS	P glycoprotein inhibitor				Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	Preclinical	5
BRD-K55344148-003-02-6::2.5::HTS	0.222261320242	BRD-K55344148-003-02-6::2.5::HTS	BRD-K55344148-003-02-6	BU-224	2.5	HTS	imidazoline receptor ligand	MAOA, MAOB			C1CN=C(N1)c1ccc2ccccc2n1	Preclinical	5
BRD-K55424922-003-02-8::2.5::HTS	-0.0334708426785	BRD-K55424922-003-02-8::2.5::HTS	BRD-K55424922-003-02-8	anpirtoline	2.5	HTS	serotonin receptor agonist	HTR1B			Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1	Phase 1	5
BRD-K55462201-001-07-3::2.5::HTS	-0.1306811083	BRD-K55462201-001-07-3::2.5::HTS	BRD-K55462201-001-07-3	AM-404	2.5	HTS	cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist	CNR1, CNR2, FAAH, TRPV1			CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1	Preclinical	5
BRD-K55468218-001-26-1::2.5::HTS	0.234971531533	BRD-K55468218-001-26-1::2.5::HTS	BRD-K55468218-001-26-1	spiperone	2.5	HTS	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1	Launched	5
BRD-K55512740-001-01-6::2.5::HTS	-0.15602857290799999	BRD-K55512740-001-01-6::2.5::HTS	BRD-K55512740-001-01-6	MK-8033	2.5	HTS	c-Met inhibitor	MET			Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1	Phase 1	5
BRD-K55567017-001-12-3::2.5::HTS	0.34814531263000004	BRD-K55567017-001-12-3::2.5::HTS	BRD-K55567017-001-12-3	formononetin	2.5	HTS	alcohol dehydrogenase inhibitor	ADH1C, SLC5A2			COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	Preclinical	5
BRD-K55675242-001-03-0::2.5::HTS	-0.32377544786699997	BRD-K55675242-001-03-0::2.5::HTS	BRD-K55675242-001-03-0	torcetrapib	2.5	HTS	cholesteryl ester transfer protein inhibitor	CETP			CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F	Phase 3	5
BRD-K55677650-003-02-9::2.5::HTS	0.142681075044	BRD-K55677650-003-02-9::2.5::HTS	BRD-K55677650-003-02-9	CO-101244	2.5	HTS	glutamate receptor antagonist	GRIN2B			Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1	Preclinical	5
BRD-K55703048-001-07-7::2.5::HTS	-0.29325524243900003	BRD-K55703048-001-07-7::2.5::HTS	BRD-K55703048-001-07-7	latrepirdine	2.5	HTS	glutamate receptor antagonist	HRH1, HTR6			CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1	Phase 3	5
BRD-K55705469-065-01-0::2.5::HTS	-0.232673718072	BRD-K55705469-065-01-0::2.5::HTS	BRD-K55705469-065-01-0	penbutolol	2.5	HTS	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR1B	cardiology	hypertension	CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1	Launched	5
BRD-K55748775-001-02-2::2.5::HTS	0.23667973487500002	BRD-K55748775-001-02-2::2.5::HTS	BRD-K55748775-001-02-2	SCH-28080	2.5	HTS	ATPase inhibitor	ATP4A			Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	Phase 1	5
BRD-K55773932-001-02-0::2.5::HTS	0.347781533622	BRD-K55773932-001-02-0::2.5::HTS	BRD-K55773932-001-02-0	BMS-806	2.5	HTS	HIV attachment inhibitor				COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12	Phase 1	5
BRD-K55781385-001-01-7::2.5::HTS	-0.264756431028	BRD-K55781385-001-01-7::2.5::HTS	BRD-K55781385-001-01-7	BMS-927711	2.5	HTS	calcitonin antagonist	CALCA			N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F	Phase 2	5
BRD-K55847762-304-01-7::2.5::HTS	-0.374762898766	BRD-K55847762-304-01-7::2.5::HTS	BRD-K55847762-304-01-7	lobenzarit	2.5	HTS	immunosuppressant		rheumatology	rheumatoid arthritis	OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O	Launched	5
BRD-K55892330-001-01-8::2.5::HTS	-0.000349759568805	BRD-K55892330-001-01-8::2.5::HTS	BRD-K55892330-001-01-8	sorbic-acid	2.5	HTS					CC=CC=CC(O)=O	Preclinical	5
BRD-K55930204-236-24-3::2.5::HTS	-0.00247451289157	BRD-K55930204-236-24-3::2.5::HTS	BRD-K55930204-236-24-3	phenytoin	2.5	HTS	hydantoin antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1	Launched	5
BRD-K55966568-001-05-4::2.5::HTS	0.09872943320969998	BRD-K55966568-001-05-4::2.5::HTS	BRD-K55966568-001-05-4	orantinib	2.5	HTS	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB			Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O	Phase 3	5
BRD-K56032964-001-02-1::2.5::HTS	-1.69081711527	BRD-K56032964-001-02-1::2.5::HTS	BRD-K56032964-001-02-1	AP26113	2.5	HTS	ALK tyrosine kinase receptor inhibitor	ALK, EGFR			COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C	Phase 2	5
BRD-K56033645-001-07-5::2.5::HTS	-0.234331811954	BRD-K56033645-001-07-5::2.5::HTS	BRD-K56033645-001-07-5	5-methylhydantoin-(L)	2.5	HTS					C[C@@H]1NC(=O)NC1=O	Preclinical	5
BRD-K56047318-001-06-3::2.5::HTS	0.189317381082	BRD-K56047318-001-06-3::2.5::HTS	BRD-K56047318-001-06-3	RHC-80267	2.5	HTS	triacylglycerol lipase inhibitor	DAGLA, DAGLB			O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1	Preclinical	5
BRD-K56077740-001-09-2::2.5::HTS	-0.284150160468	BRD-K56077740-001-09-2::2.5::HTS	BRD-K56077740-001-09-2	MMPX	2.5	HTS	phosphodiesterase inhibitor				COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1	Preclinical	5
BRD-K56104152-008-04-1::2.5::HTS	-0.08801257166760001	BRD-K56104152-008-04-1::2.5::HTS	BRD-K56104152-008-04-1	oxiconazole	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Launched	5
BRD-K56115039-003-02-1::2.5::HTS	0.274233811874	BRD-K56115039-003-02-1::2.5::HTS	BRD-K56115039-003-02-1	BU226	2.5	HTS	imidazoline receptor ligand				C1CN=C(N1)c1cc2ccccc2cn1	Preclinical	5
BRD-K56156805-001-09-6::2.5::HTS	0.17152803777199999	BRD-K56156805-001-09-6::2.5::HTS	BRD-K56156805-001-09-6	benznidazole	2.5	HTS	DNA synthesis inhibitor		infectious disease	Chagas disease	[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1	Launched	5
BRD-K56195681-001-01-0::2.5::HTS	0.22545724998799999	BRD-K56195681-001-01-0::2.5::HTS	BRD-K56195681-001-01-0	losmapimod	2.5	HTS	p38 MAPK inhibitor	MAPK14			Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1	Phase 3	5
BRD-K56277358-001-07-5::2.5::HTS	1.23310051943	BRD-K56277358-001-07-5::2.5::HTS	BRD-K56277358-001-07-5	MGCD-265	2.5	HTS	VEGFR inhibitor	AXL, MET			Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1	Preclinical	5
BRD-K56291712-001-01-0::2.5::HTS	-0.15557150356899999	BRD-K56291712-001-01-0::2.5::HTS	BRD-K56291712-001-01-0	voxtalisib	2.5	HTS	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O	Phase 2	5
BRD-K56301217-001-07-4::2.5::HTS	0.107582736223	BRD-K56301217-001-07-4::2.5::HTS	BRD-K56301217-001-07-4	ABT-737	2.5	HTS	BCL inhibitor	BCL2, BCL2L1, BCL2L2			CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1	Phase 1/Phase 2	5
BRD-K56334280-001-05-1::2.5::HTS	-1.22552263773	BRD-K56334280-001-05-1::2.5::HTS	BRD-K56334280-001-05-1	amonafide	2.5	HTS	topoisomerase inhibitor	TOP2A, TOP2B			CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23	Phase 3	5
BRD-K56343971-001-10-6::2.5::HTS	0.328908062274	BRD-K56343971-001-10-6::2.5::HTS	BRD-K56343971-001-10-6	vemurafenib	2.5	HTS	RAF inhibitor	BRAF, RAF1	oncology	melanoma	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F	Launched	5
BRD-K56405753-001-02-4::2.5::HTS	0.249270267099	BRD-K56405753-001-02-4::2.5::HTS	BRD-K56405753-001-02-4	MK-2461	2.5	HTS	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB			CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1	Phase 1/Phase 2	5
BRD-K56483981-342-06-4::2.5::HTS	0.254998738876	BRD-K56483981-342-06-4::2.5::HTS	BRD-K56483981-342-06-4	chicago-sky-blue-6b	2.5	HTS	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	MIF			COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1	Preclinical	5
BRD-K56515112-001-21-6::2.5::HTS	0.830913183759	BRD-K56515112-001-21-6::2.5::HTS	BRD-K56515112-001-21-6	medrysone	2.5	HTS	glucocorticoid receptor agonist	NR3C1	ophthalmology	conjunctivitis, episcleritis	C[C@H]1CC2C3CCC(C(C)=O)C3(C)CC(O)C2C2(C)CCC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12	Launched	5
BRD-K56542719-065-01-4::2.5::HTS	-0.0402464961819	BRD-K56542719-065-01-4::2.5::HTS	BRD-K56542719-065-01-4	cefpirome	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	5
BRD-K56543881-001-02-7::2.5::HTS	-0.3263076754	BRD-K56543881-001-02-7::2.5::HTS	BRD-K56543881-001-02-7	ADX-47273	2.5	HTS	glutamate receptor modulator	GRM5			Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1	Preclinical	5
BRD-K56558538-003-11-9::2.5::HTS	-0.858572002653	BRD-K56558538-003-11-9::2.5::HTS	BRD-K56558538-003-11-9	ambroxol	2.5	HTS	sodium channel blocker	CYP3A4	pulmonary	bronchitis	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1	Launched	5
BRD-K56596464-004-10-7::2.5::HTS	-0.023954709280400003	BRD-K56596464-004-10-7::2.5::HTS	BRD-K56596464-004-10-7	QX-314	2.5	HTS	sodium channel blocker	MAPK14, TGFBR1			CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C	Preclinical	5
BRD-K56614220-001-19-0::2.5::HTS	0.810823254703	BRD-K56614220-001-19-0::2.5::HTS	BRD-K56614220-001-19-0	clofazimine	2.5	HTS	GK0582 inhibitor		infectious disease	leprosy	CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1	Launched	5
BRD-K56691760-001-01-2::2.5::HTS	0.08129999769730001	BRD-K56691760-001-01-2::2.5::HTS	BRD-K56691760-001-01-2	pikamilone	2.5	HTS					OC(=O)CCCNC(=O)c1cccnc1	Phase 1	5
BRD-K56707426-001-02-0::2.5::HTS	-0.563986780338	BRD-K56707426-001-02-0::2.5::HTS	BRD-K56707426-001-02-0	nitarsone	2.5	HTS			dermatology	blackhead disease	O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O	Launched	5
BRD-K56735750-001-06-8::2.5::HTS	-0.0876298560806	BRD-K56735750-001-06-8::2.5::HTS	BRD-K56735750-001-06-8	carbadox	2.5	HTS	other antibiotic		infectious disease, gastroenterology	dysentry, enteritis	COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]	Launched	5
BRD-K56751279-300-01-4::2.5::HTS	0.0108160267916	BRD-K56751279-300-01-4::2.5::HTS	BRD-K56751279-300-01-4	Y-39983	2.5	HTS	rho associated kinase inhibitor	ROCK1, ROCK2			C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12	Phase 2	5
BRD-K56810756-001-03-0::2.5::HTS	-0.30676502875399997	BRD-K56810756-001-03-0::2.5::HTS	BRD-K56810756-001-03-0	fomepizole	2.5	HTS	alcohol dehydrogenase inhibitor	ADH1A, ADH1B, ADH1C, AKR1A1, CAT	critical care	poison antidote	Cc1cn[nH]c1, Cc1cn[nH]c1	Launched	5
BRD-K56851771-001-06-8::2.5::HTS	-0.411489391054	BRD-K56851771-001-06-8::2.5::HTS	BRD-K56851771-001-06-8	enzalutamide	2.5	HTS	androgen receptor antagonist	AR	oncology	prostate cancer	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F	Launched	5
BRD-K56908511-001-01-2::2.5::HTS	0.145301714951	BRD-K56908511-001-01-2::2.5::HTS	BRD-K56908511-001-01-2	fluroxene	2.5	HTS	local anesthetic				FC(F)(F)COC=C, FC(F)(F)COC=C	Preclinical	5
BRD-K56940463-001-13-8::2.5::HTS	-0.229769390197	BRD-K56940463-001-13-8::2.5::HTS	BRD-K56940463-001-13-8	oxethazaine	2.5	HTS	local anesthetic		neurology/psychiatry	local anesthetic	CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1	Launched	5
BRD-K56940914-001-04-2::2.5::HTS	0.35407937169200004	BRD-K56940914-001-04-2::2.5::HTS	BRD-K56940914-001-04-2	cresol	2.5	HTS					Cc1ccc(O)cc1	Launched	5
BRD-K56957086-001-06-3::2.5::HTS	-5.595614168250001	BRD-K56957086-001-06-3::2.5::HTS	BRD-K56957086-001-06-3	dacinostat	2.5	HTS	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1	Phase 1	5
BRD-K57033106-003-19-7::2.5::HTS	0.330129684499	BRD-K57033106-003-19-7::2.5::HTS	BRD-K57033106-003-19-7	tripelennamine	2.5	HTS	histamine receptor antagonist	HRH1	pulmonary, allergy	asthma, allergic rhinitis, urticaria	CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1	Launched	5
BRD-K57041787-001-02-6::2.5::HTS	-0.386913760698	BRD-K57041787-001-02-6::2.5::HTS	BRD-K57041787-001-02-6	dabigatran-etexilate	2.5	HTS	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1	Launched	5
BRD-K57080016-001-15-9::2.5::HTS	-3.02570766004	BRD-K57080016-001-15-9::2.5::HTS	BRD-K57080016-001-15-9	selumetinib	2.5	HTS	MEK inhibitor	MAP2K1			Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO	Phase 3	5
BRD-K57136142-001-02-4::2.5::HTS	-2.0355427426	BRD-K57136142-001-02-4::2.5::HTS	BRD-K57136142-001-02-4	CCT129202	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB, AURKC			CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1	Preclinical	5
BRD-K57169635-001-04-5::2.5::HTS	1.15766847934	BRD-K57169635-001-04-5::2.5::HTS	BRD-K57169635-001-04-5	dacomitinib	2.5	HTS	EGFR inhibitor	EGFR, ERBB2, ERBB4			COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1	Phase 3	5
BRD-K57179821-001-15-4::2.5::HTS	0.503914944581	BRD-K57179821-001-15-4::2.5::HTS	BRD-K57179821-001-15-4	crotamiton	2.5	HTS	antipruritic		infectious disease	scabies	CCN(C(=O)\C=C\C)c1ccccc1C	Launched	5
BRD-K57222227-001-30-1::2.5::HTS	-0.9611832030859999	BRD-K57222227-001-30-1::2.5::HTS	BRD-K57222227-001-30-1	indomethacin	2.5	HTS	cyclooxygenase inhibitor	GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1	rheumatology, orthopedics	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1	Launched	5
BRD-K57252450-001-02-5::2.5::HTS	-0.884531588115	BRD-K57252450-001-02-5::2.5::HTS	BRD-K57252450-001-02-5	cilengitide	2.5	HTS	integrin antagonist	ITGAV, ITGB3			CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	Phase 3	5
BRD-K57275767-001-02-4::2.61::HTS	0.2565478583	BRD-K57275767-001-02-4::2.61::HTS	BRD-K57275767-001-02-4	geniposide	2.61	HTS	GLP receptor agonist	GLP1R			COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO	Preclinical	5
BRD-K57275767-001-03-2::2.5::HTS	-0.451905328772	BRD-K57275767-001-03-2::2.5::HTS	BRD-K57275767-001-03-2	geniposide	2.5	HTS	GLP receptor agonist	GLP1R			COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO	Preclinical	5
BRD-K57284066-001-01-6::2.5::HTS	-0.5378766668980001	BRD-K57284066-001-01-6::2.5::HTS	BRD-K57284066-001-01-6	Ro-9187	2.5	HTS	HCV inhibitor				Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1	Preclinical	5
BRD-K57291914-003-09-4::2.5::HTS	0.168336813044	BRD-K57291914-003-09-4::2.5::HTS	BRD-K57291914-003-09-4	moroxydine	2.5	HTS	antiviral		infectious disease	influenza A virus infection	NC(=N)NC(=N)N1CCOCC1, NC(=N)NC(=N)N1CCOCC1	Launched	5
BRD-K57304726-003-06-9::2.5::HTS	-0.456835243376	BRD-K57304726-003-06-9::2.5::HTS	BRD-K57304726-003-06-9	PRE-084	2.5	HTS	sigma receptor agonist	SIGMAR1			O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1	Preclinical	5
BRD-K57313110-001-06-8::2.5::HTS	0.157187284341	BRD-K57313110-001-06-8::2.5::HTS	BRD-K57313110-001-06-8	pidolic-acid	2.5	HTS		ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA	dermatology	xerosis cutis	OC(=O)[C@@H]1CCC(=O)N1	Launched	5
BRD-K57371763-001-01-7::2.5::HTS	-0.16344822982999999	BRD-K57371763-001-01-7::2.5::HTS	BRD-K57371763-001-01-7	fidaxomicin	2.5	HTS	RNA polymerase inhibitor		gastroenterology	diarrhea	CC[C@H]1\C=C(C)/[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@H](C\C=C(C)\C=C(C)[C@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@H]1O)[C@@H](C)O	Launched	5
BRD-K57432881-003-21-8::2.5::HTS	-0.274804911047	BRD-K57432881-003-21-8::2.5::HTS	BRD-K57432881-003-21-8	tiapride	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	dyskinesia, abstinence from alcohol, psychosis	CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O	Launched	5
BRD-K57545991-050-23-1::2.5::HTS	0.00704495079702	BRD-K57545991-050-23-1::2.5::HTS	BRD-K57545991-050-23-1	enalapril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	Launched	5
BRD-K57569181-001-27-5::2.5::HTS	0.3263470574	BRD-K57569181-001-27-5::2.5::HTS	BRD-K57569181-001-27-5	pentoxifylline	2.5	HTS	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF	cardiology	claudication	CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	Launched	5
BRD-K57597776-001-01-2::2.5::HTS	-0.630118416555	BRD-K57597776-001-01-2::2.5::HTS	BRD-K57597776-001-01-2	org-27569	2.5	HTS	cannabinoid receptor modulator	CNR1			CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1	Preclinical	5
BRD-K57631554-003-06-2::2.5::HTS	0.159501751168	BRD-K57631554-003-06-2::2.5::HTS	BRD-K57631554-003-06-2	5-aminolevulinic-acid	2.5	HTS	oxidizing agent	ALAD			NCC(=O)CCC(O)=O, NCC(=O)CCC(O)=O	Launched	5
BRD-K57718010-001-11-9::2.5::HTS	0.0820368141779	BRD-K57718010-001-11-9::2.5::HTS	BRD-K57718010-001-11-9	pentylenetetrazol	2.5	HTS	GABA receptor antagonist				C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1	Withdrawn	5
BRD-K57754230-001-02-7::2.5::HTS	0.104778027786	BRD-K57754230-001-02-7::2.5::HTS	BRD-K57754230-001-02-7	EPZ005687	2.5	HTS	histone lysine methyltransferase inhibitor	EZH2			Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1	Preclinical	5
BRD-K57764956-001-02-8::2.5::HTS	-0.6002317738490001	BRD-K57764956-001-02-8::2.5::HTS	BRD-K57764956-001-02-8	cariprazine	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	schizophrenia	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1	Launched	5
BRD-K57853941-304-02-5::2.5::HTS	-0.5047816898740001	BRD-K57853941-304-02-5::2.5::HTS	BRD-K57853941-304-02-5	olsalazine	2.5	HTS	cyclooxygenase inhibitor	IFNG, TPMT	gastroenterology	ulcerative colitis	OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O	Launched	5
BRD-K57927309-001-01-7::2.5::HTS	-0.287780566372	BRD-K57927309-001-01-7::2.5::HTS	BRD-K57927309-001-01-7	BW-180C	2.5	HTS	opioid receptor agonist	OPRD1, OPRM1			CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O	Phase 2	5
BRD-K58010567-003-02-2::2.5::HTS	-0.653708043776	BRD-K58010567-003-02-2::2.5::HTS	BRD-K58010567-003-02-2	vilazodone	2.5	HTS	serotonin reuptake inhibitor	DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4	neurology/psychiatry	depression	NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1	Launched	5
BRD-K58046914-001-03-8::2.5::HTS	0.154214813421	BRD-K58046914-001-03-8::2.5::HTS	BRD-K58046914-001-03-8	HA-966-(R)-(+)	2.5	HTS	glutamate receptor agonist	GRIA1			N[C@@H]1CCN(O)C1=O	Preclinical	5
BRD-K58049875-001-04-7::2.5::HTS	0.308779417634	BRD-K58049875-001-04-7::2.5::HTS	BRD-K58049875-001-04-7	thiostrepton	2.5	HTS	FOXM1 inhibitor, protein synthesis inhibitor	FOXM1	obstetrics/gynecology	mastitis	CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O	Launched	5
BRD-K58114536-001-01-6::2.5::HTS	-0.27619112611200003	BRD-K58114536-001-01-6::2.5::HTS	BRD-K58114536-001-01-6	rasagiline	2.5	HTS	monoamine oxidase inhibitor	BCL2, MAOB	neurology/psychiatry	Parkinson's Disease	C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12	Launched	5
BRD-K58122457-001-02-2::2.5::HTS	-2.9243037436900003	BRD-K58122457-001-02-2::2.5::HTS	BRD-K58122457-001-02-2	hesperadin	2.5	HTS	Aurora kinase inhibitor	AURKB			CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1	Preclinical	5
BRD-K58148589-001-03-6::2.5::HTS	-0.852666493661	BRD-K58148589-001-03-6::2.5::HTS	BRD-K58148589-001-03-6	betamethasone-dipropionate	2.5	HTS	anti-inflammatory agent		dermatology	corticosteroid-responsive dermatoses	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	Launched	5
BRD-K58160573-001-05-4::2.5::HTS	0.291193716991	BRD-K58160573-001-05-4::2.5::HTS	BRD-K58160573-001-05-4	dapagliflozin	2.5	HTS	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1	Launched	5
BRD-K58262659-001-09-7::2.5::HTS	-0.416845582169	BRD-K58262659-001-09-7::2.5::HTS	BRD-K58262659-001-09-7	doxifluridine	2.5	HTS	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	Launched	5
BRD-K58265391-001-12-7::2.5::HTS	-0.0340019482613	BRD-K58265391-001-12-7::2.5::HTS	BRD-K58265391-001-12-7	meticrane	2.5	HTS	diuretic		cardiology	edema	Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O	Launched	5
BRD-K58299615-001-03-5::2.5::HTS	0.08608903000160001	BRD-K58299615-001-03-5::2.5::HTS	BRD-K58299615-001-03-5	Ro-90-7501	2.5	HTS		APP			Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1	Preclinical	5
BRD-K58343622-001-01-6::2.5::HTS	0.214731778515	BRD-K58343622-001-01-6::2.5::HTS	BRD-K58343622-001-01-6	DY131	2.5	HTS	estrogen-related receptor agonist	ESRRB, ESRRG			CCN(CC)c1ccc(cc1)\C=N\NC(=O)c1ccc(O)cc1, CCN(CC)c1ccc(cc1)\C=N\NC(=O)c1ccc(O)cc1	Preclinical	5
BRD-K58435339-001-03-0::2.5::HTS	-2.4037815408000003	BRD-K58435339-001-03-0::2.5::HTS	BRD-K58435339-001-03-0	AT13387	2.5	HTS	HSP antagonist	HSP90AA1			CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O	Phase 2	5
BRD-K58466253-003-14-0::2.5::HTS	0.0127523188806	BRD-K58466253-003-14-0::2.5::HTS	BRD-K58466253-003-14-0	palmatine-chloride	2.5	HTS	dopamine synthesis inhibitor	CYP3A4			COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC	Preclinical	5
BRD-K58486055-001-02-7::2.5::HTS	-0.267084411115	BRD-K58486055-001-02-7::2.5::HTS	BRD-K58486055-001-02-7	reparixin	2.5	HTS	CC chemokine receptor antagonist	CXCR1, CXCR2			CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O	Phase 3	5
BRD-K58497451-237-10-7::2.5::HTS	-0.113791332576	BRD-K58497451-237-10-7::2.5::HTS	BRD-K58497451-237-10-7	potassium-p-aminobenzoate	2.5	HTS			rheumatology, urology	scleroderma, dermatomyositis, Peyronie's disease	Nc1ccc(cc1)C(O)=O	Launched	5
BRD-K58501140-002-01-0::2.5::HTS	-0.00993812225469	BRD-K58501140-002-01-0::2.5::HTS	BRD-K58501140-002-01-0	TAK-875	2.5	HTS	insulin secretagogue	FFAR1			Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1	Phase 3	5
BRD-K58513245-304-02-7::2.5::HTS	0.235068771714	BRD-K58513245-304-02-7::2.5::HTS	BRD-K58513245-304-02-7	pamidronate	2.5	HTS	bone resorption inhibitor	FDPS	endocrinology, oncology, hematologic malignancy	hypercalcemia, Paget's disease, breast cancer, multiple myeloma	NCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	5
BRD-K58550667-001-08-7::2.5::HTS	-1.51174958655	BRD-K58550667-001-08-7::2.5::HTS	BRD-K58550667-001-08-7	FK-866	2.5	HTS	niacinamide phosphoribosyltransferase inhibitor	NAMPT			O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1	Phase 2	5
BRD-K58568447-001-01-1::2.5::HTS	0.286303379925	BRD-K58568447-001-01-1::2.5::HTS	BRD-K58568447-001-01-1	K02288	2.5	HTS	bone morphogenic protein inhibitor	BMP1			COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1	Preclinical	5
BRD-K58626373-003-07-8::2.5::HTS	-0.35456838010700004	BRD-K58626373-003-07-8::2.5::HTS	BRD-K58626373-003-07-8	dexfenfluramine	2.5	HTS	serotonin receptor agonist	HTR2C, SLC6A4			CCN[C@@H](C)Cc1cccc(c1)C(F)(F)F	Withdrawn	5
BRD-K58648841-001-04-7::2.5::HTS	-0.0707289930484	BRD-K58648841-001-04-7::2.5::HTS	BRD-K58648841-001-04-7	cresopirine	2.5	HTS					CC(=O)Oc1c(C)cccc1C(O)=O	Preclinical	5
BRD-K58685305-001-20-4::2.5::HTS	0.0451274793115	BRD-K58685305-001-20-4::2.5::HTS	BRD-K58685305-001-20-4	emodin	2.5	HTS	11-beta hydroxysteroid dehydrogenase inhibitor	CSNK2A1			Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1	Preclinical	5
BRD-K58736316-001-09-5::2.5::HTS	0.11226315196100001	BRD-K58736316-001-09-5::2.5::HTS	BRD-K58736316-001-09-5	cianidanol	2.5	HTS	fatty acid synthase inhibitor	PTGS1			O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1	Withdrawn	5
BRD-K58770988-001-01-8::2.5::HTS	-2.06966180936	BRD-K58770988-001-01-8::2.5::HTS	BRD-K58770988-001-01-8	NMS-E973	2.5	HTS	HSP inhibitor				CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O	Preclinical	5
BRD-K58772419-001-07-0::2.5::HTS	0.235139126058	BRD-K58772419-001-07-0::2.5::HTS	BRD-K58772419-001-07-0	AZD6482	2.5	HTS	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1	Phase 1	5
BRD-K58794715-001-01-8::2.5::HTS	-0.21234916074000001	BRD-K58794715-001-01-8::2.5::HTS	BRD-K58794715-001-01-8	bentiromide	2.5	HTS		HPN	gastroenterology	pancreas diagnostic agent	OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1	Launched	5
BRD-K58819470-001-05-9::2.5::HTS	0.346131651822	BRD-K58819470-001-05-9::2.5::HTS	BRD-K58819470-001-05-9	2-thiouracil	2.5	HTS					Oc1ccnc(S)n1, Oc1ccnc(S)n1	Preclinical	5
BRD-K58930050-050-15-8::2.5::HTS	0.0468280338687	BRD-K58930050-050-15-8::2.5::HTS	BRD-K58930050-050-15-8	dizocilpine-(+)	2.5	HTS	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21	Preclinical	5
BRD-K58937086-001-01-4::2.5::HTS	-0.44186885521700003	BRD-K58937086-001-01-4::2.5::HTS	BRD-K58937086-001-01-4	glutathione-monoisopropyl-ester	2.5	HTS	lipid peroxidase inhibitor				CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O, CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	Phase 2	5
BRD-K58968598-001-03-6::2.5::HTS	0.298625898098	BRD-K58968598-001-03-6::2.5::HTS	BRD-K58968598-001-03-6	sucralose	2.5	HTS					OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl	Launched	5
BRD-K59013864-001-01-1::2.5::HTS	-0.1033635356	BRD-K59013864-001-01-1::2.5::HTS	BRD-K59013864-001-01-1	AM-24	2.5	HTS	lipoxygenase inhibitor	ALOX5			Oc1c(I)cc(I)cc1I	Phase 2	5
BRD-K59036917-001-16-7::2.5::HTS	-0.06780832634459999	BRD-K59036917-001-16-7::2.5::HTS	BRD-K59036917-001-16-7	ML161	2.5	HTS	protease-activated receptor inhibitor				CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1, CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1	Preclinical	5
BRD-K59037100-001-14-7::2.5::HTS	0.252378548167	BRD-K59037100-001-14-7::2.5::HTS	BRD-K59037100-001-14-7	oxybenzone	2.5	HTS	lipase inhibitor	LIPE	dermatology	sunscreen lotion	COc1ccc(C(=O)c2ccccc2)c(O)c1	Launched	5
BRD-K59045783-001-01-1::2.5::HTS	-0.29602365605500003	BRD-K59045783-001-01-1::2.5::HTS	BRD-K59045783-001-01-1	faropenem-medoxomil	2.5	HTS	lactamase inhibitor		otolaryngology, infectious disease, pulmonary	sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C	Launched	5
BRD-K59058747-001-18-3::2.5::HTS	-0.239771404224	BRD-K59058747-001-18-3::2.5::HTS	BRD-K59058747-001-18-3	acetylcysteine	2.5	HTS	mucolytic agent	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O	Launched	5
BRD-K59058747-001-20-9::2.5::HTS	0.21247837047899998	BRD-K59058747-001-20-9::2.5::HTS	BRD-K59058747-001-20-9	acetylcysteine	2.5	HTS	mucolytic agent	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O	Launched	5
BRD-K59110290-238-01-7::2.5::HTS	-0.421407023138	BRD-K59110290-238-01-7::2.5::HTS	BRD-K59110290-238-01-7	fosamprenavir	2.5	HTS	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	Launched	5
BRD-K59146805-001-03-7::2.5::HTS	-1.3170654198	BRD-K59146805-001-03-7::2.5::HTS	BRD-K59146805-001-03-7	AZ3146	2.5	HTS	monopolar spindle 1 kinase inhibitor				COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1	Preclinical	5
BRD-K59184148-001-21-6::2.5::HTS	0.235620846594	BRD-K59184148-001-21-6::2.5::HTS	BRD-K59184148-001-21-6	SB-216763	2.5	HTS	glycogen synthase kinase inhibitor	CCNA2, CDK2, GSK3A, GSK3B			Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12	Preclinical	5
BRD-K59197931-001-04-5::2.5::HTS	0.0877538064483	BRD-K59197931-001-04-5::2.5::HTS	BRD-K59197931-001-04-5	naproxen	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology	pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	Launched	5
BRD-K59204667-001-03-1::2.5::HTS	-0.298726431694	BRD-K59204667-001-03-1::2.5::HTS	BRD-K59204667-001-03-1	DBeQ	2.5	HTS	ATPase inhibitor	CASP3			C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1	Preclinical	5
BRD-K59227464-334-02-4::2.5::HTS	0.161087373509	BRD-K59227464-334-02-4::2.5::HTS	BRD-K59227464-334-02-4	LY2228820	2.5	HTS	p38 MAPK inhibitor	MAPK14			CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1[nH]c(nc1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1[nH]c(nc1-c1ccc(F)cc1)C(C)(C)C	Phase 2	5
BRD-K59273480-001-10-6::2.5::HTS	-0.7768032130779999	BRD-K59273480-001-10-6::2.5::HTS	BRD-K59273480-001-10-6	propentofylline	2.5	HTS	adenosine reuptake inhibitor, phosphodiesterase inhibitor	PDE1A	neurology/psychiatry	stroke	CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12	Launched	5
BRD-K59284035-001-07-9::2.5::HTS	-0.40940537128700005	BRD-K59284035-001-07-9::2.5::HTS	BRD-K59284035-001-07-9	chrysophanic-acid	2.5	HTS	EGFR inhibitor	EGFR, MTOR			Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Preclinical	5
BRD-K59317601-001-05-5::2.5::HTS	-2.28758467518	BRD-K59317601-001-05-5::2.5::HTS	BRD-K59317601-001-05-5	MLN0128	2.5	HTS	mTOR inhibitor	MTOR, PIK3CA, PIK3CD, PIK3CG			CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12	Phase 2	5
BRD-K59325863-001-02-8::2.5::HTS	-5.8563203455199995	BRD-K59325863-001-02-8::2.5::HTS	BRD-K59325863-001-02-8	delanzomib	2.5	HTS	proteasome inhibitor	CMA1, CTSG, CYP3A4, ELANE			CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	Phase 1/Phase 2	5
BRD-K59325863-001-03-6::2.46::HTS	-5.7139627302400005	BRD-K59325863-001-03-6::2.46::HTS	BRD-K59325863-001-03-6	delanzomib	2.46	HTS	proteasome inhibitor	CMA1, CTSG, CYP3A4, ELANE			CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	Phase 1/Phase 2	5
BRD-K59332007-300-02-7::2.5::HTS	0.160464436051	BRD-K59332007-300-02-7::2.5::HTS	BRD-K59332007-300-02-7	linopirdine	2.5	HTS	potassium channel blocker	KCNQ2, KCNQ3, KCNQ4, KCNQ5			O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1	Phase 3	5
BRD-K59333713-003-02-0::2.5::HTS	0.127546668261	BRD-K59333713-003-02-0::2.5::HTS	BRD-K59333713-003-02-0	niguldipine-(S)-(+)	2.5	HTS	adrenergic receptor antagonist	ADRA1A			COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1	Preclinical	5
BRD-K59339270-001-02-6::2.5::HTS	0.222364282882	BRD-K59339270-001-02-6::2.5::HTS	BRD-K59339270-001-02-6	AH6809	2.5	HTS	prostanoid receptor antagonist	PTGDR, PTGER1, PTGER2, PTGER3			CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O	Preclinical	5
BRD-K59369769-001-20-3::2.5::HTS	-0.363713799627	BRD-K59369769-001-20-3::2.5::HTS	BRD-K59369769-001-20-3	tozasertib	2.5	HTS	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	AURKA, AURKB, AURKC, LCK			CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1	Phase 2	5
BRD-K59390331-045-01-5::2.5::HTS	-0.287478233496	BRD-K59390331-045-01-5::2.5::HTS	BRD-K59390331-045-01-5	tarafenacin	2.5	HTS	acetylcholine receptor antagonist	CHRM3			Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1CN2CCC1CC2	Phase 2	5
BRD-K59419204-001-02-7::2.5::HTS	-0.09826658413560001	BRD-K59419204-001-02-7::2.5::HTS	BRD-K59419204-001-02-7	AM-281	2.5	HTS	cannabinoid receptor antagonist	CNR1, CNR2, GPR55			Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1	Preclinical	5
BRD-K59424860-001-01-4::2.5::HTS	0.06725600086540001	BRD-K59424860-001-01-4::2.5::HTS	BRD-K59424860-001-01-4	val	2.5	HTS		BCAT1, PCCB, VARS			CC(C)[C@@H](N)C(O)=O	Phase 2	5
BRD-K59433843-001-01-7::2.5::HTS	0.0386158042719	BRD-K59433843-001-01-7::2.5::HTS	BRD-K59433843-001-01-7	ICI-192605	2.5	HTS	thromboxane receptor antagonist	TBXA2R			OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl	Phase 2	5
BRD-K59436580-001-01-7::2.5::HTS	-0.9624037801180001	BRD-K59436580-001-01-7::2.5::HTS	BRD-K59436580-001-01-7	tedizolid	2.5	HTS	bacterial 50S ribosomal subunit inhibitor		infectious disease	skin infections	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O	Launched	5
BRD-K59456551-001-22-6::2.51::HTS	-1.90689939664	BRD-K59456551-001-22-6::2.51::HTS	BRD-K59456551-001-22-6	methotrexate	2.51	HTS	dihydrofolate reductase inhibitor	DHFR	oncology, hematologic malignancy, dermatology, rheumatology	gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O	Launched	5
BRD-K59469039-001-08-0::2.5::HTS	-0.0425870312031	BRD-K59469039-001-08-0::2.5::HTS	BRD-K59469039-001-08-0	tyrphostin-AG-879	2.5	HTS	tyrosine kinase inhibitor	ERBB2, KDR, NTRK1			CC(C)(C)c1cc(cc(c1O)C(C)(C)C)\C=C(/C#N)C(N)=S, CC(C)(C)c1cc(cc(c1O)C(C)(C)C)\C=C(/C#N)C(N)=S	Preclinical	5
BRD-K59506194-015-04-9::2.5::HTS	-0.0602471609844	BRD-K59506194-015-04-9::2.5::HTS	BRD-K59506194-015-04-9	targinine	2.5	HTS	nitric oxide synthase inhibitor	NOS3			CNC(=N)NCCC[C@H](N)C(O)=O	Phase 3	5
BRD-K59522102-001-14-6::2.5::HTS	-0.69871032747	BRD-K59522102-001-14-6::2.5::HTS	BRD-K59522102-001-14-6	piperine	2.5	HTS	monoamine oxidase inhibitor	MAOA, MAOB, TRPV1			O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	Phase 1	5
BRD-K59522102-001-15-3::2.46::HTS	0.335249178922	BRD-K59522102-001-15-3::2.46::HTS	BRD-K59522102-001-15-3	piperine	2.46	HTS	monoamine oxidase inhibitor	MAOA, MAOB, TRPV1			O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	Phase 1	5
BRD-K59524082-001-01-3::2.5::HTS	-0.0568286261091	BRD-K59524082-001-01-3::2.5::HTS	BRD-K59524082-001-01-3	maribavir	2.5	HTS	cytomegalovirus inhibitor, protein kinase inhibitor	PYGM			CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O	Phase 3	5
BRD-K59527975-236-01-8::2.5::HTS	0.41931355228	BRD-K59527975-236-01-8::2.5::HTS	BRD-K59527975-236-01-8	S-Sulfo-L-cysteine-sodium-salt	2.5	HTS	glutamate receptor agonist				N[C@@H](CSS(O)(=O)=O)C(O)=O	Preclinical	5
BRD-K59574735-001-11-8::2.5::HTS	-0.081260738169	BRD-K59574735-001-11-8::2.5::HTS	BRD-K59574735-001-11-8	ubenimex	2.5	HTS	leukotriene synthesis inhibitor	LTA4H, RNPEP	hematologic malignancy	acute myeloid leukemia (AML)	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O	Launched	5
BRD-K59597909-001-17-6::2.5::HTS	-0.38240566886	BRD-K59597909-001-17-6::2.5::HTS	BRD-K59597909-001-17-6	phenothiazine	2.5	HTS	dopamine receptor antagonist				N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12	Preclinical	5
BRD-K59632282-052-03-1::2.5::HTS	-0.788176881469	BRD-K59632282-052-03-1::2.5::HTS	BRD-K59632282-052-03-1	quinidine	2.5	HTS	sodium channel blocker	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	Launched	5
BRD-K59647213-001-10-5::2.5::HTS	-0.443002143505	BRD-K59647213-001-10-5::2.5::HTS	BRD-K59647213-001-10-5	levocarnitine	2.5	HTS			endocrinology	carnitine deficiency	C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O	Launched	5
BRD-K59715032-362-01-4::2.5::HTS	0.276518054872	BRD-K59715032-362-01-4::2.5::HTS	BRD-K59715032-362-01-4	pasireotide	2.5	HTS	somatostatin receptor agonist	SSTR1, SSTR2, SSTR3, SSTR5	endocrinology	Cushing's syndrome, acromegaly	NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1	Launched	5
BRD-K59745944-001-02-0::2.5::HTS	-1.28828276562	BRD-K59745944-001-02-0::2.5::HTS	BRD-K59745944-001-02-0	PHT-427	2.5	HTS	AKT inhibitor, pyruvate dehydrogenase inhibitor	AKT2, PDPK1			CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	Preclinical	5
BRD-K59831625-001-01-6::2.5::HTS	-2.1508047978200002	BRD-K59831625-001-01-6::2.5::HTS	BRD-K59831625-001-01-6	LDN-212854	2.5	HTS	bone morphogenic protein inhibitor	ABL1, ACVR1, RIPK2			C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	Preclinical	5
BRD-K59875992-001-01-8::2.5::HTS	-0.390811611354	BRD-K59875992-001-01-8::2.5::HTS	BRD-K59875992-001-01-8	FPL-62064	2.5	HTS	cyclooxygenase inhibitor, lipoxygenase inhibitor				COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1	Phase 2	5
BRD-K59929863-001-01-9::2.5::HTS	0.0452714879025	BRD-K59929863-001-01-9::2.5::HTS	BRD-K59929863-001-01-9	CB-10-277	2.5	HTS	DNA synthesis inhibitor				CN(C)\N=N\c1ccc(cc1)C(O)=O	Phase 1	5
BRD-K59983611-001-21-9::2.5::HTS	0.60704650831	BRD-K59983611-001-21-9::2.5::HTS	BRD-K59983611-001-21-9	sulfabenzamide	2.5	HTS	bacterial antifolate				Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1	Launched	5
BRD-K59998349-003-01-4::2.5::HTS	0.0327395909942	BRD-K59998349-003-01-4::2.5::HTS	BRD-K59998349-003-01-4	aminolevulinic-acid-benzyl-ester	2.5	HTS					NCC(=O)CCC(=O)OCc1ccccc1	Phase 1	5
BRD-K60005752-001-01-9::2.5::HTS	0.084992696076	BRD-K60005752-001-01-9::2.5::HTS	BRD-K60005752-001-01-9	S-111	2.5	HTS	PARP inhibitor	PARP1			CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	Phase 2	5
BRD-K60025295-003-06-6::2.5::HTS	-3.97407293812	BRD-K60025295-003-06-6::2.5::HTS	BRD-K60025295-003-06-6	crystal-violet	2.5	HTS	other antibiotic				CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C	Launched	5
BRD-K60036103-003-01-6::2.5::HTS	-0.123640857028	BRD-K60036103-003-01-6::2.5::HTS	BRD-K60036103-003-01-6	L-NIL	2.5	HTS	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			CC(=N)NCCCC[C@H](N)C(O)=O	Preclinical	5
BRD-K60038276-001-09-0::2.5::HTS	-0.029879086837	BRD-K60038276-001-09-0::2.5::HTS	BRD-K60038276-001-09-0	irbesartan	2.5	HTS	angiotensin receptor antagonist	AGTR1, JUN, SLC10A1	cardiology, nephrology	hypertension, diabetic nephropathy	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Launched	5
BRD-K60060639-005-02-2::2.5::HTS	0.299327936089	BRD-K60060639-005-02-2::2.5::HTS	BRD-K60060639-005-02-2	N-methyllidocaine-iodide	2.5	HTS	antiarrhythmic medication				CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C	Preclinical	5
BRD-K60102752-001-02-2::2.5::HTS	0.22649534395100002	BRD-K60102752-001-02-2::2.5::HTS	BRD-K60102752-001-02-2	alibendol	2.5	HTS	antispasmodic		gastroenterology	bile stimulation	COc1cc(CC=C)cc(C(=O)NCCO)c1O	Launched	5
BRD-K60150510-001-15-6::2.5::HTS	0.121670441569	BRD-K60150510-001-15-6::2.5::HTS	BRD-K60150510-001-15-6	N6-cyclopentyladenosine	2.5	HTS	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	Preclinical	5
BRD-K60160658-003-11-2::2.5::HTS	0.113797584689	BRD-K60160658-003-11-2::2.5::HTS	BRD-K60160658-003-11-2	tiagabine	2.5	HTS	GABA uptake inhibitor	SLC6A1	neurology/psychiatry	seizures	Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C	Launched	5
BRD-K60184833-001-05-6::2.5::HTS	-0.239510675848	BRD-K60184833-001-05-6::2.5::HTS	BRD-K60184833-001-05-6	tyrphostin-AG-99	2.5	HTS	tyrosine kinase inhibitor	EGFR			NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N	Preclinical	5
BRD-K60212747-236-01-1::2.5::HTS	-0.256521459115	BRD-K60212747-236-01-1::2.5::HTS	BRD-K60212747-236-01-1	neridronic-acid	2.5	HTS	bone resorption inhibitor	FDPS	endocrinology	brittle bone disease, Paget's disease	NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	5
BRD-K60230970-001-17-5::2.4::HTS	-5.82852495839	BRD-K60230970-001-17-5::2.4::HTS	BRD-K60230970-001-17-5	MG-132	2.4	HTS	proteasome inhibitor	PSMB1			CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	Preclinical	5
BRD-K60237333-001-27-1::2.5::HTS	-0.19064854244600002	BRD-K60237333-001-27-1::2.5::HTS	BRD-K60237333-001-27-1	niacin	2.5	HTS	NAD precursor, vitamin B	DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT	endocrinology	hypertriglyceridemia	OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1	Launched	5
BRD-K60240222-001-01-4::2.5::HTS	0.0616059440409	BRD-K60240222-001-01-4::2.5::HTS	BRD-K60240222-001-01-4	carglumic-acid	2.5	HTS	carbamoyl phosphate synthase activator	CPS1	metabolism	hyperammonemia	NC(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	5
BRD-K60287130-001-05-7::2.5::HTS	0.0259882892202	BRD-K60287130-001-05-7::2.5::HTS	BRD-K60287130-001-05-7	5,7-dichlorokynurenic-acid	2.5	HTS	glutamate receptor antagonist	GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			OC(=O)c1cc(O)c2c(Cl)cc(Cl)cc2n1, OC(=O)c1cc(O)c2c(Cl)cc(Cl)cc2n1	Preclinical	5
BRD-K60341624-001-02-2::2.5::HTS	-0.6534007015609999	BRD-K60341624-001-02-2::2.5::HTS	BRD-K60341624-001-02-2	GSK1292263	2.5	HTS	glucose dependent insulinotropic receptor agonist	GRPR			CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1	Phase 2	5
BRD-K60348325-065-09-9::2.5::HTS	-5.31077051695	BRD-K60348325-065-09-9::2.5::HTS	BRD-K60348325-065-09-9	brilliant-green	2.5	HTS					CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC	Launched	5
BRD-K60369935-001-18-3::2.5::HTS	-0.59375852143	BRD-K60369935-001-18-3::2.5::HTS	BRD-K60369935-001-18-3	ribavirin	2.5	HTS	antiviral	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Launched	5
BRD-K60441002-001-04-8::2.5::HTS	-0.15219469668	BRD-K60441002-001-04-8::2.5::HTS	BRD-K60441002-001-04-8	muscimol	2.5	HTS	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			NCc1cc(O)no1	Phase 1	5
BRD-K60443845-001-08-6::2.5::HTS	-0.06284503500540001	BRD-K60443845-001-08-6::2.5::HTS	BRD-K60443845-001-08-6	chlormidazole	2.5	HTS	fungal lanosterol demethylase inhibitor		infectious disease	fungal infection	Cc1nc2ccccc2n1Cc1ccc(Cl)cc1	Launched	5
BRD-K60446698-001-01-2::2.5::HTS	-2.70616066246	BRD-K60446698-001-01-2::2.5::HTS	BRD-K60446698-001-01-2	ONX-0914	2.5	HTS	proteasome inhibitor				COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1	Preclinical	5
BRD-K60511616-236-08-9::2.5::HTS	0.400603423297	BRD-K60511616-236-08-9::2.5::HTS	BRD-K60511616-236-08-9	pravastatin	2.5	HTS	HMGCR inhibitor	HMGCR, SLCO1B1	endocrinology, cardiology	hypercholesterolemia, myocardial infarction, hyperlipidemia	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12, CCC(C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)C12, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12	Launched	5
BRD-K60567437-001-10-2::2.5::HTS	0.33983638155	BRD-K60567437-001-10-2::2.5::HTS	BRD-K60567437-001-10-2	dimpylate	2.5	HTS	acetylcholinesterase inhibitor	ACHE			CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C	Launched	5
BRD-K60585088-001-01-5::2.5::HTS	-0.6780006045870001	BRD-K60585088-001-01-5::2.5::HTS	BRD-K60585088-001-01-5	paricalcitol	2.5	HTS	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperthyroidism	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1	Launched	5
BRD-K60640630-001-11-0::2.5::HTS	0.220491076812	BRD-K60640630-001-11-0::2.5::HTS	BRD-K60640630-001-11-0	mometasone-furoate	2.5	HTS	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl	Launched	5
BRD-K60690191-001-03-3::2.5::HTS	0.262398601385	BRD-K60690191-001-03-3::2.5::HTS	BRD-K60690191-001-03-3	MPEP	2.5	HTS	glutamate receptor antagonist	GRM1, GRM4, GRM5			Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1	Preclinical	5
BRD-K60770992-066-25-0::2.47::HTS	0.0952443365161	BRD-K60770992-066-25-0::2.47::HTS	BRD-K60770992-066-25-0	pergolide	2.47	HTS	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	Withdrawn	5
BRD-K60866521-001-07-1::2.5::HTS	0.179609151634	BRD-K60866521-001-07-1::2.5::HTS	BRD-K60866521-001-07-1	idelalisib	2.5	HTS	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1	Launched	5
BRD-K60907894-003-23-5::2.5::HTS	0.0531954153636	BRD-K60907894-003-23-5::2.5::HTS	BRD-K60907894-003-23-5	adiphenine	2.5	HTS	acetylcholine receptor antagonist	CHRNA1	neurology/psychiatry	spasms	CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1	Launched	5
BRD-K60914966-001-01-4::2.5::HTS	0.347928165457	BRD-K60914966-001-01-4::2.5::HTS	BRD-K60914966-001-01-4	etosalamide	2.5	HTS	anti-inflammatory agent				CCOCCOc1ccccc1C(N)=O	Preclinical	5
BRD-K60918217-001-03-8::2.56::HTS	0.573712333317	BRD-K60918217-001-03-8::2.56::HTS	BRD-K60918217-001-03-8	laquinimod	2.56	HTS	immunosuppressant	CXCL2			CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1	Phase 3	5
BRD-K60984070-001-01-0::2.5::HTS	0.0777542927527	BRD-K60984070-001-01-0::2.5::HTS	BRD-K60984070-001-01-0	PD-166793	2.5	HTS	collagenase inhibitor, metalloproteinase inhibitor	MMP13, MMP2, MMP3			CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O	Preclinical	5
BRD-K60997853-001-02-3::2.5::HTS	-2.5058899006999997	BRD-K60997853-001-02-3::2.5::HTS	BRD-K60997853-001-02-3	PHA-848125	2.5	HTS	CDK inhibitor, growth factor receptor inhibitor	CDK2, CDK4, CDK7, NTRK1			CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21	Phase 2	5
BRD-K61032563-001-02-9::2.5::HTS	0.24159170692600002	BRD-K61032563-001-02-9::2.5::HTS	BRD-K61032563-001-02-9	neohesperidin-dihydrochalcone	2.5	HTS					COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O	Preclinical	5
BRD-K61036791-001-01-6::2.5::HTS	0.154649693035	BRD-K61036791-001-01-6::2.5::HTS	BRD-K61036791-001-01-6	rucinol	2.5	HTS	tyrosinase inhibitor	TYR			CCCCc1ccc(O)cc1O	Phase 1	5
BRD-K61097567-001-08-5::2.5::HTS	-0.670800441703	BRD-K61097567-001-08-5::2.5::HTS	BRD-K61097567-001-08-5	SB-218795	2.5	HTS	tachykinin antagonist	TACR3			COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1	Preclinical	5
BRD-K61128465-001-09-9::2.5::HTS	0.32384443709800004	BRD-K61128465-001-09-9::2.5::HTS	BRD-K61128465-001-09-9	mdivi-1	2.5	HTS	dynamin inhibitor	DNM1			COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O	Preclinical	5
BRD-K61177364-003-02-9::2.5::HTS	-0.15535907787699998	BRD-K61177364-003-02-9::2.5::HTS	BRD-K61177364-003-02-9	NBI-27914	2.5	HTS	corticosteroid releasing factor receptor antagonist	CRHR1			CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl	Preclinical	5
BRD-K61192372-001-05-5::2.54::HTS	-0.458441302226	BRD-K61192372-001-05-5::2.54::HTS	BRD-K61192372-001-05-5	capecitabine	2.54	HTS	DNA synthesis inhibitor, thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	Launched	5
BRD-K61192372-001-08-9::2.5::HTS	0.154053260438	BRD-K61192372-001-08-9::2.5::HTS	BRD-K61192372-001-08-9	capecitabine	2.5	HTS	DNA synthesis inhibitor, thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	Launched	5
BRD-K61195623-001-01-4::2.5::HTS	-4.654253488769999	BRD-K61195623-001-01-4::2.5::HTS	BRD-K61195623-001-01-4	combretastatin-A-4	2.5	HTS	tubulin polymerization inhibitor				COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1	Phase 2	5
BRD-K61228301-001-01-2::2.5::HTS	0.937994457489	BRD-K61228301-001-01-2::2.5::HTS	BRD-K61228301-001-01-2	SGI-1027	2.5	HTS	DNA methyltransferase inhibitor	DNMT1, DNMT3A, DNMT3B			Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1	Preclinical	5
BRD-K61236135-001-08-2::2.5::HTS	-0.130517759026	BRD-K61236135-001-08-2::2.5::HTS	BRD-K61236135-001-08-2	tiratricol	2.5	HTS	thyroid hormone stimulant	THRA, THRB	endocrinology	Refetoff syndrome	OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1	Launched	5
BRD-K61237927-001-01-7::2.5::HTS	0.0497689576016	BRD-K61237927-001-01-7::2.5::HTS	BRD-K61237927-001-01-7	eslicarbazepine-acetate	2.5	HTS	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12	Launched	5
BRD-K61250484-001-02-3::2.5::HTS	-0.222687111804	BRD-K61250484-001-02-3::2.5::HTS	BRD-K61250484-001-02-3	FPH1-(BRD-6125)	2.5	HTS	hepatocyte function enhancer				Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O	Preclinical	5
BRD-K61250553-003-32-2::2.5::HTS	-0.202007351834	BRD-K61250553-003-32-2::2.5::HTS	BRD-K61250553-003-32-2	loperamide	2.5	HTS	opioid receptor agonist	CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC	gastroenterology	diarrhea	CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1	Launched	5
BRD-K61269089-001-05-5::2.5::HTS	0.316856713598	BRD-K61269089-001-05-5::2.5::HTS	BRD-K61269089-001-05-5	daphnetin	2.5	HTS	protein kinase inhibitor				Oc1ccc2ccc(=O)oc2c1O	Preclinical	5
BRD-K61279411-001-02-0::2.5::HTS	0.018734217972	BRD-K61279411-001-02-0::2.5::HTS	BRD-K61279411-001-02-0	oxaloacetate	2.5	HTS	glutamate release inhibitor	CS, SPR			OC(=O)CC(=O)C(O)=O, OC(=O)CC(=O)C(O)=O	Phase 2/Phase 3	5
BRD-K61295575-001-03-6::2.5::HTS	-0.565957379952	BRD-K61295575-001-03-6::2.5::HTS	BRD-K61295575-001-03-6	blebbistatin-(-)	2.5	HTS	ATPase inhibitor				Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1	Preclinical	5
BRD-K61314889-001-04-4::2.5::HTS	-0.8572891289679999	BRD-K61314889-001-04-4::2.5::HTS	BRD-K61314889-001-04-4	endo-IWR-1	2.5	HTS	PARP inhibitor	TNKS, TNKS2			O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O	Preclinical	5
BRD-K61314889-001-05-1::2.5::HTS	0.058833371060800006	BRD-K61314889-001-05-1::2.5::HTS	BRD-K61314889-001-05-1	endo-IWR-1	2.5	HTS	PARP inhibitor	TNKS, TNKS2			O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O	Preclinical	5
BRD-K61323504-001-04-0::2.5::HTS	-0.882335956766	BRD-K61323504-001-04-0::2.5::HTS	BRD-K61323504-001-04-0	SB-225002	2.5	HTS	CC chemokine receptor antagonist	CXCR2			Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O	Preclinical	5
BRD-K61337602-003-02-1::2.5::HTS	0.400743053217	BRD-K61337602-003-02-1::2.5::HTS	BRD-K61337602-003-02-1	naratriptan	2.5	HTS	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1	Launched	5
BRD-K61397605-001-03-4::2.5::HTS	-5.890055153830001	BRD-K61397605-001-03-4::2.5::HTS	BRD-K61397605-001-03-4	romidepsin	2.5	HTS	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C	Launched	5
BRD-K61443506-239-01-6::2.5::HTS	0.101035639359	BRD-K61443506-239-01-6::2.5::HTS	BRD-K61443506-239-01-6	esomeprazole	2.5	HTS	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)	COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	Launched	5
BRD-K61443650-236-13-1::2.5::HTS	-0.319888649135	BRD-K61443650-236-13-1::2.5::HTS	BRD-K61443650-236-13-1	thiomersal	2.5	HTS	other antibiotic	OXCT1			CC[Hg]Sc1ccccc1C(O)=O	Launched	5
BRD-K61452026-001-04-6::2.5::HTS	0.219132508941	BRD-K61452026-001-04-6::2.5::HTS	BRD-K61452026-001-04-6	emtricitabine	2.5	HTS	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1	Launched	5
BRD-K61496577-001-20-2::2.5::HTS	-0.00335879715434	BRD-K61496577-001-20-2::2.5::HTS	BRD-K61496577-001-20-2	flumethasone	2.5	HTS	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	Launched	5
BRD-K61536336-001-01-7::2.5::HTS	-1.18700482664	BRD-K61536336-001-01-7::2.5::HTS	BRD-K61536336-001-01-7	SB-366791	2.5	HTS	TRPV antagonist	TRPV1			COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1	Preclinical	5
BRD-K61567297-001-01-9::2.5::HTS	-0.34800080607600004	BRD-K61567297-001-01-9::2.5::HTS	BRD-K61567297-001-01-9	resatorvid	2.5	HTS	toll-like receptor antagonist	TLR4			CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl	Phase 3	5
BRD-K61585876-001-01-0::2.5::HTS	0.17021858487999997	BRD-K61585876-001-01-0::2.5::HTS	BRD-K61585876-001-01-0	3-carboxy-4-hydroxyphenylglycine-(S)	2.5	HTS	glutamate receptor antagonist	GRM1, GRM5			N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	Preclinical	5
BRD-K61642990-001-01-0::2.5::HTS	0.09958649049139999	BRD-K61642990-001-01-0::2.5::HTS	BRD-K61642990-001-01-0	FERb-033	2.5	HTS	EGFR inhibitor	ERBB2			O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O	Preclinical	5
BRD-K61665160-001-01-5::2.5::HTS	0.0284201393872	BRD-K61665160-001-01-5::2.5::HTS	BRD-K61665160-001-01-5	BYK-204165	2.5	HTS	PARP inhibitor	PARP1			Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12	Preclinical	5
BRD-K61688984-001-02-9::2.5::HTS	0.441347434104	BRD-K61688984-001-02-9::2.5::HTS	BRD-K61688984-001-02-9	RGFP966	2.5	HTS	HDAC inhibitor	HDAC3			Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1	Preclinical	5
BRD-K61691541-001-01-1::2.5::HTS	0.11192350096100001	BRD-K61691541-001-01-1::2.5::HTS	BRD-K61691541-001-01-1	PF-03084014	2.5	HTS	gamma secretase inhibitor				CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C	Phase 2	5
BRD-K61693562-300-01-7::2.5::HTS	0.227139800515	BRD-K61693562-300-01-7::2.5::HTS	BRD-K61693562-300-01-7	pyrazinoylguanidine	2.5	HTS	diuretic				NC(=N)NC(=O)c1cnccn1	Phase 1	5
BRD-K61717546-001-04-3::2.5::HTS	0.00466052190316	BRD-K61717546-001-04-3::2.5::HTS	BRD-K61717546-001-04-3	fleroxacin	2.5	HTS	topoisomerase inhibitor		infectious disease, gastroenterology	gonorrhea, enteritis, diarrhea, respiratory tract infections	CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O	Launched	5
BRD-K61717546-001-05-0::2.47::HTS	-0.014218973139	BRD-K61717546-001-05-0::2.47::HTS	BRD-K61717546-001-05-0	fleroxacin	2.47	HTS	topoisomerase inhibitor		infectious disease, gastroenterology	gonorrhea, enteritis, diarrhea, respiratory tract infections	CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O	Launched	5
BRD-K61734568-003-02-1::2.5::HTS	0.731907567729	BRD-K61734568-003-02-1::2.5::HTS	BRD-K61734568-003-02-1	2,3-DCPE	2.5	HTS	Bcl-XL downregulator	BCL2L1			OCCNCCCOc1cccc(Cl)c1Cl	Preclinical	5
BRD-K61802864-001-08-8::2.5::HTS	0.30444034481800003	BRD-K61802864-001-08-8::2.5::HTS	BRD-K61802864-001-08-8	chlorindione	2.5	HTS					Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O	Preclinical	5
BRD-K61868322-050-01-7::2.5::HTS	0.21750767377900002	BRD-K61868322-050-01-7::2.5::HTS	BRD-K61868322-050-01-7	tenofovir-disoproxil	2.5	HTS	nucleoside reverse transcriptase inhibitor	CYP1A2	infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C	Launched	5
BRD-K61936403-001-01-7::2.5::HTS	-0.043463351053200004	BRD-K61936403-001-01-7::2.5::HTS	BRD-K61936403-001-01-7	AS-1949490	2.5	HTS	SHIP2 phosphatase inhibitor	INPP5D			C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1	Preclinical	5
BRD-K61937613-001-01-1::2.5::HTS	-0.6006794978800001	BRD-K61937613-001-01-1::2.5::HTS	BRD-K61937613-001-01-1	doconexent-ethyl-ester	2.5	HTS	omega 3 fatty acid stimulant				CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	Launched	5
BRD-K61951118-001-07-9::2.5::HTS	-0.374432001603	BRD-K61951118-001-07-9::2.5::HTS	BRD-K61951118-001-07-9	FG-7142	2.5	HTS	GABA benzodiazepine site receptor inverse agonist				CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21	Preclinical	5
BRD-K61988078-001-01-2::2.5::HTS	0.0446177622809	BRD-K61988078-001-01-2::2.5::HTS	BRD-K61988078-001-01-2	moxidectin	2.5	HTS	chloride channel antagonist		infectious disease	gastrointestinal parasites	CO\N=C1\C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\C)=C\C(C)C	Launched	5
BRD-K62008436-001-22-1::2.5::HTS	-0.961044769805	BRD-K62008436-001-22-1::2.5::HTS	BRD-K62008436-001-22-1	paclitaxel	2.5	HTS	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1	Launched	5
BRD-K62012036-001-14-4::2.44::HTS	-0.0198804818567	BRD-K62012036-001-14-4::2.44::HTS	BRD-K62012036-001-14-4	acitretin	2.44	HTS	retinoid receptor agonist	RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3	dermatology	psoriasis	COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C	Launched	5
BRD-K62056274-332-01-8::2.5::HTS	-0.35001497873899995	BRD-K62056274-332-01-8::2.5::HTS	BRD-K62056274-332-01-8	N-methylquipazine	2.5	HTS	serotonin receptor agonist	HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4			CN1CCN(CC1)c1ccc2ccccc2n1	Preclinical	5
BRD-K62186992-334-02-8::2.5::HTS	-0.524830509052	BRD-K62186992-334-02-8::2.5::HTS	BRD-K62186992-334-02-8	hydroxystilbamidine	2.5	HTS					NC(=N)c1ccc(cc1)\C=C\c1ccc(cc1O)C(N)=N	Launched	5
BRD-K62196610-001-01-6::2.5::HTS	-0.47151380076099997	BRD-K62196610-001-01-6::2.5::HTS	BRD-K62196610-001-01-6	AVN-944	2.5	HTS	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1	Phase 2	5
BRD-K62200014-003-10-5::2.5::HTS	0.437340200232	BRD-K62200014-003-10-5::2.5::HTS	BRD-K62200014-003-10-5	anagrelide	2.5	HTS	phosphodiesterase inhibitor	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl	Launched	5
BRD-K62213621-001-01-6::2.5::HTS	0.119183761089	BRD-K62213621-001-01-6::2.5::HTS	BRD-K62213621-001-01-6	dihydroartemisinin	2.5	HTS	antimalarial agent		infectious disease	malaria	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched	5
BRD-K62277907-001-01-6::1.2::HTS	-0.10070360863	BRD-K62277907-001-01-6::1.2::HTS	BRD-K62277907-001-01-6	PYM50028	1.2	HTS	neurotrophic agent				C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1	Phase 2	4
BRD-K62304154-001-04-2::2.5::HTS	-0.480496373659	BRD-K62304154-001-04-2::2.5::HTS	BRD-K62304154-001-04-2	deforolimus	2.5	HTS	mTOR inhibitor	MTOR			CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O	Phase 3	5
BRD-K62310379-001-10-5::2.5::HTS	0.0332060997679	BRD-K62310379-001-10-5::2.5::HTS	BRD-K62310379-001-10-5	fluticasone-propionate	2.5	HTS	glucocorticoid receptor agonist	NR3C1, NR3C2, PGR, PLA2G4A	dermatology	corticosteroid-responsive dermatoses	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF	Launched	5
BRD-K62326629-001-19-0::2.5::HTS	-0.567071870317	BRD-K62326629-001-19-0::2.5::HTS	BRD-K62326629-001-19-0	dichlorophen	2.5	HTS	anticestodal agent				Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O	Launched	5
BRD-K62353271-001-04-7::2.5::HTS	-0.681178225074	BRD-K62353271-001-04-7::2.5::HTS	BRD-K62353271-001-04-7	baclofen-(R)	2.5	HTS	benzodiazepine receptor agonist	GABBR1, GABBR2			NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1	Preclinical	5
BRD-K62363391-001-24-9::2.5::HTS	-0.300938599623	BRD-K62363391-001-24-9::2.5::HTS	BRD-K62363391-001-24-9	dapsone	2.5	HTS	bacterial antifolate	DHFR	dermatology, infectious disease	dermatitis herpetiformis (DH), leprosy	Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1	Launched	5
BRD-K62374253-001-07-8::2.5::HTS	0.17430493188	BRD-K62374253-001-07-8::2.5::HTS	BRD-K62374253-001-07-8	rufloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O	Launched	5
BRD-K62387885-001-01-9::2.5::HTS	-0.299967646958	BRD-K62387885-001-01-9::2.5::HTS	BRD-K62387885-001-01-9	basimglurant	2.5	HTS	glutamate receptor antagonist	GRM5			Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1	Phase 2	5
BRD-K62391742-001-03-0::2.5::HTS	-0.443271004752	BRD-K62391742-001-03-0::2.5::HTS	BRD-K62391742-001-03-0	venetoclax	2.5	HTS	BCL inhibitor	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1	Launched	5
BRD-K62398570-300-01-2::2.5::HTS	0.149175389425	BRD-K62398570-300-01-2::2.5::HTS	BRD-K62398570-300-01-2	lerisetron	2.5	HTS	serotonin receptor antagonist	HTR3A			C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1	Phase 3	5
BRD-K62412084-001-07-1::2.5::HTS	-0.32134092791700003	BRD-K62412084-001-07-1::2.5::HTS	BRD-K62412084-001-07-1	para-toluenesulfonamide	2.5	HTS		CA12, CA2, CA6, CA9			Cc1ccc(cc1)S(N)(=O)=O	Phase 3	5
BRD-K62414032-001-12-0::2.5::HTS	-0.0834152879225	BRD-K62414032-001-12-0::2.5::HTS	BRD-K62414032-001-12-0	NMDA	2.5	HTS	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O	Preclinical	5
BRD-K62427771-001-01-0::2.5::HTS	0.454484271728	BRD-K62427771-001-01-0::2.5::HTS	BRD-K62427771-001-01-0	AS-77	2.5	HTS	potassium channel blocker	KCNA3, KCNA5, KCNN4			O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1	Preclinical	5
BRD-K62456038-003-07-1::2.5::HTS	-0.0907474684299	BRD-K62456038-003-07-1::2.5::HTS	BRD-K62456038-003-07-1	PD-128907	2.5	HTS	dopamine receptor agonist	DRD2, DRD3			CCCN1CCO[C@H]2[C@@H]1COc1ccc(O)cc21, CCCN1CCO[C@@H]2[C@@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21	Preclinical	5
BRD-K62537556-001-02-5::2.5::HTS	-0.17345664057	BRD-K62537556-001-02-5::2.5::HTS	BRD-K62537556-001-02-5	4-IBP	2.5	HTS	sigma receptor agonist	SIGMAR1			Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1	Preclinical	5
BRD-K62562723-003-02-7::2.5::HTS	-0.152712766304	BRD-K62562723-003-02-7::2.5::HTS	BRD-K62562723-003-02-7	SR-2640	2.5	HTS	leukotriene receptor antagonist	CYSLTR1			OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1	Phase 2	5
BRD-K62581435-001-03-8::2.5::HTS	-0.249062448336	BRD-K62581435-001-03-8::2.5::HTS	BRD-K62581435-001-03-8	3-MPPI	2.5	HTS	adrenergic receptor ligand	ADRA1A			COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1	Preclinical	5
BRD-K62594868-082-08-6::2.5::HTS	-0.181300371847	BRD-K62594868-082-08-6::2.5::HTS	BRD-K62594868-082-08-6	GR125487	2.5	HTS	serotonin receptor antagonist	HTR4			COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1	Preclinical	5
BRD-K62607865-001-09-7::2.62::HTS	-0.657173934051	BRD-K62607865-001-09-7::2.62::HTS	BRD-K62607865-001-09-7	aztreonam	2.62	HTS	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	Launched	5
BRD-K62621335-001-01-7::2.5::HTS	0.641659119853	BRD-K62621335-001-01-7::2.5::HTS	BRD-K62621335-001-01-7	SRPIN340	2.5	HTS	serine arginine protein kinase inhibitor	SRPK1, SRPK2			FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1	Preclinical	5
BRD-K62627508-001-01-5::2.5::HTS	-3.6514400331199997	BRD-K62627508-001-01-5::2.5::HTS	BRD-K62627508-001-01-5	idasanutlin	2.5	HTS	MDM inhibitor	MDM2, TP53			COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O	Phase 3	5
BRD-K62676709-065-05-5::2.5::HTS	-0.464904917462	BRD-K62676709-065-05-5::2.5::HTS	BRD-K62676709-065-05-5	guanethidine	2.5	HTS	adrenergic inhibitor	SLC6A2	cardiology	hypertension	NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1	Launched	5
BRD-K62685538-001-01-7::2.5::HTS	0.206949056318	BRD-K62685538-001-01-7::2.5::HTS	BRD-K62685538-001-01-7	triptorelin	2.5	HTS	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology, endocrinology, obstetrics/gynecology	prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria	CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	Launched	5
BRD-K62696033-001-01-4::2.5::HTS	-0.527659631221	BRD-K62696033-001-01-4::2.5::HTS	BRD-K62696033-001-01-4	G-1	2.5	HTS	G protein-coupled receptor agonist	GPER1			CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br	Preclinical	5
BRD-K62734952-001-01-0::2.5::HTS	-0.06484536864780001	BRD-K62734952-001-01-0::2.5::HTS	BRD-K62734952-001-01-0	arglabin	2.5	HTS	farnesyltransferase inhibitor	FNTA, NFKB1			CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13	Launched	5
BRD-K62736196-015-11-0::2.41::HTS	-0.592459249058	BRD-K62736196-015-11-0::2.41::HTS	BRD-K62736196-015-11-0	guanaben-acetate	2.41	HTS	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl	Launched	5
BRD-K62736196-015-13-6::2.5::HTS	0.05545961987919999	BRD-K62736196-015-13-6::2.5::HTS	BRD-K62736196-015-13-6	guanaben-acetate	2.5	HTS	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl	Launched	5
BRD-K62737565-003-02-6::2.5::HTS	0.056441483443099995	BRD-K62737565-003-02-6::2.5::HTS	BRD-K62737565-003-02-6	gabapentin	2.5	HTS	calcium channel blocker	ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	infectious disease, neurology/psychiatry	virus herpes simplex (HSV), shingles, seizures, restless leg syndrome	NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1	Launched	5
BRD-K62762455-001-01-3::2.5::HTS	-0.214493266414	BRD-K62762455-001-01-3::2.5::HTS	BRD-K62762455-001-01-3	RU-58841	2.5	HTS	androgen receptor antagonist	AR			CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F	Phase 2	5
BRD-K62779383-001-05-5::2.38::HTS	0.320776072887	BRD-K62779383-001-05-5::2.38::HTS	BRD-K62779383-001-05-5	cholecalciferol	2.38	HTS		VDR	endocrinology	vitamin D deficiency	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Launched	5
BRD-K62782754-337-02-5::2.5::HTS	0.389168137206	BRD-K62782754-337-02-5::2.5::HTS	BRD-K62782754-337-02-5	tiotropium	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1	Launched	5
BRD-K62810658-001-12-2::2.5::HTS	-0.753112593911	BRD-K62810658-001-12-2::2.5::HTS	BRD-K62810658-001-12-2	PD-98059	2.5	HTS	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N	Preclinical	5
BRD-K62814476-001-03-3::2.5::HTS	-0.9292951550059999	BRD-K62814476-001-03-3::2.5::HTS	BRD-K62814476-001-03-3	BMS-265246	2.5	HTS	CDK inhibitor	CDK1, CDK2			CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F	Preclinical	5
BRD-K62858456-001-01-8::2.5::HTS	0.329999774634	BRD-K62858456-001-01-8::2.5::HTS	BRD-K62858456-001-01-8	lomerizine	2.5	HTS	calcium channel blocker	CACNA1B, SCN5A	neurology/psychiatry	migraine headache	COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC	Launched	5
BRD-K62929068-001-16-5::2.5::HTS	0.208515279452	BRD-K62929068-001-16-5::2.5::HTS	BRD-K62929068-001-16-5	6-benzylaminopurine	2.5	HTS	purinergic receptor activator				N(Cc1ccccc1)c1ncnc2nc[nH]c12	Preclinical	5
BRD-K62965247-001-04-9::2.5::HTS	-0.07240152398689999	BRD-K62965247-001-04-9::2.5::HTS	BRD-K62965247-001-04-9	tipifarnib	2.5	HTS	farnesyltransferase inhibitor	FNTA, FNTB			Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1	Phase 3	5
BRD-K62996583-001-10-3::2.5::HTS	0.302751538927	BRD-K62996583-001-10-3::2.5::HTS	BRD-K62996583-001-10-3	lidoflazine	2.5	HTS	calcium channel blocker	SCN1A, SCN3A, SLC29A1			Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	Launched	5
BRD-K63001556-001-08-8::2.5::HTS	0.6367642775419999	BRD-K63001556-001-08-8::2.5::HTS	BRD-K63001556-001-08-8	orbifloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	Launched	5
BRD-K63001556-001-09-6::2.57::HTS	0.11775096200099999	BRD-K63001556-001-09-6::2.57::HTS	BRD-K63001556-001-09-6	orbifloxacin	2.57	HTS	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	Launched	5
BRD-K63068307-001-08-9::2.5::HTS	-1.31674017634	BRD-K63068307-001-08-9::2.5::HTS	BRD-K63068307-001-08-9	ZSTK-474	2.5	HTS	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1	Phase 1/Phase 2	5
BRD-K63123526-001-01-2::2.5::HTS	-0.0381123098702	BRD-K63123526-001-01-2::2.5::HTS	BRD-K63123526-001-01-2	S-methylcysteine	2.5	HTS		CTSD, MGMT			CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O	Phase 1	5
BRD-K63126190-003-01-6::2.5::HTS	-0.825982903962	BRD-K63126190-003-01-6::2.5::HTS	BRD-K63126190-003-01-6	epinephrine	2.5	HTS	adrenergic receptor agonist, neurotransmitter	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1	Launched	5
BRD-K63150726-001-02-1::2.5::HTS	-0.15926884956499998	BRD-K63150726-001-02-1::2.5::HTS	BRD-K63150726-001-02-1	JTE-907	2.5	HTS	cannabinoid receptor inverse agonist	CNR2			CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12	Phase 1	5
BRD-K63151507-001-02-4::2.5::HTS	-0.148086360622	BRD-K63151507-001-02-4::2.5::HTS	BRD-K63151507-001-02-4	MNITMT	2.5	HTS	lymphocyte inhibitor				Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O	Preclinical	5
BRD-K63165456-001-10-8::2.5::HTS	0.112318607037	BRD-K63165456-001-10-8::2.5::HTS	BRD-K63165456-001-10-8	norcyclobenzaprine	2.5	HTS	adrenergic receptor agonist, serotonin receptor antagonist				CNCCC=C1c2ccccc2C=Cc2ccccc12	Preclinical	5
BRD-K63169195-001-01-5::2.5::HTS	-0.11921673355799998	BRD-K63169195-001-01-5::2.5::HTS	BRD-K63169195-001-01-5	U-0124	2.5	HTS	MEK inhibitor				CS\C(N)=C(C#N)\C(C#N)=C(/N)SC	Preclinical	5
BRD-K63178091-001-01-1::2.5::HTS	-0.422839625604	BRD-K63178091-001-01-1::2.5::HTS	BRD-K63178091-001-01-1	telotristat	2.5	HTS	tryptophan hydroxylase inhibitor	TPH1			Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	Launched	5
BRD-K63343048-001-12-2::2.5::HTS	-0.055685684568	BRD-K63343048-001-12-2::2.5::HTS	BRD-K63343048-001-12-2	orlistat	2.5	HTS	lipase inhibitor	CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP	endocrinology	weight-loss aid	CCCCCCCCCCC[C@@H](C[C@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	Launched	5
BRD-K63430059-001-17-2::2.5::HTS	0.145027488869	BRD-K63430059-001-17-2::2.5::HTS	BRD-K63430059-001-17-2	methoxsalen	2.5	HTS	DNA synthesis inhibitor	CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4	dermatology	psoriasis	COc1c2occc2cc2ccc(=O)oc12, COc1c2occc2cc2ccc(=O)oc12	Launched	5
BRD-K63504947-001-15-4::2.5::HTS	0.225808131375	BRD-K63504947-001-15-4::2.5::HTS	BRD-K63504947-001-15-4	semaxanib	2.5	HTS	VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	Phase 3	5
BRD-K63516691-003-02-0::2.5::HTS	0.116381017128	BRD-K63516691-003-02-0::2.5::HTS	BRD-K63516691-003-02-0	T-0156	2.5	HTS	phosphodiesterase inhibitor	PDE5A			COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1	Preclinical	5
BRD-K63533170-001-02-9::2.5::HTS	0.407990013291	BRD-K63533170-001-02-9::2.5::HTS	BRD-K63533170-001-02-9	AM-630	2.5	HTS	cannabinoid receptor antagonist	CNR1, CNR2			COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12	Preclinical	5
BRD-K63550407-001-12-7::2.5::HTS	-0.0776880953048	BRD-K63550407-001-12-7::2.5::HTS	BRD-K63550407-001-12-7	erythromycin	2.5	HTS	NFkB pathway inhibitor	MLNR	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	5
BRD-K63550407-001-13-5::2.5::HTS	0.257945221004	BRD-K63550407-001-13-5::2.5::HTS	BRD-K63550407-001-13-5	erythromycin	2.5	HTS	NFkB pathway inhibitor	MLNR	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	5
BRD-K63630713-001-25-8::2.5::HTS	0.259900213508	BRD-K63630713-001-25-8::2.5::HTS	BRD-K63630713-001-25-8	etacrynic-acid	2.5	HTS	sodium/potassium/chloride transporter inhibitor	ATP1A1, SLC12A1	cardiology, gastroenterology, nephrology, rheumatology	hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome	CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl	Launched	5
BRD-K63675182-003-23-6::2.5::HTS	0.477540249747	BRD-K63675182-003-23-6::2.5::HTS	BRD-K63675182-003-23-6	triflupromazine	2.5	HTS	dopamine receptor antagonist	CHRM1, CHRM2, DRD1, DRD2, HTR2B	neurology/psychiatry, gastroenterology	psychosis, nausea, vomiting	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F	Launched	5
BRD-K63712959-001-01-8::2.5::HTS	0.173954236417	BRD-K63712959-001-01-8::2.5::HTS	BRD-K63712959-001-01-8	temoporfin	2.5	HTS	radical formation stimulant		oncology	head and neck squamous cell carcinoma (HNSCC)	Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2	Launched	5
BRD-K63736853-001-04-8::2.5::HTS	-1.20591841936	BRD-K63736853-001-04-8::2.5::HTS	BRD-K63736853-001-04-8	acipimox	2.5	HTS	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O	Launched	5
BRD-K63750851-001-20-7::2.5::HTS	-0.229371758919	BRD-K63750851-001-20-7::2.5::HTS	BRD-K63750851-001-20-7	mycophenolic-acid	2.5	HTS	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	Launched	5
BRD-K63784565-001-06-2::2.51::HTS	-4.364458990909999	BRD-K63784565-001-06-2::2.51::HTS	BRD-K63784565-001-06-2	10-hydroxycamptothecin	2.51	HTS	topoisomerase inhibitor	TOP1			CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O	Preclinical	5
BRD-K63792901-075-02-1::2.5::HTS	0.24032818109700002	BRD-K63792901-075-02-1::2.5::HTS	BRD-K63792901-075-02-1	arecaidine-but-2-ynyl-ester	2.5	HTS	acetylcholine receptor agonist	CHRM2			CC#CCOC(=O)C1=CCCN(C)C1	Preclinical	5
BRD-K63806092-236-02-6::2.5::HTS	-0.39130016488200003	BRD-K63806092-236-02-6::2.5::HTS	BRD-K63806092-236-02-6	sitaxentan	2.5	HTS	endothelin receptor antagonist	EDNRA			Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	Withdrawn	5
BRD-K63828191-003-32-1::2.5::HTS	0.0962897862949	BRD-K63828191-003-32-1::2.5::HTS	BRD-K63828191-003-32-1	raloxifene	2.5	HTS	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1	Launched	5
BRD-K63861289-001-19-6::2.5::HTS	-0.119799837952	BRD-K63861289-001-19-6::2.5::HTS	BRD-K63861289-001-19-6	molsidomine	2.5	HTS	guanylate cyclase stimulant	GUCY1A3	cardiology	coronary artery disease (CAD)	CCOC(=O)Nc1c[n+](no1)N1CCOCC1	Launched	5
BRD-K63874012-001-02-9::2.5::HTS	-0.0957501283435	BRD-K63874012-001-02-9::2.5::HTS	BRD-K63874012-001-02-9	thioperamide	2.5	HTS	histamine receptor antagonist	HRH3, HRH4			S=C(NC1CCCCC1)N1CCC(CC1)c1c[nH]cn1, S=C(NC1CCCCC1)N1CCC(CC1)c1c[nH]cn1	Preclinical	5
BRD-K63915849-001-03-7::2.5::HTS	0.307878047432	BRD-K63915849-001-03-7::2.5::HTS	BRD-K63915849-001-03-7	AS-604850	2.5	HTS	PI3K inhibitor	PIK3CA, PIK3CG			FC1(F)Oc2ccc(cc2O1)\C=C1/SC(=O)NC1=O	Preclinical	5
BRD-K63919159-003-07-0::2.5::HTS	0.273593719259	BRD-K63919159-003-07-0::2.5::HTS	BRD-K63919159-003-07-0	aptiganel	2.5	HTS	glutamate receptor antagonist	GRIN1			CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12	Phase 3	5
BRD-K63923597-001-10-0::2.5::HTS	-1.03838501473	BRD-K63923597-001-10-0::2.5::HTS	BRD-K63923597-001-10-0	barasertib-HQPA	2.5	HTS	Aurora kinase inhibitor	AURKB			CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1	Phase 2/Phase 3	5
BRD-K63932022-001-01-5::2.5::HTS	-0.11336179510700001	BRD-K63932022-001-01-5::2.5::HTS	BRD-K63932022-001-01-5	2'-MeCCPA	2.5	HTS	adenosine receptor agonist	ADORA1			C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12	Preclinical	5
BRD-K64052750-001-17-5::2.5::HTS	0.369742845304	BRD-K64052750-001-17-5::2.5::HTS	BRD-K64052750-001-17-5	gefitinib	2.5	HTS	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1	Launched	5
BRD-K64054020-001-03-5::0.25::HTS	0.06734415819209999	BRD-K64054020-001-03-5::0.25::HTS	BRD-K64054020-001-03-5	epoprostenol	0.25	HTS	prostacyclin analog	P2RY12, PTGER1, PTGER4, PTGIR, PTGIS	cardiology	hypertension	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O	Launched	3
BRD-K64137799-003-02-5::2.5::HTS	-0.375954854184	BRD-K64137799-003-02-5::2.5::HTS	BRD-K64137799-003-02-5	2-methyl-5-hydroxytryptamine	2.5	HTS	serotonin receptor agonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6			Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN	Preclinical	5
BRD-K64157027-003-02-7::2.5::HTS	-0.20146626875	BRD-K64157027-003-02-7::2.5::HTS	BRD-K64157027-003-02-7	ZD-2079	2.5	HTS	adrenergic receptor agonist	ADRB3			O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1	Phase 2	5
BRD-K64178227-001-09-0::2.5::HTS	0.48505258256399997	BRD-K64178227-001-09-0::2.5::HTS	BRD-K64178227-001-09-0	BTS	2.5	HTS					Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1	Preclinical	5
BRD-K64191834-001-03-1::2.5::HTS	0.053118879434	BRD-K64191834-001-03-1::2.5::HTS	BRD-K64191834-001-03-1	CBS,-N-Cyclohexyl-2-benzothiazolesulfenamide	2.5	HTS					C1CCC(CC1)NSc1nc2ccccc2s1	Preclinical	5
BRD-K64338723-001-01-6::2.5::HTS	-0.10431171365	BRD-K64338723-001-01-6::2.5::HTS	BRD-K64338723-001-01-6	milacemide	2.5	HTS	monoamine oxidase inhibitor	MAOB			CCCCCNCC(N)=O	Phase 3	5
BRD-K64341947-003-02-4::2.5::HTS	0.35031781480999996	BRD-K64341947-003-02-4::2.5::HTS	BRD-K64341947-003-02-4	CFM-1571	2.5	HTS	guanylate cyclase activator				COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1, COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1	Preclinical	5
BRD-K64381438-001-03-8::2.5::HTS	-0.17711037866999998	BRD-K64381438-001-03-8::2.5::HTS	BRD-K64381438-001-03-8	ulipristal	2.5	HTS	progesterone receptor antagonist	PGR	endocrinology	contraceptive	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12	Launched	5
BRD-K64400208-001-08-3::2.5::HTS	-0.049057778727000005	BRD-K64400208-001-08-3::2.5::HTS	BRD-K64400208-001-08-3	DNQX	2.5	HTS	glutamate receptor antagonist	GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B			[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O	Preclinical	5
BRD-K64422603-300-02-7::2.5::HTS	0.019768804849400003	BRD-K64422603-300-02-7::2.5::HTS	BRD-K64422603-300-02-7	N-alpha-Methylhistamine-dihydrochloride	2.5	HTS	histamine receptor agonist	HRH4			CNCCc1cnc[nH]1	Phase 3	5
BRD-K64514229-001-05-2::2.5::HTS	-0.360223491345	BRD-K64514229-001-05-2::2.5::HTS	BRD-K64514229-001-05-2	toltrazuril	2.5	HTS	antiprotozoal agent		infectious disease	coccidiosis	Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O	Launched	5
BRD-K64538373-001-01-4::2.5::HTS	-4.24490530169	BRD-K64538373-001-01-4::2.5::HTS	BRD-K64538373-001-01-4	Ro-4987655	2.5	HTS	MEK inhibitor	MAP2K1			OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	Phase 1	5
BRD-K64557645-001-02-4::2.5::HTS	0.20011780636	BRD-K64557645-001-02-4::2.5::HTS	BRD-K64557645-001-02-4	zotepine	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4	neurology/psychiatry	schizophrenia	CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12	Launched	5
BRD-K64614248-001-12-3::2.5::HTS	-0.027708544789400002	BRD-K64614248-001-12-3::2.5::HTS	BRD-K64614248-001-12-3	salicin	2.5	HTS	anti-inflammatory agent				OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O	Phase 1	5
BRD-K64636206-001-02-7::2.5::HTS	-0.242242480497	BRD-K64636206-001-02-7::2.5::HTS	BRD-K64636206-001-02-7	D-alpha-tocopheryl-succinate	2.5	HTS					CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1	Launched	5
BRD-K64659768-001-12-8::2.5::HTS	0.0628473774102	BRD-K64659768-001-12-8::2.5::HTS	BRD-K64659768-001-12-8	phthalylsulfathiazole	2.5	HTS	dihydropteroate synthetase inhibitor		infectious disease, gastroenterology	dysentry, colitis	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Launched	5
BRD-K64716392-001-01-3::2.5::HTS	0.446981005422	BRD-K64716392-001-01-3::2.5::HTS	BRD-K64716392-001-01-3	nedocromil	2.5	HTS	histamine receptor antagonist	CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR	neurology/psychiatry, ophthalmology	itching, conjunctivitis	CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O	Launched	5
BRD-K64755930-003-03-2::2.5::HTS	-0.520106748121	BRD-K64755930-003-03-2::2.5::HTS	BRD-K64755930-003-03-2	etazolate	2.5	HTS	phosphodiesterase inhibitor	GABRB3, PDE4A			CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C	Phase 2	5
BRD-K64785675-001-04-0::2.5::HTS	-0.17979772177499997	BRD-K64785675-001-04-0::2.5::HTS	BRD-K64785675-001-04-0	TG100-115	2.5	HTS	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1	Phase 1/Phase 2	5
BRD-K64800655-001-07-4::2.5::HTS	-3.4047314016400003	BRD-K64800655-001-07-4::2.5::HTS	BRD-K64800655-001-07-4	PHA-793887	2.5	HTS	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9			CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C	Phase 1	5
BRD-K64835161-001-02-8::2.5::HTS	0.178649043779	BRD-K64835161-001-02-8::2.5::HTS	BRD-K64835161-001-02-8	ML167	2.5	HTS	CLK inhibitor, DYRK inhibitor	CLK4, DYRK1B			Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1	Preclinical	5
BRD-K64838454-001-01-0::2.5::HTS	-0.0422691687902	BRD-K64838454-001-01-0::2.5::HTS	BRD-K64838454-001-01-0	dipraglurant	2.5	HTS	glutamate receptor negative allosteric modulator	GRM5			Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1	Phase 2	5
BRD-K64866502-001-03-9::2.5::HTS	-1.4317672916	BRD-K64866502-001-03-9::2.5::HTS	BRD-K64866502-001-03-9	CYC116	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB, KDR			Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	Phase 1	5
BRD-K64874225-001-04-7::1.13::HTS	0.18737835367400002	BRD-K64874225-001-04-7::1.13::HTS	BRD-K64874225-001-04-7	NSC-4644	1.13	HTS	ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor	PYGM			CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12	Phase 2	4
BRD-K64881305-001-03-7::2.5::HTS	-0.964089774598	BRD-K64881305-001-03-7::2.5::HTS	BRD-K64881305-001-03-7	ispinesib	2.5	HTS	kinesin inhibitor	KIF11			CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1	Phase 2	5
BRD-K64888243-001-03-7::2.5::HTS	-1.05852311363	BRD-K64888243-001-03-7::2.5::HTS	BRD-K64888243-001-03-7	AZ960	2.5	HTS	JAK inhibitor	JAK2			C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1	Preclinical	5
BRD-K64890080-001-13-8::2.5::HTS	-2.90996400598	BRD-K64890080-001-13-8::2.5::HTS	BRD-K64890080-001-13-8	BI-2536	2.5	HTS	PLK inhibitor	BRD4, PLK1, PLK2, PLK3			CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O	Phase 2	5
BRD-K64925568-001-01-8::2.5::HTS	-4.63601278764	BRD-K64925568-001-01-8::2.5::HTS	BRD-K64925568-001-01-8	AMG-232	2.5	HTS	MDM inhibitor	MDM2			CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1	Phase 1/Phase 2	5
BRD-K64931368-003-01-4::2.5::HTS	-0.142337452453	BRD-K64931368-003-01-4::2.5::HTS	BRD-K64931368-003-01-4	aminocaproic-acid	2.5	HTS	plasminogen activator inhibitor	LPA, PLAT, PLG	hematology	fibrinolytic bleeding	NCCCCCC(O)=O, NCCCCCC(O)=O, NCCCCCC(O)=O	Launched	5
BRD-K64990126-004-01-1::2.5::HTS	-0.757937880372	BRD-K64990126-004-01-1::2.5::HTS	BRD-K64990126-004-01-1	scopolamine	2.5	HTS	acetylcholine receptor antagonist		neurology/psychiatry, gastroenterology	motion sickness, vomiting, nausea	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@H](C[C@@H]1[C@@H]1O[C@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Launched	5
BRD-K64990520-001-08-4::2.5::HTS	0.41754537651600004	BRD-K64990520-001-08-4::2.5::HTS	BRD-K64990520-001-08-4	apocynin	2.5	HTS	NADPH oxidase inhibitor	NOX4			COc1cc(ccc1O)C(C)=O	Phase 1	5
BRD-K64994968-001-32-5::2.5::HTS	0.059009863974599994	BRD-K64994968-001-32-5::2.5::HTS	BRD-K64994968-001-32-5	progesterone	2.5	HTS	progesterone receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5	obstetrics/gynecology, endocrinology	infertility, amenorrhea	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K65146499-001-27-9::2.5::HTS	0.0351239270235	BRD-K65146499-001-27-9::2.5::HTS	BRD-K65146499-001-27-9	nabumetone	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1	Launched	5
BRD-K65170927-001-01-6::2.5::HTS	-0.237308587806	BRD-K65170927-001-01-6::2.5::HTS	BRD-K65170927-001-01-6	aprepitant	2.5	HTS	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	C[C@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Launched	5
BRD-K65275554-001-04-7::2.5::HTS	-0.202949294778	BRD-K65275554-001-04-7::2.5::HTS	BRD-K65275554-001-04-7	NPC-15199	2.5	HTS	ICAM1 antagonist	PPARG			CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	Phase 2	5
BRD-K65285700-001-02-3::2.5::HTS	0.411361309499	BRD-K65285700-001-02-3::2.5::HTS	BRD-K65285700-001-02-3	GP1a	2.5	HTS	cannabinoid receptor agonist	CNR2			Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1	Preclinical	5
BRD-K65359424-001-01-3::2.5::HTS	0.208394599615	BRD-K65359424-001-01-3::2.5::HTS	BRD-K65359424-001-01-3	eglumetad	2.5	HTS	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM8			N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 2	5
BRD-K65377893-001-07-4::2.58::HTS	-0.6149368296500001	BRD-K65377893-001-07-4::2.58::HTS	BRD-K65377893-001-07-4	7-aminocephalosporanic-acid	2.58	HTS	beta lactamase inhibitor				CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O	Preclinical	5
BRD-K65417056-003-10-1::2.5::HTS	-0.239614374282	BRD-K65417056-003-10-1::2.5::HTS	BRD-K65417056-003-10-1	meprylcaine	2.5	HTS	local anesthetic				CCCNC(C)(C)COC(=O)c1ccccc1	Preclinical	5
BRD-K65428967-001-08-4::2.5::HTS	-0.12800745975	BRD-K65428967-001-08-4::2.5::HTS	BRD-K65428967-001-08-4	cordycepin	2.5	HTS	DNA inhibitor				Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O	Phase 1/Phase 2	5
BRD-K65503129-001-06-3::2.5::HTS	0.272151617848	BRD-K65503129-001-06-3::2.5::HTS	BRD-K65503129-001-06-3	CCT018159	2.5	HTS	HSP inhibitor	HSP90AA1, HSP90AB1			CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O	Preclinical	5
BRD-K65518078-002-01-1::2.5::HTS	0.15392415923	BRD-K65518078-002-01-1::2.5::HTS	BRD-K65518078-002-01-1	cilazapril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](N2C1=O)C(O)=O	Launched	5
BRD-K65544384-001-15-8::2.5::HTS	0.478405260339	BRD-K65544384-001-15-8::2.5::HTS	BRD-K65544384-001-15-8	4-aminohippuric-acid	2.5	HTS		SLC22A6			Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O	Launched	5
BRD-K65639003-001-09-0::2.5::HTS	-0.41023034679799997	BRD-K65639003-001-09-0::2.5::HTS	BRD-K65639003-001-09-0	icariin	2.5	HTS	phosphodiesterase inhibitor	PDE5A			COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Phase 3	5
BRD-K65667145-001-14-0::2.5::HTS	-0.226183497837	BRD-K65667145-001-14-0::2.5::HTS	BRD-K65667145-001-14-0	kinetin	2.5	HTS	cell division inducer		dermatology	sunburn	C(Nc1ncnc2[nH]cnc12)c1ccco1	Launched	5
BRD-K65678996-001-05-5::2.5::HTS	-1.0167260955	BRD-K65678996-001-05-5::2.5::HTS	BRD-K65678996-001-05-5	nefiracetam	2.5	HTS	acetylcholine receptor agonist, benzodiazepine receptor agonist	CHRM1			Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O	Phase 3	5
BRD-K65716359-001-02-1::2.5::HTS	0.184088558598	BRD-K65716359-001-02-1::2.5::HTS	BRD-K65716359-001-02-1	exifone	2.5	HTS	nootropic agent	TYR			Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O, Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O	Withdrawn	5
BRD-K65781196-001-03-0::2.5::HTS	-0.535307534175	BRD-K65781196-001-03-0::2.5::HTS	BRD-K65781196-001-03-0	avanafil	2.5	HTS	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl	Launched	5
BRD-K65786282-001-07-5::2.5::HTS	0.0247628180394	BRD-K65786282-001-07-5::2.5::HTS	BRD-K65786282-001-07-5	CGP-7930	2.5	HTS	GABA receptor modulator	GABBR1			CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Preclinical	5
BRD-K65814004-003-02-9::2.5::HTS	-2.8124498744700004	BRD-K65814004-003-02-9::2.5::HTS	BRD-K65814004-003-02-9	diphenyleneiodonium	2.5	HTS	nitric oxide synthase inhibitor	NOS2, NOS3			[I+]1c2ccccc2-c2ccccc12	Preclinical	5
BRD-K65820248-001-01-8::2.5::HTS	0.0716974788996	BRD-K65820248-001-01-8::2.5::HTS	BRD-K65820248-001-01-8	SDZ-NKT-343	2.5	HTS	tachykinin antagonist	TACR1			CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O	Phase 1	5
BRD-K65856711-001-04-4::2.5::HTS	-0.119076882993	BRD-K65856711-001-04-4::2.5::HTS	BRD-K65856711-001-04-4	rolipram-S(+)	2.5	HTS	phosphodiesterase inhibitor				COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1	Preclinical	5
BRD-K65877271-001-01-8::2.5::HTS	-0.392944529907	BRD-K65877271-001-01-8::2.5::HTS	BRD-K65877271-001-01-8	halobetasol-propionate	2.5	HTS	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl	Launched	5
BRD-K65890018-236-01-1::2.5::HTS	0.47781554200900006	BRD-K65890018-236-01-1::2.5::HTS	BRD-K65890018-236-01-1	SSR128129E	2.5	HTS					COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12	Preclinical	5
BRD-K65904673-001-01-4::2.5::HTS	-0.048443860286800006	BRD-K65904673-001-01-4::2.5::HTS	BRD-K65904673-001-01-4	tandospirone	2.5	HTS	serotonin receptor agonist	HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD), dysthymic disorder	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1	Launched	5
BRD-K65924316-001-03-1::2.5::HTS	-0.800611219456	BRD-K65924316-001-03-1::2.5::HTS	BRD-K65924316-001-03-1	serdemetan	2.5	HTS	MDM inhibitor	MDM2			C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1	Phase 1	5
BRD-K65928735-001-04-3::2.5::HTS	-0.0171044235764	BRD-K65928735-001-04-3::2.5::HTS	BRD-K65928735-001-04-3	AZD1480	2.5	HTS	JAK inhibitor	JAK1, JAK2, JAK3			C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1	Phase 1	5
BRD-K65991129-001-02-9::2.5::HTS	-0.04400181314680001	BRD-K65991129-001-02-9::2.5::HTS	BRD-K65991129-001-02-9	SB-705498	2.5	HTS	TRPV antagonist	TRPV1			FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br	Phase 2	5
BRD-K65992024-001-01-5::2.5::HTS	-0.169143861293	BRD-K65992024-001-01-5::2.5::HTS	BRD-K65992024-001-01-5	pirenoxine	2.5	HTS	AGE inhibitor		ophthalmology	cataracts	OC(=O)c1cc(O)c2c3nc4ccccc4oc3cc(=O)c2n1	Launched	5
BRD-K66030860-001-03-6::2.5::HTS	-0.469655104999	BRD-K66030860-001-03-6::2.5::HTS	BRD-K66030860-001-03-6	salidroside	2.5	HTS	beta amyloid protein neurotoxicity inhibitor	APP			OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical	5
BRD-K66035042-001-10-1::2.5::HTS	0.187641864652	BRD-K66035042-001-10-1::2.5::HTS	BRD-K66035042-001-10-1	sorbitol	2.5	HTS	mucolytic agent				OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO	Launched	5
BRD-K66093087-001-03-1::2.5::HTS	-0.406734665052	BRD-K66093087-001-03-1::2.5::HTS	BRD-K66093087-001-03-1	FGIN-1-43	2.5	HTS	benzodiazepine receptor agonist	TSPO			CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1	Preclinical	5
BRD-K66094457-001-01-5::2.5::HTS	0.0567860835809	BRD-K66094457-001-01-5::2.5::HTS	BRD-K66094457-001-01-5	CPP	2.5	HTS	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1	Phase 2	5
BRD-K66097663-001-01-8::2.5::HTS	-0.176159305625	BRD-K66097663-001-01-8::2.5::HTS	BRD-K66097663-001-01-8	TMC-353121	2.5	HTS	RSV fusion inhibitor				Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1	Phase 2	5
BRD-K66175015-001-09-0::2.5::HTS	0.9412889396690001	BRD-K66175015-001-09-0::2.5::HTS	BRD-K66175015-001-09-0	afatinib	2.5	HTS	EGFR inhibitor	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	Launched	5
BRD-K66241279-001-01-8::2.5::HTS	-0.622418476641	BRD-K66241279-001-01-8::2.5::HTS	BRD-K66241279-001-01-8	cinromide	2.5	HTS					CCNC(=O)\C=C\c1cccc(Br)c1	Phase 3	5
BRD-K66296774-236-11-3::2.63::HTS	-2.1175186631200003	BRD-K66296774-236-11-3::2.63::HTS	BRD-K66296774-236-11-3	fluvastatin	2.63	HTS	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	Launched	5
BRD-K66353228-001-14-6::2.5::HTS	-0.226923918679	BRD-K66353228-001-14-6::2.5::HTS	BRD-K66353228-001-14-6	zoxazolamine	2.5	HTS	myorelaxant				Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1	Phase 2	5
BRD-K66404838-310-01-1::2.5::HTS	0.0987194234304	BRD-K66404838-310-01-1::2.5::HTS	BRD-K66404838-310-01-1	nalbuphine	2.5	HTS	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	neurology/psychiatry	pain relief	O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45	Launched	5
BRD-K66412701-066-01-6::2.5::HTS	-0.358130233404	BRD-K66412701-066-01-6::2.5::HTS	BRD-K66412701-066-01-6	pazufloxacin	2.5	HTS	topoisomerase inhibitor		infectious disease	pneumonia, peritonitis, bacterial septicemia	C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1	Launched	5
BRD-K66465025-001-05-1::2.5::HTS	-0.33855056231200004	BRD-K66465025-001-05-1::2.5::HTS	BRD-K66465025-001-05-1	ACPC	2.5	HTS	glutamate receptor antagonist				NC1(CC1)C(O)=O	Phase 1	5
BRD-K66480997-003-10-0::2.5::HTS	0.0900979111305	BRD-K66480997-003-10-0::2.5::HTS	BRD-K66480997-003-10-0	isoguvacine	2.5	HTS	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			OC(=O)C1=CCNCC1	Preclinical	5
BRD-K66527818-001-02-6::2.5::HTS	-1.21654597639	BRD-K66527818-001-02-6::2.5::HTS	BRD-K66527818-001-02-6	VU0364770	2.5	HTS	glutamate receptor positive allosteric modulator	GRM4			Clc1cccc(NC(=O)c2ccccn2)c1	Preclinical	5
BRD-K66538826-001-07-2::2.5::HTS	0.393223599881	BRD-K66538826-001-07-2::2.5::HTS	BRD-K66538826-001-07-2	amuvatinib	2.5	HTS	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor	KIT, MET			S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12	Phase 2	5
BRD-K66615216-003-14-8::2.5::HTS	0.0719344418986	BRD-K66615216-003-14-8::2.5::HTS	BRD-K66615216-003-14-8	moxifloxacin	2.5	HTS	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology, pulmonary, infectious disease	sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections	COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	Launched	5
BRD-K66664625-001-01-2::2.5::HTS	0.11262527735899999	BRD-K66664625-001-01-2::2.5::HTS	BRD-K66664625-001-01-2	4-iodo-L-phenylalanine	2.5	HTS		DPP4			N[C@H](Cc1ccc(I)cc1)C(O)=O	Preclinical	5
BRD-K66715657-050-01-0::2.5::HTS	-0.268200530836	BRD-K66715657-050-01-0::2.5::HTS	BRD-K66715657-050-01-0	UH-232-(+)	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR1A			CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C	Preclinical	5
BRD-K66766661-001-19-2::2.5::HTS	-0.360071335474	BRD-K66766661-001-19-2::2.5::HTS	BRD-K66766661-001-19-2	estradiol-valerate	2.5	HTS	estrogen receptor agonist	ESR1	oncology, endocrinology, obstetrics/gynecology	prostate cancer, hypoestrogenism, menopause, vaginal atrophy	CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C	Launched	5
BRD-K66788707-001-14-3::2.5::HTS	-0.0240371693344	BRD-K66788707-001-14-3::2.5::HTS	BRD-K66788707-001-14-3	fludarabine	2.5	HTS	ribonucleotide reductase inhibitor	ADA, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	5
BRD-K66808046-065-03-7::2.5::HTS	0.0491323046409	BRD-K66808046-065-03-7::2.5::HTS	BRD-K66808046-065-03-7	oxyquinoline	2.5	HTS	chelating agent	METAP2	dermatology	cosmetic	Oc1cccc2cccnc12	Launched	5
BRD-K66850609-001-07-4::2.5::HTS	0.32217862052499996	BRD-K66850609-001-07-4::2.5::HTS	BRD-K66850609-001-07-4	voglibose	2.5	HTS	glucosidase inhibitor	MGAM	endocrinology	diabetes mellitus, hyperglycemia	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	Launched	5
BRD-K66876909-001-12-6::2.5::HTS	-0.327363847734	BRD-K66876909-001-12-6::2.5::HTS	BRD-K66876909-001-12-6	linezolid	2.5	HTS	bacterial 50S ribosomal subunit inhibitor	MAOA, MAOB	infectious disease	pneumonia, skin infections	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1	Launched	5
BRD-K66896231-001-08-1::2.5::HTS	-0.059490199008599996	BRD-K66896231-001-08-1::2.5::HTS	BRD-K66896231-001-08-1	ipidacrine	2.5	HTS	acetylcholinesterase inhibitor	ACHE			Nc1c2CCCc2nc2CCCCc12	Phase 3	5
BRD-K66911501-003-01-2::2.5::HTS	0.22145214438799998	BRD-K66911501-003-01-2::2.5::HTS	BRD-K66911501-003-01-2	MK-3207	2.5	HTS	calcitonin antagonist	CALCA			Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31	Phase 2	5
BRD-K66937583-001-01-2::2.5::HTS	-0.27151314045499997	BRD-K66937583-001-01-2::2.5::HTS	BRD-K66937583-001-01-2	lodoxamide	2.5	HTS	histamine receptor antagonist		ophthalmology	vernal keratoconjunctivitis (VKC)	OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N	Launched	5
BRD-K66956375-001-11-3::2.5::HTS	0.172299910446	BRD-K66956375-001-11-3::2.5::HTS	BRD-K66956375-001-11-3	oleoylethanolamide	2.5	HTS	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	CNR1, GPR119, GPR55, PPARA			CCCCCCCC\C=C/CCCCCCCC(=O)NCCO	Preclinical	5
BRD-K67017579-001-28-1::2.5::HTS	0.13334631731899999	BRD-K67017579-001-28-1::2.5::HTS	BRD-K67017579-001-28-1	cilostazol	2.5	HTS	phosphodiesterase inhibitor	PDE3A, PDE3B	cardiology	claudication	O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1	Launched	5
BRD-K67043667-001-26-4::2.5::HTS	0.426081137791	BRD-K67043667-001-26-4::2.5::HTS	BRD-K67043667-001-26-4	altretamine	2.5	HTS	DNA synthesis inhibitor		oncology	ovarian cancer	CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C	Launched	5
BRD-K67068943-001-01-0::2.5::HTS	0.167557430198	BRD-K67068943-001-01-0::2.5::HTS	BRD-K67068943-001-01-0	ORE1001	2.5	HTS	angiotensin converting enzyme inhibitor	ACE2			CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O	Phase 1/Phase 2	5
BRD-K67080878-001-15-4::2.5::HTS	0.0353281385725	BRD-K67080878-001-15-4::2.5::HTS	BRD-K67080878-001-15-4	milrinone	2.5	HTS	phosphodiesterase inhibitor	PDE2A, PDE3A, PDE3B, PDE5A	cardiology	congestive heart failure	Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N	Launched	5
BRD-K67100011-003-06-3::2.5::HTS	-0.522554045168	BRD-K67100011-003-06-3::2.5::HTS	BRD-K67100011-003-06-3	pivmecillinam	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O	Launched	5
BRD-K67102207-236-07-7::2.5::HTS	-0.43704123691299995	BRD-K67102207-236-07-7::2.5::HTS	BRD-K67102207-236-07-7	phenylbutyrate	2.5	HTS	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1	Launched	5
BRD-K67121414-001-03-3::2.5::HTS	0.37745047456200004	BRD-K67121414-001-03-3::2.5::HTS	BRD-K67121414-001-03-3	apixaban	2.5	HTS	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)	COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O	Launched	5
BRD-K67173685-001-06-9::2.39::HTS	-0.613578803821	BRD-K67173685-001-06-9::2.39::HTS	BRD-K67173685-001-06-9	4E1RCat	2.39	HTS	protein synthesis inhibitor	EIF4E, EIF4G1			OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O	Preclinical	5
BRD-K67217586-001-08-0::2.5::HTS	0.472846156505	BRD-K67217586-001-08-0::2.5::HTS	BRD-K67217586-001-08-0	fenthion	2.5	HTS	cholinesterase inhibitor				COP(=S)(OC)Oc1ccc(SC)c(C)c1	Launched	5
BRD-K67261995-001-11-7::2.5::HTS	0.0421495110136	BRD-K67261995-001-11-7::2.5::HTS	BRD-K67261995-001-11-7	iodipamide	2.5	HTS	radiopaque medium	ALB	radiology	contrast agent	OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I	Launched	5
BRD-K67277431-002-10-5::2.5::HTS	-0.192974531499	BRD-K67277431-002-10-5::2.5::HTS	BRD-K67277431-002-10-5	picotamide	2.5	HTS	thromboxane receptor antagonist, thromboxane synthase inhibitor	TBXA2R	hematology	thrombosis	COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1	Launched	5
BRD-K67298865-001-09-0::2.5::HTS	-0.106085487373	BRD-K67298865-001-09-0::2.5::HTS	BRD-K67298865-001-09-0	SB-431542	2.5	HTS	TGF beta receptor inhibitor	ACVR1C, TGFBR1			NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1	Preclinical	5
BRD-K67304264-001-08-5::2.5::HTS	-0.029824786868599996	BRD-K67304264-001-08-5::2.5::HTS	BRD-K67304264-001-08-5	SKA-31	2.5	HTS	potassium channel activator	KCNN4			Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1	Preclinical	5
BRD-K67511046-001-02-3::2.5::HTS	-0.323735595437	BRD-K67511046-001-02-3::2.5::HTS	BRD-K67511046-001-02-3	naloxone	2.5	HTS	opioid receptor antagonist	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	Launched	5
BRD-K67525671-001-02-5::2.5::HTS	0.161702405989	BRD-K67525671-001-02-5::2.5::HTS	BRD-K67525671-001-02-5	ZK-200775	2.5	HTS	kainate receptor antagonist				OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F	Phase 2	5
BRD-K67536197-003-11-4::2.5::HTS	-2.08247751664	BRD-K67536197-003-11-4::2.5::HTS	BRD-K67536197-003-11-4	cyclocytidine	2.5	HTS	DNA synthesis inhibitor, RNA synthesis inhibitor				OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O	Preclinical	5
BRD-K67537649-001-04-5::2.5::HTS	-0.06580776190030001	BRD-K67537649-001-04-5::2.5::HTS	BRD-K67537649-001-04-5	PQ-401	2.5	HTS	IGF-1 inhibitor	IGF1R			COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12	Preclinical	5
BRD-K67563174-001-17-6::2.5::HTS	-0.115364524143	BRD-K67563174-001-17-6::2.5::HTS	BRD-K67563174-001-17-6	acemetacin	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1	Launched	5
BRD-K67566344-001-07-5::2.5::HTS	-0.495660290655	BRD-K67566344-001-07-5::2.5::HTS	BRD-K67566344-001-07-5	ku-0063794	2.5	HTS	mTOR inhibitor	MTOR			COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1	Preclinical	5
BRD-K67578145-001-09-7::2.38::HTS	-0.244627612588	BRD-K67578145-001-09-7::2.38::HTS	BRD-K67578145-001-09-7	GDC-0879	2.38	HTS	RAF inhibitor	BRAF			OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1	Preclinical	5
BRD-K67578145-001-12-1::2.5::HTS	-0.45950598892399996	BRD-K67578145-001-12-1::2.5::HTS	BRD-K67578145-001-12-1	GDC-0879	2.5	HTS	RAF inhibitor	BRAF			OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1	Preclinical	5
BRD-K67601717-037-02-4::2.5::HTS	-0.0346170762605	BRD-K67601717-037-02-4::2.5::HTS	BRD-K67601717-037-02-4	almotriptan	2.5	HTS	serotonin receptor agonist	HTR1B, HTR1D	neurology/psychiatry	migraine headache	CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12	Launched	5
BRD-K67637637-003-12-6::2.5::HTS	-0.0651594095279	BRD-K67637637-003-12-6::2.5::HTS	BRD-K67637637-003-12-6	olopatadine	2.5	HTS	histamine receptor antagonist	HRH1, S100A1, S100A12, S100A13, S100A2, S100B	ophthalmology	conjunctivitis	CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12	Launched	5
BRD-K67680372-003-02-6::2.5::HTS	-0.8559454242910001	BRD-K67680372-003-02-6::2.5::HTS	BRD-K67680372-003-02-6	CI-966	2.5	HTS	GAT inhibitor	SLC6A1			OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1	Phase 1	5
BRD-K67772619-001-05-1::2.5::HTS	0.143524360806	BRD-K67772619-001-05-1::2.5::HTS	BRD-K67772619-001-05-1	rheochrysidin	2.5	HTS	protein tyrosine kinase inhibitor	PTPN1			COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1	Preclinical	5
BRD-K67783091-001-26-1::2.5::HTS	-0.0195167605778	BRD-K67783091-001-26-1::2.5::HTS	BRD-K67783091-001-26-1	haloperidol	2.5	HTS	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1	neurology/psychiatry	schizophrenia, Tourette's disorder	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	Launched	5
BRD-K67789209-001-01-0::2.5::HTS	-0.07027434171500001	BRD-K67789209-001-01-0::2.5::HTS	BRD-K67789209-001-01-0	adatanserin	2.5	HTS	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR2A			O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2	Phase 2	5
BRD-K67831364-003-03-3::2.5::HTS	-0.479492522678	BRD-K67831364-003-03-3::2.5::HTS	BRD-K67831364-003-03-3	ZM-323881	2.5	HTS	VEGFR inhibitor	KDR			Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	Preclinical	5
BRD-K67844266-003-01-9::2.5::HTS	-1.66716902082	BRD-K67844266-003-01-9::2.5::HTS	BRD-K67844266-003-01-9	pevonedistat	2.5	HTS	nedd activating enzyme inhibitor	NAE1, UBA3			NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12	Phase 2	5
BRD-K67860401-001-05-6::2.5::HTS	0.09287316811210002	BRD-K67860401-001-05-6::2.5::HTS	BRD-K67860401-001-05-6	AR-A014418	2.5	HTS	glycogen synthase kinase inhibitor	GSK3B			COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1	Preclinical	5
BRD-K67868012-001-07-6::2.5::HTS	-1.13226644769	BRD-K67868012-001-07-6::2.5::HTS	BRD-K67868012-001-07-6	PI-103	2.5	HTS	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	Preclinical	5
BRD-K67901620-001-02-0::2.5::HTS	-0.246115082973	BRD-K67901620-001-02-0::2.5::HTS	BRD-K67901620-001-02-0	avasimibe	2.5	HTS	ACAT inhibitor	CES1			CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C	Phase 3	5
BRD-K67943528-050-01-4::2.5::HTS	0.234180067955	BRD-K67943528-050-01-4::2.5::HTS	BRD-K67943528-050-01-4	lisuride	2.5	HTS	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6	neurology/psychiatry	Parkinson's Disease	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34	Launched	5
BRD-K67966701-001-11-6::2.5::HTS	-0.108010355865	BRD-K67966701-001-11-6::2.5::HTS	BRD-K67966701-001-11-6	lisinopril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology, endocrinology	hypertension, congestive heart failure, diabetes mellitus	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Launched	5
BRD-K67966701-001-12-4::2.5::HTS	-0.231277432872	BRD-K67966701-001-12-4::2.5::HTS	BRD-K67966701-001-12-4	lisinopril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology, endocrinology	hypertension, congestive heart failure, diabetes mellitus	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Launched	5
BRD-K67977190-066-02-3::2.5::HTS	-1.8445104503	BRD-K67977190-066-02-3::2.5::HTS	BRD-K67977190-066-02-3	eprosartan	2.5	HTS	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O	Launched	5
BRD-K68065987-300-09-1::2.5::HTS	0.6945034011669999	BRD-K68065987-300-09-1::2.5::HTS	BRD-K68065987-300-09-1	MK-2206	2.5	HTS	AKT inhibitor	AKT1, AKT2, AKT3			NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	Phase 2	5
BRD-K68095457-001-10-1::2.5::HTS	-0.0148235849801	BRD-K68095457-001-10-1::2.5::HTS	BRD-K68095457-001-10-1	palmitoylethanolamide	2.5	HTS	cannabinoid receptor agonist	CNR2, GPR119, GPR55			CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO	Launched	5
BRD-K68103045-001-02-9::2.5::HTS	-0.212496082697	BRD-K68103045-001-02-9::2.5::HTS	BRD-K68103045-001-02-9	CGS-20625	2.5	HTS	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O	Phase 1	5
BRD-K68132782-003-13-8::2.5::HTS	-0.62286634674	BRD-K68132782-003-13-8::2.5::HTS	BRD-K68132782-003-13-8	terbinafine	2.5	HTS	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12	Launched	5
BRD-K68164687-001-01-6::2.5::HTS	-2.1790180438999998	BRD-K68164687-001-01-6::2.5::HTS	BRD-K68164687-001-01-6	epothilone-b	2.5	HTS	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B			C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Phase 3	5
BRD-K68174511-001-06-6::2.5::HTS	-3.8691802988199995	BRD-K68174511-001-06-6::2.5::HTS	BRD-K68174511-001-06-6	torin-2	2.5	HTS	mTOR inhibitor	MTOR			Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1	Preclinical	5
BRD-K68185022-001-14-8::2.5::HTS	0.252193196054	BRD-K68185022-001-14-8::2.5::HTS	BRD-K68185022-001-14-8	ursolic-acid	2.5	HTS	ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor	HSD11B1, PLA2G1B, PTPN1, PYGM			C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	Phase 1	5
BRD-K68188368-001-09-4::2.5::HTS	0.399862788761	BRD-K68188368-001-09-4::2.5::HTS	BRD-K68188368-001-09-4	nifuroxazide	2.5	HTS	bacterial DNA inhibitor		gastroenterology	colitis, diarrhea	Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched	5
BRD-K68202742-001-16-5::2.63::HTS	-4.01593763264	BRD-K68202742-001-16-5::2.63::HTS	BRD-K68202742-001-16-5	trichostatin-a	2.63	HTS	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C	Preclinical	5
BRD-K68232413-001-01-2::2.5::HTS	0.24742735626999995	BRD-K68232413-001-01-2::2.5::HTS	BRD-K68232413-001-01-2	etizolam	2.5	HTS	benzodiazepine receptor agonist	GABRA1	neurology/psychiatry	insomnia, anxiety	CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl	Launched	5
BRD-K68232650-001-02-2::2.5::HTS	-0.250203302817	BRD-K68232650-001-02-2::2.5::HTS	BRD-K68232650-001-02-2	lacosamide	2.5	HTS	collapsin response mediator protein inhibitor, collapsin response mediator protein stimulant, sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1	Launched	5
BRD-K68264559-045-02-4::2.5::HTS	-0.0758711335089	BRD-K68264559-045-02-4::2.5::HTS	BRD-K68264559-045-02-4	brimonidine	2.5	HTS	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12	Launched	5
BRD-K68264559-045-04-0::2.58::HTS	0.199609855649	BRD-K68264559-045-04-0::2.58::HTS	BRD-K68264559-045-04-0	brimonidine	2.58	HTS	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12	Launched	5
BRD-K68336408-001-10-9::2.5::HTS	0.051183439766199997	BRD-K68336408-001-10-9::2.5::HTS	BRD-K68336408-001-10-9	tyrphostin-AG-1478	2.5	HTS	EGFR inhibitor	EGFR, MAPK14			COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC	Preclinical	5
BRD-K68346641-001-01-4::2.5::HTS	-2.27687403765	BRD-K68346641-001-01-4::2.5::HTS	BRD-K68346641-001-01-4	amsacrine	2.5	HTS	topoisomerase inhibitor	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12	Launched	5
BRD-K68346641-001-02-2::2.5::HTS	-3.25670603426	BRD-K68346641-001-02-2::2.5::HTS	BRD-K68346641-001-02-2	amsacrine	2.5	HTS	topoisomerase inhibitor	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12	Launched	5
BRD-K68392338-003-02-0::2.5::HTS	-0.0455956549254	BRD-K68392338-003-02-0::2.5::HTS	BRD-K68392338-003-02-0	ZK-93426	2.5	HTS	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA5			CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C	Phase 1	5
BRD-K68395654-001-03-1::2.5::HTS	-1.36562383988	BRD-K68395654-001-03-1::2.5::HTS	BRD-K68395654-001-03-1	EVP4593	2.5	HTS	NFkB pathway inhibitor				Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1	Preclinical	5
BRD-K68402494-003-03-5::2.5::HTS	-0.297786757726	BRD-K68402494-003-03-5::2.5::HTS	BRD-K68402494-003-03-5	ML-9	2.5	HTS	myosin light chain kinase inhibitor	TRPC6			Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1	Preclinical	5
BRD-K68405354-001-06-4::2.5::HTS	-0.260916351323	BRD-K68405354-001-06-4::2.5::HTS	BRD-K68405354-001-06-4	spaglumic-acid	2.5	HTS	glutamate receptor antagonist	GRM3	allergy	allergic conjunctivitis, allergic rhinitis	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	5
BRD-K68405354-001-07-2::2.5::HTS	-1.0467496361700002	BRD-K68405354-001-07-2::2.5::HTS	BRD-K68405354-001-07-2	spaglumic-acid	2.5	HTS	glutamate receptor antagonist	GRM3	allergy	allergic conjunctivitis, allergic rhinitis	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	5
BRD-K68408467-065-01-8::2.5::HTS	-0.14194954563200002	BRD-K68408467-065-01-8::2.5::HTS	BRD-K68408467-065-01-8	proflavine-hemisulfate	2.5	HTS	topical anesthetic	F2			Nc1ccc2cc3ccc(N)cc3nc2c1	Phase 2	5
BRD-K68474068-001-01-8::2.5::HTS	0.21512012788	BRD-K68474068-001-01-8::2.5::HTS	BRD-K68474068-001-01-8	MM-102	2.5	HTS	WDR5/MLL interaction inhibitor				CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1	Preclinical	5
BRD-K68488863-001-04-9::2.5::HTS	-1.1412653271700002	BRD-K68488863-001-04-9::2.5::HTS	BRD-K68488863-001-04-9	ENMD-2076	2.5	HTS	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC			CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1	Phase 2	5
BRD-K68502831-001-01-2::2.5::HTS	0.0680206095692	BRD-K68502831-001-01-2::2.5::HTS	BRD-K68502831-001-01-2	dianhydrogalactitol	2.5	HTS	DNA alkylating agent				O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1	Phase 1	5
BRD-K68507560-003-24-6::2.5::HTS	0.091867943105	BRD-K68507560-003-24-6::2.5::HTS	BRD-K68507560-003-24-6	dicycloverine	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	Launched	5
BRD-K68532323-003-02-8::2.5::HTS	-2.27199207602	BRD-K68532323-003-02-8::2.5::HTS	BRD-K68532323-003-02-8	SB-743921	2.5	HTS	kinesin-like spindle protein inhibitor	KIF11			CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1	Phase 1/Phase 2	5
BRD-K68538666-001-12-3::2.5::HTS	0.255373478381	BRD-K68538666-001-12-3::2.5::HTS	BRD-K68538666-001-12-3	aceclofenac	2.5	HTS	prostanoid receptor antagonist	PTGS2	rheumatology	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia	OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	Launched	5
BRD-K68552125-001-05-3::2.03::HTS	-0.261838268768	BRD-K68552125-001-05-3::2.03::HTS	BRD-K68552125-001-05-3	12-O-tetradecanoylphorbol-13-acetate	2.03	HTS	PKC activator	KCNT2, TRPV4			CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O	Phase 2	4
BRD-K68553471-003-12-3::2.5::HTS	0.03754715991	BRD-K68553471-003-12-3::2.5::HTS	BRD-K68553471-003-12-3	todralazine	2.5	HTS	antihypertensive agent				CCOC(=O)NNc1nncc2ccccc12	Launched	5
BRD-K68558722-001-04-0::2.5::HTS	0.615830524256	BRD-K68558722-001-04-0::2.5::HTS	BRD-K68558722-001-04-0	deracoxib	2.5	HTS	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F	Launched	5
BRD-K68567222-001-01-2::2.5::HTS	-0.504836392954	BRD-K68567222-001-01-2::2.5::HTS	BRD-K68567222-001-01-2	BVT-948	2.5	HTS	tyrosine phosphatase inhibitor	PTPN1, PTPN11, PTPN2			CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O	Preclinical	5
BRD-K68620903-001-11-4::2.5::HTS	-0.00998627689489	BRD-K68620903-001-11-4::2.5::HTS	BRD-K68620903-001-11-4	dydrogesterone	2.5	HTS	progesterone receptor agonist	PGR	obstetrics/gynecology	infertility	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C	Launched	5
BRD-K68633617-003-02-9::2.5::HTS	0.290606064848	BRD-K68633617-003-02-9::2.5::HTS	BRD-K68633617-003-02-9	ACDPP	2.5	HTS	glutamate receptor antagonist	GRM5			CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1	Preclinical	5
BRD-K68653965-001-01-1::2.5::HTS	0.130328397307	BRD-K68653965-001-01-1::2.5::HTS	BRD-K68653965-001-01-1	picolamine	2.5	HTS					NCc1cccnc1	Preclinical	5
BRD-K68693535-001-03-4::2.5::HTS	-0.7794653518440001	BRD-K68693535-001-03-4::2.5::HTS	BRD-K68693535-001-03-4	lidamidine	2.5	HTS	adrenergic receptor agonist		gastroenterology	diarrhea	CNC(=N)NC(=O)Nc1c(C)cccc1C	Launched	5
BRD-K68747584-001-02-0::2.5::HTS	-1.8377071570400003	BRD-K68747584-001-02-0::2.5::HTS	BRD-K68747584-001-02-0	PF-03814735	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB			CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21	Phase 1	5
BRD-K68756823-001-07-1::2.5::HTS	0.775749929097	BRD-K68756823-001-07-1::2.5::HTS	BRD-K68756823-001-07-1	FR-180204	2.5	HTS	MAP kinase inhibitor	MAPK1, MAPK3			Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1	Preclinical	5
BRD-K68770713-001-01-8::2.5::HTS	-0.23992126175	BRD-K68770713-001-01-8::2.5::HTS	BRD-K68770713-001-01-8	azosemide	2.5	HTS	electrolyte reabsorption inhibitor	SLC12A1, SLC12A2	cardiology	edema	NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl	Launched	5
BRD-K68805147-001-01-8::2.5::HTS	-0.308140298081	BRD-K68805147-001-01-8::2.5::HTS	BRD-K68805147-001-01-8	pafuramidine	2.5	HTS	DNA synthesis inhibitor				CONC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(=N)NOC	Phase 3	5
BRD-K68810443-001-01-9::2.5::HTS	0.379504994807	BRD-K68810443-001-01-9::2.5::HTS	BRD-K68810443-001-01-9	adiporon	2.5	HTS	adiponectin receptor agonist	ADIPOR1, ADIPOR2			O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	Preclinical	5
BRD-K68867920-051-11-5::2.5::HTS	-0.310704025251	BRD-K68867920-051-11-5::2.5::HTS	BRD-K68867920-051-11-5	quetiapine	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2	neurology/psychiatry	schizophrenia, bipolar disorder	OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12	Launched	5
BRD-K68870568-066-01-5::2.5::HTS	0.032708309567100004	BRD-K68870568-066-01-5::2.5::HTS	BRD-K68870568-066-01-5	flumatinib	2.5	HTS	Bcr-Abl kinase inhibitor	ABL1, PDGFRB			CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	Phase 3	5
BRD-K68904758-001-03-5::2.5::HTS	-4.657754031600001	BRD-K68904758-001-03-5::2.5::HTS	BRD-K68904758-001-03-5	cephalomannine	2.5	HTS	DNA polymerase inhibitor				C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1	Preclinical	5
BRD-K68938568-001-01-7::2.5::HTS	-0.37441675829300003	BRD-K68938568-001-01-7::2.5::HTS	BRD-K68938568-001-01-7	GDC-0152	2.5	HTS	XIAP inhibitor	BIRC2, BIRC3, BIRC7, XIAP			CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1	Phase 1	5
BRD-K68997413-001-05-1::2.5::HTS	-0.033035522001799995	BRD-K68997413-001-05-1::2.5::HTS	BRD-K68997413-001-05-1	PF-3845	2.5	HTS	FAAH inhibitor	FAAH			FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1	Preclinical	5
BRD-K69001009-001-02-8::2.5::HTS	0.5402230576579999	BRD-K69001009-001-02-8::2.5::HTS	BRD-K69001009-001-02-8	golvatinib	2.5	HTS	VEGFR inhibitor	KDR, MET			CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1	Phase 2	5
BRD-K69035426-001-01-3::2.5::HTS	0.262295335539	BRD-K69035426-001-01-3::2.5::HTS	BRD-K69035426-001-01-3	omeprazole-sulfide	2.5	HTS	ATPase inhibitor				COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1	Phase 1	5
BRD-K69070623-003-01-7::2.5::HTS	0.197590576956	BRD-K69070623-003-01-7::2.5::HTS	BRD-K69070623-003-01-7	EPZ004777	2.5	HTS	histone lysine methyltransferase inhibitor	DOT1L			CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12	Preclinical	5
BRD-K69116396-001-04-1::2.5::HTS	0.30787151108399996	BRD-K69116396-001-04-1::2.5::HTS	BRD-K69116396-001-04-1	sertindole	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2			Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12	Withdrawn	5
BRD-K69122748-001-10-1::2.5::HTS	0.454783477675	BRD-K69122748-001-10-1::2.5::HTS	BRD-K69122748-001-10-1	diacerein	2.5	HTS	interleukin inhibitor	IL1B	rheumatology	osteoarthritis	CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O	Launched	5
BRD-K69172251-001-08-9::2.5::HTS	0.22476560230599998	BRD-K69172251-001-08-9::2.5::HTS	BRD-K69172251-001-08-9	cisplatin	2.5	HTS	DNA alkylating agent, DNA synthesis inhibitor	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl	Launched	5
BRD-K69195780-004-08-4::2.5::HTS	0.022027906468000003	BRD-K69195780-004-08-4::2.5::HTS	BRD-K69195780-004-08-4	NAN-190	2.5	HTS	serotonin receptor agonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F			COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1	Preclinical	5
BRD-K69216798-001-01-9::2.5::HTS	-0.0170821770736	BRD-K69216798-001-01-9::2.5::HTS	BRD-K69216798-001-01-9	iodoantipyrine	2.5	HTS					Cc1c(I)c(=O)n(-c2ccccc2)n1C	Preclinical	5
BRD-K69231085-003-05-7::2.86::HTS	0.210511740736	BRD-K69231085-003-05-7::2.86::HTS	BRD-K69231085-003-05-7	trigonelline	2.86	HTS					C[n+]1cccc(c1)C(O)=O	Phase 1	5
BRD-K69236721-001-02-7::2.5::HTS	-0.36770912850000004	BRD-K69236721-001-02-7::2.5::HTS	BRD-K69236721-001-02-7	lumacaftor	2.5	HTS	CFTR channel agonist	CFTR	pulmonary	cystic fibrosis	Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O	Launched	5
BRD-K69247067-001-01-8::2.5::HTS	-0.059089733247100006	BRD-K69247067-001-01-8::2.5::HTS	BRD-K69247067-001-01-8	afloqualone	2.5	HTS	acetylcholine receptor antagonist		neurology/psychiatry	sedative	Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O	Launched	5
BRD-K69253806-001-02-0::2.5::HTS	0.424394820008	BRD-K69253806-001-02-0::2.5::HTS	BRD-K69253806-001-02-0	hexestrol	2.5	HTS	synthetic estrogen	AKR1C1, ESR1, ESR2			CCC(C(CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1	Launched	5
BRD-K69280563-001-01-8::2.5::HTS	-1.2066987284200001	BRD-K69280563-001-01-8::2.5::HTS	BRD-K69280563-001-01-8	vinorelbine	2.5	HTS	tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC	Launched	5
BRD-K69346723-001-04-8::2.5::HTS	0.387440071387	BRD-K69346723-001-04-8::2.5::HTS	BRD-K69346723-001-04-8	glutathione	2.5	HTS	antioxidant	ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12			N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	Phase 3	5
BRD-K69469734-003-02-5::2.5::HTS	0.21452858426399998	BRD-K69469734-003-02-5::2.5::HTS	BRD-K69469734-003-02-5	trospium	2.5	HTS	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence, urinary frequency	OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(c1ccccc1)c1ccccc1	Launched	5
BRD-K69470111-236-08-9::2.5::HTS	0.20381574801600003	BRD-K69470111-236-08-9::2.5::HTS	BRD-K69470111-236-08-9	montelukast	2.5	HTS	leukotriene receptor antagonist	ALOX5, CYSLTR1	pulmonary, allergy	asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	Launched	5
BRD-K69577666-001-01-3::2.5::HTS	-0.06185104749649999	BRD-K69577666-001-01-3::2.5::HTS	BRD-K69577666-001-01-3	SGC-0946	2.5	HTS	histone lysine methyltransferase inhibitor				CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12	Preclinical	5
BRD-K69600043-328-05-5::2.5::HTS	0.434713706357	BRD-K69600043-328-05-5::2.5::HTS	BRD-K69600043-328-05-5	thiethylperazine	2.5	HTS	dopamine receptor antagonist	DRD1, DRD2, DRD4	gastroenterology	nausea	CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	Launched	5
BRD-K69608737-001-10-2::2.5::HTS	-0.195373231888	BRD-K69608737-001-10-2::2.5::HTS	BRD-K69608737-001-10-2	tacrolimus	2.5	HTS	calcineurin inhibitor	FKBP1A	transplant	organ rejection	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	Launched	5
BRD-K69650333-003-13-2::2.48::HTS	-3.02378716917	BRD-K69650333-003-13-2::2.48::HTS	BRD-K69650333-003-13-2	idarubicin	2.48	HTS	topoisomerase inhibitor	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O	Launched	5
BRD-K69650333-003-14-0::2.5::HTS	-5.37179063993	BRD-K69650333-003-14-0::2.5::HTS	BRD-K69650333-003-14-0	idarubicin	2.5	HTS	topoisomerase inhibitor	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O	Launched	5
BRD-K69688083-004-23-1::2.5::HTS	0.12943311624	BRD-K69688083-004-23-1::2.5::HTS	BRD-K69688083-004-23-1	mestinon	2.5	HTS	cholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1	Launched	5
BRD-K69694239-001-02-2::2.5::HTS	-4.97192043594	BRD-K69694239-001-02-2::2.5::HTS	BRD-K69694239-001-02-2	bardoxolone-methyl	2.5	HTS	nuclear factor erythroid derived, like (NRF2) activator	PPARG, STAT3			COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Phase 3	5
BRD-K69726342-238-02-4::2.5::HTS	1.1974912359799998	BRD-K69726342-238-02-4::2.5::HTS	BRD-K69726342-238-02-4	atorvastatin	2.5	HTS	HMGCR inhibitor	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	Launched	5
BRD-K69726595-001-01-2::2.5::HTS	-0.834055674128	BRD-K69726595-001-01-2::2.5::HTS	BRD-K69726595-001-01-2	mericitabine	2.5	HTS	HCV inhibitor				CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C	Phase 2	5
BRD-K69776681-001-03-8::2.5::HTS	-2.25625200001	BRD-K69776681-001-03-8::2.5::HTS	BRD-K69776681-001-03-8	volasertib	2.5	HTS	PLK inhibitor	PLK1			CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O	Phase 3	5
BRD-K69812556-305-02-0::2.5::HTS	0.141965908589	BRD-K69812556-305-02-0::2.5::HTS	BRD-K69812556-305-02-0	WAY-100635	2.5	HTS	serotonin receptor antagonist	HTR1A			COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1	Phase 1	5
BRD-K69837166-003-02-0::2.5::HTS	-0.264559574719	BRD-K69837166-003-02-0::2.5::HTS	BRD-K69837166-003-02-0	trap-101	2.5	HTS	nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist	OPRL1			CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O	Preclinical	5
BRD-K69907333-001-10-6::2.5::HTS	-0.640016188891	BRD-K69907333-001-10-6::2.5::HTS	BRD-K69907333-001-10-6	flurbiprofen-(S)-(+)	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	Launched	5
BRD-K69932463-001-10-6::2.5::HTS	-4.3494776471800005	BRD-K69932463-001-10-6::2.5::HTS	BRD-K69932463-001-10-6	AZD8055	2.5	HTS	mTOR inhibitor	MTOR			COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	Phase 1	5
BRD-K70053378-001-01-1::2.5::HTS	-0.17863730908	BRD-K70053378-001-01-1::2.5::HTS	BRD-K70053378-001-01-1	SM-108	2.5	HTS					NC(=O)c1[nH]cnc1O, NC(=O)c1[nH]cnc1O	Phase 2	5
BRD-K70088346-001-01-6::2.5::HTS	0.621042214125	BRD-K70088346-001-01-6::2.5::HTS	BRD-K70088346-001-01-6	2-chloro-N6-cyclopentyladenosine	2.5	HTS	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12	Preclinical	5
BRD-K70159787-001-01-1::2.5::HTS	0.6073523890479999	BRD-K70159787-001-01-1::2.5::HTS	BRD-K70159787-001-01-1	SMI-4a	2.5	HTS	Pim kinase inhibitor	PIM1			FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O	Preclinical	5
BRD-K70163715-300-05-7::2.42::HTS	0.0676438873735	BRD-K70163715-300-05-7::2.42::HTS	BRD-K70163715-300-05-7	vatalanib	2.42	HTS	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR, PDGFRB			Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1	Phase 3	5
BRD-K70177501-003-01-4::2.5::HTS	0.206799775885	BRD-K70177501-003-01-4::2.5::HTS	BRD-K70177501-003-01-4	INH1	2.5	HTS	Hec1 inhibitor	NDC80			Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1	Preclinical	5
BRD-K70246307-001-04-1::2.5::HTS	0.36460387663099997	BRD-K70246307-001-04-1::2.5::HTS	BRD-K70246307-001-04-1	riboflavin	2.5	HTS	vitamin B2	BLVRB, RFK	gastroenterology	jaundice	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	Launched	5
BRD-K70281171-050-08-9::2.5::HTS	0.411227549612	BRD-K70281171-050-08-9::2.5::HTS	BRD-K70281171-050-08-9	U-99194	2.5	HTS	dopamine receptor antagonist	DRD3			CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1	Preclinical	5
BRD-K70301465-001-02-6::2.5::HTS	0.280086460118	BRD-K70301465-001-02-6::2.5::HTS	BRD-K70301465-001-02-6	ibrutinib	2.5	HTS	Bruton's tyrosine kinase (BTK) inhibitor	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C	Launched	5
BRD-K70301876-034-13-7::2.5::HTS	0.034393458403300006	BRD-K70301876-034-13-7::2.5::HTS	BRD-K70301876-034-13-7	escitalopram	2.5	HTS	selective serotonin reuptake inhibitor (SSRI)	ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD)	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1	Launched	5
BRD-K70327167-348-13-4::2.5::HTS	0.778078944887	BRD-K70327167-348-13-4::2.5::HTS	BRD-K70327167-348-13-4	suramin	2.5	HTS	DNA synthesis inhibitor	F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5	infectious disease	African trypanosomiasis, onchocerciasis	Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O, Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O	Launched	5
BRD-K70327191-001-02-2::2.5::HTS	-0.33023209466200004	BRD-K70327191-001-02-2::2.5::HTS	BRD-K70327191-001-02-2	benzoxiquine	2.5	HTS	antiinfective drug				O=C(Oc1cccc2cccnc12)c1ccccc1	Preclinical	5
BRD-K70330367-003-07-9::2.5::HTS	0.013985191984299998	BRD-K70330367-003-07-9::2.5::HTS	BRD-K70330367-003-07-9	amantadine	2.5	HTS	glutamate receptor antagonist	DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A	infectious disease, neurology/psychiatry	influenza A virus infection, Parkinson's Disease	NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2	Launched	5
BRD-K70358946-001-15-7::2.5::HTS	0.740685387686	BRD-K70358946-001-15-7::2.5::HTS	BRD-K70358946-001-15-7	aripiprazole	2.5	HTS	serotonin receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7	neurology/psychiatry	depression, schizophrenia, bipolar disorder	Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl	Launched	5
BRD-K70401845-003-09-6::2.5::HTS	0.277633588625	BRD-K70401845-003-09-6::2.5::HTS	BRD-K70401845-003-09-6	erlotinib	2.5	HTS	EGFR inhibitor	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC	Launched	5
BRD-K70402238-001-02-8::2.5::HTS	0.09005806235120001	BRD-K70402238-001-02-8::2.5::HTS	BRD-K70402238-001-02-8	nexturastat-a	2.5	HTS	HDAC inhibitor	HDAC1, HDAC6			CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1	Preclinical	5
BRD-K70463136-001-01-5::2.5::HTS	-1.22867086195	BRD-K70463136-001-01-5::2.5::HTS	BRD-K70463136-001-01-5	BAY-87-2243	2.5	HTS	hypoxia inducible factor inhibitor	HIF1A			Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	Phase 1	5
BRD-K70487031-001-02-8::2.5::HTS	0.22374065739000001	BRD-K70487031-001-02-8::2.5::HTS	BRD-K70487031-001-02-8	flupentixol	2.5	HTS	dopamine receptor antagonist	ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A	neurology/psychiatry	schizophrenia, depression	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	5
BRD-K70490179-300-01-2::2.5::HTS	-0.12665607896	BRD-K70490179-300-01-2::2.5::HTS	BRD-K70490179-300-01-2	rimcazole	2.5	HTS	sigma receptor antagonist	SIGMAR1			C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1	Phase 1	5
BRD-K70505054-003-12-4::2.5::HTS	-0.253283693182	BRD-K70505054-003-12-4::2.5::HTS	BRD-K70505054-003-12-4	ranitidine	2.5	HTS	histamine receptor antagonist	HRH2	gastroenterology	heartburn	CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O	Launched	5
BRD-K70507123-001-09-7::2.5::HTS	0.36656536395800005	BRD-K70507123-001-09-7::2.5::HTS	BRD-K70507123-001-09-7	doxofylline	2.5	HTS	adenosine receptor antagonist	ADORA1, PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	asthma	Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O	Launched	5
BRD-K70511574-001-06-9::2.5::HTS	-4.509715018630001	BRD-K70511574-001-06-9::2.5::HTS	BRD-K70511574-001-06-9	HMN-214	2.5	HTS	PLK inhibitor	PLK1			COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1	Phase 1	5
BRD-K70557564-305-03-6::2.5::HTS	-0.183508059665	BRD-K70557564-305-03-6::2.5::HTS	BRD-K70557564-305-03-6	zosuquidar	2.5	HTS	P glycoprotein inhibitor	ABCB1, ABCB4			O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F, O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F	Phase 3	5
BRD-K70586315-001-02-4::2.5::HTS	0.352057436144	BRD-K70586315-001-02-4::2.5::HTS	BRD-K70586315-001-02-4	1-EBIO	2.5	HTS	potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O	Preclinical	5
BRD-K70592483-001-01-0::2.5::HTS	0.11954443494000001	BRD-K70592483-001-01-0::2.5::HTS	BRD-K70592483-001-01-0	phenylacetylglutamine	2.5	HTS	DNA methylase inhibitor, protein synthesis inhibitor				NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O	Phase 2	5
BRD-K70610771-001-02-9::2.5::HTS	-0.599089551926	BRD-K70610771-001-02-9::2.5::HTS	BRD-K70610771-001-02-9	VX-222	2.5	HTS	HCV inhibitor				C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C	Phase 2	5
BRD-K70778732-003-26-7::2.5::HTS	0.0161903580531	BRD-K70778732-003-26-7::2.5::HTS	BRD-K70778732-003-26-7	trazodone	2.5	HTS	adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4	neurology/psychiatry	depression	Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1, Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1	Launched	5
BRD-K70792160-003-04-6::2.5::HTS	0.206500028683	BRD-K70792160-003-04-6::2.5::HTS	BRD-K70792160-003-04-6	10-DEBC	2.5	HTS	AKT inhibitor	PIM1			CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12	Preclinical	5
BRD-K70821460-300-02-4::2.5::HTS	-0.613886431393	BRD-K70821460-300-02-4::2.5::HTS	BRD-K70821460-300-02-4	4-methylhistamine	2.5	HTS	histamine receptor agonist	HRH4			Cc1nc[nH]c1CCN	Preclinical	5
BRD-K70898774-001-03-5::2.5::HTS	0.44358571715499995	BRD-K70898774-001-03-5::2.5::HTS	BRD-K70898774-001-03-5	naloxone-benzoylhydrazone	2.5	HTS	opioid receptor antagonist	OPRK1, OPRM1			Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1	Preclinical	5
BRD-K70912147-001-01-8::2.5::HTS	-0.15557720491399998	BRD-K70912147-001-01-8::2.5::HTS	BRD-K70912147-001-01-8	co-102862	2.5	HTS		SCN4A, SCN9A			NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1	Phase 1	5
BRD-K70914287-300-02-8::2.5::HTS	0.565066562993	BRD-K70914287-300-02-8::2.5::HTS	BRD-K70914287-300-02-8	BIBX-1382	2.5	HTS	EGFR inhibitor	EGFR, ERBB2			CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	Phase 1	5
BRD-K70924353-001-01-2::2.5::HTS	0.380630987761	BRD-K70924353-001-01-2::2.5::HTS	BRD-K70924353-001-01-2	amtolmetin-guacil	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C	Launched	5
BRD-K71035033-001-07-1::2.5::HTS	0.17664974972800002	BRD-K71035033-001-07-1::2.5::HTS	BRD-K71035033-001-07-1	masitinib	2.5	HTS	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1	Launched	5
BRD-K71055333-224-05-8::2.5::HTS	0.340704265032	BRD-K71055333-224-05-8::2.5::HTS	BRD-K71055333-224-05-8	etamsylate	2.5	HTS	haemostatic agent		hematology	hemorrhage	Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O	Launched	5
BRD-K71058253-001-01-9::2.5::HTS	0.41685733974699996	BRD-K71058253-001-01-9::2.5::HTS	BRD-K71058253-001-01-9	luliconazole	2.5	HTS	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1	Launched	5
BRD-K71059170-001-11-6::2.5::HTS	0.126845841253	BRD-K71059170-001-11-6::2.5::HTS	BRD-K71059170-001-11-6	cefixime	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis	Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O	Launched	5
BRD-K71075609-003-01-0::2.5::HTS	0.366256626079	BRD-K71075609-003-01-0::2.5::HTS	BRD-K71075609-003-01-0	dorzolamide	2.5	HTS	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	intraocular pressure, glaucoma	CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	Launched	5
BRD-K71103788-003-12-0::2.5::HTS	-0.47143609574600004	BRD-K71103788-003-12-0::2.5::HTS	BRD-K71103788-003-12-0	duloxetine	2.5	HTS	norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	Launched	5
BRD-K71106091-001-06-1::2.5::HTS	0.26302257397	BRD-K71106091-001-06-1::2.5::HTS	BRD-K71106091-001-06-1	fludarabine-phosphate	2.5	HTS	ribonucleotide reductase inhibitor	DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O	Launched	5
BRD-K71125014-001-27-1::2.5::HTS	0.248595576536	BRD-K71125014-001-27-1::2.5::HTS	BRD-K71125014-001-27-1	sulphadimethoxine	2.5	HTS	dihydropteroate synthetase inhibitor				COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1	Launched	5
BRD-K71164191-001-01-0::2.5::HTS	0.579502719787	BRD-K71164191-001-01-0::2.5::HTS	BRD-K71164191-001-01-0	KD-023	2.5	HTS	ACAT inhibitor	ACACA, ACACB			CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O	Phase 2	5
BRD-K71221037-001-01-6::2.5::HTS	-0.695956107684	BRD-K71221037-001-01-6::2.5::HTS	BRD-K71221037-001-01-6	birinapant	2.5	HTS	XIAP inhibitor	BIRC2, XIAP			CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC	Phase 2	5
BRD-K71266197-236-02-7::2.5::HTS	0.141197992808	BRD-K71266197-236-02-7::2.5::HTS	BRD-K71266197-236-02-7	PSB-06126	2.5	HTS	NTPDase inhibitor	ENTPD3			Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O	Preclinical	5
BRD-K71281111-001-04-3::2.5::HTS	-5.75516500646	BRD-K71281111-001-04-3::2.5::HTS	BRD-K71281111-001-04-3	SNX-2112	2.5	HTS	HSP inhibitor				CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1	Phase 1	5
BRD-K71289571-001-11-4::2.5::HTS	-0.06537844566880001	BRD-K71289571-001-11-4::2.5::HTS	BRD-K71289571-001-11-4	zafirlukast	2.5	HTS	leukotriene receptor antagonist	CYSLTR1, CYSLTR2	pulmonary	asthma	COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C	Launched	5
BRD-K71350836-001-02-4::2.5::HTS	-0.00018101261153299997	BRD-K71350836-001-02-4::2.5::HTS	BRD-K71350836-001-02-4	butalbital	2.5	HTS	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	headache, muscle relaxant	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	Launched	5
BRD-K71430621-303-02-3::2.5::HTS	0.0416201534051	BRD-K71430621-303-02-3::2.5::HTS	BRD-K71430621-303-02-3	clobenpropit	2.5	HTS	histamine receptor antagonist	HRH1, HRH2, HRH3, HRH4			Clc1ccc(CNC(=N)SCCCc2c[nH]cn2)cc1	Preclinical	5
BRD-K71467466-001-02-3::2.5::HTS	-4.9676764572900005	BRD-K71467466-001-02-3::2.5::HTS	BRD-K71467466-001-02-3	KPT-185	2.5	HTS	exportin antagonist	XPO1			COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1	Preclinical	5
BRD-K71480163-001-01-4::2.5::HTS	0.41845409129	BRD-K71480163-001-01-4::2.5::HTS	BRD-K71480163-001-01-4	GDC-0068	2.5	HTS	AKT inhibitor	AKT1, AKT2, AKT3, PRKG1			CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1	Phase 2	5
BRD-K71499074-001-12-9::2.5::HTS	0.257420569619	BRD-K71499074-001-12-9::2.5::HTS	BRD-K71499074-001-12-9	diclofenamide	2.5	HTS	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA4, CA7	ophthalmology, neurology/psychiatry	glaucoma, epilepsy	NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O	Launched	5
BRD-K71512533-066-02-8::2.5::HTS	-1.40044392966	BRD-K71512533-066-02-8::2.5::HTS	BRD-K71512533-066-02-8	SNS-314	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1	Phase 1	5
BRD-K71534238-001-10-0::2.5::HTS	0.17311265965199998	BRD-K71534238-001-10-0::2.5::HTS	BRD-K71534238-001-10-0	GW-9508	2.5	HTS	free fatty acid receptor agonist, G protein-coupled receptor agonist	FFAR1, FFAR4			OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	Preclinical	5
BRD-K71603915-003-01-8::2.5::HTS	0.378768885927	BRD-K71603915-003-01-8::2.5::HTS	BRD-K71603915-003-01-8	EVP-6124	2.5	HTS	acetylcholine receptor agonist	CHRNA7			Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2	Phase 3	5
BRD-K71698503-003-01-6::2.5::HTS	-0.139892006246	BRD-K71698503-003-01-6::2.5::HTS	BRD-K71698503-003-01-6	I-BZA2	2.5	HTS					CCN(CC)CCNC(=O)c1ccccc1I	Phase 3	5
BRD-K71731651-001-04-3::2.5::HTS	0.271266448871	BRD-K71731651-001-04-3::2.5::HTS	BRD-K71731651-001-04-3	PNU-120596	2.5	HTS	acetylcholine receptor agonist	CHRNA7			COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	Preclinical	5
BRD-K71799949-001-36-4::2.5::HTS	-0.31614182098099997	BRD-K71799949-001-36-4::2.5::HTS	BRD-K71799949-001-36-4	carbamazepine	2.5	HTS	carboxamide antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	NC(=O)N1c2ccccc2C=Cc2ccccc12, NC(=O)N1c2ccccc2C=Cc2ccccc12, NC(=O)N1c2ccccc2C=Cc2ccccc12	Launched	5
BRD-K71822263-001-03-2::2.5::HTS	0.355292009741	BRD-K71822263-001-03-2::2.5::HTS	BRD-K71822263-001-03-2	D-Serine	2.5	HTS	glutamate receptor agonist	GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3			N[C@H](CO)C(O)=O	Launched	5
BRD-K71823332-001-03-7::2.5::HTS	-0.410249515525	BRD-K71823332-001-03-7::2.5::HTS	BRD-K71823332-001-03-7	epothilone-a	2.5	HTS	microtubule stabilizing agent				C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Preclinical	5
BRD-K71847383-001-12-5::2.5::HTS	0.0803014712881	BRD-K71847383-001-12-5::2.5::HTS	BRD-K71847383-001-12-5	cytarabine	2.5	HTS	ribonucleotide reductase inhibitor	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	Launched	5
BRD-K71926323-001-13-8::2.5::HTS	-0.199349256253	BRD-K71926323-001-13-8::2.5::HTS	BRD-K71926323-001-13-8	marbofloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O	Launched	5
BRD-K71926323-001-14-6::2.52::HTS	-0.09296752840839999	BRD-K71926323-001-14-6::2.52::HTS	BRD-K71926323-001-14-6	marbofloxacin	2.52	HTS	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O	Launched	5
BRD-K72004355-001-01-9::2.5::HTS	-0.202398517147	BRD-K72004355-001-01-9::2.5::HTS	BRD-K72004355-001-01-9	CFTRinh-172	2.5	HTS	chloride channel blocker	CFTR			OC(=O)c1ccc(cc1)\C=C1\SC(=S)N(C1=O)c1cccc(c1)C(F)(F)F, OC(=O)c1ccc(cc1)\C=C1\SC(=S)N(C1=O)c1cccc(c1)C(F)(F)F, OC(=O)c1ccc(cc1)\C=C1\SC(=S)N(C1=O)c1cccc(c1)C(F)(F)F	Preclinical	5
BRD-K72005722-001-01-2::2.5::HTS	0.24423866104400002	BRD-K72005722-001-01-2::2.5::HTS	BRD-K72005722-001-01-2	VT-464	2.5	HTS	cytochrome P450 inhibitor	CYP17A1			CC(C)[C@@](O)(c1c[nH]nn1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1	Phase 2	5
BRD-K72029282-001-22-0::2.5::HTS	-0.293147310804	BRD-K72029282-001-22-0::2.5::HTS	BRD-K72029282-001-22-0	probucol	2.5	HTS	atherogenesis inhibitor	ABCA1, ABCB11, CES1	cardiology	coronary artery disease (CAD)	CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Launched	5
BRD-K72093121-001-16-3::2.5::HTS	-0.023410322638500004	BRD-K72093121-001-16-3::2.5::HTS	BRD-K72093121-001-16-3	vidarabine	2.5	HTS	antiviral	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	5
BRD-K72093555-001-01-0::2.5::HTS	-0.14980157945999997	BRD-K72093555-001-01-0::2.5::HTS	BRD-K72093555-001-01-0	procyanidin-b-2	2.5	HTS					O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1	Phase 2	5
BRD-K72106461-001-02-1::2.5::HTS	0.0817132494069	BRD-K72106461-001-02-1::2.5::HTS	BRD-K72106461-001-02-1	SYM-2081	2.5	HTS	kainate receptor antagonist	GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2			C[C@H](C[C@H](N)C(O)=O)C(O)=O	Preclinical	5
BRD-K72166146-066-05-4::2.5::HTS	-0.0490822725092	BRD-K72166146-066-05-4::2.5::HTS	BRD-K72166146-066-05-4	dihydroergotamine	2.5	HTS	serotonin receptor agonist	ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	Launched	5
BRD-K72167406-001-02-1::2.5::HTS	0.133754426093	BRD-K72167406-001-02-1::2.5::HTS	BRD-K72167406-001-02-1	cefditoren-pivoxil	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1	Launched	5
BRD-K72167406-001-03-9::2.5::HTS	-0.319046663046	BRD-K72167406-001-03-9::2.5::HTS	BRD-K72167406-001-03-9	cefditoren-pivoxil	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1	Launched	5
BRD-K72215350-001-06-5::2.5::HTS	0.305539459728	BRD-K72215350-001-06-5::2.5::HTS	BRD-K72215350-001-06-5	acexamic-acid	2.5	HTS	5 alpha reductase inhibitor	GAST	dermatology	wound healing	CC(=O)NCCCCCC(O)=O	Launched	5
BRD-K72222507-003-16-8::2.5::HTS	-0.695977810062	BRD-K72222507-003-16-8::2.5::HTS	BRD-K72222507-003-16-8	quinapril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, angioedema	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	Launched	5
BRD-K72231366-001-02-3::2.5::HTS	0.37126211614	BRD-K72231366-001-02-3::2.5::HTS	BRD-K72231366-001-02-3	TAME	2.5	HTS					COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1	Preclinical	5
BRD-K72327355-001-14-7::2.5::HTS	0.415620933987	BRD-K72327355-001-14-7::2.5::HTS	BRD-K72327355-001-14-7	baicalein	2.5	HTS	lipoxygenase inhibitor	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH			Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1	Preclinical	5
BRD-K72339976-065-02-1::2.5::HTS	0.631940617111	BRD-K72339976-065-02-1::2.5::HTS	BRD-K72339976-065-02-1	cefoselis	2.5	HTS	bacterial cell wall synthesis inhibitor				CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	5
BRD-K72339976-065-03-9::2.5::HTS	-0.290879988029	BRD-K72339976-065-03-9::2.5::HTS	BRD-K72339976-065-03-9	cefoselis	2.5	HTS	bacterial cell wall synthesis inhibitor				CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	5
BRD-K72339976-065-04-7::2.5::HTS	0.38112098219000007	BRD-K72339976-065-04-7::2.5::HTS	BRD-K72339976-065-04-7	cefoselis	2.5	HTS	bacterial cell wall synthesis inhibitor				CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	5
BRD-K72369578-001-04-1::2.5::HTS	0.32409463878199996	BRD-K72369578-001-04-1::2.5::HTS	BRD-K72369578-001-04-1	AZD4282	2.5	HTS	glutamate receptor antagonist	AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9			NCC(O)=O	Phase 1	5
BRD-K72384124-001-08-0::2.5::HTS	-0.0680541900535	BRD-K72384124-001-08-0::2.5::HTS	BRD-K72384124-001-08-0	sulbentine	2.5	HTS	other antifungal				S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1	Preclinical	5
BRD-K72414522-001-06-7::2.5::HTS	-5.801550348919999	BRD-K72414522-001-06-7::2.5::HTS	BRD-K72414522-001-06-7	AZD5438	2.5	HTS	CDK inhibitor	KCNH2			CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1	Phase 1	5
BRD-K72420232-001-12-3::2.5::HTS	0.20307496165600003	BRD-K72420232-001-12-3::2.5::HTS	BRD-K72420232-001-12-3	WZ-4002	2.5	HTS	EGFR inhibitor	EGFR, ERBB2			COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1	Preclinical	5
BRD-K72462751-001-02-7::2.5::HTS	-0.512446795449	BRD-K72462751-001-02-7::2.5::HTS	BRD-K72462751-001-02-7	C-1	2.5	HTS	protein kinase inhibitor	PRKCA			O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12	Preclinical	5
BRD-K72542090-304-02-4::2.5::HTS	0.16973269148400003	BRD-K72542090-304-02-4::2.5::HTS	BRD-K72542090-304-02-4	clodronic-acid	2.5	HTS	bone resorption inhibitor	SLC25A4, SLC25A5, SLC25A6	orthopedics, endocrinology, hematologic malignancy	osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma	OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O	Launched	5
BRD-K72687424-001-02-6::2.5::HTS	0.490881865525	BRD-K72687424-001-02-6::2.5::HTS	BRD-K72687424-001-02-6	VU0364439	2.5	HTS	glutamate receptor positive allosteric modulator	GRM4			Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl	Preclinical	5
BRD-K72703948-001-10-1::2.5::HTS	-1.2528718032600001	BRD-K72703948-001-10-1::2.5::HTS	BRD-K72703948-001-10-1	ZM-447439	2.5	HTS	Aurora kinase inhibitor	AURKA, AURKB			COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1	Preclinical	5
BRD-K72723676-003-17-8::2.5::HTS	-0.735268986362	BRD-K72723676-003-17-8::2.5::HTS	BRD-K72723676-003-17-8	benzethonium	2.5	HTS	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1	Launched	5
BRD-K72726508-001-02-1::2.5::HTS	0.442720685283	BRD-K72726508-001-02-1::2.5::HTS	BRD-K72726508-001-02-1	arcyriaflavin-a	2.5	HTS	CDK inhibitor	CCND1, CDK4			O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21	Preclinical	5
BRD-K72728560-001-01-4::2.5::HTS	0.544710870088	BRD-K72728560-001-01-4::2.5::HTS	BRD-K72728560-001-01-4	dimetridazole	2.5	HTS	bacterial DNA inhibitor				Cc1ncc(n1C)[N+]([O-])=O	Launched	5
BRD-K72815923-034-01-2::2.5::HTS	-0.801962995004	BRD-K72815923-034-01-2::2.5::HTS	BRD-K72815923-034-01-2	xanomeline	2.5	HTS	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7			CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1	Phase 3	5
BRD-K72827473-001-01-0::2.5::HTS	-0.31577761160900003	BRD-K72827473-001-01-0::2.5::HTS	BRD-K72827473-001-01-0	CEP-37440	2.5	HTS	ALK tyrosine kinase receptor inhibitor	ALK			CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl	Phase 1	5
BRD-K72904818-001-01-1::2.5::HTS	0.25472571572299996	BRD-K72904818-001-01-1::2.5::HTS	BRD-K72904818-001-01-1	NNC-63-0532	2.5	HTS	opioid receptor agonist	OPRL1			COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O	Preclinical	5
BRD-K72912098-001-02-3::2.5::HTS	-0.488861234239	BRD-K72912098-001-02-3::2.5::HTS	BRD-K72912098-001-02-3	telaprevir	2.5	HTS	HCV inhibitor	CTSA, PGR	infectious disease	hepatitis C	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	Launched	5
BRD-K72915123-001-18-1::2.5::HTS	0.140223970928	BRD-K72915123-001-18-1::2.5::HTS	BRD-K72915123-001-18-1	cinchophen	2.5	HTS	analgesic agent		rheumatology	gout	OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1	Launched	5
BRD-K72925150-001-11-1::2.5::HTS	0.0429224139348	BRD-K72925150-001-11-1::2.5::HTS	BRD-K72925150-001-11-1	sclareolide	2.5	HTS	other antifungal				C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2	Launched	5
BRD-K72951360-001-01-4::2.5::HTS	-1.28777924677	BRD-K72951360-001-01-4::2.5::HTS	BRD-K72951360-001-01-4	valrubicin	2.5	HTS	DNA inhibitor, topoisomerase inhibitor	TOP2A	oncology	bladder cancer	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	Launched	5
BRD-K73073971-001-01-7::2.5::HTS	0.6867971709630001	BRD-K73073971-001-01-7::2.5::HTS	BRD-K73073971-001-01-7	ZLN005	2.5	HTS					CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1	Preclinical	5
BRD-K73107279-003-12-5::2.5::HTS	-1.30818529419	BRD-K73107279-003-12-5::2.5::HTS	BRD-K73107279-003-12-5	levamisole	2.5	HTS	acetylcholine receptor agonist	ALPL, ALPPL2, CHRNA3			C1CN2C[C@@H](N=C2S1)c1ccccc1, C1CN2C[C@@H](N=C2S1)c1ccccc1	Withdrawn	5
BRD-K73109821-001-20-1::2.5::HTS	-0.347373658265	BRD-K73109821-001-20-1::2.5::HTS	BRD-K73109821-001-20-1	diazoxide	2.5	HTS	potassium channel activator	ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3	endocrinology	hypoglycemia	CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1	Launched	5
BRD-K73157543-001-04-1::2.5::HTS	0.312971340876	BRD-K73157543-001-04-1::2.5::HTS	BRD-K73157543-001-04-1	phenyl-aminosalicylate	2.5	HTS			infectious disease	tuberculosis	Nc1ccc(C(=O)Oc2ccccc2)c(O)c1	Launched	5
BRD-K73191876-001-11-2::2.5::HTS	-0.65983356314	BRD-K73191876-001-11-2::2.5::HTS	BRD-K73191876-001-11-2	alizarin	2.5	HTS					Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O	Preclinical	5
BRD-K73196317-003-14-8::2.5::HTS	-0.093063152511	BRD-K73196317-003-14-8::2.5::HTS	BRD-K73196317-003-14-8	urapidil	2.5	HTS	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	Launched	5
BRD-K73197500-001-02-2::2.5::HTS	-4.38628427641	BRD-K73197500-001-02-2::2.5::HTS	BRD-K73197500-001-02-2	SNX-5422	2.5	HTS	HSP inhibitor	HSP90AA1			CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1	Phase 1/Phase 2	5
BRD-K73234506-235-02-1::2.5::HTS	-0.267644496757	BRD-K73234506-235-02-1::2.5::HTS	BRD-K73234506-235-02-1	lithium-acetoacetate	2.5	HTS					CC(=O)CC(O)=O	Preclinical	5
BRD-K73237276-001-01-0::2.5::HTS	0.165719383678	BRD-K73237276-001-01-0::2.5::HTS	BRD-K73237276-001-01-0	tacalcitol	2.5	HTS	vitamin D receptor agonist	VDR	dermatology	psoriasis, chapped lips	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	5
BRD-K73251053-003-22-2::2.5::HTS	0.37834864025	BRD-K73251053-003-22-2::2.5::HTS	BRD-K73251053-003-22-2	clorgiline	2.5	HTS	monoamine oxidase inhibitor	MAOA			CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C	Phase 2	5
BRD-K73290745-003-02-6::2.5::HTS	0.440072992236	BRD-K73290745-003-02-6::2.5::HTS	BRD-K73290745-003-02-6	ICI-199441	2.5	HTS	opioid receptor agonist	CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R			CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-K73293050-001-03-1::2.5::HTS	-1.8454524181999998	BRD-K73293050-001-03-1::2.5::HTS	BRD-K73293050-001-03-1	WZ-3146	2.5	HTS	EGFR inhibitor	EGFR			CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1	Preclinical	5
BRD-K73303757-001-21-6::2.5::HTS	-0.332248274247	BRD-K73303757-001-21-6::2.5::HTS	BRD-K73303757-001-21-6	4-methylgenistein	2.5	HTS	protein tyrosine kinase inhibitor	CYP19A1, ESRRA, ESRRB, ESRRG, FASN			COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	Preclinical	5
BRD-K73309154-003-02-8::2.5::HTS	0.490426789641	BRD-K73309154-003-02-8::2.5::HTS	BRD-K73309154-003-02-8	OSI-420	2.5	HTS	EGFR inhibitor	EGFR			COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO	Preclinical	5
BRD-K73319509-001-08-0::2.5::HTS	0.0632899498518	BRD-K73319509-001-08-0::2.5::HTS	BRD-K73319509-001-08-0	PF-04217903	2.5	HTS	c-Met inhibitor	MET			OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1	Phase 1	5
BRD-K73323637-003-10-9::2.5::HTS	0.195127138114	BRD-K73323637-003-10-9::2.5::HTS	BRD-K73323637-003-10-9	levobunolol-(+)	2.5	HTS	adrenergic receptor antagonist				CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12	Preclinical	5
BRD-K73368362-001-07-5::2.5::HTS	0.31670738467099996	BRD-K73368362-001-07-5::2.5::HTS	BRD-K73368362-001-07-5	BIX-02189	2.5	HTS	MEK inhibitor	MAP2K5, MAPK7			CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c1	Preclinical	5
BRD-K73381198-001-01-1::2.5::HTS	-0.229162899249	BRD-K73381198-001-01-1::2.5::HTS	BRD-K73381198-001-01-1	5-fluoro-3-pyridyl-methanol	2.5	HTS					OCc1cncc(F)c1	Preclinical	5
BRD-K73381542-003-23-4::2.5::HTS	0.38336840086900004	BRD-K73381542-003-23-4::2.5::HTS	BRD-K73381542-003-23-4	phenylephrine	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	otolaryngology, gastroenterology, cardiology	nasal congestion, hemorrhoids, hypotension	CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1	Launched	5
BRD-K73383190-001-02-3::2.56::HTS	0.0377774179239	BRD-K73383190-001-02-3::2.56::HTS	BRD-K73383190-001-02-3	C646	2.56	HTS	histone acetyltransferase inhibitor	EP300			CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O	Preclinical	5
BRD-K73383190-001-03-1::2.5::HTS	0.421219927677	BRD-K73383190-001-03-1::2.5::HTS	BRD-K73383190-001-03-1	C646	2.5	HTS	histone acetyltransferase inhibitor	EP300			CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O	Preclinical	5
BRD-K73391359-003-10-2::2.5::HTS	0.117293428994	BRD-K73391359-003-10-2::2.5::HTS	BRD-K73391359-003-10-2	dimethisoquin	2.5	HTS	local anesthetic		neurology/psychiatry	local anesthetic	CCCCc1cc2ccccc2c(OCCN(C)C)n1	Launched	5
BRD-K73394555-237-01-1::2.5::HTS	0.140450164632	BRD-K73394555-237-01-1::2.5::HTS	BRD-K73394555-237-01-1	oxolinic-acid	2.5	HTS	bacterial DNA gyrase inhibitor				CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12	Preclinical	5
BRD-K73397362-001-06-6::2.5::HTS	0.33797683458000005	BRD-K73397362-001-06-6::2.5::HTS	BRD-K73397362-001-06-6	purmorphamine	2.5	HTS	smoothened receptor agonist	SMO			C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12	Preclinical	5
BRD-K73425385-065-04-8::2.5::HTS	-0.588829913319	BRD-K73425385-065-04-8::2.5::HTS	BRD-K73425385-065-04-8	bekanamycin	2.5	HTS	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched	5
BRD-K73440166-001-01-3::2.5::HTS	-0.167479009133	BRD-K73440166-001-01-3::2.5::HTS	BRD-K73440166-001-01-3	cinaciguat	2.5	HTS	guanylate cyclase activator	GUCY1A3, GUCY1B3			OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O	Phase 2	5
BRD-K73469236-001-01-8::2.5::HTS	0.041000633470800005	BRD-K73469236-001-01-8::2.5::HTS	BRD-K73469236-001-01-8	nedaplatin	2.5	HTS	DNA inhibitor				N[Pt++]1(N)OCC(=O)O1, N[Pt]1(N)OCC(=O)O1	Launched	5
BRD-K73477617-001-08-5::2.5::HTS	0.256242996494	BRD-K73477617-001-08-5::2.5::HTS	BRD-K73477617-001-08-5	dibutyl-phthalate	2.5	HTS		TRPA1			CCCCOC(=O)c1ccccc1C(=O)OCCCC	Preclinical	5
BRD-K73524797-001-01-1::2.5::HTS	-0.59607762281	BRD-K73524797-001-01-1::2.5::HTS	BRD-K73524797-001-01-1	ST-1859	2.5	HTS	antiamyloidogenic agent				Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12	Phase 1	5
BRD-K73529671-001-02-9::2.5::HTS	-0.163572812487	BRD-K73529671-001-02-9::2.5::HTS	BRD-K73529671-001-02-9	troxerutin	2.5	HTS	antioxidant				C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	Launched	5
BRD-K73529671-001-04-5::2.5::HTS	-0.353854620429	BRD-K73529671-001-04-5::2.5::HTS	BRD-K73529671-001-04-5	troxerutin	2.5	HTS	antioxidant				C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	Launched	5
BRD-K73541271-001-03-6::2.5::HTS	-0.666073727336	BRD-K73541271-001-03-6::2.5::HTS	BRD-K73541271-001-03-6	etofenamate	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Launched	5
BRD-K73589401-001-23-6::2.5::HTS	0.329751918246	BRD-K73589401-001-23-6::2.5::HTS	BRD-K73589401-001-23-6	corticosterone	2.5	HTS	mineralocorticoid receptor agonist	HSD11B1, NCOA1, NR3C2			C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO	Preclinical	5
BRD-K73589491-001-11-2::2.5::HTS	0.532747992847	BRD-K73589491-001-11-2::2.5::HTS	BRD-K73589491-001-11-2	nizatidine	2.5	HTS	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O	Launched	5
BRD-K73642618-001-13-3::2.5::HTS	0.199637201446	BRD-K73642618-001-13-3::2.5::HTS	BRD-K73642618-001-13-3	bromopride	2.5	HTS	dopamine receptor antagonist	DRD2	gastroenterology	nausea, vomiting, gastroesophageal reflux disease (GERD)	CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC	Launched	5
BRD-K73700643-001-11-2::2.5::HTS	0.0100869934851	BRD-K73700643-001-11-2::2.5::HTS	BRD-K73700643-001-11-2	N-acetyltryptamine	2.5	HTS	melatonin receptor agonist				CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12	Preclinical	5
BRD-K73771095-001-02-5::2.44::HTS	-0.500079536939	BRD-K73771095-001-02-5::2.44::HTS	BRD-K73771095-001-02-5	geniposidic-acid	2.44	HTS	cyclooxygenase inhibitor				OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical	5
BRD-K73771095-001-03-3::2.5::HTS	0.20830375663400003	BRD-K73771095-001-03-3::2.5::HTS	BRD-K73771095-001-03-3	geniposidic-acid	2.5	HTS	cyclooxygenase inhibitor				OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical	5
BRD-K73789395-001-10-7::2.5::HTS	-0.34087303261999996	BRD-K73789395-001-10-7::2.5::HTS	BRD-K73789395-001-10-7	ZM-336372	2.5	HTS	RAF inhibitor	BRAF, LCK, MAPK14, RAF1			CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	Preclinical	5
BRD-K73815512-001-02-5::2.5::HTS	0.379700730738	BRD-K73815512-001-02-5::2.5::HTS	BRD-K73815512-001-02-5	HC-030031	2.5	HTS	TRPA1 channel blocker	TRPA1			CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1	Phase 1	5
BRD-K73838513-003-05-5::2.5::HTS	0.429914754899	BRD-K73838513-003-05-5::2.5::HTS	BRD-K73838513-003-05-5	cinacalcet	2.5	HTS	calcium channel activator	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12	Launched	5
BRD-K73923631-003-02-9::2.5::HTS	-0.08462673198130001	BRD-K73923631-003-02-9::2.5::HTS	BRD-K73923631-003-02-9	difloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		infectious disease	skin infections, urinary tract infections	CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1	Launched	5
BRD-K73982490-001-02-9::2.5::HTS	0.422068146307	BRD-K73982490-001-02-9::2.5::HTS	BRD-K73982490-001-02-9	BI-78D3	2.5	HTS	JNK inhibitor	MAPK8			Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1	Preclinical	5
BRD-K73999723-001-11-3::2.5::HTS	-0.7596604167859999	BRD-K73999723-001-11-3::2.5::HTS	BRD-K73999723-001-11-3	telmisartan	2.5	HTS	angiotensin receptor antagonist	AGTR1, PPARG	cardiology	hypertension	CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C	Launched	5
BRD-K74057757-001-01-9::2.5::HTS	-1.1178193176	BRD-K74057757-001-01-9::2.5::HTS	BRD-K74057757-001-01-9	indibulin	2.5	HTS	tubulin polymerization inhibitor				Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1	Phase 1/Phase 2	5
BRD-K74065929-001-07-2::2.5::HTS	0.37787053186999997	BRD-K74065929-001-07-2::2.5::HTS	BRD-K74065929-001-07-2	doramapimod	2.5	HTS	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C	Phase 2	5
BRD-K74117820-066-10-8::2.5::HTS	0.16497839320399998	BRD-K74117820-066-10-8::2.5::HTS	BRD-K74117820-066-10-8	nelfinavir	2.5	HTS	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	Launched	5
BRD-K74141488-003-11-2::2.5::HTS	-1.3014854084799998	BRD-K74141488-003-11-2::2.5::HTS	BRD-K74141488-003-11-2	naftifine	2.5	HTS	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12	Launched	5
BRD-K74186897-001-12-4::2.5::HTS	0.163413558205	BRD-K74186897-001-12-4::2.5::HTS	BRD-K74186897-001-12-4	cytisine	2.5	HTS	acetylcholine receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4	neurology/psychiatry	nicotinism	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	Launched	5
BRD-K74186897-001-13-2::2.5::HTS	0.438771699343	BRD-K74186897-001-13-2::2.5::HTS	BRD-K74186897-001-13-2	cytisine	2.5	HTS	acetylcholine receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4	neurology/psychiatry	nicotinism	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	Launched	5
BRD-K74190368-001-04-3::2.5::HTS	0.250034391981	BRD-K74190368-001-04-3::2.5::HTS	BRD-K74190368-001-04-3	resorcinol	2.5	HTS	phosphodiesterase inhibitor	CA12, CA14, CA2, PTGS1	dermatology	acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis	Oc1cccc(O)c1	Launched	5
BRD-K74193284-001-04-8::2.5::HTS	-5.1756140868800005	BRD-K74193284-001-04-8::2.5::HTS	BRD-K74193284-001-04-8	phenylmercuric-acetate	2.5	HTS	other antifungal				CC(=O)O[Hg]c1ccccc1	Preclinical	5
BRD-K74195153-050-12-1::2.5::HTS	0.0344589549882	BRD-K74195153-050-12-1::2.5::HTS	BRD-K74195153-050-12-1	irsogladine	2.5	HTS	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	Launched	5
BRD-K74227499-001-01-1::2.5::HTS	-1.13481778636	BRD-K74227499-001-01-1::2.5::HTS	BRD-K74227499-001-01-1	se-methylselenocysteine	2.5	HTS					C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O	Phase 2	5
BRD-K74236708-001-01-9::2.5::HTS	-0.3966179234	BRD-K74236708-001-01-9::2.5::HTS	BRD-K74236708-001-01-9	acitazanolast	2.5	HTS	mediator release inhibitor		allergy	allergic rhinitis	OC(=O)C(=O)Nc1cccc(c1)-c1nnn[nH]1, OC(=O)C(=O)Nc1cccc(c1)-c1nnn[nH]1	Launched	5
BRD-K74305673-001-06-2::2.5::HTS	-0.738558234544	BRD-K74305673-001-06-2::2.5::HTS	BRD-K74305673-001-06-2	IKK-2-inhibitor-V	2.5	HTS	IKK inhibitor, NFkB pathway inhibitor	IKBKB			Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F	Phase 1	5
BRD-K74339692-001-01-9::2.5::HTS	0.018935633234400003	BRD-K74339692-001-01-9::2.5::HTS	BRD-K74339692-001-01-9	tamsulosin	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O, CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O	Launched	5
BRD-K74363950-004-01-0::2.5::HTS	0.420261050892	BRD-K74363950-004-01-0::2.5::HTS	BRD-K74363950-004-01-0	aclidinium	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)	OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1	Launched	5
BRD-K74371986-001-01-7::2.5::HTS	-0.17953814330600001	BRD-K74371986-001-01-7::2.5::HTS	BRD-K74371986-001-01-7	NSI-189	2.5	HTS	neurotrophic agent				CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1	Phase 2	5
BRD-K74501079-001-18-1::2.5::HTS	-0.111909199344	BRD-K74501079-001-18-1::2.5::HTS	BRD-K74501079-001-18-1	azithromycin	2.5	HTS	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	5
BRD-K74514084-001-03-9::2.5::HTS	-0.057200944644300006	BRD-K74514084-001-03-9::2.5::HTS	BRD-K74514084-001-03-9	pazopanib	2.5	HTS	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1	Launched	5
BRD-K74603273-003-01-1::2.5::HTS	-0.361630597873	BRD-K74603273-003-01-1::2.5::HTS	BRD-K74603273-003-01-1	ICI-118,551	2.5	HTS	adrenergic receptor antagonist	ADRB2, ADRB3			CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12	Phase 2	5
BRD-K74664543-213-01-2::2.5::HTS	0.128858164081	BRD-K74664543-213-01-2::2.5::HTS	BRD-K74664543-213-01-2	selenomethionine	2.5	HTS					C[Se]CCC(N)C(O)=O, C[Se]CC[C@H](N)C(O)=O, C[Se]CC[C@H](N)C(O)=O	Launched	5
BRD-K74717603-001-02-2::2.5::HTS	-0.251469589848	BRD-K74717603-001-02-2::2.5::HTS	BRD-K74717603-001-02-2	etravirine	2.5	HTS	non-nucleoside reverse transcriptase inhibitor	CYP2C19, CYP2C9, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N	Launched	5
BRD-K74763371-002-04-0::2.5::HTS	-0.238580554837	BRD-K74763371-002-04-0::2.5::HTS	BRD-K74763371-002-04-0	bosentan	2.5	HTS	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1	Launched	5
BRD-K74765201-001-16-7::0.25::HTS	-0.163990881082	BRD-K74765201-001-16-7::0.25::HTS	BRD-K74765201-001-16-7	tomelukast	0.25	HTS	leukotriene receptor antagonist	CYSLTR1			CCCc1c(OCCCCc2nnn[nH]2)ccc(C(C)=O)c1O	Phase 3	3
BRD-K74913225-001-12-4::2.5::HTS	0.13640853056299998	BRD-K74913225-001-12-4::2.5::HTS	BRD-K74913225-001-12-4	brinzolamide	2.5	HTS	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA5A, CA7	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	Launched	5
BRD-K74990253-001-02-8::2.5::HTS	0.0755077202466	BRD-K74990253-001-02-8::2.5::HTS	BRD-K74990253-001-02-8	BW-373U86	2.5	HTS	opioid receptor agonist	OPRD1			CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1	Preclinical	5
BRD-K75009076-001-02-1::2.43::HTS	0.324207383038	BRD-K75009076-001-02-1::2.43::HTS	BRD-K75009076-001-02-1	SCH-900776	2.43	HTS	CHK inhibitor	CDK2, CHEK1			Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1	Phase 2	5
BRD-K75024268-001-01-0::2.5::HTS	-0.011445756414700001	BRD-K75024268-001-01-0::2.5::HTS	BRD-K75024268-001-01-0	lesinurad	2.5	HTS	uric acid diuretic	SLC22A12	rheumatology	gout	OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	Launched	5
BRD-K75037734-003-13-9::2.5::HTS	-0.619980274247	BRD-K75037734-003-13-9::2.5::HTS	BRD-K75037734-003-13-9	carbachol	2.5	HTS	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	ophthalmology	intraocular pressure	C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O	Launched	5
BRD-K75080769-001-01-6::2.5::HTS	-0.182146881285	BRD-K75080769-001-01-6::2.5::HTS	BRD-K75080769-001-01-6	trans-4-[8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid	2.5	HTS					OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1	Preclinical	5
BRD-K75089421-003-24-5::2.5::HTS	0.19604902895100002	BRD-K75089421-003-24-5::2.5::HTS	BRD-K75089421-003-24-5	procainamide	2.5	HTS	sodium channel blocker	DNMT1, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	CCN(CC)CCNC(=O)c1ccc(N)cc1	Launched	5
BRD-K75250001-001-01-3::2.5::HTS	-0.193918874234	BRD-K75250001-001-01-3::2.5::HTS	BRD-K75250001-001-01-3	tiracizine	2.5	HTS	sodium channel blocker	SCN5A			CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1	Withdrawn	5
BRD-K75282704-001-02-4::2.5::HTS	0.233852209353	BRD-K75282704-001-02-4::2.5::HTS	BRD-K75282704-001-02-4	BL-5583	2.5	HTS	hypercalcaemic agent				OC(=O)c1cc2ccccc2s1	Preclinical	5
BRD-K75295174-001-05-0::2.5::HTS	-0.5929223330110001	BRD-K75295174-001-05-0::2.5::HTS	BRD-K75295174-001-05-0	alisertib	2.5	HTS	Aurora kinase inhibitor	AURKA			COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O	Phase 3	5
BRD-K75308783-001-07-0::2.5::HTS	-0.101184051388	BRD-K75308783-001-07-0::2.5::HTS	BRD-K75308783-001-07-0	SAR-245409	2.5	HTS	PI3K inhibitor	MTOR, PIK3CG			COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1	Phase 1/Phase 2	5
BRD-K75352575-001-01-3::2.5::HTS	-1.41528424348	BRD-K75352575-001-01-3::2.5::HTS	BRD-K75352575-001-01-3	KPT-276	2.5	HTS	exportin antagonist	XPO1			FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1	Preclinical	5
BRD-K75360161-001-18-0::2.5::HTS	-0.044648483306	BRD-K75360161-001-18-0::2.5::HTS	BRD-K75360161-001-18-0	protionamide	2.5	HTS			infectious disease	tuberculosis	CCCc1cc(ccn1)C(S)=N, CCCc1cc(ccn1)C(S)=N	Launched	5
BRD-K75466013-001-14-4::2.5::HTS	0.10756265991800001	BRD-K75466013-001-14-4::2.5::HTS	BRD-K75466013-001-14-4	benzocaine	2.5	HTS	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1	Launched	5
BRD-K75478907-001-02-3::2.5::HTS	0.030940158642700003	BRD-K75478907-001-02-3::2.5::HTS	BRD-K75478907-001-02-3	GS-39783	2.5	HTS	GABA receptor modulator	GABBR1			CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	Preclinical	5
BRD-K75506300-001-01-6::2.5::HTS	-0.17813742656	BRD-K75506300-001-01-6::2.5::HTS	BRD-K75506300-001-01-6	NPS-2143	2.5	HTS	calcium receptor antagonist	CASR			CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N	Preclinical	5
BRD-K75516118-001-03-3::2.5::HTS	0.136186571282	BRD-K75516118-001-03-3::2.5::HTS	BRD-K75516118-001-03-3	rolipram-R(-)	2.5	HTS	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D, PDE5A			COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1	Preclinical	5
BRD-K75527158-360-04-9::2.5::HTS	0.32034518033500003	BRD-K75527158-360-04-9::2.5::HTS	BRD-K75527158-360-04-9	alendronate	2.5	HTS	bone resorption inhibitor	ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS	orthopedics	osteoporosis	NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	5
BRD-K75608666-001-08-3::2.5::HTS	-0.024556944560199998	BRD-K75608666-001-08-3::2.5::HTS	BRD-K75608666-001-08-3	hydroxytoluic-acid	2.5	HTS					Cc1cccc(C(O)=O)c1O	Preclinical	5
BRD-K75615183-300-03-9::2.5::HTS	0.258618032872	BRD-K75615183-300-03-9::2.5::HTS	BRD-K75615183-300-03-9	talipexole	2.5	HTS	adrenergic receptor agonist, dopamine receptor agonist	ADRA2A, DRD2, HTR3A	infectious disease	genitial herpes	Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1	Launched	5
BRD-K75641298-003-25-0::2.5::HTS	-0.24012774775899998	BRD-K75641298-003-25-0::2.5::HTS	BRD-K75641298-003-25-0	metoclopramide	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	CHRM1, DRD2, HTR3A, HTR3B, HTR4	gastroenterology	gastroparesis, nausea, vomiting	CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC	Launched	5
BRD-K75649340-001-13-1::2.5::HTS	-0.525740346421	BRD-K75649340-001-13-1::2.5::HTS	BRD-K75649340-001-13-1	tioguanine	2.5	HTS	purine antagonist				Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	Phase 2	5
BRD-K75699339-057-08-1::2.5::HTS	0.40603765548199994	BRD-K75699339-057-08-1::2.5::HTS	BRD-K75699339-057-08-1	rizatriptan	2.5	HTS	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12	Launched	5
BRD-K75844781-003-08-0::2.5::HTS	-0.219661103021	BRD-K75844781-003-08-0::2.5::HTS	BRD-K75844781-003-08-0	mCPP	2.5	HTS	serotonin receptor agonist	HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6			Clc1cccc(c1)N1CCNCC1	Phase 2	5
BRD-K75855670-001-14-2::2.5::HTS	0.206176393611	BRD-K75855670-001-14-2::2.5::HTS	BRD-K75855670-001-14-2	iodoquinol	2.5	HTS	antiseptic		infectious disease	amebiasis	Oc1c(I)cc(I)c2cccnc12	Launched	5
BRD-K75868704-001-05-3::2.5::HTS	-0.43024563028499996	BRD-K75868704-001-05-3::2.5::HTS	BRD-K75868704-001-05-3	iopamidol	2.5	HTS	radiopaque medium		radiology	contrast agent	C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I	Launched	5
BRD-K75911534-001-01-6::2.5::HTS	0.554529549193	BRD-K75911534-001-01-6::2.5::HTS	BRD-K75911534-001-01-6	SU014813	2.5	HTS	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1	Phase 2	5
BRD-K75923785-003-02-1::2.5::HTS	-0.217596226972	BRD-K75923785-003-02-1::2.5::HTS	BRD-K75923785-003-02-1	scopine	2.5	HTS					CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21	Launched	5
BRD-K75956464-237-01-5::2.5::HTS	0.00279627671598	BRD-K75956464-237-01-5::2.5::HTS	BRD-K75956464-237-01-5	VCH-916	2.5	HTS	HCV inhibitor				CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1	Phase 1	5
BRD-K75958195-037-09-4::2.5::HTS	-0.494131481055	BRD-K75958195-037-09-4::2.5::HTS	BRD-K75958195-037-09-4	pizotifen	2.5	HTS	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C	neurology/psychiatry	migraine headache	CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12	Launched	5
BRD-K75958547-238-01-0::2.5::HTS	0.8891362044969999	BRD-K75958547-238-01-0::2.5::HTS	BRD-K75958547-238-01-0	pitavastatin	2.5	HTS	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O	Launched	5
BRD-K76011241-001-01-8::2.5::HTS	-0.21029480020999997	BRD-K76011241-001-01-8::2.5::HTS	BRD-K76011241-001-01-8	oseltamivir-phosphate	2.5	HTS	neuraminidase inhibitor	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1	Launched	5
BRD-K76022557-003-02-7::2.5::HTS	0.374144218449	BRD-K76022557-003-02-7::2.5::HTS	BRD-K76022557-003-02-7	r(-)-apomorphine	2.5	HTS	dopamine receptor agonist	DRD2, HTR5A	neurology/psychiatry	Parkinson's Disease	CN1CCc2cccc-3c2C1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31	Launched	5
BRD-K76037122-001-02-5::2.5::HTS	-0.12149234866900001	BRD-K76037122-001-02-5::2.5::HTS	BRD-K76037122-001-02-5	guanidine	2.5	HTS	HSP inhibitor	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	NC(N)=N, NC(N)=N	Launched	5
BRD-K76064317-001-07-3::2.5::HTS	0.256890980655	BRD-K76064317-001-07-3::2.5::HTS	BRD-K76064317-001-07-3	tyrphostin-AG-1296	2.5	HTS	FLT3 inhibitor	FLT3			COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1	Preclinical	5
BRD-K76180386-001-01-6::2.5::HTS	-0.17522944645999997	BRD-K76180386-001-01-6::2.5::HTS	BRD-K76180386-001-01-6	JIB04	2.5	HTS	histone lysine demethylase inhibitor	KDM4E			Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1	Preclinical	5
BRD-K76205745-237-16-5::2.5::HTS	0.08411840322799999	BRD-K76205745-237-16-5::2.5::HTS	BRD-K76205745-237-16-5	losartan	2.5	HTS	angiotensin receptor antagonist	AGTR1	cardiology, nephrology	hypertension, diabetic nephropathy	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Launched	5
BRD-K76210423-001-01-6::2.5::HTS	0.42796603913900005	BRD-K76210423-001-01-6::2.5::HTS	BRD-K76210423-001-01-6	resiquimod	2.5	HTS	toll-like receptor agonist	TLR7, TLR8			CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O	Phase 3	5
BRD-K76239644-001-01-8::2.5::HTS	0.158336136789	BRD-K76239644-001-01-8::2.5::HTS	BRD-K76239644-001-01-8	BMS-690514	2.5	HTS	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, FLT3, KDR			COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1	Phase 2	5
BRD-K76304753-003-20-3::2.5::HTS	0.241089845143	BRD-K76304753-003-20-3::2.5::HTS	BRD-K76304753-003-20-3	phenazopyridine	2.5	HTS	local anesthetic	SCN1A	infectious disease	urinary tract infections	Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1	Launched	5
BRD-K76304753-003-21-1::2.5::HTS	-0.314748141226	BRD-K76304753-003-21-1::2.5::HTS	BRD-K76304753-003-21-1	phenazopyridine	2.5	HTS	local anesthetic	SCN1A	infectious disease	urinary tract infections	Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1	Launched	5
BRD-K76381435-001-08-6::2.5::HTS	0.09726183693110001	BRD-K76381435-001-08-6::2.5::HTS	BRD-K76381435-001-08-6	nitromide	2.5	HTS					NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O	Launched	5
BRD-K76406695-001-02-9::2.5::HTS	0.487927790226	BRD-K76406695-001-02-9::2.5::HTS	BRD-K76406695-001-02-9	CCT128930	2.5	HTS	AKT inhibitor	PKIA, PRKACA			NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12	Preclinical	5
BRD-K76452401-001-03-6::2.5::HTS	0.7901632690929999	BRD-K76452401-001-03-6::2.5::HTS	BRD-K76452401-001-03-6	piperonyl-butoxide	2.5	HTS	cytochrome P450 inhibitor		infectious disease	lice	CCCCOCCOCCOCc1cc2OCOc2cc1CCC	Launched	5
BRD-K76534306-001-22-7::2.5::HTS	-0.23217626133000002	BRD-K76534306-001-22-7::2.5::HTS	BRD-K76534306-001-22-7	enrofloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections, gram-negative bacterial infections	CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	Launched	5
BRD-K76568384-001-02-2::2.5::HTS	0.366307035334	BRD-K76568384-001-02-2::2.5::HTS	BRD-K76568384-001-02-2	PHTPP	2.5	HTS	estrogen receptor antagonist	ESR2			Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1	Preclinical	5
BRD-K76592088-001-02-1::2.5::HTS	0.25447750598700003	BRD-K76592088-001-02-1::2.5::HTS	BRD-K76592088-001-02-1	3-carboxy-4-hydroxyphenylglycine-(R)	2.5	HTS	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	Preclinical	5
BRD-K76600340-045-04-9::2.5::HTS	0.18995327391	BRD-K76600340-045-04-9::2.5::HTS	BRD-K76600340-045-04-9	nicotinyl-alcohol-tartrate	2.5	HTS					OCc1cccnc1	Launched	5
BRD-K76606751-001-01-7::2.5::HTS	0.162000005335	BRD-K76606751-001-01-7::2.5::HTS	BRD-K76606751-001-01-7	mebicar	2.5	HTS	anxiolytic		neurology/psychiatry	anxiety	CN1C2C(N(C)C1=O)N(C)C(=O)N2C	Launched	5
BRD-K76609936-001-08-4::2.5::HTS	-0.0233409181373	BRD-K76609936-001-08-4::2.5::HTS	BRD-K76609936-001-08-4	imidacloprid	2.5	HTS	acetylcholine receptor antagonist	CHRFAM7A			[O-][N+](=O)NC1=NCCN1Cc1ccc(Cl)nc1	Launched	5
BRD-K76617868-003-11-9::2.5::HTS	-0.202564214196	BRD-K76617868-003-11-9::2.5::HTS	BRD-K76617868-003-11-9	fasudil	2.5	HTS	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1, ROCK2	neurology/psychiatry	cerebral vasospasm	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	Launched	5
BRD-K76634210-001-14-7::2.5::HTS	0.28210792335	BRD-K76634210-001-14-7::2.5::HTS	BRD-K76634210-001-14-7	idoxuridine	2.5	HTS	DNA directed DNA polymerase inhibitor		infectious disease	virus herpes simplex (HSV)	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O	Launched	5
BRD-K76674262-001-03-3::2.5::HTS	-6.066698133180001	BRD-K76674262-001-03-3::2.5::HTS	BRD-K76674262-001-03-3	homoharringtonine	2.5	HTS	protein synthesis inhibitor	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC	Launched	5
BRD-K76677554-003-02-1::2.5::HTS	-0.278070525901	BRD-K76677554-003-02-1::2.5::HTS	BRD-K76677554-003-02-1	AJ76-(+)	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3, DRD4			CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C	Preclinical	5
BRD-K76703230-004-03-3::2.5::HTS	-5.19838094747	BRD-K76703230-004-03-3::2.5::HTS	BRD-K76703230-004-03-3	YM-155	2.5	HTS	survivin inhibitor	BIRC5			COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C	Phase 2	5
BRD-K76703230-004-04-1::2.5::HTS	-3.07004085205	BRD-K76703230-004-04-1::2.5::HTS	BRD-K76703230-004-04-1	YM-155	2.5	HTS	survivin inhibitor	BIRC5			COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C	Phase 2	5
BRD-K76775527-001-30-2::2.5::HTS	-0.234622657787	BRD-K76775527-001-30-2::2.5::HTS	BRD-K76775527-001-30-2	nimesulide	2.5	HTS	cyclooxygenase inhibitor	LTF, PLA2G2E, PTGS1, PTGS2	rheumatology, obstetrics/gynecology	osteoarthritis, menstrual pain	CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O	Launched	5
BRD-K76805682-001-15-9::2.5::HTS	0.17962187799600002	BRD-K76805682-001-15-9::2.5::HTS	BRD-K76805682-001-15-9	SB-415286	2.5	HTS	glycogen synthase kinase inhibitor	GSK3A, GSK3B, RPS6KB1			Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl	Preclinical	5
BRD-K76810206-001-07-3::2.5::HTS	0.193326796006	BRD-K76810206-001-07-3::2.5::HTS	BRD-K76810206-001-07-3	nicergoline	2.5	HTS	adrenergic receptor antagonist	ADRA1A	rheumatology, neurology/psychiatry, cardiology, hematology	Raynaud's disease, migraine headache, atherosclerosis, thrombosis, Raynaud's disease, migraine headache, atherosclerosis, thrombosis	CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13	Launched	5
BRD-K76810206-001-08-1::2.5::HTS	-0.210594855398	BRD-K76810206-001-08-1::2.5::HTS	BRD-K76810206-001-08-1	nicergoline	2.5	HTS	adrenergic receptor antagonist	ADRA1A	rheumatology, neurology/psychiatry, cardiology, hematology	Raynaud's disease, migraine headache, atherosclerosis, thrombosis, Raynaud's disease, migraine headache, atherosclerosis, thrombosis	CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13	Launched	5
BRD-K76811153-003-01-3::2.5::HTS	-0.175898122413	BRD-K76811153-003-01-3::2.5::HTS	BRD-K76811153-003-01-3	L-Arginine	2.5	HTS	nitric oxide precursor	ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4	cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology	congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold	N[C@H](CCCNC(N)=N)C(O)=O	Launched	5
BRD-K76812510-236-14-8::2.5::HTS	0.223709621003	BRD-K76812510-236-14-8::2.5::HTS	BRD-K76812510-236-14-8	metamizole	2.5	HTS	cyclooxygenase inhibitor, opioid receptor agonist	PTGS1			CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O	Withdrawn	5
BRD-K76840893-003-02-5::2.5::HTS	0.21508666888	BRD-K76840893-003-02-5::2.5::HTS	BRD-K76840893-003-02-5	RS-17053	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1D			CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1	Preclinical	5
BRD-K76841105-001-04-7::2.5::HTS	-0.266513009199	BRD-K76841105-001-04-7::2.5::HTS	BRD-K76841105-001-04-7	tazarotene	2.5	HTS	retinoid receptor agonist	RARA, RARB, RARG, RXRB	dermatology	cosmetic, sunscreen lotion	CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1	Launched	5
BRD-K76845197-001-05-4::2.5::HTS	0.315511457689	BRD-K76845197-001-05-4::2.5::HTS	BRD-K76845197-001-05-4	sulfanitran	2.5	HTS					CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O	Launched	5
BRD-K76890464-001-02-3::2.5::HTS	0.284100840109	BRD-K76890464-001-02-3::2.5::HTS	BRD-K76890464-001-02-3	triazolam	2.5	HTS	GABA benzodiazepine site receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO			Cc1nnc2CN=C(c3ccccc3Cl)c3cc(Cl)ccc3-n12	Withdrawn	5
BRD-K76908866-001-07-6::2.5::HTS	-0.300082096039	BRD-K76908866-001-07-6::2.5::HTS	BRD-K76908866-001-07-6	CP-724714	2.5	HTS	EGFR inhibitor, protein tyrosine kinase inhibitor	ERBB2			COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1	Phase 2	5
BRD-K76953762-001-08-5::2.5::HTS	0.13170830726	BRD-K76953762-001-08-5::2.5::HTS	BRD-K76953762-001-08-5	indoramin	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1	Launched	5
BRD-K76973696-001-12-6::2.01::HTS	-1.4578761851299997	BRD-K76973696-001-12-6::2.01::HTS	BRD-K76973696-001-12-6	tryptanthrin	2.01	HTS	cyclooxygenase inhibitor	IDO1			O=C1c2ccccc2-n2c1nc1ccccc1c2=O	Preclinical	4
BRD-K77008974-001-03-2::2.5::HTS	0.269794028444	BRD-K77008974-001-03-2::2.5::HTS	BRD-K77008974-001-03-2	WYE-354	2.5	HTS	mTOR inhibitor	MTOR			COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1	Preclinical	5
BRD-K77012840-300-01-6::2.5::HTS	0.36743032652900004	BRD-K77012840-300-01-6::2.5::HTS	BRD-K77012840-300-01-6	AY-9944	2.5	HTS	hedgehog pathway modulator				Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1	Preclinical	5
BRD-K77060810-001-01-5::2.5::HTS	0.07230540658260001	BRD-K77060810-001-01-5::2.5::HTS	BRD-K77060810-001-01-5	AZD1283	2.5	HTS	purinergic receptor antagonist	P2RY12			CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1	Preclinical	5
BRD-K77115421-001-02-6::2.5::HTS	-0.06683657250819999	BRD-K77115421-001-02-6::2.5::HTS	BRD-K77115421-001-02-6	phthalylsulfacetamide	2.5	HTS					CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	Preclinical	5
BRD-K77171813-034-01-8::2.5::HTS	0.243346799714	BRD-K77171813-034-01-8::2.5::HTS	BRD-K77171813-034-01-8	proxyfan	2.5	HTS	histamine receptor modulator	HRH3			C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1	Preclinical	5
BRD-K77245796-003-01-6::2.5::HTS	-0.764647068546	BRD-K77245796-003-01-6::2.5::HTS	BRD-K77245796-003-01-6	gamma-aminobutyric-acid	2.5	HTS	benzodiazepine receptor agonist	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1			NCCCC(O)=O	Preclinical	5
BRD-K77251551-304-02-9::2.5::HTS	-0.132605015992	BRD-K77251551-304-02-9::2.5::HTS	BRD-K77251551-304-02-9	sodium-picosulfate	2.5	HTS			gastroenterology	constipation	OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1	Launched	5
BRD-K77258318-001-04-6::2.5::HTS	0.0852196318354	BRD-K77258318-001-04-6::2.5::HTS	BRD-K77258318-001-04-6	lactulose	2.5	HTS	laxative		gastroenterology	portal-systemic encephalopathy (PSE)	OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O	Launched	5
BRD-K77300776-001-02-5::2.5::HTS	-0.06635479141419999	BRD-K77300776-001-02-5::2.5::HTS	BRD-K77300776-001-02-5	choline	2.5	HTS	acetylcholine precursor	ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2			C[N+](C)(C)CCO, C[N+](C)(C)CCO	Phase 3	5
BRD-K77345217-001-05-0::2.5::HTS	-0.05996706593330001	BRD-K77345217-001-05-0::2.5::HTS	BRD-K77345217-001-05-0	gallic-acid	2.5	HTS	beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP			OC(=O)c1cc(O)c(O)c(O)c1	Preclinical	5
BRD-K77396579-300-01-0::2.5::HTS	-0.0742675582905	BRD-K77396579-300-01-0::2.5::HTS	BRD-K77396579-300-01-0	NVP-DPP728	2.5	HTS	dipeptidyl peptidase inhibitor	DPP4			O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N	Phase 2	5
BRD-K77484724-001-02-0::2.5::HTS	-0.295271526614	BRD-K77484724-001-02-0::2.5::HTS	BRD-K77484724-001-02-0	adefovir	2.5	HTS	DNA polymerase inhibitor		infectious disease	hepatitis B	Nc1ncnc2n(CCOCP(O)(O)=O)cnc12, Nc1ncnc2n(CCOCP(O)(O)=O)cnc12	Launched	5
BRD-K77552740-004-01-0::2.5::HTS	0.166038547154	BRD-K77552740-004-01-0::2.5::HTS	BRD-K77552740-004-01-0	tiquizium	2.5	HTS	acetylcholine receptor antagonist		neurology/psychiatry	spasms	C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1	Launched	5
BRD-K77554836-001-11-6::2.57::HTS	-0.277148875257	BRD-K77554836-001-11-6::2.57::HTS	BRD-K77554836-001-11-6	triamcinolone	2.57	HTS	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Launched	5
BRD-K77554836-001-14-0::2.5::HTS	0.30014403723	BRD-K77554836-001-14-0::2.5::HTS	BRD-K77554836-001-14-0	triamcinolone	2.5	HTS	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Launched	5
BRD-K77561571-001-01-1::2.5::HTS	0.0225319754226	BRD-K77561571-001-01-1::2.5::HTS	BRD-K77561571-001-01-1	topiroxostat	2.5	HTS	xanthine oxidase inhibitor	XDH	rheumatology, nephrology	gout, hyperuricemia	N#Cc1cc(ccn1)-c1n[nH]c(n1)-c1ccncc1	Launched	5
BRD-K77597856-003-02-5::2.5::HTS	0.00287564028564	BRD-K77597856-003-02-5::2.5::HTS	BRD-K77597856-003-02-5	detomidine	2.5	HTS	adrenergic receptor agonist	ADRA2A	neurology/psychiatry	sedative	Cc1cccc(Cc2c[nH]cn2)c1C	Launched	5
BRD-K77625799-001-07-7::2.5::HTS	0.376210063524	BRD-K77625799-001-07-7::2.5::HTS	BRD-K77625799-001-07-7	vandetanib	2.5	HTS	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1	Launched	5
BRD-K77627880-001-04-0::2.5::HTS	0.113101052466	BRD-K77627880-001-04-0::2.5::HTS	BRD-K77627880-001-04-0	A205804	2.5	HTS	ICAM1 expression inhibitor	ICAM1, SELE			Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1	Preclinical	5
BRD-K77634909-001-03-5::2.5::HTS	0.745171282692	BRD-K77634909-001-03-5::2.5::HTS	BRD-K77634909-001-03-5	AEG3482	2.5	HTS	HSP inducer				NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1	Preclinical	5
BRD-K77638923-001-02-0::2.5::HTS	-4.96217115923	BRD-K77638923-001-02-0::2.5::HTS	BRD-K77638923-001-02-0	CUDC-907	2.5	HTS	PI3K inhibitor	HDAC2, PIK3R1			COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	Phase 2	5
BRD-K77641333-003-27-1::2.5::HTS	0.198949429538	BRD-K77641333-003-27-1::2.5::HTS	BRD-K77641333-003-27-1	naphazoline	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA2A	ophthalmology	eye irritation	C(C1=NCCN1)c1cccc2ccccc12, C(C1=NCCN1)c1cccc2ccccc12	Launched	5
BRD-K77677632-003-02-6::2.5::HTS	-0.136519472248	BRD-K77677632-003-02-6::2.5::HTS	BRD-K77677632-003-02-6	SB-200646	2.5	HTS	serotonin receptor antagonist	HTR2B, HTR2C			Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12	Preclinical	5
BRD-K77685957-300-09-1::2.5::HTS	-2.15099927211	BRD-K77685957-300-09-1::2.5::HTS	BRD-K77685957-300-09-1	dequalinium	2.5	HTS	PKC inhibitor	KCNN1, KCNN3			Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12	Launched	5
BRD-K77695569-001-30-0::2.5::HTS	-0.0241914270412	BRD-K77695569-001-30-0::2.5::HTS	BRD-K77695569-001-30-0	tiabendazole	2.5	HTS	angiogenesis inhibitor		infectious disease	gastrointestinal roundworms, hookworm	c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1	Launched	5
BRD-K77771411-003-10-7::2.5::HTS	-0.00858130081187	BRD-K77771411-003-10-7::2.5::HTS	BRD-K77771411-003-10-7	moxonidine	2.5	HTS	imidazoline receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	COc1nc(C)nc(Cl)c1NC1=NCCN1, COc1nc(C)nc(Cl)c1NC1=NCCN1, COc1nc(C)nc(Cl)c1NC1=NCCN1	Launched	5
BRD-K77791657-001-01-1::2.5::HTS	0.437092398635	BRD-K77791657-001-01-1::2.5::HTS	BRD-K77791657-001-01-1	3-deazaneplanocin-A	2.5	HTS	histone lysine methyltransferase inhibitor	EZH2			Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O	Preclinical	5
BRD-K77791657-003-01-7::2.67::HTS	-0.177036436335	BRD-K77791657-003-01-7::2.67::HTS	BRD-K77791657-003-01-7	3-deazaneplanocin-A	2.67	HTS	histone lysine methyltransferase inhibitor	EZH2			Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O	Preclinical	5
BRD-K77793136-003-03-0::2.5::HTS	-0.170215335154	BRD-K77793136-003-03-0::2.5::HTS	BRD-K77793136-003-03-0	hydroxyfasudil	2.5	HTS	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1			Oc1nccc2c(cccc12)S(=O)(=O)N1CCCNCC1	Preclinical	5
BRD-K77821588-364-01-2::2.5::HTS	0.572213247039	BRD-K77821588-364-01-2::2.5::HTS	BRD-K77821588-364-01-2	azatadine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12	Launched	5
BRD-K77841042-001-14-1::2.5::HTS	-5.4936036262900005	BRD-K77841042-001-14-1::2.5::HTS	BRD-K77841042-001-14-1	brefeldin-a	2.5	HTS	protein synthesis inhibitor	ARF1, CYTH2			C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1	Preclinical	5
BRD-K77867004-001-02-7::2.5::HTS	-0.6690154183	BRD-K77867004-001-02-7::2.5::HTS	BRD-K77867004-001-02-7	U-104	2.5	HTS	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA9			NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	Preclinical	5
BRD-K77908580-001-09-6::2.5::HTS	-1.7541704226599997	BRD-K77908580-001-09-6::2.5::HTS	BRD-K77908580-001-09-6	entinostat	2.5	HTS	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC9			Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	Phase 3	5
BRD-K77925998-050-14-3::2.5::HTS	-0.240048352143	BRD-K77925998-050-14-3::2.5::HTS	BRD-K77925998-050-14-3	quipazine	2.5	HTS	serotonin receptor agonist				C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1	Preclinical	5
BRD-K77943374-001-02-8::2.5::HTS	0.09800397011980001	BRD-K77943374-001-02-8::2.5::HTS	BRD-K77943374-001-02-8	NVP-BVU972	2.5	HTS	MET inhibitor	MET			Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1	Preclinical	5
BRD-K77947974-001-16-3::2.5::HTS	-0.426280146141	BRD-K77947974-001-16-3::2.5::HTS	BRD-K77947974-001-16-3	fluspirilene	2.5	HTS	dopamine receptor antagonist	CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia	Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1	Launched	5
BRD-K77950083-001-03-3::2.5::HTS	-0.332056468019	BRD-K77950083-001-03-3::2.5::HTS	BRD-K77950083-001-03-3	UPF-1069	2.5	HTS	PARP inhibitor	PARP2			O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	Preclinical	5
BRD-K77987382-001-13-2::2.5::HTS	-1.13717751153	BRD-K77987382-001-13-2::2.5::HTS	BRD-K77987382-001-13-2	mebendazole	2.5	HTS	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	pinworm, whipworm, hookworm, ascariasis	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1	Launched	5
BRD-K78010432-001-21-5::2.5::HTS	0.272487488001	BRD-K78010432-001-21-5::2.5::HTS	BRD-K78010432-001-21-5	furosemide	2.5	HTS	diuretic	CA2, GPR35, SLC12A1, SLC12A2	cardiology, rheumatology	edema, hypertension, congestive heart failure, nephrotic syndrome	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	Launched	5
BRD-K78055238-001-01-8::2.5::HTS	0.9440183929449999	BRD-K78055238-001-01-8::2.5::HTS	BRD-K78055238-001-01-8	LY2090314	2.5	HTS	glycogen synthase kinase inhibitor	GSK3B			Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1	Phase 2	5
BRD-K78061844-050-01-9::2.5::HTS	0.019175185756999998	BRD-K78061844-050-01-9::2.5::HTS	BRD-K78061844-050-01-9	4-PPBP	2.5	HTS	sigma receptor ligand	SIGMAR1			C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1	Preclinical	5
BRD-K78086729-001-02-7::2.5::HTS	-0.16619514873299998	BRD-K78086729-001-02-7::2.5::HTS	BRD-K78086729-001-02-7	GW-788388	2.5	HTS	ALK tyrosine kinase receptor inhibitor	LCK, MAPK14, TGFBR1			O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1	Preclinical	5
BRD-K78096648-001-05-7::2.5::HTS	0.226893969434	BRD-K78096648-001-05-7::2.5::HTS	BRD-K78096648-001-05-7	oxiperomide	2.5	HTS	dopamine receptor antagonist				Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1	Phase 2	5
BRD-K78113049-001-16-2::2.5::HTS	-0.00864032565676	BRD-K78113049-001-16-2::2.5::HTS	BRD-K78113049-001-16-2	enoxacin	2.5	HTS	topoisomerase inhibitor	TOP2A	infectious disease	urinary tract infections, gonorrhea	CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1	Launched	5
BRD-K78118466-001-03-3::2.5::HTS	0.6788146778049999	BRD-K78118466-001-03-3::2.5::HTS	BRD-K78118466-001-03-3	LY2157299	2.5	HTS	TGF beta receptor inhibitor	TGFBR1			Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O	Phase 2/Phase 3	5
BRD-K78122587-300-02-7::2.5::HTS	0.423889216908	BRD-K78122587-300-02-7::2.5::HTS	BRD-K78122587-300-02-7	NNC-55-0396	2.5	HTS	T-type calcium channel blocker	CATSPER1, CATSPER2, CATSPER3, CATSPER4			CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1	Preclinical	5
BRD-K78126613-001-28-5::2.5::HTS	0.625976081022	BRD-K78126613-001-28-5::2.5::HTS	BRD-K78126613-001-28-5	menadione	2.5	HTS	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis	CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O	Launched	5
BRD-K78177893-001-02-4::2.5::HTS	-4.89796276869	BRD-K78177893-001-02-4::2.5::HTS	BRD-K78177893-001-02-4	A-674563	2.5	HTS	AKT inhibitor	AKT1, PKIA, PRKACA			Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1	Preclinical	5
BRD-K78294846-001-12-4::2.5::HTS	-0.0859314286964	BRD-K78294846-001-12-4::2.5::HTS	BRD-K78294846-001-12-4	osthol	2.5	HTS	calcium channel blocker				COc1ccc2ccc(=O)oc2c1CC=C(C)C	Preclinical	5
BRD-K78299798-001-02-2::2.5::HTS	0.260454709893	BRD-K78299798-001-02-2::2.5::HTS	BRD-K78299798-001-02-2	mepiroxol	2.5	HTS					OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1	Preclinical	5
BRD-K78303961-001-02-3::2.5::HTS	-0.469081050058	BRD-K78303961-001-02-3::2.5::HTS	BRD-K78303961-001-02-3	glycitein	2.5	HTS	tumor necrosis factor release inhibitor	TNF			COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O	Phase 3	5
BRD-K78318619-001-02-7::2.5::HTS	-0.29873812129099997	BRD-K78318619-001-02-7::2.5::HTS	BRD-K78318619-001-02-7	PF-4981517	2.5	HTS	cytochrome P450 inhibitor	CYP3A4			Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12	Preclinical	5
BRD-K78342372-001-02-4::2.5::HTS	-0.114320613106	BRD-K78342372-001-02-4::2.5::HTS	BRD-K78342372-001-02-4	hematoxylin	2.5	HTS					Oc1cc2C[C@@]3(O)COc4c(ccc(O)c4O)[C@H]3c2cc1O, Oc1cc2C[C@@]3(O)COc4c(ccc(O)c4O)[C@H]3c2cc1O	Preclinical	5
BRD-K78431006-001-10-2::2.5::HTS	-0.145287169518	BRD-K78431006-001-10-2::2.5::HTS	BRD-K78431006-001-10-2	crizotinib	2.5	HTS	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	Launched	5
BRD-K78455053-001-01-2::2.5::HTS	-0.507161630137	BRD-K78455053-001-01-2::2.5::HTS	BRD-K78455053-001-01-2	wnt-c59	2.5	HTS	porcupine inhibitor	PORCN			Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1	Preclinical	5
BRD-K78485176-001-07-8::2.5::HTS	0.0067557315976199996	BRD-K78485176-001-07-8::2.5::HTS	BRD-K78485176-001-07-8	olmesartan-medoxomil	2.5	HTS	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Launched	5
BRD-K78496197-001-03-9::2.5::HTS	0.406720733595	BRD-K78496197-001-03-9::2.5::HTS	BRD-K78496197-001-03-9	SCS	2.5	HTS					Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O	Preclinical	5
BRD-K78513633-001-15-7::2.5::HTS	0.057184851234599994	BRD-K78513633-001-15-7::2.5::HTS	BRD-K78513633-001-15-7	lonidamine	2.5	HTS	glucokinase inhibitor	GCK			OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	Launched	5
BRD-K78567475-001-01-4::2.5::HTS	-1.12211619129	BRD-K78567475-001-01-4::2.5::HTS	BRD-K78567475-001-01-4	dolastatin-10	2.5	HTS	tubulin polymerization inhibitor	TUBB			CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	Phase 2	5
BRD-K78633253-001-10-3::2.5::HTS	0.293550479478	BRD-K78633253-001-10-3::2.5::HTS	BRD-K78633253-001-10-3	EXO-1	2.5	HTS	ARF inhibitor				COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1	Preclinical	5
BRD-K78637815-001-02-2::2.5::HTS	-0.000423012518635	BRD-K78637815-001-02-2::2.5::HTS	BRD-K78637815-001-02-2	LY320135	2.5	HTS	cannabinoid receptor antagonist	CNR1			COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N	Preclinical	5
BRD-K78643075-001-11-6::2.5::HTS	0.09702335998940001	BRD-K78643075-001-11-6::2.5::HTS	BRD-K78643075-001-11-6	bromperidol	2.5	HTS	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1	Launched	5
BRD-K78659596-001-03-9::2.5::HTS	-4.24322964504	BRD-K78659596-001-03-9::2.5::HTS	BRD-K78659596-001-03-9	ixazomib	2.5	HTS	proteasome inhibitor		hematologic malignancy	multiple myeloma	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O	Launched	5
BRD-K78666826-003-01-6::2.5::HTS	0.05338141928949999	BRD-K78666826-003-01-6::2.5::HTS	BRD-K78666826-003-01-6	procaterol	2.5	HTS	adrenergic receptor agonist	ADRB2	pulmonary	asthma	CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	Launched	5
BRD-K78692225-001-24-5::2.5::HTS	0.840238060747	BRD-K78692225-001-24-5::2.5::HTS	BRD-K78692225-001-24-5	leflunomide	2.5	HTS	dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor	AHR, DHODH, PTK2B	rheumatology	rheumatoid arthritis	Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F	Launched	5
BRD-K78720403-001-01-6::2.5::HTS	-0.190907821867	BRD-K78720403-001-01-6::2.5::HTS	BRD-K78720403-001-01-6	SB-328437	2.5	HTS	CCR antagonist				COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12	Preclinical	5
BRD-K78781788-003-01-9::2.5::HTS	0.145977320568	BRD-K78781788-003-01-9::2.5::HTS	BRD-K78781788-003-01-9	barnidipine	2.5	HTS	calcium channel blocker		cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1	Launched	5
BRD-K78789465-001-01-6::2.5::HTS	-0.109875725353	BRD-K78789465-001-01-6::2.5::HTS	BRD-K78789465-001-01-6	pentagastrin	2.5	HTS	CCK receptor agonist	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	Launched	5
BRD-K78789465-001-02-4::2.5::HTS	-0.0847235443336	BRD-K78789465-001-02-4::2.5::HTS	BRD-K78789465-001-02-4	pentagastrin	2.5	HTS	CCK receptor agonist	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	Launched	5
BRD-K78809024-001-05-7::2.5::HTS	-0.483006869803	BRD-K78809024-001-05-7::2.5::HTS	BRD-K78809024-001-05-7	SB-590885	2.5	HTS	RAF inhibitor	BRAF			CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1	Preclinical	5
BRD-K78815826-001-14-6::2.5::HTS	0.7514499727060001	BRD-K78815826-001-14-6::2.5::HTS	BRD-K78815826-001-14-6	suxibuzone	2.5	HTS	cyclooxygenase inhibitor		rheumatology, neurology/psychiatry	joint pain, muscle pain	CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	Launched	5
BRD-K78844995-001-02-6::2.5::HTS	0.34744855205799996	BRD-K78844995-001-02-6::2.5::HTS	BRD-K78844995-001-02-6	N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide	2.5	HTS	sigma receptor ligand				Ic1ccc(cc1)C(=O)NCCN1CCCCC1	Preclinical	5
BRD-K78941306-001-02-4::2.5::HTS	0.050851551977900006	BRD-K78941306-001-02-4::2.5::HTS	BRD-K78941306-001-02-4	SB-742457	2.5	HTS	serotonin receptor antagonist	HTR6			O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1	Phase 3	5
BRD-K78959463-001-13-2::2.5::HTS	0.039072966935199994	BRD-K78959463-001-13-2::2.5::HTS	BRD-K78959463-001-13-2	FPL-64176	2.5	HTS	calcium channel activator	CACNA1C, CACNA1S			COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1	Preclinical	5
BRD-K78960041-001-03-2::2.5::HTS	-2.62262503757	BRD-K78960041-001-03-2::2.5::HTS	BRD-K78960041-001-03-2	oxaliplatin	2.5	HTS	DNA inhibitor		oncology	colorectal cancer	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	Launched	5
BRD-K78960041-001-05-7::2.54::HTS	-1.4472094517899998	BRD-K78960041-001-05-7::2.54::HTS	BRD-K78960041-001-05-7	oxaliplatin	2.54	HTS	DNA inhibitor		oncology	colorectal cancer	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	Launched	5
BRD-K79092138-001-11-0::2.5::HTS	-0.134526081002	BRD-K79092138-001-11-0::2.5::HTS	BRD-K79092138-001-11-0	nitrofurazone	2.5	HTS	bacterial DNA inhibitor		infectious disease	first-aid antibiotic	NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched	5
BRD-K79095980-001-09-6::2.5::HTS	0.600031385179	BRD-K79095980-001-09-6::2.5::HTS	BRD-K79095980-001-09-6	broxuridine	2.5	HTS	antimetabolite				OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O	Phase 2	5
BRD-K79102359-003-01-6::2.5::HTS	-0.039484497073900005	BRD-K79102359-003-01-6::2.5::HTS	BRD-K79102359-003-01-6	idalopirdine	2.5	HTS	serotonin receptor antagonist	HTR6			FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1	Phase 3	5
BRD-K79116891-003-15-1::2.5::HTS	0.42533760008	BRD-K79116891-003-15-1::2.5::HTS	BRD-K79116891-003-15-1	proxymetacaine	2.5	HTS	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	anesthetic	CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC	Launched	5
BRD-K79124250-001-08-9::2.5::HTS	-0.07292762170599999	BRD-K79124250-001-08-9::2.5::HTS	BRD-K79124250-001-08-9	ioxaglic-acid	2.5	HTS	radiopaque medium		radiology	contrast agent	CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I	Launched	5
BRD-K79131256-001-17-9::2.5::HTS	-1.0034589285200002	BRD-K79131256-001-17-9::2.5::HTS	BRD-K79131256-001-17-9	albendazole	2.5	HTS	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1	Launched	5
BRD-K79132813-001-09-0::2.5::HTS	-0.239133714789	BRD-K79132813-001-09-0::2.5::HTS	BRD-K79132813-001-09-0	pibenzimol	2.5	HTS	DNA inhibitor				c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1	Phase 2	5
BRD-K79145628-001-05-5::2.5::HTS	0.0483396483071	BRD-K79145628-001-05-5::2.5::HTS	BRD-K79145628-001-05-5	nimorazole	2.5	HTS	bacterial DNA inhibitor		oncology	head and neck squamous cell carcinoma (HNSCC)	[O-][N+](=O)c1cncn1CCN1CCOCC1	Launched	5
BRD-K79145749-003-02-2::2.5::HTS	-0.153384985279	BRD-K79145749-003-02-2::2.5::HTS	BRD-K79145749-003-02-2	dibenzepine	2.5	HTS	norepinephrine reputake inhibitor				CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O	Preclinical	5
BRD-K79239947-001-06-8::2.5::HTS	0.482299913495	BRD-K79239947-001-06-8::2.5::HTS	BRD-K79239947-001-06-8	PF-573228	2.5	HTS	focal adhesion kinase inhibitor	CDK1, CDK2, CDK7, GSK3B, IKBKB			CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1	Preclinical	5
BRD-K79254416-001-22-6::2.5::HTS	-0.888603549279	BRD-K79254416-001-22-6::2.5::HTS	BRD-K79254416-001-22-6	decitabine	2.5	HTS	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	Launched	5
BRD-K79259477-001-04-9::2.5::HTS	0.47455399253799996	BRD-K79259477-001-04-9::2.5::HTS	BRD-K79259477-001-04-9	NVP-BHG712	2.5	HTS	ephrin inhibitor	EPHB4			Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical	5
BRD-K79277568-003-04-7::2.5::HTS	-0.31414888636300003	BRD-K79277568-003-04-7::2.5::HTS	BRD-K79277568-003-04-7	methoxyamine	2.5	HTS	DNA repair enzyme inhibitor	APEX1			CON	Phase 2	5
BRD-K79315489-001-07-8::2.5::HTS	-0.28545808699	BRD-K79315489-001-07-8::2.5::HTS	BRD-K79315489-001-07-8	erythritol	2.5	HTS					OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO	Launched	5
BRD-K79404599-001-09-3::2.5::HTS	0.205315634082	BRD-K79404599-001-09-3::2.5::HTS	BRD-K79404599-001-09-3	enzastaurin	2.5	HTS	PKC inhibitor	AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG			Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12	Phase 3	5
BRD-K79425933-001-09-3::2.5::HTS	0.24519014891600002	BRD-K79425933-001-09-3::2.5::HTS	BRD-K79425933-001-09-3	benperidol	2.5	HTS	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	Launched	5
BRD-K79437791-001-05-7::2.5::HTS	0.139454750863	BRD-K79437791-001-05-7::2.5::HTS	BRD-K79437791-001-05-7	acetyl-farnesyl-cysteine	2.5	HTS	methyltransferase inhibitor	PPARG	dermatology	acne vulgaris (AV)	CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O, CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O	Launched	5
BRD-K79501723-001-04-6::2.5::HTS	0.422277867332	BRD-K79501723-001-04-6::2.5::HTS	BRD-K79501723-001-04-6	cyclizine	2.5	HTS	histamine receptor modulator	HRH1, SULT1E1	gastroenterology, neurology/psychiatry	nausea, vomiting, vertigo, motion sickness	CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	5
BRD-K79555887-001-01-0::2.5::HTS	-0.0542533230495	BRD-K79555887-001-01-0::2.5::HTS	BRD-K79555887-001-01-0	RI-1	2.5	HTS		RAD51			ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-K79584249-001-01-3::2.5::HTS	-2.5613034607599996	BRD-K79584249-001-01-3::2.5::HTS	BRD-K79584249-001-01-3	CGM097	2.5	HTS	MDM inhibitor	MDM2			COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1	Phase 1	5
BRD-K79595931-312-01-3::2.5::HTS	-0.236113901442	BRD-K79595931-312-01-3::2.5::HTS	BRD-K79595931-312-01-3	bavisant	2.5	HTS	histamine receptor antagonist	HRH3			O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1	Phase 2	5
BRD-K79602928-003-19-9::2.5::HTS	0.37062384353600003	BRD-K79602928-003-19-9::2.5::HTS	BRD-K79602928-003-19-9	metformin	2.5	HTS	insulin sensitizer	ACACB, PRKAB1	endocrinology	diabetes mellitus	CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N	Launched	5
BRD-K79612754-001-19-1::2.62::HTS	1.13902637794	BRD-K79612754-001-19-1::2.62::HTS	BRD-K79612754-001-19-1	inosine	2.62	HTS	neurotrophic agent	PARP1, PNP			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12	Launched	5
BRD-K79612754-001-21-7::2.5::HTS	-0.0196071360247	BRD-K79612754-001-21-7::2.5::HTS	BRD-K79612754-001-21-7	inosine	2.5	HTS	neurotrophic agent	PARP1, PNP			OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12	Launched	5
BRD-K79633074-001-01-8::2.5::HTS	-0.422817007281	BRD-K79633074-001-01-8::2.5::HTS	BRD-K79633074-001-01-8	xilobam	2.5	HTS					CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C	Phase 1	5
BRD-K79684402-300-02-8::2.5::HTS	0.377008716743	BRD-K79684402-300-02-8::2.5::HTS	BRD-K79684402-300-02-8	Ro-10-5824	2.5	HTS	dopamine receptor agonist	DRD4			Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1	Preclinical	5
BRD-K79711234-001-18-3::2.5::HTS	-0.324367357635	BRD-K79711234-001-18-3::2.5::HTS	BRD-K79711234-001-18-3	thiamphenicol	2.5	HTS	bacterial 50S ribosomal subunit inhibitor		infectious disease	pelvic inflammatory disease	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	Launched	5
BRD-K79753741-001-01-7::2.5::HTS	0.400651041287	BRD-K79753741-001-01-7::2.5::HTS	BRD-K79753741-001-01-7	UBP-302	2.5	HTS	glutamate receptor antagonist	GRIK1			N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	Preclinical	5
BRD-K79759585-048-04-8::2.5::HTS	0.33424352487	BRD-K79759585-048-04-8::2.5::HTS	BRD-K79759585-048-04-8	sildenafil	2.5	HTS	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3	cardiology	hypertension	CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1	Launched	5
BRD-K79884267-001-01-4::2.5::HTS	-0.45529553815800006	BRD-K79884267-001-01-4::2.5::HTS	BRD-K79884267-001-01-4	retinaldehyde	2.5	HTS			dermatology	cosmetic	CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O	Launched	5
BRD-K79892937-001-02-5::2.5::HTS	0.0176353901367	BRD-K79892937-001-02-5::2.5::HTS	BRD-K79892937-001-02-5	phenolsulfonphthalein	2.5	HTS					Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1	Launched	5
BRD-K79905821-004-03-6::2.5::HTS	-1.10345983281	BRD-K79905821-004-03-6::2.5::HTS	BRD-K79905821-004-03-6	gabazine	2.5	HTS	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2			COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1	Preclinical	5
BRD-K79930101-300-03-7::2.5::HTS	0.37760800328199995	BRD-K79930101-300-03-7::2.5::HTS	BRD-K79930101-300-03-7	GW-583340	2.5	HTS	EGFR inhibitor	EGFR, ERBB2			CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	Preclinical	5
BRD-K79966802-034-01-2::2.5::HTS	0.0568125614544	BRD-K79966802-034-01-2::2.5::HTS	BRD-K79966802-034-01-2	rivanicline	2.5	HTS	acetylcholine receptor agonist	CHRNA4, CHRNB2, CXCL8			CNCC\C=C\c1cccnc1	Phase 2	5
BRD-K79989959-001-01-4::2.5::HTS	0.26015332257	BRD-K79989959-001-01-4::2.5::HTS	BRD-K79989959-001-01-4	nesbuvir	2.5	HTS	RNA polymerase inhibitor				CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1	Phase 2	5
BRD-K80025777-001-01-4::2.5::HTS	0.36817843341	BRD-K80025777-001-01-4::2.5::HTS	BRD-K80025777-001-01-4	cis-9,trans-11-Conjugated-linoleic-acid	2.5	HTS					CCCCCC\C=C\C=C/CCCCCCCC(O)=O	Launched	5
BRD-K80028314-303-02-6::2.5::HTS	0.190637833497	BRD-K80028314-303-02-6::2.5::HTS	BRD-K80028314-303-02-6	alpha-methylhistamine-dihydrobromide-(R)-(-)	2.5	HTS	histamine receptor agonist	HRH3			C[C@@H](N)Cc1c[nH]cn1	Preclinical	5
BRD-K80036624-001-04-0::2.5::HTS	0.137325822302	BRD-K80036624-001-04-0::2.5::HTS	BRD-K80036624-001-04-0	clopidol	2.5	HTS			infectious disease	coccidiosis	Cc1nc(C)c(Cl)c(O)c1Cl	Launched	5
BRD-K80043866-236-01-1::2.5::HTS	0.08812552596960001	BRD-K80043866-236-01-1::2.5::HTS	BRD-K80043866-236-01-1	sodium-gualenate	2.5	HTS	antacid				CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O	Launched	5
BRD-K80060353-303-03-9::2.46::HTS	-0.0627064981699	BRD-K80060353-303-03-9::2.46::HTS	BRD-K80060353-303-03-9	IEM1754	2.46	HTS	glutamate receptor antagonist	GRIA1			NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2	Preclinical	5
BRD-K80082640-001-01-0::2.5::HTS	0.26614814950300003	BRD-K80082640-001-01-0::2.5::HTS	BRD-K80082640-001-01-0	otamixaban	2.5	HTS	coagulation factor inhibitor	F10			COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1	Phase 3	5
BRD-K80129304-001-08-1::2.5::HTS	0.0192546539913	BRD-K80129304-001-08-1::2.5::HTS	BRD-K80129304-001-08-1	uracil	2.5	HTS		DPYD, UCKL1			Oc1ccnc(O)n1, Oc1ccnc(O)n1	Launched	5
BRD-K80262108-001-07-0::2.5::HTS	-0.346085603487	BRD-K80262108-001-07-0::2.5::HTS	BRD-K80262108-001-07-0	amifampridine	2.5	HTS	potassium channel blocker		neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	Nc1ccncc1N	Launched	5
BRD-K80267133-001-17-7::2.5::HTS	0.0979007067801	BRD-K80267133-001-17-7::2.5::HTS	BRD-K80267133-001-17-7	aminosalicylate	2.5	HTS	cyclooxygenase inhibitor	ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2	gastroenterology	inflammatory bowel disease, ulcerative colitis	Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1	Launched	5
BRD-K80267133-001-19-3::2.5::HTS	-1.0252204935	BRD-K80267133-001-19-3::2.5::HTS	BRD-K80267133-001-19-3	aminosalicylate	2.5	HTS	cyclooxygenase inhibitor	ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2	gastroenterology	inflammatory bowel disease, ulcerative colitis	Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1	Launched	5
BRD-K80315159-051-02-0::2.5::HTS	-0.419658876261	BRD-K80315159-051-02-0::2.5::HTS	BRD-K80315159-051-02-0	DPPE	2.5	HTS	histamine receptor antagonist	ABCB1, HRH1			CCN(CC)CCOc1ccc(Cc2ccccc2)cc1	Phase 3	5
BRD-K80343549-001-02-6::2.5::HTS	-0.21543239931299998	BRD-K80343549-001-02-6::2.5::HTS	BRD-K80343549-001-02-6	TAK-285	2.5	HTS	EGFR inhibitor	ERBB2			CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12	Phase 1	5
BRD-K80353138-001-12-1::2.5::HTS	-0.233164311964	BRD-K80353138-001-12-1::2.5::HTS	BRD-K80353138-001-12-1	silibinin	2.5	HTS	cytochrome P450 inhibitor	ALOX5	gastroenterology	hepatic cirrhosis	COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O	Launched	5
BRD-K80396088-001-12-0::2.5::HTS	-0.309823500085	BRD-K80396088-001-12-0::2.5::HTS	BRD-K80396088-001-12-0	gliquidone	2.5	HTS	sulfonylurea	ABCC8, KCNJ10, KCNJ8	endocrinology	diabetes mellitus	COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C	Launched	5
BRD-K80431395-001-07-3::2.49::HTS	0.45939951550499997	BRD-K80431395-001-07-3::2.49::HTS	BRD-K80431395-001-07-3	triciribine	2.49	HTS	AKT inhibitor	AKT1, AKT2, AKT3			Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	Phase 1/Phase 2	5
BRD-K80431395-001-09-9::2.5::HTS	0.537894283755	BRD-K80431395-001-09-9::2.5::HTS	BRD-K80431395-001-09-9	triciribine	2.5	HTS	AKT inhibitor	AKT1, AKT2, AKT3			Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	Phase 1/Phase 2	5
BRD-K80451230-051-02-6::2.5::HTS	0.0167099501045	BRD-K80451230-051-02-6::2.5::HTS	BRD-K80451230-051-02-6	zamifenacin	2.5	HTS	acetylcholine receptor antagonist	CHRM3			C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1	Phase 3	5
BRD-K80480517-001-02-4::2.5::HTS	-0.045841357398899996	BRD-K80480517-001-02-4::2.5::HTS	BRD-K80480517-001-02-4	repsox	2.5	HTS	TGF beta receptor inhibitor	TGFBR1			Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1	Preclinical	5
BRD-K80608265-001-01-6::2.5::HTS	-0.587108624758	BRD-K80608265-001-01-6::2.5::HTS	BRD-K80608265-001-01-6	erteberel	2.5	HTS	estrogen receptor agonist	ESR1, ESR2			Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12	Phase 2	5
BRD-K80639402-003-02-9::2.5::HTS	-0.020688682545700002	BRD-K80639402-003-02-9::2.5::HTS	BRD-K80639402-003-02-9	SB-258585	2.5	HTS	serotonin receptor antagonist	HTR6			COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1	Preclinical	5
BRD-K80653534-001-01-7::2.5::HTS	-0.13696873578	BRD-K80653534-001-01-7::2.5::HTS	BRD-K80653534-001-01-7	N-acetyl-D-glucosamine	2.5	HTS		B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP			CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	Phase 2/Phase 3	5
BRD-K80700417-001-04-2::2.5::HTS	0.1940332823	BRD-K80700417-001-04-2::2.5::HTS	BRD-K80700417-001-04-2	SGI-1776	2.5	HTS	Pim kinase inhibitor	FLT3, PIM1, PIM2, PIM3			CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1	Phase 1	5
BRD-K80725821-300-02-9::2.5::HTS	-0.161728157023	BRD-K80725821-300-02-9::2.5::HTS	BRD-K80725821-300-02-9	RS-16566	2.5	HTS	serotonin receptor antagonist				CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2	Preclinical	5
BRD-K80778372-001-02-5::2.5::HTS	-0.592697864913	BRD-K80778372-001-02-5::2.5::HTS	BRD-K80778372-001-02-5	Ro-19-4605	2.5	HTS		GABRA1, GABRA2, GABRA3, GABRA5			CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C	Preclinical	5
BRD-K80935598-001-01-1::2.5::HTS	0.497266402736	BRD-K80935598-001-01-1::2.5::HTS	BRD-K80935598-001-01-1	AZ191	2.5	HTS	DYRK inhibitor	DYRK1B			COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1	Preclinical	5
BRD-K81016934-001-02-0::2.5::HTS	-0.16054684859	BRD-K81016934-001-02-0::2.5::HTS	BRD-K81016934-001-02-0	INC-280	2.5	HTS	c-Met inhibitor	MET			CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1	Phase 2	5
BRD-K81062487-001-05-8::2.5::HTS	-0.444788073151	BRD-K81062487-001-05-8::2.5::HTS	BRD-K81062487-001-05-8	taurocholate	2.5	HTS	G protein-coupled receptor agonist	CEL, FABP6, SLCO1C1			C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Phase 1	5
BRD-K81074237-001-02-3::2.5::HTS	-0.12097022350400001	BRD-K81074237-001-02-3::2.5::HTS	BRD-K81074237-001-02-3	azilsartan	2.5	HTS	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	Launched	5
BRD-K81092066-311-01-6::2.5::HTS	0.0833831145733	BRD-K81092066-311-01-6::2.5::HTS	BRD-K81092066-311-01-6	phenacaine	2.5	HTS	local anesthetic		neurology/psychiatry	local anesthetic	CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1	Launched	5
BRD-K81101512-234-01-9::2.5::HTS	0.39880743245899997	BRD-K81101512-234-01-9::2.5::HTS	BRD-K81101512-234-01-9	fosfomycin	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	C[C@@H]1O[C@@H]1P(O)(O)=O, CC1OC1P(O)(O)=O	Launched	5
BRD-K81128206-003-24-4::2.5::HTS	-0.0295171972682	BRD-K81128206-003-24-4::2.5::HTS	BRD-K81128206-003-24-4	edrophonium	2.5	HTS	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	CC[N+](C)(C)c1cccc(O)c1	Launched	5
BRD-K81130846-001-17-4::2.5::HTS	0.514535679291	BRD-K81130846-001-17-4::2.5::HTS	BRD-K81130846-001-17-4	salicylamide	2.5	HTS	analgesic agent		neurology/psychiatry, endocrinology	pain relief, fever	NC(=O)c1ccccc1O	Launched	5
BRD-K81136890-003-01-6::2.5::HTS	-0.18908474108800002	BRD-K81136890-003-01-6::2.5::HTS	BRD-K81136890-003-01-6	leucylleucine-methyl-ester	2.5	HTS					COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C	Phase 2	5
BRD-K81144366-003-19-7::2.5::HTS	-0.403788065624	BRD-K81144366-003-19-7::2.5::HTS	BRD-K81144366-003-19-7	moxisylyte	2.5	HTS	adrenergic receptor antagonist				CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C	Withdrawn	5
BRD-K81197548-003-01-4::2.5::HTS	-1.27378920073	BRD-K81197548-003-01-4::2.5::HTS	BRD-K81197548-003-01-4	NSC-632839	2.5	HTS	ubiquitin specific protease inhibitor	SENP2, USP1, USP2, USP7			Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1	Preclinical	5
BRD-K81225797-001-02-3::2.5::HTS	0.591869626314	BRD-K81225797-001-02-3::2.5::HTS	BRD-K81225797-001-02-3	SCH-58261	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1	Preclinical	5
BRD-K81272440-236-13-5::2.5::HTS	0.255177867683	BRD-K81272440-236-13-5::2.5::HTS	BRD-K81272440-236-13-5	dantrolene	2.5	HTS	calcium channel blocker	RYR1, RYR3	neurology/psychiatry, endocrinology	spasms, malignant hyperthermia (MH)	[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1	Launched	5
BRD-K81316007-001-01-8::2.5::HTS	0.5805661540529999	BRD-K81316007-001-01-8::2.5::HTS	BRD-K81316007-001-01-8	4-mu-8C	2.5	HTS	IRE1 inhibitor	ERN1			Cc1cc(=O)oc2c(C=O)c(O)ccc12	Preclinical	5
BRD-K81326768-001-04-0::2.5::HTS	-0.559892603883	BRD-K81326768-001-04-0::2.5::HTS	BRD-K81326768-001-04-0	zomepirac	2.5	HTS	prostaglandin synthesis inhibitor	PTGDR2			Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1	Withdrawn	5
BRD-K81330143-001-04-8::2.38::HTS	-0.5884778133649999	BRD-K81330143-001-04-8::2.38::HTS	BRD-K81330143-001-04-8	tideglusib	2.38	HTS	glycogen synthase kinase inhibitor	GSK3B			O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1	Phase 2	5
BRD-K81332461-001-01-4::2.5::HTS	0.194950138182	BRD-K81332461-001-01-4::2.5::HTS	BRD-K81332461-001-01-4	maxacalcitol	2.5	HTS	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H]	Launched	5
BRD-K81376179-001-04-8::2.5::HTS	0.241636520125	BRD-K81376179-001-04-8::2.5::HTS	BRD-K81376179-001-04-8	TCS-359	2.5	HTS	FLT3 inhibitor	FLT3			COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	Preclinical	5
BRD-K81418486-001-47-5::2.5::HTS	-1.57629939898	BRD-K81418486-001-47-5::2.5::HTS	BRD-K81418486-001-47-5	vorinostat	2.5	HTS	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1	Launched	5
BRD-K81447180-003-21-4::2.58::HTS	0.308366624754	BRD-K81447180-003-21-4::2.58::HTS	BRD-K81447180-003-21-4	lincomycin	2.58	HTS	bacterial 30S ribosomal subunit inhibitor		gastroenterology	enteritis	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H]([C@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O	Launched	5
BRD-K81458380-001-04-9::2.5::HTS	0.648044407217	BRD-K81458380-001-04-9::2.5::HTS	BRD-K81458380-001-04-9	CX-4945	2.5	HTS	casein kinase inhibitor	CSNK2A1, CSNK2A2, DAPK3, HIPK3			OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21	Phase 1/Phase 2	5
BRD-K81473043-001-14-6::2.5::HTS	-1.1501884733	BRD-K81473043-001-14-6::2.5::HTS	BRD-K81473043-001-14-6	tanespimycin	2.5	HTS	HSP inhibitor	HSP90AA1			CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O	Phase 3	5
BRD-K81473089-003-26-1::2.5::HTS	0.08691012773830001	BRD-K81473089-003-26-1::2.5::HTS	BRD-K81473089-003-26-1	tacrine	2.5	HTS	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease	Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12	Launched	5
BRD-K81528515-001-13-8::2.5::HTS	-0.205540102593	BRD-K81528515-001-13-8::2.5::HTS	BRD-K81528515-001-13-8	nilotinib	2.5	HTS	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F	Launched	5
BRD-K81548480-001-01-2::2.5::HTS	-0.631326428535	BRD-K81548480-001-01-2::2.5::HTS	BRD-K81548480-001-01-2	AC-264613	2.5	HTS	PAR agonist	F2RL1			C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1	Preclinical	5
BRD-K81572616-001-01-9::2.5::HTS	0.156939754358	BRD-K81572616-001-01-9::2.5::HTS	BRD-K81572616-001-01-9	CK-636	2.5	HTS	actin related protein inhibitor	ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5			Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1	Preclinical	5
BRD-K81613478-001-01-8::2.5::HTS	-1.08612204481	BRD-K81613478-001-01-8::2.5::HTS	BRD-K81613478-001-01-8	gastrodin	2.5	HTS					OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	5
BRD-K81623406-004-08-3::2.5::HTS	0.431319821258	BRD-K81623406-004-08-3::2.5::HTS	BRD-K81623406-004-08-3	EIT-hydrobromide	2.5	HTS	nitric oxide synthase inhibitor	NOS2, NOS3			CCSC(N)=N	Preclinical	5
BRD-K81645297-236-01-1::2.5::HTS	-0.128836578434	BRD-K81645297-236-01-1::2.5::HTS	BRD-K81645297-236-01-1	NKP-1339	2.5	HTS	HSP inhibitor				Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1, Cl[Ru](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1	Phase 1	5
BRD-K81645907-001-01-1::2.5::HTS	-1.6026118961700002	BRD-K81645907-001-01-1::2.5::HTS	BRD-K81645907-001-01-1	captamine	2.5	HTS					CN(C)CCS	Preclinical	5
BRD-K81647657-001-04-3::2.5::HTS	-0.0642477461484	BRD-K81647657-001-04-3::2.5::HTS	BRD-K81647657-001-04-3	3-methyladenine	2.5	HTS	PI3K inhibitor	PI3			Cn1cnc(=N)c2nc[nH]c12, Cn1cnc(=N)c2nc[nH]c12	Preclinical	5
BRD-K81672972-001-03-1::2.5::HTS	-0.326129072408	BRD-K81672972-001-03-1::2.5::HTS	BRD-K81672972-001-03-1	dinoprost	2.5	HTS	prostacyclin analog	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R	obstetrics/gynecology	labor induction	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	Launched	5
BRD-K81694556-003-01-9::2.5::HTS	-1.57927773964	BRD-K81694556-003-01-9::2.5::HTS	BRD-K81694556-003-01-9	VTP-27999	2.5	HTS	renin inhibitor	REN			CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1	Phase 1	5
BRD-K81728688-001-04-4::2.5::HTS	0.0277860535188	BRD-K81728688-001-04-4::2.5::HTS	BRD-K81728688-001-04-4	WZ8040	2.5	HTS	EGFR inhibitor	EGFR			CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1	Preclinical	5
BRD-K81729199-001-02-8::2.5::HTS	-0.08033540868080001	BRD-K81729199-001-02-8::2.5::HTS	BRD-K81729199-001-02-8	AQ-RA741	2.5	HTS	acetylcholine receptor antagonist	CHRM2			CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	Preclinical	5
BRD-K81795818-019-01-4::2.5::HTS	0.540957585761	BRD-K81795818-019-01-4::2.5::HTS	BRD-K81795818-019-01-4	exherin	2.5	HTS	cadherin antagonist	CDH2			CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	Phase 2	5
BRD-K81801188-001-02-8::2.5::HTS	-2.22888077398	BRD-K81801188-001-02-8::2.5::HTS	BRD-K81801188-001-02-8	PP-121	2.5	HTS	protein tyrosine kinase inhibitor	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC			C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12	Preclinical	5
BRD-K81807412-001-10-6::2.5::HTS	0.028242858778400003	BRD-K81807412-001-10-6::2.5::HTS	BRD-K81807412-001-10-6	N6-methyladenosine	2.5	HTS					CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical	5
BRD-K81839095-001-25-1::2.6::HTS	0.0917105285615	BRD-K81839095-001-25-1::2.6::HTS	BRD-K81839095-001-25-1	estrone	2.6	HTS	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2			C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	Launched	5
BRD-K81839095-001-30-1::2.5::HTS	0.582360384341	BRD-K81839095-001-30-1::2.5::HTS	BRD-K81839095-001-30-1	estrone	2.5	HTS	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2			C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	Launched	5
BRD-K81855038-003-13-9::2.5::HTS	0.121168417927	BRD-K81855038-003-13-9::2.5::HTS	BRD-K81855038-003-13-9	roxatidine-acetate	2.5	HTS	histamine receptor antagonist	HRH2	gastroenterology	Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis	CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1	Launched	5
BRD-K81876028-300-02-0::2.5::HTS	0.152359795296	BRD-K81876028-300-02-0::2.5::HTS	BRD-K81876028-300-02-0	CP-93129	2.5	HTS	serotonin receptor agonist	HTR1A			O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1	Preclinical	5
BRD-K81916719-001-13-9::2.5::HTS	-0.6412187124490001	BRD-K81916719-001-13-9::2.5::HTS	BRD-K81916719-001-13-9	triclabendazole	2.5	HTS	microtubule inhibitor	DNMT1	infectious disease	tapeworm	CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1	Launched	5
BRD-K81957469-001-01-0::2.5::HTS	-0.431037928846	BRD-K81957469-001-01-0::2.5::HTS	BRD-K81957469-001-01-0	semagacestat	2.5	HTS	gamma secretase inhibitor	PSEN1			CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1c2ccccc2CCN(C)C1=O	Phase 3	5
BRD-K82002057-001-01-2::2.5::HTS	-0.47341351393299996	BRD-K82002057-001-01-2::2.5::HTS	BRD-K82002057-001-01-2	DFB	2.5	HTS	glutamate receptor agonist	GRM5			Fc1cccc(c1)\C=N\N=C\c1cccc(F)c1	Preclinical	5
BRD-K82027074-001-07-5::2.5::HTS	0.5913223671769999	BRD-K82027074-001-07-5::2.5::HTS	BRD-K82027074-001-07-5	2-hydroxyflutamide	2.5	HTS	androgen receptor antagonist	AR			CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Phase 1/Phase 2	5
BRD-K82028950-300-02-9::2.5::HTS	-0.306623123629	BRD-K82028950-300-02-9::2.5::HTS	BRD-K82028950-300-02-9	CGH2466	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1	Preclinical	5
BRD-K82036761-003-20-3::2.5::HTS	-0.125760916932	BRD-K82036761-003-20-3::2.5::HTS	BRD-K82036761-003-20-3	sertraline	2.5	HTS	selective serotonin reuptake inhibitor (SSRI)	SLC6A3, SLC6A4	neurology/psychiatry, obstetrics/gynecology	depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	Launched	5
BRD-K82091397-001-03-0::2.5::HTS	0.26680072473	BRD-K82091397-001-03-0::2.5::HTS	BRD-K82091397-001-03-0	SB-239063	2.5	HTS	p38 MAPK inhibitor	MAPK11, MAPK14, PTGS2			COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1	Preclinical	5
BRD-K82104468-001-05-0::2.5::HTS	-0.420210524628	BRD-K82104468-001-05-0::2.5::HTS	BRD-K82104468-001-05-0	ethyl-vanillin	2.5	HTS					CCOc1cc(C=O)ccc1O	Preclinical	5
BRD-K82122102-323-01-1::2.5::HTS	-0.32571755409	BRD-K82122102-323-01-1::2.5::HTS	BRD-K82122102-323-01-1	amfenac	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1	Launched	5
BRD-K82135108-001-04-3::2.5::HTS	-1.9968045762	BRD-K82135108-001-04-3::2.5::HTS	BRD-K82135108-001-04-3	elesclomol	2.5	HTS	oxidative stress inducer	HSPA1A			CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1	Phase 3	5
BRD-K82142815-001-19-1::2.5::HTS	0.42069086313299997	BRD-K82142815-001-19-1::2.5::HTS	BRD-K82142815-001-19-1	betamipron	2.5	HTS	panipenem uptake inhibitor		nephrology	renal toxicity	OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1	Launched	5
BRD-K82143716-001-19-9::2.5::HTS	0.327469564092	BRD-K82143716-001-19-9::2.5::HTS	BRD-K82143716-001-19-9	flucytosine	2.5	HTS	other antifungal	DNMT1	infectious disease	bacterial septicemia, endocarditis, urinary tract infections, meningitis	Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F	Launched	5
BRD-K82164249-001-03-5::2.5::HTS	0.44211903878799996	BRD-K82164249-001-03-5::2.5::HTS	BRD-K82164249-001-03-5	andarine	2.5	HTS	androgen receptor modulator	AR			CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1	Phase 1	5
BRD-K82166906-236-02-8::2.5::HTS	0.92113855456	BRD-K82166906-236-02-8::2.5::HTS	BRD-K82166906-236-02-8	sodium-oxybate	2.5	HTS	benzodiazepine receptor agonist	GABRB1, HCAR1, SLC52A2	neurology/psychiatry	narcolepsy	OCCCC(O)=O	Launched	5
BRD-K82181219-001-04-3::2.5::HTS	-0.9977028662190001	BRD-K82181219-001-04-3::2.5::HTS	BRD-K82181219-001-04-3	pyritinol	2.5	HTS			rheumatology, neurology/psychiatry	rheumatoid arthritis, senile dementia	Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O	Launched	5
BRD-K82225283-001-03-1::2.5::HTS	0.043850404122199996	BRD-K82225283-001-03-1::2.5::HTS	BRD-K82225283-001-03-1	isosorbide-mononitrate	2.5	HTS	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	angina pectoris, coronary artery disease (CAD)	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	Launched	5
BRD-K82234479-001-09-4::2.5::HTS	-0.141863372105	BRD-K82234479-001-09-4::2.5::HTS	BRD-K82234479-001-09-4	tramiprosate	2.5	HTS	beta amyloid protein neurotoxicity inhibitor	APP			NCCCS(O)(=O)=O	Phase 3	5
BRD-K82236108-001-04-9::2.5::HTS	0.19032509301800002	BRD-K82236108-001-04-9::2.5::HTS	BRD-K82236108-001-04-9	N-methyl-(-)ephedrine-[1r,2s]	2.5	HTS					C[C@@H]([C@H](O)c1ccccc1)N(C)C	Preclinical	5
BRD-K82236179-213-01-0::2.5::HTS	-0.18105114093	BRD-K82236179-213-01-0::2.5::HTS	BRD-K82236179-213-01-0	dicoumarol	2.5	HTS	NADPH inhibitor	CRYZ, NQO1, VKORC1	hematology	deep vein thrombosis (DVT)	Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12	Launched	5
BRD-K82244583-001-01-3::2.5::HTS	-2.31909089035	BRD-K82244583-001-01-3::2.5::HTS	BRD-K82244583-001-01-3	MEK162	2.5	HTS	MEK inhibitor	MAP2K1, MAP2K2			Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO	Phase 3	5
BRD-K82255054-001-15-9::2.5::HTS	0.315400403688	BRD-K82255054-001-15-9::2.5::HTS	BRD-K82255054-001-15-9	propofol	2.5	HTS	benzodiazepine receptor agonist	FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A	neurology/psychiatry	anesthetic	CC(C)c1cccc(C(C)C)c1O, CC(C)c1cccc(C(C)C)c1O	Launched	5
BRD-K82343404-003-02-4::2.5::HTS	0.161032229842	BRD-K82343404-003-02-4::2.5::HTS	BRD-K82343404-003-02-4	adrenalone	2.5	HTS	adrenergic receptor agonist	ADRA1A	hematology	hemorrhage	CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1	Launched	5
BRD-K82357231-001-17-5::2.5::HTS	-0.453293723096	BRD-K82357231-001-17-5::2.5::HTS	BRD-K82357231-001-17-5	desloratadine	2.5	HTS	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1	Launched	5
BRD-K82381502-003-23-1::2.5::HTS	0.056807484668500004	BRD-K82381502-003-23-1::2.5::HTS	BRD-K82381502-003-23-1	acetylcholine	2.5	HTS	acetylcholine receptor agonist	ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	neurology/psychiatry, gastroenterology, pulmonary	drowsiness, fatigue, headache, indigestion, chest congestion	CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C	Launched	5
BRD-K82421491-001-02-6::2.5::HTS	-0.562944874644	BRD-K82421491-001-02-6::2.5::HTS	BRD-K82421491-001-02-6	IPAG	2.5	HTS					Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1	Preclinical	5
BRD-K82467063-001-02-7::2.5::HTS	-0.03642601234830001	BRD-K82467063-001-02-7::2.5::HTS	BRD-K82467063-001-02-7	SB-271046	2.5	HTS	serotonin receptor antagonist	HTR6			COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1	Phase 1	5
BRD-K82484965-003-03-5::2.5::HTS	0.207732337185	BRD-K82484965-003-03-5::2.5::HTS	BRD-K82484965-003-03-5	carmoxirole	2.5	HTS	dopamine receptor agonist	DRD2			OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1	Phase 2	5
BRD-K82522873-001-01-1::2.5::HTS	0.232574066919	BRD-K82522873-001-01-1::2.5::HTS	BRD-K82522873-001-01-1	N6022	2.5	HTS	alcohol dehydrogenase inhibitor	ADH5			Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O	Phase 1/Phase 2	5
BRD-K82562631-236-04-6::2.5::HTS	0.299443140312	BRD-K82562631-236-04-6::2.5::HTS	BRD-K82562631-236-04-6	tolmetin	2.5	HTS	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C	Launched	5
BRD-K82603084-408-01-1::2.5::HTS	-0.267935815933	BRD-K82603084-408-01-1::2.5::HTS	BRD-K82603084-408-01-1	ethylenediaminetetraacetic-acid	2.5	HTS	PKC inhibitor		neurology/psychiatry	metal toxicity	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O	Launched	5
BRD-K82677201-001-01-6::2.5::HTS	-0.32289251802499996	BRD-K82677201-001-01-6::2.5::HTS	BRD-K82677201-001-01-6	almitrine	2.5	HTS	neurotransmitter agonist	ATP1A1	pulmonary	chronic obstructive pulmonary disease (COPD)	Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1	Launched	5
BRD-K82731415-001-07-0::2.5::HTS	0.00284459779676	BRD-K82731415-001-07-0::2.5::HTS	BRD-K82731415-001-07-0	olomoucine	2.5	HTS	CDK inhibitor	CDK1, CDK2, CDK5, MAPK1			Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12	Preclinical	5
BRD-K82746043-001-15-1::2.5::HTS	0.033933134725700004	BRD-K82746043-001-15-1::2.5::HTS	BRD-K82746043-001-15-1	navitoclax	2.5	HTS	BCL inhibitor	BCL2, BCL2L1, BCL2L2			CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1	Phase 2	5
BRD-K82767007-001-01-1::2.5::HTS	0.329797899779	BRD-K82767007-001-01-1::2.5::HTS	BRD-K82767007-001-01-1	dazoxiben	2.5	HTS	thromboxane synthase inhibitor	TBXAS1			OC(=O)c1ccc(OCCn2ccnc2)cc1	Phase 2	5
BRD-K82795137-001-26-2::2.5::HTS	-0.0530236762179	BRD-K82795137-001-26-2::2.5::HTS	BRD-K82795137-001-26-2	loratadine	2.5	HTS	histamine receptor antagonist	HRH1	allergy, neurology/psychiatry	allergic rhinitis, itching	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	Launched	5
BRD-K82800842-001-01-9::2.5::HTS	-0.060227583899300004	BRD-K82800842-001-01-9::2.5::HTS	BRD-K82800842-001-01-9	inositol-hexanicotinate	2.5	HTS			dermatology, cardiology, rheumatology, neurology/psychiatry	statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)	O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1	Launched	5
BRD-K82818427-001-02-2::2.39::HTS	0.34495346014600003	BRD-K82818427-001-02-2::2.39::HTS	BRD-K82818427-001-02-2	batimastat	2.39	HTS	matrix metalloprotease inhibitor	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8			CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO	Phase 3	5
BRD-K82818427-001-04-8::2.5::HTS	-0.16989039482	BRD-K82818427-001-04-8::2.5::HTS	BRD-K82818427-001-04-8	batimastat	2.5	HTS	matrix metalloprotease inhibitor	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8			CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO	Phase 3	5
BRD-K82823076-001-02-6::2.5::HTS	0.571307471722	BRD-K82823076-001-02-6::2.5::HTS	BRD-K82823076-001-02-6	Ro-15-4513	2.5	HTS		GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]	Preclinical	5
BRD-K82823804-001-04-1::2.5::HTS	1.0756146573	BRD-K82823804-001-04-1::2.5::HTS	BRD-K82823804-001-04-1	PD-407824	2.5	HTS	PKC inhibitor	WEE1			Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1	Preclinical	5
BRD-K82846253-001-15-4::2.5::HTS	-0.213876104474	BRD-K82846253-001-15-4::2.5::HTS	BRD-K82846253-001-15-4	repaglinide	2.5	HTS	insulin secretagogue	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	Launched	5
BRD-K82850175-001-01-1::2.5::HTS	0.468633933411	BRD-K82850175-001-01-1::2.5::HTS	BRD-K82850175-001-01-1	navarixin	2.5	HTS	CC chemokine receptor antagonist	CXCR1, CXCR2			CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1	Phase 2	5
BRD-K82861010-001-02-5::2.5::HTS	-0.293876516255	BRD-K82861010-001-02-5::2.5::HTS	BRD-K82861010-001-02-5	daclatasvir	2.5	HTS	HCV inhibitor		infectious disease	hepatitis C	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched	5
BRD-K82903013-001-01-4::2.5::HTS	0.482399407811	BRD-K82903013-001-01-4::2.5::HTS	BRD-K82903013-001-01-4	3,3'-dichlorobenzaldazine	2.5	HTS	glutamate receptor allosteric ligand	GRM5			Clc1cccc(c1)\C=N\N=C\c1cccc(Cl)c1	Preclinical	5
BRD-K82928847-001-04-7::2.5::HTS	0.7164860306659999	BRD-K82928847-001-04-7::2.5::HTS	BRD-K82928847-001-04-7	ACY-1215	2.5	HTS	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8			ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1	Phase 1/Phase 2	5
BRD-K82928892-001-02-5::2.46::HTS	-0.6568778620100001	BRD-K82928892-001-02-5::2.46::HTS	BRD-K82928892-001-02-5	doxercalciferol	2.46	HTS	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched	5
BRD-K82941592-238-04-5::2.5::HTS	0.255328833698	BRD-K82941592-238-04-5::2.5::HTS	BRD-K82941592-238-04-5	rosuvastatin	2.5	HTS	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	Launched	5
BRD-K82960980-003-01-9::2.5::HTS	-0.310731280951	BRD-K82960980-003-01-9::2.5::HTS	BRD-K82960980-003-01-9	ceftiofur	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, respiratory tract infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	5
BRD-K82960980-003-02-7::2.36::HTS	-0.0775350061318	BRD-K82960980-003-02-7::2.36::HTS	BRD-K82960980-003-02-7	ceftiofur	2.36	HTS	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, respiratory tract infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	5
BRD-K82967685-300-01-2::2.5::HTS	-0.75242032669	BRD-K82967685-300-01-2::2.5::HTS	BRD-K82967685-300-01-2	mirodenafil	2.5	HTS	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1	Launched	5
BRD-K82983861-001-04-3::2.5::HTS	-0.500429091852	BRD-K82983861-001-04-3::2.5::HTS	BRD-K82983861-001-04-3	GW-0742	2.5	HTS	PPAR receptor agonist	PPARD			Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	Preclinical	5
BRD-K83003151-057-02-4::2.35::HTS	0.0306779661391	BRD-K83003151-057-02-4::2.35::HTS	BRD-K83003151-057-02-4	alogliptin	2.35	HTS	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	Launched	5
BRD-K83022601-001-01-0::2.5::HTS	-0.959846200459	BRD-K83022601-001-01-0::2.5::HTS	BRD-K83022601-001-01-0	CI-844	2.5	HTS					O(c1ccccc1)c1cccnc1	Phase 2	5
BRD-K83023055-001-02-7::2.5::HTS	0.103775438533	BRD-K83023055-001-02-7::2.5::HTS	BRD-K83023055-001-02-7	GR-135531	2.5	HTS	melatonin receptor agonist				COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1	Preclinical	5
BRD-K83036479-001-09-2::2.5::HTS	0.20535279354000002	BRD-K83036479-001-09-2::2.5::HTS	BRD-K83036479-001-09-2	salicylanilide	2.5	HTS	other antibiotic				Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1	Preclinical	5
BRD-K83063356-003-02-5::2.5::HTS	0.025624970315799998	BRD-K83063356-003-02-5::2.5::HTS	BRD-K83063356-003-02-5	RS-102895	2.5	HTS	CCR antagonist	CCR2			FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1	Preclinical	5
BRD-K83064458-001-23-0::2.5::HTS	-0.0672834744897	BRD-K83064458-001-23-0::2.5::HTS	BRD-K83064458-001-23-0	etofylline	2.5	HTS	adenosine receptor antagonist	ADORA1	pulmonary	asthma, bronchitis	Cn1c2ncn(CCO)c2c(=O)n(C)c1=O	Launched	5
BRD-K83186168-001-01-8::2.5::HTS	0.084283522593	BRD-K83186168-001-01-8::2.5::HTS	BRD-K83186168-001-01-8	AZD1981	2.5	HTS	CRTH receptor antagonist	PTGDR2			CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12	Phase 2	5
BRD-K83189926-001-03-1::2.5::HTS	-0.0877102380796	BRD-K83189926-001-03-1::2.5::HTS	BRD-K83189926-001-03-1	UNC1215	2.5	HTS	L3MBTL antagonist	L3MBTL3			O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1	Preclinical	5
BRD-K83192048-050-02-7::2.5::HTS	0.163984500843	BRD-K83192048-050-02-7::2.5::HTS	BRD-K83192048-050-02-7	dimethindene-(S)-(+)	2.5	HTS	acetylcholine receptor antagonist	HRH1			C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1	Preclinical	5
BRD-K83245588-001-01-4::2.5::HTS	-0.484419744968	BRD-K83245588-001-01-4::2.5::HTS	BRD-K83245588-001-01-4	pilsicainide	2.5	HTS	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2	Launched	5
BRD-K83257731-003-23-5::2.5::HTS	-2.03867678531	BRD-K83257731-003-23-5::2.5::HTS	BRD-K83257731-003-23-5	chloropyramine	2.5	HTS	histamine receptor antagonist	HRH1	cardiology, ophthalmology, allergy, pulmonary	edema, conjunctivitis, allergic rhinitis, asthma	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1	Launched	5
BRD-K83322645-050-01-9::2.5::HTS	0.380640118812	BRD-K83322645-050-01-9::2.5::HTS	BRD-K83322645-050-01-9	L-693403	2.5	HTS	sigma receptor agonist, sigma receptor antagonist	DRD2, SIGMAR1			C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1	Preclinical	5
BRD-K83335125-001-07-0::2.5::HTS	0.132573238711	BRD-K83335125-001-07-0::2.5::HTS	BRD-K83335125-001-07-0	chloroxoquinoline	2.5	HTS					Oc1ccnc2cc(Cl)ccc12	Launched	5
BRD-K83359602-001-02-3::2.5::HTS	0.322232708075	BRD-K83359602-001-02-3::2.5::HTS	BRD-K83359602-001-02-3	barbital	2.5	HTS	sedative	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GRIA2, GRIK2	neurology/psychiatry	sedative, seizures	CCC1(CC)C(=O)NC(=O)NC1=O	Launched	5
BRD-K83405785-001-01-5::2.5::HTS	0.09425770585889999	BRD-K83405785-001-01-5::2.5::HTS	BRD-K83405785-001-01-5	pimavanserin	2.5	HTS	serotonin receptor inverse agonist	DRD2, HTR2A			CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1	Launched	5
BRD-K83459933-001-05-4::2.5::HTS	0.0167213659315	BRD-K83459933-001-05-4::2.5::HTS	BRD-K83459933-001-05-4	sinomenine	2.5	HTS	angiogenesis inhibitor				COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O	Preclinical	5
BRD-K83508485-001-02-7::2.5::HTS	0.22429267774199999	BRD-K83508485-001-02-7::2.5::HTS	BRD-K83508485-001-02-7	FK-888	2.5	HTS	tachykinin antagonist	TACR1, TACR2			CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12	Phase 2	5
BRD-K83551379-001-01-8::2.5::HTS	-0.0149879941819	BRD-K83551379-001-01-8::2.5::HTS	BRD-K83551379-001-01-8	levodropropizine	2.5	HTS	antitussive		pulmonary	cough suppressant	OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1	Launched	5
BRD-K83551379-001-02-6::2.5::HTS	0.561509077221	BRD-K83551379-001-02-6::2.5::HTS	BRD-K83551379-001-02-6	levodropropizine	2.5	HTS	antitussive		pulmonary	cough suppressant	OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1	Launched	5
BRD-K83597974-003-22-2::2.5::HTS	-0.639983385048	BRD-K83597974-003-22-2::2.5::HTS	BRD-K83597974-003-22-2	pargyline	2.5	HTS	monoamine oxidase inhibitor	MAOA, MAOB	cardiology	hypertension	CN(CC#C)Cc1ccccc1	Launched	5
BRD-K83607951-001-02-2::2.5::HTS	0.21023849919399998	BRD-K83607951-001-02-2::2.5::HTS	BRD-K83607951-001-02-2	skepinone-l	2.5	HTS	p38 MAPK inhibitor	MAPK14			OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1	Preclinical	5
BRD-K83636919-001-04-8::2.5::HTS	0.08764681933150001	BRD-K83636919-001-04-8::2.5::HTS	BRD-K83636919-001-04-8	entacapone	2.5	HTS	catechol O methyltransferase inhibitor	COMT	neurology/psychiatry	Parkinson's Disease	CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O, CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O, CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O	Launched	5
BRD-K83699324-001-01-1::2.5::HTS	-1.44065236534	BRD-K83699324-001-01-1::2.5::HTS	BRD-K83699324-001-01-1	NMS-1286937	2.5	HTS	PLK inhibitor	FLT3, PLK1, PLK2, PLK3			CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1	Phase 1	5
BRD-K83720053-001-03-8::2.5::HTS	0.111955343359	BRD-K83720053-001-03-8::2.5::HTS	BRD-K83720053-001-03-8	avagacestat	2.5	HTS	gamma secretase inhibitor	PSEN1			NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1	Phase 2	5
BRD-K83766205-001-03-8::2.5::HTS	-0.071504922548	BRD-K83766205-001-03-8::2.5::HTS	BRD-K83766205-001-03-8	metirosine	2.5	HTS	tyrosine hydroxylase inhibitor	TH	cardiology	hypertension	C[C@](N)(Cc1ccc(O)cc1)C(O)=O	Launched	5
BRD-K83794243-001-01-8::2.5::HTS	-0.24207450224100002	BRD-K83794243-001-01-8::2.5::HTS	BRD-K83794243-001-01-8	palovarotene	2.5	HTS	retinoid receptor agonist	RARG			CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12	Phase 2	5
BRD-K83834509-001-01-1::2.5::HTS	-0.700458207643	BRD-K83834509-001-01-1::2.5::HTS	BRD-K83834509-001-01-1	PTC-209	2.5	HTS	BMI-1 inhibitor				COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	Preclinical	5
BRD-K83837640-001-04-8::2.5::HTS	-3.30088543238	BRD-K83837640-001-04-8::2.5::HTS	BRD-K83837640-001-04-8	JNJ-26481585	2.5	HTS	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2			Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12	Phase 2	5
BRD-K83896451-001-06-7::2.5::HTS	0.502542645987	BRD-K83896451-001-06-7::2.5::HTS	BRD-K83896451-001-06-7	glutamine-(l)	2.5	HTS		CTPS1, GLUL, GPRC6A, PPAT	gastroenterology, dental, neurology/psychiatry, rheumatology	diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, anxiety, insomnia	N[C@@H](CCC(N)=O)C(O)=O, N[C@@H](CCC(N)=O)C(O)=O	Launched	5
BRD-K83963101-001-06-9::2.5::HTS	-0.622078582375	BRD-K83963101-001-06-9::2.5::HTS	BRD-K83963101-001-06-9	MLN-8054	2.5	HTS	Aurora kinase inhibitor	AURKA			OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1	Phase 1	5
BRD-K83988098-001-02-0::2.5::HTS	-1.70060196039	BRD-K83988098-001-02-0::2.5::HTS	BRD-K83988098-001-02-0	alvespimycin	2.5	HTS	HSP inhibitor	HSP90AA1			CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O	Phase 2	5
BRD-K83988098-003-03-4::2.5::HTS	-1.28069281808	BRD-K83988098-003-03-4::2.5::HTS	BRD-K83988098-003-03-4	alvespimycin	2.5	HTS	HSP inhibitor	HSP90AA1			CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O	Phase 2	5
BRD-K84011460-051-01-7::2.5::HTS	-0.822885098344	BRD-K84011460-051-01-7::2.5::HTS	BRD-K84011460-051-01-7	nizofenone	2.5	HTS	ion channel antagonist		neurology/psychiatry	stroke	CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O	Launched	5
BRD-K84075000-001-05-5::2.5::HTS	0.47309048599200004	BRD-K84075000-001-05-5::2.5::HTS	BRD-K84075000-001-05-5	2-Chloropyrazine	2.5	HTS					Clc1cnccn1	Preclinical	5
BRD-K84091759-001-07-1::2.5::HTS	-0.9895224548270001	BRD-K84091759-001-07-1::2.5::HTS	BRD-K84091759-001-07-1	candesartan	2.5	HTS	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Launched	5
BRD-K84163249-001-01-9::2.5::HTS	-0.8828730005600001	BRD-K84163249-001-01-9::2.5::HTS	BRD-K84163249-001-01-9	ercalcitriol	2.5	HTS	vitamin D receptor agonist	VDR			C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Phase 1	5
BRD-K84214706-001-05-7::2.5::HTS	0.139168092286	BRD-K84214706-001-05-7::2.5::HTS	BRD-K84214706-001-05-7	7-chlorokynurenic-acid	2.5	HTS	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			OC(=O)c1cc(O)c2ccc(Cl)cc2n1, OC(=O)c1cc(O)c2ccc(Cl)cc2n1	Preclinical	5
BRD-K84266862-001-03-2::2.5::HTS	0.294515886032	BRD-K84266862-001-03-2::2.5::HTS	BRD-K84266862-001-03-2	BRL-50481	2.5	HTS	phosphodiesterase inhibitor	PDE7A, PDE7B			CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	Preclinical	5
BRD-K84466663-001-05-4::2.5::HTS	-0.138404738093	BRD-K84466663-001-05-4::2.5::HTS	BRD-K84466663-001-05-4	nelarabine	2.5	HTS	DNA synthesis inhibitor, T cell inhibitor	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	5
BRD-K84544951-236-01-0::2.5::HTS	-0.7983669272730001	BRD-K84544951-236-01-0::2.5::HTS	BRD-K84544951-236-01-0	sodium-tetradecyl-sulfate	2.5	HTS		PROC, PROS1	dermatology	varicose veins, varicose veins	CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O, CCCCCCCCCCCCCCOS(O)(=O)=O	Launched	5
BRD-K84564571-001-02-4::2.5::HTS	0.21055659716400002	BRD-K84564571-001-02-4::2.5::HTS	BRD-K84564571-001-02-4	telatinib	2.5	HTS	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1	Phase 2	5
BRD-K84663978-003-02-9::2.5::HTS	-0.0283744203487	BRD-K84663978-003-02-9::2.5::HTS	BRD-K84663978-003-02-9	trequinsin	2.5	HTS	phosphodiesterase inhibitor	PDE5A			COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC	Phase 1	5
BRD-K84683831-001-01-0::2.5::HTS	-0.533227956935	BRD-K84683831-001-01-0::2.5::HTS	BRD-K84683831-001-01-0	radezolid	2.5	HTS	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor				CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1	Phase 2	5
BRD-K84698278-001-03-4::2.5::HTS	0.0465245437722	BRD-K84698278-001-03-4::2.5::HTS	BRD-K84698278-001-03-4	agomelatine	2.5	HTS	melatonin receptor agonist, serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B	neurology/psychiatry	depression	COc1ccc2cccc(CCNC(C)=O)c2c1	Launched	5
BRD-K84748119-050-01-1::2.5::HTS	0.507367418662	BRD-K84748119-050-01-1::2.5::HTS	BRD-K84748119-050-01-1	vicriviroc	2.5	HTS	CC chemokine receptor antagonist	CCR5			COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F	Phase 3	5
BRD-K84783599-001-01-0::2.5::HTS	-0.513884817252	BRD-K84783599-001-01-0::2.5::HTS	BRD-K84783599-001-01-0	riociguat	2.5	HTS	guanylate cyclase stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	Launched	5
BRD-K84794093-001-07-5::2.5::HTS	0.223704020711	BRD-K84794093-001-07-5::2.5::HTS	BRD-K84794093-001-07-5	dideoxyadenosine	2.5	HTS	nucleoside reverse transcriptase inhibitor				Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1	Phase 1	5
BRD-K84798689-236-02-9::2.5::HTS	-0.381843168877	BRD-K84798689-236-02-9::2.5::HTS	BRD-K84798689-236-02-9	sodium-tanshinone-ii-a-sulfonate	2.5	HTS	potassium channel activator				Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O	Phase 2	5
BRD-K84810405-003-01-1::2.5::HTS	-0.7236832850370001	BRD-K84810405-003-01-1::2.5::HTS	BRD-K84810405-003-01-1	almorexant	2.5	HTS	orexin receptor antagonist	HCRTR1, HCRTR2			CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1	Phase 3	5
BRD-K84892605-001-01-1::2.5::HTS	-0.299824170631	BRD-K84892605-001-01-1::2.5::HTS	BRD-K84892605-001-01-1	IOWH032	2.5	HTS	CFTR channel antagonist	CFTR			Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1	Phase 2	5
BRD-K84895041-001-02-4::2.5::HTS	-0.392749929817	BRD-K84895041-001-02-4::2.5::HTS	BRD-K84895041-001-02-4	BMY-45778	2.5	HTS	IP1 prostacyclin receptor agonist	PTGIR			OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1	Preclinical	5
BRD-K84925803-001-01-9::2.5::HTS	0.523716162648	BRD-K84925803-001-01-9::2.5::HTS	BRD-K84925803-001-01-9	T-5224	2.5	HTS	AP inhibitor	JUN			OC(=O)CCc1cc(ccc1OCc1ccc2c(O)noc2c1)C(=O)c1ccc(OC2CCCC2)cc1O	Phase 2	5
BRD-K84937637-001-09-9::2.5::HTS	-1.0291570599700002	BRD-K84937637-001-09-9::2.5::HTS	BRD-K84937637-001-09-9	sirolimus	2.5	HTS	mTOR inhibitor	FGF2, FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O	Launched	5
BRD-K84986517-001-01-8::2.5::HTS	0.532858137839	BRD-K84986517-001-01-8::2.5::HTS	BRD-K84986517-001-01-8	darunavir	2.5	HTS	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1	Launched	5
BRD-K84996356-001-01-1::2.5::HTS	0.428850568278	BRD-K84996356-001-01-1::2.5::HTS	BRD-K84996356-001-01-1	AZD3514	2.5	HTS	androgen receptor modulator	AR			CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1	Phase 1	5
BRD-K85014146-001-02-5::2.5::HTS	0.022949861507999998	BRD-K85014146-001-02-5::2.5::HTS	BRD-K85014146-001-02-5	AZD2461	2.5	HTS	PARP inhibitor				COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F	Phase 1	5
BRD-K85015012-003-02-9::2.5::HTS	0.43883584255099994	BRD-K85015012-003-02-9::2.5::HTS	BRD-K85015012-003-02-9	NNC-05-2090	2.5	HTS	GABA uptake inhibitor, GAT inhibitor	SLC6A12			COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1	Preclinical	5
BRD-K85046107-003-01-2::2.5::HTS	0.41656023463799996	BRD-K85046107-003-01-2::2.5::HTS	BRD-K85046107-003-01-2	ramosetron	2.5	HTS	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting, irritable bowel syndrome	Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12	Launched	5
BRD-K85066592-001-01-6::2.5::HTS	0.546918356437	BRD-K85066592-001-01-6::2.5::HTS	BRD-K85066592-001-01-6	gly-gln	2.5	HTS					NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	Phase 2	5
BRD-K85090592-008-22-7::2.5::HTS	-0.303303127633	BRD-K85090592-008-22-7::2.5::HTS	BRD-K85090592-008-22-7	pilocarpine	2.5	HTS	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	Launched	5
BRD-K85119730-001-28-9::2.5::HTS	-0.012442566328700002	BRD-K85119730-001-28-9::2.5::HTS	BRD-K85119730-001-28-9	tolbutamide	2.5	HTS	ATP channel blocker	ABCC8, KCNJ1, KCNJ11, KCNJ8	endocrinology	diabetes mellitus	CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1	Launched	5
BRD-K85140930-001-12-7::2.5::HTS	-5.239917542200001	BRD-K85140930-001-12-7::2.5::HTS	BRD-K85140930-001-12-7	aphidicolin	2.5	HTS	RNA synthesis inhibitor				C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO	Phase 1	5
BRD-K85146014-314-05-4::2.5::HTS	-0.179924433704	BRD-K85146014-314-05-4::2.5::HTS	BRD-K85146014-314-05-4	foscarnet	2.5	HTS	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)	OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O	Launched	5
BRD-K85178109-001-02-3::2.5::HTS	0.536504359094	BRD-K85178109-001-02-3::2.5::HTS	BRD-K85178109-001-02-3	fostamatinib	2.5	HTS	SYK inhibitor	SYK	hematology	chronic immune thrombocytopenia (ITP)	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC	Launched	5
BRD-K85307935-236-09-5::2.5::HTS	0.572758712319	BRD-K85307935-236-09-5::2.5::HTS	BRD-K85307935-236-09-5	novobiocin	2.5	HTS	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	Launched	5
BRD-K85307935-236-10-3::2.5::HTS	-0.123886047038	BRD-K85307935-236-10-3::2.5::HTS	BRD-K85307935-236-10-3	novobiocin	2.5	HTS	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	Launched	5
BRD-K85333151-003-13-4::2.5::HTS	-0.0998149173656	BRD-K85333151-003-13-4::2.5::HTS	BRD-K85333151-003-13-4	ramifenazone	2.5	HTS	cyclooxygenase inhibitor		neurology/psychiatry, endocrinology	pain relief, fever	CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O	Launched	5
BRD-K85337334-004-02-6::2.5::HTS	0.144652275731	BRD-K85337334-004-02-6::2.5::HTS	BRD-K85337334-004-02-6	otilonium	2.5	HTS	acetylcholine receptor antagonist	CACNA1C	gastroenterology	irritable bowel syndrome	CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC	Launched	5
BRD-K85402309-001-06-6::2.5::HTS	-2.61022886887	BRD-K85402309-001-06-6::2.5::HTS	BRD-K85402309-001-06-6	dovitinib	2.5	HTS	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB			CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	Phase 3	5
BRD-K85402309-389-03-2::2.5::HTS	-0.6329902263080001	BRD-K85402309-389-03-2::2.5::HTS	BRD-K85402309-389-03-2	dovitinib	2.5	HTS	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB			CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	Phase 3	5
BRD-K85406984-001-01-0::2.5::HTS	-0.23045173991700002	BRD-K85406984-001-01-0::2.5::HTS	BRD-K85406984-001-01-0	sobetirome	2.5	HTS	thyroid hormone receptor agonist	THRA, THRB			CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O	Phase 1	5
BRD-K85479953-001-11-3::2.5::HTS	-0.21194699797699998	BRD-K85479953-001-11-3::2.5::HTS	BRD-K85479953-001-11-3	STF-62247	2.5	HTS	autophagy inducer				Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1, Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1	Preclinical	5
BRD-K85503079-001-02-8::2.5::HTS	0.348696367327	BRD-K85503079-001-02-8::2.5::HTS	BRD-K85503079-001-02-8	perospirone	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia, bipolar disorder	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12	Launched	5
BRD-K85554912-001-06-3::2.5::HTS	-0.78971190434	BRD-K85554912-001-06-3::2.5::HTS	BRD-K85554912-001-06-3	ivermectin	2.5	HTS	benzodiazepine receptor agonist	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2	Launched	5
BRD-K85554912-001-08-9::2.5::HTS	-0.301999382779	BRD-K85554912-001-08-9::2.5::HTS	BRD-K85554912-001-08-9	ivermectin	2.5	HTS	benzodiazepine receptor agonist	CHRNA7, GABRB3, GLRA3, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2	Launched	5
BRD-K85606544-001-09-1::2.5::HTS	0.486092509755	BRD-K85606544-001-09-1::2.5::HTS	BRD-K85606544-001-09-1	neratinib	2.5	HTS	EGFR inhibitor	EGFR, ERBB2, KDR			CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 3	5
BRD-K85751432-001-03-3::2.5::HTS	-1.7275690433700002	BRD-K85751432-001-03-3::2.5::HTS	BRD-K85751432-001-03-3	refametinib	2.5	HTS	MEK inhibitor	MAP2K1, MAP2K2			COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1	Phase 2	5
BRD-K85757157-001-01-7::2.5::HTS	-0.20022905969799998	BRD-K85757157-001-01-7::2.5::HTS	BRD-K85757157-001-01-7	nifursol	2.5	HTS	bacterial DNA inhibitor				Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched	5
BRD-K85849709-001-01-5::2.5::HTS	1.13248578181	BRD-K85849709-001-01-5::2.5::HTS	BRD-K85849709-001-01-5	AZD2858	2.5	HTS	glycogen synthase kinase inhibitor	GSK3B			CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1	Preclinical	5
BRD-K85872723-001-15-9::2.5::HTS	-0.166754609666	BRD-K85872723-001-15-9::2.5::HTS	BRD-K85872723-001-15-9	kynurenic-acid	2.5	HTS	glutamate receptor antagonist	GPR35, GRIN1, GRIN2A, GRIN2B			OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1	Preclinical	5
BRD-K85883481-001-25-7::2.5::HTS	-0.0154310944609	BRD-K85883481-001-25-7::2.5::HTS	BRD-K85883481-001-25-7	prednisone	2.5	HTS	glucocorticoid receptor agonist	HSD11B1, NR3C1	endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry	congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	Launched	5
BRD-K85920262-001-02-1::2.5::HTS	0.195391678063	BRD-K85920262-001-02-1::2.5::HTS	BRD-K85920262-001-02-1	WAY-600	2.5	HTS	mTOR inhibitor	MTOR			C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1	Preclinical	5
BRD-K85925969-001-17-4::2.5::HTS	0.23059419364	BRD-K85925969-001-17-4::2.5::HTS	BRD-K85925969-001-17-4	zalcitabine	2.5	HTS	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1	Launched	5
BRD-K86003836-001-10-5::2.5::HTS	-0.512360677495	BRD-K86003836-001-10-5::2.5::HTS	BRD-K86003836-001-10-5	flubendazole	2.5	HTS	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites	COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1	Launched	5
BRD-K86109159-001-02-6::2.5::HTS	0.0470654081202	BRD-K86109159-001-02-6::2.5::HTS	BRD-K86109159-001-02-6	VU0357121	2.5	HTS	glutamate receptor positive allosteric modulator	GRM5			CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F	Preclinical	5
BRD-K86118762-001-01-8::2.5::HTS	0.467450165007	BRD-K86118762-001-01-8::2.5::HTS	BRD-K86118762-001-01-8	linsitinib	2.5	HTS	IGF-1 inhibitor	IGF1R, INSR, INSRR			C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12	Phase 3	5
BRD-K86161929-001-11-7::2.52::HTS	-0.132915172829	BRD-K86161929-001-11-7::2.52::HTS	BRD-K86161929-001-11-7	cortisone-acetate	2.52	HTS	glucocorticoid receptor agonist	NR3C1	pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease	asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	Launched	5
BRD-K86161929-001-13-3::2.5::HTS	0.125793588612	BRD-K86161929-001-13-3::2.5::HTS	BRD-K86161929-001-13-3	cortisone-acetate	2.5	HTS	glucocorticoid receptor agonist	NR3C1	pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease	asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	Launched	5
BRD-K86204871-001-16-2::2.5::HTS	-0.5275731717909999	BRD-K86204871-001-16-2::2.5::HTS	BRD-K86204871-001-16-2	terconazole	2.5	HTS	sterol demethylase inhibitor		infectious disease	vulvovaginal candidiasis	CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1	Launched	5
BRD-K86294588-001-01-9::2.5::HTS	-0.896319031601	BRD-K86294588-001-01-9::2.5::HTS	BRD-K86294588-001-01-9	schisandrin-b	2.5	HTS	antioxidant	ATR			COc1cc2C[C@H](C)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	Preclinical	5
BRD-K86301799-001-34-8::2.5::HTS	0.250185829978	BRD-K86301799-001-34-8::2.5::HTS	BRD-K86301799-001-34-8	dipyridamole	2.5	HTS	phosphodiesterase inhibitor	ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1	cardiology	coronary artery disease (CAD), peripheral artery disease (PAD), hypertension	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	Launched	5
BRD-K86307448-001-17-5::2.5::HTS	0.205203186482	BRD-K86307448-001-17-5::2.5::HTS	BRD-K86307448-001-17-5	allopurinol	2.5	HTS	xanthine oxidase inhibitor	XDH	rheumatology, urology	gout, kidney stones	O=c1[nH]cnc2[nH]ncc12, O=c1[nH]cnc2[nH]ncc12, O=c1[nH]cnc2[nH]ncc12	Launched	5
BRD-K86307448-001-19-1::2.5::HTS	0.0838429420013	BRD-K86307448-001-19-1::2.5::HTS	BRD-K86307448-001-19-1	allopurinol	2.5	HTS	xanthine oxidase inhibitor	XDH	rheumatology, urology	gout, kidney stones	O=c1[nH]cnc2[nH]ncc12, O=c1[nH]cnc2[nH]ncc12, O=c1[nH]cnc2[nH]ncc12	Launched	5
BRD-K86344238-003-04-6::2.5::HTS	-0.0351238850706	BRD-K86344238-003-04-6::2.5::HTS	BRD-K86344238-003-04-6	linsidomine	2.5	HTS	nitric oxide donor		urology	erectile dysfunction	Nc1c[n+](no1)N1CCOCC1, Nc1c[n+](no1)N1CCOCC1	Launched	5
BRD-K86435560-001-01-0::2.5::HTS	0.0244997992331	BRD-K86435560-001-01-0::2.5::HTS	BRD-K86435560-001-01-0	perchlozone	2.5	HTS			infectious disease	tuberculosis	NC(=S)NN=Cc1ccncc1	Launched	5
BRD-K86436199-003-01-3::2.5::HTS	0.0026436378476799994	BRD-K86436199-003-01-3::2.5::HTS	BRD-K86436199-003-01-3	landiolol	2.5	HTS	adrenergic receptor antagonist	ADRB1	cardiology	cardiac arrythmia	CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1	Launched	5
BRD-K86525559-001-04-5::2.5::HTS	-2.7001263811	BRD-K86525559-001-04-5::2.5::HTS	BRD-K86525559-001-04-5	AZD7762	2.5	HTS	CHK inhibitor	CHEK1, CHEK2			NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	Phase 1	5
BRD-K86525559-001-07-8::2.52::HTS	-5.11087570119	BRD-K86525559-001-07-8::2.52::HTS	BRD-K86525559-001-07-8	AZD7762	2.52	HTS	CHK inhibitor	CHEK1, CHEK2			NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	Phase 1	5
BRD-K86600316-003-02-0::2.5::HTS	0.0593281271533	BRD-K86600316-003-02-0::2.5::HTS	BRD-K86600316-003-02-0	RS-79948	2.5	HTS	adrenergic receptor antagonist	ADRA2A			CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12	Preclinical	5
BRD-K86687746-001-01-3::2.5::HTS	-5.00737100132	BRD-K86687746-001-01-3::2.5::HTS	BRD-K86687746-001-01-3	R306465	2.5	HTS	HDAC inhibitor				ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1	Phase 1	5
BRD-K86727142-001-12-4::2.5::HTS	-0.237347530444	BRD-K86727142-001-12-4::2.5::HTS	BRD-K86727142-001-12-4	embelin	2.5	HTS	HCV inhibitor, XIAP inhibitor	XIAP			CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O	Preclinical	5
BRD-K86797399-001-04-4::2.5::HTS	-2.98704234145	BRD-K86797399-001-04-4::2.5::HTS	BRD-K86797399-001-04-4	SB-939	2.5	HTS	HDAC inhibitor	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9			CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO	Phase 2	5
BRD-K86797399-001-05-1::2.55::HTS	-4.05548974241	BRD-K86797399-001-05-1::2.55::HTS	BRD-K86797399-001-05-1	SB-939	2.55	HTS	HDAC inhibitor	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9			CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO	Phase 2	5
BRD-K86799112-001-02-0::2.5::HTS	-0.24390129888700002	BRD-K86799112-001-02-0::2.5::HTS	BRD-K86799112-001-02-0	5-HMF	2.5	HTS					OCc1ccc(C=O)o1, OCc1ccc(C=O)o1, OCc1ccc(C=O)o1	Phase 2	5
BRD-K86816506-001-01-8::2.5::HTS	-0.0692871490838	BRD-K86816506-001-01-8::2.5::HTS	BRD-K86816506-001-01-8	PF-04457845	2.5	HTS	FAAH inhibitor	FAAH			FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1	Phase 2	5
BRD-K86882815-001-03-2::2.5::HTS	-0.42131910085999996	BRD-K86882815-001-03-2::2.5::HTS	BRD-K86882815-001-03-2	cabergoline	2.5	HTS	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7	endocrinology	hyperprolactinemia	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1	Launched	5
BRD-K86887724-001-10-6::2.59::HTS	-0.28409591042599996	BRD-K86887724-001-10-6::2.59::HTS	BRD-K86887724-001-10-6	dofetilide	2.59	HTS	potassium channel blocker	KCNH1, KCNH2, KCNJ12, KCNK2			CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1	Withdrawn	5
BRD-K86892782-001-17-0::2.5::HTS	-0.10001872146099999	BRD-K86892782-001-17-0::2.5::HTS	BRD-K86892782-001-17-0	edoxudine	2.5	HTS	DNA directed DNA polymerase inhibitor		infectious disease	virus herpes simplex (HSV)	CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O	Launched	5
BRD-K86930074-001-05-0::2.5::HTS	0.122549616284	BRD-K86930074-001-05-0::2.5::HTS	BRD-K86930074-001-05-0	cediranib	2.5	HTS	KIT inhibitor, VEGFR inhibitor	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB			COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1	Phase 3	5
BRD-K86972824-001-01-4::2.5::HTS	-0.126360100559	BRD-K86972824-001-01-4::2.5::HTS	BRD-K86972824-001-01-4	oltipraz	2.5	HTS	nuclear factor erythroid derived, like (NRF2) activator	ANG			Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1	Phase 3	5
BRD-K86972824-001-02-2::2.5::HTS	-0.0932664769807	BRD-K86972824-001-02-2::2.5::HTS	BRD-K86972824-001-02-2	oltipraz	2.5	HTS	nuclear factor erythroid derived, like (NRF2) activator	ANG			Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1	Phase 3	5
BRD-K87024524-065-17-7::2.5::HTS	-0.311992013665	BRD-K87024524-065-17-7::2.5::HTS	BRD-K87024524-065-17-7	phenelzine	2.5	HTS	monoamine oxidase inhibitor	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1	Launched	5
BRD-K87028197-001-01-3::2.5::HTS	0.12150151465299999	BRD-K87028197-001-01-3::2.5::HTS	BRD-K87028197-001-01-3	asunaprevir	2.5	HTS	HCV inhibitor				COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12	Phase 3	5
BRD-K87036601-001-01-6::2.5::HTS	-0.637414913426	BRD-K87036601-001-01-6::2.5::HTS	BRD-K87036601-001-01-6	azodicarbonamide	2.5	HTS	DNA synthesis inhibitor				NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O	Phase 2	5
BRD-K87048468-003-02-7::2.5::HTS	-0.22561465717300003	BRD-K87048468-003-02-7::2.5::HTS	BRD-K87048468-003-02-7	RS-102221	2.5	HTS	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	Preclinical	5
BRD-K87112191-001-04-5::2.5::HTS	-0.787155115963	BRD-K87112191-001-04-5::2.5::HTS	BRD-K87112191-001-04-5	PP242	2.5	HTS	mTOR inhibitor	MTOR, PASK			CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12	Preclinical	5
BRD-K87124298-001-03-4::2.5::HTS	0.21347181841899998	BRD-K87124298-001-03-4::2.5::HTS	BRD-K87124298-001-03-4	OSI-027	2.5	HTS	mTOR inhibitor	MTOR			COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12	Phase 1	5
BRD-K87156652-001-12-7::2.5::HTS	0.0799197777177	BRD-K87156652-001-12-7::2.5::HTS	BRD-K87156652-001-12-7	carbimazole	2.5	HTS	antithyroid agent	TPO	endocrinology	hyperthyroidism	CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S	Launched	5
BRD-K87158025-001-01-6::2.5::HTS	0.267763164166	BRD-K87158025-001-01-6::2.5::HTS	BRD-K87158025-001-01-6	benzamil	2.5	HTS	sodium channel blocker	ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1			NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N	Phase 2	5
BRD-K87202646-001-32-6::2.5::HTS	-0.09757522738160002	BRD-K87202646-001-32-6::2.5::HTS	BRD-K87202646-001-32-6	isoniazid	2.5	HTS	FABI inhibitor	CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4	infectious disease	tuberculosis	NNC(=O)c1ccncc1, NNC(=O)c1ccncc1	Launched	5
BRD-K87202646-061-04-9::2.5::HTS	0.565385150819	BRD-K87202646-061-04-9::2.5::HTS	BRD-K87202646-061-04-9	pasiniazid	2.5	HTS	cyclooxygenase inhibitor		infectious disease	tuberculosis	NNC(=O)c1ccncc1, NNC(=O)c1ccncc1	Launched	5
BRD-K87278688-001-01-0::2.5::HTS	0.105471310622	BRD-K87278688-001-01-0::2.5::HTS	BRD-K87278688-001-01-0	armodafinil	2.5	HTS	adrenergic receptor agonist	SLC6A3	pulmonary, neurology/psychiatry	obstructive sleep apnea, narcolepsy, shift work disorder (SWD)	NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1	Launched	5
BRD-K87349602-001-03-8::2.5::HTS	-0.52087428646	BRD-K87349602-001-03-8::2.5::HTS	BRD-K87349602-001-03-8	beta-CCB	2.5	HTS	benzodiazepine receptor ligand	GABRA1, GABRG2			CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21	Launched	5
BRD-K87349682-347-03-8::2.36::HTS	-2.40204833537	BRD-K87349682-347-03-8::2.36::HTS	BRD-K87349682-347-03-8	norepinephrine	2.36	HTS	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1	Launched	5
BRD-K87492696-001-16-5::2.5::HTS	0.17359851505999999	BRD-K87492696-001-16-5::2.5::HTS	BRD-K87492696-001-16-5	sulfameter	2.5	HTS	dihydrofolate reductase inhibitor	DHFR	infectious disease	urinary tract infections	COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1	Launched	5
BRD-K87510569-001-02-8::2.5::HTS	-0.049795931422	BRD-K87510569-001-02-8::2.5::HTS	BRD-K87510569-001-02-8	RS-504393	2.5	HTS	CC chemokine receptor antagonist	CCL2, CCR2			Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1	Preclinical	5
BRD-K87512222-019-01-7::2.5::HTS	-5.8338076737	BRD-K87512222-019-01-7::2.5::HTS	BRD-K87512222-019-01-7	taltobulin	2.5	HTS	tubulin polymerization inhibitor				CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1	Phase 1	5
BRD-K87535339-001-01-6::2.53::HTS	-0.10705901941700001	BRD-K87535339-001-01-6::2.53::HTS	BRD-K87535339-001-01-6	5-Amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione	2.53	HTS					Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)sc2c(=O)[nH]1	Preclinical	5
BRD-K87696786-003-04-4::2.5::HTS	-0.571650138326	BRD-K87696786-003-04-4::2.5::HTS	BRD-K87696786-003-04-4	LY456236	2.5	HTS	glutamate receptor antagonist	GRM1			COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1	Preclinical	5
BRD-K87700323-003-05-1::2.5::HTS	-0.962425856368	BRD-K87700323-003-05-1::2.5::HTS	BRD-K87700323-003-05-1	cetylpyridinium	2.5	HTS			dental	gingivitis, mouth inflammation	CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1	Launched	5
BRD-K87737963-001-06-0::2.5::HTS	-0.0937211371197	BRD-K87737963-001-06-0::2.5::HTS	BRD-K87737963-001-06-0	cyt387	2.5	HTS		JAK1, JAK2, JAK3			O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	Phase 3	5
BRD-K87774949-001-03-9::2.5::HTS	0.155407145118	BRD-K87774949-001-03-9::2.5::HTS	BRD-K87774949-001-03-9	istradefylline	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3	neurology/psychiatry	Parkinson's Disease, dyskinesia	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	Launched	5
BRD-K87782578-001-01-4::2.5::HTS	0.141625645443	BRD-K87782578-001-01-4::2.5::HTS	BRD-K87782578-001-01-4	AVL-292	2.5	HTS	Bruton's tyrosine kinase (BTK) inhibitor	BTK, YES1			COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1	Phase 2	5
BRD-K87827419-001-16-8::2.5::HTS	-0.138890029238	BRD-K87827419-001-16-8::2.5::HTS	BRD-K87827419-001-16-8	melphalan	2.5	HTS	DNA alkylating agent, DNA inhibitor		hematologic malignancy	multiple myeloma	N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O	Launched	5
BRD-K87909389-003-03-4::2.5::HTS	-4.404731792790001	BRD-K87909389-003-03-4::2.5::HTS	BRD-K87909389-003-03-4	alvocidib	2.5	HTS	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM			CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	Phase 2	5
BRD-K87932577-001-02-4::2.5::HTS	0.05953325645409999	BRD-K87932577-001-02-4::2.5::HTS	BRD-K87932577-001-02-4	CDK1-5-inhibitor	2.5	HTS	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3B			Nc1n[nH]c2nc3ccccc3nc12	Preclinical	5
BRD-K87990216-001-10-2::2.5::HTS	0.0670641137968	BRD-K87990216-001-10-2::2.5::HTS	BRD-K87990216-001-10-2	piretanide	2.5	HTS	glucocorticoid receptor agonist	SLC12A1, SLC12A2	cardiology	hypertension, edema	NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O	Launched	5
BRD-K88025533-003-03-3::2.5::HTS	0.5299304903800001	BRD-K88025533-003-03-3::2.5::HTS	BRD-K88025533-003-03-3	fingolimod	2.5	HTS	immunosuppressant, sphingosine phosphate receptor agonist	S1PR1, S1PR5	neurology/psychiatry	multiple sclerosis	CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1	Launched	5
BRD-K88052444-001-08-8::2.5::HTS	-0.198159344993	BRD-K88052444-001-08-8::2.5::HTS	BRD-K88052444-001-08-8	urea	2.5	HTS	hydroxy radical formation stimulant	ARG1, CA2, CTNNB1	dermatology	psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis	NC(N)=O	Launched	5
BRD-K88061624-001-21-4::2.5::HTS	-0.0341333455728	BRD-K88061624-001-21-4::2.5::HTS	BRD-K88061624-001-21-4	mizoribine	2.5	HTS	immunosuppressant, inosine monophosphate dehydrogenase inhibitor	IMPDH1			NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O	Launched	5
BRD-K88090157-050-10-8::2.5::HTS	0.17954913689100002	BRD-K88090157-050-10-8::2.5::HTS	BRD-K88090157-050-10-8	pimethixene	2.5	HTS	antihistamine		neurology/psychiatry, allergy	attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis	CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12	Launched	5
BRD-K88172511-003-20-3::2.42::HTS	-0.76624628559	BRD-K88172511-003-20-3::2.42::HTS	BRD-K88172511-003-20-3	naltrexone	2.42	HTS	opioid receptor antagonist	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	Launched	5
BRD-K88172511-003-21-1::2.5::HTS	-0.13801204327	BRD-K88172511-003-21-1::2.5::HTS	BRD-K88172511-003-21-1	naltrexone	2.5	HTS	opioid receptor antagonist	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	Launched	5
BRD-K88186167-001-04-8::2.5::HTS	-0.268723629945	BRD-K88186167-001-04-8::2.5::HTS	BRD-K88186167-001-04-8	GW-4064	2.5	HTS	FXR agonist	NR1H4			CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl	Preclinical	5
BRD-K88219015-001-10-8::2.5::HTS	0.278943940312	BRD-K88219015-001-10-8::2.5::HTS	BRD-K88219015-001-10-8	asaraldehyde	2.5	HTS	cyclooxygenase inhibitor	PTGS2			COc1cc(OC)c(C=O)cc1OC	Preclinical	5
BRD-K88308881-001-06-8::2.5::HTS	0.255213445029	BRD-K88308881-001-06-8::2.5::HTS	BRD-K88308881-001-06-8	ethenzamide	2.5	HTS	analgesic agent		neurology/psychiatry, endocrinology, otolaryngology	headache, fever, common cold	CCOc1ccccc1C(N)=O	Launched	5
BRD-K88358234-003-04-8::2.5::HTS	-0.9508069120139999	BRD-K88358234-003-04-8::2.5::HTS	BRD-K88358234-003-04-8	xaliproden	2.5	HTS	serotonin receptor agonist	HTR1A			FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1	Phase 3	5
BRD-K88366685-300-06-0::2.5::HTS	-0.105660597994	BRD-K88366685-300-06-0::2.5::HTS	BRD-K88366685-300-06-0	trimetazidine	2.5	HTS	3-ketoacyl CoA thiolase inhibitor	ACAA2	cardiology	angina pectoris	COc1ccc(CN2CCNCC2)c(OC)c1OC	Launched	5
BRD-K88405679-003-03-1::2.5::HTS	0.19664168256700001	BRD-K88405679-003-03-1::2.5::HTS	BRD-K88405679-003-03-1	thonzylamine	2.5	HTS	antihistamine		neurology/psychiatry	itching	COc1ccc(CN(CCN(C)C)c2ncccn2)cc1	Launched	5
BRD-K88429204-001-35-1::2.5::HTS	-0.768366110519	BRD-K88429204-001-35-1::2.5::HTS	BRD-K88429204-001-35-1	pyrimethamine	2.5	HTS	dihydrofolate reductase inhibitor	DHFR, SLC47A1	infectious disease	malaria	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	Launched	5
BRD-K88506063-001-01-8::2.5::HTS	0.24923947571199997	BRD-K88506063-001-01-8::2.5::HTS	BRD-K88506063-001-01-8	KD025	2.5	HTS	rho associated kinase inhibitor	ROCK2			CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1	Phase 2	5
BRD-K88510285-001-11-1::2.5::HTS	-2.7827651484200002	BRD-K88510285-001-11-1::2.5::HTS	BRD-K88510285-001-11-1	bortezomib	2.5	HTS	NFkB pathway inhibitor, proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	Launched	5
BRD-K88544581-001-06-1::2.5::HTS	0.294924053664	BRD-K88544581-001-06-1::2.5::HTS	BRD-K88544581-001-06-1	CI-976	2.5	HTS	ACAT inhibitor	ACAT1, CES1			CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC	Phase 1	5
BRD-K88553858-001-02-7::2.5::HTS	0.162126383918	BRD-K88553858-001-02-7::2.5::HTS	BRD-K88553858-001-02-7	benurestat	2.5	HTS	urease inhibitor				ONC(=O)CNC(=O)c1ccc(Cl)cc1	Phase 1	5
BRD-K88560311-011-06-3::2.5::HTS	0.43441524690800004	BRD-K88560311-011-06-3::2.5::HTS	BRD-K88560311-011-06-3	rucaparib	2.5	HTS	PARP inhibitor	PARP1, PARP2			CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23	Phase 3	5
BRD-K88568253-011-19-9::2.5::HTS	-1.23332166802	BRD-K88568253-011-19-9::2.5::HTS	BRD-K88568253-011-19-9	iproniazid	2.5	HTS	monoamine oxidase inhibitor	MAOA, MAOB			CC(C)NNC(=O)c1ccncc1	Withdrawn	5
BRD-K88611939-001-22-4::2.5::HTS	0.178266319093	BRD-K88611939-001-22-4::2.5::HTS	BRD-K88611939-001-22-4	aniracetam	2.5	HTS	glutamate receptor agonist	DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A			COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O	Launched	5
BRD-K88625236-001-04-2::2.5::HTS	-1.0388046599299998	BRD-K88625236-001-04-2::2.5::HTS	BRD-K88625236-001-04-2	nonoxynol-9	2.5	HTS	membrane integrity inhibitor		endocrinology	contraceptive	CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1	Launched	5
BRD-K88646909-004-16-2::2.5::HTS	-0.29316294685	BRD-K88646909-004-16-2::2.5::HTS	BRD-K88646909-004-16-2	arecoline	2.5	HTS	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			COC(=O)C1=CCCN(C)C1, COC(=O)C1=CCCN(C)C1	Phase 1	5
BRD-K88677950-001-03-9::2.5::HTS	-0.658408608374	BRD-K88677950-001-03-9::2.5::HTS	BRD-K88677950-001-03-9	PD-198306	2.5	HTS	MAP kinase inhibitor, MEK inhibitor	MAP2K1, MAP2K2			Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1	Preclinical	5
BRD-K88682005-001-15-8::2.5::HTS	0.361007611189	BRD-K88682005-001-15-8::2.5::HTS	BRD-K88682005-001-15-8	chlorothiazide	2.5	HTS	diuretic	CA1, CA2, CA4, SLC12A3	cardiology	hypertension	NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O	Launched	5
BRD-K88701661-001-02-9::2.5::HTS	0.046860556113300006	BRD-K88701661-001-02-9::2.5::HTS	BRD-K88701661-001-02-9	dimercaptosuccinic-acid	2.5	HTS	chelating agent	DNMT1	neurology/psychiatry	metal toxicity	OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O	Launched	5
BRD-K88742110-001-07-9::2.5::HTS	0.37102814415799995	BRD-K88742110-001-07-9::2.5::HTS	BRD-K88742110-001-07-9	PCI-34051	2.5	HTS	HDAC inhibitor	HDAC1, HDAC10, HDAC6, HDAC8			COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1	Preclinical	5
BRD-K88759641-003-02-8::2.5::HTS	-0.456421108439	BRD-K88759641-003-02-8::2.5::HTS	BRD-K88759641-003-02-8	EMD-66684	2.5	HTS	angiotensin receptor antagonist	AGTR1			CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Preclinical	5
BRD-K88789588-001-14-9::2.5::HTS	0.7833985276809999	BRD-K88789588-001-14-9::2.5::HTS	BRD-K88789588-001-14-9	letrozole	2.5	HTS	aromatase inhibitor	CYP19A1	oncology	breast cancer	N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1	Launched	5
BRD-K88807631-001-01-3::2.5::HTS	0.6049139215730001	BRD-K88807631-001-01-3::2.5::HTS	BRD-K88807631-001-01-3	elacridar	2.5	HTS	P glycoprotein inhibitor	ABCB1			COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC	Phase 1	5
BRD-K88956297-003-01-9::2.5::HTS	0.19747714449499998	BRD-K88956297-003-01-9::2.5::HTS	BRD-K88956297-003-01-9	1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium	2.5	HTS					Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2	Preclinical	5
BRD-K89014967-001-04-3::2.5::HTS	-4.16417276535	BRD-K89014967-001-04-3::2.5::HTS	BRD-K89014967-001-04-3	AS-703026	2.5	HTS	MEK inhibitor	MAP2K1, MAP2K2			OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F	Phase 2	5
BRD-K89015388-001-01-7::2.5::HTS	-0.36633331261299995	BRD-K89015388-001-01-7::2.5::HTS	BRD-K89015388-001-01-7	GSK923295	2.5	HTS	centromere associated protein inhibitor	CENPE			CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1	Phase 1	5
BRD-K89048337-001-06-9::2.5::HTS	0.255659730703	BRD-K89048337-001-06-9::2.5::HTS	BRD-K89048337-001-06-9	puerarin	2.5	HTS	serotonin receptor antagonist				OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	Phase 2	5
BRD-K89053832-001-01-0::2.5::HTS	-2.80380089842	BRD-K89053832-001-01-0::2.5::HTS	BRD-K89053832-001-01-0	VLX600	2.5	HTS	ubiquitin C-terminal hydrolase inhibitor	USP14			C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	Phase 1	5
BRD-K89055274-048-22-7::2.5::HTS	-0.38465923475100006	BRD-K89055274-048-22-7::2.5::HTS	BRD-K89055274-048-22-7	alverine	2.5	HTS	muscle relaxant	HTR1A	gastroenterology	irritable bowel syndrome, diverticular disease	CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1	Launched	5
BRD-K89056082-001-07-7::2.5::HTS	-0.109572163839	BRD-K89056082-001-07-7::2.5::HTS	BRD-K89056082-001-07-7	chlorocresol	2.5	HTS	ryanodine receptor activator		infectious disease	first-aid antiseptic	Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl	Launched	5
BRD-K89071957-001-01-1::0.25::HTS	0.142929863436	BRD-K89071957-001-01-1::0.25::HTS	BRD-K89071957-001-01-1	CTS21166	0.25	HTS	beta-secretase inhibitor	BACE1			CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O	Phase 1	3
BRD-K89072800-001-01-8::2.5::HTS	0.450874962826	BRD-K89072800-001-01-8::2.5::HTS	BRD-K89072800-001-01-8	2-TEDC	2.5	HTS	lipoxygenase inhibitor	ALOX12			Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O	Preclinical	5
BRD-K89104321-003-14-8::2.5::HTS	-0.220059166741	BRD-K89104321-003-14-8::2.5::HTS	BRD-K89104321-003-14-8	gaboxadol	2.5	HTS	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3			Oc1noc2CNCCc12, Oc1noc2CNCCc12, Oc1noc2CNCCc12	Phase 3	5
BRD-K89125793-001-26-0::2.5::HTS	0.330547853287	BRD-K89125793-001-26-0::2.5::HTS	BRD-K89125793-001-26-0	tinidazole	2.5	HTS	antiprotozoal agent		infectious disease, obstetrics/gynecology	giardiasis, amebiasis, bacterial vaginosis, trichomoniasis	CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O	Launched	5
BRD-K89152108-236-07-6::2.5::HTS	0.00612149740886	BRD-K89152108-236-07-6::2.5::HTS	BRD-K89152108-236-07-6	liothyronine	2.5	HTS	thyroid hormone stimulant	THRA, THRB	endocrinology	hypothyroidism, myxedema coma	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	Launched	5
BRD-K89162000-001-06-4::2.5::HTS	0.046588335280999996	BRD-K89162000-001-06-4::2.5::HTS	BRD-K89162000-001-06-4	tandutinib	2.5	HTS	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFD, PDGFRB			COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1	Phase 2	5
BRD-K89208535-051-01-5::2.5::HTS	-0.20474811704100002	BRD-K89208535-051-01-5::2.5::HTS	BRD-K89208535-051-01-5	indacaterol	2.5	HTS	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	Launched	5
BRD-K89210380-001-13-7::2.5::HTS	0.310816517219	BRD-K89210380-001-13-7::2.5::HTS	BRD-K89210380-001-13-7	biotin	2.5	HTS	vitamin B	ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6			OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	Launched	5
BRD-K89272762-001-12-7::2.5::HTS	-0.5769893043850001	BRD-K89272762-001-12-7::2.5::HTS	BRD-K89272762-001-12-7	NPPB	2.5	HTS	chloride channel blocker	ANO1, CLCN2, CLCN7, TRPA1			OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O	Preclinical	5
BRD-K89274813-001-02-3::2.5::HTS	-0.194170422856	BRD-K89274813-001-02-3::2.5::HTS	BRD-K89274813-001-02-3	DMP-543	2.5	HTS	acetylcholine release enhancer				Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1	Phase 2	5
BRD-K89299012-001-06-0::2.5::HTS	0.254046400465	BRD-K89299012-001-06-0::2.5::HTS	BRD-K89299012-001-06-0	DCEBIO	2.5	HTS	potassium channel activator	KCNN2, KCNN3, KCNN4			CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12	Preclinical	5
BRD-K89306950-001-12-5::2.5::HTS	-0.774426560608	BRD-K89306950-001-12-5::2.5::HTS	BRD-K89306950-001-12-5	ML130	2.5	HTS	NOD1 inhibitor				Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12	Preclinical	5
BRD-K89348303-001-14-7::2.5::HTS	0.0348882157752	BRD-K89348303-001-14-7::2.5::HTS	BRD-K89348303-001-14-7	ramipril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O	Launched	5
BRD-K89375097-300-08-8::2.5::HTS	0.09806235709789998	BRD-K89375097-300-08-8::2.5::HTS	BRD-K89375097-300-08-8	pirenzepine	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	Launched	5
BRD-K89391146-001-08-0::2.5::HTS	-0.510237793629	BRD-K89391146-001-08-0::2.5::HTS	BRD-K89391146-001-08-0	RG108	2.5	HTS	DNA methyltransferase inhibitor	DNMT1, DNMT3B			OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O	Preclinical	5
BRD-K89402695-001-02-3::2.5::HTS	-0.741712389024	BRD-K89402695-001-02-3::2.5::HTS	BRD-K89402695-001-02-3	L-655240	2.5	HTS	thromboxane receptor antagonist	PTGES			Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12, Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12	Phase 1	5
BRD-K89561498-001-01-7::2.5::HTS	-5.23287847759	BRD-K89561498-001-01-7::2.5::HTS	BRD-K89561498-001-01-7	SN-38	2.5	HTS	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12	Launched	5
BRD-K89588135-001-01-9::2.5::HTS	0.11498869047499999	BRD-K89588135-001-01-9::2.5::HTS	BRD-K89588135-001-01-9	tagatose	2.5	HTS	phosphorylase inhibitor	PYGL			OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO	Phase 3	5
BRD-K89634775-001-09-9::2.5::HTS	0.271745153934	BRD-K89634775-001-09-9::2.5::HTS	BRD-K89634775-001-09-9	allylthiourea	2.5	HTS	nitrification inhibitor				NC(S)=NCC=C, NC(S)=NCC=C	Preclinical	5
BRD-K89657519-001-01-8::2.5::HTS	0.21499276797400002	BRD-K89657519-001-01-8::2.5::HTS	BRD-K89657519-001-01-8	testosterone-enanthate	2.5	HTS	androgen receptor agonist	AR	endocrinology	hypogonadism	CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K89665618-003-02-5::2.5::HTS	-0.10250368980699999	BRD-K89665618-003-02-5::2.5::HTS	BRD-K89665618-003-02-5	1-deoxymannojirimycin	2.5	HTS	alpha mannosidase inhibitor	MAN2A1			OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O	Preclinical	5
BRD-K89704198-001-12-3::2.5::HTS	0.042141751034199995	BRD-K89704198-001-12-3::2.5::HTS	BRD-K89704198-001-12-3	vincamine	2.5	HTS	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC	Withdrawn	5
BRD-K89712525-001-02-1::2.57::HTS	-0.443015602437	BRD-K89712525-001-02-1::2.57::HTS	BRD-K89712525-001-02-1	2-oxoglutaric-acid	2.57	HTS		OXGR1			OC(=O)CCC(=O)C(O)=O	Preclinical	5
BRD-K89714990-001-01-5::2.5::HTS	0.33791502560099995	BRD-K89714990-001-01-5::2.5::HTS	BRD-K89714990-001-01-5	tepoxalin	2.5	HTS	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1	Launched	5
BRD-K89732114-300-14-7::2.5::HTS	-0.027740795347700003	BRD-K89732114-300-14-7::2.5::HTS	BRD-K89732114-300-14-7	trifluoperazine	2.5	HTS	dopamine receptor antagonist	ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1	neurology/psychiatry	schizophrenia	CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	5
BRD-K89839824-001-05-3::2.5::HTS	-0.41253289939099996	BRD-K89839824-001-05-3::2.5::HTS	BRD-K89839824-001-05-3	raltitrexed	2.5	HTS	thymidylate synthase inhibitor	FPGS, TYMS	oncology	mesothelioma	CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	5
BRD-K89917372-001-01-2::2.5::HTS	0.199478456204	BRD-K89917372-001-01-2::2.5::HTS	BRD-K89917372-001-01-2	retigabine	2.5	HTS	potassium channel activator	KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5	neurology/psychiatry	epilepsy	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N	Launched	5
BRD-K89997465-003-43-0::2.5::HTS	0.234258783811	BRD-K89997465-003-43-0::2.5::HTS	BRD-K89997465-003-43-0	chlorpromazine	2.5	HTS	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5	neurology/psychiatry, gastroenterology, hematology, infectious disease	schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12	Launched	5
BRD-K90027121-003-01-7::2.5::HTS	-0.00931470199918	BRD-K90027121-003-01-7::2.5::HTS	BRD-K90027121-003-01-7	amprolium	2.5	HTS	thiamine uptake blocker		infectious disease	coccidiosis	CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1	Launched	5
BRD-K90027355-001-13-3::2.44::HTS	0.0594174573488	BRD-K90027355-001-13-3::2.44::HTS	BRD-K90027355-001-13-3	spironolactone	2.44	HTS	mineralocorticoid receptor antagonist	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12	Launched	5
BRD-K90027355-001-19-0::2.5::HTS	-0.30483342066999997	BRD-K90027355-001-19-0::2.5::HTS	BRD-K90027355-001-19-0	spironolactone	2.5	HTS	mineralocorticoid receptor antagonist	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12	Launched	5
BRD-K90065682-300-02-6::2.5::HTS	0.229726467492	BRD-K90065682-300-02-6::2.5::HTS	BRD-K90065682-300-02-6	5-iodo-A-85380	2.5	HTS	acetylcholine receptor agonist				Ic1cncc(OC[C@@H]2CCN2)c1, Ic1cncc(OC[C@@H]2CCN2)c1	Phase 2	5
BRD-K90168339-001-08-6::2.5::HTS	0.551049838867	BRD-K90168339-001-08-6::2.5::HTS	BRD-K90168339-001-08-6	thiophanate	2.5	HTS					COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC	Preclinical	5
BRD-K90195324-003-02-5::2.5::HTS	-0.122374925997	BRD-K90195324-003-02-5::2.5::HTS	BRD-K90195324-003-02-5	bazedoxifene	2.5	HTS	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, endocrinology	osteoporosis, menopause	Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12	Launched	5
BRD-K90239174-001-01-8::2.5::HTS	0.23066512035	BRD-K90239174-001-01-8::2.5::HTS	BRD-K90239174-001-01-8	AMG-487	2.5	HTS	CC chemokine receptor antagonist				CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Phase 2	5
BRD-K90333595-003-21-4::2.5::HTS	-0.0051814767422	BRD-K90333595-003-21-4::2.5::HTS	BRD-K90333595-003-21-4	phentolamine	2.5	HTS	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	endocrinology, cardiology	pheochromocytoma, hypertension	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1	Launched	5
BRD-K90374350-001-09-2::2.5::HTS	0.334829995367	BRD-K90374350-001-09-2::2.5::HTS	BRD-K90374350-001-09-2	chlorquinaldol	2.5	HTS	other antibiotic		infectious disease	fungal infection	Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	Launched	5
BRD-K90382497-001-10-7::2.5::HTS	-0.788110486865	BRD-K90382497-001-10-7::2.5::HTS	BRD-K90382497-001-10-7	GW-843682X	2.5	HTS	PLK inhibitor	PLK1, PLK3			COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC	Preclinical	5
BRD-K90497590-001-04-2::2.5::HTS	-0.37565725441799996	BRD-K90497590-001-04-2::2.5::HTS	BRD-K90497590-001-04-2	AR-12	2.5	HTS	phosphoinositide dependent kinase inhibitor	PDPK1			NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	Phase 1	5
BRD-K90524085-001-07-8::2.5::HTS	0.5886454314940001	BRD-K90524085-001-07-8::2.5::HTS	BRD-K90524085-001-07-8	MY-5445	2.5	HTS	phosphodiesterase inhibitor, platelet aggregation inhibitor	PDE5A			Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1	Preclinical	5
BRD-K90574421-001-03-5::2.5::HTS	-0.234591498809	BRD-K90574421-001-03-5::2.5::HTS	BRD-K90574421-001-03-5	ipsapirone	2.5	HTS	serotonin receptor agonist	HTR1A			O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12	Phase 3	5
BRD-K90630139-003-05-9::2.5::HTS	0.19193533281	BRD-K90630139-003-05-9::2.5::HTS	BRD-K90630139-003-05-9	butenafine	2.5	HTS	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12	Launched	5
BRD-K90647725-001-06-5::2.5::HTS	0.000213770885482	BRD-K90647725-001-06-5::2.5::HTS	BRD-K90647725-001-06-5	oleanolic-acid	2.5	HTS	G protein-coupled receptor agonist	GPBAR1			CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O	Preclinical	5
BRD-K90647725-001-07-3::2.5::HTS	-0.697983802082	BRD-K90647725-001-07-3::2.5::HTS	BRD-K90647725-001-07-3	oleanolic-acid	2.5	HTS	G protein-coupled receptor agonist	GPBAR1			CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O	Preclinical	5
BRD-K90777969-300-01-2::2.5::HTS	-0.46863177767700004	BRD-K90777969-300-01-2::2.5::HTS	BRD-K90777969-300-01-2	cutamesine	2.5	HTS	sigma receptor agonist	SIGMAR1			COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC	Phase 2	5
BRD-K90789829-001-07-8::2.5::HTS	0.016055920969	BRD-K90789829-001-07-8::2.5::HTS	BRD-K90789829-001-07-8	nefazodone	2.5	HTS	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4			CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1	Withdrawn	5
BRD-K90817094-001-02-6::2.5::HTS	0.257798834924	BRD-K90817094-001-02-6::2.5::HTS	BRD-K90817094-001-02-6	bedaquiline	2.5	HTS	ATPase inhibitor		infectious disease	tuberculosis	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Launched	5
BRD-K90825648-001-02-0::2.5::HTS	0.0416052779525	BRD-K90825648-001-02-0::2.5::HTS	BRD-K90825648-001-02-0	RS-127445	2.5	HTS	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12	Phase 1	5
BRD-K90868879-001-03-8::2.5::HTS	0.633322870959	BRD-K90868879-001-03-8::2.5::HTS	BRD-K90868879-001-03-8	canagliflozin	2.5	HTS	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Launched	5
BRD-K90885812-004-24-2::2.5::HTS	-0.342781818641	BRD-K90885812-004-24-2::2.5::HTS	BRD-K90885812-004-24-2	propantheline	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD)	CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C	Launched	5
BRD-K90947825-001-02-7::2.5::HTS	-0.641184793697	BRD-K90947825-001-02-7::2.5::HTS	BRD-K90947825-001-02-7	carboplatin	2.5	HTS	DNA alkylating agent, DNA inhibitor		oncology	ovarian cancer	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	Launched	5
BRD-K90948141-001-01-4::2.5::HTS	0.934696778681	BRD-K90948141-001-01-4::2.5::HTS	BRD-K90948141-001-01-4	indiplon	2.5	HTS	benzodiazepine receptor agonist	GABRA1			CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1	Phase 3	5
BRD-K90993449-001-02-7::2.5::HTS	0.214406792301	BRD-K90993449-001-02-7::2.5::HTS	BRD-K90993449-001-02-7	KRN-633	2.5	HTS	VEGFR inhibitor	FLT1, FLT4, KDR			CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl	Preclinical	5
BRD-K91065602-003-05-5::2.5::HTS	0.25947041375700003	BRD-K91065602-003-05-5::2.5::HTS	BRD-K91065602-003-05-5	vancomycin	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	Launched	5
BRD-K91111634-001-01-2::2.5::HTS	-0.15252819324300002	BRD-K91111634-001-01-2::2.5::HTS	BRD-K91111634-001-01-2	rotigotine	2.5	HTS	dopamine receptor agonist	ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1	Launched	5
BRD-K91147684-001-01-5::2.5::HTS	-0.280532201135	BRD-K91147684-001-01-5::2.5::HTS	BRD-K91147684-001-01-5	m-THP	2.5	HTS					Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2	Phase 1	5
BRD-K91159026-001-01-7::2.5::HTS	-0.136988441597	BRD-K91159026-001-01-7::2.5::HTS	BRD-K91159026-001-01-7	telcagepant	2.5	HTS	calcitonin antagonist	CALCRL, RAMP1			Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F	Phase 3	5
BRD-K91188791-001-18-3::2.5::HTS	-0.05887455052709999	BRD-K91188791-001-18-3::2.5::HTS	BRD-K91188791-001-18-3	aloxistatin	2.5	HTS	protease inhibitor	CTSG			CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	Phase 3	5
BRD-K91263825-003-21-4::2.5::HTS	0.0534458542724	BRD-K91263825-003-21-4::2.5::HTS	BRD-K91263825-003-21-4	nortriptyline	2.5	HTS	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	CNCCC=C1c2ccccc2CCc2ccccc12	Launched	5
BRD-K91290917-300-01-8::2.5::HTS	0.5471796994	BRD-K91290917-300-01-8::2.5::HTS	BRD-K91290917-300-01-8	amodiaquine	2.5	HTS	histamine receptor agonist	HNMT	infectious disease	malaria	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	Launched	5
BRD-K91301684-003-05-5::2.5::HTS	-0.22187123058299998	BRD-K91301684-003-05-5::2.5::HTS	BRD-K91301684-003-05-5	noscapine	2.5	HTS	bradykinin receptor antagonist, tubulin polymerization inhibitor	SIGMAR1	pulmonary	cough suppressant	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12	Launched	5
BRD-K91308639-001-02-7::2.5::HTS	0.009945459992719998	BRD-K91308639-001-02-7::2.5::HTS	BRD-K91308639-001-02-7	apalutamide	2.5	HTS	androgen receptor antagonist		oncology	prostate cancer	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F	Launched	5
BRD-K91315211-300-05-7::2.5::HTS	-0.158062245174	BRD-K91315211-300-05-7::2.5::HTS	BRD-K91315211-300-05-7	betahistine	2.5	HTS	histamine receptor agonist, histamine receptor antagonist	HRH1, HRH3	neurology/psychiatry	Meniere's disease	CNCCc1ccccn1, CNCCc1ccccn1	Launched	5
BRD-K91336023-003-01-0::2.5::HTS	0.226690499417	BRD-K91336023-003-01-0::2.5::HTS	BRD-K91336023-003-01-0	mesulergine	2.5	HTS	dopamine receptor agonist	HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7			CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1	Phase 2	5
BRD-K91370081-001-25-1::2.5::HTS	-4.159304553309999	BRD-K91370081-001-25-1::2.5::HTS	BRD-K91370081-001-25-1	anisomycin	2.5	HTS	DNA synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1	Preclinical	5
BRD-K91422571-001-01-8::2.5::HTS	0.162755201961	BRD-K91422571-001-01-8::2.5::HTS	BRD-K91422571-001-01-8	tromaril	2.5	HTS	prostanoid receptor antagonist				OC(=O)c1ccccc1NCCc1ccccc1	Launched	5
BRD-K91456750-238-01-7::2.5::HTS	-0.8547854110259999	BRD-K91456750-238-01-7::2.5::HTS	BRD-K91456750-238-01-7	sacubitril	2.5	HTS	neprilysin inhibitor	MME	cardiology	congestive heart failure	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O	Launched	5
BRD-K91495480-001-02-2::2.5::HTS	-0.0907195359736	BRD-K91495480-001-02-2::2.5::HTS	BRD-K91495480-001-02-2	AGP-103	2.5	HTS	membrane permeability inhibitor				CCCCCCCCCCCCCCCCCCCCCC(O)=O	Launched	5
BRD-K91509126-001-23-6::2.5::HTS	0.227339457608	BRD-K91509126-001-23-6::2.5::HTS	BRD-K91509126-001-23-6	piceatannol	2.5	HTS	SYK inhibitor	ATP5A1, ATP5B, ATP5C1, IRF3			Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1, Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1, Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1	Preclinical	5
BRD-K91544578-001-03-8::2.5::HTS	-0.0411991297315	BRD-K91544578-001-03-8::2.5::HTS	BRD-K91544578-001-03-8	nikethamide	2.5	HTS	immunostimulant				CCN(CC)C(=O)c1cccnc1	Withdrawn	5
BRD-K91601245-001-12-0::2.5::HTS	-0.248020303779	BRD-K91601245-001-12-0::2.5::HTS	BRD-K91601245-001-12-0	mercaptopurine	2.5	HTS	immunosuppressant, protein synthesis inhibitor, purine antagonist	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12	Launched	5
BRD-K91614056-001-02-2::2.5::HTS	-0.787804605047	BRD-K91614056-001-02-2::2.5::HTS	BRD-K91614056-001-02-2	trans-4-Hydroxycrotonic-acid	2.5	HTS	gamma hydroxybutyric acid ligand				OC\C=C\C(O)=O	Preclinical	5
BRD-K91623615-001-05-0::2.46::HTS	-0.42994234133000003	BRD-K91623615-001-05-0::2.46::HTS	BRD-K91623615-001-05-0	ABT-751	2.46	HTS	tubulin polymerization inhibitor	TUBB			COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1	Phase 2	5
BRD-K91699951-001-10-2::2.5::HTS	-0.310072032735	BRD-K91699951-001-10-2::2.5::HTS	BRD-K91699951-001-10-2	benzonatate	2.5	HTS	local anesthetic	SCN5A	pulmonary	cough suppressant	CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC	Launched	5
BRD-K91701654-001-03-1::2.38::HTS	-0.550279480572	BRD-K91701654-001-03-1::2.38::HTS	BRD-K91701654-001-03-1	U-0126	2.38	HTS	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N	Preclinical	5
BRD-K91740057-001-19-8::2.5::HTS	0.024896571162999998	BRD-K91740057-001-19-8::2.5::HTS	BRD-K91740057-001-19-8	felbinac	2.5	HTS	cyclooxygenase inhibitor	CTSL	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	OC(=O)Cc1ccc(cc1)-c1ccccc1	Launched	5
BRD-K91758890-001-10-0::2.5::HTS	0.342981400569	BRD-K91758890-001-10-0::2.5::HTS	BRD-K91758890-001-10-0	4-HQN	2.5	HTS	PARP inhibitor	PARP1			Oc1ncnc2ccccc12	Preclinical	5
BRD-K91822704-003-07-2::2.5::HTS	-0.689543803568	BRD-K91822704-003-07-2::2.5::HTS	BRD-K91822704-003-07-2	torcitabine	2.5	HTS	DNA polymerase inhibitor	DCK, TK2			Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	Phase 2	5
BRD-K91825936-001-01-2::2.5::HTS	-0.597771123567	BRD-K91825936-001-01-2::2.5::HTS	BRD-K91825936-001-01-2	ZK811752	2.5	HTS	CC chemokine receptor antagonist	CCR1			C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O	Phase 2	5
BRD-K91868854-001-03-6::2.5::HTS	-0.149531698611	BRD-K91868854-001-03-6::2.5::HTS	BRD-K91868854-001-03-6	2-[1-(4-piperonyl)piperazinyl]benzothiazole	2.5	HTS	serotonin receptor agonist	HTR4			C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1	Preclinical	5
BRD-K91904471-001-02-4::2.5::HTS	0.36360923259499994	BRD-K91904471-001-02-4::2.5::HTS	BRD-K91904471-001-02-4	SD-169	2.5	HTS	p38 MAPK inhibitor	MAPK14			NC(=O)c1ccc2[nH]ccc2c1	Preclinical	5
BRD-K92000912-001-12-6::2.5::HTS	-1.21646979578	BRD-K92000912-001-12-6::2.5::HTS	BRD-K92000912-001-12-6	AM-251	2.5	HTS	cannabinoid receptor antagonist	CNR1, GPR18, GPR55			Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Preclinical	5
BRD-K92015269-300-01-2::2.5::HTS	-0.0916526424616	BRD-K92015269-300-01-2::2.5::HTS	BRD-K92015269-300-01-2	GBR-12783	2.5	HTS	dopamine uptake inhibitor				C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1	Preclinical	5
BRD-K92041145-001-09-5::2.5::HTS	-0.390236544719	BRD-K92041145-001-09-5::2.5::HTS	BRD-K92041145-001-09-5	O6-Benzylguanine	2.5	HTS	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			Nc1nc(OCc2ccccc2)c2[nH]cnc2n1	Phase 3	5
BRD-K92049597-001-20-8::2.5::HTS	0.217064734296	BRD-K92049597-001-20-8::2.5::HTS	BRD-K92049597-001-20-8	triamterene	2.5	HTS	sodium channel blocker	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1	Launched	5
BRD-K92073408-001-16-5::2.5::HTS	-0.177786624765	BRD-K92073408-001-16-5::2.5::HTS	BRD-K92073408-001-16-5	norethindrone	2.5	HTS	progesterone receptor agonist	PGR	obstetrics/gynecology	endometriosis	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Launched	5
BRD-K92093830-003-30-8::2.5::HTS	-6.323563398150001	BRD-K92093830-003-30-8::2.5::HTS	BRD-K92093830-003-30-8	doxorubicin	2.5	HTS	topoisomerase inhibitor	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	Launched	5
BRD-K92107055-001-01-9::2.5::HTS	-0.39911451536700004	BRD-K92107055-001-01-9::2.5::HTS	BRD-K92107055-001-01-9	pimecrolimus	2.5	HTS	calcineurin inhibitor	FKBP1A, MTOR	dermatology	eczema	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC	Launched	5
BRD-K92116564-001-01-4::2.5::HTS	0.115511888052	BRD-K92116564-001-01-4::2.5::HTS	BRD-K92116564-001-01-4	isoxepac	2.5	HTS	anti-inflammatory agent				OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1	Phase 2	5
BRD-K92150287-066-01-2::2.5::HTS	-6.650383698130001	BRD-K92150287-066-01-2::2.5::HTS	BRD-K92150287-066-01-2	exatecan-mesylate	2.5	HTS	topoisomerase inhibitor	TOP1			CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45	Phase 3	5
BRD-K92213669-001-01-3::2.5::HTS	0.00867237445981	BRD-K92213669-001-01-3::2.5::HTS	BRD-K92213669-001-01-3	lomitapide	2.5	HTS	microsomal trigylceride transfer protein inhibitor	MTTP	endocrinology	hypercholesterolemia	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12	Launched	5
BRD-K92241597-001-06-0::2.5::HTS	-0.238457946755	BRD-K92241597-001-06-0::2.5::HTS	BRD-K92241597-001-06-0	tosedostat	2.5	HTS	peptidase inhibitor	ANPEP, LAP3, NPEPPS			CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	Phase 2	5
BRD-K92301463-001-05-5::0.25::HTS	0.08153466029010001	BRD-K92301463-001-05-5::0.25::HTS	BRD-K92301463-001-05-5	16,16-dimethylprostaglandin-e2	0.25	HTS	prostanoid receptor agonist	HPGD			CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	Phase 2	3
BRD-K92303087-001-01-6::2.5::HTS	0.33889611571199996	BRD-K92303087-001-01-6::2.5::HTS	BRD-K92303087-001-01-6	oglemilast	2.5	HTS	phosphodiesterase inhibitor				CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1	Phase 2	5
BRD-K92382976-050-01-1::2.5::HTS	0.32446176836	BRD-K92382976-050-01-1::2.5::HTS	BRD-K92382976-050-01-1	5-carboxamidotryptamine	2.5	HTS	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			NCCc1c[nH]c2ccc(cc12)C(N)=O	Preclinical	5
BRD-K92404805-001-07-0::2.5::HTS	-0.19293988104600002	BRD-K92404805-001-07-0::2.5::HTS	BRD-K92404805-001-07-0	L-Quisqualic-acid	2.5	HTS	glutamate receptor agonist	FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8			N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O	Preclinical	5
BRD-K92428153-001-04-4::2.5::HTS	-0.56750154716	BRD-K92428153-001-04-4::2.5::HTS	BRD-K92428153-001-04-4	mycophenolate-mofetil	2.5	HTS	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	Launched	5
BRD-K92428232-001-10-6::2.5::HTS	-3.56397871296	BRD-K92428232-001-10-6::2.5::HTS	BRD-K92428232-001-10-6	GSK461364	2.5	HTS	PLK inhibitor	PLK1			C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F	Phase 1	5
BRD-K92441787-001-04-1::2.5::HTS	-0.215064286276	BRD-K92441787-001-04-1::2.5::HTS	BRD-K92441787-001-04-1	bexarotene	2.5	HTS	retinoid receptor agonist	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C	Launched	5
BRD-K92446736-003-02-2::2.5::HTS	0.248050231107	BRD-K92446736-003-02-2::2.5::HTS	BRD-K92446736-003-02-2	zatebradine	2.5	HTS	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC	Phase 3	5
BRD-K92467929-001-01-1::2.5::HTS	0.061132363805400006	BRD-K92467929-001-01-1::2.5::HTS	BRD-K92467929-001-01-1	oxandrolone	2.5	HTS	androgen receptor agonist	AR	endocrinology	weight-gain aid	C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K92492521-001-02-9::2.5::HTS	-0.31749624009300004	BRD-K92492521-001-02-9::2.5::HTS	BRD-K92492521-001-02-9	LY255283	2.5	HTS	leukotriene receptor antagonist	LTB4R, LTB4R2			CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1	Preclinical	5
BRD-K92493880-001-03-0::2.5::HTS	0.158648462512	BRD-K92493880-001-03-0::2.5::HTS	BRD-K92493880-001-03-0	AMPA-(S)	2.5	HTS	glutamate receptor agonist	GRIN1			Cc1onc(O)c1C[C@H](N)C(O)=O	Preclinical	5
BRD-K92577649-300-01-2::2.5::HTS	-0.0198455860589	BRD-K92577649-300-01-2::2.5::HTS	BRD-K92577649-300-01-2	GBR-13069	2.5	HTS	dopamine uptake inhibitor	SLC6A3			Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	Preclinical	5
BRD-K92588747-051-02-7::2.5::HTS	-1.02294142504	BRD-K92588747-051-02-7::2.5::HTS	BRD-K92588747-051-02-7	2-CMDO	2.5	HTS	dopamine receptor antagonist	DRD2, DRD4			CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12	Preclinical	5
BRD-K92613113-066-02-7::2.5::HTS	0.11275728586200001	BRD-K92613113-066-02-7::2.5::HTS	BRD-K92613113-066-02-7	safinamide	2.5	HTS	dopamine uptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor	MAOB	neurology/psychiatry	Parkinson's Disease	C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O	Launched	5
BRD-K92657060-001-05-7::2.5::HTS	-1.88851953616	BRD-K92657060-001-05-7::2.5::HTS	BRD-K92657060-001-05-7	zaleplon	2.5	HTS	benzodiazepine receptor agonist	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N	Launched	5
BRD-K92723993-001-06-7::2.5::HTS	-1.13971790515	BRD-K92723993-001-06-7::2.5::HTS	BRD-K92723993-001-06-7	imatinib	2.5	HTS	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	Launched	5
BRD-K92731339-227-04-9::2.5::HTS	0.116902058012	BRD-K92731339-227-04-9::2.5::HTS	BRD-K92731339-227-04-9	perindopril	2.5	HTS	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction, coronary artery disease (CAD)	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	Launched	5
BRD-K92758126-001-18-8::1.44::HTS	-0.18847589002	BRD-K92758126-001-18-8::1.44::HTS	BRD-K92758126-001-18-8	MD-920	1.44	HTS	NFkB pathway inhibitor	AADACL2			C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O	Phase 1	4
BRD-K92760278-001-07-3::2.43::HTS	-0.433257211622	BRD-K92760278-001-07-3::2.43::HTS	BRD-K92760278-001-07-3	riboflavin	2.43	HTS	vitamin B2	BLVRB, RFK	gastroenterology	jaundice	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	Launched	5
BRD-K92778217-001-32-7::2.5::HTS	-0.144863332652	BRD-K92778217-001-32-7::2.5::HTS	BRD-K92778217-001-32-7	mefenamic-acid	2.5	HTS	cyclooxygenase inhibitor	KCNQ1, PTGS1, PTGS2, TRPM3	endocrinology	primary dysmenorrhea (PD)	Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C	Launched	5
BRD-K92830582-003-10-5::2.5::HTS	0.17872301170000002	BRD-K92830582-003-10-5::2.5::HTS	BRD-K92830582-003-10-5	propranolol-(R)	2.5	HTS	adrenergic receptor antagonist	ADRB2, ADRB3			CC(C)NC[C@@H](O)COc1cccc2ccccc12	Preclinical	5
BRD-K92838188-001-01-9::2.5::HTS	0.340903401011	BRD-K92838188-001-01-9::2.5::HTS	BRD-K92838188-001-01-9	rifaximin	2.5	HTS	RNA synthesis inhibitor	NR1I2	gastroenterology	diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)	CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C	Launched	5
BRD-K92844263-001-09-8::2.5::HTS	0.9660518150730001	BRD-K92844263-001-09-8::2.5::HTS	BRD-K92844263-001-09-8	triacetin	2.5	HTS					CC(=O)OCC(COC(C)=O)OC(C)=O	Launched	5
BRD-K92848252-001-01-9::2.5::HTS	0.105084345079	BRD-K92848252-001-01-9::2.5::HTS	BRD-K92848252-001-01-9	diminazene-aceturate	2.5	HTS	angiotensin converting enzyme activator	AOC1, PRDX5, PRSS1			NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1	Phase 3	5
BRD-K92872987-001-02-9::2.5::HTS	-0.207725340375	BRD-K92872987-001-02-9::2.5::HTS	BRD-K92872987-001-02-9	cefpiramide	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1	Launched	5
BRD-K92968657-001-01-6::2.5::HTS	0.331175387265	BRD-K92968657-001-01-6::2.5::HTS	BRD-K92968657-001-01-6	tirapazamine	2.5	HTS	DNA inhibitor				Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]	Phase 3	5
BRD-K92976206-001-01-5::2.5::HTS	0.0374107896511	BRD-K92976206-001-01-5::2.5::HTS	BRD-K92976206-001-01-5	guanosine	2.5	HTS		PNP			Nc1nc2n(cnc2c(=O)[nH]1)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H]1O	Preclinical	5
BRD-K92980438-001-03-3::2.5::HTS	-0.10958040868100001	BRD-K92980438-001-03-3::2.5::HTS	BRD-K92980438-001-03-3	3-bromopyruvate	2.5	HTS	hexokinase inhibitor	HK2			OC(=O)C(=O)CBr, OC(=O)C(=O)CBr, OC(=O)C(=O)CBr	Preclinical	5
BRD-K92984783-003-05-7::2.5::HTS	-0.40360850707699997	BRD-K92984783-003-05-7::2.5::HTS	BRD-K92984783-003-05-7	melperone	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	psychosis	CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1	Launched	5
BRD-K92988025-001-01-9::2.5::HTS	0.10222604420399999	BRD-K92988025-001-01-9::2.5::HTS	BRD-K92988025-001-01-9	perflubron	2.5	HTS	contrast agent		radiology	contrast agent	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br, FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	Launched	5
BRD-K92991072-001-04-9::2.5::HTS	0.45135921783999994	BRD-K92991072-001-04-9::2.5::HTS	BRD-K92991072-001-04-9	PAC-1	2.5	HTS	caspase activator	CASP3			Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1	Phase 1	5
BRD-K93034159-001-25-8::2.5::HTS	-5.4180833134899995	BRD-K93034159-001-25-8::2.5::HTS	BRD-K93034159-001-25-8	cladribine	2.5	HTS	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B	hematologic malignancy	hairy cell leukemia	Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1	Launched	5
BRD-K93035859-001-07-6::2.5::HTS	0.0649143263197	BRD-K93035859-001-07-6::2.5::HTS	BRD-K93035859-001-07-6	butylated-hydroxyanisole	2.5	HTS	antioxidant				COc1ccc(O)c(c1)C(C)(C)C	Preclinical	5
BRD-K93045741-001-01-0::2.5::HTS	0.16881382465199998	BRD-K93045741-001-01-0::2.5::HTS	BRD-K93045741-001-01-0	tozadenant	2.5	HTS	adenosine receptor antagonist	ADORA2A			COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12	Phase 3	5
BRD-K93123848-001-04-1::2.5::HTS	0.857743349588	BRD-K93123848-001-04-1::2.5::HTS	BRD-K93123848-001-04-1	RAF265	2.5	HTS	RAF inhibitor, VEGFR inhibitor	BRAF			Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12	Phase 2	5
BRD-K93176058-001-03-6::2.5::HTS	-0.39562306982900003	BRD-K93176058-001-03-6::2.5::HTS	BRD-K93176058-001-03-6	AC-55649	2.5	HTS	retinoid receptor agonist	RARA, RARB			CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O	Preclinical	5
BRD-K93188295-300-02-2::2.5::HTS	-0.418367288574	BRD-K93188295-300-02-2::2.5::HTS	BRD-K93188295-300-02-2	ARC-239	2.5	HTS	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1	Preclinical	5
BRD-K93208532-001-02-5::2.5::HTS	0.0914629373722	BRD-K93208532-001-02-5::2.5::HTS	BRD-K93208532-001-02-5	apremilast	2.5	HTS	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology, rheumatology	psoriasis, psoriatic arthritis	CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O	Launched	5
BRD-K93231391-300-05-6::2.5::HTS	-0.250871715315	BRD-K93231391-300-05-6::2.5::HTS	BRD-K93231391-300-05-6	ethambutol	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO	Launched	5
BRD-K93240442-001-08-4::2.5::HTS	0.508628828527	BRD-K93240442-001-08-4::2.5::HTS	BRD-K93240442-001-08-4	dinitolmide	2.5	HTS			infectious disease	coccidiosis	Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O	Launched	5
BRD-K93255255-001-02-1::2.5::HTS	-0.230159650333	BRD-K93255255-001-02-1::2.5::HTS	BRD-K93255255-001-02-1	indoximod	2.5	HTS	indoleamine 2,3-dioxygenase inhibitor	IDO1			Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12	Phase 2	5
BRD-K93258693-001-17-3::2.5::HTS	-0.138141571825	BRD-K93258693-001-17-3::2.5::HTS	BRD-K93258693-001-17-3	GW-9662	2.5	HTS	PPAR receptor antagonist	NCOA2, PPARG, RXRA			[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1	Preclinical	5
BRD-K93441486-067-12-8::2.5::HTS	0.110672537426	BRD-K93441486-067-12-8::2.5::HTS	BRD-K93441486-067-12-8	diphemanil	2.5	HTS	acetylcholine receptor antagonist	CHRM3	neurology/psychiatry	spasms	C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1	Launched	5
BRD-K93460210-001-23-7::2.5::HTS	-0.485611422205	BRD-K93460210-001-23-7::2.5::HTS	BRD-K93460210-001-23-7	lamotrigine	2.5	HTS	serotonin receptor antagonist, sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, bipolar disorder	Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl	Launched	5
BRD-K93461745-003-25-0::2.5::HTS	-0.429930564924	BRD-K93461745-003-25-0::2.5::HTS	BRD-K93461745-003-25-0	buspirone	2.5	HTS	serotonin receptor agonist	DRD2, HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	Launched	5
BRD-K93468883-001-02-0::2.5::HTS	0.34216201406499996	BRD-K93468883-001-02-0::2.5::HTS	BRD-K93468883-001-02-0	IPI-145	2.5	HTS	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1	Phase 3	5
BRD-K93502141-001-01-6::2.5::HTS	0.29110679252	BRD-K93502141-001-01-6::2.5::HTS	BRD-K93502141-001-01-6	amylene-hydrate	2.5	HTS	local anesthetic				CCC(C)(C)O, CCC(C)(C)O	Preclinical	5
BRD-K93524252-001-24-7::2.5::HTS	0.5104537955899999	BRD-K93524252-001-24-7::2.5::HTS	BRD-K93524252-001-24-7	sulfamerazine	2.5	HTS	bacterial antifolate		infectious disease	coccidiosis, cholera	Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1	Launched	5
BRD-K93568044-001-32-0::2.5::HTS	-0.06165398990180001	BRD-K93568044-001-32-0::2.5::HTS	BRD-K93568044-001-32-0	hydrocortisone	2.5	HTS	glucocorticoid receptor agonist		dermatology, neurology/psychiatry	eczema, psoriasis, seborrheic dermatitis, itching	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	Launched	5
BRD-K93611241-001-02-2::2.5::HTS	-0.0918026083343	BRD-K93611241-001-02-2::2.5::HTS	BRD-K93611241-001-02-2	diacetamate	2.5	HTS					CC(=O)Nc1ccc(OC(C)=O)cc1	Preclinical	5
BRD-K93618743-001-21-0::2.5::HTS	-0.0827497331268	BRD-K93618743-001-21-0::2.5::HTS	BRD-K93618743-001-21-0	ipriflavone	2.5	HTS	bone resorption inhibitor		orthopedics	osteoporosis	CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O	Launched	5
BRD-K93631643-001-02-4::2.5::HTS	-0.367208905394	BRD-K93631643-001-02-4::2.5::HTS	BRD-K93631643-001-02-4	hordenine	2.5	HTS					CN(C)CCc1ccc(O)cc1, CN(C)CCc1ccc(O)cc1	Preclinical	5
BRD-K93632104-001-17-2::2.5::HTS	0.0553289186887	BRD-K93632104-001-17-2::2.5::HTS	BRD-K93632104-001-17-2	salicylic-acid	2.5	HTS	cyclooxygenase inhibitor	AKR1C1, PTGS1, PTGS2	dermatology	acne vulgaris (AV)	OC(=O)c1ccccc1O	Launched	5
BRD-K93632104-001-18-0::2.5::HTS	-0.334487789876	BRD-K93632104-001-18-0::2.5::HTS	BRD-K93632104-001-18-0	sodium-salicylate	2.5	HTS	prostanoid receptor antagonist	ASIC3, PTGS1, PTGS2	endocrinology, neurology/psychiatry	fever, pain relief	OC(=O)c1ccccc1O, OC(=O)c1ccccc1O	Launched	5
BRD-K93645900-001-11-3::2.5::HTS	-0.423215037153	BRD-K93645900-001-11-3::2.5::HTS	BRD-K93645900-001-11-3	tadalafil	2.5	HTS	phosphodiesterase inhibitor	PDE11A, PDE5A	cardiology	hypertension	CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O	Launched	5
BRD-K93754473-048-20-2::2.5::HTS	-0.10318752904100001	BRD-K93754473-048-20-2::2.5::HTS	BRD-K93754473-048-20-2	tamoxifen	2.5	HTS	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1	Launched	5
BRD-K93767137-001-01-1::2.5::HTS	0.412602869345	BRD-K93767137-001-01-1::2.5::HTS	BRD-K93767137-001-01-1	oseltamivir-carboxylate	2.5	HTS	neuraminidase inhibitor		infectious disease	influenza A virus infection	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O	Launched	5
BRD-K93779381-001-01-9::2.5::HTS	-1.8264188297200001	BRD-K93779381-001-01-9::2.5::HTS	BRD-K93779381-001-01-9	ingenol-mebutate	2.5	HTS	PKC activator	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C	Launched	5
BRD-K93806173-003-01-8::2.5::HTS	-0.22149416475699998	BRD-K93806173-003-01-8::2.5::HTS	BRD-K93806173-003-01-8	N-MPPP	2.5	HTS	opioid receptor agonist				CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1	Preclinical	5
BRD-K93869735-001-01-1::2.5::HTS	-0.158317238138	BRD-K93869735-001-01-1::2.5::HTS	BRD-K93869735-001-01-1	taltirelin	2.5	HTS	thyrotropin releasing hormone receptor agonist	TRHR	neurology/psychiatry	spinocerebellar ataxia	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O	Launched	5
BRD-K93880783-001-26-6::2.5::HTS	-0.568384672576	BRD-K93880783-001-26-6::2.5::HTS	BRD-K93880783-001-26-6	stavudine	2.5	HTS	DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O	Launched	5
BRD-K93918653-001-08-9::2.5::HTS	-0.0456591463054	BRD-K93918653-001-08-9::2.5::HTS	BRD-K93918653-001-08-9	quizartinib	2.5	HTS	FLT3 inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET			CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1	Phase 3	5
BRD-K93944989-001-08-0::0.25::HTS	0.104738622337	BRD-K93944989-001-08-0::0.25::HTS	BRD-K93944989-001-08-0	safingol	0.25	HTS	PKC inhibitor	TRPM3			CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO	Phase 1	3
BRD-K94080537-001-09-7::2.5::HTS	-0.425712581928	BRD-K94080537-001-09-7::2.5::HTS	BRD-K94080537-001-09-7	diethyltoluamide	2.5	HTS	ionotropic receptor IR40a activator		dermatology	sunscreen lotion	CCN(CC)C(=O)c1cccc(C)c1	Launched	5
BRD-K94144010-001-13-9::2.5::HTS	0.293695750234	BRD-K94144010-001-13-9::2.5::HTS	BRD-K94144010-001-13-9	cotinine	2.5	HTS	nicotine metabolite				CN1[C@@H](CCC1=O)c1cccnc1	Phase 2	5
BRD-K94176593-001-09-4::2.5::HTS	0.386487380501	BRD-K94176593-001-09-4::2.5::HTS	BRD-K94176593-001-09-4	TWS-119	2.5	HTS	glycogen synthase kinase inhibitor	GSK3B, JUN, MYC			Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1	Preclinical	5
BRD-K94239562-001-05-5::2.5::HTS	0.18016136689800002	BRD-K94239562-001-05-5::2.5::HTS	BRD-K94239562-001-05-5	paeonol	2.5	HTS	anti-inflammatory agent				COc1ccc(C(C)=O)c(O)c1	Preclinical	5
BRD-K94266545-001-24-1::2.5::HTS	0.251639660024	BRD-K94266545-001-24-1::2.5::HTS	BRD-K94266545-001-24-1	ronidazole	2.5	HTS	antiprotozoal agent		infectious disease	histomoniasis, dysentry	Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O	Launched	5
BRD-K94288301-001-01-7::2.5::HTS	0.0257815970113	BRD-K94288301-001-01-7::2.5::HTS	BRD-K94288301-001-01-7	letermovir	2.5	HTS	CMV terminase inhibitor				COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F	Phase 3	5
BRD-K94293891-001-01-3::2.5::HTS	-0.795759000388	BRD-K94293891-001-01-3::2.5::HTS	BRD-K94293891-001-01-3	suvorexant	2.5	HTS	orexin receptor antagonist	HCRTR1, HCRTR2	neurology/psychiatry	insomnia	C[C@@H]1CCN(CCN1C(=O)c1cc(C)ccc1-n1nccn1)c1nc2cc(Cl)ccc2o1	Launched	5
BRD-K94353609-001-21-6::2.5::HTS	-0.269596765202	BRD-K94353609-001-21-6::2.5::HTS	BRD-K94353609-001-21-6	fluocinolone-acetonide	2.5	HTS	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	Launched	5
BRD-K94358652-001-02-1::2.5::HTS	0.447963784616	BRD-K94358652-001-02-1::2.5::HTS	BRD-K94358652-001-02-1	daptomycin	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, endocarditis	CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O, CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O	Launched	5
BRD-K94379058-001-06-8::2.5::HTS	-0.169154060471	BRD-K94379058-001-06-8::2.5::HTS	BRD-K94379058-001-06-8	BML-190	2.5	HTS	cannabinoid receptor inverse agonist	CNR2			COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1	Preclinical	5
BRD-K94420399-001-01-9::2.5::HTS	-0.482075087259	BRD-K94420399-001-01-9::2.5::HTS	BRD-K94420399-001-01-9	PF-04136309	2.5	HTS	CC chemokine receptor antagonist				O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1	Phase 2	5
BRD-K94436377-001-10-2::2.5::HTS	0.00921129987484	BRD-K94436377-001-10-2::2.5::HTS	BRD-K94436377-001-10-2	diosmin	2.5	HTS	aryl hydrocarbon receptor agonist, capillary stabilizing agent	AHR	cardiology, hematology, dermatology	chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1	Launched	5
BRD-K94441233-001-13-0::2.6::HTS	0.752865887578	BRD-K94441233-001-13-0::2.6::HTS	BRD-K94441233-001-13-0	mevastatin	2.6	HTS	HMGCR inhibitor	HMGCR			CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	Preclinical	5
BRD-K94441233-001-17-1::2.5::HTS	0.470790550672	BRD-K94441233-001-17-1::2.5::HTS	BRD-K94441233-001-17-1	mevastatin	2.5	HTS	HMGCR inhibitor	HMGCR			CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	Preclinical	5
BRD-K94455792-001-01-8::2.5::HTS	-0.472775250481	BRD-K94455792-001-01-8::2.5::HTS	BRD-K94455792-001-01-8	ICG-001	2.5	HTS	beta-catenin inhibitor	CTNNB1			Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1	Preclinical	5
BRD-K94485812-001-02-9::2.55::HTS	0.9085908846340001	BRD-K94485812-001-02-9::2.55::HTS	BRD-K94485812-001-02-9	LDN-57444	2.55	HTS	ubiquitin C-terminal hydrolase inhibitor				CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12	Preclinical	5
BRD-K94534639-001-02-5::2.5::HTS	-0.133802408126	BRD-K94534639-001-02-5::2.5::HTS	BRD-K94534639-001-02-5	LY2811376	2.5	HTS	beta-secretase inhibitor	BACE1			C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1	Phase 1	5
BRD-K94559059-091-01-6::2.5::HTS	0.06782346389140001	BRD-K94559059-091-01-6::2.5::HTS	BRD-K94559059-091-01-6	telotristat-ethyl	2.5	HTS	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1	Launched	5
BRD-K94649603-001-10-6::2.5::HTS	0.106755502753	BRD-K94649603-001-10-6::2.5::HTS	BRD-K94649603-001-10-6	taxifolin	2.5	HTS	opioid receptor antagonist	ADIPOR2			O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1	Phase 2	5
BRD-K94689771-001-09-0::1.95::HTS	0.00861478414209	BRD-K94689771-001-09-0::1.95::HTS	BRD-K94689771-001-09-0	pinocembrin	1.95	HTS	cytochrome P450 inhibitor	CYP1B1			Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1	Phase 2	4
BRD-K94720315-001-10-4::2.5::HTS	0.6194772864720001	BRD-K94720315-001-10-4::2.5::HTS	BRD-K94720315-001-10-4	chromocarb	2.5	HTS	antispasmodic				OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1	Launched	5
BRD-K94723713-001-10-6::2.5::HTS	0.784764062503	BRD-K94723713-001-10-6::2.5::HTS	BRD-K94723713-001-10-6	rutaecarpine	2.5	HTS	cyclooxygenase inhibitor	PTGS2			O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12	Preclinical	5
BRD-K94780074-001-06-7::2.5::HTS	0.030092400704200002	BRD-K94780074-001-06-7::2.5::HTS	BRD-K94780074-001-06-7	S-Nitrosoglutathione	2.5	HTS	nitric oxide stimulant	PTPN1			N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O, N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O	Phase 1	5
BRD-K94830329-001-03-0::2.5::HTS	-0.205942640415	BRD-K94830329-001-03-0::2.5::HTS	BRD-K94830329-001-03-0	ataluren	2.5	HTS	CFTR channel agonist, dystrophin stimulant	DMD	genetics, pulmonary	duchenne muscular dystrophy (DMD), cystic fibrosis	OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F	Launched	5
BRD-K94832621-001-02-3::2.5::HTS	-0.144457280885	BRD-K94832621-001-02-3::2.5::HTS	BRD-K94832621-001-02-3	Y-134	2.5	HTS	estrogen receptor antagonist	ESR1, ESR2			CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1	Preclinical	5
BRD-K95015809-001-02-8::5::HTS	-0.589945977667	BRD-K95015809-001-02-8::5::HTS	BRD-K95015809-001-02-8	2-cyanopyrimidine	5.0	HTS	cathepsin inhibitor				N#Cc1ncccn1	Preclinical	5
BRD-K95053546-001-01-9::2.5::HTS	-1.6301704739700003	BRD-K95053546-001-01-9::2.5::HTS	BRD-K95053546-001-01-9	tempol	2.5	HTS	free radical scavenger				CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O	Phase 2	5
BRD-K95053546-001-02-7::2.5::HTS	0.00454945263321	BRD-K95053546-001-02-7::2.5::HTS	BRD-K95053546-001-02-7	tempol	2.5	HTS	free radical scavenger				CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O	Phase 2	5
BRD-K95053546-001-03-5::2.5::HTS	-0.144721125022	BRD-K95053546-001-03-5::2.5::HTS	BRD-K95053546-001-03-5	tempol	2.5	HTS	free radical scavenger				CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O	Phase 2	5
BRD-K95110148-003-01-5::2.5::HTS	0.07614837103	BRD-K95110148-003-01-5::2.5::HTS	BRD-K95110148-003-01-5	beta-funaltrexamine	2.5	HTS	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45	Preclinical	5
BRD-K95142244-001-01-5::2.5::HTS	-0.279065731461	BRD-K95142244-001-01-5::2.5::HTS	BRD-K95142244-001-01-5	talazoparib	2.5	HTS	PARP inhibitor	PARP2			Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1	Phase 3	5
BRD-K95161686-001-02-8::2.5::HTS	0.050869159994400004	BRD-K95161686-001-02-8::2.5::HTS	BRD-K95161686-001-02-8	octisalate	2.5	HTS			dermatology	sunscreen lotion	CCCC[C@@H](CC)COC(=O)c1ccccc1O	Launched	5
BRD-K95237249-001-26-5::2.5::HTS	-0.682288128427	BRD-K95237249-001-26-5::2.5::HTS	BRD-K95237249-001-26-5	probenecid	2.5	HTS	uricosuric blocker	PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1	nephrology, rheumatology	hyperuricemia, gout	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	Launched	5
BRD-K95260951-050-03-1::2.5::HTS	0.182448406489	BRD-K95260951-050-03-1::2.5::HTS	BRD-K95260951-050-03-1	asenapine	2.5	HTS	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, HRH1, HRH2, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder	CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21, CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21.CN1C[C@@H]2[C@@H](C1)c1cc(Cl)ccc1Oc1ccccc21, CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21	Launched	5
BRD-K95292280-001-01-3::2.5::HTS	0.17907868304000002	BRD-K95292280-001-01-3::2.5::HTS	BRD-K95292280-001-01-3	SB-657510	2.5	HTS	urotensin receptor antagonist	UTS2R			COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1	Preclinical	5
BRD-K95309561-001-24-7::2.5::HTS	-0.211892431356	BRD-K95309561-001-24-7::2.5::HTS	BRD-K95309561-001-24-7	dienestrol	2.5	HTS	estrogen receptor agonist	ESR1	endocrinology	menopause	C\C=C(c1ccc(O)cc1)\C(c1ccc(O)cc1)=C\C	Launched	5
BRD-K95412502-003-01-5::2.5::HTS	-0.267840926526	BRD-K95412502-003-01-5::2.5::HTS	BRD-K95412502-003-01-5	istaroxime	2.5	HTS	ATPase inhibitor	ATP1A1			C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O	Phase 2	5
BRD-K95435023-001-08-5::2.5::HTS	-2.93880327696	BRD-K95435023-001-08-5::2.5::HTS	BRD-K95435023-001-08-5	PHA-665752	2.5	HTS	c-Met inhibitor	MET			Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	Preclinical	5
BRD-K95435023-001-10-1::2.5::HTS	0.11801951156300002	BRD-K95435023-001-10-1::2.5::HTS	BRD-K95435023-001-10-1	PHA-665752	2.5	HTS	c-Met inhibitor	MET			Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	Preclinical	5
BRD-K95523387-001-09-6::2.5::HTS	0.329335397078	BRD-K95523387-001-09-6::2.5::HTS	BRD-K95523387-001-09-6	OLDA	2.5	HTS	TRPV agonist	GPR119			CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1	Preclinical	5
BRD-K95573441-001-01-2::2.5::HTS	-0.557568423505	BRD-K95573441-001-01-2::2.5::HTS	BRD-K95573441-001-01-2	PFK-015	2.5	HTS	phosphofructokinase inhibitor	PFKFB3			O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1	Phase 1	5
BRD-K95581532-001-01-5::2.5::HTS	-0.208095511866	BRD-K95581532-001-01-5::2.5::HTS	BRD-K95581532-001-01-5	RN-1734	2.5	HTS	TRPV antagonist	TRPV4			CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl	Preclinical	5
BRD-K95600043-001-01-5::2.5::HTS	-0.0730628680112	BRD-K95600043-001-01-5::2.5::HTS	BRD-K95600043-001-01-5	NPY-5RA972	2.5	HTS	neuropeptide receptor antagonist	NPY5R			CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12	Preclinical	5
BRD-K95609758-001-03-7::2.5::HTS	0.664232952863	BRD-K95609758-001-03-7::2.5::HTS	BRD-K95609758-001-03-7	BMS-191011	2.5	HTS	potassium channel activator	KCNMA1			Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F	Preclinical	5
BRD-K95739795-001-03-7::2.5::HTS	0.0772399321832	BRD-K95739795-001-03-7::2.5::HTS	BRD-K95739795-001-03-7	tetrabenazine	2.5	HTS	vesicular monoamine transporter inhibitor	DRD2, SLC18A1, SLC18A2	infectious disease, neurology/psychiatry	cholera, Huntington's disease	COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC	Launched	5
BRD-K95763993-001-19-3::2.5::HTS	-0.126676682012	BRD-K95763993-001-19-3::2.5::HTS	BRD-K95763993-001-19-3	trapidil	2.5	HTS	PDGFR tyrosine kinase receptor inhibitor	PDGFRA	cardiology	coronary artery disease (CAD)	CCN(CC)c1cc(C)nc2ncnn12	Launched	5
BRD-K95773607-004-03-8::2.5::HTS	-0.591405935156	BRD-K95773607-004-03-8::2.5::HTS	BRD-K95773607-004-03-8	darifenacin	2.5	HTS	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1	Launched	5
BRD-K95785345-300-14-8::2.5::HTS	-0.352713620066	BRD-K95785345-300-14-8::2.5::HTS	BRD-K95785345-300-14-8	thiamine	2.5	HTS	vitamin B	SLC19A2, SLC19A3, TPK1	metabolism	thiamine deficiency	Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N	Launched	5
BRD-K95785537-001-23-1::2.5::HTS	0.0914618551598	BRD-K95785537-001-23-1::2.5::HTS	BRD-K95785537-001-23-1	PP-2	2.5	HTS	src inhibitor	ABL1, LCK, LYN, RIPK2, SRC			CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12	Preclinical	5
BRD-K95828359-001-01-0::2.5::HTS	-0.042269005546	BRD-K95828359-001-01-0::2.5::HTS	BRD-K95828359-001-01-0	MK-3697	2.5	HTS	orexin receptor antagonist	HCRTR2			COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC	Phase 2	5
BRD-K95837862-300-01-7::2.5::HTS	-0.07975416608960001	BRD-K95837862-300-01-7::2.5::HTS	BRD-K95837862-300-01-7	JDTic	2.5	HTS	opioid receptor antagonist	OPRK1			CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1	Phase 1	5
BRD-K95851186-001-07-8::2.5::HTS	-0.551580617464	BRD-K95851186-001-07-8::2.5::HTS	BRD-K95851186-001-07-8	CGP-13501	2.5	HTS	GABA receptor modulator	GABBR1			CC(C)(Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)C=O	Preclinical	5
BRD-K95880107-001-02-4::2.5::HTS	-0.582063381277	BRD-K95880107-001-02-4::2.5::HTS	BRD-K95880107-001-02-4	PH-797804	2.5	HTS	p38 MAPK inhibitor	MAPK11, MAPK14			CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O	Phase 2	5
BRD-K95899059-003-02-8::2.5::HTS	0.131587789201	BRD-K95899059-003-02-8::2.5::HTS	BRD-K95899059-003-02-8	LY344864	2.5	HTS	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7			CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1	Preclinical	5
BRD-K95901403-001-04-5::2.5::HTS	-0.09355906123810001	BRD-K95901403-001-04-5::2.5::HTS	BRD-K95901403-001-04-5	XL-147	2.5	HTS	PI3K inhibitor	PIK3CA, PIK3CD, PIK3CG			Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1	Phase 2	5
BRD-K95921201-001-14-6::2.5::HTS	-0.299626835815	BRD-K95921201-001-14-6::2.5::HTS	BRD-K95921201-001-14-6	reserpine	2.5	HTS	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	cardiology	hypertension	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	Launched	5
BRD-K95926480-003-03-6::2.5::HTS	1.07396660491	BRD-K95926480-003-03-6::2.5::HTS	BRD-K95926480-003-03-6	SRT1720	2.5	HTS	SIRT activator	SIRT1			O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1	Preclinical	5
BRD-K95957366-001-02-6::2.5::HTS	0.378022831189	BRD-K95957366-001-02-6::2.5::HTS	BRD-K95957366-001-02-6	isaxonine	2.5	HTS	nerve growth factor agonist				CC(C)Nc1ncccn1	Withdrawn	5
BRD-K96006502-001-02-6::2.5::HTS	-0.22853352308699998	BRD-K96006502-001-02-6::2.5::HTS	BRD-K96006502-001-02-6	deflazacort	2.5	HTS	glucocorticoid receptor agonist	NR3C1	rheumatology	joint inflammation	CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C	Launched	5
BRD-K96029467-003-01-9::2.5::HTS	0.499178002694	BRD-K96029467-003-01-9::2.5::HTS	BRD-K96029467-003-01-9	alagebrium	2.5	HTS	glycosylation inhibitor				Cc1sc[n+](CC(=O)c2ccccc2)c1C	Phase 2/Phase 3	5
BRD-K96042922-001-09-8::2.5::HTS	0.345513573372	BRD-K96042922-001-09-8::2.5::HTS	BRD-K96042922-001-09-8	etanidazole	2.5	HTS	bacterial cell wall synthesis inhibitor				OCCNC(=O)Cn1ccnc1[N+]([O-])=O	Phase 3	5
BRD-K96055017-003-02-7::2.5::HTS	-0.331049639236	BRD-K96055017-003-02-7::2.5::HTS	BRD-K96055017-003-02-7	1-acetyl-4-methylpiperazine	2.5	HTS	acetylcholine receptor agonist				CN1CCN(CC1)C(C)=O	Preclinical	5
BRD-K96104201-001-01-5::2.5::HTS	-5.11774429635	BRD-K96104201-001-01-5::2.5::HTS	BRD-K96104201-001-01-5	azalomycin-b	2.5	HTS	bacterial 50S ribosomal subunit inhibitor				CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1	Preclinical	5
BRD-K96123349-236-02-8::2.5::HTS	-0.48438141849	BRD-K96123349-236-02-8::2.5::HTS	BRD-K96123349-236-02-8	brequinar	2.5	HTS	dihydroorotate dehydrogenase inhibitor	DHODH			Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F	Phase 2	5
BRD-K96137854-001-17-1::2.5::HTS	0.600085033855	BRD-K96137854-001-17-1::2.5::HTS	BRD-K96137854-001-17-1	enoxolone	2.5	HTS	gap junction modulator	HSD11B1	gastroenterology, otolaryngology	peptic ulcer disease (PUD), common cold	C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O, C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O	Launched	5
BRD-K96153583-001-05-1::2.52::HTS	0.206494052667	BRD-K96153583-001-05-1::2.52::HTS	BRD-K96153583-001-05-1	cidofovir	2.52	HTS	DNA polymerase inhibitor		infectious disease	acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis	Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1	Launched	5
BRD-K96159438-001-06-3::2.5::HTS	0.04915641151859999	BRD-K96159438-001-06-3::2.5::HTS	BRD-K96159438-001-06-3	adefovir-dipivoxil	2.5	HTS	DNA polymerase inhibitor		infectious disease	hepatitis B	CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C	Launched	5
BRD-K96188950-001-16-9::2.5::HTS	-0.0299447173373	BRD-K96188950-001-16-9::2.5::HTS	BRD-K96188950-001-16-9	caffeic-acid-phenethyl-ester	2.5	HTS	HIV integrase inhibitor	RELA			Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O	Preclinical	5
BRD-K96194081-001-10-2::2.5::HTS	0.123333247653	BRD-K96194081-001-10-2::2.5::HTS	BRD-K96194081-001-10-2	cepharanthine	2.5	HTS	NFkB pathway inhibitor				COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34	Phase 2	5
BRD-K96233303-001-01-9::2.5::HTS	-0.473442491492	BRD-K96233303-001-01-9::2.5::HTS	BRD-K96233303-001-01-9	TMS	2.5	HTS					COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1	Preclinical	5
BRD-K96253961-046-03-1::2.5::HTS	-1.0119427809200001	BRD-K96253961-046-03-1::2.5::HTS	BRD-K96253961-046-03-1	metaraminol	2.5	HTS	adrenergic receptor agonist	ADRA1A	cardiology	hypotension	C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1	Launched	5
BRD-K96259238-001-01-4::2.5::HTS	-3.40012962944	BRD-K96259238-001-01-4::2.5::HTS	BRD-K96259238-001-01-4	Y-320	2.5	HTS	interleukin inhibitor	IL17A			Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N	Preclinical	5
BRD-K96263742-001-14-8::2.5::HTS	0.0628102176461	BRD-K96263742-001-14-8::2.5::HTS	BRD-K96263742-001-14-8	GW-7647	2.5	HTS	PPAR receptor agonist	PPARA			CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O	Preclinical	5
BRD-K96299080-001-02-7::2.5::HTS	-0.216486050282	BRD-K96299080-001-02-7::2.5::HTS	BRD-K96299080-001-02-7	neohesperidin	2.5	HTS					COc1cc(O)cc(c1)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O1	Preclinical	5
BRD-K96319534-003-03-9::2.5::HTS	0.21059411669199998	BRD-K96319534-003-03-9::2.5::HTS	BRD-K96319534-003-03-9	phentermine	2.5	HTS	dopamine uptake inhibitor, serotonin reuptake inhibitor	MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	endocrinology	weight-loss aid	CC(C)(N)Cc1ccccc1	Launched	5
BRD-K96358241-001-01-9::0.94::HTS	-3.7219323385500003	BRD-K96358241-001-01-9::0.94::HTS	BRD-K96358241-001-01-9	harringtonine	0.94	HTS	protein synthesis inhibitor				COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC	Phase 3	4
BRD-K96391852-001-02-8::2.5::HTS	-0.257227314919	BRD-K96391852-001-02-8::2.5::HTS	BRD-K96391852-001-02-8	aloperine	2.5	HTS					C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1	Preclinical	5
BRD-K96424892-001-02-9::2.5::HTS	0.6830878041670001	BRD-K96424892-001-02-9::2.5::HTS	BRD-K96424892-001-02-9	chloramphenicol-palmitate	2.5	HTS	protein synthesis inhibitor		infectious disease, endocrinology	meningitis, fever, cholera	CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	Launched	5
BRD-K96436774-001-01-8::2.5::HTS	-0.30144946272	BRD-K96436774-001-01-8::2.5::HTS	BRD-K96436774-001-01-8	pelanserin	2.5	HTS	serotonin receptor antagonist	HTR2A			O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1	Phase 2	5
BRD-K96550715-001-02-6::2.5::HTS	-0.616634671166	BRD-K96550715-001-02-6::2.5::HTS	BRD-K96550715-001-02-6	linagliptin	2.5	HTS	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	Launched	5
BRD-K96615647-001-01-2::2.5::HTS	-0.837621326682	BRD-K96615647-001-01-2::2.5::HTS	BRD-K96615647-001-01-2	AV-608	2.5	HTS	tachykinin antagonist	TACR1			FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12	Phase 2	5
BRD-K96631475-001-02-4::2.43::HTS	-1.0596574105299998	BRD-K96631475-001-02-4::2.43::HTS	BRD-K96631475-001-02-4	10-deacetylbaccatin	2.43	HTS	antitumor agent				CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C	Preclinical	5
BRD-K96631475-001-04-0::2.5::HTS	0.282795495485	BRD-K96631475-001-04-0::2.5::HTS	BRD-K96631475-001-04-0	10-deacetylbaccatin	2.5	HTS	antitumor agent				CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C	Preclinical	5
BRD-K96671969-001-03-1::2.5::HTS	-1.34982634891	BRD-K96671969-001-03-1::2.5::HTS	BRD-K96671969-001-03-1	PA-824	2.5	HTS	nitric oxide donor	FASN			[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1	Phase 3	5
BRD-K96714749-001-01-0::2.5::HTS	-0.48872782841000006	BRD-K96714749-001-01-0::2.5::HTS	BRD-K96714749-001-01-0	isobutamben	2.5	HTS	local anesthetic				CC(C)COC(=O)c1ccc(N)cc1	Preclinical	5
BRD-K96720755-001-02-6::2.5::HTS	-0.282716188892	BRD-K96720755-001-02-6::2.5::HTS	BRD-K96720755-001-02-6	relcovaptan	2.5	HTS	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR			COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl	Phase 2	5
BRD-K96740444-001-02-1::2.5::HTS	0.0462312004754	BRD-K96740444-001-02-1::2.5::HTS	BRD-K96740444-001-02-1	itopride	2.5	HTS	dopamine receptor antagonist	CHRM3, DRD2	gastroenterology, neurology/psychiatry	dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia	COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	Launched	5
BRD-K96758128-001-01-8::2.5::HTS	-0.09134892120200001	BRD-K96758128-001-01-8::2.5::HTS	BRD-K96758128-001-01-8	WAY-213613	2.5	HTS	glutamate inhibitor	SLC1A2			N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O	Preclinical	5
BRD-K96786677-236-02-4::2.5::HTS	-0.819528822697	BRD-K96786677-236-02-4::2.5::HTS	BRD-K96786677-236-02-4	oxacillin	2.5	HTS	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	Launched	5
BRD-K96786677-323-02-0::2.58::HTS	-0.20342019547899998	BRD-K96786677-323-02-0::2.58::HTS	BRD-K96786677-323-02-0	oxacillin	2.58	HTS	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	Launched	5
BRD-K96799727-001-06-6::2.5::HTS	0.684962875642	BRD-K96799727-001-06-6::2.5::HTS	BRD-K96799727-001-06-6	pifithrin-mu	2.5	HTS	HSP inhibitor	HSPA1A, TP53			NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1	Preclinical	5
BRD-K96809896-300-02-3::2.5::HTS	0.554301808866	BRD-K96809896-300-02-3::2.5::HTS	BRD-K96809896-300-02-3	SKF-86002	2.5	HTS	p38 MAPK inhibitor	ALOX5, MAPK14			Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1	Preclinical	5
BRD-K96862998-001-15-5::2.5::HTS	-0.375217052614	BRD-K96862998-001-15-5::2.5::HTS	BRD-K96862998-001-15-5	pirfenidone	2.5	HTS	TGF beta receptor inhibitor	FURIN, TNF	pulmonary	idiopathic pulmonary fibrosis (IPF)	Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1	Launched	5
BRD-K96936751-001-01-4::2.5::HTS	-0.0603339510608	BRD-K96936751-001-01-4::2.5::HTS	BRD-K96936751-001-01-4	bretazenil	2.5	HTS	GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21	Phase 2	5
BRD-K97009491-238-03-8::2.58::HTS	0.032374832082599996	BRD-K97009491-238-03-8::2.58::HTS	BRD-K97009491-238-03-8	calcium-levofolinate	2.58	HTS					Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	Launched	5
BRD-K97010173-001-04-1::2.5::HTS	0.453234586575	BRD-K97010173-001-04-1::2.5::HTS	BRD-K97010173-001-04-1	deferasirox	2.5	HTS	chelating agent	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O	Launched	5
BRD-K97019106-005-02-9::2.5::HTS	-0.38612099450599996	BRD-K97019106-005-02-9::2.5::HTS	BRD-K97019106-005-02-9	4-acetyl-1,1-dimethylpiperazinium	2.5	HTS	acetylcholine receptor agonist				CC(=O)N1CC[N+](C)(C)CC1	Preclinical	5
BRD-K97025174-001-01-4::2.5::HTS	-0.23000565391	BRD-K97025174-001-01-4::2.5::HTS	BRD-K97025174-001-01-4	capadenoson	2.5	HTS	adenosine receptor agonist	ADORA1			Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N	Phase 2	5
BRD-K97028990-001-04-4::2.5::HTS	0.0714183964435	BRD-K97028990-001-04-4::2.5::HTS	BRD-K97028990-001-04-4	quinine-ethyl-carbonate	2.5	HTS			infectious disease	malaria	CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccc(OC)cc12	Launched	5
BRD-K97045029-001-02-7::2.5::HTS	-0.40697646826899997	BRD-K97045029-001-02-7::2.5::HTS	BRD-K97045029-001-02-7	pranlukast	2.5	HTS	leukotriene receptor antagonist	CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF	pulmonary	bronchospasm, asthma, bronchospasm, asthma	O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1	Launched	5
BRD-K97045029-001-04-3::2.5::HTS	-0.198121067489	BRD-K97045029-001-04-3::2.5::HTS	BRD-K97045029-001-04-3	pranlukast	2.5	HTS	leukotriene receptor antagonist	CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF	pulmonary	bronchospasm, asthma, bronchospasm, asthma	O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1	Launched	5
BRD-K97056771-001-13-1::2.5::HTS	0.301926053436	BRD-K97056771-001-13-1::2.5::HTS	BRD-K97056771-001-13-1	GNF-2	2.5	HTS	Bcr-Abl kinase inhibitor	ABL1, BCR			NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	Preclinical	5
BRD-K97061094-001-21-4::2.63::HTS	-0.0535371736367	BRD-K97061094-001-21-4::2.63::HTS	BRD-K97061094-001-21-4	azacyclonol	2.63	HTS	histamine receptor antagonist	HRH1			OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1	Preclinical	5
BRD-K97072811-001-11-4::2.5::HTS	-0.490593680018	BRD-K97072811-001-11-4::2.5::HTS	BRD-K97072811-001-11-4	TG-003	2.5	HTS	CLK inhibitor	CLK1, CLK4, DYRK1A, DYRK1B			CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O	Preclinical	5
BRD-K97101532-001-02-8::2.5::HTS	-0.72864983182	BRD-K97101532-001-02-8::2.5::HTS	BRD-K97101532-001-02-8	tezacaftor	2.5	HTS	CFTR channel agonist		pulmonary	cystic fibrosis	CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO	Launched	5
BRD-K97118047-001-03-8::2.5::HTS	-0.49294555632299997	BRD-K97118047-001-03-8::2.5::HTS	BRD-K97118047-001-03-8	4,5,6,7-tetrabromobenzotriazole	2.5	HTS	casein kinase inhibitor	AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			Brc1c(Br)c(Br)c2[nH]nnc2c1Br, Brc1c(Br)c(Br)c2[nH]nnc2c1Br	Preclinical	5
BRD-K97158071-001-18-1::2.5::HTS	-0.013189223948	BRD-K97158071-001-18-1::2.5::HTS	BRD-K97158071-001-18-1	droperidol	2.5	HTS	dopamine receptor antagonist	ADRA1A, DRD2, DRD3, DRD4, HTR2A	gastroenterology	nausea, vomiting	Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O	Launched	5
BRD-K97163964-001-03-3::2.5::HTS	-0.354197378346	BRD-K97163964-001-03-3::2.5::HTS	BRD-K97163964-001-03-3	L-Aspartic-Acid	2.5	HTS	metallic radical formation stimulant	ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13			N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O	Launched	5
BRD-K97181089-003-24-7::2.5::HTS	-0.0249628989821	BRD-K97181089-003-24-7::2.5::HTS	BRD-K97181089-003-24-7	amiloride	2.5	HTS	sodium channel blocker	AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2	cardiology	hypertension, congestive heart failure	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	Launched	5
BRD-K97181463-003-01-1::2.5::HTS	0.18513243785300001	BRD-K97181463-003-01-1::2.5::HTS	BRD-K97181463-003-01-1	benidipine	2.5	HTS	calcium channel blocker	CACNA1C, CACNA1G	cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1	Launched	5
BRD-K97197005-001-03-2::2.5::HTS	0.132643480456	BRD-K97197005-001-03-2::2.5::HTS	BRD-K97197005-001-03-2	gestodene	2.5	HTS	contraceptive agent		endocrinology	contraceptive	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C	Launched	5
BRD-K97233161-003-01-5::2.5::HTS	0.435307563107	BRD-K97233161-003-01-5::2.5::HTS	BRD-K97233161-003-01-5	ABT-491	2.5	HTS	platelet activating factor receptor antagonist	PTAFR			CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C	Phase 1	5
BRD-K97309399-001-09-4::2.5::HTS	0.13076557496400001	BRD-K97309399-001-09-4::2.5::HTS	BRD-K97309399-001-09-4	thiothixene	2.5	HTS	dopamine receptor antagonist	DRD1, DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C/CCN3CCN(C)CC3)c2c1	Launched	5
BRD-K97365803-001-02-1::2.5::HTS	0.289790602992	BRD-K97365803-001-02-1::2.5::HTS	BRD-K97365803-001-02-1	PI-828	2.5	HTS	PI3K inhibitor				Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1	Preclinical	5
BRD-K97399794-001-15-3::2.5::HTS	0.38059451002800004	BRD-K97399794-001-15-3::2.5::HTS	BRD-K97399794-001-15-3	quercetin	2.5	HTS	polar auxin transport inhibitor	ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1	neurology/psychiatry, allergy	fatigue, allergic rhinitis, drowsiness	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	Launched	5
BRD-K97417064-001-02-4::2.5::HTS	0.149920473875	BRD-K97417064-001-02-4::2.5::HTS	BRD-K97417064-001-02-4	acedapsone	2.5	HTS			infectious disease	leprosy	CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1	Launched	5
BRD-K97428065-001-01-2::2.5::HTS	0.0612677191883	BRD-K97428065-001-01-2::2.5::HTS	BRD-K97428065-001-01-2	netupitant	2.5	HTS	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1	Launched	5
BRD-K97440753-066-18-1::2.5::HTS	0.37120577726099996	BRD-K97440753-066-18-1::2.5::HTS	BRD-K97440753-066-18-1	dihydroergocristine	2.5	HTS	adrenergic receptor antagonist, prolactin inhibitor	ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7			CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	Launched	5
BRD-K97464279-001-03-5::2.5::HTS	0.265690240097	BRD-K97464279-001-03-5::2.5::HTS	BRD-K97464279-001-03-5	diaveridine	2.5	HTS	dihydrofolate reductase inhibitor				COc1ccc(Cc2cnc(N)nc2N)cc1OC	Launched	5
BRD-K97472745-001-01-8::2.5::HTS	0.130255549753	BRD-K97472745-001-01-8::2.5::HTS	BRD-K97472745-001-01-8	gestrinone	2.5	HTS	progesterone receptor antagonist	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C	Launched	5
BRD-K97521363-001-16-1::2.5::HTS	-0.0749457577803	BRD-K97521363-001-16-1::2.5::HTS	BRD-K97521363-001-16-1	clorsulon	2.5	HTS	glycolysis inhibitor		infectious disease	gastrointestinal roundworms, lungworms, liver flukes, lice, mites	Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O	Launched	5
BRD-K97530723-001-20-9::2.5::HTS	0.339481222024	BRD-K97530723-001-20-9::2.5::HTS	BRD-K97530723-001-20-9	melatonin	2.5	HTS	melatonin receptor agonist, nitric oxide synthase inhibitor	ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB	neurology/psychiatry	sleep cycle support	COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1	Launched	5
BRD-K97564742-050-32-7::2.5::HTS	-0.06744788582330001	BRD-K97564742-050-32-7::2.5::HTS	BRD-K97564742-050-32-7	mepyramine	2.5	HTS	histamine receptor antagonist	HRH1	otolaryngology, obstetrics/gynecology	common cold, menstrual pain	COc1ccc(cc1)CN(CCN(C)C)c1ccccn1, COc1ccc(cc1)CN(CCN(C)C)c1ccccn1, COc1ccc(cc1)CN(CCN(C)C)c1ccccn1	Launched	5
BRD-K97643133-003-09-3::2.5::HTS	-0.182852671717	BRD-K97643133-003-09-3::2.5::HTS	BRD-K97643133-003-09-3	amiprilose	2.5	HTS	CD antagonist				CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO	Phase 3	5
BRD-K97714174-001-01-3::2.5::HTS	0.45103987577	BRD-K97714174-001-01-3::2.5::HTS	BRD-K97714174-001-01-3	P22077	2.5	HTS	ubiquitin specific protease inhibitor	USP7			CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O	Preclinical	5
BRD-K97746869-001-27-0::2.5::HTS	-1.38143603299	BRD-K97746869-001-27-0::2.5::HTS	BRD-K97746869-001-27-0	chlorpropamide	2.5	HTS	ATP channel blocker	ABCC8, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1	Launched	5
BRD-K97752965-001-16-4::2.5::HTS	0.0386910196019	BRD-K97752965-001-16-4::2.5::HTS	BRD-K97752965-001-16-4	nicorandil	2.5	HTS	nitric oxide donor, potassium channel activator	KCNJ11	cardiology	angina pectoris	[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1	Launched	5
BRD-K97764662-001-17-3::2.5::HTS	0.771030593503	BRD-K97764662-001-17-3::2.5::HTS	BRD-K97764662-001-17-3	PD-173074	2.5	HTS	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB			CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1	Preclinical	5
BRD-K97799481-001-16-0::2.5::HTS	-0.401835339332	BRD-K97799481-001-16-0::2.5::HTS	BRD-K97799481-001-16-0	theophylline	2.5	HTS	adenosine receptor antagonist		pulmonary	asthma, emphysema, bronchitis	Cn1c2nc[nH]c2c(=O)n(C)c1=O	Launched	5
BRD-K97799481-230-01-7::2.5::HTS	0.211028910634	BRD-K97799481-230-01-7::2.5::HTS	BRD-K97799481-230-01-7	aminophylline	2.5	HTS	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	asthma, bronchitis, emphysema	Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O	Launched	5
BRD-K97808269-001-02-7::2.5::HTS	0.0384737709133	BRD-K97808269-001-02-7::2.5::HTS	BRD-K97808269-001-02-7	2-deoxyglucose	2.5	HTS	glycolysis inhibitor	SLC2A1, SLC2A2, SLC2A3, SLC2A4			OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O	Phase 2	5
BRD-K97810537-001-12-8::2.54::HTS	-0.33715479077699995	BRD-K97810537-001-12-8::2.54::HTS	BRD-K97810537-001-12-8	beclomethasone-dipropionate	2.54	HTS	glucocorticoid receptor agonist	GPR97, NR3C1	allergy	allergic rhinitis	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C	Launched	5
BRD-K97810537-001-13-6::2.5::HTS	-0.569349659614	BRD-K97810537-001-13-6::2.5::HTS	BRD-K97810537-001-13-6	beclomethasone-dipropionate	2.5	HTS	glucocorticoid receptor agonist	GPR97, NR3C1	allergy	allergic rhinitis	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C	Launched	5
BRD-K97883416-001-01-4::2.5::HTS	-0.103906259891	BRD-K97883416-001-01-4::2.5::HTS	BRD-K97883416-001-01-4	BMS-626529	2.5	HTS	HIV attachment inhibitor				COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	Phase 3	5
BRD-K97884852-001-05-4::2.5::HTS	0.0357460411737	BRD-K97884852-001-05-4::2.5::HTS	BRD-K97884852-001-05-4	malotilate	2.5	HTS	protein synthesis stimulant		gastroenterology	hepatic cirrhosis	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1	Launched	5
BRD-K97963946-001-01-3::2.5::HTS	-0.18328568877700002	BRD-K97963946-001-01-3::2.5::HTS	BRD-K97963946-001-01-3	EMD-1214063	2.5	HTS	hepatocyte growth factor receptor inhibitor	MET			CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1	Phase 1	5
BRD-K98004573-051-02-8::2.5::HTS	0.061791918897799995	BRD-K98004573-051-02-8::2.5::HTS	BRD-K98004573-051-02-8	rupatadine	2.5	HTS	histamine receptor antagonist, platelet activating factor receptor antagonist	HRH1, PTAFR	allergy	allergic rhinitis, urticaria	Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1	Launched	5
BRD-K98143539-001-02-2::2.5::HTS	-0.153829609671	BRD-K98143539-001-02-2::2.5::HTS	BRD-K98143539-001-02-2	compound-w	2.5	HTS	beta-secretase inhibitor	BACE1			OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1	Preclinical	5
BRD-K98155362-001-07-7::2.5::HTS	-0.015496636526799999	BRD-K98155362-001-07-7::2.5::HTS	BRD-K98155362-001-07-7	GR46611	2.5	HTS	serotonin receptor agonist	HTR1D			COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1	Preclinical	5
BRD-K98157055-001-10-9::2.5::HTS	-1.28448282464	BRD-K98157055-001-10-9::2.5::HTS	BRD-K98157055-001-10-9	SIB-1757	2.5	HTS	glutamate receptor antagonist	GRM5			Cc1ccc(O)c(N=Nc2ccccc2)n1	Preclinical	5
BRD-K98174813-001-18-0::2.5::HTS	0.37761950981299996	BRD-K98174813-001-18-0::2.5::HTS	BRD-K98174813-001-18-0	chlorzoxazone	2.5	HTS	bacterial 30S ribosomal subunit inhibitor	KCNMA1, KCNN4	neurology/psychiatry	muscle relaxant	Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1	Launched	5
BRD-K98203492-003-04-1::2.5::HTS	0.317118576409	BRD-K98203492-003-04-1::2.5::HTS	BRD-K98203492-003-04-1	GSK-J4	2.5	HTS	histone lysine demethylase inhibitor	KDM6A, KDM6B			CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	Preclinical	5
BRD-K98251413-001-04-0::2.5::HTS	0.300527768448	BRD-K98251413-001-04-0::2.5::HTS	BRD-K98251413-001-04-0	IOX2	2.5	HTS	hypoxia inducible factor inhibitor	EGLN1, KDM2A, KDM5C			OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O	Preclinical	5
BRD-K98357249-001-02-9::2.5::HTS	0.44979734791299997	BRD-K98357249-001-02-9::2.5::HTS	BRD-K98357249-001-02-9	IRL-2500	2.5	HTS	endothelin receptor antagonist	EDNRB			CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1	Preclinical	5
BRD-K98372770-001-08-2::2.5::HTS	0.369507970926	BRD-K98372770-001-08-2::2.5::HTS	BRD-K98372770-001-08-2	L-165041	2.5	HTS	PPAR receptor agonist	PPARD			CCCc1c(OCCCOc2ccc(OCC(O)=O)cc2)ccc(C(C)=O)c1O, CCCc1c(OCCCOc2ccc(OCC(O)=O)cc2)ccc(C(C)=O)c1O	Preclinical	5
BRD-K98384930-003-01-5::2.5::HTS	-0.379371279886	BRD-K98384930-003-01-5::2.5::HTS	BRD-K98384930-003-01-5	finafloxacin	2.5	HTS	bacterial DNA gyrase inhibitor		infectious disease, pulmonary	intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis	OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O	Launched	5
BRD-K98453471-001-01-7::2.5::HTS	0.197588055242	BRD-K98453471-001-01-7::2.5::HTS	BRD-K98453471-001-01-7	salirasib	2.5	HTS	mTOR inhibitor	TRPA1			CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O	Phase 2	5
BRD-K98493452-001-14-9::2.5::HTS	-0.340270312924	BRD-K98493452-001-14-9::2.5::HTS	BRD-K98493452-001-14-9	honokiol	2.5	HTS	AKT inhibitor	ALOX5, PTGS1, PTGS2			Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O	Phase 3	5
BRD-K98521173-001-19-4::2.5::HTS	-0.7535365388099999	BRD-K98521173-001-19-4::2.5::HTS	BRD-K98521173-001-19-4	desoxycortone	2.5	HTS	mineralocorticoid receptor agonist	NR3C1, NR3C2			C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO	Preclinical	5
BRD-K98530306-003-18-3::2.5::HTS	0.188791816488	BRD-K98530306-003-18-3::2.5::HTS	BRD-K98530306-003-18-3	clonidine	2.5	HTS	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, neurology/psychiatry	hypertension, attention-deficit/hyperactivity disorder (ADHD)	Clc1cccc(Cl)c1N=C1NCCN1, Clc1cccc(Cl)c1N=C1NCCN1, Clc1cccc(Cl)c1N=C1NCCN1	Launched	5
BRD-K98548675-001-05-9::2.5::HTS	0.657344931087	BRD-K98548675-001-05-9::2.5::HTS	BRD-K98548675-001-05-9	parthenolide	2.5	HTS	NFkB pathway inhibitor				C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	Phase 1	5
BRD-K98572433-001-02-9::2.5::HTS	0.273649038899	BRD-K98572433-001-02-9::2.5::HTS	BRD-K98572433-001-02-9	AZD8931	2.5	HTS	EGFR inhibitor	EGFR, ERBB2, ERBB3			CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC	Phase 2	5
BRD-K98624455-074-02-8::2.5::HTS	0.700454102941	BRD-K98624455-074-02-8::2.5::HTS	BRD-K98624455-074-02-8	bepotastine	2.5	HTS	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1	Launched	5
BRD-K98684188-001-02-9::2.5::HTS	-0.47104471441000006	BRD-K98684188-001-02-9::2.5::HTS	BRD-K98684188-001-02-9	GSK-0660	2.5	HTS	PPAR receptor antagonist	PPARD			COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC	Preclinical	5
BRD-K98763141-001-30-8::2.5::HTS	-0.104497595111	BRD-K98763141-001-30-8::2.5::HTS	BRD-K98763141-001-30-8	niflumic-acid	2.5	HTS	cyclooxygenase inhibitor	ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9	rheumatology, neurology/psychiatry	joint pain, muscle pain	OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F	Launched	5
BRD-K98769987-001-23-7::2.5::HTS	0.42152117044299997	BRD-K98769987-001-23-7::2.5::HTS	BRD-K98769987-001-23-7	flumazenil	2.5	HTS	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	sedative	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	Launched	5
BRD-K98795921-001-01-7::2.5::HTS	-3.27708351565	BRD-K98795921-001-01-7::2.5::HTS	BRD-K98795921-001-01-7	SB-2343	2.5	HTS	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1	Phase 1	5
BRD-K98963219-001-01-2::2.5::HTS	0.198707524965	BRD-K98963219-001-01-2::2.5::HTS	BRD-K98963219-001-01-2	ezatiostat	2.5	HTS	glutathione transferase inhibitor	GSTP1			CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1	Phase 2	5
BRD-K99023089-001-03-7::2.5::HTS	0.558645794819	BRD-K99023089-001-03-7::2.5::HTS	BRD-K99023089-001-03-7	AZD5363	2.5	HTS	AKT inhibitor	AKT1, AKT2, AKT3			NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1	Phase 2	5
BRD-K99048103-001-18-4::2.5::HTS	-0.34364722275	BRD-K99048103-001-18-4::2.5::HTS	BRD-K99048103-001-18-4	acetarsol	2.5	HTS			gastroenterology	diarrhea	CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O	Launched	5
BRD-K99063460-001-13-1::2.5::HTS	-0.567596372024	BRD-K99063460-001-13-1::2.5::HTS	BRD-K99063460-001-13-1	didanosine	2.5	HTS	nucleoside reverse transcriptase inhibitor	PNP	infectious disease	human immunodeficiency virus (HIV-1)	OC[C@@H]1CC[C@@H](O1)n1cnc2c(O)ncnc12, OC[C@@H]1CC[C@@H](O1)n1cnc2c(O)ncnc12	Launched	5
BRD-K99092662-001-01-1::2.5::HTS	0.243037084357	BRD-K99092662-001-01-1::2.5::HTS	BRD-K99092662-001-01-1	PS178990	2.5	HTS	androgen receptor modulator	AR			Cc1c(ccc(C#N)c1Cl)N1C(=O)[C@@H]2[C@H](O)CCN2C1=O	Phase 1	5
BRD-K99107520-001-24-1::2.5::HTS	0.21237655648499998	BRD-K99107520-001-24-1::2.5::HTS	BRD-K99107520-001-24-1	felbamate	2.5	HTS	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1	Launched	5
BRD-K99113996-001-02-0::2.5::HTS	-1.9077155229299998	BRD-K99113996-001-02-0::2.5::HTS	BRD-K99113996-001-02-0	AZD2014	2.5	HTS	mTOR inhibitor	MTOR			CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	Phase 2	5
BRD-K99121711-003-19-7::2.5::HTS	0.115234860216	BRD-K99121711-003-19-7::2.5::HTS	BRD-K99121711-003-19-7	cinchocaine	2.5	HTS	sodium channel blocker	CALM1, SCN10A, SCN5A	neurology/psychiatry	local anesthetic	CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1	Launched	5
BRD-K99149715-001-01-6::2.5::HTS	0.11053342358200001	BRD-K99149715-001-01-6::2.5::HTS	BRD-K99149715-001-01-6	plurisin-#1	2.5	HTS	stearoyl-CoA desaturase inhibitor	SCD			O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1	Preclinical	5
BRD-K99170882-001-04-3::2.5::HTS	-1.55890999589	BRD-K99170882-001-04-3::2.5::HTS	BRD-K99170882-001-04-3	NSC-319726	2.5	HTS	p53 activator				C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1	Preclinical	5
BRD-K99174507-003-02-0::2.5::HTS	0.0831698830177	BRD-K99174507-003-02-0::2.5::HTS	BRD-K99174507-003-02-0	cardiogenol-c	2.5	HTS	cardiomyogenesis inducer				COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1	Preclinical	5
BRD-K99241550-001-03-5::2.5::HTS	0.165382002005	BRD-K99241550-001-03-5::2.5::HTS	BRD-K99241550-001-03-5	metrizoic-acid	2.5	HTS	radiopaque medium		radiology	contrast agent	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Launched	5
BRD-K99300445-003-21-6::2.5::HTS	-0.171631689348	BRD-K99300445-003-21-6::2.5::HTS	BRD-K99300445-003-21-6	antazoline	2.5	HTS	antihistamine	HRH1	ophthalmology, otolaryngology	conjunctivitis, nasal congestion	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1	Launched	5
BRD-K99308954-304-02-4::2.5::HTS	0.006959747523949999	BRD-K99308954-304-02-4::2.5::HTS	BRD-K99308954-304-02-4	sodium-monofluorophosphate	2.5	HTS		PYGM	dental	cavities	OP(O)(F)=O, OP(O)(F)=O, OP(O)(F)=O	Launched	5
BRD-K99383816-001-02-7::2.5::HTS	0.36860555509900006	BRD-K99383816-001-02-7::2.5::HTS	BRD-K99383816-001-02-7	ftorafur	2.5	HTS	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	Launched	5
BRD-K99383816-001-03-5::2.5::HTS	-0.142864421574	BRD-K99383816-001-03-5::2.5::HTS	BRD-K99383816-001-03-5	ftorafur	2.5	HTS	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	Launched	5
BRD-K99451608-001-07-3::2.5::HTS	0.21850035790999997	BRD-K99451608-001-07-3::2.5::HTS	BRD-K99451608-001-07-3	lopinavir	2.5	HTS	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1	Launched	5
BRD-K99475619-001-01-2::2.5::HTS	-5.54738101226	BRD-K99475619-001-01-2::2.5::HTS	BRD-K99475619-001-01-2	genz-644282	2.5	HTS	topoisomerase inhibitor	TOP1			CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O	Phase 1	5
BRD-K99498722-001-02-6::2.5::HTS	-0.892888432897	BRD-K99498722-001-02-6::2.5::HTS	BRD-K99498722-001-02-6	plinabulin	2.5	HTS	tubulin polymerization inhibitor				CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O	Phase 3	5
BRD-K99504665-001-01-2::2.5::HTS	0.0101282592491	BRD-K99504665-001-01-2::2.5::HTS	BRD-K99504665-001-01-2	goserelin-acetate	2.5	HTS	gonadotropin releasing factor hormone receptor agonist	GNRHR, LHCGR	oncology, obstetrics/gynecology	prostate cancer, breast cancer, endometriosis	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	Launched	5
BRD-K99545815-001-06-3::2.5::HTS	-0.780301132937	BRD-K99545815-001-06-3::2.5::HTS	BRD-K99545815-001-06-3	PF-562271	2.5	HTS	focal adhesion kinase inhibitor	PTK2, PTK2B			CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	Phase 1	5
BRD-K99604664-001-01-1::2.5::HTS	-0.150063916777	BRD-K99604664-001-01-1::2.5::HTS	BRD-K99604664-001-01-1	tanaproget	2.5	HTS	progesterone receptor agonist	PGR			Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N	Phase 2	5
BRD-K99615199-001-18-5::2.5::HTS	0.298500273288	BRD-K99615199-001-18-5::2.5::HTS	BRD-K99615199-001-18-5	medroxyprogesterone	2.5	HTS	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12	Launched	5
BRD-K99621550-300-01-8::2.5::HTS	0.096971240424	BRD-K99621550-300-01-8::2.5::HTS	BRD-K99621550-300-01-8	tubocurarine	2.5	HTS	acetylcholine receptor antagonist	ACHE, CHRNA2, HTR3A, HTR3B, KCNN1, KCNN2, KCNN3, ZACN	neurology/psychiatry	anesthetic	COc1cc2CCN(C)[C@H]3Cc4ccc(Oc5c(O)c(OC)cc6CC[N+](C)(C)[C@H](Cc7ccc(O)c(Oc1cc23)c7)c56)cc4	Launched	5
BRD-K99622919-001-23-0::2.5::HTS	-0.6051686957069999	BRD-K99622919-001-23-0::2.5::HTS	BRD-K99622919-001-23-0	butacaine	2.5	HTS	local anesthetic		neurology/psychiatry	local anesthetic	CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1	Launched	5
BRD-K99741577-001-01-7::2.5::HTS	0.14018600626299998	BRD-K99741577-001-01-7::2.5::HTS	BRD-K99741577-001-01-7	SANT-1	2.5	HTS	smoothened receptor antagonist	SHH, SMO			Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	Preclinical	5
BRD-K99749624-001-07-0::2.5::HTS	-0.0566959626135	BRD-K99749624-001-07-0::2.5::HTS	BRD-K99749624-001-07-0	linifanib	2.5	HTS	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK			Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1	Phase 3	5
BRD-K99792991-001-34-9::2.5::HTS	0.770078917497	BRD-K99792991-001-34-9::2.5::HTS	BRD-K99792991-001-34-9	hexachlorophene	2.5	HTS	potassium channel activator	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl	Launched	5
BRD-K99922388-001-02-0::2.5::HTS	0.0634164898909	BRD-K99922388-001-02-0::2.5::HTS	BRD-K99922388-001-02-0	DPO-1	2.5	HTS	potassium channel blocker	KCNA5			CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1	Preclinical	5
BRD-K99946902-001-07-5::2.5::HTS	0.244132624758	BRD-K99946902-001-07-5::2.5::HTS	BRD-K99946902-001-07-5	hexylresorcinol	2.5	HTS	local anesthetic	TYR	infectious disease	skin infections, first-aid antiseptic	CCCCCCc1ccc(O)cc1O	Launched	5
BRD-K99964838-001-11-9::2.5::HTS	-0.16171559147	BRD-K99964838-001-11-9::2.5::HTS	BRD-K99964838-001-11-9	bosutinib	2.5	HTS	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl	Launched	5
BRD-K99984802-100-13-5::2.5::HTS	0.07977163689830001	BRD-K99984802-100-13-5::2.5::HTS	BRD-K99984802-100-13-5	flunixin-meglumin	2.5	HTS	prostanoid receptor antagonist				Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F	Launched	5
BRD-M02075109-001-01-1::2.5::HTS	-0.6388406564519999	BRD-M02075109-001-01-1::2.5::HTS	BRD-M02075109-001-01-1	chromanol-(+/-)	2.5	HTS	potassium channel blocker				CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Preclinical	5
BRD-M02179497-001-01-1::2.5::HTS	0.08968231536879999	BRD-M02179497-001-01-1::2.5::HTS	BRD-M02179497-001-01-1	bismuth-oxalate	2.5	HTS					[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O	Preclinical	5
BRD-M08274809-001-01-7::2.5::HTS	0.369840299484	BRD-M08274809-001-01-7::2.5::HTS	BRD-M08274809-001-01-7	indium(iii)-isopropoxide	2.5	HTS					[In].CC(C)O.CC(C)O.CC(C)O	Preclinical	5
BRD-M17926088-001-01-3::2.5::HTS	-0.15423964352800001	BRD-M17926088-001-01-3::2.5::HTS	BRD-M17926088-001-01-3	FPA-124	2.5	HTS	AKT inhibitor				Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O, Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O	Preclinical	5
BRD-M29182745-001-01-4::2.5::HTS	0.19353000061	BRD-M29182745-001-01-4::2.5::HTS	BRD-M29182745-001-01-4	ammonium-lactate	2.5	HTS		HCAR1	dermatology	xerosis cutis, ichthyosis vulgaris	N.CC(O)C(O)=O	Launched	5
BRD-M29936662-001-02-0::2.5::HTS	-0.188095608224	BRD-M29936662-001-02-0::2.5::HTS	BRD-M29936662-001-02-0	cis-ACPD	2.5	HTS	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM7, GRM8			N[C@]1(CC[C@@H](C1)C(O)=O)C(O)=O.N[C@@]1(CC[C@H](C1)C(O)=O)C(O)=O	Preclinical	5
BRD-M30288325-001-01-4::2.5::HTS	0.272638156066	BRD-M30288325-001-01-4::2.5::HTS	BRD-M30288325-001-01-4	G-15	2.5	HTS	estrogen receptor antagonist	GPER1			Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12.Brc1cc2OCOc2cc1[C@@H]1Nc2ccccc2[C@@H]2C=CC[C@H]12	Preclinical	5
BRD-M39350793-334-01-1::2.5::HTS	0.558659691126	BRD-M39350793-334-01-1::2.5::HTS	BRD-M39350793-334-01-1	reboxetine	2.5	HTS	adrenergic receptor antagonist	SLC6A2	neurology/psychiatry	depression	CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1.CCOc1ccccc1O[C@H]([C@@H]1CNCCO1)c1ccccc1, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1, CCOc1ccccc1OC(C1CNCCO1)c1ccccc1, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1.CCOc1ccccc1O[C@H]([C@@H]1CNCCO1)c1ccccc1	Launched	5
BRD-M41245765-001-04-2::2.5::HTS	0.068822961373	BRD-M41245765-001-04-2::2.5::HTS	BRD-M41245765-001-04-2	lithium-citrate	2.5	HTS			neurology/psychiatry	bipolar disorder, depression	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	Launched	5
BRD-M54096567-001-01-9::2.5::HTS	0.08361396870839999	BRD-M54096567-001-01-9::2.5::HTS	BRD-M54096567-001-01-9	sodium-gluconate	2.5	HTS					OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O, [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O, [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O	Launched	5
BRD-M56276249-001-01-1::2.5::HTS	0.006618388239	BRD-M56276249-001-01-1::2.5::HTS	BRD-M56276249-001-01-1	bismuth(iii)-trifluoromethanesulfonate	2.5	HTS	direct substitution catalyst				[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F	Preclinical	5
BRD-M77041484-001-01-8::2.5::HTS	-0.425183274756	BRD-M77041484-001-01-8::2.5::HTS	BRD-M77041484-001-01-8	TBOA-(DL)	2.5	HTS	excitatory amino acid transporter inhibitor	SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7			N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O	Preclinical	5
BRD-M80207679-001-01-5::2.5::HTS	-0.330136571047	BRD-M80207679-001-01-5::2.5::HTS	BRD-M80207679-001-01-5	nemonapride	2.5	HTS	dopamine receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C	Launched	5
BRD-M89827113-001-01-5::2.5::HTS	-1.0678019657	BRD-M89827113-001-01-5::2.5::HTS	BRD-M89827113-001-01-5	cromakalim	2.5	HTS		KCNJ8			CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N	Phase 2	5
BRD-M92352362-002-02-3::2.5::HTS	-0.18819430976799997	BRD-M92352362-002-02-3::2.5::HTS	BRD-M92352362-002-02-3	talc	2.5	HTS					O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O, O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O	Launched	5
BRD-M92675308-003-07-1::2.5::HTS	0.323508212801	BRD-M92675308-003-07-1::2.5::HTS	BRD-M92675308-003-07-1	efonidipine-monoethanolate	2.5	HTS	L-type calcium channel blocker, T-type calcium channel blocker	CACNA1C, CACNA1G			CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1	Launched	5
BRD-M97302542-001-03-6::2.5::HTS	-0.45983104173699996	BRD-M97302542-001-03-6::2.5::HTS	BRD-M97302542-001-03-6	dichloroacetate	2.5	HTS	pyruvate dehydrogenase kinase inhibitor	PDK1			[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl	Phase 3	5
BRD-M98279124-300-01-1::2.5::HTS	-0.48084291960299996	BRD-M98279124-300-01-1::2.5::HTS	BRD-M98279124-300-01-1	cevimeline	2.5	HTS	acetylcholine receptor agonist	CHRM1, CHRM3	rheumatology	sjogren's syndrome	C[C@H]1O[C@]2(CS1)CN1CCC2CC1.C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1	Launched	5
BRD-U08520523-000-01-0::2.5::HTS	-0.679415265487	BRD-U08520523-000-01-0::2.5::HTS	BRD-U08520523-000-01-0	colesevalam	2.5	HTS						Preclinical	5
BRD-U25960968-000-01-9::2.5::HTS	-0.75059743374	BRD-U25960968-000-01-9::2.5::HTS	BRD-U25960968-000-01-9	tyloxapol	2.5	HTS	NFkB pathway inhibitor	LPL, NFKB2			C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1	Launched	5
BRD-U45393375-000-01-6::2.5::HTS	0.100954678567	BRD-U45393375-000-01-6::2.5::HTS	BRD-U45393375-000-01-6	sevelamer	2.5	HTS	phosphate antagonist		nephrology	chronic kidney disease (CKD)	, NCC=C.ClCC1CO1	Launched	5
BRD-U48018661-000-01-9::2.5::HTS	0.0826699048393	BRD-U48018661-000-01-9::2.5::HTS	BRD-U48018661-000-01-9	tyloxapol	2.5	HTS	NFkB pathway inhibitor	LPL, NFKB2			C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1	Launched	5
BRD-U51753822-000-01-1::2.5::HTS	0.124265554706	BRD-U51753822-000-01-1::2.5::HTS	BRD-U51753822-000-01-1	phosphatidylcholine	2.5	HTS		PCTP	infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology	hepatitis B, hepatitis C, eczema, gallbladder disease, cholesterol, premenstrual syndrome	, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC	Launched	5
BRD-A00055058-001-01-0::2.325889319::MTS004	0.160981756907	BRD-A00055058-001-01-0::2.325889319::MTS004	BRD-A00055058-001-01-0	RS-0481	2.325889319	MTS004	immunostimulant				CC(NC(=O)C1CSCN1C(=O)c1ccccc1)c1ccccc1	Phase 2	5
BRD-A00842753-001-01-9::2.5::MTS004	-0.402227188148	BRD-A00842753-001-01-9::2.5::MTS004	BRD-A00842753-001-01-9	oleuropein	2.5	MTS004	estrogen receptor agonist	GPER1			COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)\C(=C/C)C1CC(=O)OCCc1ccc(O)c(O)c1	Phase 2	5
BRD-A02232681-001-01-8::2.5::MTS004	-0.187666704764	BRD-A02232681-001-01-8::2.5::MTS004	BRD-A02232681-001-01-8	isoleucine	2.5	MTS004		ACADSB, BCAT1, BCAT2, IARS, IARS2			CCC(C)C(N)C(O)=O	Launched	5
BRD-A04447196-001-01-8::2.5::MTS004	0.195119522492	BRD-A04447196-001-01-8::2.5::MTS004	BRD-A04447196-001-01-8	gepefrine	2.5	MTS004	adrenergic receptor agonist		cardiology	hypotension	CC(N)Cc1cccc(O)c1	Launched	5
BRD-A04971881-003-01-3::2.65294603::MTS004	0.103841000597	BRD-A04971881-003-01-3::2.65294603::MTS004	BRD-A04971881-003-01-3	cloranolol	2.65294603	MTS004	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			CC(C)(C)NCC(O)COc1cc(Cl)ccc1Cl	Launched	5
BRD-A08316590-001-01-3::2.5::MTS004	-0.013309604894	BRD-A08316590-001-01-3::2.5::MTS004	BRD-A08316590-001-01-3	broxaterol	2.5	MTS004	adrenergic receptor agonist	ADRB2			CC(C)(C)NCC(O)c1cc(Br)no1	Phase 3	5
BRD-A08772153-001-02-4::2.500028879::MTS004	0.33315891559	BRD-A08772153-001-02-4::2.500028879::MTS004	BRD-A08772153-001-02-4	SQ-109	2.5000288790000003	MTS004	bacterial cell wall synthesis inhibitor	FDFT1			CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2, CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2	Phase 3	5
BRD-A09911125-001-01-4::2.5::MTS004	0.0703587342651	BRD-A09911125-001-01-4::2.5::MTS004	BRD-A09911125-001-01-4	prolylleucylglycinamide	2.5	MTS004	melanocyte-stimulating hormone release inhibitor				CC(C)CC(NC(=O)C1CCCN1)C(=O)NCC(N)=O	Phase 2	5
BRD-A10188456-001-04-9::2.5::MTS004	-0.29539995983600004	BRD-A10188456-001-04-9::2.5::MTS004	BRD-A10188456-001-04-9	dexamethasone	2.5	MTS004	glucocorticoid receptor agonist	ANXA1, NOS2, NR0B1, NR3C1, NR3C2	endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	Launched	5
BRD-A10773072-001-03-4::2.496712929::MTS004	0.13320968483200002	BRD-A10773072-001-03-4::2.496712929::MTS004	BRD-A10773072-001-03-4	glycerol-monolaurate	2.496712929	MTS004	beta lactamase inhibitor				CCCCCCCCCCCC(=O)OCC(O)CO	Launched	5
BRD-A13116749-003-01-6::2.713967431::MTS004	0.285290715789	BRD-A13116749-003-01-6::2.713967431::MTS004	BRD-A13116749-003-01-6	mabuterol	2.7139674310000004	MTS004	adrenergic receptor agonist	ADRB2			CC(C)(C)NCC(O)c1cc(Cl)c(N)c(c1)C(F)(F)F	Launched	5
BRD-A14577621-001-01-5::2.5::MTS004	0.174460320545	BRD-A14577621-001-01-5::2.5::MTS004	BRD-A14577621-001-01-5	peficitinib	2.5	MTS004	JAK inhibitor	JAK1, JAK2, JAK3			NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2, NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1C2C[C@@H]3C[C@H]1C[C@@](O)(C3)C2	Phase 3	5
BRD-A15687940-001-05-6::2.5::MTS004	0.0653852207751	BRD-A15687940-001-05-6::2.5::MTS004	BRD-A15687940-001-05-6	clofedanol	2.5	MTS004	histamine receptor antagonist	HRH1	pulmonary	cough suppressant	CN(C)CCC(O)(c1ccccc1)c1ccccc1Cl	Launched	5
BRD-A15739803-001-01-0::2.726366321::MTS004	0.07917282675250001	BRD-A15739803-001-01-0::2.726366321::MTS004	BRD-A15739803-001-01-0	polythiazide	2.7263663210000004	MTS004	sodium/chloride cotransporter inhibitor	SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension	CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O	Launched	5
BRD-A16263897-001-06-6::2.5::MTS004	0.13451808853299999	BRD-A16263897-001-06-6::2.5::MTS004	BRD-A16263897-001-06-6	misonidazole	2.5	MTS004					COCC(O)Cn1ccnc1[N+]([O-])=O	Phase 3	5
BRD-A17009129-001-01-3::2.499993124::MTS004	0.19285245166099999	BRD-A17009129-001-01-3::2.499993124::MTS004	BRD-A17009129-001-01-3	isavuconazole	2.499993124	MTS004	cytochrome P450 inhibitor	CYP3A4			C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)C(O)(Cn1cncn1)c1cc(F)ccc1F	Phase 3	5
BRD-A18992208-003-02-7::2.5::MTS004	-0.17797257396299998	BRD-A18992208-003-02-7::2.5::MTS004	BRD-A18992208-003-02-7	lercanidipine	2.5	MTS004	calcium channel blocker	CACNA2D1, CACNG1	cardiology	hypertension	COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1	Launched	5
BRD-A19053834-050-09-5::2.5::MTS004	0.22949177743299998	BRD-A19053834-050-09-5::2.5::MTS004	BRD-A19053834-050-09-5	clorotepine	2.5	MTS004	dopamine receptor antagonist, adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6	neurology/psychiatry	psychosis	CN1CCN(CC1)C1Cc2ccccc2Sc2ccc(Cl)cc12	Launched	5
BRD-A19777893-236-01-9::2.596350183::MTS004	0.036954375843300004	BRD-A19777893-236-01-9::2.596350183::MTS004	BRD-A19777893-236-01-9	menadione-bisulfite	2.596350183	MTS004	vitamin K	GGCX, VKORC1, VKORC1L1			CC1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O	Phase 2	5
BRD-A21280314-001-06-8::2.5::MTS004	0.142077729015	BRD-A21280314-001-06-8::2.5::MTS004	BRD-A21280314-001-06-8	nifenalol	2.5	MTS004	adrenergic receptor antagonist	ADRB1, ADRB2			CC(C)NCC(O)c1ccc(cc1)[N+]([O-])=O	Launched	5
BRD-A21446384-001-01-1::2.5::MTS004	-0.08968768564379999	BRD-A21446384-001-01-1::2.5::MTS004	BRD-A21446384-001-01-1	xibenolol	2.5	MTS004	adrenergic receptor antagonist				Cc1cccc(OCC(O)CNC(C)(C)C)c1C	Phase 3	5
BRD-A21474126-001-01-6::2.5::MTS004	0.0761105795374	BRD-A21474126-001-01-6::2.5::MTS004	BRD-A21474126-001-01-6	methoxyphenamine	2.5	MTS004	adrenergic receptor agonist		pulmonary	asthma	CNC(C)Cc1ccccc1OC	Launched	5
BRD-A21544762-303-01-5::2.5::MTS004	0.088941120539	BRD-A21544762-303-01-5::2.5::MTS004	BRD-A21544762-303-01-5	pipecuronium	2.5	MTS004	neuromuscular blocker	CHRM2, CHRM3, CHRNA2	neurology/psychiatry	anesthetic	CC(=O)OC1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1	Launched	5
BRD-A23124853-001-01-4::2.5::MTS004	-0.159348898347	BRD-A23124853-001-01-4::2.5::MTS004	BRD-A23124853-001-01-4	PF-06463922	2.5	MTS004	ALK tyrosine kinase receptor inhibitor	ALK, FES, ROS1			CC1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	Phase 2	5
BRD-A23418262-001-01-5::2.519094866::MTS004	0.09548796110430001	BRD-A23418262-001-01-5::2.519094866::MTS004	BRD-A23418262-001-01-5	floctafenine	2.519094866	MTS004	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	OCC(O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F	Launched	5
BRD-A24857382-001-03-4::2.488183422::MTS004	0.164602210351	BRD-A24857382-001-03-4::2.488183422::MTS004	BRD-A24857382-001-03-4	N-acetyl-tyrosine	2.488183422	MTS004					CC(=O)NC(Cc1ccc(O)cc1)C(O)=O	Launched	5
BRD-A25492003-003-14-1::2.568211596::MTS004	0.201419664116	BRD-A25492003-003-14-1::2.568211596::MTS004	BRD-A25492003-003-14-1	chlortetracycline	2.568211596	MTS004	protein synthesis inhibitor		ophthalmology	conjunctivitis	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	Launched	5
BRD-A27274504-001-01-6::2.400106631::MTS004	0.15046469681900002	BRD-A27274504-001-01-6::2.400106631::MTS004	BRD-A27274504-001-01-6	butofilolol	2.400106631	MTS004	adrenergic receptor antagonist				CCCC(=O)c1cc(F)ccc1OCC(O)CNC(C)(C)C	Phase 2	5
BRD-A30774155-001-01-2::2.499990706::MTS004	-0.0760432208553	BRD-A30774155-001-01-2::2.499990706::MTS004	BRD-A30774155-001-01-2	efinaconazole	2.4999907059999997	MTS004	lanosterol demethylase inhibitor	CYP51A1	infectious disease	onychomycosis	C[C@@H](N1CCC(=C)CC1)C(O)(Cn1cncn1)c1ccc(F)cc1F	Launched	5
BRD-A31362467-065-01-3::2.499984736::MTS004	-0.11061992972899999	BRD-A31362467-065-01-3::2.499984736::MTS004	BRD-A31362467-065-01-3	capreomycin	2.499984736	MTS004	protein synthesis inhibitor		infectious disease	tuberculosis	NCCCC(N)CC(=O)NCC1NC(=O)C(CO)NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC1=O)=C/NC(N)=O)C1CCNC(=N)N1, CC1NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC(=O)C(CNC(=O)CC(N)CCCN)NC1=O)=C/NC(N)=O)C1CCNC(=N)N1	Launched	5
BRD-A33352494-316-01-6::2.499995956::MTS004	-0.454535501642	BRD-A33352494-316-01-6::2.499995956::MTS004	BRD-A33352494-316-01-6	oritavancin	2.499995956	MTS004	bacterial cell wall synthesis inhibitor		infectious disease	skin infections	CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(OC5CC(C)(N)C(O)C(C)O5)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)C(O)C(C)O1)c(Cl)c2	Launched	5
BRD-A33479817-003-03-7::2.490825408::MTS004	0.0585719522277	BRD-A33479817-003-03-7::2.490825408::MTS004	BRD-A33479817-003-03-7	terodiline	2.490825408	MTS004	cholinergic receptor antagonist				CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C	Phase 3	5
BRD-A33894669-065-01-9::2.312630829::MTS004	-0.0410167755067	BRD-A33894669-065-01-9::2.312630829::MTS004	BRD-A33894669-065-01-9	hexoprenaline	2.312630829	MTS004	adrenergic receptor agonist	ADRB2	pulmonary	asthma	OC(CNCCCCCCNCC(O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1	Launched	5
BRD-A34603619-001-01-9::2.427905848::MTS004	0.0611773844728	BRD-A34603619-001-01-9::2.427905848::MTS004	BRD-A34603619-001-01-9	tropesin	2.427905848	MTS004	cyclooxygenase inhibitor	PTGS1, PTGS2			COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(C(O)=O)c3ccccc3)c2c1	Launched	5
BRD-A34788695-003-10-2::2.375699424::MTS004	0.46078174480899997	BRD-A34788695-003-10-2::2.375699424::MTS004	BRD-A34788695-003-10-2	tetracycline	2.375699424	MTS004	bacterial 30S ribosomal subunit inhibitor	PRNP	infectious disease, dermatology	respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis	CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	Launched	5
BRD-A35667010-001-01-8::2.5::MTS004	0.247237939323	BRD-A35667010-001-01-8::2.5::MTS004	BRD-A35667010-001-01-8	propylhexedrine	2.5	MTS004	adrenergic receptor agonist	SLC18A2, TAAR1	otolaryngology, endocrinology, allergy	nasal congestion, fever, allergic rhinitis	CNC(C)CC1CCCCC1	Launched	5
BRD-A38706605-001-01-2::2.5::MTS004	0.146103997809	BRD-A38706605-001-01-2::2.5::MTS004	BRD-A38706605-001-01-2	dromostanolone-propionate	2.5	MTS004	androgen receptor modulator	AR	oncology	breast cancer	CCC(=O)OC1CCC2C3CCC4CC(=O)C(C)CC4(C)C3CCC12C	Launched	5
BRD-A40302156-001-01-9::2.503151999::MTS004	0.299224962416	BRD-A40302156-001-01-9::2.503151999::MTS004	BRD-A40302156-001-01-9	A-33903	2.503151999	MTS004					CC(=O)NC1C(=O)Nc2ccccc2C(=N1)c1ccccc1	Phase 2	5
BRD-A40546373-001-01-8::2.500029443::MTS004	0.007095514597819999	BRD-A40546373-001-01-8::2.500029443::MTS004	BRD-A40546373-001-01-8	morinidazole	2.5000294430000003	MTS004	other antibiotic	CYP51A1			Cc1ncc(n1CC(O)CN1CCOCC1)[N+]([O-])=O	Launched	5
BRD-A41698174-003-12-0::2.499982171::MTS004	0.24713295444400002	BRD-A41698174-003-12-0::2.499982171::MTS004	BRD-A41698174-003-12-0	bacampicillin	2.499982171	MTS004	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O, CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O, CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O	Launched	5
BRD-A42423104-001-01-4::2.495664958::MTS004	-0.0320222186442	BRD-A42423104-001-01-4::2.495664958::MTS004	BRD-A42423104-001-01-4	benproperine	2.4956649580000003	MTS004	antitussive	SCN5A	pulmonary	cough suppressant	CC(COc1ccccc1Cc1ccccc1)N1CCCCC1	Launched	5
BRD-A42881122-001-01-1::2.648380541::MTS004	0.08675676317469999	BRD-A42881122-001-01-1::2.648380541::MTS004	BRD-A42881122-001-01-1	cyamemazine	2.648380541	MTS004	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C, HTR7	neurology/psychiatry	schizophrenia, anxiety	CC(CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N	Launched	5
BRD-A44181516-001-01-8::2.666476303::MTS004	0.16849137122699998	BRD-A44181516-001-01-8::2.666476303::MTS004	BRD-A44181516-001-01-8	flumecinol	2.666476303	MTS004					CCC(O)(c1ccccc1)c1cccc(c1)C(F)(F)F	Launched	5
BRD-A44188509-001-01-2::2.639346634::MTS004	0.47649109808799994	BRD-A44188509-001-01-2::2.639346634::MTS004	BRD-A44188509-001-01-2	AZD1446	2.6393466340000002	MTS004	acetylcholine receptor agonist	CHRNA4, CHRNB2			Clc1ccc(o1)C(=O)N1CC2CNCC2C1	Phase 2	5
BRD-A44511856-001-01-4::2.499987042::MTS004	-0.241201714945	BRD-A44511856-001-01-4::2.499987042::MTS004	BRD-A44511856-001-01-4	ginsenoside-rg3	2.499987042	MTS004	angiogenesis inhibitor, apoptosis stimulant	KCNH2			CC(C)=CCCC(C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	Launched	5
BRD-A44971162-001-02-7::2.5::MTS004	0.301748989396	BRD-A44971162-001-02-7::2.5::MTS004	BRD-A44971162-001-02-7	ODM-201	2.5	MTS004	androgen receptor antagonist	AR			C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc([nH]n1)C(C)O, C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc([nH]n1)C(C)O	Phase 3	5
BRD-A46335897-003-27-8::2.499949994::MTS004	-0.00719095681056	BRD-A46335897-003-27-8::2.499949994::MTS004	BRD-A46335897-003-27-8	promethazine	2.499949994	MTS004	histamine receptor antagonist	ADRA1A, CALM1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A	neurology/psychiatry, allergy	sedative, allergic rhinitis	CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C	Launched	5
BRD-A48376327-003-01-5::2.426818202::MTS004	0.187085931079	BRD-A48376327-003-01-5::2.426818202::MTS004	BRD-A48376327-003-01-5	igmesine	2.4268182019999998	MTS004	sigma receptor agonist	SIGMAR1			CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1	Phase 2	5
BRD-A48420483-001-02-3::2.5::MTS004	0.114556288577	BRD-A48420483-001-02-3::2.5::MTS004	BRD-A48420483-001-02-3	bupranolol	2.5	MTS004	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology, ophthalmology	hypertension, glaucoma	Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1, Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1	Launched	5
BRD-A48938994-001-14-1::2.5::MTS004	0.27187213804	BRD-A48938994-001-14-1::2.5::MTS004	BRD-A48938994-001-14-1	monoctanoin	2.5	MTS004			gastroenterology	gallstones	CCCCCCCC(=O)OCC(O)CO, CCCCCCCC(=O)OCC(O)CO	Launched	5
BRD-A50675490-001-01-0::2.412483069::MTS004	-0.17623285555399998	BRD-A50675490-001-01-0::2.412483069::MTS004	BRD-A50675490-001-01-0	carazolol	2.412483069	MTS004	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, cardiac arrythmia, hypertension, myocardial infarction	CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12	Launched	5
BRD-A53077924-001-01-2::2.499990763::MTS004	-0.33596064133599995	BRD-A53077924-001-01-2::2.499990763::MTS004	BRD-A53077924-001-01-2	tianeptine	2.499990763	MTS004	selective serotonin reuptake enhancer (SSRE)	OPRD1, OPRK1, OPRM1	neurology/psychiatry, pulmonary, gastroenterology	depression, asthma, irritable bowel syndrome	CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O	Launched	5
BRD-A55416093-001-06-4::2.5::MTS004	-0.0334085013364	BRD-A55416093-001-06-4::2.5::MTS004	BRD-A55416093-001-06-4	colforsin	2.5	MTS004	adenylyl cyclase activator	ADCY2, ADCY5			CC(=O)O[C@H]1[C@@H](O)C2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	Phase 2	5
BRD-A56241705-003-01-2::2.639158457::MTS004	-0.152063678435	BRD-A56241705-003-01-2::2.639158457::MTS004	BRD-A56241705-003-01-2	trimethoquinol	2.6391584569999997	MTS004	adrenergic receptor antagonist	ADRB2, ADRB3			COc1cc(CC2NCCc3cc(O)c(O)cc23)cc(OC)c1OC	Launched	5
BRD-A56613951-004-01-1::2.642522873::MTS004	-0.298355292697	BRD-A56613951-004-01-1::2.642522873::MTS004	BRD-A56613951-004-01-1	valethamate	2.6425228730000003	MTS004	acetylcholine receptor antagonist	CHRM1, CHRM4, CHRM5	obstetrics/gynecology	labor induction	CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1	Launched	5
BRD-A56892734-001-09-4::2.5::MTS004	0.7422584289899999	BRD-A56892734-001-09-4::2.5::MTS004	BRD-A56892734-001-09-4	omeprazole-magnesium	2.5	MTS004	proton pump inhibitor	ATP4A, ATP4B	gastroenterology	gastroesophageal reflux disease (GERD), heartburn	COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)S(=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)S(=O)Cc1ncc(C)c(OC)c1C	Launched	5
BRD-A58947127-001-01-6::2.5::MTS004	-0.086667364125	BRD-A58947127-001-01-6::2.5::MTS004	BRD-A58947127-001-01-6	AMG319	2.5	MTS004	PI3K inhibitor	PIK3CD			CC(Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1	Phase 2	5
BRD-A59378440-001-01-3::2.499948202::MTS004	0.153947323982	BRD-A59378440-001-01-3::2.499948202::MTS004	BRD-A59378440-001-01-3	butylphthalide	2.4999482019999997	MTS004	potassium channel antagonist	KCNK2	neurology/psychiatry	stroke	CCCCC1OC(=O)c2ccccc12	Launched	5
BRD-A59825838-326-01-4::2.499983757::MTS004	0.291991299599	BRD-A59825838-326-01-4::2.499983757::MTS004	BRD-A59825838-326-01-4	netilmicin	2.499983757	MTS004	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O, CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O, CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O, CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O	Launched	5
BRD-A59961917-001-01-0::2.5::MTS004	0.21213495879799998	BRD-A59961917-001-01-0::2.5::MTS004	BRD-A59961917-001-01-0	BQ-123	2.5	MTS004	endothelin receptor antagonist	EDNRA			CC(C)CC1NC(=O)C(NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O)C(C)C	Phase 2	5
BRD-A60498477-001-01-2::2.508127434::MTS004	0.10839207498600001	BRD-A60498477-001-01-2::2.508127434::MTS004	BRD-A60498477-001-01-2	tolamolol	2.508127434	MTS004	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Cc1ccccc1OCC(O)CNCCOc1ccc(cc1)C(N)=O	Phase 3	5
BRD-A61633223-001-02-8::2.678394161::MTS004	0.041233842392	BRD-A61633223-001-02-8::2.678394161::MTS004	BRD-A61633223-001-02-8	ulifloxacin	2.678394161	MTS004					CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1, CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1	Launched	5
BRD-A62197763-001-01-1::2.532450362::MTS004	0.14899273540400002	BRD-A62197763-001-01-1::2.532450362::MTS004	BRD-A62197763-001-01-1	enciprazine	2.532450362	MTS004	GABA receptor modulator	GABRA1			COc1ccccc1N1CCN(CC(O)COc2cc(OC)c(OC)c(OC)c2)CC1	Phase 3	5
BRD-A63431791-001-01-9::2.5::MTS004	-0.000620720754492	BRD-A63431791-001-01-9::2.5::MTS004	BRD-A63431791-001-01-9	sulbactam-pivoxil	2.5	MTS004	beta lactamase inhibitor		infectious disease	skin infections	CC(C)(C)C(=O)OCOC(=O)C1N2C(CC2=O)S(=O)(=O)C1(C)C	Launched	5
BRD-A64173453-015-02-3::2.500011906::MTS004	0.06457921929589999	BRD-A64173453-015-02-3::2.500011906::MTS004	BRD-A64173453-015-02-3	octreotide	2.500011906	MTS004	somatostatin receptor agonist	SSTR1, SSTR2, SSTR3, SSTR5	gastroenterology, endocrinology, oncology	diarrhea, acromegaly, carcinoid tumors	CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1, CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1, CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1	Launched	5
BRD-A65562236-001-01-2::2.499987842::MTS004	0.212775531308	BRD-A65562236-001-01-2::2.499987842::MTS004	BRD-A65562236-001-01-2	solamargine	2.499987842	MTS004	apoptosis inhibitor				CC1C2C(CC3C4CC=C5CC(CCC5(C)C4CCC23C)OC2OC(CO)C(OC3OC(C)C(O)C(O)C3O)C(O)C2OC2OC(C)C(O)C(O)C2O)OC11CCC(C)CN1	Phase 3	5
BRD-A65683612-001-07-7::2.499972087::MTS004	0.028842845381900004	BRD-A65683612-001-07-7::2.499972087::MTS004	BRD-A65683612-001-07-7	phenylpiracetam	2.4999720869999997	MTS004	noradrenaline uptake inhibitor		neurology/psychiatry	anxiety, fatigue, depression	NC(=O)CN1CC(CC1=O)c1ccccc1	Launched	5
BRD-A67182178-001-01-7::2.5::MTS004	0.134202298689	BRD-A67182178-001-01-7::2.5::MTS004	BRD-A67182178-001-01-7	toloxatone	2.5	MTS004	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	Cc1cccc(c1)N1CC(CO)OC1=O	Launched	5
BRD-A67305656-001-01-5::2.5::MTS004	0.129316735323	BRD-A67305656-001-01-5::2.5::MTS004	BRD-A67305656-001-01-5	spiramycin	2.5	MTS004	bacterial 50S ribosomal subunit inhibitor		infectious disease	toxoplasmosis, soft tissue infection	CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1OC1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C, CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1OC1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C, CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1OC1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C	Launched	5
BRD-A71765060-001-01-4::2.5::MTS004	-0.042037370857300006	BRD-A71765060-001-01-4::2.5::MTS004	BRD-A71765060-001-01-4	picartamide	2.5	MTS004	H+/K+-ATPase inhibitor	ATP4A			CNC(=S)C1(CCCS1)c1ccccn1	Phase 2	5
BRD-A72297358-001-01-8::2.5::MTS004	0.43391968296800004	BRD-A72297358-001-01-8::2.5::MTS004	BRD-A72297358-001-01-8	ozolinone	2.5	MTS004	diuretic				CN1C(=O)C(S\C1=C/C(O)=O)N1CCCCC1	Phase 3	5
BRD-A72351335-001-04-5::2.463310717::MTS004	0.23898246461199998	BRD-A72351335-001-04-5::2.463310717::MTS004	BRD-A72351335-001-04-5	misoprostol	2.4633107169999997	MTS004	prostanoid receptor agonist	PTGER2, PTGER3, PTGER4, PTGIR	gastroenterology	duodenal ulcer disease	CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	Launched	5
BRD-A72401848-001-02-2::2.551316459::MTS004	-0.268153415293	BRD-A72401848-001-02-2::2.551316459::MTS004	BRD-A72401848-001-02-2	gadoteridol	2.551316459	MTS004	radiopaque medium		radiology	MRI contrast agent	CC(O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3, CC(O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3	Launched	5
BRD-A72988804-001-11-1::2.5::MTS004	0.172830892264	BRD-A72988804-001-11-1::2.5::MTS004	BRD-A72988804-001-11-1	tiaprofenic-acid	2.5	MTS004	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis	CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1, CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1	Launched	5
BRD-A73385064-001-01-5::2.603473418::MTS004	-0.268966358645	BRD-A73385064-001-01-5::2.603473418::MTS004	BRD-A73385064-001-01-5	beclomethasone	2.603473418	MTS004	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(O)C(=O)CO	Launched	5
BRD-A73566563-001-01-6::2.5::MTS004	0.36457018729900004	BRD-A73566563-001-01-6::2.5::MTS004	BRD-A73566563-001-01-6	tiprenolol	2.5	MTS004	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			CSc1ccccc1OCC(O)CNC(C)C	Phase 2	5
BRD-A73679382-236-01-8::2.499981367::MTS004	0.39450308922	BRD-A73679382-236-01-8::2.499981367::MTS004	BRD-A73679382-236-01-8	MK-571	2.4999813669999997	MTS004	leukotriene receptor antagonist	ABCC2, CYSLTR1			CN(C)C(=O)CCSC(SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	Phase 2	5
BRD-A74975734-004-09-9::2.5::MTS004	0.09024813698239999	BRD-A74975734-004-09-9::2.5::MTS004	BRD-A74975734-004-09-9	homatropine	2.5	MTS004	acetylcholine receptor antagonist	CES1, CHRM1	ophthalmology	pupil dilation	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)c1ccccc1	Launched	5
BRD-A75224450-001-02-4::2.662563322::MTS004	0.0988501758151	BRD-A75224450-001-02-4::2.662563322::MTS004	BRD-A75224450-001-02-4	ibuprofen-piconol	2.662563322	MTS004	cyclooxygenase inhibitor	PTGS1, PTGS2			CC(C)Cc1ccc(cc1)C(C)C(=O)OCc1ccccn1, CC(C)Cc1ccc(cc1)C(C)C(=O)OCc1ccccn1	Launched	5
BRD-A75975749-001-01-4::2.5::MTS004	-0.17554374229000003	BRD-A75975749-001-01-4::2.5::MTS004	BRD-A75975749-001-01-4	bafetinib	2.5	MTS004	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	ABL1, BCR, LYN			CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1	Phase 2	5
BRD-A76533773-001-01-9::2.5::MTS004	-0.00898288704708	BRD-A76533773-001-01-9::2.5::MTS004	BRD-A76533773-001-01-9	lisadimate	2.5	MTS004	topical sunscreen agent		dermatology	sunscreen lotion	Nc1ccc(cc1)C(=O)OCC(O)CO	Launched	5
BRD-A78277353-001-01-9::2.492599937::MTS004	0.0648361336067	BRD-A78277353-001-01-9::2.492599937::MTS004	BRD-A78277353-001-01-9	metazosin	2.492599937	MTS004	adrenergic receptor antagonist	ADRA1A			COC(C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1	Phase 2	5
BRD-A78965079-036-01-8::2.640168331::MTS004	0.484609988915	BRD-A78965079-036-01-8::2.640168331::MTS004	BRD-A78965079-036-01-8	tafenoquine	2.640168331	MTS004	antimalarial agent				COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(NC(C)CCCN)c2n1	Phase 3	5
BRD-A79052425-003-01-5::2.5::MTS004	-0.012402236695299999	BRD-A79052425-003-01-5::2.5::MTS004	BRD-A79052425-003-01-5	SIB-1553A	2.5	MTS004	acetylcholine receptor agonist	CHRNB4			CN1CCCC1CCSc1ccc(O)cc1	Phase 2	5
BRD-A80280426-001-03-8::2.43120883::MTS004	-0.135640417276	BRD-A80280426-001-03-8::2.43120883::MTS004	BRD-A80280426-001-03-8	AD-5467	2.43120883	MTS004	aldose reductase inhibitor	AKR1B1			CC(C)C1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C, CC(C)C1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C	Phase 2	5
BRD-A84810646-001-01-6::2.500007302::MTS004	-0.0343321839121	BRD-A84810646-001-01-6::2.500007302::MTS004	BRD-A84810646-001-01-6	ginsenoside-rd	2.5000073019999998	MTS004	calcium channel blocker				CC(C)=CCCC(C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	Phase 3	5
BRD-A85295731-001-06-4::2.500008824::MTS004	-0.0902282664879	BRD-A85295731-001-06-4::2.500008824::MTS004	BRD-A85295731-001-06-4	tiopronin	2.500008824	MTS004	chelating agent, reducing agent		urology	kidney stones	CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O	Launched	5
BRD-A86665761-001-01-1::2.5::MTS004	0.028737478196799997	BRD-A86665761-001-01-1::2.5::MTS004	BRD-A86665761-001-01-1	gabapentin-enacarbil	2.5	MTS004	adrenergic receptor agonist	CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8	neurology/psychiatry	restless leg syndrome, postherpetic neuralgia	CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1	Launched	5
BRD-A88254928-001-07-9::2.5::MTS004	-0.145106369901	BRD-A88254928-001-07-9::2.5::MTS004	BRD-A88254928-001-07-9	albuterol	2.5	MTS004	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	asthma	CC(C)(C)NCC(O)c1ccc(O)c(CO)c1, CC(C)(C)NCC(O)c1ccc(O)c(CO)c1	Launched	5
BRD-A88562598-001-01-7::2.500008795::MTS004	-0.140703348345	BRD-A88562598-001-01-7::2.500008795::MTS004	BRD-A88562598-001-01-7	degarelix	2.500008795	MTS004	gonadotropin releasing factor hormone receptor antagonist	GNRHR	oncology	prostate cancer	CC(C)CC(NC(=O)C(Cc1ccc(NC(N)=O)cc1)NC(=O)C(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)NC(=O)C(CO)NC(=O)C(Cc1cccnc1)NC(=O)C(Cc1ccc(Cl)cc1)NC(=O)C(Cc1ccc2ccccc2c1)NC(C)=O)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O	Launched	5
BRD-A89082344-001-08-7::2.500026693::MTS004	-0.21619024546	BRD-A89082344-001-08-7::2.500026693::MTS004	BRD-A89082344-001-08-7	perifosine	2.500026693	MTS004	AKT inhibitor	AKT1			CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1	Phase 3	5
BRD-A89207210-001-01-6::2.378054241::MTS004	-0.22688054076900002	BRD-A89207210-001-01-6::2.378054241::MTS004	BRD-A89207210-001-01-6	terguride	2.378054241	MTS004	dopamine receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			CCN(CC)C(=O)N[C@H]1CC2C(Cc3c[nH]c4cccc2c34)N(C)C1	Launched	5
BRD-A91444184-300-01-9::2.5::MTS004	0.0545559980022	BRD-A91444184-300-01-9::2.5::MTS004	BRD-A91444184-300-01-9	buclizine	2.5	MTS004	histamine receptor antagonist	CHRM1, HRH1	neurology/psychiatry	migraine headache	CC(C)(C)c1ccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)cc1	Launched	5
BRD-A91728607-236-11-9::2.5::MTS004	0.258809534534	BRD-A91728607-236-11-9::2.5::MTS004	BRD-A91728607-236-11-9	citicoline	2.5	MTS004	membrane permeability enhancer, glutathione transferase stimulant	ACHE, SLC1A2	neurology/psychiatry, ophthalmology	stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma	C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O	Launched	5
BRD-A92177080-001-02-1::2.5::MTS004	-0.0506628466422	BRD-A92177080-001-02-1::2.5::MTS004	BRD-A92177080-001-02-1	betamethasone-acetate	2.5	MTS004	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O	Launched	5
BRD-A92262698-001-02-5::2.5::MTS004	-0.029839223353300002	BRD-A92262698-001-02-5::2.5::MTS004	BRD-A92262698-001-02-5	chlorphenesin	2.5	MTS004	muscle relaxant		neurology/psychiatry	muscle relaxant, sedative	OCC(O)COc1ccc(Cl)cc1, OCC(O)COc1ccc(Cl)cc1	Launched	5
BRD-A92341659-001-04-0::2.499993321::MTS004	0.24473907012899998	BRD-A92341659-001-04-0::2.499993321::MTS004	BRD-A92341659-001-04-0	prulifloxacin	2.499993321	MTS004	bacterial DNA gyrase inhibitor		infectious disease, pulmonary, gastroenterology	urinary tract infections, bronchitis, diarrhea	CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1, CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1	Launched	5
BRD-A93683007-001-01-9::2.5::MTS004	0.07177421469930001	BRD-A93683007-001-01-9::2.5::MTS004	BRD-A93683007-001-01-9	mabuprofen	2.5	MTS004	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	CC(C)Cc1ccc(cc1)C(C)C(=O)NCCO	Launched	5
BRD-A96466199-001-01-4::2.442131966::MTS004	0.0157387215579	BRD-A96466199-001-01-4::2.442131966::MTS004	BRD-A96466199-001-01-4	nuclomedone	2.442131966	MTS004	immunosuppressant				Clc1ccc(CC2C(=O)N=C3SCCN3C2=O)cc1	Phase 3	5
BRD-A99899486-004-01-9::2.293696319::MTS004	-0.0259642447357	BRD-A99899486-004-01-9::2.293696319::MTS004	BRD-A99899486-004-01-9	cimetropium	2.293696319	MTS004	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	C[N+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Launched	5
BRD-K00531707-001-01-3::2.608376789::MTS004	0.22593785894699997	BRD-K00531707-001-01-3::2.608376789::MTS004	BRD-K00531707-001-01-3	cinepazet	2.6083767890000003	MTS004	vasodilator				CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1	Launched	5
BRD-K00634421-001-01-0::2.500042819::MTS004	-0.525860983003	BRD-K00634421-001-01-0::2.500042819::MTS004	BRD-K00634421-001-01-0	brivaracetam	2.500042819	MTS004	voltage-gated sodium channel blocker	SV2A	neurology/psychiatry	seizures	CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1	Launched	5
BRD-K00739965-001-01-9::2.675904798::MTS004	0.14820289293	BRD-K00739965-001-01-9::2.675904798::MTS004	BRD-K00739965-001-01-9	guacetisal	2.675904798	MTS004	immunosuppressant				COc1ccccc1OC(=O)c1ccccc1OC(C)=O	Launched	5
BRD-K01291782-001-01-1::2.50002964::MTS004	0.341324304475	BRD-K01291782-001-01-1::2.50002964::MTS004	BRD-K01291782-001-01-1	molidustat	2.50002964	MTS004	hypoxia inducible factor inhibitor	EGLN2			O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1	Phase 2	5
BRD-K01638814-011-01-4::2.587084236::MTS004	0.32179696655900003	BRD-K01638814-011-01-4::2.587084236::MTS004	BRD-K01638814-011-01-4	rilmenidine	2.587084236	MTS004	adrenergic receptor agonist, imidazoline receptor agonist	ADRA2A	cardiology	hypertension	C1CC1C(NC1=NCCO1)C1CC1, C1CC1C(NC1=NCCO1)C1CC1	Launched	5
BRD-K01662324-001-01-8::2.618953925::MTS004	0.0855807782495	BRD-K01662324-001-01-8::2.618953925::MTS004	BRD-K01662324-001-01-8	priralfinamide	2.618953925	MTS004	sodium channel blocker	CACNA1B			C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O	Phase 3	5
BRD-K01666412-001-02-0::2.5::MTS004	0.126928448802	BRD-K01666412-001-02-0::2.5::MTS004	BRD-K01666412-001-02-0	L-proline	2.5	MTS004	glutamate receptor agonist	EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7			OC(=O)[C@@H]1CCCN1	Launched	5
BRD-K01773083-001-01-4::2.303758671::MTS004	0.0416039956245	BRD-K01773083-001-01-4::2.303758671::MTS004	BRD-K01773083-001-01-4	denotivir	2.3037586709999998	MTS004	antiviral		infectious disease	virus herpes simplex (HSV), skin infections	Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1	Launched	5
BRD-K02152879-414-02-1::2.500013375::MTS004	-0.299153276558	BRD-K02152879-414-02-1::2.500013375::MTS004	BRD-K02152879-414-02-1	sivelestat	2.500013375	MTS004	elastase inhibitor	CELA1, ELANE	pulmonary	acute lung injury	CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O	Launched	5
BRD-K02275692-300-02-6::2.499989889::MTS004	0.500696642233	BRD-K02275692-300-02-6::2.499989889::MTS004	BRD-K02275692-300-02-6	cefotiam	2.499989889	MTS004	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections	CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O, CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O	Launched	5
BRD-K02528732-001-02-4::2.425128585::MTS004	-0.31771477891800004	BRD-K02528732-001-02-4::2.425128585::MTS004	BRD-K02528732-001-02-4	fluorometholone-acetate	2.425128585	MTS004		NR3C1	ophthalmology	eye inflammation	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12	Launched	5
BRD-K02554563-001-01-6::2.5::MTS004	-0.208713785304	BRD-K02554563-001-01-6::2.5::MTS004	BRD-K02554563-001-01-6	PF-05190457	2.5	MTS004	growth hormone secretagogue receptor inverse agonist	GHSR			Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1	Phase 2	5
BRD-K02729857-001-01-9::2.50244046::MTS004	-0.21340866164900002	BRD-K02729857-001-01-9::2.50244046::MTS004	BRD-K02729857-001-01-9	phenylbenzimidazole-sulfonic-acid	2.50244046	MTS004			dermatology	sunscreen lotion	OS(=O)(=O)c1ccc2[nH]c(nc2c1)-c1ccccc1	Launched	5
BRD-K02750403-001-01-4::2.499962046::MTS004	0.226434666221	BRD-K02750403-001-01-4::2.499962046::MTS004	BRD-K02750403-001-01-4	piboserod	2.499962046	MTS004	serotonin receptor antagonist	HTR2B, HTR4			CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1	Phase 2	5
BRD-K02988401-001-01-2::2.5::MTS004	-0.051675269223199996	BRD-K02988401-001-01-2::2.5::MTS004	BRD-K02988401-001-01-2	UNC0737	2.5	MTS004	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C	Preclinical	5
BRD-K02995728-003-01-9::2.499993866::MTS004	-0.0393060202592	BRD-K02995728-003-01-9::2.499993866::MTS004	BRD-K02995728-003-01-9	quinagolide	2.499993866	MTS004	dopamine receptor agonist	DRD2	endocrinology	hyperprolactinemia	CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC	Launched	5
BRD-K03165895-001-01-9::2.499970324::MTS004	0.176045767814	BRD-K03165895-001-01-9::2.499970324::MTS004	BRD-K03165895-001-01-9	elafibranor	2.499970324	MTS004	PPAR receptor agonist	PPARA, PPARD			CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1	Phase 3	5
BRD-K03503561-001-01-4::2.339952449::MTS004	0.268548345143	BRD-K03503561-001-01-4::2.339952449::MTS004	BRD-K03503561-001-01-4	ravuconazole	2.339952449	MTS004	sterol demethylase inhibitor				C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Phase 2	5
BRD-K03765900-001-01-9::2.499986292::MTS004	0.517530965583	BRD-K03765900-001-01-9::2.499986292::MTS004	BRD-K03765900-001-01-9	XL-647	2.499986292	MTS004	EGFR inhibitor, VEGFR inhibitor	EGFR, EPHB4, ERBB2, FLT4, KDR			COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1	Phase 3	5
BRD-K03894385-001-01-1::2.500025266::MTS004	0.0535308604299	BRD-K03894385-001-01-1::2.500025266::MTS004	BRD-K03894385-001-01-1	MK-6096	2.5000252659999997	MTS004	orexin receptor antagonist	HCRTR1, HCRTR2			C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1	Phase 2	5
BRD-K04603573-376-01-3::2.542651982::MTS004	0.0589152480855	BRD-K04603573-376-01-3::2.542651982::MTS004	BRD-K04603573-376-01-3	1,12-Besm	2.5426519819999998	MTS004	polyamine biosynthesis inhibitor				CCNCCCNCCCCNCCCNCC	Phase 2	5
BRD-K04643877-001-03-2::2.633096501::MTS004	0.037154121290300005	BRD-K04643877-001-03-2::2.633096501::MTS004	BRD-K04643877-001-03-2	perzinfotel	2.633096501	MTS004	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B			OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O	Phase 2	5
BRD-K04701033-001-04-7::2.499987566::MTS004	-0.17915031892299998	BRD-K04701033-001-04-7::2.499987566::MTS004	BRD-K04701033-001-04-7	VE-822	2.499987566	MTS004	ATR kinase inhibitor	ATM, ATR, MTOR, PIK3CG			CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C	Phase 2	5
BRD-K04710043-001-17-8::2.5::MTS004	0.25981776506	BRD-K04710043-001-17-8::2.5::MTS004	BRD-K04710043-001-17-8	hexamethylenebisacetamide	2.5	MTS004	AKT inhibitor, differentiation inducer, NFKB pathway inhibitor	AKT1			CC(=O)NCCCCCCNC(C)=O	Phase 2	5
BRD-K05858796-001-01-7::2.500017956::MTS004	0.11147606887	BRD-K05858796-001-01-7::2.500017956::MTS004	BRD-K05858796-001-01-7	GSK2330672	2.5000179559999998	MTS004	bile acid transporter inhibitor	SLC10A2			CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1	Phase 2	5
BRD-K06182768-001-02-3::2.5::MTS004	0.06397810721649999	BRD-K06182768-001-02-3::2.5::MTS004	BRD-K06182768-001-02-3	A-366	2.5	MTS004	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1	Preclinical	5
BRD-K06273313-001-07-9::2.5::MTS004	0.30169954869000004	BRD-K06273313-001-07-9::2.5::MTS004	BRD-K06273313-001-07-9	E-64	2.5	MTS004	cysteine protease inhibitor, calpain inhibitor	CTSS			CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N, CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N	Preclinical	5
BRD-K06328344-015-01-7::2.500004254::MTS004	-0.0437178476664	BRD-K06328344-015-01-7::2.500004254::MTS004	BRD-K06328344-015-01-7	bremelanotide	2.5000042540000003	MTS004	melanocortin receptor agonist	MC1R, MC2R, MC3R, MC4R, MC5R			CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O	Phase 3	5
BRD-K06357403-001-01-4::2.49996939::MTS004	-0.227664529155	BRD-K06357403-001-01-4::2.49996939::MTS004	BRD-K06357403-001-01-4	velneperit	2.49996939	MTS004	neuropeptide receptor antagonist	NPY5R			CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F	Phase 2	5
BRD-K06388517-001-01-2::2.5::MTS004	-0.204715567535	BRD-K06388517-001-01-2::2.5::MTS004	BRD-K06388517-001-01-2	lofemizole	2.5	MTS004	cyclooxygenase inhibitor				Cc1nc[nH]c1-c1ccc(Cl)cc1	Phase 3	5
BRD-K06455935-001-01-3::2.499992329::MTS004	0.139712785818	BRD-K06455935-001-01-3::2.499992329::MTS004	BRD-K06455935-001-01-3	daprodustat	2.499992329	MTS004	hypoxia inducible factor inhibitor	EGLN1			OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O	Phase 3	5
BRD-K06467130-304-02-7::2.5::MTS004	-0.530139986396	BRD-K06467130-304-02-7::2.5::MTS004	BRD-K06467130-304-02-7	CL316243	2.5	MTS004	adrenergic receptor agonist	ADRB3, UCP1, UCP2, UCP3			C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1	Phase 2	5
BRD-K06502269-001-02-6::2.5::MTS004	0.150940270453	BRD-K06502269-001-02-6::2.5::MTS004	BRD-K06502269-001-02-6	L-methionine	2.5	MTS004	voltage-gated calcium channel ligand				CSCC[C@H](N)C(O)=O	Launched	5
BRD-K06519765-001-01-1::2.5::MTS004	-0.42841751989200005	BRD-K06519765-001-01-1::2.5::MTS004	BRD-K06519765-001-01-1	vinblastine	2.5	MTS004	microtubule inhibitor, tubulin polymerization inhibitor	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC	Launched	5
BRD-K06883221-001-01-9::2.686662955::MTS004	0.354820944426	BRD-K06883221-001-01-9::2.686662955::MTS004	BRD-K06883221-001-01-9	apratastat	2.686662955	MTS004	matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor	ADAM17, MMP1, MMP13, MMP9			CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1	Phase 2	5
BRD-K07070922-001-01-4::2.5::MTS004	-0.152322535141	BRD-K07070922-001-01-4::2.5::MTS004	BRD-K07070922-001-01-4	PF-03049423	2.5	MTS004	phosphodiesterase inhibitor	PDE5A			CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1	Phase 2	5
BRD-K07409305-001-01-1::2.391201575::MTS004	-0.103985680399	BRD-K07409305-001-01-1::2.391201575::MTS004	BRD-K07409305-001-01-1	Org-12962	2.391201575	MTS004	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			FC(F)(F)c1ccc(nc1Cl)N1CCNCC1	Phase 2	5
BRD-K07625016-001-01-2::2.50703254::MTS004	0.290748162396	BRD-K07625016-001-01-2::2.50703254::MTS004	BRD-K07625016-001-01-2	norethisterone-enanthate	2.50703254	MTS004	contraceptive agent		endocrinology	contraceptive	CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C	Launched	5
BRD-K07682953-001-01-8::2.499993276::MTS004	0.09866046280190001	BRD-K07682953-001-01-8::2.499993276::MTS004	BRD-K07682953-001-01-8	palosuran	2.499993276	MTS004	urotensin receptor antagonist	UTS2R			Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1	Phase 2	5
BRD-K07785030-001-01-6::2.29884119::MTS004	0.13026691986800001	BRD-K07785030-001-01-6::2.29884119::MTS004	BRD-K07785030-001-01-6	7-keto-DHEA	2.29884119	MTS004	steroid				CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1	Launched	5
BRD-K07790550-001-01-6::2.500001908::MTS004	0.0774475454156	BRD-K07790550-001-01-6::2.500001908::MTS004	BRD-K07790550-001-01-6	mavoglurant	2.500001908	MTS004	glutamate receptor antagonist	GRM5			COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1	Phase 2	5
BRD-K08255599-365-01-1::2.656154742::MTS004	0.0363161486866	BRD-K08255599-365-01-1::2.656154742::MTS004	BRD-K08255599-365-01-1	frovatriptan	2.656154742	MTS004	serotonin receptor agonist	HTR1A, HTR1B, HTR1D	neurology/psychiatry	migraine headache	CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O	Launched	5
BRD-K09436144-001-01-7::2.487366457::MTS004	-0.0146917102115	BRD-K09436144-001-01-7::2.487366457::MTS004	BRD-K09436144-001-01-7	YM022	2.487366457	MTS004	CCK receptor antagonist	CCKBR			Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1	Phase 2	5
BRD-K09735259-001-01-3::2.500007896::MTS004	0.05112650075590001	BRD-K09735259-001-01-3::2.500007896::MTS004	BRD-K09735259-001-01-3	elbasvir	2.500007896	MTS004	HCV inhibitor		infectious disease	hepatitis C	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched	5
BRD-K09821361-066-25-8::2.499990088::MTS004	0.345362075594	BRD-K09821361-066-25-8::2.499990088::MTS004	BRD-K09821361-066-25-8	deferoxamine-mesylate	2.499990088	MTS004	chelating agent		hematology	acute iron intoxication, iron overload	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	Launched	5
BRD-K10415035-001-04-4::2.5::MTS004	0.123803963543	BRD-K10415035-001-04-4::2.5::MTS004	BRD-K10415035-001-04-4	tasuldine	2.5	MTS004	mucolytic agent				C(Sc1ncccn1)c1cccnc1, C(Sc1ncccn1)c1cccnc1	Phase 3	5
BRD-K10667240-001-01-7::2.485820406::MTS004	0.00874760032335	BRD-K10667240-001-01-7::2.485820406::MTS004	BRD-K10667240-001-01-7	ethacizin	2.4858204059999998	MTS004	anticonvulsant		cardiology	ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1	Launched	5
BRD-K10995081-001-27-9::2.316458322::MTS004	0.102461984178	BRD-K10995081-001-27-9::2.316458322::MTS004	BRD-K10995081-001-27-9	perphenazine	2.316458322	MTS004	dopamine receptor antagonist	CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry, gastroenterology	schizophrenia, nausea, vomiting	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched	5
BRD-K11256763-001-01-5::2.5::MTS004	-0.092094549272	BRD-K11256763-001-01-5::2.5::MTS004	BRD-K11256763-001-01-5	niceritrol	2.5	MTS004	NAD precursor		endocrinology	hyperlipidemia	O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1	Launched	5
BRD-K11443721-003-01-6::2.403980733::MTS004	0.166320165927	BRD-K11443721-003-01-6::2.403980733::MTS004	BRD-K11443721-003-01-6	NE-100	2.403980733	MTS004	sigma receptor antagonist	SIGMAR1			CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1	Phase 2	5
BRD-K11452913-001-01-9::2.5000112::MTS004	0.331512383502	BRD-K11452913-001-01-9::2.5000112::MTS004	BRD-K11452913-001-01-9	evatanepag	2.5000112	MTS004	prostaglandin inhibitor	PTGER2, PTGER4			CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1	Phase 2	5
BRD-K11463116-304-03-5::2.500052374::MTS004	-0.0761332724118	BRD-K11463116-304-03-5::2.500052374::MTS004	BRD-K11463116-304-03-5	eprodisate	2.500052374	MTS004	antiamyloidogenic agent, amyloid protein inhibitor	SAA1			OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O	Phase 3	5
BRD-K11792081-001-01-4::2.500009305::MTS004	0.22827632961199998	BRD-K11792081-001-01-4::2.500009305::MTS004	BRD-K11792081-001-01-4	ABT-639	2.500009305	MTS004	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F	Phase 2	5
BRD-K11851476-003-01-7::2.499993171::MTS004	-0.0362792890483	BRD-K11851476-003-01-7::2.499993171::MTS004	BRD-K11851476-003-01-7	pardoprunox	2.499993171	MTS004	serotonin receptor agonist, dopamine receptor agonist	DRD2, DRD3, DRD4, HTR1A, HTR7			CN1CCN(CC1)c1cccc2[nH]c(=O)oc12	Phase 3	5
BRD-K12261274-001-02-4::2.499953183::MTS004	0.161209623873	BRD-K12261274-001-02-4::2.499953183::MTS004	BRD-K12261274-001-02-4	zaltidine	2.499953183	MTS004	histamine receptor antagonist	HRH2			Cc1ncc([nH]1)-c1csc(NC(N)=N)n1, Cc1ncc([nH]1)-c1csc(NC(N)=N)n1	Phase 3	5
BRD-K12742203-003-01-7::2.512196931::MTS004	0.0511308983581	BRD-K12742203-003-01-7::2.512196931::MTS004	BRD-K12742203-003-01-7	moxaverine	2.512196931	MTS004	phosphodiesterase inhibitor		neurology/psychiatry	spasms	CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1	Launched	5
BRD-K12852738-001-01-2::2.584725941::MTS004	0.151192133963	BRD-K12852738-001-01-2::2.584725941::MTS004	BRD-K12852738-001-01-2	veliflapon	2.584725941	MTS004	leukotriene synthesis inhibitor	ALOX5AP			OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1	Phase 3	5
BRD-K12906202-001-06-2::2.5::MTS004	0.35952804671599997	BRD-K12906202-001-06-2::2.5::MTS004	BRD-K12906202-001-06-2	carbendazim	2.5	MTS004	microtubule inhibitor, tubulin polymerization inhibitor	TP53, TUBB	infectious disease	fungicide	COC(=O)Nc1nc2ccccc2[nH]1	Launched	5
BRD-K13060017-001-02-1::2.499994836::MTS004	0.680479075272	BRD-K13060017-001-02-1::2.499994836::MTS004	BRD-K13060017-001-02-1	UNC0631	2.499994836	MTS004	histone lysine methyltransferase inhibitor	EHMT2			COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	Preclinical	5
BRD-K13277760-001-01-2::2.5::MTS004	-0.239521742254	BRD-K13277760-001-01-2::2.5::MTS004	BRD-K13277760-001-01-2	rifamycin-sv	2.5	MTS004	RNA synthesis inhibitor				CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c(O)c2c(O)c3C	Phase 3	5
BRD-K13394247-003-01-4::2.499991328::MTS004	-0.00223225857913	BRD-K13394247-003-01-4::2.499991328::MTS004	BRD-K13394247-003-01-4	radafaxine	2.499991328	MTS004	dopamine-norepinephrine reuptake inhibitor	SLC6A3			C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1	Phase 2	5
BRD-K13414800-001-01-3::2.499970601::MTS004	0.48273751357	BRD-K13414800-001-01-3::2.499970601::MTS004	BRD-K13414800-001-01-3	vesnarinone	2.499970601	MTS004	phosphodiesterase inhibitor	KCNH2, PDE3A	cardiology	congestive heart failure	COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1	Launched	5
BRD-K13533483-001-16-2::2.5::MTS004	-0.139645865669	BRD-K13533483-001-16-2::2.5::MTS004	BRD-K13533483-001-16-2	cyclosporine	2.5	MTS004	calcineurin inhibitor	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	transplant, rheumatology, dermatology	organ rejection, rheumatoid arthritis, psoriasis	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	Launched	5
BRD-K13664493-316-02-5::2.500014041::MTS004	0.306740277056	BRD-K13664493-316-02-5::2.500014041::MTS004	BRD-K13664493-316-02-5	naphthoquine-phosphate	2.500014041	MTS004	antimalarial agent				CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O	Launched	5
BRD-K13769342-001-01-5::2.50001379::MTS004	-0.40722801334299996	BRD-K13769342-001-01-5::2.50001379::MTS004	BRD-K13769342-001-01-5	danirixin	2.50001379	MTS004	CC chemokine receptor antagonist	CXCR2			Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1	Phase 2	5
BRD-K14171291-001-01-4::2.499985403::MTS004	0.17458060301800002	BRD-K14171291-001-01-4::2.499985403::MTS004	BRD-K14171291-001-01-4	omarigliptin	2.499985403	MTS004	dipeptidyl peptidase inhibitor	DPP4			CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F	Launched	5
BRD-K14276241-001-01-2::2.49998187::MTS004	0.25998320455400004	BRD-K14276241-001-01-2::2.49998187::MTS004	BRD-K14276241-001-01-2	daucosterol	2.49998187	MTS004	apoptosis stimulant				CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C	Phase 2	5
BRD-K14571191-001-01-6::2.5::MTS004	0.268934028927	BRD-K14571191-001-01-6::2.5::MTS004	BRD-K14571191-001-01-6	zometapine	2.5	MTS004					Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1	Phase 2	5
BRD-K14658796-003-01-6::2.368766292::MTS004	-0.0445673604674	BRD-K14658796-003-01-6::2.368766292::MTS004	BRD-K14658796-003-01-6	drotaverine	2.3687662919999997	MTS004	phosphodiesterase inhibitor	CACNA1C, PDE4A	obstetrics/gynecology	labor induction	CCOc1ccc(\C=C2\NCCc3cc(OCC)c(OCC)cc23)cc1OCC, CCOc1ccc(\C=C2\NCCc3cc(OCC)c(OCC)cc23)cc1OCC	Launched	5
BRD-K14681867-001-01-6::2.5::MTS004	0.57790703978	BRD-K14681867-001-01-6::2.5::MTS004	BRD-K14681867-001-01-6	somatostatin	2.5	MTS004	somatostatin receptor agonist	OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	hematology	hemorrhage	C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC1=O)[C@@H](C)O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N	Launched	5
BRD-K15014948-001-10-3::2.500062642::MTS004	-0.205643559879	BRD-K15014948-001-10-3::2.500062642::MTS004	BRD-K15014948-001-10-3	tranexamic-acid	2.500062642	MTS004	antifibrinolytic, plasminogen activator inhibitor	PLG	hematology	hemophilia	NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O	Launched	5
BRD-K15262564-001-15-0::2.500002693::MTS004	0.126119836082	BRD-K15262564-001-15-0::2.500002693::MTS004	BRD-K15262564-001-15-0	mupirocin	2.5000026930000003	MTS004	isoleucyl-tRNA synthetase inhibitor		infectious disease	impetigo	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O	Launched	5
BRD-K15327298-001-05-5::2.444207768::MTS004	-0.0662807244453	BRD-K15327298-001-05-5::2.444207768::MTS004	BRD-K15327298-001-05-5	fmoc-l-leucine	2.444207768	MTS004	PPAR receptor agonist				CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	Phase 2	5
BRD-K15360631-325-01-4::2.404560312::MTS004	-0.266839622341	BRD-K15360631-325-01-4::2.404560312::MTS004	BRD-K15360631-325-01-4	dehydroepiandrosterone-sulfate	2.404560312	MTS004	androgen receptor agonist, estrogen receptor agonist	AR, ESR1, ESR2	endocrinology	menopause	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O	Launched	5
BRD-K15691453-236-01-6::2.499981005::MTS004	-0.015577497578100001	BRD-K15691453-236-01-6::2.499981005::MTS004	BRD-K15691453-236-01-6	GSK2190915	2.499981005	MTS004	lipoxygenase inhibitor	ALOX5AP			CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1	Phase 2	5
BRD-K16180792-001-01-7::2.5::MTS004	-0.298332923964	BRD-K16180792-001-01-7::2.5::MTS004	BRD-K16180792-001-01-7	bis(maltolato)oxovanadium(IV)	2.5	MTS004	tyrosine phosphatase inhibitor	PTPN1			Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O	Phase 2	5
BRD-K16505263-003-02-9::2.49996754::MTS004	0.529173830726	BRD-K16505263-003-02-9::2.49996754::MTS004	BRD-K16505263-003-02-9	forodesine	2.49996754	MTS004	purinergic receptor antagonist	PNP			OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O	Phase 2	5
BRD-K16546375-001-01-4::2.393310671::MTS004	-0.258984297202	BRD-K16546375-001-01-4::2.393310671::MTS004	BRD-K16546375-001-01-4	bicyclol	2.393310671	MTS004	NFkB pathway inhibitor	HSPA1A, HSPB1			COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO	Launched	5
BRD-K17295893-001-01-0::2.499987615::MTS004	0.09929417471799999	BRD-K17295893-001-01-0::2.499987615::MTS004	BRD-K17295893-001-01-0	nastorazepide	2.499987615	MTS004	CCK receptor antagonist	CCKBR			CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1	Phase 2	5
BRD-K17480742-001-01-1::2.5::MTS004	0.11507189010800001	BRD-K17480742-001-01-1::2.5::MTS004	BRD-K17480742-001-01-1	delamanid	2.5	MTS004	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O	Launched	5
BRD-K17610631-001-03-3::2.421190843::MTS004	0.004980026875	BRD-K17610631-001-03-3::2.421190843::MTS004	BRD-K17610631-001-03-3	indisulam	2.421190843	MTS004	CDK inhibitor	CA1, CA12, CA14, CA2, CA6, CA7, CA9			NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12	Phase 2	5
BRD-K17641316-001-04-8::2.500015146::MTS004	-0.224760547236	BRD-K17641316-001-04-8::2.500015146::MTS004	BRD-K17641316-001-04-8	decoquinate	2.500015146	MTS004	antiprotozoal agent		infectious disease	coccidiosis	CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC, CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC, CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC, CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC	Launched	5
BRD-K17828029-001-01-5::2.536141856::MTS004	-0.305278228617	BRD-K17828029-001-01-5::2.536141856::MTS004	BRD-K17828029-001-01-5	cinoxate	2.536141856	MTS004			dermatology	sunscreen lotion	CCOCCOC(=O)\C=C\c1ccc(OC)cc1	Launched	5
BRD-K18135438-001-14-2::2.5::MTS004	0.0777608369244	BRD-K18135438-001-14-2::2.5::MTS004	BRD-K18135438-001-14-2	chenodeoxycholic-acid	2.5	MTS004	11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist	HSD11B1, NR1H4	cardiology, gastroenterology	cerebral cholesterosis, gallstones	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K18749874-003-08-9::2.5::MTS004	0.17612660955499998	BRD-K18749874-003-08-9::2.5::MTS004	BRD-K18749874-003-08-9	melevodopa	2.5	MTS004	dopamine precursor, dopamine receptor agonist	DDC	neurology/psychiatry	Parkinson's Disease	COC(=O)C(N)Cc1ccc(O)c(O)c1, COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	Launched	5
BRD-K18878288-001-06-4::2.457947881::MTS004	0.0853847633876	BRD-K18878288-001-06-4::2.457947881::MTS004	BRD-K18878288-001-06-4	schisandrol-b	2.457947881	MTS004	lipid peroxidase inhibitor				COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC, COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	Phase 3	5
BRD-K18898553-001-01-1::2.5::MTS004	0.35158832533100004	BRD-K18898553-001-01-1::2.5::MTS004	BRD-K18898553-001-01-1	salvianolic-acid-B	2.5	MTS004	metalloproteinase inhibitor, EGFR inhibitor	MMP9			OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1	Phase 2	5
BRD-K19515365-001-02-6::2.33859482::MTS004	0.0788281314003	BRD-K19515365-001-02-6::2.33859482::MTS004	BRD-K19515365-001-02-6	bendazac	2.33859482	MTS004	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	OC(=O)COc1nn(Cc2ccccc2)c2ccccc12	Launched	5
BRD-K20093108-001-02-3::2.5::MTS004	0.0929607166524	BRD-K20093108-001-02-3::2.5::MTS004	BRD-K20093108-001-02-3	BMS-587101	2.5	MTS004	integrin antagonist	ITGAL, ITGB2			CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1	Phase 2	5
BRD-K20463415-300-01-4::2.499966791::MTS004	0.698035102912	BRD-K20463415-300-01-4::2.499966791::MTS004	BRD-K20463415-300-01-4	LY2606368	2.499966791	MTS004	CHK inhibitor	CHEK1			COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1	Phase 2	5
BRD-K20468903-001-01-6::2.49996519::MTS004	-0.423123050014	BRD-K20468903-001-01-6::2.49996519::MTS004	BRD-K20468903-001-01-6	BNC105	2.49996519	MTS004	tubulin polymerization inhibitor				COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O	Phase 2	5
BRD-K21077415-001-01-5::2.656085278::MTS004	0.11388935855900001	BRD-K21077415-001-01-5::2.656085278::MTS004	BRD-K21077415-001-01-5	AMG-319	2.656085278	MTS004	PI3K inhibitor	PIK3CD			C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1	Phase 2	5
BRD-K21152241-001-07-3::2.5082643::MTS004	0.08321228032089999	BRD-K21152241-001-07-3::2.5082643::MTS004	BRD-K21152241-001-07-3	enoximone	2.5082642999999996	MTS004	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C	Launched	5
BRD-K21191422-001-01-5::2.499985534::MTS004	0.270933732138	BRD-K21191422-001-01-5::2.499985534::MTS004	BRD-K21191422-001-01-5	selexipag	2.499985534	MTS004	platelet aggregation inhibitor, IP1 prostacyclin receptor agonist	PTGIR			CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1, CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1	Phase 3	5
BRD-K21237892-376-01-3::2.5::MTS004	0.285347558673	BRD-K21237892-376-01-3::2.5::MTS004	BRD-K21237892-376-01-3	semapimod	2.5	MTS004	cytokine production inhibitor, p38 MAPK inhibitor	MAPK14			NC(=N)NNC(=C)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(=C)NNC(N)=N)C(=C)NNC(N)=N)cc(c1)C(=C)NNC(N)=N	Phase 2	5
BRD-K21586122-001-01-9::2.50000801::MTS004	0.101552239451	BRD-K21586122-001-01-9::2.50000801::MTS004	BRD-K21586122-001-01-9	fimasartan	2.50000801	MTS004	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure, hypertension, congestive heart failure	CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	Launched	5
BRD-K21612934-001-01-1::2.473727942::MTS004	0.029928873385400005	BRD-K21612934-001-01-1::2.473727942::MTS004	BRD-K21612934-001-01-1	leteprinim	2.473727942	MTS004	nerve growth factor agonist				OC(=O)c1ccc(NC(=O)CCn2cnc3c(O)ncnc23)cc1	Phase 2	5
BRD-K22064724-001-01-8::2.499989634::MTS004	-3.86853847121	BRD-K22064724-001-01-8::2.499989634::MTS004	BRD-K22064724-001-01-8	napabucasin	2.499989634	MTS004	STAT inhibitor	STAT3			CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O	Phase 3	5
BRD-K22149900-001-03-9::2.371298578::MTS004	-3.21282376662	BRD-K22149900-001-03-9::2.371298578::MTS004	BRD-K22149900-001-03-9	ceritinib	2.371298578	MTS004	ALK tyrosine kinase receptor inhibitor	ALK, FLT3, IGF1R, INSR, TSSK1B	oncology	non-small cell lung cancer (NSCLC)	CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1	Launched	5
BRD-K22514639-001-05-7::2.500015058::MTS004	0.344375964712	BRD-K22514639-001-05-7::2.500015058::MTS004	BRD-K22514639-001-05-7	EGF816	2.5000150580000002	MTS004	EGFR inhibitor	EGFR			CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12	Phase 2	5
BRD-K22518984-001-01-8::2.5::MTS004	0.152612457164	BRD-K22518984-001-01-8::2.5::MTS004	BRD-K22518984-001-01-8	metacresol	2.5	MTS004		INS			Cc1cccc(O)c1	Launched	5
BRD-K22525962-001-05-0::2.500010949::MTS004	0.0530623672791	BRD-K22525962-001-05-0::2.500010949::MTS004	BRD-K22525962-001-05-0	dihydrotestosterone	2.500010949	MTS004	androgen receptor agonist	AR, HSD17B1	neurology/psychiatry, endocrinology	tetany, hypoparathyroidism	C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O	Launched	5
BRD-K22588750-001-07-0::2.654665484::MTS004	-0.047672844709000003	BRD-K22588750-001-07-0::2.654665484::MTS004	BRD-K22588750-001-07-0	gidazepam	2.654665484	MTS004	GABA benzodiazepine site receptor agonist				NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1	Launched	5
BRD-K23791635-001-01-3::2.499966688::MTS004	0.043977016561400004	BRD-K23791635-001-01-3::2.499966688::MTS004	BRD-K23791635-001-01-3	AFN-1252	2.499966688	MTS004	FABI inhibitor				CN(Cc1oc2ccccc2c1C)C(=O)\C=C\C1=CNC2=NC(=O)CCC2=C1	Phase 2	5
BRD-K23848629-401-03-7::2.5::MTS004	-0.242037288074	BRD-K23848629-401-03-7::2.5::MTS004	BRD-K23848629-401-03-7	fosaprepitant-dimeglumine	2.5	MTS004	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Launched	5
BRD-K24221957-003-01-6::2.5::MTS004	-0.10517426775000001	BRD-K24221957-003-01-6::2.5::MTS004	BRD-K24221957-003-01-6	pralidoxime-chloride	2.5	MTS004	acetylcholinesterase inhibitor	ACHE, BCHE	pulmonary	respiratory depression	C[n+]1ccccc1C[N+][O-]	Launched	5
BRD-K24452555-001-01-7::2.599377769::MTS004	0.107121277293	BRD-K24452555-001-01-7::2.599377769::MTS004	BRD-K24452555-001-01-7	methylprednisolone-aceponate	2.599377769	MTS004	anti-inflammatory agent, glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology	congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O	Launched	5
BRD-K24476327-001-01-3::2.50002878::MTS004	0.371636235712	BRD-K24476327-001-01-3::2.50002878::MTS004	BRD-K24476327-001-01-3	icaritin	2.50002878	MTS004	PPAR receptor antagonist	PDE5A			COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O	Phase 2	5
BRD-K24497734-001-01-6::2.499993902::MTS004	-0.173546104898	BRD-K24497734-001-01-6::2.499993902::MTS004	BRD-K24497734-001-01-6	setipiprant	2.499993902	MTS004	prostaglandin inhibitor	PTGDR2			OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12	Phase 3	5
BRD-K24610819-003-01-8::2.33438271::MTS004	-0.100935305592	BRD-K24610819-003-01-8::2.33438271::MTS004	BRD-K24610819-003-01-8	amibegron	2.33438271	MTS004	adrenergic receptor agonist	ADRB3			CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1	Phase 3	5
BRD-K24666289-001-04-9::2.499988887::MTS004	-3.0714164220099995	BRD-K24666289-001-04-9::2.499988887::MTS004	BRD-K24666289-001-04-9	copanlisib	2.4999888869999998	MTS004	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	follicular lymphoma	COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12	Launched	5
BRD-K24864897-001-01-0::2.5::MTS004	0.189454320527	BRD-K24864897-001-01-0::2.5::MTS004	BRD-K24864897-001-01-0	JNJ-26990990	2.5	MTS004	anticonvulsant				NS(=O)(=O)NCc1csc2ccccc12	Phase 2	5
BRD-K25029121-001-05-8::2.446932239::MTS004	-0.185569317992	BRD-K25029121-001-05-8::2.446932239::MTS004	BRD-K25029121-001-05-8	triclocarban	2.446932239	MTS004	other antibiotic				Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1	Launched	5
BRD-K25146005-001-01-0::2.5::MTS004	-0.144050357503	BRD-K25146005-001-01-0::2.5::MTS004	BRD-K25146005-001-01-0	cis-urocanic acid	2.5	MTS004	serotonin receptor agonist	HTR2A			OC(=O)\C=C/c1c[nH]cn1	Phase 2	5
BRD-K25154476-001-01-4::2.5::MTS004	0.21713626063299998	BRD-K25154476-001-01-4::2.5::MTS004	BRD-K25154476-001-01-4	cinflumide	2.5	MTS004	muscle relaxant				Fc1cccc(c1)\C=C\C(=O)NC1CC1	Phase 2	5
BRD-K25243230-001-01-2::2.5::MTS004	0.172456132866	BRD-K25243230-001-01-2::2.5::MTS004	BRD-K25243230-001-01-2	oxytocin	2.5	MTS004	oxytocin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	obstetrics/gynecology	labor induction	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O, CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	Launched	5
BRD-K25494650-003-01-8::2.660853131::MTS004	0.24874437079700001	BRD-K25494650-003-01-8::2.660853131::MTS004	BRD-K25494650-003-01-8	chlorproguanil	2.660853131	MTS004	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1	Launched	5
BRD-K25570267-001-01-4::2.436963824::MTS004	-0.0860709218086	BRD-K25570267-001-01-4::2.436963824::MTS004	BRD-K25570267-001-01-4	ezutromid	2.4369638240000002	MTS004	utrophin enhancer	UTRN			CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1	Phase 2	5
BRD-K25970317-001-01-6::2.50000335::MTS004	-3.21720730522	BRD-K25970317-001-01-6::2.50000335::MTS004	BRD-K25970317-001-01-6	resibufogenin	2.50000335	MTS004	Na/K-ATPase inhibitor				C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1	Phase 2	5
BRD-K26024145-001-01-9::2.5::MTS004	0.102768036994	BRD-K26024145-001-01-9::2.5::MTS004	BRD-K26024145-001-01-9	desoxycorticosterone-pivalate	2.5	MTS004	corticosteroid agonist	NR3C2	endocrinology	Addison's disease	CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K26026438-001-01-0::2.499979456::MTS004	0.25657316587400003	BRD-K26026438-001-01-0::2.499979456::MTS004	BRD-K26026438-001-01-0	tucatinib	2.499979456	MTS004	EGFR inhibitor	ERBB2			Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1	Phase 2	5
BRD-K26323068-001-01-8::2.5::MTS004	0.255784198317	BRD-K26323068-001-01-8::2.5::MTS004	BRD-K26323068-001-01-8	leuprolide	2.5	MTS004	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology	prostate cancer	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	Launched	5
BRD-K26530649-001-01-6::2.568078778::MTS004	-0.042130757316300005	BRD-K26530649-001-01-6::2.568078778::MTS004	BRD-K26530649-001-01-6	carboxypyridine-disulfide	2.5680787780000003	MTS004					OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1	Phase 2	5
BRD-K26813177-001-03-2::2.46430412::MTS004	0.019667279776900002	BRD-K26813177-001-03-2::2.46430412::MTS004	BRD-K26813177-001-03-2	daltroban	2.46430412	MTS004	thromboxane receptor antagonist	TBXA2R			OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1	Phase 3	5
BRD-K26818574-305-07-6::2.5::MTS004	-2.02993592504	BRD-K26818574-305-07-6::2.5::MTS004	BRD-K26818574-305-07-6	BIX-01294	2.5	MTS004	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	Preclinical	5
BRD-K27061362-001-01-6::2.499998598::MTS004	0.27347466104	BRD-K27061362-001-01-6::2.499998598::MTS004	BRD-K27061362-001-01-6	AMG-337	2.499998598	MTS004	MET inhibitor	MET			COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1	Phase 2	5
BRD-K27293958-001-01-5::2.450321909::MTS004	0.226870540825	BRD-K27293958-001-01-5::2.450321909::MTS004	BRD-K27293958-001-01-5	tiaramide	2.450321909	MTS004	anti-inflammatory agent		pulmonary	asthma	OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O	Launched	5
BRD-K27515606-003-01-3::2.5::MTS004	-0.132637804025	BRD-K27515606-003-01-3::2.5::MTS004	BRD-K27515606-003-01-3	cefcapene-pivoxil	2.5	MTS004	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia, urinary tract infections	CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1	Launched	5
BRD-K27625831-001-02-9::2.499990597::MTS004	0.47043872290600003	BRD-K27625831-001-02-9::2.499990597::MTS004	BRD-K27625831-001-02-9	pleconaril	2.499990597	MTS004					Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1, Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1	Phase 3	5
BRD-K27755542-001-01-6::2.49693186::MTS004	0.31806553991500003	BRD-K27755542-001-01-6::2.49693186::MTS004	BRD-K27755542-001-01-6	PF-04937319	2.49693186	MTS004	glucokinase activator	GCK			CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1	Phase 2	5
BRD-K27798832-001-01-5::2.350625651::MTS004	0.061853676433699996	BRD-K27798832-001-01-5::2.350625651::MTS004	BRD-K27798832-001-01-5	cefetamet	2.350625651	MTS004	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	5
BRD-K27885593-001-06-8::2.500027849::MTS004	-0.0782329324252	BRD-K27885593-001-06-8::2.500027849::MTS004	BRD-K27885593-001-06-8	corosolic-acid	2.500027849	MTS004	PKC inhibitor, protein tyrosine kinase inhibitor	HSD11B1, PTPN1			C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O	Phase 2	5
BRD-K28061410-001-06-6::2.5::MTS004	-0.663294203927	BRD-K28061410-001-06-6::2.5::MTS004	BRD-K28061410-001-06-6	beta-lapachone	2.5	MTS004	topoisomerase inhibitor	TOP1			CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O	Phase 2	5
BRD-K28537285-001-01-8::2.499968715::MTS004	0.0842901541096	BRD-K28537285-001-01-8::2.499968715::MTS004	BRD-K28537285-001-01-8	chidamide	2.499968715	MTS004	HDAC inhibitor	HDAC10, HDAC3			Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	Launched	5
BRD-K28687144-001-08-7::2.5::MTS004	0.11702877152300001	BRD-K28687144-001-08-7::2.5::MTS004	BRD-K28687144-001-08-7	fosfosal	2.5	MTS004	phosphodiesterase inhibitor	PTGS1, PTGS2			OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O	Launched	5
BRD-K29570907-001-07-3::2.420672872::MTS004	0.391637584052	BRD-K29570907-001-07-3::2.420672872::MTS004	BRD-K29570907-001-07-3	sulmetozine	2.420672872	MTS004	gastrin inhibitor	GAST	gastroenterology	peptic ulcer disease (PUD)	COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1	Launched	5
BRD-K29626940-001-01-5::2.682001852::MTS004	0.258858713966	BRD-K29626940-001-01-5::2.682001852::MTS004	BRD-K29626940-001-01-5	imidafenacin	2.682001852	MTS004	acetylcholine receptor antagonist	CHRM1, CHRM3	neurology/psychiatry	spasms, spasms	Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1	Launched	5
BRD-K29812331-011-01-7::2.472474424::MTS004	-0.205935635154	BRD-K29812331-011-01-7::2.472474424::MTS004	BRD-K29812331-011-01-7	dimemorfan	2.472474424	MTS004	sigma receptor agonist	SIGMAR1	pulmonary	cough suppressant	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31	Launched	5
BRD-K30159788-001-01-9::2.49998123::MTS004	0.24721911738299998	BRD-K30159788-001-01-9::2.49998123::MTS004	BRD-K30159788-001-01-9	RSV604	2.49998123	MTS004	RSV replication inhibitor				Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O	Phase 2	5
BRD-K30485548-050-01-6::2.479775098::MTS004	0.311652758013	BRD-K30485548-050-01-6::2.479775098::MTS004	BRD-K30485548-050-01-6	sumanirole	2.479775098	MTS004	dopamine receptor agonist	DRD2			CN[C@@H]1Cc2cccc3nc(O)n(C1)c23	Phase 3	5
BRD-K30764557-001-01-5::2.5::MTS004	0.19682458069000003	BRD-K30764557-001-01-5::2.5::MTS004	BRD-K30764557-001-01-5	miocamycin	2.5	MTS004	other antibiotic		infectious disease	urinary tract infections, chlamydia	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C	Launched	5
BRD-K30968378-001-01-9::2.500026128::MTS004	-0.011834496659899999	BRD-K30968378-001-01-9::2.500026128::MTS004	BRD-K30968378-001-01-9	INT-747	2.500026128	MTS004	FXR agonist				CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	Phase 3	5
BRD-K31417912-001-01-9::2.499995989::MTS004	0.415286149404	BRD-K31417912-001-01-9::2.499995989::MTS004	BRD-K31417912-001-01-9	PF-3274167	2.499995989	MTS004	oxytocin receptor antagonist	AVPR1A, OXTR			COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1	Phase 2	5
BRD-K31802667-001-01-9::2.530781625::MTS004	0.0597992316596	BRD-K31802667-001-01-9::2.530781625::MTS004	BRD-K31802667-001-01-9	JNJ-37822681	2.530781625	MTS004	dopamine receptor antagonist	DRD2			Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F	Phase 2	5
BRD-K32256160-001-01-9::2.499998021::MTS004	-0.184130693556	BRD-K32256160-001-01-9::2.499998021::MTS004	BRD-K32256160-001-01-9	solithromycin	2.499998021	MTS004	protein synthesis inhibitor				CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC	Phase 3	5
BRD-K32804101-001-01-8::2.5::MTS004	-0.0158918181828	BRD-K32804101-001-01-8::2.5::MTS004	BRD-K32804101-001-01-8	valrocemide	2.5	MTS004					CCCC(CCC)C(=O)NCC(N)=O	Phase 2	5
BRD-K32842773-434-01-8::2.5::MTS004	-0.17730674304000002	BRD-K32842773-434-01-8::2.5::MTS004	BRD-K32842773-434-01-8	pemetrexed	2.5	MTS004	dihydrofolate reductase inhibitor, thymidylate synthase inhibitor	ATIC, DHFR, GART, TYMS	oncology	non-small cell lung cancer (NSCLC), mesothelioma	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	Launched	5
BRD-K32891457-001-15-5::2.719791572::MTS004	0.500650975205	BRD-K32891457-001-15-5::2.719791572::MTS004	BRD-K32891457-001-15-5	cortodoxone	2.719791572	MTS004	androgen receptor antagonist	AR			C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO	Phase 3	5
BRD-K33131085-001-07-2::2.644499841::MTS004	0.0813986567905	BRD-K33131085-001-07-2::2.644499841::MTS004	BRD-K33131085-001-07-2	gentiopicrin	2.644499841	MTS004	glutamate receptor downregulator	GRIN2B			OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O	Phase 3	5
BRD-K33133047-001-01-8::2.5::MTS004	-0.0833235149917	BRD-K33133047-001-01-8::2.5::MTS004	BRD-K33133047-001-01-8	dapiprazole	2.5	MTS004	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	ophthalmology	mydriasis	Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1	Launched	5
BRD-K33240821-001-06-2::2.50000539::MTS004	0.184218462555	BRD-K33240821-001-06-2::2.50000539::MTS004	BRD-K33240821-001-06-2	plerixafor	2.50000539	MTS004	CC chemokine receptor antagonist	ACKR3, CCR4, CXCR4	hematologic malignancy	non-Hodgkin lymphoma (NHL), multiple myeloma	C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	Launched	5
BRD-K33245965-001-03-4::2.50001558::MTS004	0.235520517699	BRD-K33245965-001-03-4::2.50001558::MTS004	BRD-K33245965-001-03-4	BMS-833923	2.50001558	MTS004	smoothened receptor antagonist	SMO			CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1	Phase 2	5
BRD-K33637378-001-01-7::2.500021224::MTS004	0.023896774337900002	BRD-K33637378-001-01-7::2.500021224::MTS004	BRD-K33637378-001-01-7	flibanserin	2.500021224	MTS004	serotonin receptor agonist	DRD4, HTR1A, HTR2A	neurology/psychiatry	hypoactive sexual desire disorder	FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1	Launched	5
BRD-K34068325-066-03-7::2.499970684::MTS004	0.058396795176	BRD-K34068325-066-03-7::2.499970684::MTS004	BRD-K34068325-066-03-7	delavirdine	2.499970684	MTS004	non-nucleoside reverse transcriptase inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1	Launched	5
BRD-K34251960-036-01-6::2.459743274::MTS004	-0.052700491475	BRD-K34251960-036-01-6::2.459743274::MTS004	BRD-K34251960-036-01-6	cibenzoline	2.459743274	MTS004	sodium channel blocker				C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1	Launched	5
BRD-K34277641-001-01-2::2.569027627::MTS004	0.267691451921	BRD-K34277641-001-01-2::2.569027627::MTS004	BRD-K34277641-001-01-2	L-365260	2.569027627	MTS004	CCK receptor antagonist	CCKAR, CCKBR, KCNQ1			CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1	Phase 2	5
BRD-K34445261-001-02-2::2.334266471::MTS004	0.199554282049	BRD-K34445261-001-02-2::2.334266471::MTS004	BRD-K34445261-001-02-2	SLV-320	2.334266471	MTS004	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1	Phase 2	5
BRD-K34508702-001-02-4::2.499975465::MTS004	-0.165570228456	BRD-K34508702-001-02-4::2.499975465::MTS004	BRD-K34508702-001-02-4	CHF5074	2.499975465	MTS004	gamma secretase modulator	PSEN1			OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1	Phase 2	5
BRD-K35304636-001-01-0::2.5::MTS004	0.196754193956	BRD-K35304636-001-01-0::2.5::MTS004	BRD-K35304636-001-01-0	examorelin	2.5	MTS004	growth hormone releasing factor agonist	GHRHR, GHSR			C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Phase 2	5
BRD-K35367061-001-01-1::2.5::MTS004	-0.023212587293400002	BRD-K35367061-001-01-1::2.5::MTS004	BRD-K35367061-001-01-1	LY223982	2.5	MTS004	leukotriene receptor antagonist	LTB4R			COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1	Phase 2	5
BRD-K35626314-003-01-1::2.499986242::MTS004	0.07286925328369999	BRD-K35626314-003-01-1::2.499986242::MTS004	BRD-K35626314-003-01-1	TRV130	2.499986242	MTS004	opioid receptor agonist	OPRM1			COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1	Phase 3	5
BRD-K35798650-001-01-4::2.5::MTS004	-0.752203568091	BRD-K35798650-001-01-4::2.5::MTS004	BRD-K35798650-001-01-4	polidocanol	2.5	MTS004	local anesthetic		dermatology	varicose veins	CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO	Launched	5
BRD-K35882976-001-04-7::2.444346727::MTS004	0.177446675827	BRD-K35882976-001-04-7::2.444346727::MTS004	BRD-K35882976-001-04-7	mitoflaxone	2.4443467269999997	MTS004	antitumor agent	VWF			OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1	Phase 2	5
BRD-K36379990-001-01-1::2.547414282::MTS004	0.158935883499	BRD-K36379990-001-01-1::2.547414282::MTS004	BRD-K36379990-001-01-1	riodipine	2.547414282	MTS004	calcium channel blocker				COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC	Phase 2	5
BRD-K36463073-001-03-9::2.499956047::MTS004	0.23374418406599998	BRD-K36463073-001-03-9::2.499956047::MTS004	BRD-K36463073-001-03-9	OC000459	2.499956047	MTS004	CRTH receptor antagonist	PTGDR2			Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O	Phase 2	5
BRD-K36524108-065-04-0::2.500001799::MTS004	0.21627046043099998	BRD-K36524108-065-04-0::2.500001799::MTS004	BRD-K36524108-065-04-0	paromomycin	2.500001799	MTS004	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched	5
BRD-K36574127-001-01-3::2.5::MTS004	-0.131896539656	BRD-K36574127-001-01-3::2.5::MTS004	BRD-K36574127-001-01-3	LOXO-101	2.5	MTS004	tropomyosin receptor kinase inhibitor	NTRK1, NTRK2, NTRK3			O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F	Phase 2	5
BRD-K36636143-001-01-0::2.518926249::MTS004	-0.0816911283895	BRD-K36636143-001-01-0::2.518926249::MTS004	BRD-K36636143-001-01-0	nolatrexed	2.518926249	MTS004	thymidylate synthase inhibitor	TYMS			Cc1ccc2nc(N)nc(O)c2c1Sc1ccncc1	Phase 3	5
BRD-K36741660-001-01-1::2.499963039::MTS004	0.23308680614799998	BRD-K36741660-001-01-1::2.499963039::MTS004	BRD-K36741660-001-01-1	verinurad	2.4999630390000003	MTS004	urate transporter inhibitor	SLC22A12			CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O	Phase 2	5
BRD-K37543758-001-01-3::2.588829083::MTS004	0.0547893267636	BRD-K37543758-001-01-3::2.588829083::MTS004	BRD-K37543758-001-01-3	trepibutone	2.5888290830000003	MTS004	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	irritable bowel syndrome	CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O	Launched	5
BRD-K37708699-001-01-4::2.530276706::MTS004	0.153980722691	BRD-K37708699-001-01-4::2.530276706::MTS004	BRD-K37708699-001-01-4	exisulind	2.530276706	MTS004	phosphodiesterase inhibitor	PDE5A			CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)(=O)=O	Phase 3	5
BRD-K38168441-001-03-7::2.422985058::MTS004	0.121478785925	BRD-K38168441-001-03-7::2.422985058::MTS004	BRD-K38168441-001-03-7	dabigatran	2.422985058	MTS004	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	Launched	5
BRD-K38398115-001-01-9::2.418470509::MTS004	0.178008378935	BRD-K38398115-001-01-9::2.418470509::MTS004	BRD-K38398115-001-01-9	YM-511	2.418470509	MTS004	aromatase inhibitor	CYP19A1			Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1	Phase 2	5
BRD-K38477637-001-01-0::2.652726792::MTS004	0.188620454979	BRD-K38477637-001-01-0::2.652726792::MTS004	BRD-K38477637-001-01-0	droloxifene	2.6527267919999997	MTS004	selective estrogen receptor modulator (SERM)	ESR1			CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1	Phase 3	5
BRD-K38527262-300-01-0::2.300987371::MTS004	-0.0634040745008	BRD-K38527262-300-01-0::2.300987371::MTS004	BRD-K38527262-300-01-0	atiprimod	2.3009873709999997	MTS004	JAK inhibitor, STAT inhibitor	JAK2, STAT3			CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1	Phase 2	5
BRD-K38564664-001-01-1::2.5::MTS004	0.252224547954	BRD-K38564664-001-01-1::2.5::MTS004	BRD-K38564664-001-01-1	rolziracetam	2.5	MTS004					O=C1CCC2CCC(=O)N12	Phase 2	5
BRD-K39009484-001-01-4::2.5::MTS004	0.00394274724148	BRD-K39009484-001-01-4::2.5::MTS004	BRD-K39009484-001-01-4	entrectinib	2.5	MTS004	ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor	ALK, NTRK1, NTRK2, NTRK3, ROS1			CN1CCN(CC1)c1ccc(C(=O)Nc2n[nH]c3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1	Phase 2	5
BRD-K39560679-001-01-1::2.500010466::MTS004	-0.030232496428900003	BRD-K39560679-001-01-1::2.500010466::MTS004	BRD-K39560679-001-01-1	eluxadoline	2.500010466	MTS004	opioid receptor modulator	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	COc1ccc(CN([C@@H](C)c2ncc([nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O	Launched	5
BRD-K40002998-001-01-5::2.5::MTS004	0.346527858367	BRD-K40002998-001-01-5::2.5::MTS004	BRD-K40002998-001-01-5	org-26576	2.5	MTS004	glutamate receptor modulator				O=C1N2CCC[C@H]2COc2ncccc12	Phase 2	5
BRD-K41267922-001-01-4::2.5::MTS004	-0.24343799724100001	BRD-K41267922-001-01-4::2.5::MTS004	BRD-K41267922-001-01-4	F351	2.5	MTS004	TGF beta receptor inhibitor	TGFB1			Cc1ccc(=O)n(c1)-c1ccc(O)cc1	Phase 2	5
BRD-K41458421-034-01-6::2.500006592::MTS004	0.109225001355	BRD-K41458421-034-01-6::2.500006592::MTS004	BRD-K41458421-034-01-6	naloxegol	2.500006592	MTS004	opioid receptor antagonist	OPRM1	gastroenterology	constipation	COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45	Launched	5
BRD-K41592905-001-01-6::2.5::MTS004	0.029880456153	BRD-K41592905-001-01-6::2.5::MTS004	BRD-K41592905-001-01-6	7-methylxanthine	2.5	MTS004	adenosine receptor antagonist				Cn1cnc2nc(O)nc(O)c12	Phase 2	5
BRD-K41662846-003-01-5::2.517380705::MTS004	0.229260263133	BRD-K41662846-003-01-5::2.517380705::MTS004	BRD-K41662846-003-01-5	tecalcet	2.517380705	MTS004	calcium-sensing receptor agonist	CASR			COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl	Phase 2	5
BRD-K42066335-001-01-0::2.499995517::MTS004	0.149854001737	BRD-K42066335-001-01-0::2.499995517::MTS004	BRD-K42066335-001-01-0	lorediplon	2.499995517	MTS004	GABA receptor modulator	GABRA1			CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1	Phase 2	5
BRD-K42140276-402-01-4::2.500009363::MTS004	0.133442349657	BRD-K42140276-402-01-4::2.500009363::MTS004	BRD-K42140276-402-01-4	alarelin	2.500009363	MTS004	gonadotropin releasing factor hormone receptor antagonist	GNRH1			CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	Launched	5
BRD-K42504537-001-01-6::2.500037177::MTS004	0.28409013914000003	BRD-K42504537-001-01-6::2.500037177::MTS004	BRD-K42504537-001-01-6	norelgestromin	2.500037177	MTS004		PGR	endocrinology	contraceptive	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C	Launched	5
BRD-K42673188-001-01-1::2.363355746::MTS004	-0.633747904902	BRD-K42673188-001-01-1::2.363355746::MTS004	BRD-K42673188-001-01-1	verubulin	2.363355746	MTS004	tubulin polymerization inhibitor	TUBB			COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12	Phase 2	5
BRD-K42816473-001-01-0::2.38330586::MTS004	-0.22708797538199998	BRD-K42816473-001-01-0::2.38330586::MTS004	BRD-K42816473-001-01-0	zilpaterol	2.38330586	MTS004	adrenergic receptor agonist	ADRB2	endocrinology	weight-gain aid	CC(C)N[C@H]1CCn2c(O)nc3cccc([C@@H]1O)c23	Launched	5
BRD-K43230258-001-01-4::2.50004725::MTS004	-0.112661966436	BRD-K43230258-001-01-4::2.50004725::MTS004	BRD-K43230258-001-01-4	crisaborole	2.50004725	MTS004	phosphodiesterase inhibitor	PDE4B			OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12	Phase 3	5
BRD-K43316319-001-01-8::2.356803189::MTS004	-0.005563993309310001	BRD-K43316319-001-01-8::2.356803189::MTS004	BRD-K43316319-001-01-8	MK-2295	2.356803189	MTS004	TRPV antagonist	TRPV1			FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1	Phase 2	5
BRD-K43639297-001-01-9::2.500038533::MTS004	0.07935418926639999	BRD-K43639297-001-01-9::2.500038533::MTS004	BRD-K43639297-001-01-9	hemoglobin-modulators-1	2.500038533	MTS004	hemoglobin modulator				CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	Phase 3	5
BRD-K43647122-001-01-3::2.5::MTS004	0.189397584547	BRD-K43647122-001-01-3::2.5::MTS004	BRD-K43647122-001-01-3	nerbacadol	2.5	MTS004	cyclooxygenase inhibitor				Cc1oncc1C(=O)N1CCCCC1	Phase 3	5
BRD-K43837174-003-01-3::2.479237222::MTS004	0.273174030722	BRD-K43837174-003-01-3::2.479237222::MTS004	BRD-K43837174-003-01-3	pruvanserin	2.479237222	MTS004	serotonin receptor antagonist	HTR2A, HTR2C			Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1	Phase 2	5
BRD-K43890836-001-01-6::2.5::MTS004	0.487708195905	BRD-K43890836-001-01-6::2.5::MTS004	BRD-K43890836-001-01-6	gemcadiol	2.5	MTS004	antilipemic				CC(C)(CO)CCCCCCC(C)(C)CO	Phase 2	5
BRD-K43975632-001-01-1::2.499995729::MTS004	0.10501128028100001	BRD-K43975632-001-01-1::2.499995729::MTS004	BRD-K43975632-001-01-1	terutroban	2.499995729	MTS004	prostanoid receptor antagonist	TBXA2R			Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1	Phase 3	5
BRD-K44030614-001-01-6::2.500000065::MTS004	-0.234198357955	BRD-K44030614-001-01-6::2.500000065::MTS004	BRD-K44030614-001-01-6	ponesimod	2.500000065	MTS004	sphingosine 1 phosphate receptor agonist	S1PR1			CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C	Phase 3	5
BRD-K44164034-003-01-1::2.54181785::MTS004	0.172328810278	BRD-K44164034-003-01-1::2.54181785::MTS004	BRD-K44164034-003-01-1	pumosetrag	2.54181785	MTS004	serotonin receptor agonist	HTR3A, HTR4			Oc1c(cnc2ccsc12)C(=O)N[C@H]1CN2CCC1CC2	Phase 2	5
BRD-K44184170-001-01-7::2.5::MTS004	-0.5809465494380001	BRD-K44184170-001-01-7::2.5::MTS004	BRD-K44184170-001-01-7	ospemifene	2.5	MTS004	selective estrogen receptor modulator (SERM)	ESR1, ESR2	obstetrics/gynecology, endocrinology	vaginal atrophy, dyspareunia, menopause	OCCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1	Launched	5
BRD-K44471774-001-01-8::2.670187358::MTS004	0.257441079575	BRD-K44471774-001-01-8::2.670187358::MTS004	BRD-K44471774-001-01-8	bay-w-9798	2.670187358	MTS004	antioxidant				COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC	Phase 2	5
BRD-K45125084-001-01-4::2.5::MTS004	0.18831038228	BRD-K45125084-001-01-4::2.5::MTS004	BRD-K45125084-001-01-4	zolimidine	2.5	MTS004	mucus protecting agent				CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1	Launched	5
BRD-K45906612-001-01-8::2.499991411::MTS004	0.0571031379563	BRD-K45906612-001-01-8::2.499991411::MTS004	BRD-K45906612-001-01-8	presatovir	2.499991411	MTS004	RSV fusion inhibitor				Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O	Phase 2	5
BRD-K46580984-001-03-6::2.584121204::MTS004	-0.04797569781330001	BRD-K46580984-001-03-6::2.584121204::MTS004	BRD-K46580984-001-03-6	phenserine	2.584121204	MTS004	acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor	ACHE, BCHE			CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21	Phase 3	5
BRD-K46625559-001-01-8::2.50003993::MTS004	0.154238688537	BRD-K46625559-001-01-8::2.50003993::MTS004	BRD-K46625559-001-01-8	ozanimod	2.50003993	MTS004	sphingosine 1 phosphate receptor agonist	S1PR1			CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO	Phase 3	5
BRD-K46843573-001-01-9::2.5::MTS004	0.14843255850099998	BRD-K46843573-001-01-9::2.5::MTS004	BRD-K46843573-001-01-9	zotarolimus	2.5	MTS004	mTOR inhibitor	FKBP1A	cardiology	coronary artery restenosis	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1	Launched	5
BRD-K46862739-001-14-3::2.499952208::MTS004	-0.459430658451	BRD-K46862739-001-14-3::2.499952208::MTS004	BRD-K46862739-001-14-3	metyrapone	2.4999522080000003	MTS004	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1	Launched	5
BRD-K47492008-001-02-7::2.5::MTS004	0.0051469258584	BRD-K47492008-001-02-7::2.5::MTS004	BRD-K47492008-001-02-7	alclofenac	2.5	MTS004	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis	OC(=O)Cc1ccc(OCC=C)c(Cl)c1	Launched	5
BRD-K47690382-001-03-0::2.5::MTS004	0.190647716525	BRD-K47690382-001-03-0::2.5::MTS004	BRD-K47690382-001-03-0	bipenamol	2.5	MTS004	dipeptidyl peptidase inhibitor	CTSC			NCc1ccccc1Sc1ccccc1CO	Phase 2	5
BRD-K47887731-001-01-4::2.5::MTS004	0.0702812855145	BRD-K47887731-001-01-4::2.5::MTS004	BRD-K47887731-001-01-4	nitenpyram	2.5	MTS004			infectious disease	flea control	CCN(Cc1ccc(Cl)nc1)C(\NC)=C\[N+]([O-])=O	Launched	5
BRD-K47929404-001-01-0::2.500019706::MTS004	-0.034128034555200006	BRD-K47929404-001-01-0::2.500019706::MTS004	BRD-K47929404-001-01-0	vercirnon	2.500019706	MTS004	CC chemokine receptor antagonist	CCR9			CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1	Phase 3	5
BRD-K48429278-001-01-3::2.5::MTS004	0.247693887947	BRD-K48429278-001-01-3::2.5::MTS004	BRD-K48429278-001-01-3	pipotiazine-palmitate	2.5	MTS004	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, DRD2, HTR1A, HTR2A			CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1	Launched	5
BRD-K48452630-001-01-8::2.5::MTS004	0.2107080873	BRD-K48452630-001-01-8::2.5::MTS004	BRD-K48452630-001-01-8	SRT2104	2.5	MTS004	SIRT activator	SIRT1			Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1, Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1	Phase 2	5
BRD-K49372556-001-04-1::2.5::MTS004	0.42455393358599997	BRD-K49372556-001-04-1::2.5::MTS004	BRD-K49372556-001-04-1	mofezolac	2.5	MTS004	cyclooxygenase inhibitor	PTGS1	rheumatology, orthopedics	rheumatoid arthritis, osteoporosis	COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1	Launched	5
BRD-K49659468-436-01-2::2.500002467::MTS004	0.157411551244	BRD-K49659468-436-01-2::2.500002467::MTS004	BRD-K49659468-436-01-2	TMC647055	2.500002467	MTS004	RNA polymerase inhibitor				COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O	Phase 2	5
BRD-K49793107-402-02-6::2.5::MTS004	0.118091799335	BRD-K49793107-402-02-6::2.5::MTS004	BRD-K49793107-402-02-6	caspofungin-acetate	2.5	MTS004	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, esophageal candidiasis, aspergillosis, peritonitis	CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN, CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN	Launched	5
BRD-K49841478-001-01-6::2.690488579::MTS004	0.153010442028	BRD-K49841478-001-01-6::2.690488579::MTS004	BRD-K49841478-001-01-6	rosoxacin	2.6904885789999997	MTS004	topoisomerase inhibitor		infectious disease	urinary tract infections	CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1	Launched	5
BRD-K50010139-001-02-3::2.5::MTS004	0.107194787454	BRD-K50010139-001-02-3::2.5::MTS004	BRD-K50010139-001-02-3	poziotinib	2.5	MTS004	EGFR inhibitor	EGFR, ERBB2, ERBB4			COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C	Phase 2	5
BRD-K50055394-001-03-6::2.701086832::MTS004	0.399598500753	BRD-K50055394-001-03-6::2.701086832::MTS004	BRD-K50055394-001-03-6	halopemide	2.7010868319999997	MTS004	phospholipase inhibitor	PLD1, PLD2			Oc1nc2cc(Cl)ccc2n1C1CCN(CCNC(=O)c2ccc(F)cc2)CC1	Phase 2	5
BRD-K50122911-001-01-2::2.5::MTS004	0.365914411979	BRD-K50122911-001-01-2::2.5::MTS004	BRD-K50122911-001-01-2	boronophenylalanine	2.5	MTS004					N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O, N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O	Phase 2	5
BRD-K50489389-001-01-8::2.500007911::MTS004	0.0179176604426	BRD-K50489389-001-01-8::2.500007911::MTS004	BRD-K50489389-001-01-8	ranirestat	2.500007911	MTS004	aldose reductase inhibitor	AKR1B1			Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O	Phase 3	5
BRD-K50660797-001-05-1::2.499989832::MTS004	0.302158256306	BRD-K50660797-001-05-1::2.499989832::MTS004	BRD-K50660797-001-05-1	epicatechin-gallate-(-)	2.499989832	MTS004	bacterial DNA gyrase inhibitor	BACE1, FASN			Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1	Phase 2	5
BRD-K50813454-001-01-9::2.592830582::MTS004	0.020521937000400003	BRD-K50813454-001-01-9::2.592830582::MTS004	BRD-K50813454-001-01-9	amflutizole	2.592830582	MTS004	xanthine oxidase inhibitor	XDH			Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O	Phase 2	5
BRD-K51730347-001-06-4::2.5::MTS004	0.223484660196	BRD-K51730347-001-06-4::2.5::MTS004	BRD-K51730347-001-06-4	diphencyprone	2.5	MTS004	immunostimulant				O=c1c(c1-c1ccccc1)-c1ccccc1, O=c1c(c1-c1ccccc1)-c1ccccc1	Phase 2	5
BRD-K51784806-001-01-6::2.297010706::MTS004	-0.23842739789099998	BRD-K51784806-001-01-6::2.297010706::MTS004	BRD-K51784806-001-01-6	alacepril	2.297010706	MTS004	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O	Launched	5
BRD-K51899933-001-02-6::2.500004375::MTS004	0.25614288132	BRD-K51899933-001-02-6::2.500004375::MTS004	BRD-K51899933-001-02-6	azeliragon	2.500004375	MTS004	RAGE receptor antagonist	AGER			CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1	Phase 3	5
BRD-K51956333-001-03-8::2.52122192::MTS004	-0.38275267501599997	BRD-K51956333-001-03-8::2.52122192::MTS004	BRD-K51956333-001-03-8	iopodic-acid	2.52122192	MTS004			radiology	contrast agent	CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I	Launched	5
BRD-K52579889-001-01-9::2.499985811::MTS004	0.0795310328031	BRD-K52579889-001-01-9::2.499985811::MTS004	BRD-K52579889-001-01-9	TGR-1202	2.4999858109999997	MTS004	PI3K inhibitor				CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12	Phase 3	5
BRD-K52681925-050-01-6::2.472084005::MTS004	0.360816147737	BRD-K52681925-050-01-6::2.472084005::MTS004	BRD-K52681925-050-01-6	altinicline	2.472084005	MTS004	nicotinic receptor agonist	CHRNA4, CHRNB2			CN1CCC[C@H]1c1cncc(c1)C#C	Phase 2	5
BRD-K52914072-001-01-5::2.5::MTS004	0.056830822463999994	BRD-K52914072-001-01-5::2.5::MTS004	BRD-K52914072-001-01-5	LTA	2.5	MTS004					N=C(Nc1ccccc1)c1cccs1	Phase 2	5
BRD-K52960356-001-15-5::2.499955314::MTS004	0.251360715794	BRD-K52960356-001-15-5::2.499955314::MTS004	BRD-K52960356-001-15-5	acetohexamide	2.499955314	MTS004	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched	5
BRD-K53156626-001-01-3::2.5::MTS004	0.281221655127	BRD-K53156626-001-01-3::2.5::MTS004	BRD-K53156626-001-01-3	7-methoxytacrine	2.5	MTS004	acetylcholinesterase inhibitor	ACHE			COc1ccc2nc3CCCCc3c(N)c2c1	Phase 2	5
BRD-K53195974-001-01-9::2.298572309::MTS004	0.252765153637	BRD-K53195974-001-01-9::2.298572309::MTS004	BRD-K53195974-001-01-9	sipatrigine	2.298572309	MTS004	voltage-gated sodium channel blocker	CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A			CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl	Phase 2	5
BRD-K53236343-003-03-7::2.625172304::MTS004	0.30792907693300003	BRD-K53236343-003-03-7::2.625172304::MTS004	BRD-K53236343-003-03-7	aprindine	2.625172304	MTS004	voltage-gated sodium channel blocker	CALM1, SCN5A	cardiology	cardiac arrythmia	CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1	Launched	5
BRD-K53319039-001-01-8::2.5::MTS004	0.190077539465	BRD-K53319039-001-01-8::2.5::MTS004	BRD-K53319039-001-01-8	estradiol-acetate	2.5	MTS004	estrogen receptor agonist	ESR1	endocrinology, obstetrics/gynecology	menopause, vaginal atrophy	CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1	Launched	5
BRD-K53809807-304-02-4::2.7277447::MTS004	-0.0624369482259	BRD-K53809807-304-02-4::2.7277447::MTS004	BRD-K53809807-304-02-4	fosphenytoin	2.7277447	MTS004	sodium channel blocker	SCN5A	neurology/psychiatry	epilepsy, seizures	OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1	Launched	5
BRD-K54339150-001-01-8::2.5::MTS004	0.167688528935	BRD-K54339150-001-01-8::2.5::MTS004	BRD-K54339150-001-01-8	proquazone	2.5	MTS004	cyclooxygenase inhibitor	PTGS1, PTGS2			CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1	Launched	5
BRD-K54519451-001-02-9::2.499971332::MTS004	-0.08894243549769999	BRD-K54519451-001-02-9::2.499971332::MTS004	BRD-K54519451-001-02-9	pexidartinib	2.499971332	MTS004	tyrosine kinase inhibitor	CSF1R, FLT3, KIT			FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1	Phase 3	5
BRD-K54863166-001-01-9::2.693644572::MTS004	0.259076256613	BRD-K54863166-001-01-9::2.693644572::MTS004	BRD-K54863166-001-01-9	darusentan	2.6936445719999997	MTS004	endothelin receptor antagonist	EDNRA			COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1	Phase 3	5
BRD-K54907283-001-01-2::2.4999956::MTS004	0.200496891595	BRD-K54907283-001-01-2::2.4999956::MTS004	BRD-K54907283-001-01-2	AKBA	2.4999956	MTS004	lipoxygenase inhibitor	ALOX5			C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C	Phase 3	5
BRD-K54955827-001-02-2::2.49997945::MTS004	0.31025701442299997	BRD-K54955827-001-02-2::2.49997945::MTS004	BRD-K54955827-001-02-2	niraparib	2.49997945	MTS004	PARP inhibitor	PARP1	oncology	primary peritoneal cancer (PPC)	NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1	Launched	5
BRD-K55029398-001-01-6::2.499962393::MTS004	0.210577695185	BRD-K55029398-001-01-6::2.499962393::MTS004	BRD-K55029398-001-01-6	JNJ-40411813	2.499962393	MTS004	glutamate receptor positive allosteric modulator	GRM2			CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O	Phase 2	5
BRD-K55172746-001-01-3::2.5::MTS004	0.332246993306	BRD-K55172746-001-01-3::2.5::MTS004	BRD-K55172746-001-01-3	apricitabine	2.5	MTS004	nucleoside reverse transcriptase inhibitor				Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1	Phase 3	5
BRD-K55696337-003-24-4::2.50001813::MTS004	-1.4103976115099999	BRD-K55696337-003-24-4::2.50001813::MTS004	BRD-K55696337-003-24-4	topotecan	2.50001813	MTS004	topoisomerase inhibitor	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	Launched	5
BRD-K55808645-001-01-4::2.500006596::MTS004	-0.104298814594	BRD-K55808645-001-01-4::2.500006596::MTS004	BRD-K55808645-001-01-4	elagolix	2.500006596	MTS004	gonadotropin releasing factor hormone receptor antagonist	GNRHR			COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O	Phase 3	5
BRD-K55991142-001-01-6::2.5::MTS004	-0.0256363635421	BRD-K55991142-001-01-6::2.5::MTS004	BRD-K55991142-001-01-6	alcaftadine	2.5	MTS004	histamine receptor antagonist	HRH1	allergy	allergic conjunctivitis	CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12	Launched	5
BRD-K56107812-001-01-7::2.499996486::MTS004	0.16665487462	BRD-K56107812-001-01-7::2.499996486::MTS004	BRD-K56107812-001-01-7	carbetocin	2.499996486	MTS004	oxytocin receptor agonist	OXTR	hematology	hemorrhage	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	Launched	5
BRD-K56155962-001-12-1::2.355251659::MTS004	0.09399093277899999	BRD-K56155962-001-12-1::2.355251659::MTS004	BRD-K56155962-001-12-1	ergocalciferol	2.355251659	MTS004	vitamin analog	VDR	endocrinology, orthopedics	hypoparathyroidism, rickets, hypophosphatemia	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C	Launched	5
BRD-K56211775-001-03-8::2.5::MTS004	-2.42937581574	BRD-K56211775-001-03-8::2.5::MTS004	BRD-K56211775-001-03-8	RTA-408	2.5	MTS004	nitric oxide production inhibitor	NFE2L2			CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2	Phase 2	5
BRD-K56429665-001-09-6::2.500032186::MTS004	-0.309008635014	BRD-K56429665-001-09-6::2.500032186::MTS004	BRD-K56429665-001-09-6	calcipotriol	2.500032186	MTS004	vitamin D receptor agonist	VDR	dermatology	psoriasis	C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	5
BRD-K56740996-001-01-3::2.601527794::MTS004	0.0330656762402	BRD-K56740996-001-01-3::2.601527794::MTS004	BRD-K56740996-001-01-3	flindokalner	2.601527794	MTS004	potassium channel agonist	KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5			COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F	Phase 3	5
BRD-K56807945-001-01-2::2.500001454::MTS004	-0.06405871677609999	BRD-K56807945-001-01-2::2.500001454::MTS004	BRD-K56807945-001-01-2	FG-2216	2.500001454	MTS004	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, HIF1A			OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O	Phase 2	5
BRD-K56912469-003-02-0::2.499992214::MTS004	0.145562391209	BRD-K56912469-003-02-0::2.499992214::MTS004	BRD-K56912469-003-02-0	SAR407899	2.499992214	MTS004	rho associated kinase inhibitor	ROCK1			O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12	Phase 2	5
BRD-K56981171-001-01-0::2.500008954::MTS004	-0.159520987418	BRD-K56981171-001-01-0::2.500008954::MTS004	BRD-K56981171-001-01-0	brigatinib	2.500008954	MTS004	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1	Launched	5
BRD-K57155378-001-01-1::2.499996307::MTS004	0.345730236792	BRD-K57155378-001-01-1::2.499996307::MTS004	BRD-K57155378-001-01-1	TAK-063	2.499996307	MTS004	phosphodiesterase inhibitor	PDE10A			COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1	Phase 2	5
BRD-K57427145-001-01-6::2.5::MTS004	-0.126908539619	BRD-K57427145-001-01-6::2.5::MTS004	BRD-K57427145-001-01-6	ripazepam	2.5	MTS004	benzodiazepine receptor agonist	GABRA1			CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1	Phase 2	5
BRD-K57774929-001-01-3::2.643351543::MTS004	0.193939181892	BRD-K57774929-001-01-3::2.643351543::MTS004	BRD-K57774929-001-01-3	foropafant	2.643351543	MTS004	platelet activating factor receptor antagonist	PTAFR			CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C	Phase 3	5
BRD-K57886322-001-16-6::2.5::MTS004	-0.0584709744851	BRD-K57886322-001-16-6::2.5::MTS004	BRD-K57886322-001-16-6	fluocinonide	2.5	MTS004	glucocorticoid receptor agonist	NR3C1, SERPINA6, SMO	dermatology	seborrheic dermatitis, eczema	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C	Launched	5
BRD-K58277159-001-01-7::2.5::MTS004	0.115167252479	BRD-K58277159-001-01-7::2.5::MTS004	BRD-K58277159-001-01-7	NPC-01	2.5	MTS004	steroid				C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O	Phase 3	5
BRD-K58529924-001-01-5::2.648577938::MTS004	0.423572469673	BRD-K58529924-001-01-5::2.648577938::MTS004	BRD-K58529924-001-01-5	ONC201	2.6485779380000003	MTS004	AKT inhibitor, MAP kinase inhibitor	TNFSF10			Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O	Phase 2	5
BRD-K58810291-001-16-2::2.564588683::MTS004	-0.646061270783	BRD-K58810291-001-16-2::2.564588683::MTS004	BRD-K58810291-001-16-2	clobetasone-butyrate	2.564588683	MTS004	corticosteroid agonist	NR3C1	dermatology	eczema, psoriasis, dermatitis	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl	Launched	5
BRD-K59256312-066-15-7::2.431061328::MTS004	-0.117371918402	BRD-K59256312-066-15-7::2.431061328::MTS004	BRD-K59256312-066-15-7	gabexate	2.431061328	MTS004	serine protease inhibitor	PRSS1, TPSAB1	gastroenterology	pancreatitis	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	Launched	5
BRD-K59391348-001-01-7::2.5::MTS004	-0.0365127478868	BRD-K59391348-001-01-7::2.5::MTS004	BRD-K59391348-001-01-7	lixivaptan	2.5	MTS004	vasopressin receptor antagonist	AVPR2			Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1	Phase 3	5
BRD-K59753975-001-02-6::2.5::MTS004	0.10086386416099999	BRD-K59753975-001-02-6::2.5::MTS004	BRD-K59753975-001-02-6	vindesine	2.5	MTS004	tubulin polymerization inhibitor	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O	Launched	5
BRD-K59866480-001-07-3::2.379655165::MTS004	0.232222171142	BRD-K59866480-001-07-3::2.379655165::MTS004	BRD-K59866480-001-07-3	cyclovalone	2.379655165	MTS004	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1	Launched	5
BRD-K59895502-001-01-9::2.591975371::MTS004	-0.257509660327	BRD-K59895502-001-01-9::2.591975371::MTS004	BRD-K59895502-001-01-9	caramiphen	2.5919753709999998	MTS004	cholinergic receptor antagonist	CHRM1, CHRM2	neurology/psychiatry	Parkinson's Disease	CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1	Launched	5
BRD-K60130390-001-02-1::2.5::MTS004	-0.0560789493531	BRD-K60130390-001-02-1::2.5::MTS004	BRD-K60130390-001-02-1	UNC0642	2.5	MTS004	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1	Preclinical	5
BRD-K60241851-001-11-9::2.5::MTS004	0.239017720691	BRD-K60241851-001-11-9::2.5::MTS004	BRD-K60241851-001-11-9	isodibut	2.5	MTS004	aldehyde reductase inhibitor				OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23	Phase 2	5
BRD-K60284353-001-01-3::2.5::MTS004	0.0537374556061	BRD-K60284353-001-01-3::2.5::MTS004	BRD-K60284353-001-01-3	titanocene-dichloride	2.5	MTS004	apoptosis stimulant				Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1	Phase 2	5
BRD-K60421517-001-01-4::2.499975038::MTS004	0.0628722089302	BRD-K60421517-001-01-4::2.499975038::MTS004	BRD-K60421517-001-01-4	olmutinib	2.499975038	MTS004	EGFR inhibitor, Bruton's tyrosine kinase (BTK) inhibitor	BTK, EGFR			CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1	Launched	5
BRD-K60762818-003-26-0::2.467864576::MTS004	-0.0513723698307	BRD-K60762818-003-26-0::2.467864576::MTS004	BRD-K60762818-003-26-0	desipramine	2.4678645759999998	MTS004	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1	neurology/psychiatry	depression	CNCCCN1c2ccccc2CCc2ccccc12, CNCCCN1c2ccccc2CCc2ccccc12	Launched	5
BRD-K60798049-001-03-8::2.665505334::MTS004	0.24540787609499998	BRD-K60798049-001-03-8::2.665505334::MTS004	BRD-K60798049-001-03-8	fanetizole	2.665505334	MTS004	neutrophil superoxide production				C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1	Phase 3	5
BRD-K61496577-001-19-4::2.5::MTS004	-0.509424640326	BRD-K61496577-001-19-4::2.5::MTS004	BRD-K61496577-001-19-4	flumethasone	2.5	MTS004	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	Launched	5
BRD-K61536264-001-01-3::2.499924728::MTS004	-0.317830907548	BRD-K61536264-001-01-3::2.499924728::MTS004	BRD-K61536264-001-01-3	fagomine	2.4999247280000003	MTS004	glucosidase inhibitor	GLB1			OC[C@H]1NCC[C@@H](O)[C@@H]1O	Phase 2	5
BRD-K61923022-001-02-4::2.499990535::MTS004	-0.0224976037351	BRD-K61923022-001-02-4::2.499990535::MTS004	BRD-K61923022-001-02-4	GDC-0810	2.499990535	MTS004	selective estrogen receptor destabilizer	ESR1			CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl	Phase 2	5
BRD-K62040061-001-01-0::2.500015381::MTS004	0.433230659722	BRD-K62040061-001-01-0::2.500015381::MTS004	BRD-K62040061-001-01-0	toceranib	2.500015381	MTS004	protein tyrosine kinase inhibitor	FLT1, FLT3, KDR, PDGFRA, PDGFRB	oncology	cutaneous mast cell tumors, cutaneous mast cell tumors	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1	Launched	5
BRD-K62050508-001-01-0::2.499980818::MTS004	0.283186569795	BRD-K62050508-001-01-0::2.499980818::MTS004	BRD-K62050508-001-01-0	grapiprant	2.499980818	MTS004	prostaglandin inhibitor	PTGER4	rheumatology	osteoarthritis	CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1	Launched	5
BRD-K62240499-001-05-9::2.500058444::MTS004	0.101458847984	BRD-K62240499-001-05-9::2.500058444::MTS004	BRD-K62240499-001-05-9	huperzine-a	2.500058444	MTS004	acetylcholinesterase inhibitor	ACHE			C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2	Phase 2	5
BRD-K62309135-001-05-2::3.119534994::MTS004	-0.332083463032	BRD-K62309135-001-05-2::3.119534994::MTS004	BRD-K62309135-001-05-2	L-glutamic-acid	3.119534994	MTS004	glutamate receptor agonist	AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT			N[C@@H](CCC(O)=O)C(O)=O	Launched	5
BRD-K62374002-001-01-5::2.499972663::MTS004	-0.319192829734	BRD-K62374002-001-01-5::2.499972663::MTS004	BRD-K62374002-001-01-5	PI3K-IN-2	2.4999726630000003	MTS004	PI3K inhibitor				Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	Phase 2	5
BRD-K62384160-001-02-0::2.499970983::MTS004	0.13306703487299998	BRD-K62384160-001-02-0::2.499970983::MTS004	BRD-K62384160-001-02-0	siponimod	2.4999709830000003	MTS004	sphingosine phosphate receptor modulator	S1PR1			CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F	Phase 3	5
BRD-K62490786-001-01-1::2.495325825::MTS004	-0.08706927462089999	BRD-K62490786-001-01-1::2.495325825::MTS004	BRD-K62490786-001-01-1	ibrolipim	2.495325825	MTS004	lipoprotein lipase activator	LPL			CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC	Phase 2	5
BRD-K62971431-001-01-9::2.5::MTS004	-0.0138024904219	BRD-K62971431-001-01-9::2.5::MTS004	BRD-K62971431-001-01-9	tasimelteon	2.5	MTS004	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder	CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12	Launched	5
BRD-K63018010-001-01-7::2.500011413::MTS004	0.104397738748	BRD-K63018010-001-01-7::2.500011413::MTS004	BRD-K63018010-001-01-7	relebactam	2.500011413	MTS004	beta lactamase inhibitor				OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O	Phase 3	5
BRD-K63177377-001-01-8::2.499971604::MTS004	0.012504843377399998	BRD-K63177377-001-01-8::2.499971604::MTS004	BRD-K63177377-001-01-8	ETC-1002	2.499971604	MTS004	AMPK inhibitor	ACLY			CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O	Phase 3	5
BRD-K63772874-001-02-2::2.499989061::MTS004	0.1994054143	BRD-K63772874-001-02-2::2.499989061::MTS004	BRD-K63772874-001-02-2	icatibant-acetate	2.499989061	MTS004	bradykinin receptor antagonist	ANPEP, BDKRB2	cardiology	angioedema	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	Launched	5
BRD-K64034691-001-01-9::2.499981916::MTS004	0.0811359640145	BRD-K64034691-001-01-9::2.499981916::MTS004	BRD-K64034691-001-01-9	acalabrutinib	2.499981916	MTS004	Bruton's tyrosine kinase (BTK) inhibitor	BTK			CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12	Phase 3	5
BRD-K64120610-001-01-4::2.5::MTS004	0.158142811621	BRD-K64120610-001-01-4::2.5::MTS004	BRD-K64120610-001-01-4	vinflunine	2.5	MTS004	microtubule inhibitor		oncology	bladder cancer	CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC	Launched	5
BRD-K65498798-001-01-7::2.5::MTS004	0.009562219037459999	BRD-K65498798-001-01-7::2.5::MTS004	BRD-K65498798-001-01-7	abametapir	2.5	MTS004	metalloproteinase inhibitor	MMP9			Cc1ccc(nc1)-c1ccc(C)cn1	Phase 3	5
BRD-K65900713-003-01-0::2.686421113::MTS004	0.399679251584	BRD-K65900713-003-01-0::2.686421113::MTS004	BRD-K65900713-003-01-0	caroverine	2.686421113	MTS004	glutamate receptor antagonist, calcium channel blocker		neurology/psychiatry	tinnitus	CCN(CC)CCN1C(=O)C(Nc2ccccc12)=Cc1ccc(OC)cc1	Launched	5
BRD-K66192203-001-02-2::2.50001534::MTS004	0.105239523143	BRD-K66192203-001-02-2::2.50001534::MTS004	BRD-K66192203-001-02-2	opicapone	2.50001534	MTS004	catechol O methyltransferase inhibitor	COMT			Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O	Phase 3	5
BRD-K66295376-001-13-1::2.5::MTS004	-0.0367818535874	BRD-K66295376-001-13-1::2.5::MTS004	BRD-K66295376-001-13-1	ferulic-acid	2.5	MTS004	antioxidant	CA1, CA12, CA14, CA2, CA4, CA6, CA9			COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O	Phase 2	5
BRD-K66437909-001-01-0::2.49636183::MTS004	-0.131321360218	BRD-K66437909-001-01-0::2.49636183::MTS004	BRD-K66437909-001-01-0	KT-433	2.49636183	MTS004	uricosuric agent				CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1	Phase 2	5
BRD-K66786476-001-01-3::2.500037331::MTS004	0.18891852645100002	BRD-K66786476-001-01-3::2.500037331::MTS004	BRD-K66786476-001-01-3	pregabalin	2.500037331	MTS004	voltage-gated calcium channel ligand	CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8	neurology/psychiatry, rheumatology	peripheral neuropathy, seizures, fibromyalgia, postherpetic neuralgia	CC(C)C[C@H](CN)CC(O)=O, CC(C)C[C@H](CN)CC(O)=O	Launched	5
BRD-K66845263-001-03-0::2.5::MTS004	-0.0144522645404	BRD-K66845263-001-03-0::2.5::MTS004	BRD-K66845263-001-03-0	sophocarpine	2.5	MTS004					O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	Phase 3	5
BRD-K67117832-001-01-9::2.5::MTS004	0.08211075802569999	BRD-K67117832-001-01-9::2.5::MTS004	BRD-K67117832-001-01-9	dextran	2.5	MTS004			hematology, critical care	thrombosis, hypovolemia	OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Launched	5
BRD-K67186445-001-02-1::2.500004874::MTS004	0.350710212954	BRD-K67186445-001-02-1::2.500004874::MTS004	BRD-K67186445-001-02-1	dehydrocorydaline	2.500004874	MTS004	acetylcholinesterase inhibitor	ACHE			COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4c(C)c3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4c(C)c3-c2cc1OC	Phase 3	5
BRD-K67482377-001-01-8::2.500004112::MTS004	0.28753969770599996	BRD-K67482377-001-01-8::2.500004112::MTS004	BRD-K67482377-001-01-8	itacitinib	2.500004112	MTS004	JAK inhibitor	JAK1			Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	Phase 2	5
BRD-K67628093-001-01-9::2.500004949::MTS004	0.17885541471000002	BRD-K67628093-001-01-9::2.500004949::MTS004	BRD-K67628093-001-01-9	INCB-3284	2.500004949	MTS004	CC chemokine receptor antagonist	CCR2			COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	Phase 2	5
BRD-K68408772-001-05-4::2.420640995::MTS004	-0.36642659661700006	BRD-K68408772-001-05-4::2.420640995::MTS004	BRD-K68408772-001-05-4	carboxyamidotriazole	2.420640995	MTS004	calcium channel blocker	CXCL8			NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N	Phase 3	5
BRD-K68432770-236-23-1::2.500029469::MTS004	0.21466545573399998	BRD-K68432770-236-23-1::2.500029469::MTS004	BRD-K68432770-236-23-1	ampicillin	2.5000294690000002	MTS004	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched	5
BRD-K68544925-001-01-1::2.500014712::MTS004	0.058104676553699997	BRD-K68544925-001-01-1::2.500014712::MTS004	BRD-K68544925-001-01-1	avatrombopag	2.500014712	MTS004	thrombopoietin receptor agonist	MPL	hematology	thrombocytopenia	OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1	Launched	5
BRD-K68764924-001-03-2::2.5::MTS004	0.127868724056	BRD-K68764924-001-03-2::2.5::MTS004	BRD-K68764924-001-03-2	pantethine	2.5	MTS004	coenzyme A precursor				CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO	Launched	5
BRD-K69636617-001-01-7::2.49998713::MTS004	0.113392123164	BRD-K69636617-001-01-7::2.49998713::MTS004	BRD-K69636617-001-01-7	testolactone	2.49998713	MTS004	aromatase inhibitor	CYP19A1	oncology	breast cancer	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2	Launched	5
BRD-K69669039-001-01-8::2.499979212::MTS004	0.08593130484410001	BRD-K69669039-001-01-8::2.499979212::MTS004	BRD-K69669039-001-01-8	GSK163090	2.499979212	MTS004	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D			Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1	Phase 2	5
BRD-K70262971-001-01-9::2.499966077::MTS004	-0.32334190454399997	BRD-K70262971-001-01-9::2.499966077::MTS004	BRD-K70262971-001-01-9	AGN-194310	2.499966077	MTS004	retinoid receptor antagonist	RXRA, RXRB, RXRG			CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O	Phase 3	5
BRD-K70330032-001-01-1::2.50000853::MTS004	-0.09868341490489999	BRD-K70330032-001-01-1::2.50000853::MTS004	BRD-K70330032-001-01-1	JNJ-42165279	2.50000853	MTS004	FAAH inhibitor	FAAH			FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1	Phase 2	5
BRD-K70504253-001-01-3::2.500017504::MTS004	0.255233443424	BRD-K70504253-001-01-3::2.500017504::MTS004	BRD-K70504253-001-01-3	fruquintinib	2.500017504	MTS004	VEGFR inhibitor	KDR			CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12	Phase 3	5
BRD-K70592963-001-31-6::2.5::MTS004	0.112013598324	BRD-K70592963-001-31-6::2.5::MTS004	BRD-K70592963-001-31-6	phenindione	2.5	MTS004	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1	Launched	5
BRD-K70601687-001-01-3::2.500008826::MTS004	-0.30165672742	BRD-K70601687-001-01-3::2.500008826::MTS004	BRD-K70601687-001-01-3	enasidenib	2.5000088259999997	MTS004	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F	Launched	5
BRD-K70650177-001-01-7::2.500008535::MTS004	0.29078952094599997	BRD-K70650177-001-01-7::2.500008535::MTS004	BRD-K70650177-001-01-7	testosterone-undecanoate	2.500008535	MTS004	androgen receptor agonist	AR	endocrinology	hypogonadism	CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K71026158-304-01-0::2.397404387::MTS004	-0.0121377234213	BRD-K71026158-304-01-0::2.397404387::MTS004	BRD-K71026158-304-01-0	carumonam	2.397404387	MTS004	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	Launched	5
BRD-K71977764-001-01-2::2.5::MTS004	0.274808973017	BRD-K71977764-001-01-2::2.5::MTS004	BRD-K71977764-001-01-2	piroximone	2.5	MTS004	phosphodiesterase inhibitor	PDE3A			CCc1[nH]c(O)nc1C(=O)c1ccncc1	Phase 2	5
BRD-K72259270-003-25-6::2.444857586::MTS004	-0.0540310639984	BRD-K72259270-003-25-6::2.444857586::MTS004	BRD-K72259270-003-25-6	dyclonine	2.444857586	MTS004	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	local anesthetic	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	Launched	5
BRD-K72264770-001-03-2::2.5::MTS004	0.35553391764200004	BRD-K72264770-001-03-2::2.5::MTS004	BRD-K72264770-001-03-2	BRD4770	2.5	MTS004	histone lysine methyltransferase inhibitor	EHMT2			COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1	Preclinical	5
BRD-K72280606-001-01-2::2.499993939::MTS004	-0.179445699412	BRD-K72280606-001-01-2::2.499993939::MTS004	BRD-K72280606-001-01-2	gilteritinib	2.499993939	MTS004	FLT3 inhibitor	FLT3			CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1	Phase 3	5
BRD-K72533376-001-01-2::2.5::MTS004	-0.600281858357	BRD-K72533376-001-01-2::2.5::MTS004	BRD-K72533376-001-01-2	etoposide-phosphate	2.5	MTS004	topoisomerase inhibitor	TOP2A	oncology	testicular carcinoma, small cell lung cancer	COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	Launched	5
BRD-K73027814-003-01-0::2.693425643::MTS004	0.217186753539	BRD-K73027814-003-01-0::2.693425643::MTS004	BRD-K73027814-003-01-0	oxyfedrine	2.6934256430000003	MTS004	adrenergic receptor agonist		cardiology	angina pectoris	COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1	Launched	5
BRD-K73028949-001-02-8::2.5::MTS004	0.150187376102	BRD-K73028949-001-02-8::2.5::MTS004	BRD-K73028949-001-02-8	vasopressin	2.5	MTS004	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	gastroenterology	abdominal distension	N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	Launched	5
BRD-K73132780-001-01-2::2.5::MTS004	0.38887286751999994	BRD-K73132780-001-01-2::2.5::MTS004	BRD-K73132780-001-01-2	pyronaridine	2.5	MTS004	antimalarial agent				COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1, COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1	Phase 3	5
BRD-K73451719-001-01-2::2.5::MTS004	-0.124793101052	BRD-K73451719-001-01-2::2.5::MTS004	BRD-K73451719-001-01-2	terlipressin	2.5	MTS004	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2	cardiology	hypotension	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	Launched	5
BRD-K73504359-001-01-3::2.5::MTS004	0.059048558160499996	BRD-K73504359-001-01-3::2.5::MTS004	BRD-K73504359-001-01-3	bivalirudin	2.5	MTS004	thrombin inhibitor	F2	cardiology	angina pectoris	[2H]N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O	Launched	5
BRD-K73585091-001-02-3::2.499988098::MTS004	0.0846352040943	BRD-K73585091-001-02-3::2.499988098::MTS004	BRD-K73585091-001-02-3	GS-9620	2.499988098	MTS004	toll-like receptor agonist	TLR7			CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1	Phase 2	5
BRD-K73753850-003-01-6::2.499957259::MTS004	0.35887880267	BRD-K73753850-003-01-6::2.499957259::MTS004	BRD-K73753850-003-01-6	hexaminolevulinate	2.499957259	MTS004			radiology	diagnostic agent	CCCCCCOC(=O)CCC(=O)CN	Launched	5
BRD-K73881242-003-04-6::2.500023768::MTS004	0.0281394452559	BRD-K73881242-003-04-6::2.500023768::MTS004	BRD-K73881242-003-04-6	arbidol	2.500023768	MTS004	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	Launched	5
BRD-K74236984-001-04-8::2.5::MTS004	0.246776276835	BRD-K74236984-001-04-8::2.5::MTS004	BRD-K74236984-001-04-8	UNC0321	2.5	MTS004	histone lysine methyltransferase inhibitor	EHMT2			COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1	Preclinical	5
BRD-K74671368-001-01-8::2.5::MTS004	0.343486486779	BRD-K74671368-001-01-8::2.5::MTS004	BRD-K74671368-001-01-8	idronoxil	2.5	MTS004	XIAP inhibitor	ENOX2, SPHK1			Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1	Phase 3	5
BRD-K74759733-065-01-4::2.5::MTS004	0.24842609322200002	BRD-K74759733-065-01-4::2.5::MTS004	BRD-K74759733-065-01-4	isepamicin	2.5	MTS004	protein synthesis inhibitor		infectious disease	pneumonia, peritonitis	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O	Launched	5
BRD-K75385383-001-01-5::2.548558667::MTS004	0.18765925692899998	BRD-K75385383-001-01-5::2.548558667::MTS004	BRD-K75385383-001-01-5	DIPT	2.548558667	MTS004	dopamine reuptake inhibitor, serotonin reuptake inhibitor	HTR1A, HTR2A, HTR2C			CC(C)N(CCc1c[nH]c2ccccc12)C(C)C	Launched	5
BRD-K75445017-001-01-1::2.5::MTS004	0.18076372447	BRD-K75445017-001-01-1::2.5::MTS004	BRD-K75445017-001-01-1	estetrol	2.5	MTS004	selective estrogen receptor modulator (SERM)	ESR1			C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O	Phase 3	5
BRD-K76204040-001-03-8::2.5::MTS004	0.170982210973	BRD-K76204040-001-03-8::2.5::MTS004	BRD-K76204040-001-03-8	pyridoxal	2.5	MTS004		PDXK	neurology/psychiatry	epilepsy	Cc1ncc(CO)c(C=O)c1O	Launched	5
BRD-K76315403-015-02-5::2.5::MTS004	0.200618168705	BRD-K76315403-015-02-5::2.5::MTS004	BRD-K76315403-015-02-5	cetrorelix	2.5	MTS004	gonadotropin releasing factor hormone receptor antagonist	GNRHR, LHCGR	endocrinology	premature luteinizing hormone surges	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	Launched	5
BRD-K76594255-001-01-6::2.5000235::MTS004	0.237540855818	BRD-K76594255-001-01-6::2.5000235::MTS004	BRD-K76594255-001-01-6	maropitant	2.5000235	MTS004	neurokinin receptor antagonist	TACR1	gastroenterology	vomiting	COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C	Launched	5
BRD-K76614248-001-01-2::2.707477898::MTS004	0.00867907312727	BRD-K76614248-001-01-2::2.707477898::MTS004	BRD-K76614248-001-01-2	atizoram	2.707477898	MTS004	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1	Phase 2	5
BRD-K76634210-001-12-1::2.5::MTS004	-0.37821027841399996	BRD-K76634210-001-12-1::2.5::MTS004	BRD-K76634210-001-12-1	idoxuridine	2.5	MTS004	DNA directed DNA polymerase inhibitor		infectious disease	virus herpes simplex (HSV)	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O	Launched	5
BRD-K76713213-001-02-1::2.499961706::MTS004	-0.565035601928	BRD-K76713213-001-02-1::2.499961706::MTS004	BRD-K76713213-001-02-1	tavaborole	2.499961706	MTS004	leucyl-tRNA synthetase inhibitor		infectious disease	onychomycosis	OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12	Launched	5
BRD-K76719364-001-02-5::2.466617435::MTS004	0.012333794379	BRD-K76719364-001-02-5::2.466617435::MTS004	BRD-K76719364-001-02-5	GS-9973	2.466617435	MTS004	syk inhibitor	SYK			C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1	Phase 2	5
BRD-K76927775-001-11-8::2.500019441::MTS004	0.130362375835	BRD-K76927775-001-11-8::2.500019441::MTS004	BRD-K76927775-001-11-8	nitrofurantoin	2.500019441	MTS004	DNA inhibitor		infectious disease	urinary tract infections, pyelonephritis	[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1	Launched	5
BRD-K77038618-356-01-3::2.500022896::MTS004	0.39928878548299995	BRD-K77038618-356-01-3::2.500022896::MTS004	BRD-K77038618-356-01-3	garenoxacin	2.500022896	MTS004	topoisomerase inhibitor	TOP2A	infectious disease	respiratory tract infections	C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1	Launched	5
BRD-K77073709-435-01-2::2.5::MTS004	0.267432530166	BRD-K77073709-435-01-2::2.5::MTS004	BRD-K77073709-435-01-2	cefminox	2.5	MTS004	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O	Launched	5
BRD-K77175907-001-08-0::2.555048691::MTS004	-0.257205543156	BRD-K77175907-001-08-0::2.555048691::MTS004	BRD-K77175907-001-08-0	calcifediol	2.555048691	MTS004	vitamin D receptor agonist	VDR			C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C	Launched	5
BRD-K77320845-001-01-2::2.29566066::MTS004	0.094808091621	BRD-K77320845-001-01-2::2.29566066::MTS004	BRD-K77320845-001-01-2	secoisolariciresinol-diglucoside	2.29566066	MTS004	antioxidant				COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O	Phase 2	5
BRD-K77428767-001-01-7::2.5::MTS004	0.19188494726100003	BRD-K77428767-001-01-7::2.5::MTS004	BRD-K77428767-001-01-7	UNC0224	2.5	MTS004	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1	Preclinical	5
BRD-K77432251-001-01-2::2.715966218::MTS004	-0.504340658851	BRD-K77432251-001-01-2::2.715966218::MTS004	BRD-K77432251-001-01-2	abafungin	2.715966218	MTS004	sterol methyltransferase inhibitor				Cc1ccc(Oc2ccccc2-c2csc(N=C3NCCCN3)n2)c(C)c1	Phase 3	5
BRD-K77564118-001-03-1::2.67296817::MTS004	-0.143869862973	BRD-K77564118-001-03-1::2.67296817::MTS004	BRD-K77564118-001-03-1	fenoverine	2.67296817	MTS004	acetylcholine receptor antagonist		neurology/psychiatry	spasms	O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12	Launched	5
BRD-K78666663-001-01-6::2.499978008::MTS004	-0.0471762004782	BRD-K78666663-001-01-6::2.499978008::MTS004	BRD-K78666663-001-01-6	lemborexant	2.4999780080000003	MTS004	orexin receptor antagonist	HCRTR1, HCRTR2			Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1	Phase 3	5
BRD-K78841970-001-13-8::2.388586862::MTS004	-0.128743519112	BRD-K78841970-001-13-8::2.388586862::MTS004	BRD-K78841970-001-13-8	aspartame	2.388586862	MTS004		TAS1R2, TRPV1			COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	Launched	5
BRD-K79450420-001-01-8::2.499997604::MTS004	-0.030343110191599996	BRD-K79450420-001-01-8::2.499997604::MTS004	BRD-K79450420-001-01-8	INCB-024360	2.4999976040000003	MTS004	indoleamine 2,3-dioxygenase inhibitor	IDO1			NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O	Phase 2	5
BRD-K79450420-001-02-6::2.5::MTS004	-0.298379577478	BRD-K79450420-001-02-6::2.5::MTS004	BRD-K79450420-001-02-6	epacadostat	2.5	MTS004	indoleamine 2,3-dioxygenase inhibitor	IDO1			NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O, NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O	Phase 3	5
BRD-K79710622-001-02-9::2.5::MTS004	0.026476775292	BRD-K79710622-001-02-9::2.5::MTS004	BRD-K79710622-001-02-9	GKT137831	2.5	MTS004	NADPH oxidase inhibitor	NOX1, NOX4			CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12	Phase 2	5
BRD-K79803033-300-01-3::2.5::MTS004	-0.07503724355769999	BRD-K79803033-300-01-3::2.5::MTS004	BRD-K79803033-300-01-3	pozanicline	2.5	MTS004	acetylcholine receptor antagonist	CHRNA4, CHRNB2			Cc1ncccc1OC[C@@H]1CCCN1	Phase 2	5
BRD-K79821389-001-03-5::2.562009205::MTS004	-3.8168921002900005	BRD-K79821389-001-03-5::2.562009205::MTS004	BRD-K79821389-001-03-5	rubitecan	2.562009205	MTS004	topoisomerase inhibitor	TOP1			CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O	Phase 3	5
BRD-K80076813-001-08-8::2.356620242::MTS004	-0.167577148674	BRD-K80076813-001-08-8::2.356620242::MTS004	BRD-K80076813-001-08-8	diftalone	2.356620242	MTS004	cyclooxygenase inhibitor		endocrinology	thyroiditis	O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12	Launched	5
BRD-K80353807-001-25-3::2.5::MTS004	0.0214803491351	BRD-K80353807-001-25-3::2.5::MTS004	BRD-K80353807-001-25-3	khellin	2.5	MTS004	vasodilator				COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12, COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12	Phase 2	5
BRD-K80359953-001-01-3::2.500041136::MTS004	0.0792710200259	BRD-K80359953-001-01-3::2.500041136::MTS004	BRD-K80359953-001-01-3	talampanel	2.500041136	MTS004	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1	Phase 2	5
BRD-K80419150-001-02-4::2.5::MTS004	-0.0982299547368	BRD-K80419150-001-02-4::2.5::MTS004	BRD-K80419150-001-02-4	debrisoquin	2.5	MTS004	adrenergic neuron blocker	SLC6A2	cardiology	hypertension	NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1	Launched	5
BRD-K80607346-001-01-1::2.5::MTS004	0.0773369315432	BRD-K80607346-001-01-1::2.5::MTS004	BRD-K80607346-001-01-1	FK-962	2.5	MTS004	somatostatin receptor agonist				CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1	Phase 2	5
BRD-K80738081-001-46-8::2.500037854::MTS004	0.1399534822	BRD-K80738081-001-46-8::2.500037854::MTS004	BRD-K80738081-001-46-8	resveratrol	2.500037854	MTS004	cytochrome P450 inhibitor, SIRT activator	CSNK2A1, NQO2, PTGS1, PTGS2			Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1	Launched	5
BRD-K80762071-236-02-5::2.5::MTS004	0.17210596334800002	BRD-K80762071-236-02-5::2.5::MTS004	BRD-K80762071-236-02-5	indocyanine-green	2.5	MTS004	contrast agent	SLCO1B1			CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12	Launched	5
BRD-K80859331-001-01-5::2.5::MTS004	0.06829073286330001	BRD-K80859331-001-01-5::2.5::MTS004	BRD-K80859331-001-01-5	haloperidol-decanoate	2.5	MTS004	psychoactive drug	DRD2, DRD3, DRD4, HTR2A	neurology/psychiatry	schizophrenia	CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	Launched	5
BRD-K81405859-300-01-4::2.5::MTS004	0.270953161839	BRD-K81405859-300-01-4::2.5::MTS004	BRD-K81405859-300-01-4	JTE-607	2.5	MTS004	cytokine production inhibitor	IL10, IL1B, IL6, TNF			CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O	Phase 2	5
BRD-K81616657-001-01-4::2.665005855::MTS004	0.24222697600499998	BRD-K81616657-001-01-4::2.665005855::MTS004	BRD-K81616657-001-01-4	PNU-142633	2.665005855	MTS004	serotonin receptor agonist	HTR1D			CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1	Phase 2	5
BRD-K81981783-236-02-9::2.570718613::MTS004	0.34596699818800003	BRD-K81981783-236-02-9::2.570718613::MTS004	BRD-K81981783-236-02-9	gavestinel	2.570718613	MTS004	glutamate receptor antagonist	GLRB			OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1	Phase 3	5
BRD-K82103381-003-09-4::2.500073689::MTS004	0.0860046009856	BRD-K82103381-003-09-4::2.500073689::MTS004	BRD-K82103381-003-09-4	hydralazine	2.500073689	MTS004	vasodilator	AOC3, P4HA1	cardiology	hypertension	NNc1nncc2ccccc12, NNc1nncc2ccccc12, NNc1nncc2ccccc12, NNc1nncc2ccccc12	Launched	5
BRD-K82118441-001-03-7::2.646883368::MTS004	-0.11802148221599999	BRD-K82118441-001-03-7::2.646883368::MTS004	BRD-K82118441-001-03-7	pyrantel	2.646883368	MTS004	nicotinic receptor agonist		infectious disease	gastrointestinal roundworms, gastrointestinal roundworms	OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O	Launched	5
BRD-K82687598-001-01-6::2.5::MTS004	0.0977585082074	BRD-K82687598-001-01-6::2.5::MTS004	BRD-K82687598-001-01-6	tolonidine	2.5	MTS004	adrenergic receptor antagonist	ADRA2A			Cc1ccc(NC2=NCCN2)c(Cl)c1	Launched	5
BRD-K82908348-001-01-9::2.434467427::MTS004	-0.374644436374	BRD-K82908348-001-01-9::2.434467427::MTS004	BRD-K82908348-001-01-9	darglitazone	2.434467427	MTS004	PPAR receptor antagonist	PPARG			Cc1oc(nc1CCC(=O)c1ccc(Cc2sc(O)nc2O)cc1)-c1ccccc1	Phase 2	5
BRD-K82967180-001-01-6::2.500024493::MTS004	-2.14047910357	BRD-K82967180-001-01-6::2.500024493::MTS004	BRD-K82967180-001-01-6	LY3023414	2.500024493	MTS004	PI3K inhibitor, mTOR inhibitor	MTOR			CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O	Phase 2	5
BRD-K83029223-001-01-3::2.500025378::MTS004	-0.325922533495	BRD-K83029223-001-01-3::2.500025378::MTS004	BRD-K83029223-001-01-3	litronesib	2.500025378	MTS004	kinesin-like spindle protein inhibitor	KIF11			CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1	Phase 2	5
BRD-K83144676-001-09-5::2.5::MTS004	0.19970495604400001	BRD-K83144676-001-09-5::2.5::MTS004	BRD-K83144676-001-09-5	olmesartan	2.5	MTS004	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	Launched	5
BRD-K83776863-001-08-9::2.5::MTS004	0.292645459085	BRD-K83776863-001-08-9::2.5::MTS004	BRD-K83776863-001-08-9	tryptophan	2.5	MTS004	serotonin receptor partial agonist	CASR, IDO1, SLC36A1, WARS, WARS2	neurology/psychiatry, gastroenterology	anxiety, bloating, constipation, fatigue, sleeplessness	N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	Launched	5
BRD-K84036904-001-08-8::2.500018826::MTS004	0.0099643607663	BRD-K84036904-001-08-8::2.500018826::MTS004	BRD-K84036904-001-08-8	17-alpha-methyltestosterone	2.500018826	MTS004	aromatase inhibitor	AR			C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	5
BRD-K84173274-001-01-6::2.5::MTS004	0.264123111036	BRD-K84173274-001-01-6::2.5::MTS004	BRD-K84173274-001-01-6	ufenamate	2.5	MTS004	cyclooxygenase inhibitor	PTGS1, PTGS2	dermatology	eczema, dermatitis	CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Launched	5
BRD-K84281997-003-08-4::2.500011105::MTS004	0.260724694734	BRD-K84281997-003-08-4::2.500011105::MTS004	BRD-K84281997-003-08-4	pralidoxime	2.500011105	MTS004	acetylcholinesterase inhibitor	ACHE, BCHE	critical care	organophosphate poisoning	C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O	Launched	5
BRD-K84459715-001-01-6::2.403005639::MTS004	0.104139606692	BRD-K84459715-001-01-6::2.403005639::MTS004	BRD-K84459715-001-01-6	zopolrestat	2.403005639	MTS004					OC(=O)C=C1NN(Cc2nc3cc(ccc3s2)C(F)(F)F)C(=O)c2ccccc12	Phase 2	5
BRD-K84868168-001-01-0::2.500006364::MTS004	0.37479519540899997	BRD-K84868168-001-01-0::2.500006364::MTS004	BRD-K84868168-001-01-0	erdafitinib	2.500006364	MTS004	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4			COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1	Phase 2	5
BRD-K84971356-001-01-4::2.632189712::MTS004	0.181562110478	BRD-K84971356-001-01-4::2.632189712::MTS004	BRD-K84971356-001-01-4	etafenone	2.6321897119999997	MTS004	calcium channel blocker				CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1	Launched	5
BRD-K85882401-323-01-5::2.500009065::MTS004	0.0830153017439	BRD-K85882401-323-01-5::2.500009065::MTS004	BRD-K85882401-323-01-5	avibactam	2.500009065	MTS004	beta lactamase inhibitor		infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis, intra-abdominal infections, urinary tract infections, pyelonephritis, intra-abdominal infections, urinary tract infections, pyelonephritis	NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	Launched	5
BRD-K86171477-001-01-3::2.5::MTS004	0.321091295747	BRD-K86171477-001-01-3::2.5::MTS004	BRD-K86171477-001-01-3	eltoprazine	2.5	MTS004	serotonin receptor agonist	HTR1A, HTR1B			C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12	Phase 2	5
BRD-K86358349-001-02-0::2.440473496::MTS004	0.16900940693500002	BRD-K86358349-001-02-0::2.440473496::MTS004	BRD-K86358349-001-02-0	bromantan	2.440473496	MTS004	dopamine reuptake inhibitor, serotonin reuptake inhibitor		neurology/psychiatry	neurasthenia	Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1	Launched	5
BRD-K86410485-046-01-0::2.499987354::MTS004	0.0459358168786	BRD-K86410485-046-01-0::2.499987354::MTS004	BRD-K86410485-046-01-0	eliglustat	2.499987354	MTS004	Glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease, Gaucher disease	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	Launched	5
BRD-K86670086-001-02-5::2.500040519::MTS004	-0.195804047271	BRD-K86670086-001-02-5::2.500040519::MTS004	BRD-K86670086-001-02-5	sutezolid	2.500040519	MTS004	protein synthesis inhibitor				CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1	Phase 2	5
BRD-K86856088-001-06-9::2.5::MTS004	-0.245312906122	BRD-K86856088-001-06-9::2.5::MTS004	BRD-K86856088-001-06-9	UNC0638	2.5	MTS004	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1	Preclinical	5
BRD-K86864073-001-01-1::2.5::MTS004	-0.0432357217329	BRD-K86864073-001-01-1::2.5::MTS004	BRD-K86864073-001-01-1	chloroprocaine	2.5	MTS004	sodium channel blocker	ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3	neurology/psychiatry	local anesthetic	CCN(CC)CCOC(=O)c1ccc(N)cc1Cl	Launched	5
BRD-K86873305-236-14-7::2.448463554::MTS004	0.11325401031400001	BRD-K86873305-236-14-7::2.448463554::MTS004	BRD-K86873305-236-14-7	piperacillin	2.448463554	MTS004	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)NC(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	Launched	5
BRD-K87316765-001-01-4::2.499975056::MTS004	0.38042021274800003	BRD-K87316765-001-01-4::2.499975056::MTS004	BRD-K87316765-001-01-4	prinaberel	2.499975056	MTS004	estrogen receptor agonist	ESR2, NCOA1			Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1	Phase 2	5
BRD-K87386013-001-01-7::2.5::MTS004	-0.0297856946823	BRD-K87386013-001-01-7::2.5::MTS004	BRD-K87386013-001-01-7	diroximel-fumarate	2.5	MTS004	anti-inflammatory agent				COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O	Phase 3	5
BRD-K87465484-001-02-7::2.5::MTS004	0.253010646683	BRD-K87465484-001-02-7::2.5::MTS004	BRD-K87465484-001-02-7	UNC0646	2.5	MTS004	histone lysine methyltransferase inhibitor	EHMT2			COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	Preclinical	5
BRD-K87573013-001-01-0::2.5::MTS004	0.0833945398466	BRD-K87573013-001-01-0::2.5::MTS004	BRD-K87573013-001-01-0	CL-225385	2.5	MTS004					O=C(CC#N)c1ccccc1	Phase 2	5
BRD-K87777313-001-02-2::2.5::MTS004	0.18214688370499998	BRD-K87777313-001-02-2::2.5::MTS004	BRD-K87777313-001-02-2	irosustat	2.5	MTS004	steroid sulfatase inhibitor	CA2, STS			NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1	Phase 2	5
BRD-K87948281-001-01-9::2.499985333::MTS004	-0.0241929651211	BRD-K87948281-001-01-9::2.499985333::MTS004	BRD-K87948281-001-01-9	F-11440	2.499985333	MTS004	serotonin receptor agonist	HTR1A			Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O	Phase 2	5
BRD-K88143662-001-01-5::2.5::MTS004	-0.174817572232	BRD-K88143662-001-01-5::2.5::MTS004	BRD-K88143662-001-01-5	metharbital	2.5	MTS004	GABA receptor modulator	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	epilepsy	CCC1(CC)C(=O)NC(=O)N(C)C1=O	Launched	5
BRD-K88854110-001-01-5::2.499975441::MTS004	0.170869865764	BRD-K88854110-001-01-5::2.499975441::MTS004	BRD-K88854110-001-01-5	taprenepag	2.499975441	MTS004	prostaglandin receptor agonist	PTGER2			OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1	Phase 2	5
BRD-K89085489-001-23-2::2.499967871::MTS004	0.0342343968202	BRD-K89085489-001-23-2::2.499967871::MTS004	BRD-K89085489-001-23-2	fenretinide	2.499967871	MTS004	apoptosis stimulant, retinoid receptor agonist	RARA			CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1	Phase 3	5
BRD-K89121095-001-01-7::2.499999138::MTS004	0.515238844015	BRD-K89121095-001-01-7::2.499999138::MTS004	BRD-K89121095-001-01-7	tedizolid-phosphate	2.499999138	MTS004	protein synthesis inhibitor		infectious disease	skin infections	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O	Launched	5
BRD-K89272869-003-01-8::2.499996082::MTS004	-0.157372461454	BRD-K89272869-003-01-8::2.499996082::MTS004	BRD-K89272869-003-01-8	nalfurafine	2.499996082	MTS004	opioid receptor agonist	OPRK1, OPRM1	nephrology	uremic pruritus	CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1	Launched	5
BRD-K89413285-074-01-5::2.500023482::MTS004	0.45460003573799995	BRD-K89413285-074-01-5::2.500023482::MTS004	BRD-K89413285-074-01-5	remimazolam	2.500023482	MTS004	benzodiazepine receptor agonist	GABBR1			COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12	Phase 3	5
BRD-K89490285-001-08-1::2.521612095::MTS004	0.27042422904	BRD-K89490285-001-08-1::2.521612095::MTS004	BRD-K89490285-001-08-1	bentazepam	2.521612095	MTS004	benzodiazepine receptor agonist		neurology/psychiatry	anxiety, sedative, muscle relaxant	O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1	Launched	5
BRD-K89920762-001-01-4::2.500013597::MTS004	0.17378362957600002	BRD-K89920762-001-01-4::2.500013597::MTS004	BRD-K89920762-001-01-4	paritaprevir	2.5000135969999997	MTS004	HCV inhibitor		infectious disease	hepatitis C	Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1	Launched	5
BRD-K90069354-001-03-7::2.5::MTS004	-0.34202059438500004	BRD-K90069354-001-03-7::2.5::MTS004	BRD-K90069354-001-03-7	isovaleramide	2.5	MTS004	alcohol dehydrogenase inhibitor				CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O	Phase 2	5
BRD-K90171280-001-01-4::2.328630918::MTS004	-0.251147668424	BRD-K90171280-001-01-4::2.328630918::MTS004	BRD-K90171280-001-01-4	LY2452473	2.328630918	MTS004	androgen receptor modulator	AR			CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N	Phase 2	5
BRD-K90563805-001-02-6::2.5::MTS004	-0.149900023102	BRD-K90563805-001-02-6::2.5::MTS004	BRD-K90563805-001-02-6	natamycin	2.5	MTS004	fungal ergosterol inhibitor		ophthalmology, infectious disease	conjunctivitis, fungal keratosis, blepharitis	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O	Launched	5
BRD-K90629600-001-01-4::2.5::MTS004	0.172160953508	BRD-K90629600-001-01-4::2.5::MTS004	BRD-K90629600-001-01-4	emorfazone	2.5	MTS004	antiinflammatory agent, cyclooxygenase inhibitor		dental	mouth inflammation	CCOc1c(cnn(C)c1=O)N1CCOCC1	Launched	5
BRD-K90982969-001-01-2::2.5::MTS004	0.377668984615	BRD-K90982969-001-01-2::2.5::MTS004	BRD-K90982969-001-01-2	etilevodopa	2.5	MTS004	dopamine receptor agonist	DRD3			CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	Phase 3	5
BRD-K91244729-003-01-3::2.316613157::MTS004	0.40377515335600006	BRD-K91244729-003-01-3::2.316613157::MTS004	BRD-K91244729-003-01-3	propiverine	2.316613157	MTS004	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence	CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1	Launched	5
BRD-K91405252-001-01-9::2.500076093::MTS004	-0.193311508822	BRD-K91405252-001-01-9::2.500076093::MTS004	BRD-K91405252-001-01-9	MK-0354	2.500076093	MTS004	niacin receptor agonist	HCAR2, HCAR3			C1Cc2[nH]nc(-c3nnn[nH]3)c2C1	Phase 2	5
BRD-K91543828-001-02-0::2.500044381::MTS004	0.125229846359	BRD-K91543828-001-02-0::2.500044381::MTS004	BRD-K91543828-001-02-0	pentostatin	2.500044381	MTS004	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA	hematologic malignancy	hairy cell leukemia	OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12	Launched	5
BRD-K91900765-001-07-6::2.500030257::MTS004	0.225611988356	BRD-K91900765-001-07-6::2.500030257::MTS004	BRD-K91900765-001-07-6	VX-745	2.5000302569999997	MTS004	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK14			Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	Phase 2	5
BRD-K92073408-001-15-7::2.5::MTS004	0.0937933637161	BRD-K92073408-001-15-7::2.5::MTS004	BRD-K92073408-001-15-7	norethindrone	2.5	MTS004	progesterone receptor agonist	PGR	obstetrics/gynecology	endometriosis	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C	Launched	5
BRD-K92413528-001-06-9::2.5::MTS004	-0.14312682675799998	BRD-K92413528-001-06-9::2.5::MTS004	BRD-K92413528-001-06-9	procysteine	2.5	MTS004	glutathione synthase stimulant				OC(=O)[C@@H]1CSC(=O)N1	Phase 3	5
BRD-K92426617-001-06-3::2.5::MTS004	-0.0353103003442	BRD-K92426617-001-06-3::2.5::MTS004	BRD-K92426617-001-06-3	esaprazole	2.5	MTS004					O=C(CN1CCNCC1)NC1CCCCC1, O=C(CN1CCNCC1)NC1CCCCC1	Phase 2	5
BRD-K92490248-001-06-6::2.500037393::MTS004	-0.290288244724	BRD-K92490248-001-06-6::2.500037393::MTS004	BRD-K92490248-001-06-6	anethole-trithione	2.500037393	MTS004	glutathione transferase stimulant				COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1	Launched	5
BRD-K92581468-001-01-6::2.389082227::MTS004	0.332858268575	BRD-K92581468-001-01-6::2.389082227::MTS004	BRD-K92581468-001-01-6	ocinaplon	2.389082227	MTS004	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5			O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1	Phase 3	5
BRD-K92902018-001-01-9::2.507952536::MTS004	-0.025132447715799998	BRD-K92902018-001-01-9::2.507952536::MTS004	BRD-K92902018-001-01-9	hydroxyprogesterone-acetate	2.507952536	MTS004	progesterone receptor agonist	PGR			CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O	Launched	5
BRD-K92908289-001-01-8::2.501017998::MTS004	0.0252211595805	BRD-K92908289-001-01-8::2.501017998::MTS004	BRD-K92908289-001-01-8	medica-16	2.501017998	MTS004	ATP citrase lyase inhibitor	FFAR1			CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O	Phase 2	5
BRD-K93442924-001-03-4::2.5::MTS004	0.27901884156199996	BRD-K93442924-001-03-4::2.5::MTS004	BRD-K93442924-001-03-4	vorapaxar	2.5	MTS004	thrombin receptor antagonist	F2R	cardiology	myocardial infarction, peripheral artery disease (PAD)	CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1	Launched	5
BRD-K93900986-001-15-0::2.613957824::MTS004	0.130169361387	BRD-K93900986-001-15-0::2.613957824::MTS004	BRD-K93900986-001-15-0	stetaderm	2.613957824	MTS004					CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C	Launched	5
BRD-K94072573-001-09-9::2.5::MTS004	0.304659856257	BRD-K94072573-001-09-9::2.5::MTS004	BRD-K94072573-001-09-9	medronic-acid	2.5	MTS004	bone resorption inhibitor		radiology	skeletal imaging agent	OP(O)(=O)CP(O)(O)=O	Launched	5
BRD-K94146583-001-01-6::2.500085506::MTS004	-0.0301154661223	BRD-K94146583-001-01-6::2.500085506::MTS004	BRD-K94146583-001-01-6	didox	2.500085506	MTS004	ribonucleotide reductase inhibitor	RRM1	oncology	breast cancer	ONC(=O)c1ccc(O)c(O)c1	Launched	5
BRD-K94830213-001-01-3::2.635005669::MTS004	-2.92485930566e-05	BRD-K94830213-001-01-3::2.635005669::MTS004	BRD-K94830213-001-01-3	tofisopam	2.635005669	MTS004	phosphodiesterase inhibitor, cytochrome P450 inhibitor	CYP3A4, PDE10A, PDE2A, PDE3A, PDE4A	neurology/psychiatry	anxiety, abstinence from alcohol	CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12	Launched	5
BRD-K95362002-001-01-1::2.354783058::MTS004	-0.07525166126550001	BRD-K95362002-001-01-1::2.354783058::MTS004	BRD-K95362002-001-01-1	cipemastat	2.354783058	MTS004	metalloproteinase inhibitor	ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9			CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C	Phase 3	5
BRD-K95941975-001-01-5::2.5::MTS004	-0.135424470676	BRD-K95941975-001-01-5::2.5::MTS004	BRD-K95941975-001-01-5	piperazinedione	2.5	MTS004	DNA synthesis inhibitor				O=C1CNC(=O)CN1	Phase 2	5
BRD-K96206066-001-07-9::2.591957442::MTS004	0.09763042936339998	BRD-K96206066-001-07-9::2.591957442::MTS004	BRD-K96206066-001-07-9	difenpiramide	2.591957442	MTS004	cyclooxygenase inhibitor, prostaglandin inhibitor				O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1	Launched	5
BRD-K96344439-002-02-7::2.500011072::MTS004	0.31995431463	BRD-K96344439-002-02-7::2.500011072::MTS004	BRD-K96344439-002-02-7	tofogliflozin	2.500011072	MTS004	sodium/glucose cotransporter inhibitor	GCK	endocrinology	diabetes mellitus, diabetes mellitus	CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1	Launched	5
BRD-K96471533-001-09-0::2.592774962::MTS004	0.072411205269	BRD-K96471533-001-09-0::2.592774962::MTS004	BRD-K96471533-001-09-0	nitazoxanide	2.592774962	MTS004	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	Launched	5
BRD-K96669468-300-01-1::2.5::MTS004	-0.0085876791327	BRD-K96669468-300-01-1::2.5::MTS004	BRD-K96669468-300-01-1	pyridoxamine	2.5	MTS004	AGE inhibitor				Cc1ncc(CO)c(CN)c1O	Phase 3	5
BRD-K96691275-001-01-2::2.5::MTS004	-0.0038604690136199997	BRD-K96691275-001-01-2::2.5::MTS004	BRD-K96691275-001-01-2	mebrofenin	2.5	MTS004			radiology	diagnostic agent	Cc1cc(C)c(NC(=O)CN(CC(O)=O)CC(O)=O)c(C)c1Br	Launched	5
BRD-K96734425-304-01-7::2.500007729::MTS004	0.0495150363629	BRD-K96734425-304-01-7::2.500007729::MTS004	BRD-K96734425-304-01-7	ceftriaxone	2.500007729	MTS004	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1	Launched	5
BRD-K96874295-015-01-0::2.500009134::MTS004	0.167634720609	BRD-K96874295-015-01-0::2.500009134::MTS004	BRD-K96874295-015-01-0	gonadorelin	2.500009134	MTS004	gonadotropin releasing factor hormone receptor agonist	GNRHR, GNRHR2	obstetrics/gynecology	cystic ovaries, reproductive synchrony	CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	Launched	5
BRD-K97939847-001-12-0::2.5::MTS004	0.331864508514	BRD-K97939847-001-12-0::2.5::MTS004	BRD-K97939847-001-12-0	cridanimod	2.5	MTS004	progesterone receptor agonist	PGR			OC(=O)Cn1c2ccccc2c(=O)c2ccccc12, OC(=O)Cn1c2ccccc2c(=O)c2ccccc12	Launched	5
BRD-K98054437-001-09-9::2.494413182::MTS004	-0.0356061809086	BRD-K98054437-001-09-9::2.494413182::MTS004	BRD-K98054437-001-09-9	epalrestat	2.4944131819999997	MTS004	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	Launched	5
BRD-K98557884-001-01-6::2.5::MTS004	0.0708665381655	BRD-K98557884-001-01-6::2.5::MTS004	BRD-K98557884-001-01-6	suritozole	2.5	MTS004	GABA receptor inverse agonist	GABBR1			Cn1nc(-c2cccc(F)c2)n(C)c1=S	Phase 2	5
BRD-K99077012-001-01-9::2.332734192::MTS004	0.151981110754	BRD-K99077012-001-01-9::2.332734192::MTS004	BRD-K99077012-001-01-9	befuraline	2.3327341919999998	MTS004					O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1	Phase 2	5
BRD-K99199077-001-16-1::2.603211317::MTS004	0.283828062301	BRD-K99199077-001-16-1::2.603211317::MTS004	BRD-K99199077-001-16-1	hydrocortisone-butyrate	2.603211317	MTS004	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses, eczema	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO, CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO	Launched	5
BRD-K99431849-001-01-7::2.500018158::MTS004	-0.417677434394	BRD-K99431849-001-01-7::2.500018158::MTS004	BRD-K99431849-001-01-7	peretinoin	2.500018158	MTS004	retinoid receptor agonist	RXRA			CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(C)=C\C(O)=O	Phase 3	5
BRD-K99447003-335-04-1::2.37737659::MTS004	0.133539578866	BRD-K99447003-335-04-1::2.37737659::MTS004	BRD-K99447003-335-04-1	enalaprilat	2.37737659	MTS004	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Launched	5
BRD-K99506538-001-03-8::2.5::MTS004	0.346387644336	BRD-K99506538-001-03-8::2.5::MTS004	BRD-K99506538-001-03-8	xenalipin	2.5	MTS004					OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F	Phase 2	5
BRD-K99616396-001-05-1::2.499991421::MTS004	-0.190294556146	BRD-K99616396-001-05-1::2.499991421::MTS004	BRD-K99616396-001-05-1	motesanib	2.499991421	MTS004	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT1, FLT4, KDR, KIT			CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	Phase 3	5
BRD-K99879819-001-02-1::2.5187366::MTS004	-0.31636880202100004	BRD-K99879819-001-02-1::2.5187366::MTS004	BRD-K99879819-001-02-1	lorlatinib	2.5187366	MTS004	ALK tyrosine kinase receptor inhibitor	ALK			C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	Phase 2	5
BRD-K99919177-001-01-3::2.5::MTS004	-2.7311548376599997	BRD-K99919177-001-01-3::2.5::MTS004	BRD-K99919177-001-01-3	deslanoside	2.5	MTS004	Na/K-ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	Launched	5
BRD-M63173034-001-03-6::2.64076472::MTS004	-0.10057995047599999	BRD-M63173034-001-03-6::2.64076472::MTS004	BRD-M63173034-001-03-6	clonixin-lysinate	2.64076472	MTS004	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O, NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	Launched	5
